aspirin has been researched along with Blood Clot in 2193 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Low-dose intravenous tirofiban is superior to intravenous aspirin in avoiding in-stent thrombosis in patients undergoing MT plus carotid stenting in the setting of AIS due to TL." | 9.69 | Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol. ( Aguilar-Pérez, M; Ainz-Gómez, L; Amaya Pascasio, L; Baena-Palomino, P; Bravo Rey, I; Cabezas-Rodríguez, JA; Castellanos Rodrigo, MDM; de Albóniga-Chindurza, A; Delgado-Acosta, F; Díaz Pérez, J; Escudero-Martínez, I; Fernandez Prudencio, L; Freijo Guerrero, MDM; Gamero-García, MÁ; González Díaz, E; González García, A; Hidalgo, C; Jiménez Jorge, S; Jiménez-Gómez, E; Medina-Rodríguez, M; Moniche, F; Montaner, J; Morales Caba, L; Mosteiro, S; Ortega-Quintanilla, J; Oteros Fernández, R; Pardo-Galiana, B; Ramirez Moreno, JM; Rosso Fernández, C; Sanz-Fernandez, G; Vielba-Gomez, I; Zamora, A; Zapata-Arriaza, E, 2023) |
| "Clopidogrel is recommended in international guidelines to prevent arterial thrombotic events in patients with peripheral arterial disease (PAD)." | 9.51 | CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD). ( Adang, E; Coenen, M; Deneer, V; Donders, R; Kramers, C; Kranendonk, J; Reijnen, M; Vijver-Coppen, RV; Warlé, MC; Willems, LH; Zeebregts, CJ, 2022) |
| "The efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valves and atrial fibrillation or flutter remain uncertain." | 9.41 | A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. ( Almeida, AP; Ardito, RV; Atik, FA; Barreto, DO; Berwanger, O; Campos, VB; Cavalcante, MA; Cavalcanti, AB; D'Oliveira Vieira, R; Damiani, L; de Barros E Silva, PGM; de Lima, CEB; de Souza Neto, JD; Dos Santos, JRY; Farias, FR; Ferreira, JFM; Figueira, FAMS; Fonseca, FH; Guimarães, HP; Hoffmann-Filho, CR; Junior, RA; Kalil, PSA; Kojima, F; Lamprea, D; Laranjeira, L; Leiria, TLL; Liporace, IL; Lopes, RD; Magalhães, CC; Maldonado, JGA; Mesas, CE; Moisés, VA; Nakagawa, RH; Paiva, MSMO; Paixão, M; Patriota, R; Pavanello, R; Pinto, IM; Precoma, DB; Sampaio, BS; Sampaio, RO; Saraiva, JFK; Silveira, FS; Tarasoutchi, F; Zilli, AC, 2021) |
| "The Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET) study is a multi-center double-blind randomized controlled trial enrolling patients who have undergone multi-vessel CABG with at least one saphenous vein graft." | 9.27 | Impact of ticagrelor versus aspirin on graft patency after CABG: Rationale and design of the TARGET (ticagrelor antiplatelet therapy to reduce graft events and thrombosis) randomized controlled trial (NCT02053909). ( Abreu, AM; Boronat, V; Kouchoukos, NT; Kulik, A; Ruel, M, 2018) |
| "P2Y12 inhibitors, including aspirin, are key components of dual-antiplatelet therapy (DAPT), which is the optimal therapeutic strategy for preventing arterial thrombosis in patients with acute coronary syndromes (ACS) who underwent stent implantation." | 9.22 | A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases. ( Chen, C; Chen, Z; Gu, X; Liu, W; Mao, X; Ren, S; Tao, L; Zhang, L; Zhao, Y, 2022) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 9.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia." | 9.22 | Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. ( Bae, HJ; Cha, JK; Chang, DI; Cho, KH; Cho, YJ; Choi, JC; Hong, KS; Kang, DW; Kim, DE; Kim, EG; Kim, GM; Kim, HY; Kwon, SU; Lee, J; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Park, KY; Rha, JH; Sohn, CH; Sohn, SI; Yoon, BW; Yu, KH, 2016) |
| "There is insufficient data on the efficacy of prasugrel and ticagrelor in Korean patients with ST-segment elevation myocardial infarction (STEMI)." | 9.20 | Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. ( Cho, YR; Guo, LZ; Jin, CD; Kim, MH; Kim, YD; Lee, YS; Park, JS; Park, K; Park, TH, 2015) |
| "The aim of this study was to determine if rivaroxaban is associated with a reduction in stent thrombosis among patients with acute coronary syndromes (ACS) in the ATLAS-ACS 2 TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51) trial." | 9.17 | Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. ( Bassand, JP; Bhatt, DL; Bode, C; Braunwald, E; Burton, P; Chakrabarti, AK; Cohen, M; Gibson, CM; Goto, S; Mega, J; Mohanavelu, S; Stone, G; Verheugt, FW, 2013) |
| "This study was conducted to evaluate preventive effect of a combination of heparin and aspirin on vascular thrombosis and kidney transplant outcomes of pediatric kidney transplant recipients." | 9.16 | Protective effect of heparin and aspirin against vascular thrombosis in pediatric kidney transplants. ( Esfandiar, N; Hoseini, R; Otukesh, H; Sharifian, M, 2012) |
| "Aspirin resistance and chronic renal failure are both potentially important clinical issues in coronary artery disease." | 9.16 | Renal function and aspirin resistance in patients with coronary artery disease. ( Blann, AD; Kuzniatsova, N; Lip, GY; Velu, S, 2012) |
| "The aim of this study was to assess the degree of platelet inhibition by adjunctive cilostazol in patients with acute myocardial infarction (AMI) according to hepatic cytochrome P450 2C19 (CYP2C19) genotype." | 9.15 | Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. ( Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Kwak, CH; Park, JR; Park, KS; Park, Y; Yun, SE, 2011) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 9.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel." | 9.14 | Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR ( Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2010) |
| " Major hemorrhages were observed more frequently in the combination (warfarin plus low-dose aspirin) therapy group than in the warfarin monotherapy group." | 9.14 | [Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin]. ( Aleksandrova, EN; Kondrat'eva, LV; Kovalenko, TF; Ostriakova, EV; Patrushev, LI; Patrusheva, NL; Reshetniak, TM, 2010) |
| " 25,086 individuals with acute coronary syndromes and intended early PCI were randomly assigned to double-dose (600 mg on day 1, 150 mg on days 2-7, then 75 mg daily) versus standard-dose (300 mg on day 1 then 75 mg daily) clopidogrel, and high-dose (300-325 mg daily) versus low-dose (75-100 mg daily) aspirin." | 9.14 | Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. ( Ajani, AE; Avezum, A; Bassand, JP; Budaj, A; Chrolavicius, S; Di Pasquale, G; Eikelboom, JW; Faxon, DP; Fox, KA; Gao, P; Granger, CB; Jolly, SS; Joyner, CD; Macaya, C; Mehta, SR; Montalescot, G; Niemela, K; Rupprecht, HJ; Steg, PG; Tanguay, JF; White, HD; Widimsky, P; Yusuf, S, 2010) |
| "Although clopidogrel is a frequently used antiplatelet medication to treat and prevent atherothrombotic disease, clinicians must balance its clinical effectiveness with the potential side effect of bleeding." | 9.12 | Risk Factors for Bleeding and Clinical Ineffectiveness Associated With Clopidogrel Therapy: A Comprehensive Meta-Analysis. ( Duong, K; Eadon, MT; Fekete, K; Kenneally, A; Milway, E; Nguyen, KA; Oh, H; Schleyer, TK; Whipple, EC; Yoo, R, 2021) |
| "Aspirin combined with LMWH for APS may improve live birth rate, and detection of d-dimer levels in APS pregnant women may predict pregnancy complications and guide the use of anticoagulants." | 9.12 | Meta-analysis on aspirin combined with low-molecular-weight heparin for improving the live birth rate in patients with antiphospholipid syndrome and its correlation with d-dimer levels. ( Diao, QZ; Gu, ZD; Shi, T, 2021) |
| "For prevention of stroke in patients with NVAF, aspirin at 150 to 200 mg per day does not seem to be either effective or safe." | 9.12 | Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. ( Doi, Y; Fukuyama, T; Hiramori, K; Hori, M; Ishikawa, K; Izumi, T; Kitabatake, A; Maruyama, Y; Matsumoto, M; Mochizuki, S; Ogawa, S; Origasa, H; Sato, H; Takekoshi, N; Uchiyama, S; Yamaguchi, T; Yokota, Y; Yoshida, K, 2006) |
| "It was the objective of this study to compare the antithrombotic effects and bleeding profiles of the oral direct thrombin inhibitor ximelagatran, an anticoagulant, and the antiplatelet agent clopidogrel on top of steady-state acetylsalicylic acid (ASA) in a human arterial thrombosis model." | 9.12 | Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. ( Badimon, JJ; Bylock, A; Elg, M; Eriksson, UG; Eriksson-Lepkowska, M; Kalies, I; Nyström, P; Sarich, TC; Wåhlander, K, 2006) |
| "Thrombocytopenia, though uncommon, was associated with orbofiban use and an increased risk of bleeding, but also death and MI." | 9.12 | Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. ( Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM, 2006) |
| "To determine the efficacy of a daily dose of 81 mg aspirin in primary thrombosis prevention in asymptomatic, persistently antiphospholipid antibody (aPL)-positive individuals (those with positive aPL but no vascular and/or pregnancy events)." | 9.12 | Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. ( Erkan, D; Harrison, MJ; Levy, R; Lockshin, MD; Peterson, M; Petri, M; Sammaritano, L; Unalp-Arida, A; Vilela, V; Yazici, Y, 2007) |
| "To assess efficacy and safety of warfarin therapy and its combination with low-dose acetylsalicylic acid (ASA) in antiphospholipid syndrome (APS)." | 9.12 | [Warfarin in the treatment of antiphospholipid syndrome]. ( Kondrat'eva, LV; Patrushev, LI; Patrusheva, NL; Reshetniak, TM, 2007) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 9.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| "The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial." | 9.11 | Efficacy and safety of low-dose aspirin in polycythemia vera. ( Barbui, T; Gisslinger, H; Kutti, J; Landolfi, R; Marchioli, R; Patrono, C; Tognoni, G, 2004) |
| "The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease." | 9.11 | Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. ( Bogousslavsky, J; Brass, LM; Cimminiello, C; Csiba, L; Diener, HC; Kaste, M; Leys, D; Matias-Guiu, J; Rupprecht, HJ, 2004) |
| "We compared the effects of ticlopidine and cilostazol on the prevention of subacute stent thrombosis (SAT) in acute myocardial infarction (AMI) patients with stenting." | 9.11 | Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. ( Adachi, K; Kataoka, T; Kawata, M; Kuramoto, E; Matsuura, A; Saito, A; Sakamoto, S, 2005) |
| "0 in 52 patients or aspirin alone, 100 mg day(-1) in three patients) to determine whether intensive anticoagulation is superior to standard treatment in preventing symptomatic thromboembolism without increasing the bleeding risk." | 9.11 | A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). ( Barbui, T; Baudo, F; Berrettini, M; Brancaccio, V; D'Angelo, A; Finazzi, G; Marchioli, R; Musial, J; Schinco, P; Testa, S; Tognoni, G; Wisloff, F, 2005) |
| "The Thrombosis Prevention Trial was a primary prevention factorial trial that reported a reduction in the risk of coronary heart disease (CHD) with warfarin and/or aspirin." | 9.10 | Thrombosis prevention trial: compliance with warfarin treatment and investigation of a retained effect. ( Ashby, D; Brennan, P; Meade, T; Rudnicka, AR, 2003) |
| " We studied the antithrombotic efficacy of the vitamin K antagonist fluindione in a human ex vivo model of arterial thrombosis and determined whether aspirin enhances fluindione efficacy." | 9.09 | Antithrombotic efficacy of the vitamin K antagonist fluindione in a human Ex vivo model of arterial thrombosis : effect of anticoagulation level and combination therapy with aspirin. ( Boneu, B; Bossavy, JP; Cadroy, Y; Sakariassen, KS; Thalamas, C, 1999) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 9.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| " We conducted a pilot study to evaluate the use of the platelet GP IIb/IIIa receptor antagonist abciximab versus aspirin in conjunction with thrombolysis in patients with acute peripheral occlusive arterial disease associated with arterial thrombosis." | 9.09 | Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis. ( Forkmann, L; Hellner, G; Kirch, W; Koch, R; Müller, A; Schweizer, J, 2000) |
| " Combined warfarin and aspirin therapy was associated with greater fecal hemoglobin excretion than standard warfarin therapy, suggesting the potential for increased gastrointestinal hemorrhage." | 9.08 | Fecal hemoglobin excretion in elderly patients with atrial fibrillation: combined aspirin and low-dose warfarin vs conventional warfarin therapy. ( Ahlquist, DA; Baker, VS; Blackshear, JL; Ellefson, R; Hart, RG; Holland, A; Koehler, J; Litin, SC, 1996) |
| "Data from the early stages of the thrombosis prevention trial (TPT) have been used to establish and quantify the risk of extracranial bleeding due to low dose aspirin (75 mg) and low intensity oral anticoagulation with warfarin (international normalised ratio, INR, 1." | 9.07 | Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. ( Brennan, PJ; Kelleher, CC; Meade, TW; Roderick, PJ; Wilkes, HC, 1992) |
| "We carried out a pilot study in 15 hemodialysis patients with recurrent vascular access thrombosis to examine whether the combination of low dose aspirin (85 mg once daily) and sulfinpyrazone (200 mg three times daily) is safe and effective in the prevention of vascular access thrombosis." | 9.07 | Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. ( Bauman, JE; Domoto, DT; Joist, JH, 1991) |
| "The MRC Epidemiology Unit in Cardiff, Wales conducted three randomized, controlled trials of aspirin use in patients who had had myocardial infarction." | 9.05 | British studies of aspirin and myocardial infarction. ( Elwood, PC, 1983) |
| "Since platelet cyclo-oxygenase is much more sensitive to inactivation by aspirin than is the enzyme in the arterial wall and low doses of aspirin may prevent thrombosis by blocking thromboxane synthesis, we conducted a randomized, double-blind trial of aspirin (160 mg per day) vs." | 9.04 | Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. ( Anderson, CB; Burch, JW; Delmez, JA; Harter, HR; Majerus, PW; Stanford, N; Weerts, CA, 1979) |
| "In this analysis, we aimed to systematically compare stent thrombosis (ST) and its different subtypes following treatment with DAPT (aspirin + clopidogrel) versus TAPT (aspirin + clopidogrel + cilostazol)." | 8.98 | Stent thrombosis associated with drug eluting stents on addition of cilostazol to the standard dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis of published randomized controlled trials. ( Huang, F, 2018) |
| "The relative bleeding risk of aspirin versus vitamin K antagonists (VKA) is unclear." | 8.95 | Meta-analysis of major bleeding events on aspirin versus vitamin K antagonists in randomized trials. ( Ambrosi, P; Daumas, A; Giorgi, R; Villani, P, 2017) |
| "The use of low-dose aspirin and heparinoids has improved the pregnancy outcome in obstetric antiphospholipid syndrome (APS)." | 8.93 | The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. ( Branch, DW; Hunt, BJ; Khamashta, M; Levy, RA; Middeldorp, S; Pavord, S; Roccatello, D; Ruiz-Irastorza, G; Schreiber, K; Sciascia, S; Tincani, A, 2016) |
| "Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically." | 8.93 | Prasugrel hydrochloride for the treatment of acute coronary syndrome patients. ( Gershlick, AH; Gunarathne, A; Hussain, S, 2016) |
| "We performed an individual patient meta-analysis to determine whether aspirin has a significant protective effect on the risk of first thrombosis among patients with antiphospholipid antibodies (aPL)." | 8.91 | Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. ( Amoura, Z; Arnaud, L; Balasch, J; Devilliers, H; Forastiero, R; Lambert, M; Lefevre, G; Martinez-Zamora, MA; Mathian, A; Pengo, V; Ruffatti, A; Tektonidou, M; Wahl, D, 2015) |
| " We found no evidence that the net benefit of aspirin increased with increasing risk of thrombosis, haemorrhage or poor functional outcome in all three trials." | 8.91 | Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta-analysis of three large randomized trials. ( Candelise, L; Chen, Z; Murray, GD; Sandercock, PA; Thompson, DD; Whiteley, WN, 2015) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 8.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "We performed a meta-analysis to determine whether aspirin has a significant protective effect on risk of first thrombosis among patients with antiphospholipid antibodies (aPL+)." | 8.90 | Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. ( Amoura, Z; Arnaud, L; Balasch, J; Cervera, R; Erkan, D; Forastiero, R; Lambert, M; Martinez-Zamora, MA; Mathian, A; Pengo, V; Ruffatti, A; Tektonidou, M; Wahl, D; Zuily, S, 2014) |
| "To provide a pooled estimate of the bleeding risk from randomized controlled trials (RCTs) comparing warfarin and ASA at the dose ranges recommended in evidence-based guidelines." | 8.88 | Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis. ( Crowther, M; Donadini, MP; Lim, W; Spencer, FA; Warkentin, AE, 2012) |
| "Clopidogrel prevents more vascular events, including stroke, in patients with a recent myocardial infarction, stroke or peripheral vascular disease than aspirin." | 8.87 | Clopidogrel hydrogen sulphate for atrial fibrillation. ( Flaker, G; Garg, N; Rajpurohit, N, 2011) |
| " The risk of VTE is higher in multiple myeloma (MM) patients who receive thalidomide or lenalidomide, especially in combination with dexamethasone or chemotherapy." | 8.84 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. ( Anderson, KC; Attal, M; Barlogie, B; Belch, A; Bladé, J; Boccadoro, M; Bringhen, S; Cavo, M; Dimopoulos, MA; Durie, BG; Harousseau, J; Hussein, MA; Joshua, D; Knop, S; Kyle, R; Lonial, S; Ludwig, H; Morgan, GJ; Niesvizky, R; Orlowski, RZ; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Vesole, D; von Lilienfeld-Toal, M; Waage, A; Weber, D; Westin, J; Zangari, M; Zonder, JA, 2008) |
| "To compare the risk of vascular and bleeding events in patients with nonvalvular AF treated with vitamin K -inhibiting oral anticoagulants or acetylsalicylic acid (aspirin)." | 8.81 | Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. ( Chang, Y; Connolly, S; Hart, RG; Hellemons, B; Koudstaal, PJ; Laupacis, A; Petersen, P; Singer, DE; van Walraven, C, 2002) |
| " In patients with arterial or venous thrombosis, there is a high rate of recurrence during the two first years except if high-dose warfarin was used (i." | 8.80 | [Aspirin and antiphospholipid syndrome]. ( Blétry, O; Hachulla, E; Hatron, PY; Piette, AM, 2000) |
| "To determine the impact of fibrin clot inhibitor (FCI) use on oncological outcomes in a large contemporary cohort of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adequate bacille Calmette-Guérin (BCG)." | 8.12 | Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette-Guérin? ( Bree, KK; Dinney, CP; Hensley, PJ; Kamat, AM; Lobo, N; Navai, N; Nogueras-Gonzalez, GM, 2022) |
| " Therefore, we investigated the risk of discontinuing aspirin concerning thrombotic complications in laparoscopic colorectal cancer surgery." | 8.12 | Impact of aspirin discontinuation on thrombotic complications in laparoscopic colorectal cancer surgery. ( Dono, K; Hamabe, A; Harino, T; Noura, S; Ogino, T; Suzuki, Y; Takeyama, H; Tanida, T; Tomita, N, 2022) |
| "A 65-year-old man developed 3-vessel stent thrombosis after percutaneous coronary intervention with aspirin and clopidogrel." | 8.02 | Successful Therapy With Ticagrelor in Three-Vessel Stent Thrombosis Related to Clopidogrel Resistance. ( Cho, JY; Lee, SY; Oh, SK; Yun, KH, 2021) |
| "Thrombosis occurred in 11% (14/126) of grafts in group 1, 9% (11/128) of grafts in group 2, and 1% (2/202) of grafts in group 3 (odds ratio for aspirin group = 0." | 7.96 | Low-Dose Aspirin Reduces the Rate of Renal Allograft Thrombosis in Pediatric Renal Transplant Recipients. ( Al Midani, A; Fidan, K; Kessaris, N; Marks, SD; Matthias, M; Nagra, A; Ridout, D; Rudarakanchana, N; Tugtepe, H, 2020) |
| " Despite long-term antiplatelet therapy with aspirin, recurrent cardiovascular events remain common in patients with coronary artery disease (CAD)." | 7.96 | Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease. ( Ajjan, RA; Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S, 2020) |
| " Among current therapies, low-dose aspirin has been shown to reduce cardiovascular thrombosis." | 7.96 | A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis. ( Burchiel, S; Eaton, RP; Schade, DS, 2020) |
| "To evaluate the effect of prestroke aspirin (PA) use on initial stroke severity, early neurologic deterioration (END), stroke recurrence, hemorrhagic transformation (HT), and functional outcome in patients with ischemic stroke (IS)." | 7.91 | Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke. ( Han, Z; Lin, J; Luo, H; Yi, X; Zhou, J; Zhou, Q, 2019) |
| "The aim of this study is to investigate the impact of ticagrelor as compared to clopidogrel based dual antiplatelet therapy (DAPT) during post-discharge management on the incidence of left ventricular (LV) thrombus in patients with first acute anterior ST elevation myocardial infarction (STEMI)." | 7.91 | The effect of ticagrelor based dual antiplatelet therapy on development of late left ventricular thrombus after acute anterior ST elevation myocardial infarction. ( Altındağ, R; Altıntaş, B; Baysal, E; Bilge, Ö; Burak, C; Ede, H; Karahan, MZ; Öztürk, Ö; Tanboğa, İH; Yaylak, B, 2019) |
| " The aim of this pilot prospective study was to evaluate 12-month cardiovascular outcomes in elderly patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy (aspirin and clopidogrel) according to the clustering of CYP2C19 and ABCB1 genetic variants." | 7.88 | Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel. ( Antonicelli, R; Cecchini, S; Di Pillo, R; Galeazzi, R; Giovagnetti, S; Malatesta, G; Montesanto, A; Olivieri, F; Rose, G; Spazzafumo, L, 2018) |
| " This study involves the development, characterization and optimization of composite wafers for potential oral and buccal delivery of low dose aspirin to prevent thrombosis in elderly patients with dysphagia." | 7.88 | Development and functional characterization of composite freeze dried wafers for potential delivery of low dose aspirin for elderly people with dysphagia. ( Boateng, JS; Farias, S, 2018) |
| "Elderly, hospitalized coronary artery disease patients on regular aspirin treatment were enrolled from January 2014 to September 2016." | 7.85 | Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease. ( Chen, XH; Feng, XR; Fu, SW; He, XQ; Liang, WY; Liu, ML; Liu, WW; McCaffrey, TA; Zhang, JW, 2017) |
| "The effect of prior use of aspirin (ASA) on the onset of acute coronary syndrome (ACS) has not been clarified." | 7.85 | Association Between Prior Aspirin Use and Morphological Features of Culprit Lesions at First Presentation of Acute Coronary Syndrome Assessed by Optical Coherence Tomography. ( Araki, M; Hada, M; Hamaya, R; Hoshino, M; Ichijo, S; Kakuta, T; Kanaji, Y; Kanno, Y; Lee, T; Matsuda, J; Murai, T; Niida, T; Usui, E; Yonetsu, T, 2017) |
| "To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)." | 7.85 | State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017) |
| "The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events." | 7.83 | A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016) |
| "Co-administration of FO and low-dose aspirin may act synergistically to protect against thrombosis and injury-induced vascular remodelling in mice." | 7.81 | Aspirin enhances protective effect of fish oil against thrombosis and injury-induced vascular remodelling. ( Funk, CD; Gong, Y; Li, X; Lin, M; Piao, L; Song, WL; Xiao, B; Yang, F; Yin, H; Yu, Y; Zhang, J; Zhang, Q; Zhu, L, 2015) |
| "Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)." | 7.81 | Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015) |
| "The mechanism of action of the widely used in vivo ferric chloride (FeCl3) thrombosis model remains poorly understood; although endothelial cell denudation is historically cited, a recent study refutes this and implicates a role for erythrocytes." | 7.81 | Resolving the multifaceted mechanisms of the ferric chloride thrombosis model using an interdisciplinary microfluidic approach. ( Ciciliano, JC; Dixon, JB; Fay, ME; Gachet, C; Hechler, B; Lam, WA; Li, R; Lyon, LA; Meeks, S; Myers, DR; Sakurai, Y, 2015) |
| " The effects of AEE on platelet aggregation and anticoagulant in vitro showed that AEE could inhibit adenosine diphosphate (ADP)-induced platelet aggregation as dose-dependence but no notable effect on blood clotting." | 7.81 | Preventive Effect of Aspirin Eugenol Ester on Thrombosis in κ-Carrageenan-Induced Rat Tail Thrombosis Model. ( Li, JY; Liu, GR; Liu, XW; Ma, N; Mohamed, I; Yang, YJ; Zhang, JY, 2015) |
| "Postoperative thrombosis is associated with aspirin unresponsiveness in this patient population." | 7.80 | Aspirin unresponsiveness predicts thrombosis in high-risk pediatric patients after cardiac surgery. ( Baird, CW; Emani, S; Emani, SM; Fynn-Thompson, FE; Pigula, FA; Trainor, B; Zurakowski, D, 2014) |
| "The effectiveness of low-dose aspirin in the primary prevention of thrombosis in patients with high-risk essential thrombocythaemia (ET) treated with cytoreductive drugs is not well established." | 7.79 | Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. ( Alvarez-Larrán, A; Arellano-Rodrigo, E; Besses, C; Cervantes, F; Hernández-Boluda, JC; Pereira, A, 2013) |
| " Additional subgroup analysis included the presence of hypertension, diabetes, low-density lipoprotein levels, sex, and use of aspirin." | 7.79 | Hyperhomocysteinemia and vascular access thrombosis in hemodialysis patients: a retrospective study. ( El-Charabaty, E; El-Sayegh, S; Saifan, C, 2013) |
| "Patients with peripheral artery disease (PAD) following peripheral percutaneous transluminal angioplasty (PTA) with stent implantation are prone to stent thrombosis despite treatment with aspirin and clopidogrel." | 7.79 | Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. ( Frołow, M; Mazur, P; Niżankowski, R; Sadowski, J; Undas, A, 2013) |
| "To assess thromboprophylaxis prescribing patterns against current guidelines and report thromboembolism (TE) incidence in multiple myeloma (MM) patients treated with thalidomide (thal) or lenalidomide (len) at a specialist cancer hospital over a one-year period." | 7.79 | Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. ( Alexander, M; Kirsa, S; Lingaratnam, S; Mellor, JD; Teoh, KC, 2013) |
| "A 73-year-old woman was admitted to our hospital with anterior acute myocardial infarction due to subacute thrombosis after coronary stenting with a zotarolimus-eluting stent (ZES), which is a newly developed drug-eluting stent that has been widely used since May 2009 in Japan." | 7.78 | A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent. ( Arima, M; Matsuda, A; Nitta, M; Shimizu, M; Yoshida, K, 2012) |
| "Our data on the inhibitory effect of rivaroxaban alone or with DAT are consistent with the ATLAS 2 trial findings, and support its potential use for preventing stent thrombosis after stent deployment." | 7.78 | Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis. ( Badimon, JJ; Becker, EM; Bütehorn, U; Kast, R; Klipp, A; Laux, V; Lücker, C; Perzborn, E, 2012) |
| "To test the hypothesis that HRPR after clopidogrel loading is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treatment adjusted according to the results of platelet function tests." | 7.77 | High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011) |
| "Combined antiplatelet agents (cAPA), aspirin plus clopidogrel, increase the risk of bleeding." | 7.76 | Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel. ( Bachelot-Loza, C; Dizier, B; Emmerich, J; Gaussem, P; Godier, A; Grelac, F; Hindy-François, C; Le Bonniec, B; Samama, CM, 2010) |
| "This study sought to evaluate the platelet response to aspirin and the immature platelet fraction in patients with previous stent thrombosis (ST)." | 7.76 | Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. ( Grove, EL; Hvas, AM; Jensen, LO; Kaltoft, AK; Kristensen, SD; Tilsted, HH; Wulff, LN; Würtz, M, 2010) |
| "High-dose aspirin (≥500 mg daily) reduces long-term incidence of colorectal cancer, but adverse effects might limit its potential for long-term prevention." | 7.76 | Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. ( Algra, A; Elwin, CE; Meade, TW; Norrving, B; Rothwell, PM; Warlow, CP; Wilson, M, 2010) |
| "Previous cost-effectiveness analyses analyzed warfarin for stroke prevention in randomized trial settings." | 7.75 | Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. ( Dewilde, S; Goldhaber, SZ; Monz, BU; Plumb, JM; Singer, DE; Sorensen, SV, 2009) |
| "The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)." | 7.74 | Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. ( Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M, 2008) |
| "We describe a case of fatal stent thrombosis after Carbostent implantation and clopidogrel alone antiplatelet therapy in a patient affected by rectal cancer who does not tolerate aspirin." | 7.74 | A case of fatal stent thrombosis after Carbostent implantation: is clopidogrel alone antiplatelet therapy a safe alternative to aspirin alone antiplatelet therapy? ( Altamura, L; Crea, F; De Vita, M; Ferrante, G; Fusco, B; Leone, AM; Niccoli, G; Rebuzzi, AG; Siviglia, M, 2007) |
| " Aspirin non-responsiveness is more frequent in severe infections, such as pneumonia." | 7.74 | Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. ( Karlsson, F; Modica, A; Mooe, T, 2007) |
| "Using prescriptions for digoxin as a surrogate for atrial fibrillation, we identified its coprescription with antithrombotic therapy, aspirin or warfarin in a national prescribing database in 27 571 patients over 45 years old." | 7.74 | National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing. ( Bennett, K; Feely, J; Mahmud, A; Okechukwu, I, 2007) |
| "The need for prolonged aspirin and thienopyridine therapy and the risk of stent thrombosis (ST) remain as drawbacks associated with drug-eluting stents." | 7.74 | Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. ( Airoldi, F; Bonizzoni, E; Briguori, C; Buellesfeld, L; Carlino, M; Chieffo, A; Colombo, A; Cosgrave, J; Gerckens, U; Godino, C; Grube, E; Latib, A; Melzi, G; Michev, I; Montorfano, M; Morici, N; Qasim, A; Sangiorgi, GM, 2007) |
| "Recent clinical trials involving patients with acute coronary syndromes have demonstrated significant reduction in the progression of coronary artery thrombosis using a regimen of aspirin, heparin, and the glycoprotein IIb/IIIa inhibitor tirofiban." | 7.74 | Prevention of microsurgical anastomotic thrombosis using aspirin, heparin, and the glycoprotein IIb/IIIa inhibitor tirofiban. ( Chung, TL; Holton, LH; Pumplin, DW; Rodriguez, ED; Silverman, RP; Taylor, JA, 2007) |
| "The incidence of stent thrombosis was evaluated in 1,029 patients receiving ticlopidine and aspirin after SES deployment." | 7.74 | Late stent thrombosis in patients receiving ticlopidine and aspirin after sirolimus-eluting stent implantation. ( Fujimoto, Y; Himi, T; Kitahara, H; Kobayashi, Y; Komuro, I; Kuroda, N; Miyazaki, A; Nakamura, Y; Nakayama, T, 2008) |
| "Acetylsalicylic acid (ASA) and the thienopyridine clopidogrel are established anti-platelet drugs that significantly reduce secondary cardiovascular events in patients with manifest atherosclerosis." | 7.74 | Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. ( Koellnberger, M; Konrad, I; Lorenz, R; Massberg, S; Orschiedt, L; Sauer, S; Schulz, C; Walter, U, 2008) |
| "Patients with atrial fibrillation taking either indirect anticoagulant acenocumarol or most often prescribed antiaggregant aspirin were followed for 1 year." | 7.74 | [Effect of acenocoumarol and aspirin on platelet function, markers of thrombinemia, and intracardiac thrombosis in patients with atrial fibrillation]. ( Ataullakhanova, DM; Bykova, ES; Dobrovol'skiĭ, AB; Kropacheva, ES; Panchenko, EP; Titaeva, EV; Zharkova, TV, 2007) |
| " The patient had decided to take low-molecular-weight heparin (LMWH) and aspirin throughout her pregnancy." | 7.74 | Acute thrombosis of a prosthetic mitral valve in pregnancy in spite of adjusted-dose low-molecular-weight heparin and aspirin. ( Curtis, SL; Stuart, AG; Trinder, J, 2008) |
| "Between September 1999 and April 2002, a total of 1,236 patients hospitalized for acute coronary syndrome (ACS) were questioned in order to determine whether aspirin intake had been interrupted." | 7.73 | Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. ( Benhamou, M; Cerboni, P; Ferrari, E; Marcel, B, 2005) |
| " All suffered stent thrombosis after discontinuation (in three cases prematurely) of clopidogrel therapy." | 7.73 | [Thrombosis of a coronary stent after discontinuing treatment with clopidogrel]. ( de Boer, MJ; Hautvast, RW; Heestermans, AA; Jaarsma, W; ten Berg, JM; van Werkum, JW, 2006) |
| "We conclude that under our experimental conditions, rofecoxib diminished platelet aggregation induced by different agonists and inhibited platelet-mediated thrombogenesis in an in vitro model of thrombosis." | 7.72 | Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. ( Arderiu, G; Escolar, G; Hernandez, MR; Pino, M; Serradell, M; Tonda, R, 2004) |
| "Although the central role of thrombin in arterial thrombosis is well established, the efficacy of vitamin K-dependent factor depletion by warfarin at preventing this process has not been established." | 7.72 | The impact of vitamin K-dependent factor depletion by warfarin on platelet-rich thrombosis after deep arterial injury. ( Chesebro, JH; Grill, DE; Hassinger, NL; McBane, RD, 2004) |
| "There was a significantly lower rate of primary allograft thrombosis in patients treated with aspirin (none of 105) compared with that in the control group (six (5 per cent) of 121; P = 0." | 7.71 | Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation. ( Metcalfe, M; Murphy, GJ; Nicholson, ML; Taha, R; Windmill, DC, 2001) |
| "We compared the combination of aspirin plus clopidrogrel (A+C) with aspirin and ticlopidine (A+T) for prevention of subacute stent thrombosis in 827 patients." | 7.71 | Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. ( Abizaid, AS; Curry, BH; Dangas, G; Kent, KM; Lansky, AJ; Leon, MB; Mehran, R; Paliou, M; Pichard, AD; Satler, LF; Stone, GW, 2001) |
| " The nonionic CM iohexol triggers platelet beta-thromboglobulin (beta-TG) secretion, and thus may activate the platelets and promote thrombosis." | 7.70 | Iohexol, platelet activation and thrombosis. II. Iohexol-induced platelet secretion does not affect collagen-induced or tissue-factor-induced thrombus formation in blood that is anticoagulated with heparin and aspirin. ( Buchmann, M; Hamers, MJ; Sakariassen, KS; Stormorken, H, 1998) |
| " We report on the antithrombotic effect of xemilofiban (SC-54684A), an oral GP IIb/IIIa antagonist, administered alone or with aspirin (ASA) in an acute thrombosis model." | 7.70 | Protective effect of oral xemilofiban in arterial thrombosis in dogs: increased activity in combination with aspirin. ( Feigen, LP; Frederick, LG; King, LW; Nicholson, NS; Salyers, AK; Suleymanov, OD; Szalony, JA; Taite, BB, 1998) |
| "In patients receiving coronary stents treated with aspirin and coumadin, the peak incidence of stent thrombosis occurs on the fifth and sixth days following the implantation procedure." | 7.70 | Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. ( Bell, MR; Berger, PB; Holmes, DR; Rihal, CS; Velianou, JL; Wilson, SH, 1999) |
| "Further to characterize the processes involved in the FeCl3-induced thrombosis model, we determined the effect of aspirin, heparin, hirudin, trans-4-(aminomethyl) cyclohexane carboxylic acid (AMCHA), thrombocytopenia, and flow modifications on time to occlusion (TTO) and thrombus weight (TW) in the rat carotid artery." | 7.70 | Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis. ( Kambayashi, J; Lockyer, S, 1999) |
| "Adding NTG to a thrombolytic regimen with rt-PA, aspirin and heparin increases the magnitude of restored flow and total patency duration following recanalization in a rabbit model of arterial thrombosis." | 7.69 | Beneficial effect of nitroglycerin on arterial rethrombosis after thrombolysis. Results from a rabbit thrombosis model. ( Battler, A; Chernine, A; Hasdai, D; Kornowski, R; Ovadia, Z, 1995) |
| " To compare its antiaggregating capacity with that of aspirin, experimental thrombosis was induced in all dogs by means of direct current applied to the carotid artery." | 7.69 | Prevention of arterial thrombosis by a monoclonal antibody against the 100 to 109 amino acid sequence stretch of the beta-subunit of the human platelet fibrinogen receptor: a comparative study with low dose aspirin. ( Alvarez, L; Alvarez, MV; Castillo-Olivares, JL; de Haro, J; Escudero, C; González, J; Jorge-Herrero, E; Millán, I, 1994) |
| "Inogatran (MW 439 Da), a new, selective, active site inhibitor of thrombin, was evaluated in three rat models of thrombosis." | 7.69 | Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. ( Börjesson, I; Elg, M; Gustafsson, D; Lenfors, S; Teger-Nilsson, AC, 1996) |
| "We determined the effects of aspirin and a novel thromboxane A2/prostaglandin endoperoxide (TP)-receptor antagonist, BMS-180291, on thrombosis and bleeding times in skin and mesenteric arteries." | 7.68 | Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis. ( Heran, CL; Ogletree, ML; Schumacher, WA; Steinbacher, TE; Youssef, S, 1993) |
| "The antithrombotic effects of the thromboxane (TX) A2-receptor antagonist and aspirin were determined using a photochemically-induced arterial thrombosis model in the femoral arteries of guinea pigs." | 7.68 | Inhibitory effect of KW-3635, a new thromboxane A2-receptor antagonist, on arterial thrombosis in guinea pigs. ( Higo, K; Karasawa, A, 1993) |
| "The antithrombotic effects of the stable PGI2-analogue Cicaprost, acetylsalicylic acid (Aspisol), the low molecular weight heparin CY 216 (Fraxiparin) and Molsidomin (Corvaton) have been investigated alone and in combinations in a thrombosis model in rats in which mesenteric venules with a diameter of 20-30 microns were injured by defined argon laser lesions." | 7.68 | Effects of combinations of a prostacyclin analogue (Cicaprost) with different antithrombotic agents in a rat microcirculatory thrombosis model. ( Breddin, HK; Giedrojc, J, 1992) |
| "Two recombinant hirudins (r-hirudin), natural hirudin and hirudin in combination with heparin or acetylsalicylic acid (ASA) have been studied in a thrombosis model in which rat mesenteric venules of a diameter of 20-30 microns were injured by well-defined argon laser lesions." | 7.68 | Effects of different hirudins and combinations of low doses of hirudin, heparin and acetylsalicylic acid in a rat microcirculatory thrombosis model. ( Breddin, HK; Krupinski, K, 1991) |
| "Defibrotide, acetylsalicylic acid, low molecular weight heparin (CY 216), sodium heparin, Molsidomin and a thromboxane receptor antagonist have been investigated separately and in combinations in an animal thrombosis model in which rat mesenteric venules are damaged by defined laser energy." | 7.68 | Anticoagulant and antithrombotic effects of combinations of defibrotide with heparins and other antithrombotic agents in an animal thrombosis model. ( Breddin, HK; Giedrojc, J, 1991) |
| "The antithrombotic effects of four compounds structurally related to aspirin (acetylsalicylic acid, ASA) were examined in a rat model of arterial thrombosis and compared to ASA." | 7.67 | The effects of high doses of aspirin and related benzoic acid derivatives on arterial thrombosis in male rats. ( Killackey, BA; Killackey, JJ; Philp, RB, 1984) |
| "We have studied the effect of different doses of aspirin on platelet function, PGI2 formation, platelet survival, thrombosis, fibrinolysis, and prothrombin time in rabbits with indwelling aortic catheters." | 7.66 | Effect of aspirin and sodium salicylate on thrombosis, fibrinolysis, prothrombin time, and platelet survival In rabbits with indwelling aortic catheters. ( Cattaneo, M; Chahil, A; Kinlough-Rathbone, RL; Mustard, JF; Packham, MA; Somers, D, 1983) |
| "The effect of different dosage regimens of aspirin was investigated in an experimental model of arterial thrombosis." | 7.66 | Paradoxical effect of high and low dose aspirin in experimental arterial thrombosis. ( Mörl, H; Thiessen, M; Walter, E; Zimmermann, R, 1980) |
| "Recurrent mesenteric arterial thrombosis developed in a 56-year-old man with polycythemia vera (PV) despite therapy with heparin sodium, warfarin sodium, and standard doses of aspirin and dipyridamole." | 7.66 | Polycythemia vera and mesenteric arterial thrombosis. A disease association resulting from decreased platelet sensitivity to aspirin. ( Myers, TJ; Rickles, FR; Steinberg, WM, 1979) |
| "An experimental model of canine arterial thrombosis was used to study by prophylactic antithrombotic effectiveness of carbenicillin and ticarcillin, two semisynthetic penicillins which have been shown to inhibit platelet function in vivo." | 7.66 | Dose-dependent inhibition of experimental arterial thrombosis by carbenicillin and ticarcillin. ( Johnson, GJ; Lyman, BT; White, JG, 1978) |
| "Patients with type 2 diabetes mellitus (T2DM) are at higher risk of thrombotic complications." | 6.87 | Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease. ( Cao, PG; Guo, DD; Quan, AJ; Shang, LL; Zhao, HY, 2018) |
| "Dabigatran is a direct acting (anti-II) oral anticoagulant which does not interfere with CYP and has favourable safety and efficacy profiles compared with VKAs." | 6.82 | Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. ( Ajjan, RA; Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Franchi, F; Guzman, LA; King, R; Phoenix, F; Rollini, F; Tello-Montoliu, A; Zenni, MM, 2016) |
| "Metabolic syndrome is associated with intravascular inflammation, as determined by increased levels of inflammatory biomarkers and an increased risk of ischemic atherothrombotic events." | 6.74 | PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. ( Cable, G; Willerson, JT; Yeh, ET, 2009) |
| "Catheter thrombosis has never been reported in any trial using bivalirudin." | 6.73 | Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study. ( Buerke, M; Carter, JM; Hauroeder, B; Maegdefessel, L; Michel, T; Peetz, D; Reindl, I; Schlitt, A; Schubert, S; Werdan, K, 2008) |
| "Both aspirin and dextran were well tolerated." | 6.69 | Prophylaxis for deep vein thrombosis with aspirin or low molecular weight dextran in Korean patients undergoing total hip replacement. A randomized controlled trial. ( Cho, JL; Choi, IY; Kim, YH; Park, MR; Park, TS, 1998) |
| " Dosing for neuroendovascular conditions is often extrapolated from the cardiac literature, although outcomes in cardiac patients may not be relevant to neurologic patients, making prophylactic treatment recommendations challenging for these patients." | 6.61 | Periprocedural Neuroendovascular Antiplatelet Strategies for Thrombosis Prevention in Clopidogrel-Hyporesponsive Patients. ( Barra, ME; Berger, K; Brophy, GM; Tesoro, EP, 2019) |
| "Fibrin is an important contributor to thrombogenesis and may account for the residual event rates." | 6.50 | Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome. ( White, H, 2014) |
| " In the forth communication we consider data of randomized studies in which efficacy and safety of clopidogrel in combination with has acetylsalicylic acid (ASA) been assessed in comparison with (ASA) in various acute coronary syndromes (ACS), as well as before, during, and after percutaneous coronary interventions (PCI)." | 6.45 | [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part IV. therapeutic application of clopidogrel in combination with acetylsalicylic acid in acute coronary syndromes and percutaneous coronary interventions]. ( Avsar, O; Batyraliev, TA; Fettser, DV; Islek, M; Preobrazhenskiĭ, DV; Sidorenko, BA; Vural, A, 2009) |
| "Aspirin treatment of erythromelalgia in thrombocythemia patients resulted in the disappearance of the erythromelalgic, thrombotic signs and symptoms, correction of the shortened platelet survival times, and a significant reduction of the increased levels of beta-TG, PF4, TM and urinary TxB2 excretion to normal." | 6.42 | Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. ( Michiels, JJ, 2003) |
| "Aspirin is an approximately 150- to 200-fold more potent inhibitor of the (constitutive) isoform of the platelet enzyme (COX-1) than the (inducible) isoform (COX-2) which is expressed by cytokines, inflammatory stimuli, and some growth factors." | 6.40 | Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. ( Schrör, K, 1997) |
| "Aspirin has been recognized as inhibiting normal platelet function and the mechanism has been clearly delineated." | 6.38 | Aspirin in the prevention of thrombosis. ( Bell, WR; Lekstrom, JA, 1991) |
| "Large-scale clinical trials of the use of aspirin in post-myocardial infarction patients were based on the assumption that inhibition of platelet activity would reduce thromboembolism associated with atherosclerosis, and that thromboembolism is a major cause of the clinical complications of atherosclerosis." | 6.15 | Aspirin in the treatment of cardiovascular disease: a review. ( Kinlough-Rathbone, RL; Mustard, JF; Packham, MA, 1983) |
| "A review is given on the clinical studies performed with aspirin in patients with chronic vascular occlusions of the limbs and on studies in cerebral ischemia using aspirin and sulfinpyrazone." | 6.14 | Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders. ( Breddin, K, 1977) |
| " The collection days (CD) were the second and seventh days after stable aspirin dosing and then a convalescent time point 2-9 months later." | 5.72 | Urinary 11-dehydrothromboxane B2 aspirin efficacy testing is sensitive to perioperative inflammation in pediatric solid-organ transplant patients. ( Boucher, AA; Francisco, BJ; Luchtman-Jones, L; Martin, J; Martin, M; Nathan, JD; Pfeiffer, A; Shova, A; Tiao, GM, 2022) |
| "Rates of hemorrhage were similar for aspirin in combination with warfarin or direct-acting oral anticoagulants." | 5.72 | Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. ( Colucci, PM; Grunwald, MR; Lessen, DS; Paranagama, D; Zwicker, JI, 2022) |
| "In Chinese patients with negative cardiac troponin undergoing drug-eluting stent implantation, indobufen plus clopidogrel DAPT compared with aspirin plus clopidogrel DAPT significantly reduced the risk of 1-year net clinical outcomes, which was driven mainly by a reduction in bleeding events without an increase in ischemic events." | 5.69 | Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial. ( Chen, M; Cheng, K; Ge, J; Huang, J; Lan, J; Li, G; Qian, J; Wang, X; Wang, Y; Wei, G; Wu, H; Xu, L; Zhang, C; Zhang, H; Zhao, X, 2023) |
| "Low-dose intravenous tirofiban is superior to intravenous aspirin in avoiding in-stent thrombosis in patients undergoing MT plus carotid stenting in the setting of AIS due to TL." | 5.69 | Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol. ( Aguilar-Pérez, M; Ainz-Gómez, L; Amaya Pascasio, L; Baena-Palomino, P; Bravo Rey, I; Cabezas-Rodríguez, JA; Castellanos Rodrigo, MDM; de Albóniga-Chindurza, A; Delgado-Acosta, F; Díaz Pérez, J; Escudero-Martínez, I; Fernandez Prudencio, L; Freijo Guerrero, MDM; Gamero-García, MÁ; González Díaz, E; González García, A; Hidalgo, C; Jiménez Jorge, S; Jiménez-Gómez, E; Medina-Rodríguez, M; Moniche, F; Montaner, J; Morales Caba, L; Mosteiro, S; Ortega-Quintanilla, J; Oteros Fernández, R; Pardo-Galiana, B; Ramirez Moreno, JM; Rosso Fernández, C; Sanz-Fernandez, G; Vielba-Gomez, I; Zamora, A; Zapata-Arriaza, E, 2023) |
| "SIGNIFICANCE: Thrombosis is a threat to human health, and there is an urgent need for new drug." | 5.56 | Plasma metabonomics and proteomics studies on the anti-thrombosis mechanism of aspirin eugenol ester in rat tail thrombosis model. ( Li, J; Li, S; Liu, X; Ma, N; Qin, Z; Yang, Y, 2020) |
| "The presence or absence of thrombus in the vein graft samples was recorded under light microscopy." | 5.56 | Drug-eluting Vein Graft with Acetylsalicylic Acid-Ticagrelor-Unfractionated Heparin Complex Inhibits Early Graft Thrombosis ( Akşit, E; Büyük, B; Çokkalender, Ö; Kurt, T, 2020) |
| "Clopidogrel is recommended in international guidelines to prevent arterial thrombotic events in patients with peripheral arterial disease (PAD)." | 5.51 | CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD). ( Adang, E; Coenen, M; Deneer, V; Donders, R; Kramers, C; Kranendonk, J; Reijnen, M; Vijver-Coppen, RV; Warlé, MC; Willems, LH; Zeebregts, CJ, 2022) |
| "Only aspirin nonresponders were early identified by repeating the aggregometry after 7 days of aspirin administration." | 5.51 | Early Aspirin Nonresponders Identification by Routine Use of Aggregometry Test in Patients With Left Ventricle Assist Devices Reduces the Risk of Pump Thrombosis. ( Cammardella, A; Comisso, M; Gherli, R; Montalto, A; Musumeci, F; Nicolò, F; Palermo, A; Pulcinelli, F, 2019) |
| "Aspirin resistance was measured by the PFA-100 system (collagen/epinephrine cartridge) and glycoprotein IIIa P1A1/A2 polymorphism was determined by PCR." | 5.43 | Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients. ( Ataç, BF; Bayraktar, N; Can, U; Çelikkol, C; Derle, E; Kibaroğlu, S; Öcal, R; Verdi, H, 2016) |
| "7, p NS], and in adverse cardiac or cerebrovascular events (MACCE) (5 vs." | 5.42 | Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. ( Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M, 2015) |
| "Most parameters of thrombus formation under flow were similarly high for the patient and control groups." | 5.42 | Normal platelet activation profile in patients with peripheral arterial disease on aspirin. ( Baaten, CC; Clemetson, KJ; Cosemans, JM; de Laat, B; Heemskerk, JW; Kleinegris, MC; Roest, M; Ten Cate, H; van Geffen, JP; Verdoold, R, 2015) |
| " Antiplatelet drugs such as aspirin and P2Y12 inhibitors are commonly used to reduce the risk of thrombotic events, including myocardial infarction, stroke, and stent thrombosis." | 5.41 | Personalised antiplatelet therapies for coronary artery disease: what the future holds. ( Angiolillo, DJ; Capodanno, D, 2023) |
| "Dual antiplatelet therapy with aspirin and P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction (STEMI) has been shown to be associated with better outcomes." | 5.41 | Effectiveness and Safety of P2Y12 Inhibitor Pretreatment for Primary PCI in STEMI: Systematic Review and Meta-analysis. ( Aguiar, C; Albuquerque, F; Almeida, M; Ferreira, J; Gomes, DA; Mendes, M; Presume, J; Uva, MS, 2023) |
| "The efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valves and atrial fibrillation or flutter remain uncertain." | 5.41 | A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. ( Almeida, AP; Ardito, RV; Atik, FA; Barreto, DO; Berwanger, O; Campos, VB; Cavalcante, MA; Cavalcanti, AB; D'Oliveira Vieira, R; Damiani, L; de Barros E Silva, PGM; de Lima, CEB; de Souza Neto, JD; Dos Santos, JRY; Farias, FR; Ferreira, JFM; Figueira, FAMS; Fonseca, FH; Guimarães, HP; Hoffmann-Filho, CR; Junior, RA; Kalil, PSA; Kojima, F; Lamprea, D; Laranjeira, L; Leiria, TLL; Liporace, IL; Lopes, RD; Magalhães, CC; Maldonado, JGA; Mesas, CE; Moisés, VA; Nakagawa, RH; Paiva, MSMO; Paixão, M; Patriota, R; Pavanello, R; Pinto, IM; Precoma, DB; Sampaio, BS; Sampaio, RO; Saraiva, JFK; Silveira, FS; Tarasoutchi, F; Zilli, AC, 2021) |
| "We evaluated patients from the Atrial Fibrillation and Ischaemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial who received rivaroxaban plus an antiplatelet agent; the choice of antiplatelet agent was left to the physician's discretion." | 5.41 | Aspirin versus P2Y ( Akao, M; Ako, J; Fukaya, H; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamra, M; Ogawa, H; Yasuda, S, 2021) |
| "Stent thrombosis is a morbid complication after percutaneous coronary intervention." | 5.40 | Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. ( Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J, 2014) |
| "Once-daily aspirin is standard treatment, but recent studies point towards increased platelet function at the end of the dosing interval." | 5.40 | 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. ( Grove, EL; Hvas, AM; Jensen, LO; Kaltoft, AK; Kristensen, SD; Tilsted, HH; Würtz, M, 2014) |
| "Thrombosis is the main cause of failure of small-diameter synthetic vascular grafts when used for by-pass procedures." | 5.39 | Aspirin-loaded electrospun poly(ε-caprolactone) tubular scaffolds: potential small-diameter vascular grafts for thrombosis prevention. ( Baiguera, S; Bianco, A; Del Gaudio, C; Ercolani, E; Galloni, P; Polizzi, L; Santilli, F, 2013) |
| "Aspirin has a beneficial role in prevention of cardiovascular and thromboembolic events." | 5.38 | High frequency of aspirin resistance in patients with nephrotic syndrome. ( Agbaht, K; Akoglu, H; Dede, F; Falay, MY; Odabas, AR; Ozet, G; Piskinpasa, S, 2012) |
| "Dyspnea was diagnosed in 157 (4." | 5.35 | Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting. ( Atar, D; Kuliczkowski, W; Pokov, I; Serebruany, V; Vahabi, J, 2008) |
| "Stent thrombosis is a feared complication of percutaneous coronary intervention." | 5.35 | Catastrophic early drug eluting stents thrombosis and aspirin hypersensitivity. ( Di Bella, G; Marte, F; Patanè, S, 2008) |
| "Among patients undergoing TAVI who did not have an indication for oral anticoagulation, the incidence of bleeding and the composite of bleeding or thromboembolic events at 1 year were significantly less frequent with aspirin than with aspirin plus clopidogrel administered for 3 months." | 5.34 | Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. ( Baan, J; Brouwer, J; Buysschaert, I; Chan Pin Yin, DRPP; De Bruyne, B; Delewi, R; Dubois, CLF; Ferdinande, B; Frambach, P; Hermanides, RS; Holvoet, W; Kelder, JC; Nijenhuis, VJ; Peper, J; Rensing, BJWM; Roosen, J; Schotborgh, CE; Stella, PR; Swaans, MJ; Ten Berg, JM; Thielen, FWF; Timmers, L; Toušek, P; van 't Hof, AWJ; van der Harst, P; Van Der Heyden, JAS; van der Kley, F; van Houwelingen, GK; Veenstra, L, 2020) |
| " Low-dose razaxaban was useful in combination with sub-optimal doses of aspirin and/or clopidogrel for the prevention of occlusive arterial thrombosis without excessive bleeding." | 5.34 | Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. ( Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC, 2007) |
| "Thalidomide has been associated with venous thrombotic events, as reported in the post-marketing surveillance reports by Celgene Corporation; as well as case reports in the literature." | 5.33 | Arterial thrombosis in four patients treated with thalidomide. ( Brown, K; Chanan-Khan, A; Hahn, T; McCarthy, PL; Paplham, P; Roy, H; Scarpace, SL; van Besien, K, 2005) |
| "Thrombosis was achieved by perfusion of human and murine blood through type III collagen-coated capillaries at arterial shear rate." | 5.32 | Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. ( André, P; Conley, PB; Delaney, SM; LaRocca, T; Lin, PH; Phillips, DR; Sinha, U; Vincent, D, 2003) |
| "However, systemic study of thrombus formation in vein grafts is still lacking, and few effective techniques are available to prevent this event." | 5.32 | Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection. ( Hu, Y; Mayr, U; Thompson, WD; Torsney, E; Xu, Q; Zou, Y, 2004) |
| "Main parameter was thrombus weight." | 5.32 | Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004) |
| "Long-term ticagrelor monotherapy following 1-month DAPT can favorably balance ischemic and bleeding risks in patients with multivessel PCI." | 5.30 | Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. ( Carrie, D; Chang, CC; Chichareon, P; Chowdhary, S; de Winter, RJ; Eitel, I; Garg, S; Hamm, C; Kogame, N; Magro, M; Modolo, R; Ong, P; Onuma, Y; Ottesen, MM; Serruys, PW; Steg, PG; Stoll, HP; Takahashi, K; Tijssen, JGP; Tomaniak, M; Valgimigli, M; Vranckx, P; Windecker, S; Wykrzykowska, JJ; Zweiker, R, 2019) |
| "Thrombosis is an important limitation of metallic coronary stents, especially in smaller vessels in which shear rates are high." | 5.30 | Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. ( Eigler, NL; Forrester, JS; Ivey, PA; Jordan, RE; Kaul, S; Litvack, F; Makkar, RR; Nakamura, M; Shah, PK, 1997) |
| "Aspirin and heparin were embedded in chitosan/polyethylene vinyl acetate co-matrix to develop a prolonged release form." | 5.30 | Development of chitosan/polyethylene vinyl acetate co-matrix: controlled release of aspirin-heparin for preventing cardiovascular thrombosis. ( Chandy, T; Sharma, CP; Vasudev, SC, 1997) |
| "Aspirin was not administered to the remaining 175 patients." | 5.30 | Low-dose aspirin therapy is associated with few side effects but does not prevent hepatic artery thrombosis in liver transplant recipients. ( Birnbaum, A; Boccagni, P; Bodenheimer, HC; Chodoff, L; Freni, MA; Miller, CM; Mor, E; Schwartz, ME; Wolf, DC, 1997) |
| "Venous thrombosis was reduced 56% by oral soluble acetylsalicylic acid and 27% by oral aspirin." | 5.30 | Some effects of prophylactic aspirins and heparins on concurrent arterial and venous thrombosis in the same animal. ( Iomhair, MM; Lavelle, SM, 1998) |
| "This produced an occlusive thrombus in all vehicle-treated ferrets within 41 +/- 3 min with an average weight of 8 +/- 1 mg (n = 7)." | 5.29 | A ferret model of electrical-induction of arterial thrombosis that is sensitive to aspirin. ( Durham, SK; Megill, JR; Schumacher, WA; Steinbacher, TE, 1996) |
| "Thrombus was formed within seconds after laser injury and grew rapidly." | 5.29 | Antithrombotic effects of aspirin and LMWH in a laser-induced model of arterials and venous thrombosis. ( Aguejouf, O; Doutremepuich, C; Doutremepuich, F; Imbault, P, 1996) |
| "Ellagic acid trebled mean thrombus weight and ASA/D reduced this by 49%, but did not restore normality." | 5.29 | Effect of aspirin-dipyridamole and heparin and their combination on venous thrombosis in hypercoagulable or thrombotic animals. ( Iomhair, MM; Lavelle, SM, 1996) |
| "injection inhibited thrombus formation in small mesenteric vessels for more than 12 hours but less than 24 hours." | 5.28 | [Evaluation of the antithrombotic effects of pentoxifylline, acetylsalicylic acid and low molecular weight heparin in the laser model of thrombosis]. ( Bielawiec, M; Breddin, HK; Krupiński, K; Płonowski, A, 1992) |
| "Thrombosis was induced in 18 dog and 16 rabbit arteries by surgically inverting a vascular wall flap into its lumen." | 5.28 | Local prevention of thrombosis in animal arteries by means of magnetic targeting of aspirin-loaded red cells. ( Akchurin, RS; Belyaev, AA; Orekhov, AN; Orekhova, NM; Ragimov, SE; Smirnov, MD, 1990) |
| "The Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET) study is a multi-center double-blind randomized controlled trial enrolling patients who have undergone multi-vessel CABG with at least one saphenous vein graft." | 5.27 | Impact of ticagrelor versus aspirin on graft patency after CABG: Rationale and design of the TARGET (ticagrelor antiplatelet therapy to reduce graft events and thrombosis) randomized controlled trial (NCT02053909). ( Abreu, AM; Boronat, V; Kouchoukos, NT; Kulik, A; Ruel, M, 2018) |
| "These results suggest that patients who have undergone EVT have similar risks for major and life-threatening bleeding events with edoxaban and aspirin compared with clopidogrel and aspirin." | 5.27 | Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. ( Adams, G; Ansel, G; Baumgartner, I; Grosso, M; Jaff, M; Lin, M; Mercur, MF; Minar, E; Moll, F; Nwachuku, C; Rundback, J; Tangelder, M; Zeller, T, 2018) |
| " Thrombin, at a dosage producing a fibrinogen consumption of 70% within 4 h (1 unit/kg/min), failed to produce extrapulmonary microthrombi unless fibrinolysis inhibition (epsilon-aminocaproic acid-EACA) or alpha-adrenergic stimulation (norepinephrine) were provided simultaneously." | 5.27 | Vasoactive agents and production of thrombosis during intravascular coagulation 1--comparative effects of norepinephrine in thrombin and adenosine diphosphate (ADP) treated rabbits. ( Daoust-Fiorilli, J; Latour, JG; Léger-Gauthier, C, 1984) |
| "1 Acute thrombosis was induced in the carotid arteries of anaesthetized rabbits by local electrical stimulation (1 mA for 2 min) of the vessel wall." | 5.27 | Acute arterial thrombosis in rabbits: reduced platelet accumulation after treatment with dazoxiben hydrochloride (UK 37,248-01). ( Randall, MJ; Wilding, RI, 1983) |
| "A high dose (200 mg/kg) did not inhibit thrombus formation whereas a low dose (20 mg/kg) reduced the incidence of occlusion and the mean thrombus weight." | 5.26 | Effects of 6-[p-(4-phenylacetylpiperazin-l-yl)-phenyl]-4,5-dihydro-3(2H)-pyridazinone (CCl 17810) and aspirin on experimental arterial thrombosis in rats. ( Kumar, A; Lecker, D, 1980) |
| "The aim of this study was to compare aspirin plus clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the prevention of ischemic events, bleeding events, and death." | 5.24 | Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi ( Al-Qoofi, F; Chamandi, C; Côté, M; Dumont, E; Garcia Del Blanco, B; Généreux, P; Maluenda, G; Masson, JB; Paradis, JM; Pelletier, M; Rodés-Cabau, J; Serra, V; Thoenes, M; Webb, JG; Welsh, RC, 2017) |
| " It was designed to test whether low dose rivaroxaban as an antithrombotic agent is as safe as aspirin in patients with acute coronary syndromes (ACS)." | 5.24 | [After the GEMINI-ACS-1 trial]. ( Yılmaz, MB, 2017) |
| "Tranexamic acid reduces the risk of bleeding among patients undergoing cardiac surgery, but it is unclear whether this leads to improved outcomes." | 5.24 | Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. ( Bussières, JS; Byrne, K; Chan, MT; Cooper, DJ; Forbes, A; Jayarajah, M; Landoni, G; Marasco, S; McGuinness, S; McNeil, J; Myles, PS; Painter, T; Silbert, B; Smith, JA; Wallace, S, 2017) |
| "Our results suggest that aspirin might be equally effective as warfarin in preventing thromboembolic events after BAVR, but with less major bleedings." | 5.24 | Antithrombotic therapy after bioprosthetic aortic valve implantation: Warfarin versus aspirin, a randomized controlled trial. ( Køber, L; Lilleør, NB; Lund, JT; Møller, CH; Olsen, PS; Rafiq, S; Steinbrüchel, DA; Thiis, JJ, 2017) |
| "In the PRODIGY trial, prolonging clopidogrel-based DAPT beyond six months in elderly patients increased the risk of bleeding, without affording a significant prevention of ischaemic events." | 5.24 | Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. ( Ariotti, S; Franzone, A; Gargiulo, G; Heg, D; Magnani, G; Marino, M; Piccolo, R; Santucci, A; Tebaldi, M; Valgimigli, M; Windecker, S, 2017) |
| " Aspirin affects platelet function by irreversibly inhibiting cyclooxygenase activity, reducing the risk of thrombosis." | 5.22 | The Effect of Aspirin on the Prevention of Pro-thrombotic States in Hospitalized COVID-19 Patients: Systematic Review. ( Abadi, SSD; Abdi, M; Lamardi, ZH; Massoudi, N; Mohammadi, L; Nasiri, MJ; Shirjan, F; Zangiabadian, M, 2022) |
| "P2Y12 inhibitors, including aspirin, are key components of dual-antiplatelet therapy (DAPT), which is the optimal therapeutic strategy for preventing arterial thrombosis in patients with acute coronary syndromes (ACS) who underwent stent implantation." | 5.22 | A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases. ( Chen, C; Chen, Z; Gu, X; Liu, W; Mao, X; Ren, S; Tao, L; Zhang, L; Zhao, Y, 2022) |
| " One study (CAPRIE; ASA versus clopidogrel) included patients diagnosed with hypertension (mean age 62." | 5.22 | Antiplatelet agents and anticoagulants for hypertension. ( Kozieł-Siołkowska, M; Lip, GY; Shantsila, E, 2022) |
| " The prediction rule assigned 1 point each for myocardial infarction at presentation, prior myocardial infarction or PCI, diabetes, stent diameter less than 3 mm, smoking, and paclitaxel-eluting stent; 2 points each for history of congestive heart failure/low ejection fraction and vein graft intervention; -1 point for age 65 to younger than 75 years; and -2 points for age 75 years or older." | 5.22 | Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. ( Apruzzese, PK; Camenzind, E; Cohen, DJ; Cutlip, DE; Gershlick, AH; Kereiakes, DJ; Massaro, JM; Mauri, L; Normand, SL; Rinaldi, MJ; Secemsky, EA; Song, Y; Spertus, JA; Steg, PG; Wijns, W; Yeh, RW, 2016) |
| " Patients randomized to continued thienopyridine and aspirin after 12 months had lower ischemic risk but higher bleeding risk than those treated with placebo and aspirin." | 5.22 | DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. ( Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Steg, PG; Wiviott, SD; Yeh, RW, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 5.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia." | 5.22 | Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. ( Bae, HJ; Cha, JK; Chang, DI; Cho, KH; Cho, YJ; Choi, JC; Hong, KS; Kang, DW; Kim, DE; Kim, EG; Kim, GM; Kim, HY; Kwon, SU; Lee, J; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Park, KY; Rha, JH; Sohn, CH; Sohn, SI; Yoon, BW; Yu, KH, 2016) |
| "A total of 55 patients with a history of thrombosis and SPS phenotype were prospectively studied before and after treatment with aspirin and/or clopidogrel." | 5.20 | Primary thrombophilia in México X: a prospective study of the treatment of the sticky platelet syndrome. ( García-Chavez, J; Hernández-Reyes, J; Rosales-Padrón, J; Ruiz-Arguelles, A; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Vargas-Espinosa, J; Velázquez-Sánchez-de-Cima, S; Zamora-Ortiz, G, 2015) |
| " Between 12 and 30 months, continued thienopyridine reduced stent thrombosis compared with placebo in patients with and without MI at presentation (MI group, 0." | 5.20 | Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. ( Cohen, DJ; Cutlip, DE; Gershlick, AH; Iancu, AC; Jacobs, A; Kereiakes, DJ; Massaro, JM; Mauri, L; Rinaldi, MJ; Steg, PG; Tanguay, JF; Windecker, S; Wiviott, SD; Yeh, RW, 2015) |
| "There is insufficient data on the efficacy of prasugrel and ticagrelor in Korean patients with ST-segment elevation myocardial infarction (STEMI)." | 5.20 | Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. ( Cho, YR; Guo, LZ; Jin, CD; Kim, MH; Kim, YD; Lee, YS; Park, JS; Park, K; Park, TH, 2015) |
| " Aspirin or heparin was recommended for patients at high thrombosis risk." | 5.20 | Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). ( Bartlett, NL; Blum, KA; Cheson, BD; Czuczman, M; Giguere, JK; Johnson, J; Jung, SH; Leonard, JP; Pitcher, BN, 2015) |
| "The objectives of this study are to examine the efficacy and safety of low-dose aspirin (LDA) vs LDA plus low-intensity warfarin (LDA + W) in the primary thrombosis prevention of aPL-positive patients with SLE and/or obstetric morbidity and the role of clinical and serological markers in the development of thrombosis." | 5.19 | Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). ( Aguirre, A; Akil, M; Amigo, MC; Bertolaccini, ML; Cuadrado, MJ; Egurbide, MV; Espinosa, G; Galindo, M; Gil, A; Gordon, C; Houssiau, F; Khamashta, MA; Martin, H; McHugh, N; Mico, L; Murru, V; Rahman, A; Ruiz-Irastorza, G; Seed, PT; Tektonidou, MG, 2014) |
| "(1) PF4/H antibody-positive patients suffered a significantly higher incidence of thrombosis than those who were antibody-negative; (2) PF4/H antibody-positive patients who survived a thrombosis manifested a significantly longer bleeding time and decreased maximum percentage of platelet aggregation inhibition; (3) aspirin and clopidogrel decreased the incidence of thrombosis in PF4/H antibody-positive patients by inhibiting platelet activation." | 5.19 | Inhibition of platelet activation could decrease thrombotic events in hemodialysis PF4/H antibody-positive patients. ( Chen, G; Kong, D; Ma, L; Qi, K; Shan, F; Wang, C; Yang, Y, 2014) |
| "Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding." | 5.19 | Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. ( Braunwald, E; Cohen, DJ; Cutlip, DE; Dauerman, HL; Driscoll-Shempp, P; Garratt, KN; Hermiller, J; Holmes, DR; Kandzari, DE; Kereiakes, DJ; Krucoff, MW; Lee, DP; Massaro, JM; Mauri, L; Normand, SL; Pow, TK; Rinaldi, MJ; Simon, DI; Steg, PG; Ver Lee, P; Wiviott, SD; Yeh, RW, 2014) |
| " Then, patients with no MACCE or major bleeding will be randomized to receive either 36 additional months of clopidogrel plus aspirin or aspirin only." | 5.17 | Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. ( Carrie, D; Cattan, S; Cayla, G; Eltchaninoff, H; Furber, A; Georges, JL; Helft, G; Le Feuvre, C; Leclercq, F; Metzger, JP; Prunier, F; Sebagh, L; Vicaut, E, 2013) |
| "The aim of this study was to determine if rivaroxaban is associated with a reduction in stent thrombosis among patients with acute coronary syndromes (ACS) in the ATLAS-ACS 2 TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51) trial." | 5.17 | Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. ( Bassand, JP; Bhatt, DL; Bode, C; Braunwald, E; Burton, P; Chakrabarti, AK; Cohen, M; Gibson, CM; Goto, S; Mega, J; Mohanavelu, S; Stone, G; Verheugt, FW, 2013) |
| "The results indicate that tirofiban and warfarin combined with aspirin and clopidogrel could reduce the rates of MACCE and bleeding, and it could prevent non-acute stent thrombosis safely and effectively after percutaneous coronary intervention with DES." | 5.17 | [Prevention of non-acute stent thrombosis after drug-eluting stent implantation]. ( Gao, YX; Li, L; Li, Y; Sun, TW; Yu, XZ; Yuan, YQ; Zhao, XY, 2013) |
| "Rivaroxaban, a direct factor Xa inhibitor, has demonstrated effectiveness for the management of both venous and arterial thrombosis." | 5.17 | Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber. ( Becka, M; Gouya, G; Kapiotis, S; Kubitza, D; Mueck, W; Wolzt, M, 2013) |
| " Eligible patients were those with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents." | 5.17 | Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. ( Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R, 2013) |
| "More favorable thromboprophylaxis strategies are needed in light of the difficulties in controlling warfarin therapy and the high prevalence of thrombosis in this population." | 5.17 | Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure. ( Andrew, M; Cochrane, A; Hughes, M; Manlhiot, C; McCrindle, BW; Monagle, P; Roberts, R; Szechtman, B; Weintraub, R, 2013) |
| "This study was conducted to evaluate preventive effect of a combination of heparin and aspirin on vascular thrombosis and kidney transplant outcomes of pediatric kidney transplant recipients." | 5.16 | Protective effect of heparin and aspirin against vascular thrombosis in pediatric kidney transplants. ( Esfandiar, N; Hoseini, R; Otukesh, H; Sharifian, M, 2012) |
| "A regimen of 24 months of clopidogrel therapy in patients who had received a balanced mixture of drug-eluting or bare-metal stents was not significantly more effective than a 6-month clopidogrel regimen in reducing the composite of death due to any cause, myocardial infarction, or cerebrovascular accident." | 5.16 | Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. ( Borghesi, M; Campo, G; Cangiano, E; Castriota, F; Cavazza, C; Colombo, F; Ferrari, R; Frangione, A; Fucà, G; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P, 2012) |
| "Aspirin resistance and chronic renal failure are both potentially important clinical issues in coronary artery disease." | 5.16 | Renal function and aspirin resistance in patients with coronary artery disease. ( Blann, AD; Kuzniatsova, N; Lip, GY; Velu, S, 2012) |
| "Clopidogrel is recommended in addition to aspirin to prevent atherothrombotic events in patients with acute coronary syndromes (ACS) and in those undergoing percutaneous coronary intervention (PCI)." | 5.16 | The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population. ( de la Peña, NC; Isordia-Salas, I; Olalde-Román, MJ; Santiago-Germán, D; Valencia-Sánchez, JS, 2012) |
| " Thrombus area was measured in T2DM and non-diabetic patients receiving aspirin and clopidogrel 7-10 days after troponin positive Non ST-elevation acute coronary syndrome (NSTE-ACS)." | 5.16 | Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina. ( Badimon, JJ; Balasubramaniam, K; Marshall, SM; Schechter, CB; Viswanathan, GN; Zaman, AG, 2012) |
| "The aim of this study was to assess the degree of platelet inhibition by adjunctive cilostazol in patients with acute myocardial infarction (AMI) according to hepatic cytochrome P450 2C19 (CYP2C19) genotype." | 5.15 | Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. ( Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Kwak, CH; Park, JR; Park, KS; Park, Y; Yun, SE, 2011) |
| "The goal of this study was to investigate whether omega-3 polyunsaturated fatty acids (n-3 PUFA) are able to alter plasma fibrin clot properties and reduce thrombin formation in stable coronary artery disease patients undergoing percutaneous coronary intervention (PCI)." | 5.15 | Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). ( Gajos, G; Nessler, J; Piwowarska, W; Rostoff, P; Undas, A; Zalewski, J, 2011) |
| "This was a prospective observational study of 15 532 patients enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial who were randomly assigned to clopidogrel or placebo, and followed-up for a median of 28 months for the occurrence of the primary endpoint (cardiovascular death, myocardial infarction, or stroke), all-cause mortality, and bleeding complications." | 5.14 | The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. ( Bhatt, DL; Fox, KA; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2009) |
| "This multicenter registry documents satisfactory safety and efficacy profiles, as evidenced by low rates of major adverse cardiac events and stent thrombosis up to 18 months, for the Excel biodegradable polymer-based sirolimus-eluting stent when used with 6 months of dual antiplatelet therapy in a "real-world" setting." | 5.14 | Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. ( Chen, X; Gao, R; Han, Y; Jiang, T; Jing, Q; Li, H; Li, Y; Li, Z; Liu, H; Liu, Y; Qiu, J; Shang, X; Xu, B; Yang, L; Zhang, H, 2009) |
| "Thirty-two high risk acute coronary syndrome patients were randomised to bivalirudin and provisional GPIIb/IIIa inhibition (GPIIb/IIIa) or unfractionated heparin (UFH) and mandatory GPIIb/IIIa." | 5.14 | A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagu ( Bett, N; Juneja, M; Ray, MJ; Walters, DL, 2009) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 5.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "The use of dual antiplatelet therapy for a period longer than 12 months in patients who had received drug-eluting stents was not significantly more effective than aspirin monotherapy in reducing the rate of myocardial infarction or death from cardiac causes." | 5.14 | Duration of dual antiplatelet therapy after implantation of drug-eluting stents. ( Chae, JK; Cheong, SS; Choi, YJ; Chung, WS; Han, KH; Hur, SH; Jang, JS; Jeon, DS; Jeong, MH; Kang, SJ; Kim, KS; Kim, YH; Lee, BK; Lee, CW; Lee, K; Lee, NH; Lee, SG; Lee, SW; Lim, DS; Nah, DY; Park, DW; Park, HS; Park, SJ; Park, SW; Rha, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2010) |
| "In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel." | 5.14 | Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR ( Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2010) |
| " Major hemorrhages were observed more frequently in the combination (warfarin plus low-dose aspirin) therapy group than in the warfarin monotherapy group." | 5.14 | [Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin]. ( Aleksandrova, EN; Kondrat'eva, LV; Kovalenko, TF; Ostriakova, EV; Patrushev, LI; Patrusheva, NL; Reshetniak, TM, 2010) |
| " 25,086 individuals with acute coronary syndromes and intended early PCI were randomly assigned to double-dose (600 mg on day 1, 150 mg on days 2-7, then 75 mg daily) versus standard-dose (300 mg on day 1 then 75 mg daily) clopidogrel, and high-dose (300-325 mg daily) versus low-dose (75-100 mg daily) aspirin." | 5.14 | Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. ( Ajani, AE; Avezum, A; Bassand, JP; Budaj, A; Chrolavicius, S; Di Pasquale, G; Eikelboom, JW; Faxon, DP; Fox, KA; Gao, P; Granger, CB; Jolly, SS; Joyner, CD; Macaya, C; Mehta, SR; Montalescot, G; Niemela, K; Rupprecht, HJ; Steg, PG; Tanguay, JF; White, HD; Widimsky, P; Yusuf, S, 2010) |
| "1% male) patients receiving 300 mg daily enteric coated aspirin for at least 7 days with documented coronary artery disease were included in the study." | 5.13 | Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions. ( Aydinalp, A; Ertan, C; Gulmez, O; Kaynar, G; Konas, D; Muderrisoglu, H; Ozin, B; Yildirir, A, 2008) |
| "Although clopidogrel is a frequently used antiplatelet medication to treat and prevent atherothrombotic disease, clinicians must balance its clinical effectiveness with the potential side effect of bleeding." | 5.12 | Risk Factors for Bleeding and Clinical Ineffectiveness Associated With Clopidogrel Therapy: A Comprehensive Meta-Analysis. ( Duong, K; Eadon, MT; Fekete, K; Kenneally, A; Milway, E; Nguyen, KA; Oh, H; Schleyer, TK; Whipple, EC; Yoo, R, 2021) |
| "Aspirin combined with LMWH for APS may improve live birth rate, and detection of d-dimer levels in APS pregnant women may predict pregnancy complications and guide the use of anticoagulants." | 5.12 | Meta-analysis on aspirin combined with low-molecular-weight heparin for improving the live birth rate in patients with antiphospholipid syndrome and its correlation with d-dimer levels. ( Diao, QZ; Gu, ZD; Shi, T, 2021) |
| "For prevention of stroke in patients with NVAF, aspirin at 150 to 200 mg per day does not seem to be either effective or safe." | 5.12 | Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. ( Doi, Y; Fukuyama, T; Hiramori, K; Hori, M; Ishikawa, K; Izumi, T; Kitabatake, A; Maruyama, Y; Matsumoto, M; Mochizuki, S; Ogawa, S; Origasa, H; Sato, H; Takekoshi, N; Uchiyama, S; Yamaguchi, T; Yokota, Y; Yoshida, K, 2006) |
| "It was the objective of this study to compare the antithrombotic effects and bleeding profiles of the oral direct thrombin inhibitor ximelagatran, an anticoagulant, and the antiplatelet agent clopidogrel on top of steady-state acetylsalicylic acid (ASA) in a human arterial thrombosis model." | 5.12 | Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. ( Badimon, JJ; Bylock, A; Elg, M; Eriksson, UG; Eriksson-Lepkowska, M; Kalies, I; Nyström, P; Sarich, TC; Wåhlander, K, 2006) |
| " Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes." | 5.12 | Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. ( Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Booth, J; Brennan, DM; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA, 2006) |
| "Thrombocytopenia, though uncommon, was associated with orbofiban use and an increased risk of bleeding, but also death and MI." | 5.12 | Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. ( Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM, 2006) |
| "In an analysis of the Melagatran Thrombosis Prophylaxis in Orthopedic Surgery (METHRO) III study, we evaluated whether concomitant administration of aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) with the direct thrombin inhibitor melagatran/ximelagatran or the low-molecular-weight heparin enoxaparin increased bleeding in patients undergoing major joint surgery." | 5.12 | Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty. ( Agnelli, G; Andersson, M; Bylock, A; Cohen, AT; Dahl, OE; Eriksson, BI; Mouret, P; Ogren, M; Panfilov, S; Rosencher, N, 2006) |
| "To determine the efficacy of a daily dose of 81 mg aspirin in primary thrombosis prevention in asymptomatic, persistently antiphospholipid antibody (aPL)-positive individuals (those with positive aPL but no vascular and/or pregnancy events)." | 5.12 | Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. ( Erkan, D; Harrison, MJ; Levy, R; Lockshin, MD; Peterson, M; Petri, M; Sammaritano, L; Unalp-Arida, A; Vilela, V; Yazici, Y, 2007) |
| "To assess efficacy and safety of warfarin therapy and its combination with low-dose acetylsalicylic acid (ASA) in antiphospholipid syndrome (APS)." | 5.12 | [Warfarin in the treatment of antiphospholipid syndrome]. ( Kondrat'eva, LV; Patrushev, LI; Patrusheva, NL; Reshetniak, TM, 2007) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 5.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| "Low-response to the P2Y12 adenosine diphosphate (ADP)-receptor antagonist clopidogrel was suggested to correspond to a higher incidence of stent thrombosis (ST)." | 5.12 | The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. ( Blindt, R; de Taeye, A; Hoffmann, R; Kelm, M; Kiefer, P; Müller, R; Stellbrink, K; Weber, C; Yagmur, E, 2007) |
| "The early results of this WoA Epic pilot trial did not support the suggestion that patients receiving the SJEP, and tissue valves in general, should be administered warfarin to prevent valve thrombosis and peripheral arterial embolic phenomena." | 5.12 | Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. ( Castella, M; Colli, A; Gherli, T; Mestres, CA, 2007) |
| "The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial." | 5.11 | Efficacy and safety of low-dose aspirin in polycythemia vera. ( Barbui, T; Gisslinger, H; Kutti, J; Landolfi, R; Marchioli, R; Patrono, C; Tognoni, G, 2004) |
| "The Antiphospholipid Antibodies and Stroke Study (APASS), a prospective cohort study within the Warfarin vs Aspirin Recurrent Stroke Study (WARSS), a randomized double-blind trial (N = 2206) conducted at multiple US clinical sites from June 1993 through June 2000 and comparing adjusted-dose warfarin (target international normalized ratio, 1." | 5.11 | Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. ( Brey, RL; Costigan, TM; Levin, B; Levine, SR; Lu, Y; Mohr, JP; Murphy, A; Rhine, C; Sacco, RL; Sciacca, RR; Thompson, JL; Tilley, BC; Triplett, DA, 2004) |
| "The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease." | 5.11 | Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. ( Bogousslavsky, J; Brass, LM; Cimminiello, C; Csiba, L; Diener, HC; Kaste, M; Leys, D; Matias-Guiu, J; Rupprecht, HJ, 2004) |
| "The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study was designed to evaluate the efficacy and safety of clopidogrel plus aspirin versus placebo plus aspirin in patients with established coronary, cerebral, or peripheral arterial disease or in patients with multiple risk factors for atherothrombosis who have not yet sustained an ischemic event." | 5.11 | Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. ( Bhatt, DL; Topol, EJ, 2004) |
| "Although full platelet inhibition with aspirin and thienopyridines before coronary stenting has significantly reduced the risk of acute stent thrombosis, peri-procedural myonecrosis still occurs frequently and is associated with increased death rate." | 5.11 | Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. ( Bosmans, JM; Claeys, MJ; Michiels, JJ; Van Der Goten, P; Van der Planken, MG; Vertessen, F; Vrints, CJ; Wuyts, FL, 2005) |
| "We compared the effects of ticlopidine and cilostazol on the prevention of subacute stent thrombosis (SAT) in acute myocardial infarction (AMI) patients with stenting." | 5.11 | Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. ( Adachi, K; Kataoka, T; Kawata, M; Kuramoto, E; Matsuura, A; Saito, A; Sakamoto, S, 2005) |
| "The aim of this study was to evaluate the effects of two different prophylactic protocols, low-dose aspirin and fish oil derivates, in the treatment of patients with recurrent pregnancy loss associated with antiphospholipid antibodies (APA) syndrome." | 5.11 | Recurrent miscarriage associated with antiphospholipid antibodies: prophylactic treatment with low-dose aspirin and fish oil derivates. ( Carta, G; Falciglia, K; Iovenitti, P, 2005) |
| "0 in 52 patients or aspirin alone, 100 mg day(-1) in three patients) to determine whether intensive anticoagulation is superior to standard treatment in preventing symptomatic thromboembolism without increasing the bleeding risk." | 5.11 | A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). ( Barbui, T; Baudo, F; Berrettini, M; Brancaccio, V; D'Angelo, A; Finazzi, G; Marchioli, R; Musial, J; Schinco, P; Testa, S; Tognoni, G; Wisloff, F, 2005) |
| " As compared with hydroxyurea plus aspirin, anagrelide plus aspirin was associated with increased rates of arterial thrombosis (P=0." | 5.11 | Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. ( Bareford, D; Buck, G; Campbell, PJ; East, CL; Green, AR; Grigg, AP; Harrison, CN; Reilly, JT; Revell, P; van der Walt, JD; Wheatley, K; Wilkins, BS; Woodcock, BE, 2005) |
| "The Thrombosis Prevention Trial was a primary prevention factorial trial that reported a reduction in the risk of coronary heart disease (CHD) with warfarin and/or aspirin." | 5.10 | Thrombosis prevention trial: compliance with warfarin treatment and investigation of a retained effect. ( Ashby, D; Brennan, P; Meade, T; Rudnicka, AR, 2003) |
| " The aim of this study was to assess the practical implications of the results of the placebo-controlled primary prevention thrombosis prevention trial, in which the active treatment regimens were combined warfarin and aspirin, warfarin alone, and aspirin alone." | 5.10 | Thrombosis prevention trial: follow-up study of practical implications. ( Brennan, PJ; Fasey, N; Meade, TW, 2002) |
| " We studied the antithrombotic efficacy of the vitamin K antagonist fluindione in a human ex vivo model of arterial thrombosis and determined whether aspirin enhances fluindione efficacy." | 5.09 | Antithrombotic efficacy of the vitamin K antagonist fluindione in a human Ex vivo model of arterial thrombosis : effect of anticoagulation level and combination therapy with aspirin. ( Boneu, B; Bossavy, JP; Cadroy, Y; Sakariassen, KS; Thalamas, C, 1999) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 5.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| "We conducted a double-blind, randomized, crossover study to assess the antithrombotic effects of the combination of aspirin (acetylsalicylic acid, ASA) and clopidogrel, with or without a loading dose, versus ASA alone in a model of arterial thrombosis in humans." | 5.09 | Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. ( Boneu, B; Bossavy, JP; Cadroy, Y; Sagnard, L; Sakariassen, K; Thalamas, C, 2000) |
| " We conducted a pilot study to evaluate the use of the platelet GP IIb/IIIa receptor antagonist abciximab versus aspirin in conjunction with thrombolysis in patients with acute peripheral occlusive arterial disease associated with arterial thrombosis." | 5.09 | Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis. ( Forkmann, L; Hellner, G; Kirch, W; Koch, R; Müller, A; Schweizer, J, 2000) |
| " Combined warfarin and aspirin therapy was associated with greater fecal hemoglobin excretion than standard warfarin therapy, suggesting the potential for increased gastrointestinal hemorrhage." | 5.08 | Fecal hemoglobin excretion in elderly patients with atrial fibrillation: combined aspirin and low-dose warfarin vs conventional warfarin therapy. ( Ahlquist, DA; Baker, VS; Blackshear, JL; Ellefson, R; Hart, RG; Holland, A; Koehler, J; Litin, SC, 1996) |
| "Previous studies have shown that stents can be inserted in coronary arteries of patients who are subsequently treated safely with antiplatelet therapy only (ticlopidine and/or aspirin) with a low incidence of stent thrombosis, provided that stent expansion is adequate and there are no other flow-limiting lesions present." | 5.08 | Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. ( Albiero, R; Blengino, S; Colombo, A; Ferraro, M; Hall, P; Itoh, A; Martini, G; Nakamura, S, 1997) |
| "As compared with aspirin alone and a combination of aspirin and warfarin, treatment with aspirin and ticlopidine resulted in a lower rate of stent thrombosis, although there were more hemorrhagic complications than with aspirin alone." | 5.08 | A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. ( Baim, DS; Cutlip, DE; Diver, DJ; Giambartolomei, A; Gordon, PC; Ho, KK; Kuntz, RE; Lasorda, DM; Leon, MB; Pocock, SJ; Popma, JJ; Williams, DO, 1998) |
| "Data from the early stages of the thrombosis prevention trial (TPT) have been used to establish and quantify the risk of extracranial bleeding due to low dose aspirin (75 mg) and low intensity oral anticoagulation with warfarin (international normalised ratio, INR, 1." | 5.07 | Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. ( Brennan, PJ; Kelleher, CC; Meade, TW; Roderick, PJ; Wilkes, HC, 1992) |
| "We carried out a pilot study in 15 hemodialysis patients with recurrent vascular access thrombosis to examine whether the combination of low dose aspirin (85 mg once daily) and sulfinpyrazone (200 mg three times daily) is safe and effective in the prevention of vascular access thrombosis." | 5.07 | Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. ( Bauman, JE; Domoto, DT; Joist, JH, 1991) |
| " In addition, among HBR patients, (i) new recommendations prefer direct oral anticoagulants (DOAC) over vitamin K antagonists in DOAC-eligible patients with atrial fibrillation and coronary artery disease; (ii) measures to minimize bleedings while on DAPT should be pursued, including de-escalation of P2Y12 receptor inhibitor therapy; and (iii) new studies are testing reversal strategies for short DAPT regimens, with early discontinuation of aspirin." | 5.05 | [Short dual antiplatelet therapy: how, when and why]. ( Carrozzi, C; Ditali, V; Leonardi, S, 2020) |
| " In patients with previous myocardial infarction completing at least 1 year of DAPT, continuing DAPT with a reduced dose of ticagrelor 60 mg BID is a regimen to be considered for these patients; in general ACS patients, a reduced dose of 60 mg BID of ticagrelor after the first year of DAPT should be considered; and in the post-percutaneous coronary intervention patients, DAPT beyond 1 year should be considered after careful evaluation of the patient's thrombotic and bleeding risks." | 5.05 | Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events. ( Dobesh, PP; Finks, SW; Trujillo, TC, 2020) |
| "The MRC Epidemiology Unit in Cardiff, Wales conducted three randomized, controlled trials of aspirin use in patients who had had myocardial infarction." | 5.05 | British studies of aspirin and myocardial infarction. ( Elwood, PC, 1983) |
| "Since platelet cyclo-oxygenase is much more sensitive to inactivation by aspirin than is the enzyme in the arterial wall and low doses of aspirin may prevent thrombosis by blocking thromboxane synthesis, we conducted a randomized, double-blind trial of aspirin (160 mg per day) vs." | 5.04 | Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. ( Anderson, CB; Burch, JW; Delmez, JA; Harter, HR; Majerus, PW; Stanford, N; Weerts, CA, 1979) |
| "In this analysis, we aimed to systematically compare stent thrombosis (ST) and its different subtypes following treatment with DAPT (aspirin + clopidogrel) versus TAPT (aspirin + clopidogrel + cilostazol)." | 4.98 | Stent thrombosis associated with drug eluting stents on addition of cilostazol to the standard dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis of published randomized controlled trials. ( Huang, F, 2018) |
| "The Dual Antiplatelet Therapy (DAPT) study demonstrated that DAPT beyond 1-year after drug-eluting stent (DES) implantation, as compared with aspirin therapy alone, significantly reduced the risk of major cardiovascular and cerebrovascular events, which was mainly driven by the large risk reduction for myocardial infarction (MI)." | 4.95 | Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration. ( Kimura, T; Morimoto, T; Natsuaki, M; Shiomi, H; Toyota, T, 2017) |
| " The combination of aspirin and a P2Y12 inhibitor in patients who receive a coronary stent reduces the rate of stent thrombosis and the rates of major adverse cardiovascular events." | 4.95 | The role of prasugrel in the management of acute coronary syndromes: a systematic review. ( Athanasiou, A; Damaskos, C; Moris, D; Politou, M; Spartalis, E; Spartalis, M; Tzatzaki, E, 2017) |
| "The relative bleeding risk of aspirin versus vitamin K antagonists (VKA) is unclear." | 4.95 | Meta-analysis of major bleeding events on aspirin versus vitamin K antagonists in randomized trials. ( Ambrosi, P; Daumas, A; Giorgi, R; Villani, P, 2017) |
| "The use of low-dose aspirin and heparinoids has improved the pregnancy outcome in obstetric antiphospholipid syndrome (APS)." | 4.93 | The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. ( Branch, DW; Hunt, BJ; Khamashta, M; Levy, RA; Middeldorp, S; Pavord, S; Roccatello, D; Ruiz-Irastorza, G; Schreiber, K; Sciascia, S; Tincani, A, 2016) |
| " Current guidelines recommend various antiplatelet agents in addition to aspirin for patients with acute coronary syndromes." | 4.93 | The pharmacodynamics of antiplatelet compounds in thrombosis treatment. ( Geraldine, P; Jayakumar, T; Sheu, JR; Yang, CH; Yen, TL, 2016) |
| "With the introduction of thalidomide and multi-agent chemotherapy in the treatment of multiple myeloma around 15years ago a strongly increased risk of venous thrombosis was observed." | 4.93 | Update of thrombosis in multiple myeloma. ( Leebeek, FW, 2016) |
| "Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically." | 4.93 | Prasugrel hydrochloride for the treatment of acute coronary syndrome patients. ( Gershlick, AH; Gunarathne, A; Hussain, S, 2016) |
| "We performed an individual patient meta-analysis to determine whether aspirin has a significant protective effect on the risk of first thrombosis among patients with antiphospholipid antibodies (aPL)." | 4.91 | Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. ( Amoura, Z; Arnaud, L; Balasch, J; Devilliers, H; Forastiero, R; Lambert, M; Lefevre, G; Martinez-Zamora, MA; Mathian, A; Pengo, V; Ruffatti, A; Tektonidou, M; Wahl, D, 2015) |
| " We found no evidence that the net benefit of aspirin increased with increasing risk of thrombosis, haemorrhage or poor functional outcome in all three trials." | 4.91 | Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta-analysis of three large randomized trials. ( Candelise, L; Chen, Z; Murray, GD; Sandercock, PA; Thompson, DD; Whiteley, WN, 2015) |
| "DAPT continued beyond 6 months after second generation DES implantation decreases stent thrombosis and myocardial infarction, but increases major bleeding and all-causes mortality compared to shorter DAPT (aspirin alone)." | 4.91 | Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials. ( Abo-Salem, E; Alsidawi, S; Effat, M; Helmy, T; Jamali, H, 2015) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 4.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "We performed a meta-analysis to determine whether aspirin has a significant protective effect on risk of first thrombosis among patients with antiphospholipid antibodies (aPL+)." | 4.90 | Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. ( Amoura, Z; Arnaud, L; Balasch, J; Cervera, R; Erkan, D; Forastiero, R; Lambert, M; Martinez-Zamora, MA; Mathian, A; Pengo, V; Ruffatti, A; Tektonidou, M; Wahl, D; Zuily, S, 2014) |
| "Despite well-documented efficacy, recurrent thrombotic event occurrences, particularly stent thrombosis, have been repeatedly demonstrated in stented patients treated with aspirin and clopidogrel." | 4.90 | Resistance to antiplatelet drugs: what progress has been made? ( Bliden, KP; Gesheff, M; Gurbel, PA; Liu, F; Tantry, US, 2014) |
| "Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor (eg, ticlopidine, clopidogrel, prasugrel, ticagrelor) reduces the risk of stent thrombosis and subsequent cardiovascular events post-PCI (number needed to treat, 33-53) and is the current standard of care." | 4.89 | Medical management after coronary stent implantation: a review. ( Banerjee, S; Brilakis, ES; Patel, VG, 2013) |
| " As part of a planned re-evaluation within 2 years, we conducted an extensive literature search encompassing all topics included in the 2010 CCS Guidelines, and concluded that there were sufficient new data to merit revisiting the guidance on antiplatelet therapy for secondary prevention in the first year after acute coronary syndrome (ACS), percutaneous coronary intervention, or coronary artery bypass grafting, and the interaction between clopidogrel and proton pump inhibitors." | 4.89 | Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. ( Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G, 2013) |
| "Dual antiplatelet therapy of clopidogrel added aspirin is an established treatment strategy to prevent recurrent ischemic event occurrence in coronary artery disease patients." | 4.89 | Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. ( Gurbel, PA; Tantry, US, 2013) |
| " The existence of a common pathophysiologic background is also suggested by the evidence that aspirin, low-molecular weight heparin (LMWH) and warfarin are recommended for the prevention and treatment of both venous and arterial thrombosis." | 4.88 | Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. ( Ageno, W; Di Minno, G; Di Minno, MN; Prandoni, P; Tufano, A, 2012) |
| "To provide a pooled estimate of the bleeding risk from randomized controlled trials (RCTs) comparing warfarin and ASA at the dose ranges recommended in evidence-based guidelines." | 4.88 | Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis. ( Crowther, M; Donadini, MP; Lim, W; Spencer, FA; Warkentin, AE, 2012) |
| " In the last few years, cilostazol, a phosphodiesterase (PDE) 3 inhibitor, has been tested in the setting of acute coronary syndromes: it exerts not only anti-platelet actions, but also pleiotropic effects, including inhibition on neointimal hyperplasia, therefore preventing both stent restenosis and thrombosis." | 4.88 | Cilostazol and primary-PCI: mirage or good alternative? ( Crea, F; D'Amario, D; Porto, I, 2012) |
| "In those who have already survived myocardial infarction (MI) or stroke, or have had a transient ischaemic episode (TIA), daily low dose aspirin (ASA) reduces the risk of recurrences by an amount that greatly exceeds the risk of serious bleeding (secondary prevention)." | 4.88 | Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents. ( Meade, T, 2012) |
| " An algorithm for the treatment of patients with erythremia is proposed along with recommendations on the use of aspirin, hydroxyurea, alpha-interpheron, and imatinib." | 4.88 | [True polycythemia: current views of pathogenesis, diagnostics and treatment]. ( Bakhteeva, TD; Kalinkina, NV; Skliannaia, EV; Taradin, GG; Vatutin, NT, 2012) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is routinely indicated in patients with acute coronary syndromes and following percutaneous coronary intervention to reduce the risk of cardiovascular mortality and ischaemic events." | 4.87 | Clopidogrel withdrawal: is there a "rebound" phenomenon? ( Curzen, N; Sambu, N; Warner, T, 2011) |
| " The withdrawal of clopidogrel earlier than 4-6 weeks after bare metal stent implantation or less than 12 months after drug-eluting stent implantation is very risky and poses a high risk of stent thrombosis and high perioperative mortality." | 4.87 | Antiplatelet therapy in the perioperative period. ( Táborský, M; Václavík, J, 2011) |
| "Clopidogrel has been used (alone or in association with aspirin) to prevent vascular complications in atherothrombotic patients, to prevent stent thrombosis (ST) in patients undergoing percutaneous coronary intervention (PCI) and as a long-term prevention of cardiovascular and cerebrovascular events." | 4.87 | Genetic determinants of on-clopidogrel high platelet reactivity. ( Campo, G; Ferrari, R; Fileti, L; Marchesini, J; Miccoli, M; Monti, M; Tebaldi, M; Valgimigli, M, 2011) |
| "Clopidogrel prevents more vascular events, including stroke, in patients with a recent myocardial infarction, stroke or peripheral vascular disease than aspirin." | 4.87 | Clopidogrel hydrogen sulphate for atrial fibrillation. ( Flaker, G; Garg, N; Rajpurohit, N, 2011) |
| "Both clopidogrel and aspirin have been shown to decrease the rate of cardiovascular events and especially stent thrombosis in patients undergoing percutaneous coronary intervention (PCI)." | 4.86 | Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. ( Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Lemesle, G; Maluenda, G; Sudre, A, 2010) |
| " We give an overview of several new antiplatelet agents that are currently investigated in secondary stroke prevention: adenosine 5'-diphosphonate receptor antagonists, cilostazol, sarpogrelate, terutroban and SCH 530348." | 4.86 | Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention. ( Diener, HC; Weber, R, 2010) |
| "The administration of dual antiplatelet therapy with aspirin and a thienopyridine for the prevention of thrombosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention is proven to reduce mortality." | 4.86 | A comparison of the metabolism of clopidogrel and prasugrel. ( Laizure, SC; Parker, RB, 2010) |
| "Aspirin (ASA) use for secondary prevention in patients with cardiovascular (CV) disease is well established through its beneficial effects on the reduction of myocardial infarction, ischemic stroke and CV mortality." | 4.86 | Aspirin for the prevention of cardiovascular morbidity. ( Haider, B; Kaluski, E; Klapholz, M; Maher, J; Sanchez-Ross, M; Waller, AH, 2010) |
| "Dual antiplatelet therapy with a thienopyridine (ticlopidine or clopidogrel) and aspirin is used to reduce the risk of late stent thrombosis and complications (myocardial infarction [MI] and death) after placement of a drug-eluting stent (DES)." | 4.86 | Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies. ( Cheng, JW; Dorsch, MP; Goldberg, T; Mohammad, RA, 2010) |
| " The efficacy of acetylsalicylic acid (ASA, aspirin) and clopidogrel in decreasing the risk of adverse events in coronary heart disease patients has been well established in the past 20 years." | 4.85 | Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working ( Arnesen, H; Budaj, A; De Caterina, R; Filipiak, K; Golanski, J; Gorski, J; Huber, K; Kristensen, SD; Kuliczkowski, W; Opolski, G; Polonski, L; Pregowski, J; Sitkiewicz, D; Watala, C; Witkowski, A; Zembala, M, 2009) |
| " Monotherapy with either aspirin or clopidogrel, reduces the rate of stroke, myocardial infarction, and cardiovascular death in patients suffering from peripheral arterial disease." | 4.85 | Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy? ( Milani, RV, 2009) |
| " Low dose aspirin should be given to every pregnant woman with antiphospholipid antibodies, with the addition of low molecular weight heparin in those with previous thrombosis, previous fetal death or failure of monotherapy with aspirin." | 4.85 | [The antiphospholipid syndrome in the 21st century]. ( Egurbide, MV; Martinez-Berriotxoa, A; Ruiz-Irastorza, G, 2009) |
| "The present review focuses on the roles of thromboxane A2 (TxA2) in arterial thrombosis, atherogenesis, vascular stent-related ischemic events and renal proteinuria." | 4.85 | Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. ( Alberts, P; Bounameaux, H; Fontana, P; Mann, J; Sakariassen, KS; Sorensen, AS, 2009) |
| " The risk of VTE is higher in multiple myeloma (MM) patients who receive thalidomide or lenalidomide, especially in combination with dexamethasone or chemotherapy." | 4.84 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. ( Anderson, KC; Attal, M; Barlogie, B; Belch, A; Bladé, J; Boccadoro, M; Bringhen, S; Cavo, M; Dimopoulos, MA; Durie, BG; Harousseau, J; Hussein, MA; Joshua, D; Knop, S; Kyle, R; Lonial, S; Ludwig, H; Morgan, GJ; Niesvizky, R; Orlowski, RZ; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Vesole, D; von Lilienfeld-Toal, M; Waage, A; Weber, D; Westin, J; Zangari, M; Zonder, JA, 2008) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is currently the standard therapy after coronary stent implantation to prevent a life-threatening stent thrombosis." | 4.84 | Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. ( Gawaz, M; Geisler, T; May, AE, 2008) |
| "The long-awaited results of the Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack (MATCH) study, a large-scale trial undertaken to evaluate the safety and efficacy of clopidogrel + aspirin for secondary prevention of stroke, have been published." | 4.83 | MATCH results: implications for the internist. ( Lutsep, HL, 2006) |
| " Clopidogrel, a potent new antiplatelet compound, is the first clinical alternative to aspirin for long-term oral treatment and prevention of arterial thrombosis." | 4.82 | Antithrombotic drugs in vascular medicine: a historical perspective. ( Schrör, K, 2003) |
| "Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina,aspirin,ticlopidine,dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004." | 4.82 | Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. ( Anand, SS; Tran, H, 2004) |
| "The current standard of care for the treatment of arterial thrombosis includes anticoagulants and three classes of antiplatelet agents--aspirin, thienopyridines and glycoprotein IIb-IIIa antagonists." | 4.82 | Therapeutic approaches in arterial thrombosis. ( Andre, P; Conley, PB; Phillips, DR; Sinha, U, 2005) |
| "To compare the risk of vascular and bleeding events in patients with nonvalvular AF treated with vitamin K -inhibiting oral anticoagulants or acetylsalicylic acid (aspirin)." | 4.81 | Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. ( Chang, Y; Connolly, S; Hart, RG; Hellemons, B; Koudstaal, PJ; Laupacis, A; Petersen, P; Singer, DE; van Walraven, C, 2002) |
| " In elective de novo lesions has shown remarkably clear lumens at follow-up angiography and intravascular ultrasound within the stented segments were observed with no lesion progression at the stent margins or thrombosis after a 2 month regimen of aspirin, and ticlopodine or clopidogrel." | 4.81 | Sirolimus-eluting stents: a review of experimental and clinical findings. ( Albiero, R; Colombo, A; Corvaja, N; Di Mario, C; Falotico, R; Stankovic, G; Takagi, T; Toutouzas, K, 2002) |
| " The combination of heparin and low-dose aspirin is effective in significantly increasing the chances of a successful pregnancy in woman with recurrent pregnancy failure associated with antiphospholipid antibodies." | 4.81 | Treatment of the antiphospholipid syndrome. ( Roubey, RA, 2002) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| " In patients with arterial or venous thrombosis, there is a high rate of recurrence during the two first years except if high-dose warfarin was used (i." | 4.80 | [Aspirin and antiphospholipid syndrome]. ( Blétry, O; Hachulla, E; Hatron, PY; Piette, AM, 2000) |
| "The gold standard for treatment of the antiphospholipid antibody syndrome (APS) after thrombosis remains high-intensity warfarin, and, in pregnancy, heparin and aspirin." | 4.80 | Treatment of the antiphospholipid antibody syndrome: progress in the last five years? ( Petri, M, 2000) |
| "Randomized trials of aspirin have been conducted in three main populations: patients with evolving acute myocardial infarction (MI), patients with a history of cardiovascular disease and apparently healthy subjects." | 4.80 | Aspirin in the treatment and prevention of cardiovascular disease. ( Buring, JE; Gaziano, JM; Skerrett, PJ, 2000) |
| "Aspirin has a well established role in the prevention of arterial thrombosis." | 4.79 | Aspirin in essential thrombocythemia: status quo and quo vadis. ( Bangerter, M; Griesshammer, M; Michiels, JJ; van Vliet, HH, 1997) |
| " These studies, in conjunction with recent histopathologic studies demonstrating plaque defects and overlying thrombosis in patients with unstable ischemia and sudden death, suggest a common mechanism for unstable angina and myocardial infarction and strongly support the rationale for antithrombotic therapy with heparin and with aspirin in the management of patients with unstable angina." | 4.77 | Thrombosis in unstable angina: angiographic aspects. ( Cowley, MJ; DiSciascio, G; Rehr, RB, 1987) |
| " The purpose of this study was to compare bleeding and thrombotic events in patients treated with cangrelor plus aspirin versus oral dual antiplatelet therapy (DAPT) while supported with VA-ECMO." | 4.31 | Comparison of clinical outcomes with cangrelor plus aspirin versus oral dual antiplatelet therapy in patients supported with venoarterial extracorporeal membrane oxygenation. ( Cohan, D; Konopka, CI; Montepara, CA; Uricchio, MN; Verlinden, NJ, 2023) |
| " In this context, the effectiveness of the new direct oral anticoagulants in antiphospholipid syndrome is debated, as well as that of low-dose aspirin for primary thromboprophylaxis." | 4.31 | Controversies in the Management of Antiphospholipid Syndrome. ( Alba Moreyra, P; de Andrade, DCO; Erkan, D; Gómez-Puerta, JA; Jara, LJ; Pons-Estel, GJ; Porta, SV, 2023) |
| "We investigated whether combination of glenzocimab, a GPVI inhibitor, with aspirin and ticagrelor provides additional antithrombotic effects, as GPVI has a critical role in atherothrombosis but minimal involvement in hemostasis." | 4.31 | Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy. ( Alenazy, FO; Brady, P; Connolly, DL; Harbi, MH; Hargreaves, O; Harrison, P; Jandrot-Perrus, M; Kalia, N; Kavanagh, DP; Kirchhof, P; Mangin, PH; Nicolson, PLR; Price, J; Slater, A; Thomas, MR; Tiwari, A; Watson, SP, 2023) |
| "To determine the impact of fibrin clot inhibitor (FCI) use on oncological outcomes in a large contemporary cohort of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adequate bacille Calmette-Guérin (BCG)." | 4.12 | Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette-Guérin? ( Bree, KK; Dinney, CP; Hensley, PJ; Kamat, AM; Lobo, N; Navai, N; Nogueras-Gonzalez, GM, 2022) |
| " Therefore, we investigated the risk of discontinuing aspirin concerning thrombotic complications in laparoscopic colorectal cancer surgery." | 4.12 | Impact of aspirin discontinuation on thrombotic complications in laparoscopic colorectal cancer surgery. ( Dono, K; Hamabe, A; Harino, T; Noura, S; Ogino, T; Suzuki, Y; Takeyama, H; Tanida, T; Tomita, N, 2022) |
| "(1) To assess the clinical utility of the adjusted global antiphospholipid syndrome score (aGAPSS) to predict new obstetric events during follow-up in primary obstetric antiphospholipid syndrome (POAPS) patients under standard-of-care treatment (SC) based on the use of low-dose aspirin (LDA) + heparin and (2) to study the risk of a first thrombotic event and to evaluate whether stratification according to this score could help to identify POAPS patients who would benefit from long-term thromboprophylaxis." | 4.12 | Clinical and therapeutic value of the adjusted Global Antiphospholipid Syndrome Score in primary obstetric antiphospholipid syndrome. ( Alijotas-Reig, J; Aranda, F; Belizna, C; de Larrañaga, G; Esteve-Valverde, E; Fernández-Romero, DS; Latino, JO; Peréz, SM; Udry, S; Wingeyer, SP, 2022) |
| "The aim of this study was to compare thromboembolic events, bleeding, and all-cause mortality between DAPT and warfarin following TAVR." | 4.02 | Comparison of Warfarin to Dual Antiplatelet Therapy Following Transcatheter Aortic Valve Replacement. ( Greason, KL; Nei, SD; Scott, R; Wieruszewski, PM, 2021) |
| "A 65-year-old man developed 3-vessel stent thrombosis after percutaneous coronary intervention with aspirin and clopidogrel." | 4.02 | Successful Therapy With Ticagrelor in Three-Vessel Stent Thrombosis Related to Clopidogrel Resistance. ( Cho, JY; Lee, SY; Oh, SK; Yun, KH, 2021) |
| "Management of patients treated with Ticagrelor is challenging, as stopping Ticagrelor prior to coronary bypass graft surgery (CABG) may increase the risk of acute stent thrombosis." | 4.02 | Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes. ( Amir, O; Arazi, M; Carasso, S; Diab, S; Grosman-Rimon, L; Kachel, E; Raanani, E; Shalabi, A; Sternik, L, 2021) |
| "Thrombosis occurred in 11% (14/126) of grafts in group 1, 9% (11/128) of grafts in group 2, and 1% (2/202) of grafts in group 3 (odds ratio for aspirin group = 0." | 3.96 | Low-Dose Aspirin Reduces the Rate of Renal Allograft Thrombosis in Pediatric Renal Transplant Recipients. ( Al Midani, A; Fidan, K; Kessaris, N; Marks, SD; Matthias, M; Nagra, A; Ridout, D; Rudarakanchana, N; Tugtepe, H, 2020) |
| "5%) with a history of pregnancy morbidity alone were treated with prophylactic low molecular weight heparin (LMWH) + low-dose aspirin (LDA, 100 mg) (group I) and 40 (31." | 3.96 | Upgrading Therapy Strategy Improves Pregnancy Outcome in Antiphospholipid Syndrome: A Cohort Management Study. ( Calligaro, A; Del Ross, T; Favaro, M; Hoxha, A; Infantolino, C; Mattia, E; Ruffatti, A; Ruffatti, AT; Tonello, M, 2020) |
| " Despite long-term antiplatelet therapy with aspirin, recurrent cardiovascular events remain common in patients with coronary artery disease (CAD)." | 3.96 | Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease. ( Ajjan, RA; Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S, 2020) |
| "Bleeding is a frequently encountered complication in patients undergoing percutaneous coronary intervention (PCI) treated with a dual antiplatelet therapy regimen with aspirin plus an oral inhibitor of the P2Y12 platelet receptor (clopidogrel, prasugrel, ticagrelor) or with the combination of antiplatelet drugs and an anticoagulant in patients who have a specific indication for chronic anticoagulation therapy such as atrial fibrillation." | 3.96 | [Management of antithrombotic therapy in patients with bleeding after percutaneous coronary intervention]. ( Capodanno, D; Capranzano, P; Francaviglia, B; Tamburino, C, 2020) |
| "Antiplatelet therapy is the mainstay preventive strategy for cardiovascular diseases, and dual antiplatelet therapy comprising aspirin and a P2Y12 inhibitor is the standard treatment for patients who underwent percutaneous coronary intervention." | 3.96 | New methodological approaches for assessing thrombus formation in cardiovascular disease. ( Dahlen, J; Hosokawa, K; Nagasato, T; Ohnishi-Wada, T; Oyamada, C; Sameshima-Kaneko, H, 2020) |
| " Among current therapies, low-dose aspirin has been shown to reduce cardiovascular thrombosis." | 3.96 | A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis. ( Burchiel, S; Eaton, RP; Schade, DS, 2020) |
| "Discrepancies in preclinical studies of aspirin (ASA) antiplatelet activity in mouse models of bleeding and arterial thrombosis led us to evaluate commonly reported methods in order to propose a procedure for reliably measuring the effects of single dose ASA on mouse hemostasis." | 3.91 | Evaluation of commonly used tests to measure the effect of single-dose aspirin on mouse hemostasis. ( Bachelot-Loza, C; Belleville-Rolland, T; Decouture, B; Dizier, B; Gaussem, P; Leuci, A; Mansour, A; Martin, F; Pidard, D, 2019) |
| "To evaluate the effect of prestroke aspirin (PA) use on initial stroke severity, early neurologic deterioration (END), stroke recurrence, hemorrhagic transformation (HT), and functional outcome in patients with ischemic stroke (IS)." | 3.91 | Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke. ( Han, Z; Lin, J; Luo, H; Yi, X; Zhou, J; Zhou, Q, 2019) |
| "In contrast to that in a nonoperative setting, it has been shown that perioperative administration of aspirin did not decrease the rate of death or myocardial infarction but increased major bleeding risk." | 3.91 | Preoperative continuation of aspirin administration in patients undergoing major abdominal malignancy surgery. ( Hidaka, H; Nakatsuka, H; Ono, K; Sato, M, 2019) |
| "The aim of this study is to investigate the impact of ticagrelor as compared to clopidogrel based dual antiplatelet therapy (DAPT) during post-discharge management on the incidence of left ventricular (LV) thrombus in patients with first acute anterior ST elevation myocardial infarction (STEMI)." | 3.91 | The effect of ticagrelor based dual antiplatelet therapy on development of late left ventricular thrombus after acute anterior ST elevation myocardial infarction. ( Altındağ, R; Altıntaş, B; Baysal, E; Bilge, Ö; Burak, C; Ede, H; Karahan, MZ; Öztürk, Ö; Tanboğa, İH; Yaylak, B, 2019) |
| "Aspirin combination is prescribed for its thrombolytic activity where gastric ulceration is the major side effect of aspirin which can be prevented by combining it with proton pump inhibitor omeprazole." | 3.88 | Stability Indicating Liquid Chromatographic Method for Simultaneous Determination of Aspirin and Omeprazole. ( Patel, AD; Patel, VB; Shah, DA, 2018) |
| "The aims of the present study were to describe the proportion of patients eligible for the COMPASS trial within the Reduction of Atherothrombosis for Continued Health (REACH) registry, the reasons for ineligibility, and to put in perspective the characteristics and outcomes of trial-eligible patients from the REACH registry compared with those of patients enrolled in the reference aspirin arm of the COMPASS trial." | 3.88 | External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. ( Aboyans, V; Abtan, J; Anand, S; Bhatt, DL; Bosch, J; Branch, KR; Connolly, SJ; Darmon, A; Ducrocq, G; Dyal, L; Eagle, KA; Eikelboom, JW; Elbez, Y; Fox, KAA; Keltai, K; Probstfield, J; Sorbets, E; Steg, PG; Yusuf, S, 2018) |
| "Eighty-two consecutive patients with stable angina pectoris who received Resolute zotarolimus-eluting stents (R-ZESs; Medtronic Cardiovascular, Santa Rosa, CA, USA) were enrolled." | 3.88 | Comparison of the 9-month intra-stent conditions and 2-year clinical outcomes after Resolute zotarolimus-eluting stent implantation between 3-month and standard dual antiplatelet therapy. ( Fujimoto, W; Kawai, H; Miyata, T; Oishi, S; Onishi, T; Osue, T; Sawada, T; Shimane, A; Takahashi, Y; Takaya, T; Taniguchi, Y; Toba, T; Yasaka, Y, 2018) |
| " In vivo IQCA-TAVV targeted arterial thrombus, dose dependently inhibited arterial thrombosis with a 1 nmol/kg of minimal effective dose, and the activity waŝ1670 folds of that of aspirin." | 3.88 | Design and synthesis of nanoscaled IQCA-TAVV as a delivery system capable of antiplatelet activation, targeting arterial thrombus and releasing IQCA. ( Gui, L; He, J; Peng, S; Wang, Y; Wu, J; Yang, G; Zhang, X; Zhao, M; Zhao, S; Zhu, H, 2018) |
| " The aim of this pilot prospective study was to evaluate 12-month cardiovascular outcomes in elderly patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy (aspirin and clopidogrel) according to the clustering of CYP2C19 and ABCB1 genetic variants." | 3.88 | Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel. ( Antonicelli, R; Cecchini, S; Di Pillo, R; Galeazzi, R; Giovagnetti, S; Malatesta, G; Montesanto, A; Olivieri, F; Rose, G; Spazzafumo, L, 2018) |
| " This study involves the development, characterization and optimization of composite wafers for potential oral and buccal delivery of low dose aspirin to prevent thrombosis in elderly patients with dysphagia." | 3.88 | Development and functional characterization of composite freeze dried wafers for potential delivery of low dose aspirin for elderly people with dysphagia. ( Boateng, JS; Farias, S, 2018) |
| " Clopidogrel in combination with aspirin, given before percutaneous coronary intervention, have become the standard for stent thrombosis prevention." | 3.88 | Impact of Clopidogrel Loading for Coronarography on Bleeding After Urgent First Time CABG. ( Deveja, R; Hoxha, A; Qirjazi, T; Shehu, S, 2018) |
| " Main causes of oral anticoagulant treatment cessation were switch from vitamin K antagonists to aspirin in 15 patients, prolonged disappearance of antiphospholipid antibodies in ten, bleeding complications in nine and a poor therapeutic adherence in six." | 3.85 | Cessation of oral anticoagulants in antiphospholipid syndrome. ( Cacoub, P; Castel, B; Comarmond, C; de Menthon, M; Decaux, O; Elmaleh-Sachs, A; Ferreira-Maldent, N; Fraisse, T; Goujard, C; Hyvernat, H; Jego, P; Khau, D; Leroux, G; Marie, I; Mekinian, A; Michon, A; Monnier, S; Nguen, Y; Oziol, E; Piette, JC; Saadoun, D; Sarrot-Reynauld, F; Thiercein-Legrand, MF; Veyssier-Belot, C, 2017) |
| "Suboptimal platelet response to aspirin was detected in 64 of 430 patients (15%) and thrombosis was detected in 11 patients (2." | 3.85 | Platelet testing to guide aspirin dose adjustment in pediatric patients after cardiac surgery. ( DiNardo, JA; Emani, S; Emani, SM; Mulone, M; Trenor, CC; Zurakowski, D, 2017) |
| "Elderly, hospitalized coronary artery disease patients on regular aspirin treatment were enrolled from January 2014 to September 2016." | 3.85 | Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease. ( Chen, XH; Feng, XR; Fu, SW; He, XQ; Liang, WY; Liu, ML; Liu, WW; McCaffrey, TA; Zhang, JW, 2017) |
| "Stent fracture (SF) and peri-stent contrast staining (PSS) after sirolimus-eluting stent (SES) implantation are considered to be related to very late stent thrombosis (VLST)." | 3.85 | Impact of Dual Antiplatelet Therapy Beyond 1 Year on Clinical Outcomes of Patients With Stent Fracture or Peri-Stent Contrast Staining After Sirolimus-Eluting Stent Implantation. ( Amano, H; Fuku, Y; Goto, T; Habara, S; Kadota, K; Kubo, S; Otsuru, S; Tada, T; Tanaka, H, 2017) |
| " Dual antiplatelet therapy or at least aspirin is recommended to be continued considering the relative risk of stent thrombosis especially during the 4 weeks after DES implantation." | 3.85 | Risk of non-cardiac surgery after percutaneous coronary intervention with drug-eluting stents. ( Bahk, JH; Jung, DE; Jung, SA; Kim, WH; Park, SK, 2017) |
| " Low molecular weight heparin (LMWH) together with ticagrelor 90 mg twice a day and acetylsalicylic acid (Aspirin) were started after PCI due to high risk of stent thrombosis." | 3.85 | Diffuse alveolar hemorrhage associated with low molecular weight heparin and dual anti-platelet therapy after percutaneous coronary intervention. ( Abacı, A; Aygencel, G; Kara, İ; Okuyan, H; Türkoğlu, M; Yıldırım, F, 2017) |
| "There are few data to guide aspirin therapy to prevent shunt thrombosis in infants." | 3.85 | Platelet Inhibition in Shunted Infants on Aspirin at Short and Midterm Follow-Up. ( Bailly, DK; Burch, PT; Clawson, JR; Johnson, JT; LuAnn Minich, L; Sheng, X; Truong, DT; Witte, MK, 2017) |
| "The effect of prior use of aspirin (ASA) on the onset of acute coronary syndrome (ACS) has not been clarified." | 3.85 | Association Between Prior Aspirin Use and Morphological Features of Culprit Lesions at First Presentation of Acute Coronary Syndrome Assessed by Optical Coherence Tomography. ( Araki, M; Hada, M; Hamaya, R; Hoshino, M; Ichijo, S; Kakuta, T; Kanaji, Y; Kanno, Y; Lee, T; Matsuda, J; Murai, T; Niida, T; Usui, E; Yonetsu, T, 2017) |
| "To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)." | 3.85 | State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017) |
| "Cilostazol was associated with a significant reduction in late loss in BMS (mean difference 0." | 3.84 | Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. ( Chen, KY; Chetcuti, S; Grossman, MP; Gurm, H; Meier, P; Rha, SW; Tamhane, U, 2009) |
| "High-dose ASA in Heart Mate II patients treated concomitantly with warfarin is associated with an increased hazard of bleeding but does not reduce thrombotic events." | 3.83 | Antiplatelet Therapy and Adverse Hematologic Events During Heart Mate II Support. ( D'Alessandro, D; Goldstein, DJ; Guerrero, C; Jermyn, R; Jorde, UP; Kargoli, F; Levin, AP; Madan, S; Nguyen, J; Patel, SR; Saeed, O; Shah, A; Shin, J; Sims, DB, 2016) |
| "While the clinical efficacy of aspirin in cerebral thrombosis prevention has been well established, its mechanism of action is still controversial." | 3.83 | Vitamin D-Binding Protein Acts in the Actin Scavenge System and Can Have Increased Expression During Aspirin Therapy. ( Gao, J; Li, Z; Liu, S; Ma, Y; Qin, Z; Wang, M; Yang, M, 2016) |
| " In murine thrombosis models, nstpbp5185 significantly prolonged the latent period in triggering platelet plug formation in mesenteric and FeCl3-induced thrombi formation, and increased the survival rate in pulmonary embolism model with less bleeding than aspirin." | 3.83 | A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models. ( Hsu, MT; Huang, SW; Huang, TF; Kuo, HL; Kuo, SC; Lien, JC; Lin, SW; Peng, HC; Tseng, YJ, 2016) |
| "The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events." | 3.83 | A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016) |
| " Among 614 participants with a preoperative diagnosis of coronary artery disease (CAD), in-hospital aspirin use was significantly higher in the contemporary period (66% vs 30." | 3.83 | Perioperative antiplatelet therapy and cardiovascular outcomes in patients undergoing joint and spine surgery. ( Berger, JS; Errico, T; Iorio, R; Nukala, S; Oberweis, BS; Radford, MJ; Rosenberg, A; Smilowitz, NR; Stuchin, S, 2016) |
| "Plasma anticoagulation with warfarin during the early postoperative phase was shown statistically to be inferior to platelet aggregation inhibition by aspirin with regards to postoperative bleeding risk, cerebral ischemic events, and survival." | 3.83 | Anticoagulation After Biological Aortic Valve Replacement: Is There An Optimal Regimen? ( Breuer, M; Fuchs, J; Hüter, L; Kuntze, T; Lauer, B; Owais, T; Rouman, M, 2016) |
| " Prevention with aspirin or heparin was administered in ten cases during pregnancy, and in all the cases with heparin in postpartum." | 3.81 | [Thrombosis risk during pregnancy after history of cerebral venous thrombosis]. ( Neau, JP; Pierre, F; Pouget-Abadie, JF; Pourrat, O, 2015) |
| "Co-administration of FO and low-dose aspirin may act synergistically to protect against thrombosis and injury-induced vascular remodelling in mice." | 3.81 | Aspirin enhances protective effect of fish oil against thrombosis and injury-induced vascular remodelling. ( Funk, CD; Gong, Y; Li, X; Lin, M; Piao, L; Song, WL; Xiao, B; Yang, F; Yin, H; Yu, Y; Zhang, J; Zhang, Q; Zhu, L, 2015) |
| "Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)." | 3.81 | Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015) |
| "To characterize platelet function and responsiveness to aspirin in relation to thrombogenesis, systemic inflammation, and markers of endothelial function in adults with Fontan circulation (FC)." | 3.81 | Aspirin resistance in adult patients after Fontan surgery. ( Chłopicki, S; Komar, M; Musiałek, P; Olszowska, M; Pajak, J; Podolec, J; Podolec, P; Rubis, P; Sitek, B; Tomkiewicz-Pajak, L; Wojcik, T, 2015) |
| "This case reports the sudden development of large burden of thrombi in the left anterior descending coronary artery immediately following distal left main stenting using TAP technique in a middle aged man who presented with non ST-segment elevation acute coronary syndrome despite having been administered 7,500 units of unfractionated heparin and being given 325 mg of aspirin and 60 mg of prasugrel prior to the procedure." | 3.81 | Acute thrombosis during left main stenting using tap technique in a patient presenting with non-ST-segment elevation acute coronary syndrome. ( Natarajan, D, 2015) |
| " Post-2005 diagnosed patients were also more or less likely to receive aspirin and cytoreductive therapy, respectively, and, despite their older age distribution, displayed significantly lower risk of thrombosis in high risk disease." | 3.81 | Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. ( Barbui, T; Carobbio, A; Finazzi, G; Gisslinger, H; Pardanani, A; Passamonti, F; Pieri, L; Rambaldi, A; Randi, ML; Rodeghiero, F; Rumi, E; Tefferi, A; Thiele, J; Vannucchi, AM, 2015) |
| "Several trials have compared aspirin or warfarin with either placebo or no antithrombotic drug therapy in a total of a few hundred patients with heart failure in sinus rhythm and no particular thrombotic risk." | 3.81 | Heart failure in sinus rhythm: no routine antithrombotic therapy. ( , 2015) |
| "The mechanism of action of the widely used in vivo ferric chloride (FeCl3) thrombosis model remains poorly understood; although endothelial cell denudation is historically cited, a recent study refutes this and implicates a role for erythrocytes." | 3.81 | Resolving the multifaceted mechanisms of the ferric chloride thrombosis model using an interdisciplinary microfluidic approach. ( Ciciliano, JC; Dixon, JB; Fay, ME; Gachet, C; Hechler, B; Lam, WA; Li, R; Lyon, LA; Meeks, S; Myers, DR; Sakurai, Y, 2015) |
| "Aspirin prevention of thrombosis and death in patients undergoing HD might require consideration of the anti-PF4/H antibody status." | 3.81 | Effectiveness of and risk associated with aspirin therapy in hemodialysis patients with a background of antiplatelet factor 4/heparin complex antibody detection. ( Chen, G; Jin, L; Kong, D; Li, C; Ma, L; Qi, K; Song, M; Wang, C; Wang, Y; Yang, Y, 2015) |
| " The effects of AEE on platelet aggregation and anticoagulant in vitro showed that AEE could inhibit adenosine diphosphate (ADP)-induced platelet aggregation as dose-dependence but no notable effect on blood clotting." | 3.81 | Preventive Effect of Aspirin Eugenol Ester on Thrombosis in κ-Carrageenan-Induced Rat Tail Thrombosis Model. ( Li, JY; Liu, GR; Liu, XW; Ma, N; Mohamed, I; Yang, YJ; Zhang, JY, 2015) |
| " As stents are prone to thrombosis, which can potentially be devastating, patients are treated with dual antiplatelet therapy with aspirin plus a thienopyridine for at least 6-12 months after stent placement." | 3.81 | Assessing the optimal strategy for dual antiplatelet therapy. ( Chang, L; Yeh, RW, 2015) |
| " Shunt thrombosis prophylaxis regimens including the time of initiation of aspirin were compared between high and low outliers." | 3.80 | Defining the best practice patterns for the neonatal systemic-to-pulmonary artery shunt procedure. ( Brar, A; Eghtesady, P; Hall, M; Heidari-Bateni, G; Norouzi, S, 2014) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is used to lower the risk of arterial thrombosis." | 3.80 | The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy. ( Grybauskas, P; Gustiene, O; Jankauskiene, L; Kupstyte, N; Lesauskaite, V; Skipskis, V; Tatarunas, V, 2014) |
| "This study was designed to compare the oxidative stress parameters of patients with polycythemia vera (PV) to those of healthy volunteers and to investigate the probable relationship between vascular events and parameters of oxidative status such as total oxidative status (TOS), total antioxidant status, oxidative stress index (OSI) and malondialdehyde (MDA) in PV patients." | 3.80 | The thrombotic events in polycythemia vera patients may be related to increased oxidative stress. ( Akalin, I; Alver, A; Durmus, A; Mentese, A; Sumer, A; Topal, C; Yilmaz, M, 2014) |
| "Postoperative thrombosis is associated with aspirin unresponsiveness in this patient population." | 3.80 | Aspirin unresponsiveness predicts thrombosis in high-risk pediatric patients after cardiac surgery. ( Baird, CW; Emani, S; Emani, SM; Fynn-Thompson, FE; Pigula, FA; Trainor, B; Zurakowski, D, 2014) |
| "Patients on aspirin therapy for 1 week or longer with known or suspected coronary artery disease undergoing nonurgent cardiac catheterization (n=1172), of whom 924 were on aspirin and clopidogrel therapy, were studied." | 3.80 | Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. ( Bliden, KP; Franzese, C; Gurbel, PA; Jeong, YH; Kang, K; Lev, EI; Pandya, S; Tantry, US, 2014) |
| "Using an anaesthetized dog model of thrombosis, the effects of aspirin (50mg/kg) in addition to clopidogrel and ticagrelor were evaluated at two levels of P2Y12 inhibition, maximal (≥96%) and sub-maximal (~80%), as assessed by ex vivo ADP-induced whole blood impedence aggregometry." | 3.79 | High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition. ( Björkman, JA; Forsberg, GB; Hansson, GI; Nylander, S; von Bahr, H; Warner, TD; Zachrisson, H, 2013) |
| "The effectiveness of low-dose aspirin in the primary prevention of thrombosis in patients with high-risk essential thrombocythaemia (ET) treated with cytoreductive drugs is not well established." | 3.79 | Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. ( Alvarez-Larrán, A; Arellano-Rodrigo, E; Besses, C; Cervantes, F; Hernández-Boluda, JC; Pereira, A, 2013) |
| " Additional subgroup analysis included the presence of hypertension, diabetes, low-density lipoprotein levels, sex, and use of aspirin." | 3.79 | Hyperhomocysteinemia and vascular access thrombosis in hemodialysis patients: a retrospective study. ( El-Charabaty, E; El-Sayegh, S; Saifan, C, 2013) |
| "Antithrombotic action of the novel benzimidazole derivative RU-891 exhibiting antiaggregant activity both in vitro and in vivo has been investigated in comparison to acetylsalicylic acid using the method of thrombosis induced by 50% ferrous chloride solution in rats." | 3.79 | [Antithrombotic activity of RU-891 antiaggregant agent]. ( Anisimova, VA; Kucheriavenko, AF; Spasov, AA; Tian', M, 2013) |
| "Earlier validation studies of risk scoring by CHA2DS2VASc for assessments of appropriateness of warfarin treatment in patients with atrial fibrillation have been performed solely with diagnoses recorded in hospital based care, even though many patients to a large extent are managed in primary care." | 3.79 | Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system. ( Forslund, T; Hasselström, J; Hjemdahl, P; von Euler, M; Wändell, P; Wettermark, B, 2013) |
| "Patients with peripheral artery disease (PAD) following peripheral percutaneous transluminal angioplasty (PTA) with stent implantation are prone to stent thrombosis despite treatment with aspirin and clopidogrel." | 3.79 | Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. ( Frołow, M; Mazur, P; Niżankowski, R; Sadowski, J; Undas, A, 2013) |
| "To assess thromboprophylaxis prescribing patterns against current guidelines and report thromboembolism (TE) incidence in multiple myeloma (MM) patients treated with thalidomide (thal) or lenalidomide (len) at a specialist cancer hospital over a one-year period." | 3.79 | Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. ( Alexander, M; Kirsa, S; Lingaratnam, S; Mellor, JD; Teoh, KC, 2013) |
| "A 73-year-old woman was admitted to our hospital with anterior acute myocardial infarction due to subacute thrombosis after coronary stenting with a zotarolimus-eluting stent (ZES), which is a newly developed drug-eluting stent that has been widely used since May 2009 in Japan." | 3.78 | A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent. ( Arima, M; Matsuda, A; Nitta, M; Shimizu, M; Yoshida, K, 2012) |
| " In patients with patent foramen ovale (PFO) and stroke or transient ischemic attack, we recommend initial aspirin therapy (Grade 1B) and suggest substitution of VKA if recurrence (Grade 2C)." | 3.78 | Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. ( Fremes, SE; Rubens, FD; Sun, JC; Teoh, KH; Whitlock, RP, 2012) |
| " We examined the effects on thrombosis and haemostasis in PAR₄ -/- mice (platelets unresponsive to thrombin) treated with therapeutic doses of either aspirin or clopidogrel." | 3.78 | Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice. ( Hamilton, JR; Jackson, SP; Lee, H; Mountford, JK; Sturgeon, SA, 2012) |
| "Primary antithrombotic prevention with aspirin is not indicated in asymptomatic patients with confirmed antiphospholipid (aPL) positivity without systemic autoimmune disorders because: a) the estimated prevalence of thrombosis in unselected cases is about 1% patient-years (range 0-2." | 3.78 | Primary antithrombotic prevention in carriers of antiphospholipid antibodies without systemic autoimmune disorders. ( Finazzi, G, 2012) |
| " In particular, an herbal combination including Tribulus terrestris (TT), Avena sativa (AS), and Panax Ginseng (PG), which may be effective in treatment of atherosclerosis and thrombosis, is used by patients with coronary artery disease." | 3.78 | [Three case reports of the use of herbal combinations resulted in stent thrombosis: herbal combinations; friend or foe?]. ( Erdoğan, E; Göktekin, Ö; Tasal, A; Vatankulu, MA, 2012) |
| "Our data on the inhibitory effect of rivaroxaban alone or with DAT are consistent with the ATLAS 2 trial findings, and support its potential use for preventing stent thrombosis after stent deployment." | 3.78 | Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis. ( Badimon, JJ; Becker, EM; Bütehorn, U; Kast, R; Klipp, A; Laux, V; Lücker, C; Perzborn, E, 2012) |
| " After delivery, aspirin was prescribed to all patients as primary thrombosis prevention." | 3.77 | Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patients. ( Bacri, JL; Caron, C; Dubucquoi, S; Hachulla, E; Hatron, PY; Houfflin-Debarge, V; Kyndt, X; Lambert, M; Launay, D; Lefèvre, G; Quemeneur, T; Subtil, D, 2011) |
| "This study demonstrates that high on treatment platelet reactivity with aspirin and/or clopidogrel is common amongst patients who develop stent thrombosis." | 3.77 | High on treatment platelet reactivity and stent thrombosis. ( French, JK; Juergens, CP; Parikh, D; Rajendran, S; Shugman, I, 2011) |
| "The antithrombotic effect of the glycopreotein IIb/IIIa (GP IIb/IIIa) receptor antagonist Z4A5, exert alone or combination with heparin, and/or aspirin, was examined in a rabbit arteriovenous shunt thrombosis model." | 3.77 | Antithrombotic activity of Z4A5, a new platelet glycoprotein IIb/IIIa receptor antagonist evaluated in a rabbit arteriovenous shunt thrombosis model. ( Jing, BB; Li, YP; Li, YX; Ren, ST; Wang, B; Wang, M; Zang, WJ; Zhang, H, 2011) |
| "To test the hypothesis that HRPR after clopidogrel loading is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treatment adjusted according to the results of platelet function tests." | 3.77 | High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011) |
| " clopidogrel) is known to be essential in patients in whom percutaneous coronary intervention with stent implantation has been performed in order to prevent stent thrombosis and its fatal consequences." | 3.77 | [Diagnostic laparoscopy under dual antiplatelet therapy with clopidogrel and aspirin]. ( Buerke, M; Mannes, F; Plehn, A; Schlitt, A; Vogt, A; Werdan, K; Wolf, HH, 2011) |
| " A 35-year-old lady with ES taking aspirin with clopidogrel for thrombo-prophylaxis presented with massive epistaxis." | 3.77 | Massive epistaxis in a patient with Eisenmenger syndrome: illustrating the clot-versus-bleed conundrum. ( Liu, A; Pusalkar, P; Saman, H, 2011) |
| "Platelet hyperreactivity in MEA might be a better risk predictor for stent thrombosis than the assessment of the specific clopidogrel effect with the VASP phosphorylation assay." | 3.76 | Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. ( Christ, G; Delle-Karth, G; Huber, K; Jilma, B; Lang, IM; Siller-Matula, JM, 2010) |
| " Aspirin was injected at 100 mg/kg, 1 mg/kg and at several different aspirin dilutions along with cyclooxygenase (COX) 1 (SC-560), COX 2 (NS-398) or both selective inhibitors simultaneously using a laser-induced thrombosis model." | 3.76 | Paradoxical thrombotic effects of aspirin: experimental study on 1000 animals. ( Aguejouf, O; Desplat, V; Doutremepuich, C; Eizayaga, FX, 2010) |
| "In patients receiving the HeartMate II LVAD who were directly transitioned to warfarin and aspirin therapy without intravenous heparin there was no short-term increase in risk of thrombotic or thromboembolic events, and bleeding requiring transfusion was significantly reduced." | 3.76 | Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. ( Aaronson, KD; Boyle, A; Conte, JV; Farrar, DJ; John, R; Naka, Y; Pagani, FD; Russell, SD; Slaughter, MS; Sundareswaran, KS, 2010) |
| " Here, we investigated the potential synergy of a potent factor Xa/prothrombinase inhibitor, TAK-442, plus aspirin or clopidogrel in preventing arterial thrombosis and whole blood coagulation." | 3.76 | Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats. ( Hiroe, K; Kawamura, M; Konishi, N, 2010) |
| "Aspirin is often used to prevent thrombosis in pediatric cardiac surgery." | 3.76 | Aspirin resistance following pediatric cardiac surgery. ( Alfieris, GM; Blumberg, N; Cholette, JM; Lerner, NB; Mamikonian, L, 2010) |
| "Previous DAPT studies consistently demonstrated greater efficacy but an increased risk of bleeding compared with aspirin alone in patients with acute coronary syndromes or undergoing percutaneous coronary intervention." | 3.76 | Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective. ( Bhatt, DL; Boden, WE; Flather, MD, 2010) |
| "Combined antiplatelet agents (cAPA), aspirin plus clopidogrel, increase the risk of bleeding." | 3.76 | Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel. ( Bachelot-Loza, C; Dizier, B; Emmerich, J; Gaussem, P; Godier, A; Grelac, F; Hindy-François, C; Le Bonniec, B; Samama, CM, 2010) |
| "This study sought to evaluate the platelet response to aspirin and the immature platelet fraction in patients with previous stent thrombosis (ST)." | 3.76 | Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. ( Grove, EL; Hvas, AM; Jensen, LO; Kaltoft, AK; Kristensen, SD; Tilsted, HH; Wulff, LN; Würtz, M, 2010) |
| "The aim of the study was to evaluate the effect of the concomitant treatment with proton-pump inhibitors (PPIs) and clopidogrel on the incidence of stent thrombosis, acute coronary syndrome (ACS) and death in patients who underwent percutaneous coronary intervention (PCI) and stent implantation." | 3.76 | Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. ( Brozovic, I; Farhan, S; Geppert, A; Huber, K; Jarai, R; Siller-Matula, J; Smetana, P; Tentzeris, I; Wojta, J, 2010) |
| "High-dose aspirin (≥500 mg daily) reduces long-term incidence of colorectal cancer, but adverse effects might limit its potential for long-term prevention." | 3.76 | Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. ( Algra, A; Elwin, CE; Meade, TW; Norrving, B; Rothwell, PM; Warlow, CP; Wilson, M, 2010) |
| "Platelet deposition and thrombus formation caused by angioplasty appear to be important in the development of 2 complications: acute thrombotic occlusion and restenosis." | 3.76 | Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. ( Harker, LA, 1987) |
| "This study sought to investigate the incidence of stent thrombosis (ST) in patients treated with drug-eluting stents (DES) and clearly defined short-term dual antiplatelet therapy (DAT) for three or six months for sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES), respectively." | 3.75 | Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy. ( Hartenthaler, B; Hofmann, R; Hönig, S; Kammler, J; Kerschner, K; Kypta, A; Lambert, T; Leisch, F; Steinwender, C, 2009) |
| "Previous cost-effectiveness analyses analyzed warfarin for stroke prevention in randomized trial settings." | 3.75 | Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. ( Dewilde, S; Goldhaber, SZ; Monz, BU; Plumb, JM; Singer, DE; Sorensen, SV, 2009) |
| "Administration of aspirin (30 mg kg(-1) day(-1)) to CRPtg mice slowed the accelerated thrombosis after photochemical injury to the carotid (99 +/- 32 vs." | 3.75 | Aspirin reduces the prothrombotic activity of C-reactive protein. ( Danenberg, HD; Fitzgerald, GA; Golomb, M; Grad, E; Koroukhov, N; Lawson, JA; Lotan, C, 2009) |
| "Clopidogrel as a sole anti-platelet treatment after coronary stenting resulted in a relatively high percentage of subacute stent thrombosis." | 3.75 | Coronary artery stenting in patients treated by clopidogrel without aspirin. ( Amit, G; Leibowitz, D; Rott, D; Weiss, AT; Zahger, D, 2009) |
| "Sulfinpyrazone1 has long been recognised as a potent uricosuric agent, but has more recently been studied extensively as a platelet inhibitor and antithrombotic agent." | 3.75 | Sulfinpyrazone: a review of its pharmacological properties and therapeutic use. ( Margulies, EH; Sherry, S; White, AM, 1980) |
| "Aspirin has been shown to reduce the number of transient ischemic attacks (TIA), stroke and death in patients with multiple TIA." | 3.75 | Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. ( Turpie, AG, 1982) |
| "The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)." | 3.74 | Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. ( Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M, 2008) |
| " Because of recurrent gastrointestinal bleeding episodes, 7 patients discontinued warfarin for a total duration of 39." | 3.74 | Low thromboembolic risk for patients with the Heartmate II left ventricular assist device. ( Boyle, A; Colvin-Adams, M; John, R; Joyce, L; Kamdar, F; Liao, K; Miller, L, 2008) |
| "We describe a case of fatal stent thrombosis after Carbostent implantation and clopidogrel alone antiplatelet therapy in a patient affected by rectal cancer who does not tolerate aspirin." | 3.74 | A case of fatal stent thrombosis after Carbostent implantation: is clopidogrel alone antiplatelet therapy a safe alternative to aspirin alone antiplatelet therapy? ( Altamura, L; Crea, F; De Vita, M; Ferrante, G; Fusco, B; Leone, AM; Niccoli, G; Rebuzzi, AG; Siviglia, M, 2007) |
| " Aspirin non-responsiveness is more frequent in severe infections, such as pneumonia." | 3.74 | Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. ( Karlsson, F; Modica, A; Mooe, T, 2007) |
| "Using prescriptions for digoxin as a surrogate for atrial fibrillation, we identified its coprescription with antithrombotic therapy, aspirin or warfarin in a national prescribing database in 27 571 patients over 45 years old." | 3.74 | National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing. ( Bennett, K; Feely, J; Mahmud, A; Okechukwu, I, 2007) |
| "The need for prolonged aspirin and thienopyridine therapy and the risk of stent thrombosis (ST) remain as drawbacks associated with drug-eluting stents." | 3.74 | Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. ( Airoldi, F; Bonizzoni, E; Briguori, C; Buellesfeld, L; Carlino, M; Chieffo, A; Colombo, A; Cosgrave, J; Gerckens, U; Godino, C; Grube, E; Latib, A; Melzi, G; Michev, I; Montorfano, M; Morici, N; Qasim, A; Sangiorgi, GM, 2007) |
| "Therapy with acetylsalicylic acid (ASA) and/or clopidogrel is used to achieve prophylactic inhibition of platelet aggregation in patients with arterial thrombosis." | 3.74 | [Modified platelet aggregation test in patients on ASA and/or clopidogrel]. ( Eder, C; Funke, U; Lutze, G; Prasse, T; Schulze, M; Töpfer, G; Zimmermann, M, 2007) |
| " Fibrin(ogen) deposition, light transmittance aggregometry (LTA; collagen, U46619, and ADP), and bleeding time (BT) were also evaluated." | 3.74 | A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. ( Badimon, L; Casaní, L; Vilahur, G, 2007) |
| "Recent clinical trials involving patients with acute coronary syndromes have demonstrated significant reduction in the progression of coronary artery thrombosis using a regimen of aspirin, heparin, and the glycoprotein IIb/IIIa inhibitor tirofiban." | 3.74 | Prevention of microsurgical anastomotic thrombosis using aspirin, heparin, and the glycoprotein IIb/IIIa inhibitor tirofiban. ( Chung, TL; Holton, LH; Pumplin, DW; Rodriguez, ED; Silverman, RP; Taylor, JA, 2007) |
| "The risk for major bleeding episodes in hemodialysis patients increases significantly while on aspirin and/or warfarin, although warfarin alone did not reach statistical significance." | 3.74 | Major bleeding in hemodialysis patients. ( Day, AG; Harman, GJ; Holden, RM; Holland, D; Wang, M, 2008) |
| "Multiple myeloma (MM) patients have a propensity for thromboembolic events (TE), and treatment with thalidomide/dexamethasone or lenalidomide/dexamethasone increases this risk." | 3.74 | Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. ( Christos, P; Coleman, M; De Sancho, M; Furst, J; Jalbrzikowski, J; Jayabalan, D; Leonard, J; Mark, T; Martínez-Baños, D; Mazumdar, M; Niesvizky, R; Pearse, R; Pekle, K; Zafar, F, 2007) |
| "The incidence of stent thrombosis was evaluated in 1,029 patients receiving ticlopidine and aspirin after SES deployment." | 3.74 | Late stent thrombosis in patients receiving ticlopidine and aspirin after sirolimus-eluting stent implantation. ( Fujimoto, Y; Himi, T; Kitahara, H; Kobayashi, Y; Komuro, I; Kuroda, N; Miyazaki, A; Nakamura, Y; Nakayama, T, 2008) |
| "Acetylsalicylic acid (ASA) and the thienopyridine clopidogrel are established anti-platelet drugs that significantly reduce secondary cardiovascular events in patients with manifest atherosclerosis." | 3.74 | Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. ( Koellnberger, M; Konrad, I; Lorenz, R; Massberg, S; Orschiedt, L; Sauer, S; Schulz, C; Walter, U, 2008) |
| "Patients with atrial fibrillation taking either indirect anticoagulant acenocumarol or most often prescribed antiaggregant aspirin were followed for 1 year." | 3.74 | [Effect of acenocoumarol and aspirin on platelet function, markers of thrombinemia, and intracardiac thrombosis in patients with atrial fibrillation]. ( Ataullakhanova, DM; Bykova, ES; Dobrovol'skiĭ, AB; Kropacheva, ES; Panchenko, EP; Titaeva, EV; Zharkova, TV, 2007) |
| " We report a patient, having used aspirin for secondary stroke prevention, who had an acute cerebellar hemorrhage after taking nattokinase 400 mg daily for 7 consecutive days." | 3.74 | Cerebellar hemorrhage provoked by combined use of nattokinase and aspirin in a patient with cerebral microbleeds. ( Chang, YY; Lai, SL; Lan, MY; Liu, JS; Wu, HS, 2008) |
| "We studied the effects of ultra-low-dose aspirin (ULDA) as well as those of sc-560 and ns-398, specific COX-1 and COX-2 inhibitors, on induced hemorrhagic time and in a model of laser-induced thrombosis in rats." | 3.74 | Reverse effect of aspirin: is the prothrombotic effect after aspirin discontinuation mediated by cyclooxygenase 2 inhibition? ( Aguejouf, O; Desplat, V; Doutremepuich, C; Eizayaga, FX, 2007) |
| " The patient had decided to take low-molecular-weight heparin (LMWH) and aspirin throughout her pregnancy." | 3.74 | Acute thrombosis of a prosthetic mitral valve in pregnancy in spite of adjusted-dose low-molecular-weight heparin and aspirin. ( Curtis, SL; Stuart, AG; Trinder, J, 2008) |
| "The objective of this study was to determine if orally-administered PD0348292, a direct specific factor Xa inhibitor, inhibits thrombosis following porcine carotid arterial injury comparably to aspirin or clopidogrel alone or in combination." | 3.74 | Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis. ( Baxi, S; Karnicki, K; Leadley, RJ; McBane, RD; Peterson, T; Wysokinski, W, 2008) |
| "The current standard of care for anti-thrombotic therapy with primary PCI for acute ST elevation myocardial infarction (STEMI) is aspirin, clopidogrel, unfractionated heparin and platelet glycoprotein IIb/IIIa inhibitors." | 3.74 | What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice? ( Brodie, BR, 2008) |
"The overall rank-order of potency in thrombosis models based on per cent of vessels occluded, average carotid blood flow, and thrombus weight was aspirin=argatroban=tirofiban| 3.74 | Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis. ( Allegretto, N; Barbera, F; Bird, JE; Giancarli, MR; Ogletree, ML; Schumacher, WA; Seiffert, D; Wong, P, 2008) | |
| "At a similar level of efficacy in inhibiting secondary thrombosis, triflusal seems to better preserve Cox-2 expression than aspirin and its metabolite HTB was able to protect endothelial prostacyclin production." | 3.74 | Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2. ( Badimon, L; Duran, X; Sánchez, S; Vilahur, G, 2008) |
| "Thrombosis is not equivalent to hemostasis, but is a distortion of the hemostatic process." | 3.74 | Aspirin revisited. ( Cooke, AR; Rodvein, R, 1975) |
| "Between September 1999 and April 2002, a total of 1,236 patients hospitalized for acute coronary syndrome (ACS) were questioned in order to determine whether aspirin intake had been interrupted." | 3.73 | Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. ( Benhamou, M; Cerboni, P; Ferrari, E; Marcel, B, 2005) |
| "Our results reaffirm previous reports that the use of LMWH in combination with low dose aspirin throughout pregnancy is safe and effective." | 3.73 | Early antiplatelet and antithrombotic therapy in patients with a history of recurrent miscarriages of known and unknown aetiology. ( Delkos, D; Giannoulis, H; Gkoutzioulis, F; Kalogiros, G; Papaloukas, C; Petropoulos, P; Psarra, A; Tzafettas, J, 2005) |
| "Arachidonic acid (AA)-induced light-transmittance platelet aggregation (LTA) and thrombelastography (TEG) platelet mapping were performed on the blood of healthy subjects (n = 6) before and 24 h after receiving 325 mg aspirin, and on 223 patients reporting compliance with long-term daily aspirin treatment (n = 203 undergoing percutaneous intervention [PCI] and n = 20 with a history of stent thrombosis)." | 3.73 | Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. ( Bliden, KP; Gurbel, PA; Tantry, US, 2005) |
| "The CREDO trial demonstrated the clinical efficacy of 12-month antiplatelet therapy with clopidogrel compared to standard 28-day treatment with a 27% relative reduction in the combined risk of death, myocardial infarction, or stroke in patients undergoing percutaneous coronary intervention (PCI) and being treated with aspirin." | 3.73 | The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. ( Jönsson, B; Lindgren, P; Ringborg, A, 2005) |
| " aspirin (4-30 mg/kg), heparin (100-500 U/kg), enoxaparin (4-30 mg/kg) and clopidogrel (10-20 mg/kg) were studied in a rat Folts-like preparation of carotid arterial thrombosis." | 3.73 | Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat. ( Daykin, HJ; Jones, C; Sturgeon, SA; Wright, CE, 2006) |
| " All suffered stent thrombosis after discontinuation (in three cases prematurely) of clopidogrel therapy." | 3.73 | [Thrombosis of a coronary stent after discontinuing treatment with clopidogrel]. ( de Boer, MJ; Hautvast, RW; Heestermans, AA; Jaarsma, W; ten Berg, JM; van Werkum, JW, 2006) |
| "Thrombotic events still occur in aspirin-treated patients with coronary artery disease." | 3.73 | Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. ( Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Li, Y; Linden, MD; Michelson, AD, 2006) |
| " The dog had a history of hypothyroidism, which was controlled with levothyroxine." | 3.72 | Portal vein and aortic thromboses in a Siberian husky with ehrlichiosis and hypothyroidism. ( Bressler, C; Himes, LC; Moreau, RE, 2003) |
| "We conclude that under our experimental conditions, rofecoxib diminished platelet aggregation induced by different agonists and inhibited platelet-mediated thrombogenesis in an in vitro model of thrombosis." | 3.72 | Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. ( Arderiu, G; Escolar, G; Hernandez, MR; Pino, M; Serradell, M; Tonda, R, 2004) |
| "Although the central role of thrombin in arterial thrombosis is well established, the efficacy of vitamin K-dependent factor depletion by warfarin at preventing this process has not been established." | 3.72 | The impact of vitamin K-dependent factor depletion by warfarin on platelet-rich thrombosis after deep arterial injury. ( Chesebro, JH; Grill, DE; Hassinger, NL; McBane, RD, 2004) |
| "The possible additive antiplatelet effects of aspirin and clopidogrel have been explored in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Management of Atherothrombosis with Clopidogrel in High Risk Patients (MATCH) studies." | 3.72 | Long-term combination therapy with aspirin and clopidogrel. ( Cheung, BM; Cheung, G; Kumana, CR; Lauder, IJ, 2004) |
| "There was a significantly lower rate of primary allograft thrombosis in patients treated with aspirin (none of 105) compared with that in the control group (six (5 per cent) of 121; P = 0." | 3.71 | Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation. ( Metcalfe, M; Murphy, GJ; Nicholson, ML; Taha, R; Windmill, DC, 2001) |
| "We compared the combination of aspirin plus clopidrogrel (A+C) with aspirin and ticlopidine (A+T) for prevention of subacute stent thrombosis in 827 patients." | 3.71 | Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. ( Abizaid, AS; Curry, BH; Dangas, G; Kent, KM; Lansky, AJ; Leon, MB; Mehran, R; Paliou, M; Pichard, AD; Satler, LF; Stone, GW, 2001) |
| "This prospective audit reports pregnancy outcomes, anticoagulation complications, and anti-Xa levels in women with mechanical heart valves who were treated with therapeutic enoxaparin plus aspirin during pregnancy." | 3.71 | Enoxaparin treatment in women with mechanical heart valves during pregnancy. ( McCowan, LM; North, RA; Raudkivi, PJ; Rowan, JA, 2001) |
| " The nonionic CM iohexol triggers platelet beta-thromboglobulin (beta-TG) secretion, and thus may activate the platelets and promote thrombosis." | 3.70 | Iohexol, platelet activation and thrombosis. II. Iohexol-induced platelet secretion does not affect collagen-induced or tissue-factor-induced thrombus formation in blood that is anticoagulated with heparin and aspirin. ( Buchmann, M; Hamers, MJ; Sakariassen, KS; Stormorken, H, 1998) |
| " We report on the antithrombotic effect of xemilofiban (SC-54684A), an oral GP IIb/IIIa antagonist, administered alone or with aspirin (ASA) in an acute thrombosis model." | 3.70 | Protective effect of oral xemilofiban in arterial thrombosis in dogs: increased activity in combination with aspirin. ( Feigen, LP; Frederick, LG; King, LW; Nicholson, NS; Salyers, AK; Suleymanov, OD; Szalony, JA; Taite, BB, 1998) |
| "The effects of clopidogrel and aspirin have been compared, singly and in combination, for measurements of 111In-labeled platelets and 125I-labeled fibrin deposition in baboon models of arterial thrombosis and related to platelet aggregation and expression of activation epitopes induced by ADP, collagen, and thrombin receptor agonist peptide (TRAP) and to template bleeding times (BTs)." | 3.70 | Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. ( Chronos, NR; Hanson, SR; Harker, LA; Herbert, JM; Kelly, AB; Marzec, UM; Sundell, IB, 1998) |
| "In patients receiving coronary stents treated with aspirin and coumadin, the peak incidence of stent thrombosis occurs on the fifth and sixth days following the implantation procedure." | 3.70 | Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. ( Bell, MR; Berger, PB; Holmes, DR; Rihal, CS; Velianou, JL; Wilson, SH, 1999) |
| "Further to characterize the processes involved in the FeCl3-induced thrombosis model, we determined the effect of aspirin, heparin, hirudin, trans-4-(aminomethyl) cyclohexane carboxylic acid (AMCHA), thrombocytopenia, and flow modifications on time to occlusion (TTO) and thrombus weight (TW) in the rat carotid artery." | 3.70 | Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis. ( Kambayashi, J; Lockyer, S, 1999) |
| "In general, aspirin is indicated to prevent thrombosis in conditions associated with high shear rates (i." | 3.70 | Warfarin or aspirin: both or others? ( Peverill, RE, 1999) |
| " Aspirin, 75 mg daily was given in addition to enoxaparin to women with antiphospholipid syndrome." | 3.70 | Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. ( Blumenfeld, Z; Brenner, B; Hoffman, R; Weiner, Z; Younis, JS, 2000) |
| "Combination antiplatelet therapy using aspirin and ticlopidine has been the standard of care for prevention of subacute thrombosis following coronary stent implantation." | 3.70 | Combination therapy with clopidogrel and aspirin after coronary stenting. ( Curran, SC; Herrmann, HC; Hirshfeld, JW; Klugherz, BD; Kolansky, DM; Magness, K; Wilensky, RL, 2000) |
| "(1) In patients with atrial fibrillation and a moderate embolic risk, aspirin reduces the risk of stroke and has a comparable risk-benefit ratio to oral anticoagulants." | 3.70 | Antiplatelet drugs in cardiovascular prevention: stroke prevention in patients with thrombogenic heart disease. ( , 2000) |
| "Aspirin has a well established role in the prevention of arterial thrombosis." | 3.70 | Time related neutralization of two doses acetyl salicylic acid. ( Aguejouf, O; Belon, P; Doutremepuich, C; Malfatti, E, 2000) |
| "LMWH (Fraxiparine), and NSAIDs (Aspirin, Feldene, Indocid and Profenid) injected together in doses, 1 mg/kg (Aspirin was used at 100 mg/kg), subcutaneously into rats 30 minutes before the thrombosis induction by LASER beams, increased the number of LASER beams required to induce platelet thrombus formation, decreased the number of emboli and reduced the duration of embolization, compared with control (p < or = 0." | 3.69 | Effect of the low molecular weight heparin/non steroidal anti-inflammatory drugs association on an experimental thrombosis induced by laser. ( Aguejouf, O; Doutremepuich, C; Doutremepuich, F; Imbault, P; Oualane, FA, 1995) |
| "Adding NTG to a thrombolytic regimen with rt-PA, aspirin and heparin increases the magnitude of restored flow and total patency duration following recanalization in a rabbit model of arterial thrombosis." | 3.69 | Beneficial effect of nitroglycerin on arterial rethrombosis after thrombolysis. Results from a rabbit thrombosis model. ( Battler, A; Chernine, A; Hasdai, D; Kornowski, R; Ovadia, Z, 1995) |
| "Hirulog, a thrombin-specific inhibitor, has shown efficacy in reducing arterial thrombosis in patients treated with aspirin who require angioplasty or have unstable angina." | 3.69 | Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model. ( Alving, BM; Barr, CF; Gomez, ER; Hamelink, JK; Jackson, MR; Reid, TJ; Tang, DB, 1995) |
| " Aspirin alone or in combination with heparin has little effect on evolving thrombosis." | 3.69 | Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy. ( Badimon, JJ; Badimon, L; Chesebro, JH; Fernández-Ortiz, A; Fuster, V; Mailhac, A; Meyer, BJ, 1994) |
| " Using a described model of microarterial thrombosis, the antithrombotic effects of oral aspirin (ASA) were assessed in rats." | 3.69 | The role of various antithrombotic agents in microvascular surgery. ( Buckley, RC; Das, SK; Davidson, SF, 1994) |
| " To compare its antiaggregating capacity with that of aspirin, experimental thrombosis was induced in all dogs by means of direct current applied to the carotid artery." | 3.69 | Prevention of arterial thrombosis by a monoclonal antibody against the 100 to 109 amino acid sequence stretch of the beta-subunit of the human platelet fibrinogen receptor: a comparative study with low dose aspirin. ( Alvarez, L; Alvarez, MV; Castillo-Olivares, JL; de Haro, J; Escudero, C; González, J; Jorge-Herrero, E; Millán, I, 1994) |
| "Thrombin inhibition with heparin or r-hirudin significantly accelerated thrombolysis of occlusive platelet-rich thrombosis, but only the best antithrombotic therapy (r-hirudin) eliminated or nearly eliminated residual thrombus." | 3.69 | Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin. ( Chesebro, JH; Fuster, V; Grill, DE; Heras, M; Holmes, DR; Mruk, JS; Webster, MW; Zoldhelyi, P, 1996) |
| " The purpose of the present study was to examine the formation and resolution of left ventricular thrombi during the first month in patients with acute anterior myocardial infarction treated with streptokinase and aspirin." | 3.69 | Dynamics of left ventricular thrombi in patients with acute anterior myocardial infarction treated with thrombolytics. ( Eriksson, P; Karp, KH; Mooe, T; Teien, DE, 1995) |
| "With routine thrombolytic and aspirin treatment of anterior myocardial infarction, left ventricular thrombi usually resolve during the first month after hospital discharge." | 3.69 | Long term follow up of patients with anterior myocardial infarction complicated by left ventricular thrombus in the thrombolytic era. ( Eriksson, P; Karp, K; Mooe, T; Teien, D, 1996) |
| "Inogatran (MW 439 Da), a new, selective, active site inhibitor of thrombin, was evaluated in three rat models of thrombosis." | 3.69 | Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. ( Börjesson, I; Elg, M; Gustafsson, D; Lenfors, S; Teger-Nilsson, AC, 1996) |
| "The efficacy and safety of aspirin in the prevention and treatment of thrombosis in essential thrombocythaemia (ET) was retrospectively analysed in a cohort of 68 ET patients." | 3.69 | Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. ( Michiels, JJ; Mulder, PG; van de Moesdijk, D; van Genderen, PJ; Waleboer, M, 1997) |
| "Treatment with warfarin was most effective in preventing recurrent arterial and venous thrombosis." | 3.69 | A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. ( Harris, EN; Krnic-Barrie, S; Looney, SW; O'Connor, CR; Pierangeli, SS, 1997) |
| "We determined the effects of aspirin and a novel thromboxane A2/prostaglandin endoperoxide (TP)-receptor antagonist, BMS-180291, on thrombosis and bleeding times in skin and mesenteric arteries." | 3.68 | Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis. ( Heran, CL; Ogletree, ML; Schumacher, WA; Steinbacher, TE; Youssef, S, 1993) |
| "The antithrombotic effects of the thromboxane (TX) A2-receptor antagonist and aspirin were determined using a photochemically-induced arterial thrombosis model in the femoral arteries of guinea pigs." | 3.68 | Inhibitory effect of KW-3635, a new thromboxane A2-receptor antagonist, on arterial thrombosis in guinea pigs. ( Higo, K; Karasawa, A, 1993) |
| "This model of arterial thrombosis induced by laser was used to evaluate the effect of aspirin (Aspegic) on embolization." | 3.68 | Effects of aspirin on embolization in an arterial model of laser-induced thrombus formation. ( Doutremepuich, C; Doutremepuich, F; Lalanne, MC; Vesvres, MH, 1993) |
| "The antithrombotic effects of the stable PGI2-analogue Cicaprost, acetylsalicylic acid (Aspisol), the low molecular weight heparin CY 216 (Fraxiparin) and Molsidomin (Corvaton) have been investigated alone and in combinations in a thrombosis model in rats in which mesenteric venules with a diameter of 20-30 microns were injured by defined argon laser lesions." | 3.68 | Effects of combinations of a prostacyclin analogue (Cicaprost) with different antithrombotic agents in a rat microcirculatory thrombosis model. ( Breddin, HK; Giedrojc, J, 1992) |
| "The activity of isosorbide dinitrate (ISDN) a nitrate derivative with platelet anti-aggregant properties, was studied on a model of arterial thrombosis by electric stimulation of the rat carotid arteries." | 3.68 | [Experimental antithrombotic activity of oral isosorbide dinitrate]. ( Allix, M; Boulu, R; Guillou, J; Plotkine, M, 1992) |
| " The comparative antithrombotic efficacies of recombinant antistasin (rATS), standard heparin (Hep), and aspirin (ASA) administered adjunctly with recombinant tissue-type plasminogen activator (tPA) on thrombolytic reperfusion and reocclusion were determined in a canine model of femoral arterial thrombosis." | 3.68 | Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis. ( Dunwiddie, CT; Holahan, MA; Lynch, JJ; Mellott, MJ; Vlasuk, GP, 1992) |
| "The potential antithrombotic effect of aspirin and metoclopramide were studied in a model of arterial thrombosis in rats." | 3.68 | Enhancement of antithrombotic effect of aspirin by metoclopramide in rats. ( al-Humayyd, MS; Mobarok Ali, AT, 1991) |
| "A 28-year-old women with idiopathic thrombocytosis was treated with melphalan before pregnancy, which resulted in a normal platelet count." | 3.68 | Idiopathic thrombocythemia and pregnancy; a case report. ( Minkhorst, AG; Nováková, IR; van Dongen, PW, 1991) |
| "Two recombinant hirudins (r-hirudin), natural hirudin and hirudin in combination with heparin or acetylsalicylic acid (ASA) have been studied in a thrombosis model in which rat mesenteric venules of a diameter of 20-30 microns were injured by well-defined argon laser lesions." | 3.68 | Effects of different hirudins and combinations of low doses of hirudin, heparin and acetylsalicylic acid in a rat microcirculatory thrombosis model. ( Breddin, HK; Krupinski, K, 1991) |
| "Defibrotide, acetylsalicylic acid, low molecular weight heparin (CY 216), sodium heparin, Molsidomin and a thromboxane receptor antagonist have been investigated separately and in combinations in an animal thrombosis model in which rat mesenteric venules are damaged by defined laser energy." | 3.68 | Anticoagulant and antithrombotic effects of combinations of defibrotide with heparins and other antithrombotic agents in an animal thrombosis model. ( Breddin, HK; Giedrojc, J, 1991) |
| " Aspirin at a dose of 325 mg daily beginning after catheter placement and continuing until completion of stem cell collection has been associated with a reduction in the frequency of catheter thrombosis from 12/60 (20%) to 1/31 (3." | 3.68 | Translumbar inferior vena cava catheters. ( Haire, WD; Kessinger, A; Lieberman, RP; Lund, GB, 1991) |
| "The effects of nifedipine (Nif), aspirin (ASA) and ASA + Nif on platelet aggregation and generation of thrombosis were studied." | 3.68 | [Effects of the combination of aspirin and nifedipine on platelet aggregation and thrombogenesis]. ( Dong, E; Shi, S, 1990) |
| "A series of 1,4-dihydropyridines (DHP) bound to 1,2-benzisothiazol-3-ones were synthesized and evaluated for their ability to inhibit platelet aggregation induced by collagen in human platelet-rich plasma (PRP) and to protect mice against experimental thrombosis." | 3.67 | Synthesis, platelet aggregation inhibitory activity, and in vivo antithrombotic activity of new 1,4-dihydropyridines. ( Cillero, FJ; Fau de Casa-Juana, M; Ortega, MP; Priego, JG; Sunkel, CE, 1988) |
| "The antithrombotic effects of four compounds structurally related to aspirin (acetylsalicylic acid, ASA) were examined in a rat model of arterial thrombosis and compared to ASA." | 3.67 | The effects of high doses of aspirin and related benzoic acid derivatives on arterial thrombosis in male rats. ( Killackey, BA; Killackey, JJ; Philp, RB, 1984) |
| "Pretreatment of rats by the cyclooxygenase inhibitors diclofenac, phenylbutazone, and aminophenazone did not influence kappa-carrageenin (KC) rat tail thrombosis (RTT) whereas pretreatment by aspirin, at high doses, and particularly sulfinpyrazone decreased RTT frequency, PGI2 or iloprost i." | 3.67 | Role of eicosanoids in the kappa-carrageenin rat tail thrombosis. ( Bekemeier, H; Hirschelmann, R, 1988) |
| "Two highly sensitive models of arterial and venous thrombosis forming with the test of endothelial stability a complementary system with a maximum stress on the role of vascular lesion were used to test a series of four antithrombotic drugs (heparin, acetylsalicylic acid, dipyridamole, sulfinpyrazone) and four drugs with other indications but with an antithrombotic activity in experiment (prenylamine, troxerutin, ketanserin and pizotifen)." | 3.67 | Antithrombotics in view of thrombosis models. ( Hladovec, J, 1986) |
| "The effect of the combined oral administration of pentoxifylline (pof) and low dose acetylsalicylic acid (ASA) was evaluated with the help of the laser-induced thrombosis in rat mesenteric arterioles." | 3.67 | Surprising effects of the sequential administration of pentoxifylline and low dose acetylsalicylic acid on thrombus formation. ( Seiffge, D; Weithmann, KU, 1987) |
| " Capsaicin was effective in preventing death caused by ADP-induced acute pulmonary thromboembolism in mice at dose of 25 mg/kg, while aspirin and indomethacin had no effect at 200 mg/kg." | 3.67 | Antihemostatic and antithrombotic effects of capsaicin in comparison with aspirin and indomethacin. ( Hsu, MF; Hsu, TP; Teng, CM; Wang, JP, 1985) |
| "We have studied the effect of different doses of aspirin on platelet function, PGI2 formation, platelet survival, thrombosis, fibrinolysis, and prothrombin time in rabbits with indwelling aortic catheters." | 3.66 | Effect of aspirin and sodium salicylate on thrombosis, fibrinolysis, prothrombin time, and platelet survival In rabbits with indwelling aortic catheters. ( Cattaneo, M; Chahil, A; Kinlough-Rathbone, RL; Mustard, JF; Packham, MA; Somers, D, 1983) |
| "The effect of different dosage regimens of aspirin was investigated in an experimental model of arterial thrombosis." | 3.66 | Paradoxical effect of high and low dose aspirin in experimental arterial thrombosis. ( Mörl, H; Thiessen, M; Walter, E; Zimmermann, R, 1980) |
| " The abnormalities were increased during episodes of clinical thrombosis and could be suppressed in two-thirds of cases by aspirin therapy." | 3.66 | Platelet and plasma beta thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis. ( Allington, MJ; Boughton, BJ; King, A, 1978) |
| "Recurrent mesenteric arterial thrombosis developed in a 56-year-old man with polycythemia vera (PV) despite therapy with heparin sodium, warfarin sodium, and standard doses of aspirin and dipyridamole." | 3.66 | Polycythemia vera and mesenteric arterial thrombosis. A disease association resulting from decreased platelet sensitivity to aspirin. ( Myers, TJ; Rickles, FR; Steinberg, WM, 1979) |
| "An experimental model of canine arterial thrombosis was used to study by prophylactic antithrombotic effectiveness of carbenicillin and ticarcillin, two semisynthetic penicillins which have been shown to inhibit platelet function in vivo." | 3.66 | Dose-dependent inhibition of experimental arterial thrombosis by carbenicillin and ticarcillin. ( Johnson, GJ; Lyman, BT; White, JG, 1978) |
| "Because thrombus formation at the site of endothelial injury has been thought to be a critical step in the pathogenesis of bacterial endocarditis, the effect of aspirin on experimental valvular thrombosis and bacterial endocarditis in rabbits was evaluated." | 3.65 | Effect of aspirin on thrombogenesis and on production of experimental aortic valvular Streptococcus viridans endocarditis in rabbits. ( Carrizosa, J; Levison, ME; Rubin, W; Schick, PK; Tanphaichitra, D, 1977) |
| " Since 1968 the antithrombotic activity of Aspirin has been under study, and Aspirin has proven effective in preventing arterial thrombosis." | 3.65 | [Ovulation inhibitors from a neurological viewpoint]. ( Gschwend, J, 1976) |
| " The UNIVERSE Study evaluated the efficacy and safety of a novel liquid rivaroxaban formulation, using a body weight-adjusted dosing regimen, versus acetylsalicylic acid (ASA) in children post-Fontan." | 3.01 | Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. ( Harris, KC; Jefferies, JL; Justino, H; Li, JS; Lu, W; McCrindle, BW; Michelson, AD; Miriam Pina, L; Nessel, K; Pablo Sandoval, J; Peluso, C; Suzana Horowitz, E; Van Bergen, AH, 2021) |
| " Aspirin, a key antiplatelet agent, has inconsistent effects on outcomes in diabetes and the best dosing regimen remains unclear." | 3.01 | A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control. ( Ajjan, RA; Grant, PJ; Hawkins, F; Kurdee, Z; Naseem, KM; Parker, WAE; Sagar, R; Storey, RF, 2021) |
| "The primary endpoint was thrombus size at the post-randomization visit with platelet reactivity following stimuli to arachidonic acid, collagen, adenosine diphosphate, and thrombin as secondary endpoints." | 2.94 | Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. ( Angiolillo, DJ; Baber, U; Badimon, JJ; Dangas, G; Escolar, G; Farhan, S; Fuster, V; Gibson, CM; Gurbel, P; Joyce, L; Kini, AS; Mehran, R; Sartori, S; Sharma, SK; Vogel, B; Zafar, MU, 2020) |
| " In Part A, rivaroxaban pharmacokinetics, pharmacodynamics, safety, and tolerability are assessed to validate the pediatric dosing selected." | 2.90 | Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study). ( Bonnet, D; Dong, X; Harris, KC; Jefferies, J; Justino, H; Li, JS; McCrindle, BW; Michelson, AD; Pina, LM; Samtani, MN; Zhang, L, 2019) |
| "Patients with type 2 diabetes mellitus (T2DM) are at higher risk of thrombotic complications." | 2.87 | Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease. ( Cao, PG; Guo, DD; Quan, AJ; Shang, LL; Zhao, HY, 2018) |
| "Tiny cerebral aneurysms can be safely and effectively treated with appropriate endovascular approaches based on aneurysm specific morphology, especially neck size and neck-to-dome ratio." | 2.87 | Tiny Cerebral Aneurysms Can Be Treated Safely and Effectively with Low-Profile Visualized Intraluminal Support Stent-Assisted Coiling or Coiling Alone. ( Gao, BL; Li, L; Li, TX; Xu, GQ; Yang, BW, 2018) |
| " The optimal dosage of ASA is not known." | 2.84 | Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid. ( Ander, C; Dalén, M; Hjemdahl, P; Ivert, T; Lordkipanidzé, M; Näsman, P; Stålesen, R, 2017) |
| "Thrombus is one of the major threatening factors to human health and the prevalence of cardio-cerebrovascular diseases induced by thrombus is growing worldwide, even some persons got rare and severe blood clots after receiving the AstraZeneca COVID vaccine unexpectedly." | 2.82 | Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs. ( Bai, T; Feng, Q; Guo, T; Jia, J; Li, X; Liu, Y; Pei, J; Song, Y; Wu, L; Wu, S; Zhang, Y; Zheng, X, 2022) |
| " In terms of cardiovascular and cerebrovascular adverse events, other 3 interventions were higher than L-DAPT (Std-DAPT [OR = 1." | 2.82 | Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis. ( Feng, T; Li, D; Luo, L; Ran, J; Tang, K; Wang, D; Wang, S; Wu, J; Xu, L; Yang, X; Zhang, L; Zhao, D, 2022) |
| "Dabigatran is a direct acting (anti-II) oral anticoagulant which does not interfere with CYP and has favourable safety and efficacy profiles compared with VKAs." | 2.82 | Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. ( Ajjan, RA; Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Franchi, F; Guzman, LA; King, R; Phoenix, F; Rollini, F; Tello-Montoliu, A; Zenni, MM, 2016) |
| "Reductions in thrombus area under high shear conditions correlated with reductions in platelet count (r²=0." | 2.79 | Antithrombotic properties of rafigrelide: a phase 1, open-label, non-randomised, single-sequence, crossover study. ( Balasubramaniam, K; Dragone, J; Grose-Hodge, R; Martin, P; Preston, P; Troy, S; Viswanathan, G; Zaman, AG, 2014) |
| " Coagulation biomarkers in shed blood were assessed at 3 h after monotherapy with the medicines under study, at 3 h after triple therapy dosing and at steady state trough conditions." | 2.79 | Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects. ( Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M, 2014) |
| "The highest incidence of intra-stent thrombus was observed in tertile 1 followed by tertiles 2 and 3 in LOF carriers, whereas there was no such difference in non-carriers." | 2.78 | Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers. ( Hariki, H; Hiranuma, N; Hirata, K; Inoue, T; Iwasaki, M; Kinutani, H; Konishi, A; Kuroda, M; Nakagawa, M; Nishio, R; Osue, T; Otake, H; Shinke, T; Taniguchi, Y, 2013) |
| " Major adverse cardiovascular events, stent thrombosis, target lesion revascularization (TLR), target vessel revascularization, and bleeding events were analyzed after 1-year follow-up." | 2.78 | Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. ( Gao, W; Ge, H; Guo, Y; Zhang, Q; Zhou, Z, 2013) |
| "Primary endpoint (intention to treat) was thrombosis, intracardiac or embolic (all events adjudicated)." | 2.76 | A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. ( Andrew, M; Cochrane, A; Hughes, M; Manlhiot, C; McCrindle, BW; Monagle, P; Roberts, R; Szechtman, B; Weintraub, R, 2011) |
| "Even very short-term dual antiplatelet therapy seems safe after coronary stenting with Genous in de novo coronary artery lesions located in secondary branch vessels." | 2.76 | Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial. ( Biondi-Zoccai, G; Bramucci, E; Colombo, A; Ferlini, M; Grinfeld, L; Iadanza, A; Morice, MC; Petronio, AS; Pierli, C; Sangiorgi, GM, 2011) |
| "Treatment with dipyridamole plus aspirin significantly prolonged the duration of primary unassisted patency (hazard ratio, 0." | 2.74 | Effect of dipyridamole plus aspirin on hemodialysis graft patency. ( Allon, M; Beck, GJ; Braden, GL; Cotton, JR; Davidson, IJ; Delmez, JA; Dember, LM; Dixon, BS; Feldman, HI; Fenves, AZ; Gassman, JJ; Greenberg, A; Greene, T; Himmelfarb, J; Hu, B; Ikizler, TA; Kaufman, JS; Kusek, JW; Lawson, JH; Martin, KJ; McNeil, JW; Meyers, CM; Radeva, MK; Rahman, A; Vazquez, MA; Whiting, JF, 2009) |
| "Essential thrombocythemia is associated with an increased risk of thromboembolic complications." | 2.74 | The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia. ( Chojnowski, K; Robak, T; Smolewski, P; Treliński, J; Tybura, M, 2009) |
| "Metabolic syndrome is associated with intravascular inflammation, as determined by increased levels of inflammatory biomarkers and an increased risk of ischemic atherothrombotic events." | 2.74 | PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. ( Cable, G; Willerson, JT; Yeh, ET, 2009) |
| "Catheter thrombosis has never been reported in any trial using bivalirudin." | 2.73 | Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study. ( Buerke, M; Carter, JM; Hauroeder, B; Maegdefessel, L; Michel, T; Peetz, D; Reindl, I; Schlitt, A; Schubert, S; Werdan, K, 2008) |
| "Inhibiting thrombosis is a cornerstone of vascular protection." | 2.72 | Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction. ( Al-Omran, M; Bhatt, DL; Choi, R; Eikelboom, JW; Heffernan, M; Teoh, H; Verma, S, 2021) |
| " It has been proposed that shortening the ASA dosing interval may overcome the time-dependent renewal of the drug target, leading to a greater antiplatelet effect." | 2.72 | Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: Systematic Review and Meta-Analysis. ( Caldeira, D; Costa, J; Duarte, GS; Ferreira, J; Mainoli, B, 2021) |
| "Venous thromboembolism is a common complication of patients with hematologic malignancies, due both to release of procoagulant factors by tumor cells and to external factors, such us drugs." | 2.72 | Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going? ( Chistolini, A; Fazio, F; Lapietra, G; Petrucci, MT; Serrao, A, 2021) |
| "Graft thrombosis is a well-recognised complication of solid organ transplantation and is one of the leading causes of graft failure." | 2.72 | Interventions for preventing thrombosis in solid organ transplant recipients. ( Hanley, J; Hoather, TJ; Surianarayanan, V; Thompson, ER; Tingle, SJ; Wilson, CH, 2021) |
| " The endpoints of efficacy include major adverse cardiac events (MACEs), all-cause mortality, and the number of target vessel revascularization." | 2.72 | Efficacy and Safety of Aspirin Combined with Low-Dose P2Y12 Receptor Antagonists in East Asian Patients Undergoing PCI. ( Hu, H; Hu, X; Luo, S; Zhang, Q; Zhao, W, 2021) |
| "Arterial thrombus formation was induced ex vivo by exposing a collagen-coated surface in a parallel-plate perfusion chamber to native blood for 3 min (arterial wall shear rate 2600 s(-1))." | 2.71 | Superior efficacy of clopidogrel plus acetylsalicylic acid compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombogenesis in healthy volunteers. ( Boneu, B; Cadroy, Y; Sakariassen, K; Thalamas, C, 2005) |
| "Both aspirin and dextran were well tolerated." | 2.69 | Prophylaxis for deep vein thrombosis with aspirin or low molecular weight dextran in Korean patients undergoing total hip replacement. A randomized controlled trial. ( Cho, JL; Choi, IY; Kim, YH; Park, MR; Park, TS, 1998) |
| "Total thrombus area and areas occupied by platelet aggregates and fibrin layers were quantified by planimetry." | 2.69 | Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab. ( Ambrose, JA; Badimon, JJ; Coller, BS; Dangas, G; Fallon, JT; Hayes, RM; Marmur, JD; Meraj, P; Sharma, SK, 1998) |
| "In contrast, platelet thrombus formation was blocked by more than 90% in volunteers treated by aspirin + ticlopidine (P < ." | 2.69 | A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. ( Barret, A; Boneu, B; Bossavy, JP; Cadroy, Y; Sagnard, L; Sakariassen, K; Thalamas, C, 1998) |
| "Aspirin treatment attenuated certain signs of platelet activity in vivo at rest and fMLP-induced neutrophil activation in vitro, but it did not attenuate the prothrombotic effects of exercise." | 2.69 | Evidence for prothrombotic effects of exercise and limited protection by aspirin. ( Hjemdahl, P; Li, N; Wallén, NH, 1999) |
| "Abciximab produced a 58% reduction in thrombus formation (11,631 +/- 861 vs 4, 925 +/- 585 microm(2); p <0." | 2.69 | Antithrombotic effects of abciximab. ( Badimon, JJ; Badimon, L; Chesebro, JH; Coller, BS; Dangas, G; Fallon, JT; Fuster, V; Hayes, R; Marmur, JD; Sharma, SK, 2000) |
| " These results suggest that while waiting for the technological advancements of stents, postprocedural treatment that includes a low dosage of ticlopidine, aspirin, and low-molecular-weight heparin is a very effective alternative to conventional poststenting therapy." | 2.68 | Intracoronary stenting without coumadin: one month results of a French multicenter study. ( Benveniste, E; Biron, Y; Bourdonnec, C; Faivre, R; Fajadet, J; Gaspard, P; Glatt, B; Joly, P; Morice, MC; Zemour, G, 1995) |
| "In conclusion, LV thrombosis is frequent after thrombolytic therapy for AAMI, and impaired LV wall motion represents an independent predisposing factor." | 2.67 | Left ventricular thrombosis and arterial embolism after thrombolysis in acute anterior myocardial infarction: predictors and effects of adjunctive antithrombotic therapy. ( Dale, J; Hegrenaes, L; Kontny, F; Lem, P; Morstøl, T; Søberg, T, 1993) |
| "Indeed, Kawasaki disease is induced by overreaction of innate cells following exposition to various viruses, including herpes viruses which trigger STING." | 2.66 | Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway? ( Berthelot, JM; Drouet, L; Lioté, F, 2020) |
| "Chronic obstructive pulmonary disease (COPD) is a heterogeneous multisystem disease, causing significant morbidity and mortality worldwide." | 2.66 | Platelets in chronic obstructive pulmonary disease: An update on pathophysiology and implications for antiplatelet therapy. ( Ball, S; Mallah, H; Nugent, K; Parmar, K; Sekhon, J, 2020) |
| "LV thrombosis was detected by echocardiography in 30 (33%) of the 92 evaluable patients (15 patients given ASA and 15 given placebo)." | 2.66 | Effect of low dose acetylsalicylic acid on the frequency and hematologic activity of left ventricular thrombus in anterior wall acute myocardial infarction. ( den Hollander, W; Galema, TW; Küpper, AJ; Peels, CH; Roos, JP; Verheugt, FW, 1989) |
| " At the end of each dosing interval we measured platelet aggregation and thromboxane formation in response to four aggregating agents and to whole blood coagulation." | 2.66 | A dose-ranging study of the antiplatelet effect of enteric coated aspirin in man. ( Bochner, F; Duncan, EM; Herd, CM; Lloyd, JV; Rodgers, SE; Tunbridge, LJ, 1987) |
| " Dosing for neuroendovascular conditions is often extrapolated from the cardiac literature, although outcomes in cardiac patients may not be relevant to neurologic patients, making prophylactic treatment recommendations challenging for these patients." | 2.61 | Periprocedural Neuroendovascular Antiplatelet Strategies for Thrombosis Prevention in Clopidogrel-Hyporesponsive Patients. ( Barra, ME; Berger, K; Brophy, GM; Tesoro, EP, 2019) |
| " Efficacy outcomes included ischemic stroke, stent thrombosis, major adverse cardiovascular event (MACE), all-cause mortality and myocardial infarction (MI); safety outcome was major bleeding." | 2.58 | Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis. ( Huang, J; Liu, L; Tang, X; Zhang, X, 2018) |
| "We sampled incident prostate cancer cases from two large U." | 2.55 | Do Aspirin and Other NSAIDs Confer a Survival Benefit in Men Diagnosed with Prostate Cancer? A Pooled Analysis of NIH-AARP and PLCO Cohorts. ( Abnet, CC; Cook, MB; Daugherty, SE; Freedman, ND; Liao, LM; Pfeiffer, R; Zhou, CK, 2017) |
| "Activated platelets initiate thrombus formation." | 2.55 | Is arachidonic acid stimulation really a test for the response to aspirin? Time to think again? ( Ashby, A; Curzen, N; Khanna, V; Mahmoudi, M; Mariathas, M; Olechowski, B, 2017) |
| " Cilostazol-based TAPT compared with DAPT is associated with improved angiographic outcomes and decreased risk of TLR and TVR but does not reduce major cardiovascular events and is associated with an increase in minor adverse events." | 2.52 | Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. ( Bai, J; Chen, J; Chen, P; Eikelboom, JW; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Xu, L; Yang, Z; Zou, F, 2015) |
| "For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched June 2014) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 5)." | 2.52 | Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. ( Acosta, S; Bedenis, R; Lethaby, A; Maxwell, H; Prins, MH, 2015) |
| " Endpoints included major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR), death, stent thrombosis, bleeding and adverse drug reactions during a 9-12 months period, as well as platelet activities." | 2.52 | Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. ( Bundhun, PK; Chen, MH; Qin, T, 2015) |
| "In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb." | 2.50 | Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014) |
| "Biomarker testing for efficacy of therapy is an accepted way for clinicians to individualize dosing to genetic and/or environmental factors that may be influencing a treatment regimen." | 2.50 | The current and future landscape of urinary thromboxane testing to evaluate atherothrombotic risk. ( Berger, JS; Boone, JL; Jefferies, JL; Jesse, RL; Maisel, AS; McConnell, JP; McCullough, PA; Neath, SX; Wu, AH, 2014) |
| "Warfarin is a potent anticoagulant agent to prevent functional completion of vitamin K dependent coagulant factors." | 2.50 | [Historical and future perspective of antithrombotic agents]. ( Goto, S, 2014) |
| "Fibrin is an important contributor to thrombogenesis and may account for the residual event rates." | 2.50 | Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome. ( White, H, 2014) |
| " Currently available antiplatelet drugs have some limitations which might be overcomed by improved dosing regimens, use of combination of agents affecting different platelet functions and, in particular, by the new antiplatelet drugs (new arterial antithrombotics) with distinct pharmacodynamic properties offering new advantages, including faster onset of action, greater potency, and reversibility of effects." | 2.49 | [Present and future of pharmaco-arteriothromboprophylaxis in clinical practice. Guidelines of Angiology Section of Slovak Medical Chamber]. ( Dukát, A; Gašpar, L; Gavornik, P, 2013) |
| "Enlargement of an abdominal aortic aneurysm (AAA) is usually associated with the development of an intraluminal mural thrombus (ILT)." | 2.49 | Anti-platelet treatment of middle-sized abdominal aortic aneurysms. ( Björck, M; Lindholt, JS; Michel, JB, 2013) |
| "Obesity is associated with increased cardiovascular disease." | 2.48 | Platelet activation in obesity and metabolic syndrome. ( Davì, G; Guagnano, MT; Liani, R; Santilli, F; Vazzana, N, 2012) |
| "Treatment with busulfan or interferon-α is usually effective in hydroxyurea failures." | 2.48 | Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. ( Tefferi, A, 2012) |
| "Atherothrombosis is the major cause of mortality and morbidity in Western countries." | 2.48 | Thromboxane receptors antagonists and/or synthase inhibitors. ( Davì, G; Santilli, F; Vazzana, N, 2012) |
| "Patients with type 2 diabetes mellitus are characterized by increased incidence of cardiovascular events and enhanced thromboxane-dependent platelet activation." | 2.47 | TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus. ( Davì, G; Mucci, L; Santilli, F, 2011) |
| " The secondary end point assessed by three of these studies was major adverse cardiac events (MACEs: cardiovascular death, myocardial infarction and thromboembolic complications)." | 2.47 | Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation. ( Arora, R; Bedi, U; Khosla, S; Molnar, J; Singh, M; Singh, PP, 2011) |
| "Treatment with aspirin and heparin decreases the risk of miscarriages in APS." | 2.47 | Heparin or aspirin or both in the treatment of recurrent abortions in women with antiphospholipid antibody (syndrome). ( Burmester, GR; Dörner, T; Hoppe, B, 2011) |
| "Activated platelets stimulate thrombus formation in response to rupture of an atherosclerotic plaque or endothelial cell erosion, promoting atherothrombotic disease." | 2.47 | Antiplatelet therapy: thrombin receptor antagonists. ( Angiolillo, DJ; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011) |
| "Obstetric antiphospholipid antibody syndrome (APS) is diagnosed in the presence of certain clinical features in conjunction with positive laboratory findings." | 2.47 | Obstetric antiphospholipid syndrome: an update on pathophysiology and management. ( Ernest, JM; Kutteh, WH; Marshburn, PB, 2011) |
| "Age and history of thrombosis are the criteria used to stratify patients to the most appropriate therapeutic options." | 2.46 | JAK2 mutation and thrombosis in the myeloproliferative neoplasms. ( Vannucchi, AM, 2010) |
| "If acetylsalicylic acid therapy is maintained, short-term discontinuation of a thienopyridine may be relatively safe in patients with drug-eluting stents." | 2.45 | Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. ( Eisenberg, MJ; Filion, KB; Libersan, D; Richard, PR, 2009) |
| " In the forth communication we consider data of randomized studies in which efficacy and safety of clopidogrel in combination with has acetylsalicylic acid (ASA) been assessed in comparison with (ASA) in various acute coronary syndromes (ACS), as well as before, during, and after percutaneous coronary interventions (PCI)." | 2.45 | [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part IV. therapeutic application of clopidogrel in combination with acetylsalicylic acid in acute coronary syndromes and percutaneous coronary interventions]. ( Avsar, O; Batyraliev, TA; Fettser, DV; Islek, M; Preobrazhenskiĭ, DV; Sidorenko, BA; Vural, A, 2009) |
| "Atherothrombosis is a progressive and generalized pathologic process that affects the vascular system." | 2.44 | Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. ( Brown, MT; Kikano, GE, 2007) |
| "As well as initiating thrombus formation at the site of a ruptured atherosclerotic plaque, platelets play a key role in vascular inflammation, through release of their own pro-inflammatory mediators and interactions with other relevant cell types (endothelial cells, leukocytes, and smooth muscle cells)." | 2.44 | Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. ( Badimon, JJ; Bhatt, DL; Herbert, JM; Lüscher, TF; Steinhubl, SR, 2007) |
| "The antiphospholipid syndrome is an antibody mediated hypercoagulable state characterized by recurrent venous and arterial thromboembolic events." | 2.44 | [The antiphospholipid syndrome, an update]. ( Alonso Santor, JE; Inglada Galiana, L; Pérez Paredes, G, 2007) |
| "Aspirin has potential risks." | 2.44 | Aspirin and reproductive outcomes. ( Brancazio, LR; James, AH; Price, T, 2008) |
| "Atherothrombosis is a generalized and progressive process with an inflammatory component." | 2.44 | Role of antiplatelet agents in the primary and secondary prevention of atherothrombotic events in high risk-patients. ( Ellahham, S, 2008) |
| " There is a major thrust on the development of orally bioavailable anticoagulant drugs (anti-Xa and anti-IIa agents), which are slated to replace oral anticoagulants." | 2.44 | Survival of heparins, oral anticoagulants, and aspirin after the year 2010. ( Adiguzel, C; Bick, R; Clarke, M; Demir, M; Fareed, D; Fareed, J; Hoppensteadt, DA; Wahi, R, 2008) |
| " There is a major thrust on the development of orally bioavailable anti-Xa and IIa agents, which are slated to replace oral anticoagulants." | 2.44 | Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? ( Adiguzel, C; Bick, R; Clarke, M; Cunanan, J; Demir, M; Fareed, J; Iqbal, O; Wahi, R, 2008) |
| "Thrombosis has a proinflammatory component whereby biologically active substances are synthesized by different cell types that could not individually synthesize the metabolite(s)." | 2.43 | Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. ( Broekman, MJ; Drosopoulos, JH; Islam, N; Levi, R; Marcus, AJ; Olson, KE; Pinsky, DJ, 2005) |
| " However, since ASS does not influence the mortality but is significantly increasing the risk for bleeding, careful risk stratification is indispensable prior to preventive chronic administration of the drug." | 2.43 | [Oral antithrombotic therapy in primary and secondary prevention]. ( Elsässer, A; Hamm, CW; Möllmann, H, 2005) |
| " Regardless of the accumulated evidence on the molecular mechanisms of aspirin's action, the rationale of the appropriate dosing and monitoring of aspirin therapy and prophylaxis remains obscure." | 2.43 | [Aspirin--the prodigious panacea? Molecular mechanisms of the action of acetylsalicylic acid in the organism]. ( Czyz, M; Watała, C, 2005) |
| "The antiphospholipid syndrome is currently best treated with anticoagulation." | 2.43 | Anticoagulation therapy in the antiphospholipid syndrome: recent advances. ( Crowther, MA; Ng, HJ, 2005) |
| "Recently, the thrombophilias have been revealed as risk factors for severe preeclampsia, abruptio placentae, fetal growth retardation, abortion and still birth as well." | 2.42 | [Anticoagulation and antiaggregation during pregnancy]. ( Biasiutti, FD; Strebel, JK, 2003) |
| "Aspirin treatment of erythromelalgia in thrombocythemia patients resulted in the disappearance of the erythromelalgic, thrombotic signs and symptoms, correction of the shortened platelet survival times, and a significant reduction of the increased levels of beta-TG, PF4, TM and urinary TxB2 excretion to normal." | 2.42 | Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. ( Michiels, JJ, 2003) |
| " Intravenous glycoprotein IIb/IIIa inhibitors effectively prevent periprocedural thrombotic complications, but their short duration of action and parenteral dosing don't allow for long-term protection." | 2.42 | What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? ( Berger, P; Steinhubl, S, 2003) |
| "We describe a case of thrombus formation on the left atrial disc of a CardioSeal Septal Occlusion device 14 days after transcatheter closure of a patent foramen ovale in a patient with a history of multiple cryptogenic strokes." | 2.42 | Left atrial thrombus formation on a CardioSeal Septal Occlusion device in a patient with elevated factor VIII: resolution with medical therapy. ( Hadley, T; Recto, MR; Sobczyk, W; Yeh, T, 2003) |
| " In the VIGOR gastrointestinal outcomes trial of >8000 patients, naproxen (an NSAID with aspirin-like sustained antiplatelet effects throughout its dosing interval) was associated with a significantly lower risk of CV events than was rofecoxib." | 2.42 | Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. ( Gertz, BJ; Reicin, A; Sperling, RS; Weir, MR, 2003) |
| "Thrombosis has a proinflammatory component whereby biologically active substances are synthesized by interactions between different cell types that could not individually synthesize the product(s)." | 2.42 | Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1). ( Broekman, MJ; Drosopoulos, JH; Islam, N; Levi, R; Marcus, AJ; Pinsky, DJ; Sesti, C, 2003) |
| "Arterial and venous thrombosis are the most common and clinically relevant events of the so-called antiphospholipid syndrome; they are reported in approximately one third of patients with the antiphospholipid (aPL) antibodies." | 2.41 | The epidemiology of the antiphospholipid syndrome: who is at risk? ( Finazzi, G, 2001) |
| "Thrombosis is of greater overall clinical importance in terms of morbidity and mortality than all of the hemorrhagic disorders combined." | 2.41 | Antithrombotic agents: implications in dentistry. ( Henry, RG; Little, JW; McIntosh, BA; Miller, CS, 2002) |
| "Aspirin has stood the test of time over decades as the gold standard for relatively effective, safe, and inexpensive antiplatelet therapy." | 2.40 | Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents. ( Schafer, AI, 1997) |
| "Aspirin is an approximately 150- to 200-fold more potent inhibitor of the (constitutive) isoform of the platelet enzyme (COX-1) than the (inducible) isoform (COX-2) which is expressed by cytokines, inflammatory stimuli, and some growth factors." | 2.40 | Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. ( Schrör, K, 1997) |
| "This may reflect a reduction in restenosis, although this remains to be proven." | 2.40 | Pharmacologic prevention of acute ischemic complications of coronary angioplasty. ( Cumberland, D; Wheeldon, N, 1997) |
| "Chronic hyperglycemia is then added to these risk markers." | 2.40 | Multifactorial aspects of the treatment of the type II diabetic patient. ( Colwell, JA, 1997) |
| "Placental infarction due to thrombosis seems to be the most consistent event." | 2.40 | Fertility, pregnancy and the management of myeloproliferative disorders. ( Bergmann, L; Griesshammer, M; Pearson, T, 1998) |
| "Erythromelalgia was localized in the forefoot sole and toes in 28, the fingertips in 9, the handpalm in 2." | 2.39 | Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. ( Lindemans, J; Michiels, JJ; van Genderen, PJ; van Vliet, HH, 1996) |
| "Total prevention of mural thrombus in deeply injured arteries is impossible with aspirin or conventional antithrombotic therapy, which can reduce occlusive thrombus." | 2.38 | Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins. ( Badimon, JJ; Badimon, L; Chesebro, JH; Roche, PC; Webster, MW; Zoldhelyi, P, 1992) |
| "Type I protein C deficiency was demonstrated in this patient as well as in his asymptomatic sister." | 2.38 | [Portal vein thrombosis and hereditary protein C deficiency. Presentation of a case and review of the literature]. ( Dupuis, E; Gameiro, L; Gervais, T; Pariente, EA; Trinh, DH; Viala, JF, 1992) |
| "Aspirin has been recognized as inhibiting normal platelet function and the mechanism has been clearly delineated." | 2.38 | Aspirin in the prevention of thrombosis. ( Bell, WR; Lekstrom, JA, 1991) |
| "Bleeding and thrombosis are major causes of morbidity and mortality in patients with myeloproliferative disorders." | 2.37 | Bleeding and thrombosis in the myeloproliferative disorders. ( Schafer, AI, 1984) |
| "Aspirin has significantly reduced both the occurrence of myocardial infarction and mortality rate in patients with unstable angina and/or previous myocardial infarction; it has also proved beneficial in cerebrovascular disease." | 2.37 | Current issues in thrombosis prevention with antiplatelet drugs. ( Cerletti, C; de Gaetano, G; Dejana, E; Vermylen, J, 1986) |
| "Aspirin has been shown in clinical trials to be an effective agent in treating transient ischemic attacks and preventing infarction." | 2.36 | Aspirin for prevention of stroke: a review. ( Fields, WS, 1983) |
| "A mobile thrombus of the thoracic aorta is a rare entity, which might have serious clinical manifestations, including arterial emboli." | 1.91 | A Mobile Thrombus of the Thoracic Aorta. ( Ajaj, M; Fajer, S; Haddad, M; Shehab, M; Shnaker, A; Wolf, A, 2023) |
| "Vascular stenosis caused by atherosclerosis instigates activation and aggregation of platelets, eventually resulting in thrombus formation." | 1.91 | Studying the efficacy of antiplatelet drugs on atherosclerosis by optofluidic imaging on a chip. ( Deng, Y; Fei, X; Goda, K; Hou, HW; Nishikawa, M; Tang, X; Tay, HM; Xiao, TH; Yatomi, Y; Zhou, Y, 2023) |
| "The Total Thrombus-formation Analysis System (T-TAS) was developed for the quantitative analysis of thrombus formation using microchips with thrombogenic surfaces." | 1.91 | Utility of the Total Thrombus-Formation Analysis System as a Tool for Evaluating Thrombogenicity and Monitoring Antithrombotic Therapy in Pediatric Fontan Patients. ( Ishii, M; Kaikita, K; Matsumoto, S; Matsuo, O; Miyamura, F; Morinaga, J; Nakamura, K; Tsujita, K, 2023) |
| "Aspirin treatment appears to be a reasonable choice for thrombocytopenic (> 30 × 109/l) patients with acute coronary syndrome." | 1.91 | [Which anticoagulant or antiplatelet treatment for cancer patients with thrombocytopenia ?] ( Azizi, MA; Efthymiou, A; Paoletti, M, 2023) |
| " In age-adjusted analyses, aspirin plus LMWH regardless of dosage was associated with significantly higher odds of live birth compared with no antithrombotic use (OR = 7." | 1.91 | Management and outcomes of women with antiphospholipid syndrome during pregnancy. ( Adurty, S; D'Angelo, D; DeSancho, MT; Tao, JJ, 2023) |
| "Aspirin is a well-known anti-platelet drug widely used for the prevention of cardiovascular events and systematic reviews suggest a possible benefit of low-dose aspirin (LDA) use in the prevention and treatment of ARDS in patients with COVID-19 infection." | 1.91 | Low dose aspirin and clinical outcomes in patients with SARS-CoV-2 pneumonia: a propensity score-matched cohort analysis from the National SIMI‑COVID‑19 Registry. ( Cimellaro, A; Daidone, M; Dalbeni, A; Giontella, A; Pietrangelo, A; Rossi, I; Sesti, G; Susca, N; Talerico, G; Villani, R; Zaccone, V, 2023) |
| "Death, stroke, and device-related thrombus were also similar; major bleeding was slightly increased in DOAC/aspirin patients (DAPT = 2." | 1.91 | DAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX: A National Registry Analysis. ( Allocco, DJ; Coylewright, M; Freeman, JV; Gibson, DN; Holmes, DR; Hsu, JC; Kapadia, SR; Nair, DG; Piccini, JP; Price, MJ; Yeh, RW, 2023) |
| " The collection days (CD) were the second and seventh days after stable aspirin dosing and then a convalescent time point 2-9 months later." | 1.72 | Urinary 11-dehydrothromboxane B2 aspirin efficacy testing is sensitive to perioperative inflammation in pediatric solid-organ transplant patients. ( Boucher, AA; Francisco, BJ; Luchtman-Jones, L; Martin, J; Martin, M; Nathan, JD; Pfeiffer, A; Shova, A; Tiao, GM, 2022) |
| "Presently Coronavirus disease 2019 is a huge human misery that is almost unstoppable with little remedy on board." | 1.72 | Beneficial Effect of Low Dose Aspirin in Adult Patients with COVID-19: A Retrospective Observational Study in Bangladesh. ( Husain, A; Kamal, SM; Morshed, ME; Sayem, MA, 2022) |
| "Similarly, thrombus weights were reduced in mice with impaired ITAM signaling (Clec2mKO + JAQ1; WT + ibrutinib) but not in Clec2mKO or WT + JAQ1 mice." | 1.72 | Both G protein-coupled and immunoreceptor tyrosine-based activation motif receptors mediate venous thrombosis in mice. ( Bergmeier, W; Cooley, BC; Holle, LA; Kawano, T; Lee, RH; Mackman, N; Mwiza, JMN; Nieswandt, B; Paul, DS; Schug, WJ; Wolberg, AS, 2022) |
| "Atherothrombosis, an atherosclerotic plaque disruption condition with superimposed thrombosis, is the underlying cause of cardiovascular episodes." | 1.72 | Atherothrombosis-on-Chip: A Site-Specific Microfluidic Model for Thrombus Formation and Drug Discovery. ( Adelnia, H; Akther, F; Fallahi, H; Nguyen, NT; Phan, HP; Ta, HT; Tran, HDN; Zhang, J, 2022) |
| "OACs plus single antiplatelet therapy and dual antiplatelet therapy alone are both safe and efficacious management strategies after CVSS stent placement." | 1.72 | Safety and efficacy comparison between OACs plus single antiplatelet and dual antiplatelet therapy in patients with cerebral venous sinus stenosis poststenting. ( Bai, C; Chen, Z; Ding, Y; Ilagan, R; Ji, X; Meng, R; Wu, X, 2022) |
| "Tirofiban is a safe addition to SOC and may be an effective strategy to prevent early mBTTS thrombosis." | 1.72 | Exploratory Use of Glycoprotein IIb/IIIa Inhibition in Prevention of Blalock-Taussig Shunt Thrombosis. ( Emani, SM; Piekarski, BL; Rogers, J; Thiagarajan, R; Zurakowski, D, 2022) |
| " The aim of our study was to investigate if the Syk inhibitor fostamatinib could be repurposed as an antiplatelet drug, either alone or in combination with conventional antiplatelet therapy." | 1.72 | Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs. ( Alenazy, FO; Harbi, MH; Nicolson, PLR; Smith, CW; Thomas, MR; Tiwari, A; Watson, SP, 2022) |
| "The treatment landscape in multiple myeloma (MM) has changed drastically in the past two decades with new treatment paradigms evolving." | 1.72 | Vascular thrombotic events in the era of modern myeloma therapy. ( Mai, EK, 2022) |
| "We report a case of acute renal infarction due to underlying arterial fibrillation, where a novel interventional therapeutic method was used." | 1.72 | A rare cause of abdominal pain managed unconventionally: acute renal infarction caused by atrial fibrillation: a case report. ( Ge, T; Song, EJ; Tang, S; Wang, J; Zhou, W; Zhu, Z, 2022) |
| " Sunitinib reduced thrombus formation and phosphatidylserine (PS) exposure under flow on collagen type I and III." | 1.72 | Tyrosine Kinase Inhibitor Sunitinib Delays Platelet-Induced Coagulation: Additive Effects of Aspirin. ( Aarts, MJB; Baaten, CCFMJ; Campello, E; Eble, JA; Fernández, DI; Heemskerk, JWM; Kuijpers, MJE; Peters, LJF; Simioni, P; Spiezia, L; Tullemans, BME; van der Meijden, PEJ; van der Vorst, EPC; Veninga, A, 2022) |
| "Rates of hemorrhage were similar for aspirin in combination with warfarin or direct-acting oral anticoagulants." | 1.72 | Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. ( Colucci, PM; Grunwald, MR; Lessen, DS; Paranagama, D; Zwicker, JI, 2022) |
| "Aspirin resistance was assessed using the VerifyNow™ test on infants with single-ventricle physiology following shunt-dependent palliation operations." | 1.72 | Aspirin resistance in infants with shunt-dependent congenital heart disease. ( Cooper, DS; Henry, B; Koh, W; Nebbia, A; Rodts, M; Sawyer, J, 2022) |
| "In LPS-treated mice, the PECAM-1/thrombus ratio decreased as the dose of ASA increased in both thrombosis models, but the direction of change in the thrombus area was inconsistent." | 1.62 | Utility of Platelet Endothelial Cell Adhesion Molecule 1 in the Platelet Activity Assessment in Mouse and Human Blood. ( Chabielska, E; Gromotowicz-Poplawska, A; Marcinczyk, N; Misztal, T; Radziwon, P; Rusak, T; Zebrowska, A, 2021) |
| "The degree of neovascularization, thrombus, calcification, inflammatory infiltrates, and fibrosis were analyzed histopathologically by hematoxylin and eosin staining." | 1.62 | Anti-thrombotic and anti-inflammatory activity of sulodexide compared to aspirin in the rat model. ( Jo, WM; Kim, JW; Kim, TS; Sohn, SH; Yoo, SM, 2021) |
| "After thrombus aspiration and intracoronary administration of 0." | 1.62 | Late Stent Thrombosis After Drug-Coated Balloon Coronary Angioplasty for In-Stent Restenosis. ( Chen, Y; Wang, B; Wang, W; Wei, S, 2021) |
| "Antiphospholipid syndrome is associated with recurrent pregnancy loss." | 1.62 | "Part of the Ritual": Exploring Patient and Physician Decision Making Regarding Anticoagulation Use in Obstetric Antiphospholipid Syndrome. ( Bates, SM; Gonsalves, C; Karovitch, A; Rodger, MA; Skeith, L; Taylor, TS, 2021) |
| "VWF is critically involved in thrombus formation at sites of stenotic extracranial/intracranial arteries." | 1.62 | The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients. ( Buchtele, N; Gelbenegger, G; Gilbert, JC; Greisenegger, S; Jilma, B; Kovacevic, KD; Langer, A; Pabinger, I; Petroczi, K; Zhu, S, 2021) |
| "The Total Thrombus Analysis System (T-TAS), which is a microfluidic assay that simulates conditions in vivo, measures whole blood flow at defined shear rates under conditions designed to assess platelet function (PL-chip) or coagulation and fibrin clot formation (AR-chip)." | 1.62 | Analysis of blood clotting with the total thrombus analysis system in healthy dogs. ( Fukushima, R; Iwanaga, T; Maruyama, I; Miura, N; Nagasato, T, 2021) |
| "Platelet thrombosis is the main pathogeny resulting in the low curability of ischemic stroke, a leading cause of mortality and disability worldwide." | 1.56 | Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke. ( Chen, Z; He, Y; Huang, W; Ji, C; Lee, KH; Li, S; Li, Y; Ming, Y; Morris-Natschke, SL; Niu, H; Wei, Z; Xin, G; Xing, Z; Yang, X; Yu, K; Zhang, B; Zhang, J; Zhang, X, 2020) |
| "SIGNIFICANCE: Thrombosis is a threat to human health, and there is an urgent need for new drug." | 1.56 | Plasma metabonomics and proteomics studies on the anti-thrombosis mechanism of aspirin eugenol ester in rat tail thrombosis model. ( Li, J; Li, S; Liu, X; Ma, N; Qin, Z; Yang, Y, 2020) |
| "The presence or absence of thrombus in the vein graft samples was recorded under light microscopy." | 1.56 | Drug-eluting Vein Graft with Acetylsalicylic Acid-Ticagrelor-Unfractionated Heparin Complex Inhibits Early Graft Thrombosis ( Akşit, E; Büyük, B; Çokkalender, Ö; Kurt, T, 2020) |
| "In total, 33 patients with acute Kawasaki disease were assessed." | 1.56 | Assessment of Platelet Thrombus Formation under Flow Conditions in Patients with Acute Kawasaki Disease. ( Fukuda, K; Ishiguro, A; Nogami, K; Sakai, T; Shima, M; Tsujii, N; Yoshizawa, H, 2020) |
| "His course was complicated by cytokine storm and COVID-19-associated coagulopathy." | 1.56 | Successful management of COVID-19 and associated coagulopathy in a patient with durable left ventricular assist device. ( Estep, J; Hodges, K; Hsich, E; Insler, J; Insler, S; Mubashir, M; Soltesz, E; Tong, M, 2020) |
| "Left ventricular mural thrombus (LVMT) is a life-threatening complication in patients with left ventricular dysfunction." | 1.56 | Discontinuation of aspirin before non-cardiac surgery causing ventricular mural thrombus for a patient with left ventricular aneurysm: a case report. ( Huang, L; Wang, K; Zhou, Y; Zhu, S, 2020) |
| "Aspirin treatment antagonized vascular stiffening and rivaroxaban treatment led to a positive trend towards reduced stiffening." | 1.56 | Vascular protective effect of aspirin and rivaroxaban upon endothelial denudation of the mouse carotid artery. ( Brouns, AE; Chayoua, W; Coenen, DM; Cosemans, JMEM; Debets, J; Heitmeier, S; Karel, MFA; Konings, J; Korsten, EIJ; Kuijpers, MJE; Leenders, PJA; Mastenbroek, TG; Nagy, M; Spronk, HM; van Essen, H; van Oerle, R, 2020) |
| "After adjustment, 3-month DAPT was not inferior to longer DAPT after BP-SES implantation in terms of net adverse clinical events." | 1.56 | 1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y ( Ako, J; Hibi, K; Hioki, H; Hirohata, A; Ikari, Y; Ito, Y; Kinoshita, Y; Kozuma, K; Morino, Y; Nakagawa, Y; Nanasato, M; Shiode, N; Sonoda, S; Tanabe, K; Yamaguchi, J, 2020) |
| "Only aspirin nonresponders were early identified by repeating the aggregometry after 7 days of aspirin administration." | 1.51 | Early Aspirin Nonresponders Identification by Routine Use of Aggregometry Test in Patients With Left Ventricle Assist Devices Reduces the Risk of Pump Thrombosis. ( Cammardella, A; Comisso, M; Gherli, R; Montalto, A; Musumeci, F; Nicolò, F; Palermo, A; Pulcinelli, F, 2019) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "A total of 597 patients with gastric neoplasms treated with ESD between January 2010 and June 2017 were enrolled." | 1.51 | Feasibility of gastric endoscopic submucosal dissection with continuous low-dose aspirin for patients receiving dual antiplatelet therapy. ( Amano, Y; Harada, H; Hayasaka, K; Katsuyama, Y; Murakami, D; Nagasaka, T; Nakahara, R; Sagami, R; Suehiro, S; Ujihara, T, 2019) |
| " A randomised trial is needed to determine appropriate acetylsalicylic acid dosing in infants with modified Blalock-Taussig." | 1.51 | High acetylsalicylic acid dosing in infants after modified Blalock-Taussig shunt. ( Allen, J; Boston, US; Cowan, KM; Jones, T; Joshi, AD; Knott-Craig, CJ; Kumar, STK; Nouer, SS; Saini, A; Shah, SH; Wayne Gatewood, C, 2019) |
| "Thromboxane A2 (TXA2) was the prostanoid product of COX-1 responsible for this antimetastatic effect." | 1.51 | Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. ( Allen, PD; Armstrong, PC; Cerutti, C; Gil-Bernabé, AM; Gomes, AL; Lucotti, S; Markelc, B; Mitchell, JA; Muschel, RJ; Ridley, AJ; Smart, S; Soyer, M; Warner, TD; Watson, K, 2019) |
| "To explore the anti-platelet aggregation and anti-thrombotic mechanisms of Trichosanthis Fructus combined with aspirin based on network pharmacology and the validation of arteriovenous by pass model in rats." | 1.51 | [Anti-platelet aggregation and anti-thrombotic mechanism of Trichosanthis Fructus combined with aspirin based on network pharmacology]. ( Bian, YY; Wang, LL; Yan, HY; Zou, CC, 2019) |
| "Aspirin was discontinued on hospital admission." | 1.51 | Timing of Low-Dose Aspirin Discontinuation and the Influence on Clinical Outcome of Patients Undergoing Surgery for Chronic Subdural Hematoma. ( Cavallo, MA; D'Angelo, L; De Bonis, P; Fazzari, E; Germanò, A; Lofrese, G; Mangiola, A; Raffa, G; Scerrati, A; Trevisi, G; Visani, J, 2019) |
| "Aspirin resistance was assessed using whole blood MEA (Multiplate®, Roche Diagnostics, Meylan, France)." | 1.48 | Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms. ( Galinat, H; Ianotto, JC; Lippert, E; Mingant, F; Perrier-Cornet, A; Perrot, M, 2018) |
| "The aspirin group was older (66 vs 52 years), included more tobacco users (58." | 1.48 | The Effect of Continued Low Dose Aspirin Therapy in Patients Undergoing Percutaneous Nephrolithotomy. ( Bird, VG; Gupta, M; Hamann, HC; Lutfi, FG; Otto, BJ; Syed, JS; Terry, RS, 2018) |
| "Cilostazol effects were also shown in aspirin-treated platelets." | 1.48 | Impact of Multidrug Resistance Protein-4 Inhibitors on Modulating Platelet Function and High on-Aspirin Treatment Platelet Reactivity. ( Alemanno, L; Angiolillo, DJ; Frati, L; Guarino, ML; Klaus, V; Maltese, T; Massimi, I; Pulcinelli, FM, 2018) |
| "No thrombosis was detected." | 1.48 | Long-haul flights, edema, and thrombotic events: prevention with stockings and Pycnogenol® supplementation (LONFLIT Registry Study). ( Belcaro, G; Cornelli, U; Cotellese, R; Dugall, M; Feragalli, B; Hosoi, M, 2018) |
| "In conclusion, the thrombus‑stimulated LMVEC model exhibited induced production of TNF‑α, IL‑6, CX3CL, CX3CR1, NF‑κB and intercellular adhesion molecule‑1." | 1.48 | Aspirin modulates the inflammatory response in a thrombus‑stimulated LMVEC model. ( Cai, D; Jiang, H; Jin, Q; Kuang, J; Shi, Y; Wang, L; Yang, R; Ying, R; Zhang, Z, 2018) |
| "Recent studies suggested protruding thrombus and atheroma after stent placement could be a substrate for subsequent adverse ischemic events." | 1.48 | Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome. ( Hirata, KI; Kijima, Y; Kozuki, A; Masano, T; Nagoshi, R; Otake, H; Shibata, H; Shinke, T; Shite, J; Takeshige, R; Tsukiyama, Y; Yanaka, KI, 2018) |
| "We report cerebral embolism in 2 patients with Duchenne muscular dystrophy (DMD) after respiratory tract infection." | 1.48 | [Cerebral embolism in Duchenne muscular dystrophy after respiratory tract infection - Report of two cases]. ( Fujimura, H; Hasuike, Y; Matsumura, T; Saito, T; Sakoda, S, 2018) |
| ": A huge thrombus, developing after percutaneous left atrial appendage occlusion, has been successfully treated with dabigatran and aspirin as combination therapy." | 1.46 | Thrombosis on a left atrial appendage occluder device: the double-edged sword of stroke prevention strategies in atrial fibrillation. ( Baldi, M; Ciconte, G; Conti, M; Pappone, C; Saviano, M; Vicedomini, G, 2017) |
| " In Kawasaki disease (KD), endothelial damage and an elevation in coagulant factors provoke thrombosis." | 1.46 | [Transient detection of lupus anticoagulant in acute phase of Kawasaki disease]. ( Imadome, KI; Ishiguro, A; Ito, S; Kobayashi, T; Kubota, M; Masuda, H; Nariai, R; Ono, H, 2017) |
| "Device-related thrombus remains a major concern because it may result in recurrent embolic events." | 1.46 | WATCHMAN device-related thrombus successfully treated with apixaban: A case report. ( Chan, PH; Kwok, OH; Lam, CC; Lam, YY; Siu, CW; Wong, CK, 2017) |
| "Purpose Patients with hypoplastic left heart syndrome and its variants following palliation surgery are at risk for thrombosis." | 1.46 | Variability of antithrombotics use in patients with hypoplastic left heart syndrome and its variants following first- and second-stage palliation surgery: a national report using the National Pediatric Cardiology Quality Improvement Collaborative registry ( Anderson, JB; Beekman, RH; King, E; Nebbia, A; Ramachandran, P, 2017) |
| "The total thrombus-formation analysis system (T-TAS) was developed for quantitative analysis of platelet thrombus formation by the use of microchips with thrombogenic surfaces (collagen, platelet chip [PL-chip]; collagen plus tissue factor, atherome chip [AR-chip])." | 1.43 | Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy. ( Arima, Y; Hokimoto, S; Ishii, M; Ito, M; Kaikita, K; Kojima, S; Nakagawa, K; Ogawa, H; Oimatsu, Y; Sakamoto, K; Sueta, D; Tsujita, K, 2016) |
| "Aspirin resistance was measured by the PFA-100 system (collagen/epinephrine cartridge) and glycoprotein IIIa P1A1/A2 polymorphism was determined by PCR." | 1.43 | Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients. ( Ataç, BF; Bayraktar, N; Can, U; Çelikkol, C; Derle, E; Kibaroğlu, S; Öcal, R; Verdi, H, 2016) |
| "Patients with nephrotic syndrome are at increased risk of thrombosis." | 1.43 | Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy? ( Hofstra, JM; Wetzels, JFM, 2016) |
| "Measuring platelet thrombus formation (PTF) for evaluating antiplatelet effects was assessed." | 1.43 | Measurement of residual platelet thrombogenicity under arterial shear conditions in cerebrovascular disease patients receiving antiplatelet therapy. ( Hosokawa, K; Kawashima, A; Kitagawa, K; Ohnishi, T; Okada, Y; Uchiyama, S; Yamaguchi, K; Yamazaki, M; Yoneyama, T, 2016) |
| "Thrombosis is a devastating complication after repair of traumatic vascular injury." | 1.43 | Do Antiplatelet and Anticoagulation Agents Matter after Repair of Traumatic Arterial Injuries? ( Benjamin, E; Byerly, S; Cho, J; Demetriades, D; Inaba, K; Lam, L; Rowe, V; Wang, E, 2016) |
| "Further, we examined thrombus formation on human atherosclerotic plaque homogenates under arterial shear to address the relevance to human pathology." | 1.43 | Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis. ( Brandl, R; Braun, D; Braun, S; Chandraratne, S; Eckart, A; Hoppe, B; Jamasbi, J; Kolb, C; Konrad, I; Lennerz, C; Lorenz, M; Massberg, S; Petzold, T; Regenauer, R; Schubert, I; Schulz, C; Siess, W; Thienel, M, 2016) |
| "7, p NS], and in adverse cardiac or cerebrovascular events (MACCE) (5 vs." | 1.42 | Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. ( Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M, 2015) |
| "Most parameters of thrombus formation under flow were similarly high for the patient and control groups." | 1.42 | Normal platelet activation profile in patients with peripheral arterial disease on aspirin. ( Baaten, CC; Clemetson, KJ; Cosemans, JM; de Laat, B; Heemskerk, JW; Kleinegris, MC; Roest, M; Ten Cate, H; van Geffen, JP; Verdoold, R, 2015) |
| "Stroke is the second largest cause of death worldwide." | 1.42 | The changes in clot microstructure in patients with ischaemic stroke and the effects of therapeutic intervention: a prospective observational study. ( Brown, MR; D'Silva, L; Davidson, SJ; Evans, PA; Evans, V; Hawkins, K; Lawrence, M; Morris, RH; Potter, JF; Sabra, A; Stanford, SN; Storton, S; Wani, M; Williams, PR, 2015) |
| "Aspirin resistance was determined using thromboelastography with platelet mapping (TEG) and urine thromboxane (UTX)." | 1.42 | Aspirin Resistance in Single-Ventricle Physiology: Aspirin Prophylaxis Is Not Adequate to Inhibit Platelets in the Immediate Postoperative Period. ( Frank, S; Guleserian, K; Heistein, L; Journeycake, J; Lemler, M; Mir, A; Wolovitis, J, 2015) |
| " Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database." | 1.42 | Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database. ( Abe, J; Hara, H; Kinosada, Y; Miyamura, N; Nakamura, M; Nishibata, Y; Sekiya, Y; Suzuki, H; Suzuki, Y; Tsuchiya, T; Umetsu, R; Uranishi, H, 2015) |
| "Despite recent advances in stent design and constantly improving protective pharmacological strategies, complications and adverse events following percutaneous coronary interventions (PCI) are still major factors influencing morbidity and mortality." | 1.42 | Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up. ( Bulaeva, NI; Fortmann, S; Golukhova, EZ; Grigorian, MV; Ryabinina, MN; Serebruany, VL, 2015) |
| " These data suggest that continuation of aspirin is safe and that the continuation of aspirin should be considered acceptable and preferable, particularly in patients with perceived substantial medical need for treatment with antiplatelet therapy." | 1.40 | Safety of perioperative aspirin therapy in pancreatic operations. ( Gabale, SD; Irizarry, AM; Kennedy, EP; Lavu, H; McIntyre, CA; Pucci, MJ; Rosato, EL; Winter, JM; Wolf, AM; Yeo, CJ, 2014) |
| "Smokers have a greater relative benefit of clopidogrel therapy compared with nonsmokers, likely attributed to its enhanced pharmacodynamic (PD) effects." | 1.40 | Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study. ( Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; Darlington, A; Degroat, C; Desai, B; Ferrante, E; Ferreiro, J; Franchi, F; Guzman, LA; Muniz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Zenni, MM, 2014) |
| " Antiplatelet therapy dosing and resistance are poorly understood, leading to potential incorrect and ineffective dosing." | 1.40 | Microfluidic thrombosis under multiple shear rates and antiplatelet therapy doses. ( Forest, CR; Hotaling, NA; Ku, DN; Li, M, 2014) |
| "Fibrin-rich platelet thrombus formation was quantified by monitoring flow pressure changes." | 1.40 | Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model. ( Hosokawa, K; Koide, T; Maruyama, I; Miura, N; Ohnishi, T; Sameshima, H; Tanaka, KA, 2014) |
| "Stent thrombosis is a morbid complication after percutaneous coronary intervention." | 1.40 | Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. ( Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J, 2014) |
| "T2DM was associated with increased thrombus [14861 (8003 to 30161) vs 8908 (6812 to 11996), μ(2)/mm, median (IQR), p=0." | 1.40 | Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome. ( Badimon, JJ; Balasubramaniam, K; Marshall, SM; Viswanathan, GN; Zaman, AG, 2014) |
| "Once-daily aspirin is standard treatment, but recent studies point towards increased platelet function at the end of the dosing interval." | 1.40 | 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. ( Grove, EL; Hvas, AM; Jensen, LO; Kaltoft, AK; Kristensen, SD; Tilsted, HH; Würtz, M, 2014) |
| "Previous thrombosis, diagnosis of systemic lupus erythematosus (SLE) and triple antiphospholipid (aPL) antibody positivity have recently been found to be independent factors associated to pregnancy failure during conventional therapy in women with antiphospholipid syndrome (APS)." | 1.40 | Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. ( Alijotas-Reig, J; Andreoli, L; Bertero, MT; Bremme, K; Brucato, A; Canti, V; Caramaschi, P; De Carolis, S; Del Ross, T; Di Poi, E; Galeazzi, M; Gerosa, M; Maina, A; Mekinian, A; Meroni, PL; Mosca, M; Ramoni, V; Ruffatti, A; Salvan, E; Tincani, A; Trespidi, L, 2014) |
| "Though dextran 40 did not result in any significant adverse local or systemic complications, it is not useful as a postoperative antithrombotic agent in head and neck oncologic reconstruction with free tissue transfer." | 1.39 | Safety and efficacy of low molecular weight dextran (dextran 40) in head and neck free flap reconstruction. ( Duraisamy, S; Iyer, S; Jayaprasad, K; Mathew, J; Paul, J; Rajan, S; Sharma, M; Thankappan, K, 2013) |
| "Prosthetic valve thrombosis is an uncommon, life-threatening complication that often mandates urgent repeat surgery or thrombolytic therapy." | 1.39 | Successful treatment of mechanical mitral valve thrombosis without thrombolytic therapy or surgery. ( Al Habib, HF; Chu, MW; Diamantorous, P; Tarola, C, 2013) |
| "Aspirin is an effective treatment option for these patients." | 1.39 | Aspirin resistance in systemic lupus erythematosus. A pilot study. ( Akdogan, A; Akman, U; Bilgen, SA; Buyukasik, Y; Dogan, I; Ertenli, I; Karadag, O; Kilic, L; Kiraz, S, 2013) |
| "Thrombosis is the main cause of failure of small-diameter synthetic vascular grafts when used for by-pass procedures." | 1.39 | Aspirin-loaded electrospun poly(ε-caprolactone) tubular scaffolds: potential small-diameter vascular grafts for thrombosis prevention. ( Baiguera, S; Bianco, A; Del Gaudio, C; Ercolani, E; Galloni, P; Polizzi, L; Santilli, F, 2013) |
| "Platelet thrombus formation was analysed by measuring flow pressure changes due to the occlusion of micro-capillaries and was quantified by calculating AUC 10 (area under the flow pressure curve." | 1.39 | Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. ( Hosokawa, K; Ito, T; Koide, T; Maruyama, I; Miura, N; Ohnishi, T; Sameshima, H, 2013) |
| "Aspirin resistance is a transient phenomenon during the early postoperative period in approximately 30% of patients undergoing OPCAB." | 1.38 | Aspirin resistance in off-pump coronary artery bypass grafting. ( Gao, F; Men, J; Modi, P; Ren, J; Wang, Z; Wei, M, 2012) |
| "Aspirin has a beneficial role in prevention of cardiovascular and thromboembolic events." | 1.38 | High frequency of aspirin resistance in patients with nephrotic syndrome. ( Agbaht, K; Akoglu, H; Dede, F; Falay, MY; Odabas, AR; Ozet, G; Piskinpasa, S, 2012) |
| "Stent thrombosis is not unusual in a post-operative setting." | 1.38 | Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis. ( Agnani, S; Akkus, NI; Rajpal, S, 2012) |
| "We compared patients undergoing PCI who received aspirin and clopidogrel loading dose in addition to either conventional bivalirudin dosing (intravenous [IV] bolus of 0." | 1.38 | Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study. ( Ghosn, S; Sheikh-Taha, M, 2012) |
| "Aspirin resistance has been described in some patient populations such as those with an acute coronary syndrome, ischemic stroke, percutaneous coronary intervention with drug-eluting stent, stent re-stenosis, and diabetes mellitus (DM)." | 1.38 | Effect of hypoglycemic drugs on aspirin resistance in patients with diabetes mellitus. ( Ariturk, Z; Cil, H; Elbey, MA; Gündüz, E; Islamoglu, Y; Kaya, H; Soydinc, S; Tekbas, E; Yavuz, C, 2012) |
| "Left ventricular thrombus (LVT) and rupture are important mechanical complications following myocardial infarction (MI) and are believed to be due to unrelated mechanisms." | 1.37 | Role of intramural platelet thrombus in the pathogenesis of wall rupture and intra-ventricular thrombosis following acute myocardial infarction. ( Dart, AM; Du, XJ; Gao, XM; Head, GA; Kiriazis, H; Liu, Y; Lobo, A; Shan, L, 2011) |
| "Among hematologic malignancies, multiple myeloma (MM) confers a high risk of developing such complications, with a VTE rate of nearly 10%." | 1.37 | Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. ( Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B, 2011) |
| "The diagnosis of thoracic aortic mobile thrombus (TAMT) is rare and is usually made after debilitating embolic events." | 1.37 | Thoracic aortic mobile thrombus: is there a role for early surgical intervention? ( Ganzel, BL; Kapoor, N; Pagni, S; Ross, C; Slater, AD; Trivedi, J; Williams, M, 2011) |
| " Collagen and U46619 caused in vivo thrombus formation with the former, but not latter, sensitive to oral dosing with aspirin." | 1.37 | Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse. ( Armstrong, PC; Emerson, M; Kirkby, NS; Mitchell, JA; Warner, TD; Zain, ZN, 2011) |
| "Cerebral infarction associated with ulcerative colitis is particularly rare, but clinically important because of its high morbidity and mortality." | 1.37 | Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a). ( Bramanti, P; Calabrò, RS; Gervasi, G; Pezzini, A; Pollicino, P, 2011) |
| " Response to aspirin was reassessed 1 month after hospital discharge and non-responders received a directly observed intake of aspirin to exclude any biological non-response due to bioavailability problems." | 1.37 | Non-adherence to aspirin in patients undergoing coronary stenting: negative impact of comorbid conditions and implications for clinical management. ( Bonnet, JL; Carrieri, P; Cohen, W; Cuisset, T; Fourcade, L; Fugon, L; Gaborit, B; Molines, L; Quilici, J; Roux, P, 2011) |
| "Mechanical valve thrombosis is a rare condition in an adequately anticoagulated patient in the absence of underlying thrombophilia." | 1.37 | Anticoagulant-resistant thrombophilia in a patient with polycythemia vera: a case report. ( Cherian, SV; Das, S; Gajra, A; Garcha, AS; Jasti, S; Karachiwala, H, 2011) |
| "Cilostazol has reduced restenosis and repeat intervention after drug-eluting stent (DES) implantation." | 1.36 | Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). ( Hong, MK; Kim, JJ; Kim, WJ; Kim, YH; Lee, CW; Lee, JY; Lee, SW; Park, DW; Park, SJ; Park, SW; Yun, SC, 2010) |
| "Arterial thrombosis was induced by insertion of a silk thread (thrombogenic substrate) into an extracorporeal shunt." | 1.36 | Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat. ( Calmettes, Y; Le Grand, B; Leparq-Panissié, A; Létienne, R; Nadal-Wollbold, F; Perez, M, 2010) |
| "Thrombosis is still the first cause of microsurgery failure." | 1.36 | [Multicentric study of thrombosis prevention in upper-extremity microsurgery. Survey at the Fesum centers]. ( Dumont, LA; Gangloff, D; Garrido-Stowhas, I; Rongières, M; Tchénio, P, 2010) |
| "We describe a patient with terminal renal cell carcinoma who developed late iliac artery stent thrombosis despite dual chronic antiplatelet therapy with aspirin and clopidogrel." | 1.36 | Late common iliac artery stent thrombosis in a patient with terminal malignancy. ( Akgün, T; Can, MM; Karabay, CY; Kaymaz, C; Ozveren, O; Serebruany, V; Tanboğa, IH; Tokgöz, HC; Türkyilmaz, E, 2010) |
| "This is the first case of renal infarction that developed in the early hours of primary PCI, despite effective anticoagulant and antiplatelet treatment." | 1.36 | Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids. ( Calık, AN; Demirci, D; Güvenç, TS; Ilhan, E, 2010) |
| " Aspirin, a widely used anti-thrombotic drug, achieved comparable activity in this model system at a dosage of ca." | 1.35 | Synthesis, nano-scale assembly, and in vivo anti-thrombotic activity of novel short peptides containing L-Arg and L-Asp or L-Glu. ( Chen, Y; Cui, G; Lee, KH; Morris-Natschke, S; Peng, S; Qian, K; Wang, C; Zhao, M, 2008) |
| "The exact mechanism of blood vessel thrombus formation remains to be defined." | 1.35 | Real-time analysis of platelet aggregation and procoagulant activity during thrombus formation in vivo. ( Hayashi, T; Kanayama, N; Konno, H; Mogami, H; Murakami, Y; Nakamura, T; Urano, T, 2008) |
| "We report a case of apical thrombus formation among a group of 15 patients with takotsubo cardiomyopathy who were referred for a suspected acute coronary syndrome over a 2." | 1.35 | Apical thrombus in a patient with takotsubo cardiomyopathy. ( Amico, F; Argentino, V; Azzarelli, S; Fiscella, A; Galassi, AR; Giacoppo, M; Giordano, G, 2008) |
| "Dyspnea was diagnosed in 157 (4." | 1.35 | Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting. ( Atar, D; Kuliczkowski, W; Pokov, I; Serebruany, V; Vahabi, J, 2008) |
| "Multiple randomized clinical trials have demonstrated that drug eluting stents can significantly reduce the rates of restenosis and subsequent adverse events across lesion and patient." | 1.35 | Long-term efficacy and safety of Chinese made sirolimus eluting stents: results, including off label usage, from two centres over three years. ( Chen, JL; Gao, RL; Hu, J; Qiao, SB; Qin, XW; Shen, WF; Xu, B; Yang, YJ; Zhang, JS; Zhang, Q; Zhang, RY, 2008) |
| "Combined carotid stenting and cardiac surgery, performed in the same operating room under only heparin and aspirin, seems a safe and effective strategy for the treatment of patients with concomitant carotid and cardiac disease." | 1.35 | Safety and effectiveness of combining carotid artery stenting with cardiac surgery: preliminary results of a single-center experience. ( Capuano, F; Faraglia, V; Palombo, G; Rizzo, L; Sinatra, R; Stella, N; Taurino, M, 2009) |
| "Isolated splenic infarction as a complication of the procedure is extreme rare." | 1.35 | Athero-embolic isolated splenic infarction following left cardiac catheterization. ( Hussein, A; Irani, F; Kasmani, R; Mohan, G, 2009) |
| "Histology showed typical wedge-shaped infarction in the affected organs with endothelial proliferation and occlusion by thrombus." | 1.35 | Degos' disease: a rare condition simulating rheumatic diseases. ( Chung, HY; Mok, MY; Trendell-Smith, NJ; Yeung, CK, 2009) |
| "Spontaneous aortic thrombosis is rare." | 1.35 | Aortic thrombosis in infancy. ( Mehta, AV; Teixeira, OH, 2009) |
| "Thrombosis is the most frequent clinical manifestation of APS." | 1.35 | [Antiphospholipid antibody syndrome]. ( Chakoutio, V; Ries, F, 2009) |
| " HCPR as measured with the novel INNOVANCE P2Y cartridge was associated with clinical determinants such as BMI, female gender, impaired LVEF (left ventricular ejection fraction), renal failure and dosing of clopidogrel." | 1.35 | The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. ( Berg, JM; Bouman, HJ; Elsenberg, EH; Hackeng, CM; van de Wal, RM; van Werkum, JW; Verheugt, FW; Zomer, AC, 2009) |
| "Aspirin pre-treatment at the dose tested did not influence either endothelial injury or platelet thrombus growth, while clopidogrel pretreatment significantly inhibited 3D growth and prolonged occlusion time up to 64." | 1.35 | Imaging of structural changes in endothelial cells and thrombus formation at the site of FeCl(3)-induced injuries in mice cremasteric arteries. ( Eguchi, Y; Goto, S; Ishida, H; Kawamura, Y; Takahari, Y; Tamura, N; Urano, T, 2009) |
| "Stent thrombosis is a feared complication of percutaneous coronary intervention." | 1.35 | Catastrophic early drug eluting stents thrombosis and aspirin hypersensitivity. ( Di Bella, G; Marte, F; Patanè, S, 2008) |
| "We histologically assessed thrombus formation, cellular elements, localization of TRX and of oxidized low density lipoprotein (ox-LDL), intraplaque hemorrhage, and transition metal iron (Fe(2+), Fe(3+)) deposition in these specimens." | 1.35 | Thioredoxin in coronary culprit lesions: possible relationship to oxidative stress and intraplaque hemorrhage. ( Asada, Y; Hatakeyama, K; Imamura, T; Kitamura, K; Nakamura, H; Nishihira, K; Ogawa, H; Sato, Y; Yamashita, A; Yodoi, J, 2008) |
| " Low-dose razaxaban was useful in combination with sub-optimal doses of aspirin and/or clopidogrel for the prevention of occlusive arterial thrombosis without excessive bleeding." | 1.34 | Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. ( Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC, 2007) |
| "Aspirin was without significant effect." | 1.34 | Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. ( Brandl, R; Deckmyn, H; Penz, SM; Reininger, AJ; Siess, W; Toth, O, 2007) |
| " Platelet aggregation induced by ADP and dosing of prostanoid products 6-keto-PGF1alpha, TXB2, PGE2 and LTB4 were also performed." | 1.34 | Modifications produced by selective inhibitors of cyclooxygenase and ultra low dose aspirin on platelet activity in portal hypertension. ( Aguejouf, O; Belon, P; Desplat, V; Doutremepuich, C; Eizayaga, FX, 2007) |
| "Myocarditis and dilated cardiomyopathy is characterized by dilatation of all four cardiac chambers and decreased systolic function of the heart, especially in the left ventricle." | 1.34 | Treatment of massive cardiac thrombi in a patient with protein C and protein S deficiency. ( Cağdaş, DN; Paç, FA, 2007) |
| "Aspirin treatment of wild-type mice causes similar effects, while the thromboxane A(2) analogue U46619 was borderline effective in suppressing the embolisation in alpha2-null mice." | 1.34 | Role of murine integrin alpha2beta1 in thrombus stabilization and embolization: contribution of thromboxane A2. ( Cosemans, JM; Eckes, B; Heemskerk, JW; Kuijpers, MJ; Munnix, IC; Nieswandt, B; Pozgajova, M, 2007) |
| "Thalidomide has been associated with venous thrombotic events, as reported in the post-marketing surveillance reports by Celgene Corporation; as well as case reports in the literature." | 1.33 | Arterial thrombosis in four patients treated with thalidomide. ( Brown, K; Chanan-Khan, A; Hahn, T; McCarthy, PL; Paplham, P; Roy, H; Scarpace, SL; van Besien, K, 2005) |
| " The aim of the monitoring of ASA therapy should be the identification of nonresponders to prevent a long-term intake of the drug without adequate benefit, to justify a dose escalation, or to initiate an alternative antiplatelet drug therapy." | 1.33 | Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100. ( Feuring, M; Losel, R; Schultz, A; Wehling, M, 2005) |
| "The myeloproliferative disorders have been the "poor cousins" in the family of hematological malignancies for some time." | 1.33 | Platelets and thrombosis in myeloproliferative diseases. ( Harrison, CN, 2005) |
| "Aspirin was the sole antithrombotic agent used during the study." | 1.33 | Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. ( Brown, JM; Gammie, JS; Griffith, BP; Gu, J; Nie, L; Pierson, RN; Poston, RS; White, C, 2006) |
| " The mean aspirin dosage was 81 mg/day over a period of 6-288 weeks (mean: 86." | 1.33 | [Significance of the stool occult blood test in patients with thrombotic disease under treatment with low dose aspirin]. ( Hayashi, S; Wakizaka, A, 2005) |
| " An independent endpoint review committee adjudicated all reported major adverse cardiovascular events, stent thromboses, and target-vessel revascularizations." | 1.33 | Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. ( Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W, 2006) |
| "Atherothrombosis is associated with the presence of a microinflammatory response, usually monitored by the use of C-reactive protein (CRP) measurements." | 1.33 | Lack of significant effect of low doses of aspirin on the concentrations of C-reactive protein in a group of individuals with atherothrombotic risk factors and vascular events. ( Ben Assayag, E; Berliner, S; Bornstein, NM; Melamed, S; Rogowski, O; Shapira, I; Shirom, A; Toker, S, 2006) |
| "Acute in-stent thrombosis is a well-known complication of carotid angioplasty and stenting (CAS) and often due to resistance to or inadequate treatment with platelet-inhibiting agents." | 1.33 | Late in-stent thrombosis following carotid angioplasty and stenting. ( Buhk, JH; Knauth, M; Wellmer, A, 2006) |
| "Pump thrombus is a potentially serious complication with few available treatment options." | 1.33 | An alternative treatment strategy for pump thrombus in the DeBakey VAD Child: use of clopidogrel as a thrombolytic agent. ( Carberry, KE; Chang, AC; Dreyer, WJ; Kennedy, CE; McKenzie, ED; Moffett, BS; Morales, DL; Price, JF; Studer, MA; Teitel, ER, 2006) |
| "Pretreatment with parecoxib (20 mg/kg) almost doubled shear stress-induced platelet aggregation (188% vs." | 1.33 | Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation. ( Borgdorff, P; Paulus, WJ; Tangelder, GJ, 2006) |
| "Aspirin resistance was assayed with the VerifyNow System with > or = 550 aspirin reaction units (ARUs) used as a dichotomous indicator of aspirin resistance." | 1.33 | Frequency of aspirin resistance in a community hospital. ( Domanski, M; Greene, L; Hasan, A; Michelson, AD; Mirkhel, A; Peyster, E; Sundeen, J, 2006) |
| "The ER of the ball thrombus type group, especially the MB group, was very high in spite of therapy with anti-coagulants and/or anti-platelet agents, and such patients should be treated by early surgical intervention." | 1.32 | Embolic attack in patients with atrial fibrillation and atrial thrombus depends on the character of the thrombus. ( Abe, Y; Asakura, T; Gotou, J; Ishikawa, S; Iwai, M; Maehara, K; Maruyama, Y; Muroi, S; Nagata, K; Ono, M; Saitoh, F; Sakabe, A; Sakamoto, N; Sando, M; Satoh, M; Suzuki, S; Watanabe, Y, 2003) |
| "However, the relationship between LA thrombus and transient ischemic attack (TIA) in patients with AF is less well established." | 1.32 | Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. ( Dawn, B; Longaker, RA; Singh, P; Stoddard, MF, 2003) |
| "Arterial thrombosis is initiated following lesion of the vessel wall, either through rupture of an atherosclerotic plaque containing lipids, adhesive proteins and tissue factor or after angioplasty exposing the thrombogenic subendothelial matrix." | 1.32 | [Platelets and arterial thrombosis]. ( Cazenave, JP; Gachet, C; Lanza, F; Wiesel, ML, 2003) |
| "Thrombosis was achieved by perfusion of human and murine blood through type III collagen-coated capillaries at arterial shear rate." | 1.32 | Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. ( André, P; Conley, PB; Delaney, SM; LaRocca, T; Lin, PH; Phillips, DR; Sinha, U; Vincent, D, 2003) |
| "PHA-798 reduced thrombus formation on the thrombogenic surface in a dose-dependent manner (56+/-1." | 1.32 | Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time. ( Blom, JD; Case, BL; LaChance, RM; Nicholson, NS; Panzer-Knodle, SG; Parlow, JJ; Salyers, AK; South, MS; Suleymanov, OD; Szalony, JA; Wood, RS, 2003) |
| "However, systemic study of thrombus formation in vein grafts is still lacking, and few effective techniques are available to prevent this event." | 1.32 | Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection. ( Hu, Y; Mayr, U; Thompson, WD; Torsney, E; Xu, Q; Zou, Y, 2004) |
| "Thrombosis was the main cause of death." | 1.32 | A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). ( Finazzi, G, 2004) |
| "A novel model to induce occlusive thrombus formation was developed in mice in vivo." | 1.32 | A novel model of occlusive thrombus formation in mice. ( Cheng, XW; Iguchi, A; Kanda, S; Koike, T; Kuzuya, M; Maeda, K; Nakamura, K; Sasaki, T; Sato, K; Tamaya-Mori, N, 2004) |
| "Main parameter was thrombus weight." | 1.32 | Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004) |
| "A 48-year-old patient with dilated cardiomyopathy complained of dyspnea at rest, severe sleeplessness and a slight pain in the stomach." | 1.31 | [Increased thrombocyte activation in dilated cardiomyopathy: a risk factor for development of ventricular thrombosis despite anticoagulant therapy?]. ( Hohmann, C; Jaster, M; Kühl, U; Pauschinger, M; Rauch, U; Schultheiss, HP; Schwimmbeck, PL; Weikert, U, 2002) |
| " This rabbit model with a high dosage of clopidogrel and aspirin, and a short-time exposure of the heart valve leaflets to rabbit blood under laminar flow, should be further evaluated with respect to whether it can give information about antithrombotic regimens in patients after mechanical heart valve replacement." | 1.31 | Effects of combined therapy of clopidogrel and aspirin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model. ( Bickel, C; Buerke, M; Hauroeder, B; Hundt, F; Meyer, J; Peetz, D; Rupprecht, HJ; Schlitt, A; Victor, A, 2002) |
| "Bioprosthetic valve thrombosis is a rare complication, supporting this approach." | 1.31 | Early bioprosthetic mitral valve "pseudostenosis" after complete preservation of the native mitral apparatus. ( Korkolis, DP; Koullias, GJ; Marshalko, SJ; Passik, CS, 2002) |
| "Assessment of platelet-thrombus formation with this technique was more sensitive than change in flow in determining antithrombotic efficacy, and thrombus formation was detected earlier." | 1.31 | In vivo dynamic real-time monitoring and quantification of platelet-thrombus formation: use of a local isotope detector. ( Badimon, JJ; Chesebro, JH; Fallon, JT; Fuster, V; Gallo, R; Helft, G; Osende, JI; Padurean, A; Rodriguez, OX; Worthley, SG; Zaman, AG, 2000) |
| "Maximum inhibition of thrombus formation in arterioles (21%) was observed in N,N'-bis-2-phenylethylglyoxaldinitrone (7o) and N,N'-bis-4-nitrobenzylglyoxaldinitrone (7u)." | 1.31 | New NO donors with antithrombotic and vasodilating activities, Part 29. N-(1-cyanocyclohexyl)-C-phenylnitrones and glyoxaldinitrones. ( Camehn, R; Rehse, K, 2000) |
| "Aspirin treatment attenuated smoking-induced changes in plaque composition." | 1.31 | Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. ( Cercek, B; Chyu, KY; Dimayuga, P; Fishbein, MC; Kangavari, S; Matetzky, S; Shah, PK; Tani, S; Xu, H; Yano, J, 2000) |
| "Severe bleeding was defined by the need for admission to hospital." | 1.31 | Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment. ( Castellino, G; Cuadrado, MJ; Godfrey, T; Hughes, GR; Khamashta, MA, 2001) |
| "Aortic thrombus formation is rare in the patients with essential thrombocytosis (ET); therefore, no guidelines for its management have been established." | 1.31 | Medical management of a large aortic thrombus in a young woman with essential thrombocythemia. ( Agha, S; Cleary, JP; Fang, M; Lee, R; Lockridge, L; Mazur, EM, 2001) |
| " Be familiar with accepted dosing levels for the three agents." | 1.31 | Pharmacologic optimization of microsurgery in the new millennium. ( Adams, WP; Conrad, MH, 2001) |
| "Maximum thrombus size was larger in the desmopressin and desmopressin + aspirin groups when compared with the group treated with aspirin only." | 1.31 | Effects of desmopressin on thrombogenesis in aspirin-induced platelet dysfunction. ( Benkovic, C; Homann, HH; Kuhnen, C; Muehlberger, T; Peter, FW; Steinau, HU; Vogt, PM; Wiebalck, A, 2002) |
| "When fluorescein sodium was given at 10 microg/kg, PMC (20 microg/g) delayed occlusion time by about 1." | 1.31 | Antithrombotic effect of PMC, a potent alpha-tocopherol analogue on platelet plug formation in vivo. ( Hsiao, G; Lee, YM; Sheu, JR; Yen, MH, 2002) |
| " However, a 13-fold increase in the risk of UGIB occurs with long-term use of oral anticoagulants and NSAIDs." | 1.30 | Effect of combined anticoagulation and low-dose aspirin treatment on upper gastrointestinal bleeding. ( Cloutier, DA; Schatz, RA; Spinks, TJ; Strum, WB; Teirstein, PS; Younossi, ZM, 1997) |
| "However, only r-hirudin inhibited thrombus formation at a therapeutical prolongation of aPTT, while heparin required supratherapeutical amounts to achieve the same inhibition." | 1.30 | A technique to investigate microvascular mural thrombus formation in arteries and veins: II. Effects of aspirin, heparin, r-hirudin, and G-4120. ( Hoylaerts, MF; Nyström, A; Stassen, JM; Stockmans, F; Vermylen, J, 1997) |
| "Thrombosis is an important limitation of metallic coronary stents, especially in smaller vessels in which shear rates are high." | 1.30 | Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. ( Eigler, NL; Forrester, JS; Ivey, PA; Jordan, RE; Kaul, S; Litvack, F; Makkar, RR; Nakamura, M; Shah, PK, 1997) |
| "Aspirin and heparin were embedded in chitosan/polyethylene vinyl acetate co-matrix to develop a prolonged release form." | 1.30 | Development of chitosan/polyethylene vinyl acetate co-matrix: controlled release of aspirin-heparin for preventing cardiovascular thrombosis. ( Chandy, T; Sharma, CP; Vasudev, SC, 1997) |
| "A right intraventricular thrombus and bilateral pulmonary aneurysms were discovered." | 1.30 | Complete recovery of right intraventricular thrombus and pulmonary arteritis in Behçet's disease. ( De Zuttere, D; Dolmazon, C; Godeau, P; Huong, DL; Piette, JC; Wechsler, B, 1997) |
| "Patients with antiphospholipid syndrome are at high risk of pregnancy loss as well as maternal morbidity, especially thrombo-embolic disease." | 1.30 | Obstetric outcome in antiphospholipid syndrome. ( Farquharson, RG; Granger, KA, 1997) |
| "Aspirin was not administered to the remaining 175 patients." | 1.30 | Low-dose aspirin therapy is associated with few side effects but does not prevent hepatic artery thrombosis in liver transplant recipients. ( Birnbaum, A; Boccagni, P; Bodenheimer, HC; Chodoff, L; Freni, MA; Miller, CM; Mor, E; Schwartz, ME; Wolf, DC, 1997) |
| "Hemorrhage was present in 9 cases of group B (21." | 1.30 | [Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses]. ( Azaceta, G; Civeira, E; Cornudella, R; Iturbe, T; Moreno, JA; Olave, T; Peleato, J; Sánchez, C; Varo, MJ, 1997) |
| "The presence of residual mural thrombus may predispose to recurrent thrombotic events in acute coronary syndromes." | 1.30 | Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin. ( Badimon, JJ; Badimon, L; Chesebro, JH; Fallon, JT; Fuster, V; Meyer, BJ, 1998) |
| " In this study, we investigated the effect of a combination between a high and an ultra-low dosage (100 mg/kg+ 10(-30) mg/kg) on an arterial thrombosis induced by a laser beam." | 1.30 | Combination of two doses of acetyl salicylic acid: experimental study of arterial thrombosis. ( Aguejouf, O; Belon, P; Belougne-Malfatti, E; Doutremepuich, C; Doutremepuich, F, 1998) |
| "015), and chronic intake of nitrates (P<0." | 1.30 | Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease. ( Beckmann, R; Binder, BR; Geppert, A; Graf, S; Hornykewycz, S; Huber, K; Schuster, E, 1998) |
| "Venous thrombosis was reduced 56% by oral soluble acetylsalicylic acid and 27% by oral aspirin." | 1.30 | Some effects of prophylactic aspirins and heparins on concurrent arterial and venous thrombosis in the same animal. ( Iomhair, MM; Lavelle, SM, 1998) |
| "Oral aspirin also inhibited thrombus formation in arterioles but not in venules, although the antithrombotic effects were delayed and prolonged." | 1.30 | The differential effects of aspirin on platelets, leucocytes and vascular endothelium in an in vivo model of thrombus formation. ( Giddings, JC; Hashimoto, M; Nagamatsu, Y; Tsujioka, Y; Yamamoto, J, 1999) |
| "A transluminal thrombus was produced in the hamster femoral artery by the photochemical reaction." | 1.30 | Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates. ( Kanamaru, M; Kozawa, O; Matsuno, H; Nagashima, S; Uematsu, T, 1999) |
| " BC2 extended aPTT to a maximum of 60 to 80 seconds at 100 to 1000 nmol/L in vitro (rat and human plasma, respectively) and ex vivo (rat) after dosing of rats up to 6 mg/kg in vivo." | 1.30 | Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. ( Baker, A; Blackburn, MN; Bugelski, P; Church, WR; Feuerstein, GZ; Koster, P; Nichols, AJ; Patel, A; Toomey, JR; Valocik, R, 1999) |
| "Aspirin was found to inhibit platelet thrombosis by thrombin in low doses (optimum dose 2." | 1.29 | Effect of aspirin and iloprost on adhesion of platelets to intact endothelium in vivo. ( Kajiwara, Y; Quattrociocchi-Longe, T; Shanberge, JN, 1995) |
| "The largest thrombus fragments had a cross-sectional dimension of 2." | 1.29 | In vivo thrombogenicity of intravascular ultrasound imaging catheters. ( Bolz, KD; Nordby, A, 1995) |
| "Lesions with thrombus formation were found in four animals in the heparin/aspirin group and in nine animals in the control group." | 1.29 | Power and temperature guided radiofrequency catheter ablation of the right atrium in pigs. ( Aass, H; Amlie, JP; Foerster, A; Kongsgaard, E; Madsen, S, 1994) |
| "The rate of recurrence of thrombosis was highest (1." | 1.29 | The management of thrombosis in the antiphospholipid-antibody syndrome. ( Cuadrado, MJ; Hughes, GR; Hunt, BJ; Khamashta, MA; Mujic, F; Taub, NA, 1995) |
| "The embolic risk and changes of thrombus location and size were investigated in 29 consecutive patients with echocardiographically proven thrombi in the left atrium." | 1.29 | [Transthoracic and transesophageal follow-up in patients with left atrial thrombosis]. ( Erbel, R; Genth, S; Meyer, J; Pinnau, U; Zotz, R, 1994) |
| "Thrombosis is the most serious acute problem for small diameter arterial bypass grafts." | 1.29 | Effect of controlled local acetylsalicylic acid release on in vitro platelet adhesion to vascular grafts. ( Hall, JD; Rittgers, SE; Schmidt, SP, 1994) |
| "At reexamination, one thrombus was detected in the patient without anticoagulant treatment and one thrombus was detected in the 8 patients treated with aspirin (13%), compared with ten thrombi detected in the 20 patients (50%) treated with phenprocoumon (p = NS)." | 1.29 | Left atrial thrombi despite anticoagulant and antiplatelet therapy. ( Erbel, R; Genth, S; Meyer, J; Pinnau, U; Zotz, RJ, 1994) |
| "Blood clots were produced in a femoral artery segment with endothelial damage and distal stenosis." | 1.29 | Does external ultrasound accelerate thrombolysis? Results from a rabbit model. ( Battler, A; Chernine, A; Kornowski, R; Meltzer, RS; Vered, Z, 1994) |
| "Platelet thrombus formation and whole blood platelet aggregation were measured in 18 stable coronary patients on three separate occasions: at baseline when receiving no active medications, after 7 days of receiving oral verapamil SR (240 mg/d), and after 7 days of receiving a combination of oral verapamil SR and aspirin (325 mg/d)." | 1.29 | Oral verapamil inhibits platelet thrombus formation in humans. ( Hung, J; L-Lacoste, L; Lam, JY; Waters, D, 1994) |
| "or more) also suppressed the thrombus formation by single administration." | 1.29 | Antithrombotic effect of TA-993, a novel 1,5-benzothiazepine derivative, in conscious rats. ( Doi, H; Kaburaki, M; Murata, S; Narita, H; Yasoshima, A, 1995) |
| "One device failed at 58 days because of thrombus formation at the inflow side of the impeller." | 1.29 | Miniature axial flow pump for ventricular assistance in children and small adults. ( Jarvik, RK; Kaplon, RJ; Kwiatkowski, PA; Levin, HR; Oz, MC; Rose, EA; Shah, AS, 1996) |
| "Treatment with aspirin inhibited spontaneous platelet aggregation but had little effect on the activated platelet profile." | 1.29 | Platelet activation and thrombosis: studies in a patient with essential thrombocythemia. ( Bihour, C; Nurden, AT; Nurden, P; Raymond, JM; Smith, M, 1996) |
| "This produced an occlusive thrombus in all vehicle-treated ferrets within 41 +/- 3 min with an average weight of 8 +/- 1 mg (n = 7)." | 1.29 | A ferret model of electrical-induction of arterial thrombosis that is sensitive to aspirin. ( Durham, SK; Megill, JR; Schumacher, WA; Steinbacher, TE, 1996) |
| "However, their effects on thrombus formation have rarely been evaluated in experimental animals in vivo." | 1.29 | In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis. ( Iwamoto, Y; Naritomi, H; Nishimura, H; Sugita, M; Tachibana, H, 1996) |
| "Aspirin reduced the platelet thrombus volume at the 60% stenosis by 45% (p < 0." | 1.29 | Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow. ( Barstad, RM; Brosstad, FR; Hamers, MJ; Orvim, U; Sakariassen, KS; Tjønnfjord, GE, 1996) |
| "In contrast, time to occlusive thrombus formation did not change on intravenous bolus injection of aspirin 17 mg/kg (11." | 1.29 | Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. ( Hisamichi, N; Inagaki, O; Kaku, S; Kawasaki, T; Masuho, Y; Ohshima, N; Sakai, Y; Satoh, N; Suzuki, K; Takenaka, T; Taniuchi, Y; Terazaki, C; Yanagi, K; Yano, S, 1996) |
| "Thrombus was formed within seconds after laser injury and grew rapidly." | 1.29 | Antithrombotic effects of aspirin and LMWH in a laser-induced model of arterials and venous thrombosis. ( Aguejouf, O; Doutremepuich, C; Doutremepuich, F; Imbault, P, 1996) |
| "Ellagic acid trebled mean thrombus weight and ASA/D reduced this by 49%, but did not restore normality." | 1.29 | Effect of aspirin-dipyridamole and heparin and their combination on venous thrombosis in hypercoagulable or thrombotic animals. ( Iomhair, MM; Lavelle, SM, 1996) |
| "Ticlopidine was administered orally to rats alone or in combination with aspirin and the efficacy of the association was determined in several experimental models." | 1.29 | The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat. ( Bernat, A; Herbert, JM; Maffrand, JP; Samama, M, 1996) |
| "ST was quantified by measurement of dry thrombus weight(TW)." | 1.29 | Inhibition of acute stent thrombosis under high-shear flow conditions by a nitric oxide donor, DMHD/NO. An ex vivo porcine arteriovenous shunt study. ( Eigler, NL; Forrester, JS; Hutsell, TC; Kaul, S; Litvack, FI; Makkar, RR; Nakamura, M; Shah, PK, 1996) |
| "This difference in asymptomatic pulmonary embolism between the two groups was statistically significant." | 1.29 | Pneumatic compression or aspirin prophylaxis against thromboembolism in total hip arthroplasty. ( Holleman, JB; Kelley, S; Klein, JA; Lachiewicz, PF, 1996) |
| "injection inhibited thrombus formation in small mesenteric vessels for more than 12 hours but less than 24 hours." | 1.28 | [Evaluation of the antithrombotic effects of pentoxifylline, acetylsalicylic acid and low molecular weight heparin in the laser model of thrombosis]. ( Bielawiec, M; Breddin, HK; Krupiński, K; Płonowski, A, 1992) |
| "Pretreatment with vapiprost (0." | 1.28 | Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator. ( Matsuno, H; Nakashima, M; Takiguchi, Y; Uematsu, T; Umemura, K; Wada, K, 1992) |
| "Pretreatment with aspirin and Y-20811, a thromboxane synthetase inhibitor, significantly prolonged the time required for occlusion in the guinea-pigs, while these drugs were ineffective in the rats." | 1.28 | Arterial thrombosis model with photochemical reaction in guinea-pig and its property. ( Hirata, Y; Nakashima, M; Takiguchi, Y; Wada, K, 1992) |
| "He-Ne laser-induced thrombus formation in arterioles and in venules was significantly inhibited by 100 mg/kg ticlopidine." | 1.28 | Antithrombotic effect of ticlopidine on He-Ne laser-induced thrombus formation in rat mesenteric microvessels. ( Ando, E; Ishii, I; Matsuda, T; Nagamatsu, Y; Sasaki, Y; Yamamoto, J, 1992) |
| "A 29-year-old man with congenital protein C deficiency and acute myocardial infarction is reported." | 1.28 | Congenital protein C deficiency and myocardial infarction:concomitant factor VII hyperactivity may play a role in the onset of arterial thrombosis. ( Kario, K; Matsuo, M; Matsuo, T; Miki, T; Sakamoto, S; Tai, S; Yamada, T, 1992) |
| "Symptomatic pulmonary embolism occurred in 1." | 1.28 | The significance of calf thrombi after total knee arthroplasty. ( Becker, MW; Haas, SB; Insall, JN; Tribus, CB; Windsor, RE, 1992) |
| "It is concluded that aspirin does affect the platelet response to shear forces, but this requires higher dosage (greater than 300 mg/day), suggesting a mechanism probably different from that of interference with thromboxane formation." | 1.28 | High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation. ( Edmondson, SF; Kovacs, IB; Ratnatunga, CP; Rees, GM, 1992) |
| "Aspirin treatment of the vessel (to prevent PGI2 formation) or endothelial stripping (to remove the ability to produce nitric oxide) had no effect on the degree of inhibition." | 1.28 | Delivery of passivating proteins to sutures during passage through the vessel wall reduces subsequent platelet deposition by blocking fibrinogen adsorption. ( Brash, JL; Cornelius, RM; Garrett, KO; Johnson, PC; Kaplan, SS; Warty, V, 1992) |
| "Five warfarin-treated patients had five significant bleeding events (0." | 1.28 | Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. ( Brewer, PM; Rosove, MH, 1992) |
| "Both prednisolone and aspirin were administered with improvement of eosinophilia and partial thrombolysis." | 1.28 | [A case of hypereosinophilic syndrome followed by bronchial asthma, intraventricular thrombus, and duodenitis]. ( Aoi, K; Doi, I; Hiraga, T; Kawakami, Y; Munakata, M; Ohtsuka, Y, 1991) |
| " No effect on APTT was detectable in this dosage after 3 h infusion." | 1.28 | Reocclusion after thrombolysis: a problem solved by hirudin? ( Eschenfelder, V; Rübsamen, K, 1991) |
| "Platelet-thrombus formation is a complication of arterial wall deep injury by balloon angioplasty that may lead to acute arterial occlusion and may contribute to restenosis." | 1.28 | Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs. ( Badimon, L; Chesebro, JH; Fuster, V; Heras, M; Lam, JY; Steele, PM; Webster, MW, 1991) |
| "The composition of the thrombus is analyzed by double isotope labeling of platelets and fibrinogen." | 1.28 | [Arterioarterial shunt coated with collagen. A model of acute arterial thrombosis for testing antithrombotic agents in rats]. ( Cazenave, JP; Freund, M; Mantz, F, 1991) |
| "Thrombosis was induced in 18 dog and 16 rabbit arteries by surgically inverting a vascular wall flap into its lumen." | 1.28 | Local prevention of thrombosis in animal arteries by means of magnetic targeting of aspirin-loaded red cells. ( Akchurin, RS; Belyaev, AA; Orekhov, AN; Orekhova, NM; Ragimov, SE; Smirnov, MD, 1990) |
| "Aspirin-treated ECs also produced a marked reduction in platelet disposition (0." | 1.28 | Aspirin-independent antithrombotic effects of acutely attached cultured endothelial cells on endarterectomized arteries. ( Anderson, JS; Bass, A; Harker, LA; Kelly, AB; Krupski, WC, 1990) |
| "The composition of an evolving arterial thrombus may be a determinant of how effectively pharmacologic agents prevent reocclusion after initially successful thrombolysis." | 1.28 | Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors. ( Abendschein, DR; Adams, SP; Feigen, LP; Gorczynski, RJ; Haskel, EJ; Saffitz, JE; Sobel, BE, 1989) |
| "In the first model thrombosis is induced in the vena cava by a combination of venous stasis and hypercoagulability; these thrombi consist merely of red cells and fibrin with only a few platelets." | 1.28 | Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans. ( Bourgondiën, FG; Hobbelen, PM; Meuleman, DG; Vogel, GM, 1989) |
| "Venous thrombosis was prevented in groups II (p less than 0." | 1.28 | [Use of aspirin in the primary prevention of vascular thrombi. A comparative study with other anti-aggregant drugs]. ( Alvarez, L; Castillo-Olivares, JL; de Haro, J; Escudero, MC; Millán, I; Rodríguez, V, 1989) |
| "In conclusion, AVS inhibited thrombus formation in vivo while it was ineffective in vitro platelet alone system, which may result from the actions of this agent on both platelets and vascular endothelium." | 1.27 | Effects of AVS (1,2-bis(nicotinamido)propane) on platelet function and vascular endothelium. ( Hata, S; Koide, T; Matsushita, H; Mizukami, M; Nakano, M; Neichi, T; Noda, Y; Yamazaki, T, 1984) |
| " This action carried over to ex vivo situation following intraduodenal dosing as demonstrated in rabbits." | 1.27 | Inhibition of platelet aggregation by a new agent, 2,2'-dithiobis-(N-2-hydroxypropyl benzamide) (KF4939). ( Nakamizo, N; Shuto, K; Yamada, K, 1983) |
| " Thrombin, at a dosage producing a fibrinogen consumption of 70% within 4 h (1 unit/kg/min), failed to produce extrapulmonary microthrombi unless fibrinolysis inhibition (epsilon-aminocaproic acid-EACA) or alpha-adrenergic stimulation (norepinephrine) were provided simultaneously." | 1.27 | Vasoactive agents and production of thrombosis during intravascular coagulation 1--comparative effects of norepinephrine in thrombin and adenosine diphosphate (ADP) treated rabbits. ( Daoust-Fiorilli, J; Latour, JG; Léger-Gauthier, C, 1984) |
| "1 Acute thrombosis was induced in the carotid arteries of anaesthetized rabbits by local electrical stimulation (1 mA for 2 min) of the vessel wall." | 1.27 | Acute arterial thrombosis in rabbits: reduced platelet accumulation after treatment with dazoxiben hydrochloride (UK 37,248-01). ( Randall, MJ; Wilding, RI, 1983) |
| " These results suggest that ASA may be an effective antithrombotic agent in man if the dosage is based on pharmacological data." | 1.27 | Anti-thrombotic effect of very low doses of acetyl salicylic acid in rats. ( Fournau, P; Granero, M; Paris, J; Viens, C, 1983) |
| "Heparin-associated thrombocytopenia is mediated through IgG or IgM immunoglobulin fractions and is believed to be an immune phenomenon, with heparin acting as a hapten." | 1.27 | Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis. ( Nand, S; Robinson, JA, 1988) |
| "Graft success was evaluated by patency, thrombus-free surface area, area endothelialized, and graft production of prostacyclin." | 1.27 | Effects of antiplatelet agents in combination with endothelial cell seeding on small-diameter Dacron vascular graft performance in the canine carotid artery model. ( Evancho, MM; Falkow, LJ; Hunter, TJ; Schmidt, SP; Sharp, WV, 1985) |
| "Therapy that will reduce acute platelet-thrombus deposition appears to be an important factor for reduction of restenosis." | 1.27 | Restenosis after arterial angioplasty: a hemorrheologic response to injury. ( Badimon, L; Chesebro, JH; Fuster, V; Lam, JY, 1987) |
| "Thus aspirin is a potent agent in preventing rethrombosis after thrombolytic recanalization of prosthetic grafts." | 1.27 | Beneficial effect of aspirin in maintaining the patency of small-caliber prosthetic grafts after thrombolysis with urokinase or tissue-type plasminogen activator. ( Bush, HL; Curl, GR; Deykin, D; Jakubowski, JA, 1986) |
| " Possible explanations for these negative findings include inadequate dosage or form of omega-3 fatty acids and the antiplatelet drugs administered, excessive variability in graft response due to uncharacterized immunologic histocompatibility, and the possible influence of non-platelet-mediated mechanisms." | 1.27 | Effects of aspirin, dipyridamole, and cod liver oil on accelerated myointimal proliferation in canine veno-arterial allografts. ( DeCampli, WM; Handen, CE; Kosek, JC; Miller, DC; Mitchell, RS, 1988) |
| "Bleeding and thrombosis are well known major causes of morbidity and mortality in patients with myeloproliferative disorders (MPD) but the relationship between these clinical events and the commonly found platelet function abnormalities have not been established." | 1.27 | Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time. ( Baker, RI; Manoharan, A, 1988) |
| "Aspirin treatment significantly enhanced platelet adhesion to the exposed vascular surface." | 1.27 | Influence of anti-platelet drugs on platelet-vessel wall interactions. ( Rao, GH, 1987) |
| "More fibrin accumulation was seen in the aspirin-treated animals, while more platelet aggregation was found in the heparin-treated group." | 1.27 | Scanning electron microscopy of crush/avulsion arterial trauma:effect of heparin and aspirin administration. ( Cooley, BC; Ruas, EJ; Wilgis, EF, 1987) |
| "In no patient did the thrombus progress to occlude the vessel completely, and no new distal emboli were identified on the follow-up angiograms." | 1.27 | Intraluminal thrombus of the internal carotid arteries: angiographic demonstration of resolution with anticoagulant therapy alone. ( Barnett, HJ; Buchan, A; Fox, AJ; Pelz, DM; Vinuela, F, 1986) |
| "Aspirin treatment significantly reduced platelet thrombi on exposed subendothelium." | 1.27 | Epinephrine reverses the inhibitory influence of aspirin on platelet-vessel wall interactions. ( Escolar, G; Rao, GH; White, JG, 1986) |
| "Thrombosis was produced in the aorta by the combination of local partial obstruction and systemic administration of hypotonic saline with serotonin." | 1.27 | The effect of antithrombotics in a new model of arterial thrombosis. ( Hladovec, J, 1986) |
| "Erythromelalgia was the presenting symptom in 26 of 40 patients with thrombocythemia in its primary form or when associated with polycythemia vera." | 1.27 | Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. ( Abels, J; Michiels, JJ; Steketee, J; van Vliet, HH; Vuzevski, VD, 1985) |
| "Trapidil was expected to be an effective antithrombotic agent." | 1.26 | Antithrombotic activity and the mechanism of action of trapidil (Rocornal). ( Kitamura, Y; Ohnishi, H; Shimada, S; Suzuki, Y; Yamaguchi, K, 1982) |
| "Vascular thrombosis is the response to injury of blood and the vessel wall." | 1.26 | [Thrombogenic properties of the vessel and their inhibition]. ( Beretz, A; Cazenave, JP; Klein-Soyer, C, 1982) |
| "We hypothesize that Kawasaki disease may be an etiologic factor in some cases of early atypical coronary atherosclerosis." | 1.26 | Regression of aneurysms in Kawasaki disease: a pathological study. ( Kato, H; Sasaguri, Y, 1982) |
| " Optimum drug or combination of drugs and dosage are still controversial." | 1.26 | [Inhibition of platelet function in pediatric medicine (author's transl)]. ( Schmidt, B, 1982) |
| "A high dose (200 mg/kg) did not inhibit thrombus formation whereas a low dose (20 mg/kg) reduced the incidence of occlusion and the mean thrombus weight." | 1.26 | Effects of 6-[p-(4-phenylacetylpiperazin-l-yl)-phenyl]-4,5-dihydro-3(2H)-pyridazinone (CCl 17810) and aspirin on experimental arterial thrombosis in rats. ( Kumar, A; Lecker, D, 1980) |
| "The activity of ditazole in reducing thrombus weight was comparable to that of aspirin." | 1.26 | Ditazole activity and its interaction with urokinase on experimental thrombosis. ( Borrelli, F; Cafiero, C; Caprino, L; Falchetti, R; Gandolfo, GM, 1977) |
| "Triflusal is a new antithrombotic agent, structurally similar to acetylsalicylic acid (ASA), which has been shown to possess a different pharmacological profile, suggesting a different mechanism of action for both compounds." | 1.26 | Comparison of the inhibitory effects of acetylsalicylic acid and trifusal on enzymes related to thrombosis. ( Garcia Rafanell, J; Planas, JM; Puig-Parellada, P, 1979) |
| "Sulfinpyrazone treatment of patients with myocardial infarction (Killip--classification I and II), starting 25--35 days after the acute myocardial infarction, reduces cardiac mortality and incidence of sudden death for a period of two years." | 1.26 | [Action mechanism and clinical indications for thrombocyte aggregation inhibitors]. ( Oelz, O, 1979) |
| "Heparin reduced thrombus only when sufficient was given to reduce blood coagulation." | 1.26 | Effects of heparin, aspirin and dipyridamole on thrombus formation on venous catheters. ( Hecker, JF; Spanos, HG, 1979) |
| "Platelet adhesion and thrombus formation were compared after perfusion of native blood and of blood anticoagulated with citrate, heparin or heparin plus citrate." | 1.26 | Effects of acetylsalicylic acid, sulfinpyrazone and dipyridamole on platelet adhesion and aggregation in flowing native and anticoagulated blood. ( Baumgartner, HR, 1979) |
| "and sulfinpyrazone have been tested in several large scale clinical trials." | 1.26 | [Antiplatelet drugs (author's transl)]. ( Dechavanne, M; Follea, G; Trzeciak, MC, 1979) |
| "Of these cases 35% showed evidence of thrombus formation." | 1.26 | [Antithrombotic agents for the prevention of thromboses during infraclavicular vena cava catheterizaiton]. ( Brändli, F; Braun, U; Fassolt, A, 1979) |
| "Aspirin was about twice as less active than KC-6141 and dipyridamole showed no effect on the thrombosis." | 1.26 | Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141), an anti-aggregating compound, on experimental thrombosis in rats. ( Sanai, K; Umetsu, T, 1978) |
| "Arterial thrombus formation was induced in male and female Wistar rats (3 mo) by inserting a loop-shaped polyethylene cannula into the abdominal aorta." | 1.26 | Gonadal hormones and pathogenesis of occlusive arterial thrombosis. ( Ramey, ER; Ramwell, PW; Uzunova, AD, 1978) |
| " No results with Colfarit were noted in the branch vein thromboses, in fact bleeding recurred in almost every case in the fifth week, when Colfarit was given for longer than 4 weeks in the dosage of 3 times 0." | 1.26 | [Observations and results of photodocumentation of retinal thromboses treated with Colfarit (author's transl)]. ( Schlosshardt, H, 1978) |
| "In this model, the formation of a thrombus on a segment of Silastic tubing placed in the vena cava of a rhesus monkey is utilized to evaluate the effectiveness of antithrombotic agents." | 1.26 | Dynamics of thrombus formation on an artificial surface in vivo. Effects of antithrombotic agents. ( Mason, RG; Shinoda, BA; Wolf, RH; Zucker, WH, 1976) |
| "Factors determining thrombus formation on a foreign surface were studied with the use of plastic flow chambers introduced into extracorporeal shunts." | 1.25 | Extracorporeal model for study of factors affecting thrombus formation. ( Aledort, LM; Benis, AM; Koffsky, RM; Leonard, EF; Litwak, RS; Nossel, HL; Shiang, H; Stevenson, JF, 1975) |
| "ASA may affect two aspects of thrombus formation: platelet adherence to subendothelial structures and the platelet release reaction induced by collagen (and possibly by other subendothelial structures)." | 1.25 | Inhibition of platelet adherence to damaged surface of rabbit aorta. ( Cazenave, JP; Guccione, MA; Mustard, JF; Packham, MA, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 507 (23.12) | 18.7374 |
| 1990's | 327 (14.91) | 18.2507 |
| 2000's | 526 (23.99) | 29.6817 |
| 2010's | 638 (29.09) | 24.3611 |
| 2020's | 195 (8.89) | 2.80 |
| Authors | Studies |
|---|---|
| Sunkel, CE | 1 |
| Fau de Casa-Juana, M | 1 |
| Cillero, FJ | 1 |
| Priego, JG | 1 |
| Ortega, MP | 1 |
| Koga, Y | 1 |
| Kihara, Y | 1 |
| Okada, M | 2 |
| Inoue, Y | 1 |
| Tochizawa, S | 1 |
| Toga, K | 1 |
| Tachibana, K | 1 |
| Kimura, Y | 2 |
| Nishi, T | 1 |
| Hidaka, H | 2 |
| Chen, Y | 6 |
| Cui, G | 1 |
| Zhao, M | 6 |
| Wang, C | 4 |
| Qian, K | 1 |
| Morris-Natschke, S | 1 |
| Lee, KH | 2 |
| Peng, S | 6 |
| Yao, K | 2 |
| Zhang, X | 6 |
| Wang, Y | 13 |
| Li, L | 5 |
| Zheng, M | 4 |
| Correia-da-Silva, M | 1 |
| Sousa, E | 1 |
| Duarte, B | 1 |
| Marques, F | 1 |
| Carvalho, F | 1 |
| Cunha-Ribeiro, LM | 1 |
| Pinto, MM | 1 |
| Li, C | 4 |
| Wu, J | 5 |
| Liu, J | 3 |
| Misra, A | 2 |
| Anil Kumar, KS | 1 |
| Jain, M | 1 |
| Bajaj, K | 1 |
| Shandilya, S | 1 |
| Srivastava, S | 1 |
| Shukla, P | 1 |
| Barthwal, MK | 2 |
| Dikshit, M | 3 |
| Dikshit, DK | 2 |
| Zheng, H | 1 |
| Wei, Z | 2 |
| Xin, G | 2 |
| Ji, C | 2 |
| Wen, L | 1 |
| Xia, Q | 1 |
| Niu, H | 2 |
| Huang, W | 2 |
| Wang, X | 5 |
| Gui, L | 2 |
| Zhao, S | 4 |
| Li, Z | 4 |
| Gogoi, D | 1 |
| Pal, A | 1 |
| Chattopadhyay, P | 1 |
| Paul, S | 1 |
| Deka, RC | 1 |
| Mukherjee, AK | 1 |
| Ming, Y | 1 |
| Li, S | 3 |
| Morris-Natschke, SL | 1 |
| Yu, K | 1 |
| Li, Y | 10 |
| Zhang, B | 1 |
| Zhang, J | 5 |
| Xing, Z | 1 |
| He, Y | 1 |
| Chen, Z | 4 |
| Yang, X | 3 |
| Perrone, MG | 1 |
| Miciaccia, M | 1 |
| Vitale, P | 1 |
| Ferorelli, S | 1 |
| Araújo, CDCB | 1 |
| de Almeida, GS | 1 |
| Souza Domingos, TF | 1 |
| da Silva, LCRP | 1 |
| de Pádula, M | 1 |
| Cabral, LM | 2 |
| Sathler, PC | 3 |
| Bonaccorso, C | 1 |
| Fortuna, CG | 1 |
| Scilimati, A | 1 |
| Li, X | 5 |
| Guo, T | 2 |
| Feng, Q | 1 |
| Bai, T | 1 |
| Wu, L | 1 |
| Liu, Y | 3 |
| Zheng, X | 1 |
| Jia, J | 1 |
| Pei, J | 1 |
| Wu, S | 1 |
| Song, Y | 2 |
| Zhang, Y | 3 |
| Marcinczyk, N | 1 |
| Misztal, T | 1 |
| Gromotowicz-Poplawska, A | 1 |
| Zebrowska, A | 1 |
| Rusak, T | 1 |
| Radziwon, P | 1 |
| Chabielska, E | 1 |
| Burattini, M | 1 |
| Falsetti, L | 1 |
| Potente, E | 1 |
| Rinaldi, C | 1 |
| Bartolini, M | 1 |
| Buratti, L | 1 |
| Silvestrini, M | 1 |
| Viticchi, G | 1 |
| Viscusi, MM | 1 |
| Mangiacapra, F | 2 |
| Bressi, E | 1 |
| Sticchi, A | 2 |
| Colaiori, I | 1 |
| Capuano, M | 1 |
| Ricottini, E | 1 |
| Cavallari, I | 1 |
| Spoto, S | 1 |
| Di Sciascio, G | 1 |
| Ussia, GP | 1 |
| Grigioni, F | 1 |
| Morgan, EP | 1 |
| Hawn, JM | 1 |
| Meadows, H | 1 |
| Houston, B | 1 |
| Tedford, RJ | 1 |
| Fajardo, J | 1 |
| Perez, C | 1 |
| McCrindle, BW | 4 |
| Michelson, AD | 9 |
| Van Bergen, AH | 1 |
| Suzana Horowitz, E | 1 |
| Pablo Sandoval, J | 1 |
| Justino, H | 2 |
| Harris, KC | 2 |
| Jefferies, JL | 2 |
| Miriam Pina, L | 1 |
| Peluso, C | 1 |
| Nessel, K | 1 |
| Lu, W | 1 |
| Li, JS | 2 |
| Connors, JM | 3 |
| Brooks, MM | 1 |
| Sciurba, FC | 1 |
| Krishnan, JA | 1 |
| Bledsoe, JR | 1 |
| Kindzelski, A | 1 |
| Baucom, AL | 1 |
| Kirwan, BA | 1 |
| Eng, H | 1 |
| Martin, D | 1 |
| Zaharris, E | 1 |
| Everett, B | 1 |
| Castro, L | 1 |
| Shapiro, NL | 1 |
| Lin, JY | 1 |
| Hou, PC | 1 |
| Pepine, CJ | 1 |
| Handberg, E | 1 |
| Haight, DO | 1 |
| Wilson, JW | 1 |
| Majercik, S | 1 |
| Fu, Z | 1 |
| Zhong, Y | 1 |
| Venugopal, V | 1 |
| Beach, S | 1 |
| Wisniewski, S | 1 |
| Ridker, PM | 4 |
| Boucher, AA | 1 |
| Francisco, BJ | 1 |
| Pfeiffer, A | 1 |
| Martin, M | 1 |
| Martin, J | 1 |
| Shova, A | 1 |
| Nathan, JD | 1 |
| Tiao, GM | 1 |
| Luchtman-Jones, L | 1 |
| Melnichnikova, OS | 1 |
| Nazarova, IA | 1 |
| Sirotkina, OV | 1 |
| Panov, AV | 1 |
| Abesadze, IT | 1 |
| Alugishvili, MZ | 1 |
| Lokhovinina, NL | 1 |
| Vavilova, TV | 1 |
| Koh, CY | 1 |
| Shih, N | 1 |
| Yip, CYC | 1 |
| Li, AWL | 1 |
| Chen, W | 1 |
| Amran, FS | 1 |
| Leong, EJE | 1 |
| Iyer, JK | 1 |
| Croft, G | 1 |
| Mazlan, MIB | 1 |
| Chee, YL | 1 |
| Yap, ES | 1 |
| Monroe, DM | 1 |
| Hoffman, M | 1 |
| Becker, RC | 4 |
| de Kleijn, DPV | 1 |
| Verma, V | 1 |
| Gupta, A | 1 |
| Chaudhary, VK | 1 |
| Richards, AM | 2 |
| Kini, RM | 1 |
| Chan, MY | 2 |
| Formiga, F | 1 |
| Rubio-Rivas, M | 1 |
| Mora-Luján, JM | 1 |
| Escudero, SC | 1 |
| Martinez, RFM | 1 |
| Mendez-Bailón, M | 1 |
| Campo, PD | 1 |
| Pérez, AR | 1 |
| García-Sánchez, FJ | 1 |
| Alcalá-Pedrajas, JN | 1 |
| Hernández, SA | 1 |
| Milian, AH | 1 |
| Díez, AL | 1 |
| Sánchez, RG | 1 |
| Boixeda, R | 1 |
| Vicente, J | 1 |
| Cortes, B | 1 |
| Pérez, CM | 1 |
| Espartero, MEG | 1 |
| Castro, JL | 1 |
| Suárez, SR | 1 |
| Varona, JF | 1 |
| Gomez-Huelgas, R | 1 |
| Ramos-Rincón, JM | 1 |
| Selvadurai, MV | 1 |
| Riaz, M | 1 |
| Xie, S | 1 |
| Tonkin, AM | 1 |
| McNeil, JJ | 1 |
| Lacaze, P | 1 |
| Hamilton, JR | 2 |
| Lobo, N | 1 |
| Hensley, PJ | 1 |
| Bree, KK | 1 |
| Nogueras-Gonzalez, GM | 1 |
| Navai, N | 1 |
| Dinney, CP | 1 |
| Kamat, AM | 1 |
| Rigual, R | 1 |
| Ruiz-Ares, G | 1 |
| Rodriguez-Pardo, J | 1 |
| Fernández-Prieto, A | 1 |
| Navia, P | 1 |
| Novo, JR | 1 |
| Alonso de Leciñana, M | 1 |
| Alonso-Singer, P | 1 |
| Fuentes, B | 1 |
| Díez-Tejedor, E | 1 |
| Parker, WAE | 2 |
| Sagar, R | 1 |
| Kurdee, Z | 1 |
| Hawkins, F | 1 |
| Naseem, KM | 2 |
| Grant, PJ | 2 |
| Storey, RF | 9 |
| Ajjan, RA | 5 |
| Husain, A | 1 |
| Sayem, MA | 1 |
| Kamal, SM | 1 |
| Morshed, ME | 1 |
| Kirac, D | 1 |
| Yaman, AE | 1 |
| Doran, T | 1 |
| Mihmanli, M | 1 |
| Keles, EC | 1 |
| Hussain, H | 1 |
| Tarantino, MD | 1 |
| Chaturvedi, S | 3 |
| McCrae, KR | 2 |
| Roberts, JC | 1 |
| Harino, T | 1 |
| Noura, S | 1 |
| Hamabe, A | 1 |
| Ogino, T | 1 |
| Takeyama, H | 1 |
| Suzuki, Y | 4 |
| Tanida, T | 1 |
| Tomita, N | 1 |
| Dono, K | 1 |
| Shao, B | 1 |
| Hoover, C | 1 |
| Shi, H | 1 |
| Kondo, Y | 1 |
| Lee, RH | 2 |
| Chen, J | 2 |
| Shan, X | 1 |
| Song, J | 1 |
| McDaniel, JM | 1 |
| Zhou, M | 1 |
| McGee, S | 1 |
| Vanhoorelbeke, K | 1 |
| Bergmeier, W | 2 |
| López, JA | 1 |
| George, JN | 1 |
| Xia, L | 1 |
| Udry, S | 2 |
| Peréz, SM | 1 |
| Belizna, C | 1 |
| Aranda, F | 1 |
| Esteve-Valverde, E | 1 |
| Wingeyer, SP | 1 |
| Fernández-Romero, DS | 1 |
| Latino, JO | 2 |
| de Larrañaga, G | 1 |
| Alijotas-Reig, J | 2 |
| Berkowitz, SD | 1 |
| Bauersachs, RM | 1 |
| Szarek, M | 1 |
| Nehler, MR | 1 |
| Debus, ES | 1 |
| Patel, MR | 1 |
| Anand, SS | 4 |
| Capell, WH | 1 |
| Hess, CN | 1 |
| Hsia, J | 1 |
| Leeper, NJ | 1 |
| Brasil, D | 1 |
| Mátyás, L | 1 |
| Diaz, R | 1 |
| Brodmann, M | 1 |
| Muehlhofer, E | 1 |
| Haskell, LP | 1 |
| Bonaca, MP | 2 |
| Kirchner, VA | 1 |
| O'Farrell, B | 1 |
| Imber, C | 1 |
| McCormack, L | 1 |
| Northup, PG | 1 |
| Song, GW | 1 |
| Spiro, M | 1 |
| Raptis, DA | 1 |
| Durand, F | 1 |
| Heitmeier, S | 2 |
| Visser, M | 1 |
| Tersteegen, A | 1 |
| Dietze-Torres, J | 1 |
| Glunz, J | 1 |
| Gerdes, C | 1 |
| Laux, V | 2 |
| Stampfuss, J | 1 |
| Roehrig, S | 1 |
| Goulart, H | 1 |
| Mascarenhas, J | 1 |
| Tremblay, D | 1 |
| Mwiza, JMN | 1 |
| Paul, DS | 1 |
| Holle, LA | 1 |
| Cooley, BC | 7 |
| Nieswandt, B | 3 |
| Schug, WJ | 1 |
| Kawano, T | 1 |
| Mackman, N | 1 |
| Wolberg, AS | 1 |
| Abdi, M | 1 |
| Lamardi, ZH | 1 |
| Shirjan, F | 1 |
| Mohammadi, L | 1 |
| Abadi, SSD | 1 |
| Massoudi, N | 1 |
| Zangiabadian, M | 1 |
| Nasiri, MJ | 1 |
| Bor, WL | 1 |
| de Veer, AJW | 1 |
| Olie, RH | 1 |
| Rikken, SAOF | 1 |
| Chan Pin Yin, DRPP | 2 |
| Herrman, JPR | 1 |
| Vrolix, M | 1 |
| Meuwissen, M | 1 |
| Vandendriessche, T | 1 |
| van Mieghem, C | 1 |
| Magro, M | 2 |
| Bennaghmouch, N | 1 |
| Hermanides, R | 1 |
| Adriaenssens, T | 1 |
| Dewilde, WJM | 1 |
| Ten Berg, JM | 12 |
| Tao, L | 1 |
| Ren, S | 1 |
| Zhang, L | 6 |
| Liu, W | 1 |
| Zhao, Y | 2 |
| Chen, C | 1 |
| Mao, X | 1 |
| Gu, X | 1 |
| Verma, S | 2 |
| Eikelboom, JW | 13 |
| Al-Omran, M | 1 |
| Choi, R | 1 |
| Heffernan, M | 1 |
| Teoh, H | 1 |
| Bhatt, DL | 21 |
| Saito, MS | 2 |
| Zatta, KC | 1 |
| Furtado, PS | 1 |
| C O Miguel, N | 1 |
| Frattani, FS | 1 |
| Berger, M | 1 |
| Lavayen, V | 1 |
| Pohlmann, AR | 1 |
| Guterres, SS | 1 |
| Akther, F | 1 |
| Tran, HDN | 1 |
| Fallahi, H | 1 |
| Adelnia, H | 1 |
| Phan, HP | 1 |
| Nguyen, NT | 1 |
| Ta, HT | 1 |
| Bai, C | 1 |
| Wu, X | 1 |
| Ilagan, R | 1 |
| Ding, Y | 2 |
| Ji, X | 1 |
| Meng, R | 1 |
| Piekarski, BL | 1 |
| Rogers, J | 2 |
| Zurakowski, D | 3 |
| Thiagarajan, R | 1 |
| Emani, SM | 4 |
| Fu, X | 1 |
| Liu, P | 1 |
| Liu, S | 2 |
| Pan, Y | 1 |
| Harbi, MH | 2 |
| Smith, CW | 1 |
| Alenazy, FO | 2 |
| Nicolson, PLR | 2 |
| Tiwari, A | 2 |
| Watson, SP | 2 |
| Thomas, MR | 2 |
| Eman, A | 1 |
| Balaban, O | 1 |
| Süner, KÖ | 1 |
| Cırdı, Y | 1 |
| Şahin, F | 1 |
| Demir, G | 1 |
| Pekşen, Ö | 1 |
| Musmul, A | 1 |
| Erdem, AF | 1 |
| Shantsila, E | 3 |
| Kozieł-Siołkowska, M | 1 |
| Lip, GY | 18 |
| Herrera-Sánchez, A | 1 |
| Madriagal-Alvarado, MJ | 1 |
| Moncayo, G | 1 |
| Verdini, F | 1 |
| Stuckey, R | 1 |
| Ianotto, JC | 3 |
| Santoro, M | 1 |
| Czyż, A | 1 |
| Perez Encinas, MM | 1 |
| Gómez-Casares, MT | 1 |
| Noya Pereira, MS | 1 |
| de Nałęcz, AK | 1 |
| Gołos, A | 1 |
| Lewandowski, K | 2 |
| Szukalski, Ł | 1 |
| González-Martín, JM | 1 |
| Wróbel, T | 1 |
| Sobas, MA | 1 |
| Nagy, B | 1 |
| Sulyok, E | 1 |
| Várnagy, Á | 1 |
| Barabás, A | 1 |
| Kovács, K | 1 |
| Bódis, J | 1 |
| Lee-Riddle, GS | 1 |
| Rocca, JP | 1 |
| Kranendonk, J | 1 |
| Willems, LH | 1 |
| Vijver-Coppen, RV | 1 |
| Coenen, M | 1 |
| Adang, E | 1 |
| Donders, R | 1 |
| Zeebregts, CJ | 1 |
| Deneer, V | 1 |
| Reijnen, M | 1 |
| Kramers, C | 2 |
| Warlé, MC | 1 |
| Majumdar, M | 1 |
| Waller, D | 1 |
| Poyant, J | 1 |
| McElroy, I | 1 |
| Lella, S | 1 |
| Feldman, ZM | 1 |
| Levine, E | 1 |
| Kim, Y | 1 |
| Nuzzolo, K | 1 |
| Kirshkaln, A | 1 |
| DeCarlo, C | 1 |
| Dua, A | 1 |
| Guida, GA | 1 |
| Angelini, GD | 1 |
| Pires da Rosa, G | 1 |
| Ferreira, E | 1 |
| Sousa-Pinto, B | 1 |
| Rodríguez-Pintó, I | 2 |
| Brito, I | 1 |
| Mota, A | 1 |
| Cervera, R | 6 |
| Espinosa, G | 3 |
| Chaudhary, R | 1 |
| Sharma, T | 1 |
| Tantry, US | 12 |
| Asgar, JA | 1 |
| Kundan, P | 1 |
| Duhan, S | 1 |
| Gill, H | 1 |
| Singh, A | 1 |
| Alasadi, Y | 1 |
| Gurbel, PA | 14 |
| Bliden, KP | 5 |
| Mai, EK | 1 |
| Wolf, A | 1 |
| Fajer, S | 1 |
| Haddad, M | 2 |
| Shnaker, A | 1 |
| Ajaj, M | 1 |
| Shehab, M | 1 |
| Erba, N | 1 |
| Tosetto, A | 2 |
| Langer, M | 1 |
| Abdallah, SA | 1 |
| Giovanella, E | 1 |
| Lentini, S | 1 |
| Masini, F | 1 |
| Mocini, A | 1 |
| Portella, G | 1 |
| Salvati, AC | 1 |
| Squizzato, A | 4 |
| Testa, S | 2 |
| Lip, GYH | 1 |
| Poli, D | 1 |
| Jolly, SS | 2 |
| Belley-Cote, EP | 1 |
| Whitlock, RP | 2 |
| Rangarajan, S | 1 |
| Xu, L | 5 |
| Heenan, L | 1 |
| Bangdiwala, SI | 1 |
| Tarhuni, WM | 1 |
| Hassany, M | 1 |
| Kontsevaya, A | 1 |
| Harper, W | 1 |
| Sharma, SK | 4 |
| Lopez-Jaramillo, P | 1 |
| Dans, AL | 1 |
| Palileo-Villanueva, LM | 1 |
| Avezum, A | 2 |
| Pais, P | 1 |
| Xavier, D | 1 |
| Felix, C | 1 |
| Yusufali, A | 1 |
| Lopes, RD | 4 |
| Berwanger, O | 2 |
| Ali, Z | 1 |
| Wasserman, S | 1 |
| Bosch, J | 3 |
| Choudhri, S | 1 |
| Farkouh, ME | 1 |
| Loeb, M | 1 |
| Yusuf, S | 5 |
| Ge, T | 1 |
| Zhu, Z | 1 |
| Wang, J | 2 |
| Zhou, W | 1 |
| Song, EJ | 1 |
| Tang, S | 1 |
| Luo, L | 1 |
| Wang, S | 1 |
| Tang, K | 1 |
| Wang, D | 1 |
| Feng, T | 1 |
| Li, D | 2 |
| Ran, J | 1 |
| Zhao, D | 1 |
| Wickham, KA | 1 |
| Nørregaard, LB | 1 |
| Lundberg Slingsby, MH | 1 |
| Cheung, SS | 1 |
| Hellsten, Y | 1 |
| Wu, H | 1 |
| Zhao, X | 1 |
| Zhang, H | 4 |
| Cheng, K | 1 |
| Chen, M | 2 |
| Li, G | 1 |
| Huang, J | 4 |
| Lan, J | 1 |
| Wei, G | 1 |
| Zhang, C | 2 |
| Qian, J | 2 |
| Ge, J | 3 |
| Kang, J | 1 |
| Park, KW | 1 |
| Lee, H | 2 |
| Hwang, D | 1 |
| Yang, HM | 1 |
| Rha, SW | 4 |
| Bae, JW | 1 |
| Lee, NH | 2 |
| Hur, SH | 3 |
| Han, JK | 1 |
| Shin, ES | 1 |
| Koo, BK | 1 |
| Kim, HS | 2 |
| Deng, Y | 2 |
| Tay, HM | 2 |
| Zhou, Y | 3 |
| Fei, X | 2 |
| Tang, X | 3 |
| Nishikawa, M | 4 |
| Yatomi, Y | 3 |
| Hou, HW | 2 |
| Xiao, TH | 2 |
| Goda, K | 2 |
| Matsuo, O | 1 |
| Ishii, M | 2 |
| Kaikita, K | 5 |
| Morinaga, J | 1 |
| Miyamura, F | 1 |
| Matsumoto, S | 2 |
| Tsujita, K | 4 |
| Nakamura, K | 3 |
| Mora, B | 1 |
| Passamonti, F | 4 |
| Carlin, S | 1 |
| de Vries, TAC | 1 |
| Budaj, A | 4 |
| Eikelboom, J | 2 |
| Paoletti, M | 1 |
| Azizi, MA | 1 |
| Efthymiou, A | 1 |
| Ambati, A | 1 |
| Knight, JS | 2 |
| Zuo, Y | 2 |
| Tao, JJ | 1 |
| Adurty, S | 1 |
| D'Angelo, D | 1 |
| DeSancho, MT | 1 |
| Quan, X | 1 |
| Liang, X | 1 |
| Han, Y | 2 |
| Li, J | 3 |
| Yuan, M | 1 |
| Yuan, Z | 1 |
| Wang, R | 2 |
| Liu, FC | 1 |
| Miller, TJ | 1 |
| Henn, D | 1 |
| Nguyen, D | 1 |
| Momeni, A | 1 |
| Medina-Rodríguez, M | 1 |
| Moniche, F | 1 |
| de Albóniga-Chindurza, A | 1 |
| Ortega-Quintanilla, J | 1 |
| Ainz-Gómez, L | 1 |
| Pardo-Galiana, B | 1 |
| Cabezas-Rodríguez, JA | 1 |
| Aguilar-Pérez, M | 1 |
| Zamora, A | 1 |
| Delgado-Acosta, F | 1 |
| Jiménez-Gómez, E | 1 |
| Bravo Rey, I | 1 |
| Oteros Fernández, R | 1 |
| Freijo Guerrero, MDM | 1 |
| González Díaz, E | 1 |
| Escudero-Martínez, I | 1 |
| Morales Caba, L | 1 |
| Vielba-Gomez, I | 1 |
| Mosteiro, S | 1 |
| Castellanos Rodrigo, MDM | 1 |
| Amaya Pascasio, L | 1 |
| Hidalgo, C | 1 |
| Fernandez Prudencio, L | 1 |
| Ramirez Moreno, JM | 1 |
| Díaz Pérez, J | 1 |
| Sanz-Fernandez, G | 1 |
| Baena-Palomino, P | 1 |
| Gamero-García, MÁ | 1 |
| Jiménez Jorge, S | 1 |
| Rosso Fernández, C | 1 |
| Montaner, J | 1 |
| González García, A | 1 |
| Zapata-Arriaza, E | 1 |
| Yin, M | 1 |
| Qin, X | 1 |
| Cohan, D | 1 |
| Uricchio, MN | 1 |
| Konopka, CI | 1 |
| Montepara, CA | 1 |
| Verlinden, NJ | 1 |
| Shpigelman, J | 1 |
| Proshkina, A | 1 |
| Daly, MJ | 1 |
| Cox, D | 1 |
| Landi, A | 1 |
| Wlodarczak, A | 1 |
| Tölg, R | 1 |
| Kelbæk, H | 1 |
| Legutko, J | 1 |
| Galli, S | 1 |
| Godin, M | 1 |
| Toth, GG | 2 |
| Lhermusier, T | 1 |
| Honton, B | 1 |
| Dietrich, PL | 1 |
| Stammen, F | 1 |
| Ferdinande, B | 2 |
| Silvain, J | 1 |
| Capodanno, D | 4 |
| Cayla, G | 2 |
| Valgimigli, M | 9 |
| Solomou, EE | 1 |
| Delaporta, P | 1 |
| Mantzou, A | 1 |
| Tzannoudaki, M | 1 |
| Diamantopoulos, P | 1 |
| Salamaliki, C | 1 |
| Kontandreopoulou, CN | 1 |
| Vyniou, NA | 1 |
| Perganti, F | 1 |
| Papassotiriou, I | 1 |
| Kattamis, A | 1 |
| Ma, S | 1 |
| Jia, X | 1 |
| Bu, Y | 1 |
| Zhou, T | 1 |
| Qiu, M | 1 |
| Angiolillo, DJ | 11 |
| Porta, SV | 1 |
| de Andrade, DCO | 1 |
| Erkan, D | 5 |
| Gómez-Puerta, JA | 1 |
| Jara, LJ | 1 |
| Alba Moreyra, P | 1 |
| Pons-Estel, GJ | 1 |
| Presume, J | 1 |
| Gomes, DA | 1 |
| Ferreira, J | 2 |
| Albuquerque, F | 1 |
| Almeida, M | 1 |
| Uva, MS | 1 |
| Aguiar, C | 1 |
| Mendes, M | 1 |
| Zhou, SY | 1 |
| Xie, E | 1 |
| Li, MX | 1 |
| Cao, JH | 1 |
| Yang, XB | 1 |
| Wu, DY | 1 |
| Hoffman, MK | 1 |
| Kavanagh, DP | 1 |
| Price, J | 1 |
| Brady, P | 1 |
| Hargreaves, O | 1 |
| Harrison, P | 4 |
| Slater, A | 1 |
| Connolly, DL | 1 |
| Kirchhof, P | 1 |
| Kalia, N | 1 |
| Jandrot-Perrus, M | 1 |
| Mangin, PH | 1 |
| Dalbeni, A | 1 |
| Susca, N | 1 |
| Daidone, M | 1 |
| Rossi, I | 1 |
| Giontella, A | 1 |
| Cimellaro, A | 1 |
| Talerico, G | 1 |
| Pietrangelo, A | 1 |
| Sesti, G | 1 |
| Zaccone, V | 1 |
| Villani, R | 1 |
| Coylewright, M | 1 |
| Holmes, DR | 5 |
| Kapadia, SR | 1 |
| Hsu, JC | 1 |
| Gibson, DN | 1 |
| Freeman, JV | 1 |
| Yeh, RW | 10 |
| Piccini, JP | 1 |
| Price, MJ | 2 |
| Allocco, DJ | 1 |
| Nair, DG | 1 |
| Hu, X | 3 |
| Xu, H | 2 |
| Zhou, D | 1 |
| Zhu, Q | 1 |
| Xu, K | 1 |
| Yang, J | 2 |
| Jiang, N | 1 |
| Fang, Z | 1 |
| Fu, G | 1 |
| Guo, Y | 3 |
| Wang, M | 4 |
| Feng, D | 1 |
| Niu, G | 1 |
| Zhang, E | 1 |
| Ye, Y | 1 |
| Wu, Y | 1 |
| Al Midani, A | 1 |
| Rudarakanchana, N | 1 |
| Nagra, A | 1 |
| Fidan, K | 1 |
| Tugtepe, H | 1 |
| Matthias, M | 1 |
| Ridout, D | 1 |
| Kessaris, N | 1 |
| Marks, SD | 1 |
| Schrör, K | 8 |
| Kristensen, SD | 6 |
| Verheugt, FWA | 2 |
| Decouture, B | 1 |
| Leuci, A | 1 |
| Dizier, B | 2 |
| Belleville-Rolland, T | 1 |
| Mansour, A | 1 |
| Martin, F | 1 |
| Pidard, D | 1 |
| Gaussem, P | 2 |
| Bachelot-Loza, C | 2 |
| Lazzaroni, MG | 1 |
| Fredi, M | 1 |
| Andreoli, L | 3 |
| Chighizola, CB | 1 |
| Del Ross, T | 3 |
| Gerosa, M | 3 |
| Kuzenko, A | 1 |
| Raimondo, MG | 1 |
| Lojacono, A | 1 |
| Ramazzotto, F | 1 |
| Zatti, S | 1 |
| Trespidi, L | 2 |
| Meroni, PL | 3 |
| Pengo, V | 5 |
| Ruffatti, A | 6 |
| Tincani, A | 5 |
| Pracon, R | 1 |
| Trochimiuk, P | 1 |
| Debski, M | 1 |
| Kepka, C | 1 |
| Demkow, M | 1 |
| Saw, J | 1 |
| Nielsen-Kudsk, JE | 3 |
| Bergmann, M | 1 |
| Daniels, MJ | 1 |
| Tzikas, A | 1 |
| Reisman, M | 1 |
| Rana, BS | 1 |
| Aminian, A | 1 |
| Schmidt, B | 3 |
| Abraham, NS | 1 |
| Takahashi, K | 3 |
| Serruys, PW | 2 |
| Chichareon, P | 2 |
| Chang, CC | 2 |
| Tomaniak, M | 2 |
| Modolo, R | 2 |
| Kogame, N | 2 |
| Chowdhary, S | 1 |
| Eitel, I | 1 |
| Zweiker, R | 1 |
| Ong, P | 1 |
| Ottesen, MM | 1 |
| Tijssen, JGP | 1 |
| Wykrzykowska, JJ | 2 |
| de Winter, RJ | 1 |
| Garg, S | 2 |
| Stoll, HP | 2 |
| Hamm, C | 3 |
| Steg, PG | 19 |
| Onuma, Y | 2 |
| Vranckx, P | 3 |
| Carrie, D | 2 |
| Windecker, S | 6 |
| Kainth, R | 1 |
| Shah, P | 1 |
| Hoxha, A | 3 |
| Favaro, M | 1 |
| Calligaro, A | 1 |
| Ruffatti, AT | 1 |
| Infantolino, C | 1 |
| Tonello, M | 2 |
| Mattia, E | 1 |
| Davis, BH | 1 |
| DeFrank, G | 1 |
| Limdi, NA | 1 |
| Harada, S | 1 |
| Katzman, BM | 1 |
| Wockenfus, AM | 1 |
| Scott, RJ | 1 |
| Bryant, SC | 1 |
| Jaffe, AS | 2 |
| Karon, BS | 1 |
| Kerkmeijer, L | 1 |
| Komiyama, H | 1 |
| Moccetti, T | 1 |
| Talwar, S | 1 |
| Colombo, A | 9 |
| Maillard, L | 3 |
| Barlis, P | 1 |
| Wykrzykowska, J | 1 |
| Piek, JJ | 1 |
| Jüni, P | 1 |
| Mehran, R | 9 |
| Montalto, A | 1 |
| Comisso, M | 1 |
| Cammardella, A | 1 |
| Nicolò, F | 1 |
| Gherli, R | 1 |
| Palermo, A | 1 |
| Pulcinelli, F | 1 |
| Musumeci, F | 2 |
| Neergaard-Petersen, S | 1 |
| Larsen, SB | 1 |
| Grove, EL | 4 |
| Hvas, AM | 3 |
| Dionne, A | 1 |
| Dahdah, N | 1 |
| Singh-Grewal, D | 1 |
| Burgner, DP | 1 |
| Newburger, JW | 1 |
| de Ferranti, SD | 1 |
| Saito, Y | 1 |
| Kobayashi, Y | 2 |
| Tanabe, K | 2 |
| Ikari, Y | 2 |
| Zrimsek, M | 1 |
| Gubensek, J | 1 |
| Yang, H | 1 |
| Zhang, F | 1 |
| Cao, R | 1 |
| Dai, Y | 1 |
| Ma, N | 4 |
| Yang, Y | 3 |
| Liu, X | 1 |
| Qin, Z | 2 |
| Schulte, C | 1 |
| Barwari, T | 1 |
| Phoenix, F | 2 |
| Pearson, SM | 1 |
| Mayr, M | 2 |
| Faggioni, M | 1 |
| Redfors, B | 1 |
| Crowley, A | 1 |
| Claessen, BE | 1 |
| Farhan, S | 3 |
| Mastoris, I | 1 |
| Witzenbichler, B | 1 |
| Maehara, A | 1 |
| Weisz, G | 1 |
| Généreux, P | 2 |
| Ben-Yehuda, O | 1 |
| Kirtane, AJ | 2 |
| Stone, GW | 4 |
| Bocchino, PP | 1 |
| De Filippo, O | 1 |
| Piroli, F | 1 |
| Scacciatella, P | 1 |
| Imazio, M | 1 |
| D'Ascenzo, F | 1 |
| De Ferrari, GM | 1 |
| Scavone, M | 1 |
| Bozzi, S | 1 |
| Mencarini, T | 1 |
| Podda, G | 1 |
| Cattaneo, M | 6 |
| Redaelli, A | 2 |
| Lin, Z | 1 |
| Liu, L | 2 |
| Xuan, J | 1 |
| Baber, U | 4 |
| Zafar, MU | 1 |
| Dangas, G | 4 |
| Escolar, G | 7 |
| Kini, AS | 1 |
| Sartori, S | 1 |
| Joyce, L | 2 |
| Vogel, B | 1 |
| Gurbel, P | 4 |
| Gibson, CM | 3 |
| Fuster, V | 25 |
| Badimon, JJ | 17 |
| Beller, JP | 1 |
| Chancellor, WZ | 1 |
| Mehaffey, JH | 2 |
| Hawkins, RB | 2 |
| Byler, MR | 1 |
| Speir, AM | 1 |
| Quader, MA | 1 |
| Kiser, AC | 1 |
| Yarboro, LT | 1 |
| Ailawadi, G | 1 |
| Teman, NR | 1 |
| Khan, AA | 1 |
| Murtaza, G | 1 |
| Khalid, M | 1 |
| Finniss, M | 1 |
| Helton, T | 1 |
| Ditali, V | 1 |
| Carrozzi, C | 1 |
| Leonardi, S | 1 |
| Capranzano, P | 3 |
| Francaviglia, B | 1 |
| Tamburino, C | 1 |
| Sagar, RC | 1 |
| Dickson, SD | 1 |
| Taleb, A | 1 |
| Wiernek, S | 1 |
| Govea, A | 1 |
| Penny, W | 1 |
| Madison, JA | 1 |
| Duarte-García, A | 1 |
| Parhofer, KG | 1 |
| Ho-Tin-Noé, B | 1 |
| Gajanana, D | 1 |
| Rogers, T | 2 |
| Weintraub, WS | 1 |
| Kolm, P | 1 |
| Iantorno, M | 1 |
| Khalid, N | 1 |
| Shlofmitz, E | 2 |
| Khan, JM | 1 |
| Musallam, A | 1 |
| Ben-Dor, I | 2 |
| Satler, LF | 5 |
| Torguson, R | 1 |
| Waksman, R | 3 |
| Gustafsson, F | 1 |
| Wu, XT | 1 |
| He, RR | 1 |
| Liang, SZ | 1 |
| Ye, GY | 1 |
| Ding, SB | 1 |
| Saeed, O | 2 |
| Colombo, PC | 1 |
| Mehra, MR | 1 |
| Uriel, N | 1 |
| Goldstein, DJ | 2 |
| Cleveland, J | 1 |
| Najjar, SS | 1 |
| Mokadam, NA | 1 |
| Bansal, A | 1 |
| Crandall, DL | 1 |
| Sood, P | 1 |
| Jorde, UP | 2 |
| Akşit, E | 1 |
| Kurt, T | 1 |
| Büyük, B | 1 |
| Çokkalender, Ö | 1 |
| Zhu, J | 1 |
| Zhu, Y | 1 |
| Zhang, M | 1 |
| Xue, Q | 1 |
| Hu, J | 2 |
| Liu, H | 4 |
| Zhao, Q | 1 |
| Gencer, B | 1 |
| Li, XS | 1 |
| Gurmu, Y | 1 |
| Morrow, DA | 1 |
| Cohen, M | 5 |
| Johanson, P | 1 |
| Wang, Z | 5 |
| Hazen, SL | 2 |
| Sabatine, MS | 1 |
| King, RM | 2 |
| Langan, ET | 2 |
| Ughi, GJ | 2 |
| Raskett, CM | 1 |
| Puri, AS | 2 |
| Henkes, H | 1 |
| Gounis, MJ | 2 |
| Mainoli, B | 1 |
| Duarte, GS | 1 |
| Costa, J | 1 |
| Caldeira, D | 1 |
| Mill, J | 1 |
| Olivares, AL | 1 |
| Arzamendi, D | 1 |
| Agudelo, V | 1 |
| Regueiro, A | 1 |
| Camara, O | 1 |
| Freixa, X | 1 |
| Wang, L | 2 |
| Di, Y | 1 |
| Ming, JE | 1 |
| Kong, F | 1 |
| Yin, H | 2 |
| Xie, F | 1 |
| Yang, N | 1 |
| Ping, C | 1 |
| Hou, J | 1 |
| Caroff, J | 1 |
| Marosfoi, M | 1 |
| Raskett, C | 1 |
| Puram, RV | 1 |
| Erdil, RM | 1 |
| Weber, BN | 1 |
| Knelson, EH | 1 |
| Van Beuningen, AM | 1 |
| Wallwork, R | 1 |
| Gilyard, SN | 1 |
| Curtis, BR | 1 |
| Ranganathan, R | 1 |
| Leaf, RK | 1 |
| Malhotra, R | 1 |
| Alkhalil, M | 1 |
| Shahmohammadi, M | 1 |
| Spence, MS | 1 |
| Owens, CG | 1 |
| Tsujii, N | 1 |
| Nogami, K | 1 |
| Yoshizawa, H | 1 |
| Sakai, T | 1 |
| Fukuda, K | 2 |
| Ishiguro, A | 2 |
| Shima, M | 1 |
| Kellner, A | 1 |
| Dombi, P | 2 |
| Illes, A | 2 |
| Demeter, J | 2 |
| Homor, L | 2 |
| Ercsei, I | 1 |
| Simon, Z | 2 |
| Karadi, E | 2 |
| Herczeg, J | 1 |
| Gy Korom, V | 1 |
| Gasztonyi, Z | 1 |
| Szerafin, L | 1 |
| Udvardy, M | 2 |
| Egyed, M | 2 |
| Berthelot, JM | 1 |
| Drouet, L | 2 |
| Lioté, F | 1 |
| Crescente, M | 1 |
| Armstrong, PC | 6 |
| Kirkby, NS | 2 |
| Edin, ML | 1 |
| Chan, MV | 2 |
| Lih, FB | 1 |
| Jiao, J | 1 |
| Maffucci, T | 1 |
| Allan, HE | 1 |
| Mein, CA | 1 |
| Gaston-Massuet, C | 1 |
| Cottrell, GS | 1 |
| Mitchell, JA | 5 |
| Zeldin, DC | 1 |
| Herschman, HR | 1 |
| Warner, TD | 8 |
| Hosokawa, K | 6 |
| Ohnishi-Wada, T | 1 |
| Nagasato, T | 2 |
| Sameshima-Kaneko, H | 1 |
| Oyamada, C | 1 |
| Dahlen, J | 1 |
| Cheng, D | 1 |
| Hao, Y | 1 |
| Braunstein, EM | 1 |
| Xanthopoulos, A | 1 |
| Tryposkiadis, K | 1 |
| Triposkiadis, F | 1 |
| Fukamachi, K | 1 |
| Soltesz, EG | 1 |
| Young, JB | 1 |
| Wolski, K | 1 |
| Blackstone, EH | 1 |
| Starling, RC | 1 |
| Zimmer, V | 1 |
| Biagioni, RB | 1 |
| Agati, LB | 1 |
| Sacilotto, R | 1 |
| Wolosker, N | 1 |
| Sobreira, ML | 1 |
| de Freitas Soares, BL | 1 |
| Joviliano, EE | 1 |
| Bernardi, WH | 1 |
| Junior, VC | 1 |
| Caffaro, RA | 1 |
| Fioranelli, A | 1 |
| Van Bellen, B | 1 |
| Casella, IB | 1 |
| Fidelis, RJR | 1 |
| Flumignan, RLG | 1 |
| Comerota, AJ | 1 |
| Ramacciotti, E | 1 |
| Bärnthaler, T | 1 |
| Mahla, E | 2 |
| Schuligoi, R | 2 |
| Prüller, F | 1 |
| Buschmann, E | 1 |
| Heinemann, A | 2 |
| Mallah, H | 1 |
| Ball, S | 1 |
| Sekhon, J | 1 |
| Parmar, K | 2 |
| Nugent, K | 1 |
| Darmon, A | 2 |
| Elbez, Y | 2 |
| Abtan, J | 2 |
| Mas, JL | 3 |
| Cacoub, P | 3 |
| Montalescot, G | 10 |
| Billaut-Laden, I | 1 |
| Ducrocq, G | 2 |
| Hodges, K | 1 |
| Mubashir, M | 1 |
| Insler, J | 1 |
| Estep, J | 1 |
| Hsich, E | 1 |
| Tong, M | 1 |
| Insler, S | 1 |
| Soltesz, E | 1 |
| Huang, L | 2 |
| Wang, K | 2 |
| Zhu, S | 2 |
| Brouwer, J | 2 |
| Nijenhuis, VJ | 2 |
| Delewi, R | 1 |
| Hermanides, RS | 1 |
| Holvoet, W | 1 |
| Dubois, CLF | 1 |
| Frambach, P | 1 |
| De Bruyne, B | 1 |
| van Houwelingen, GK | 1 |
| Van Der Heyden, JAS | 1 |
| Toušek, P | 1 |
| van der Kley, F | 1 |
| Buysschaert, I | 1 |
| Schotborgh, CE | 1 |
| van der Harst, P | 1 |
| Roosen, J | 1 |
| Peper, J | 1 |
| Thielen, FWF | 1 |
| Veenstra, L | 1 |
| Swaans, MJ | 1 |
| Rensing, BJWM | 1 |
| van 't Hof, AWJ | 1 |
| Timmers, L | 1 |
| Kelder, JC | 7 |
| Stella, PR | 1 |
| Baan, J | 1 |
| Rolling, CC | 1 |
| Tomada, J | 1 |
| Frölich, AM | 1 |
| Holst, B | 1 |
| Holstein, K | 1 |
| Voigtländer, M | 1 |
| Janjetovic, S | 1 |
| Renné, T | 1 |
| Fiehler, J | 1 |
| Bokemeyer, C | 1 |
| Rolling, T | 1 |
| Langer, F | 1 |
| Dobesh, PP | 1 |
| Finks, SW | 1 |
| Trujillo, TC | 1 |
| Patti, G | 2 |
| Verolino, G | 1 |
| Pasceri, V | 1 |
| Vizzi, V | 1 |
| Brscic, E | 1 |
| Casu, G | 1 |
| Golino, P | 2 |
| Russo, V | 1 |
| Rapacciuolo, A | 1 |
| Boccuzzi, G | 1 |
| Mangieri, A | 1 |
| Pagnotta, PA | 1 |
| Florêncio, FKZ | 1 |
| Tenório, MO | 1 |
| Macedo Júnior, ARA | 1 |
| Lima, SG | 1 |
| Haque, S | 1 |
| Jawed, A | 1 |
| Akhter, N | 1 |
| Dar, SA | 1 |
| Khan, F | 1 |
| Mandal, RK | 1 |
| Areeshi, MY | 1 |
| Lohani, M | 1 |
| Wahid, M | 1 |
| Cao, D | 1 |
| Makkar, RR | 3 |
| Bangalore, S | 1 |
| Saito, S | 2 |
| Neumann, FJ | 4 |
| Hermiller, J | 2 |
| Picon, H | 1 |
| Toelg, R | 1 |
| Maksoud, A | 1 |
| Chehab, BM | 1 |
| Wang, LJ | 1 |
| Guimarães, HP | 1 |
| de Barros E Silva, PGM | 1 |
| Liporace, IL | 1 |
| Sampaio, RO | 1 |
| Tarasoutchi, F | 1 |
| Paixão, M | 1 |
| Hoffmann-Filho, CR | 1 |
| Patriota, R | 1 |
| Leiria, TLL | 1 |
| Lamprea, D | 1 |
| Precoma, DB | 1 |
| Atik, FA | 1 |
| Silveira, FS | 1 |
| Farias, FR | 1 |
| Barreto, DO | 1 |
| Almeida, AP | 1 |
| Zilli, AC | 1 |
| de Souza Neto, JD | 1 |
| Cavalcante, MA | 1 |
| Figueira, FAMS | 1 |
| Junior, RA | 1 |
| Moisés, VA | 1 |
| Mesas, CE | 1 |
| Ardito, RV | 1 |
| Kalil, PSA | 1 |
| Paiva, MSMO | 1 |
| Maldonado, JGA | 1 |
| de Lima, CEB | 1 |
| D'Oliveira Vieira, R | 1 |
| Laranjeira, L | 1 |
| Kojima, F | 1 |
| Damiani, L | 1 |
| Nakagawa, RH | 1 |
| Dos Santos, JRY | 1 |
| Sampaio, BS | 1 |
| Campos, VB | 1 |
| Saraiva, JFK | 1 |
| Fonseca, FH | 1 |
| Pinto, IM | 1 |
| Magalhães, CC | 1 |
| Ferreira, JFM | 1 |
| Pavanello, R | 1 |
| Cavalcanti, AB | 1 |
| Masic, D | 1 |
| Kwon, O | 1 |
| Rech, MA | 1 |
| Li, XL | 1 |
| Wang, Q | 1 |
| Yin, HJ | 1 |
| Wang, YH | 1 |
| Cao, J | 1 |
| Fan, L | 1 |
| Xie, J | 1 |
| Geng, L | 1 |
| Yuan, B | 1 |
| Zhang, Z | 2 |
| Edahiro, Y | 1 |
| Mastenbroek, TG | 1 |
| Karel, MFA | 1 |
| Nagy, M | 1 |
| Chayoua, W | 1 |
| Korsten, EIJ | 1 |
| Coenen, DM | 1 |
| Debets, J | 1 |
| Konings, J | 1 |
| Brouns, AE | 1 |
| Leenders, PJA | 1 |
| van Essen, H | 1 |
| van Oerle, R | 1 |
| Spronk, HM | 1 |
| Kuijpers, MJE | 2 |
| Cosemans, JMEM | 1 |
| Kozuma, K | 3 |
| Kinoshita, Y | 1 |
| Hioki, H | 1 |
| Nanasato, M | 1 |
| Ito, Y | 1 |
| Yamaguchi, J | 1 |
| Shiode, N | 1 |
| Hibi, K | 1 |
| Ako, J | 2 |
| Morino, Y | 1 |
| Hirohata, A | 1 |
| Sonoda, S | 1 |
| Nakagawa, Y | 2 |
| Nguyen, KA | 1 |
| Eadon, MT | 1 |
| Yoo, R | 1 |
| Milway, E | 1 |
| Kenneally, A | 1 |
| Fekete, K | 1 |
| Oh, H | 1 |
| Duong, K | 1 |
| Whipple, EC | 1 |
| Schleyer, TK | 1 |
| Yamato, H | 1 |
| Abe, K | 1 |
| Osumi, S | 1 |
| Yanagisawa, D | 1 |
| Kodashima, S | 1 |
| Asaoka, Y | 1 |
| Konno, K | 1 |
| Yamamoto, T | 1 |
| Tanaka, A | 1 |
| Kubota, M | 2 |
| Matsuoka, T | 1 |
| Yamasaki, T | 1 |
| Kokubun, H | 1 |
| Hagimoto, H | 1 |
| Murata, S | 2 |
| Makita, N | 1 |
| Suzuki, I | 1 |
| Abe, Y | 2 |
| Tohi, Y | 1 |
| Tsutsumi, N | 1 |
| Inoue, K | 2 |
| Kawakita, M | 1 |
| Nei, SD | 1 |
| Wieruszewski, PM | 1 |
| Scott, R | 1 |
| Greason, KL | 1 |
| Sohn, SH | 1 |
| Kim, TS | 1 |
| Kim, JW | 1 |
| Yoo, SM | 1 |
| Jo, WM | 1 |
| Lapietra, G | 1 |
| Serrao, A | 1 |
| Fazio, F | 1 |
| Petrucci, MT | 1 |
| Chistolini, A | 1 |
| Ullah, W | 1 |
| Zghouzi, M | 1 |
| Ahmad, B | 1 |
| Biswas, S | 1 |
| Zaher, N | 1 |
| Sattar, Y | 1 |
| Pacha, HM | 1 |
| Goldsweig, AM | 1 |
| Velagapudi, P | 1 |
| Fichman, DL | 1 |
| Prasad, A | 1 |
| Alraies, MC | 2 |
| Wang, W | 1 |
| Wang, B | 3 |
| Wei, S | 1 |
| Perdan Pirkmajer, K | 1 |
| Kramarič, J | 1 |
| Tomšič, M | 1 |
| Hočevar, A | 1 |
| Schade, DS | 1 |
| Burchiel, S | 1 |
| Eaton, RP | 1 |
| Skeith, L | 1 |
| Rodger, MA | 1 |
| Bates, SM | 1 |
| Gonsalves, C | 1 |
| Karovitch, A | 1 |
| Taylor, TS | 1 |
| Lee, EE | 1 |
| Jun, JK | 1 |
| Lee, EB | 1 |
| Guedeney, P | 1 |
| Collet, JP | 7 |
| Okada, Y | 2 |
| Kimura, F | 1 |
| Kovacevic, KD | 1 |
| Greisenegger, S | 1 |
| Langer, A | 1 |
| Gelbenegger, G | 1 |
| Buchtele, N | 1 |
| Pabinger, I | 1 |
| Petroczi, K | 1 |
| Gilbert, JC | 1 |
| Jilma, B | 2 |
| Iwanaga, T | 1 |
| Fukushima, R | 1 |
| Maruyama, I | 4 |
| Miura, N | 3 |
| Lubert, AM | 1 |
| Redington, AN | 1 |
| Tefferi, A | 11 |
| Szuber, N | 1 |
| Pardanani, A | 3 |
| Hanson, CA | 2 |
| Vannucchi, AM | 8 |
| Barbui, T | 12 |
| Gangat, N | 2 |
| Surianarayanan, V | 1 |
| Hoather, TJ | 1 |
| Tingle, SJ | 1 |
| Thompson, ER | 1 |
| Hanley, J | 1 |
| Wilson, CH | 1 |
| Simone, PB | 1 |
| Bullard, H | 1 |
| Siddiqi, U | 1 |
| Cohen, W | 2 |
| Combs, PS | 1 |
| Jeevanandam, V | 1 |
| Yerasi, C | 1 |
| Forrestal, BJ | 1 |
| Case, BC | 1 |
| Mintz, GS | 1 |
| O'Toole, RV | 1 |
| Stein, DM | 1 |
| Frey, KP | 1 |
| O'Hara, NN | 1 |
| Scharfstein, DO | 1 |
| Slobogean, GP | 1 |
| Taylor, TJ | 1 |
| Haac, BE | 1 |
| Carlini, AR | 1 |
| Manson, TT | 1 |
| Sudini, K | 1 |
| Mullins, CD | 1 |
| Wegener, ST | 1 |
| Firoozabadi, R | 1 |
| Haut, ER | 1 |
| Bosse, MJ | 1 |
| Seymour, RB | 1 |
| Holden, MB | 1 |
| Gitajn, IL | 1 |
| Goldhaber, SZ | 2 |
| Eastman, AL | 1 |
| Jurkovich, GJ | 1 |
| Vallier, HA | 1 |
| Gary, JL | 1 |
| Kleweno, CP | 1 |
| Cuschieri, J | 1 |
| Marvel, D | 1 |
| Castillo, RC | 1 |
| Lee, SY | 2 |
| Cho, JY | 1 |
| Yun, KH | 1 |
| Oh, SK | 1 |
| Rodés-Cabau, J | 2 |
| Stabile, E | 1 |
| Barbanti, M | 2 |
| Costa, G | 1 |
| Mahmoodi, BK | 1 |
| Ciolli, L | 1 |
| Lelli, N | 1 |
| Rosafio, F | 1 |
| Maffei, S | 1 |
| Sacchetti, F | 1 |
| Vandelli, L | 1 |
| Dell'Acqua, ML | 1 |
| Picchetto, L | 1 |
| Borzì, GM | 1 |
| Ricceri, R | 1 |
| Pentore, R | 1 |
| Tondelli, M | 1 |
| Vandelli, G | 1 |
| Rodríguez-Villatoro, N | 1 |
| Meletti, S | 1 |
| Zini, A | 1 |
| Vallone, S | 1 |
| Bigliardi, G | 1 |
| Sahai, A | 1 |
| Bhandari, R | 1 |
| Godwin, M | 1 |
| McIntyre, T | 1 |
| Chung, MK | 1 |
| Iskandar, JP | 1 |
| Kamran, H | 1 |
| Hariri, E | 1 |
| Aggarwal, A | 1 |
| Burton, R | 1 |
| Kalra, A | 1 |
| Bartholomew, JR | 1 |
| Elbadawi, A | 1 |
| Bena, J | 1 |
| Svensson, LG | 1 |
| Kapadia, S | 1 |
| Cameron, SJ | 1 |
| Diab, S | 1 |
| Arazi, M | 1 |
| Sternik, L | 1 |
| Raanani, E | 1 |
| Kachel, E | 1 |
| Grosman-Rimon, L | 1 |
| Shalabi, A | 1 |
| Amir, O | 1 |
| Carasso, S | 1 |
| Violi, F | 2 |
| Cammisotto, V | 1 |
| Pignatelli, P | 2 |
| Guglielmelli, P | 1 |
| Al-Kali, A | 1 |
| Wolanskyj-Spinner, AP | 1 |
| Camoriano, J | 1 |
| Patnaik, MM | 1 |
| Tullemans, BME | 1 |
| Fernández, DI | 1 |
| Veninga, A | 1 |
| Baaten, CCFMJ | 1 |
| Peters, LJF | 1 |
| Aarts, MJB | 1 |
| Eble, JA | 1 |
| Campello, E | 1 |
| Spiezia, L | 1 |
| Simioni, P | 1 |
| van der Vorst, EPC | 1 |
| van der Meijden, PEJ | 1 |
| Heemskerk, JWM | 1 |
| Shi, T | 1 |
| Gu, ZD | 1 |
| Diao, QZ | 1 |
| Zwicker, JI | 1 |
| Paranagama, D | 1 |
| Lessen, DS | 1 |
| Colucci, PM | 1 |
| Grunwald, MR | 1 |
| Bahrani, S | 1 |
| Teimouri-Jervekani, Z | 1 |
| Sadeghi, M | 1 |
| Zhao, W | 1 |
| Zhang, Q | 4 |
| Hu, H | 1 |
| Luo, S | 1 |
| Lahu, S | 1 |
| Bristot, P | 1 |
| Gewalt, S | 1 |
| Goedel, A | 1 |
| Giacoppo, D | 1 |
| Schüpke, S | 1 |
| Schunkert, H | 2 |
| Kastrati, A | 7 |
| Sarafoff, N | 2 |
| Fukaya, H | 1 |
| Yasuda, S | 2 |
| Akao, M | 1 |
| Matoba, T | 1 |
| Nakamra, M | 1 |
| Miyauchi, K | 1 |
| Hagiwara, N | 1 |
| Kimura, K | 2 |
| Hirayama, A | 1 |
| Matsui, K | 1 |
| Ogawa, H | 6 |
| Rivera-Caravaca, JM | 1 |
| Camelo-Castillo, A | 1 |
| Ramírez-Macías, I | 1 |
| Gil-Pérez, P | 1 |
| López-García, C | 1 |
| Esteve-Pastor, MA | 1 |
| Orenes-Piñero, E | 1 |
| Tello-Montoliu, A | 5 |
| Marín, F | 2 |
| Koh, W | 1 |
| Rodts, M | 1 |
| Nebbia, A | 2 |
| Sawyer, J | 1 |
| Henry, B | 1 |
| Cooper, DS | 1 |
| Abdelwahab, HW | 1 |
| Shaltout, SW | 1 |
| Sayed Ahmed, HA | 1 |
| Fouad, AM | 1 |
| Merrell, E | 1 |
| Riley, JB | 1 |
| Salama, R | 1 |
| Abdelrahman, AG | 1 |
| Darling, E | 1 |
| Fadel, G | 1 |
| Elfar, MSA | 1 |
| Sabry, K | 1 |
| Shah, J | 1 |
| Amin, H | 1 |
| Nieman, GF | 1 |
| Mishriky, A | 1 |
| Aiash, H | 1 |
| Naguib, D | 1 |
| Helten, C | 1 |
| Zako, S | 1 |
| Mourikis, P | 1 |
| M'Pembele, R | 1 |
| Trojovsky, K | 1 |
| Ahlbrecht, S | 1 |
| Zikeli, D | 1 |
| Zeus, T | 2 |
| Kelm, M | 3 |
| Dannenberg, L | 1 |
| Polzin, A | 2 |
| Krim, SR | 1 |
| Bennett, A | 1 |
| Pfeffer, M | 1 |
| Campbell, PT | 1 |
| Thai, S | 1 |
| Baetz, B | 1 |
| Wever-Pinzon, J | 1 |
| Eiswirth, C | 1 |
| Desai, S | 1 |
| Ventura, HO | 1 |
| Crameri, O | 1 |
| Brotschi, B | 1 |
| Achini, F | 1 |
| Rizzi, M | 1 |
| Albisetti, M | 1 |
| Lee, WJ | 1 |
| Byun, JS | 1 |
| Kim, JK | 1 |
| Nam, TK | 1 |
| Comarmond, C | 1 |
| Jego, P | 1 |
| Veyssier-Belot, C | 1 |
| Marie, I | 1 |
| Mekinian, A | 2 |
| Elmaleh-Sachs, A | 1 |
| Leroux, G | 1 |
| Saadoun, D | 2 |
| Oziol, E | 1 |
| Fraisse, T | 1 |
| Hyvernat, H | 1 |
| Thiercein-Legrand, MF | 1 |
| Sarrot-Reynauld, F | 1 |
| Ferreira-Maldent, N | 1 |
| de Menthon, M | 1 |
| Goujard, C | 1 |
| Khau, D | 1 |
| Nguen, Y | 1 |
| Monnier, S | 1 |
| Michon, A | 1 |
| Castel, B | 1 |
| Decaux, O | 1 |
| Piette, JC | 4 |
| Zhu, W | 1 |
| Tang, WHW | 1 |
| Yanagisawa, R | 1 |
| Hayashida, K | 1 |
| Jinzaki, M | 1 |
| Hage, A | 1 |
| Jacques, F | 1 |
| Chetaille, P | 1 |
| Bourdages, M | 1 |
| Cloutier, K | 1 |
| Perron, J | 1 |
| Houde, C | 1 |
| Holy, EW | 1 |
| Kebernik, J | 1 |
| Allali, A | 1 |
| El-Mawardy, M | 1 |
| Richardt, G | 1 |
| Abdel-Wahab, M | 1 |
| Zhou, CK | 1 |
| Daugherty, SE | 1 |
| Liao, LM | 1 |
| Freedman, ND | 1 |
| Abnet, CC | 1 |
| Pfeiffer, R | 1 |
| Cook, MB | 1 |
| Masson, JB | 1 |
| Welsh, RC | 3 |
| Garcia Del Blanco, B | 1 |
| Pelletier, M | 1 |
| Webb, JG | 2 |
| Al-Qoofi, F | 1 |
| Maluenda, G | 2 |
| Thoenes, M | 1 |
| Paradis, JM | 1 |
| Chamandi, C | 1 |
| Serra, V | 1 |
| Dumont, E | 1 |
| Côté, M | 1 |
| Riancho-Zarrabeitia, L | 1 |
| Daroca, G | 1 |
| Muñoz, P | 1 |
| López-Hoyos, M | 1 |
| Haya, A | 1 |
| Martínez-Taboada, VM | 1 |
| Uzu, K | 1 |
| Shinke, T | 5 |
| Otake, H | 5 |
| Takaya, T | 3 |
| Osue, T | 4 |
| Iwasaki, M | 2 |
| Kinutani, H | 3 |
| Konishi, A | 3 |
| Kuroda, M | 3 |
| Takahashi, H | 3 |
| Terashita, D | 2 |
| Hirata, KI | 3 |
| Nakamura, M | 4 |
| Shite, J | 3 |
| Akasaka, T | 1 |
| Gordon, RJ | 1 |
| Lombard, FW | 1 |
| Ramotowski, B | 1 |
| Żuk, A | 1 |
| Emani, S | 2 |
| Mulone, M | 1 |
| DiNardo, JA | 1 |
| Trenor, CC | 1 |
| Ma, R | 1 |
| Bi, Y | 1 |
| Kou, J | 1 |
| Zhou, J | 3 |
| Shi, J | 1 |
| Aceves-Velázquez, E | 1 |
| Vieyra-Herrera, G | 1 |
| Rodríguez-Chávez, L | 1 |
| Herrera-Alarcón, V | 1 |
| Yelnik, CM | 2 |
| Urbanski, G | 2 |
| Drumez, E | 2 |
| Caron, C | 4 |
| Maillard, H | 2 |
| Morell-Dubois, S | 3 |
| Dubucquoi, S | 4 |
| Launay, D | 4 |
| Hachulla, E | 5 |
| Hatron, PY | 5 |
| Duhamel, A | 2 |
| Lambert, M | 6 |
| Serebruany, V | 5 |
| Golukhova, E | 1 |
| Yee, J | 1 |
| Kumar, V | 1 |
| Anuwatworn, A | 1 |
| Petrasko, M | 1 |
| Stys, A | 1 |
| Zhang, JW | 1 |
| Liu, WW | 1 |
| McCaffrey, TA | 1 |
| He, XQ | 1 |
| Liang, WY | 1 |
| Chen, XH | 1 |
| Feng, XR | 1 |
| Fu, SW | 1 |
| Liu, ML | 1 |
| Fuku, Y | 1 |
| Kadota, K | 2 |
| Amano, H | 1 |
| Kubo, S | 1 |
| Otsuru, S | 1 |
| Habara, S | 1 |
| Tada, T | 2 |
| Tanaka, H | 1 |
| Goto, T | 1 |
| Arnaud, L | 3 |
| Conti, F | 1 |
| Massaro, L | 1 |
| Denas, G | 1 |
| Chasset, F | 1 |
| Toyota, T | 1 |
| Shiomi, H | 2 |
| Morimoto, T | 2 |
| Natsuaki, M | 2 |
| Kimura, T | 2 |
| Ciconte, G | 1 |
| Conti, M | 1 |
| Baldi, M | 1 |
| Saviano, M | 1 |
| Vicedomini, G | 1 |
| Pappone, C | 1 |
| Yılmaz, MB | 1 |
| Sebaratnam, DF | 1 |
| Agar, N | 1 |
| Patel, VB | 1 |
| Patel, AD | 1 |
| Shah, DA | 1 |
| Perrier-Cornet, A | 1 |
| Mingant, F | 2 |
| Perrot, M | 1 |
| Lippert, E | 2 |
| Galinat, H | 2 |
| Siau, K | 1 |
| Hannah, JL | 1 |
| Hodson, J | 1 |
| Widlak, M | 1 |
| Bhala, N | 1 |
| Iqbal, TH | 1 |
| Otto, BJ | 1 |
| Terry, RS | 1 |
| Lutfi, FG | 1 |
| Syed, JS | 1 |
| Hamann, HC | 1 |
| Gupta, M | 1 |
| Bird, VG | 1 |
| Spartalis, M | 1 |
| Tzatzaki, E | 1 |
| Spartalis, E | 1 |
| Damaskos, C | 1 |
| Athanasiou, A | 1 |
| Moris, D | 1 |
| Politou, M | 1 |
| Shang, LL | 1 |
| Guo, DD | 1 |
| Zhao, HY | 1 |
| Quan, AJ | 1 |
| Cao, PG | 1 |
| Park, SK | 1 |
| Jung, DE | 1 |
| Jung, SA | 1 |
| Kim, WH | 1 |
| Bahk, JH | 1 |
| Aboyans, V | 1 |
| Anand, S | 1 |
| Branch, KR | 1 |
| Connolly, SJ | 3 |
| Dyal, L | 1 |
| Fox, KAA | 3 |
| Keltai, K | 1 |
| Probstfield, J | 1 |
| Sorbets, E | 1 |
| Eagle, KA | 1 |
| Fluschnik, N | 1 |
| Becher, PM | 1 |
| Schnabel, R | 1 |
| Blankenberg, S | 1 |
| Westermann, D | 1 |
| Tilemann, L | 1 |
| Mohr, SK | 1 |
| Preusch, M | 1 |
| Chorianopoulos, E | 1 |
| Giannitsis, E | 1 |
| Katus, HA | 2 |
| Müller, OJ | 1 |
| Soehnlein, O | 1 |
| Kounis, NG | 1 |
| Koniari, I | 1 |
| Tsigkas, G | 1 |
| Chourdakis, E | 1 |
| Roumeliotis, A | 1 |
| Patsouras, N | 1 |
| Soufras, G | 1 |
| Hahalis, G | 1 |
| Prakash, P | 1 |
| Aggarwal, H | 1 |
| Dhankani, P | 1 |
| Kumar, S | 1 |
| Pandey, CP | 1 |
| Pugh, N | 1 |
| Bihan, D | 1 |
| Farndale, RW | 1 |
| Schreiber, K | 2 |
| Sciascia, S | 2 |
| de Groot, PG | 1 |
| Devreese, K | 1 |
| Jacobsen, S | 1 |
| Ruiz-Irastorza, G | 5 |
| Salmon, JE | 1 |
| Shoenfeld, Y | 6 |
| Shovman, O | 1 |
| Hunt, BJ | 5 |
| Pouwels, XGLV | 1 |
| Wolff, R | 1 |
| Ramaekers, BLT | 1 |
| Van Giessen, A | 1 |
| Lang, S | 1 |
| Ryder, S | 1 |
| Worthy, G | 1 |
| Duffy, S | 1 |
| Armstrong, N | 1 |
| Kleijnen, J | 1 |
| Joore, MA | 1 |
| Kruger, PC | 1 |
| Consolo, F | 1 |
| Pozzi, L | 1 |
| Sferrazza, G | 1 |
| Della Valle, P | 1 |
| D'Angelo, A | 2 |
| Slepian, MJ | 3 |
| Pappalardo, F | 2 |
| Nariai, R | 1 |
| Kobayashi, T | 1 |
| Masuda, H | 1 |
| Ono, H | 1 |
| Imadome, KI | 1 |
| Ito, S | 1 |
| Wong, CK | 1 |
| Chan, PH | 1 |
| Lam, CC | 1 |
| Kwok, OH | 1 |
| Lam, YY | 1 |
| Siu, CW | 1 |
| Attal, R | 1 |
| Lazareth, I | 1 |
| Angelopoulos, G | 1 |
| Priollet, P | 1 |
| de Carvalho, LP | 1 |
| Fong, A | 1 |
| Troughton, R | 1 |
| Yan, BP | 1 |
| Chin, CT | 1 |
| Poh, SC | 1 |
| Mejin, M | 1 |
| Huang, N | 1 |
| Seneviratna, A | 1 |
| Lee, CH | 1 |
| Low, AF | 1 |
| Tan, HC | 1 |
| Chan, SP | 1 |
| Frampton, C | 1 |
| Alemanno, L | 1 |
| Massimi, I | 1 |
| Klaus, V | 1 |
| Guarino, ML | 1 |
| Maltese, T | 1 |
| Frati, L | 1 |
| Pulcinelli, FM | 2 |
| Fujimoto, W | 1 |
| Sawada, T | 1 |
| Toba, T | 2 |
| Takahashi, Y | 1 |
| Miyata, T | 1 |
| Oishi, S | 1 |
| Onishi, T | 1 |
| Shimane, A | 1 |
| Taniguchi, Y | 2 |
| Kawai, H | 1 |
| Yasaka, Y | 2 |
| Gao, BL | 1 |
| Li, TX | 1 |
| Xu, GQ | 1 |
| Yang, BW | 1 |
| Godschalk, TC | 1 |
| Gimbel, ME | 1 |
| Nolet, WW | 1 |
| van Kessel, DJ | 1 |
| Amoroso, G | 1 |
| Dewilde, WJ | 1 |
| Janssen, PW | 1 |
| Bergmeijer, TO | 1 |
| Heestermans, T | 1 |
| Balceniuk, MD | 1 |
| Trakimas, LE | 1 |
| Aghaie, C | 1 |
| Mix, D | 1 |
| Rasheed, K | 1 |
| Ellis, J | 1 |
| Glocker, R | 1 |
| Doyle, A | 1 |
| Stoner, MC | 1 |
| Belcaro, G | 1 |
| Cornelli, U | 1 |
| Dugall, M | 1 |
| Hosoi, M | 1 |
| Cotellese, R | 1 |
| Feragalli, B | 1 |
| Zhu, H | 2 |
| Yang, G | 1 |
| He, J | 1 |
| Ju, L | 1 |
| McFadyen, JD | 1 |
| Al-Daher, S | 1 |
| Alwis, I | 1 |
| Tønnesen, LL | 1 |
| Maiocchi, S | 1 |
| Coulter, B | 1 |
| Calkin, AC | 1 |
| Felner, EI | 1 |
| Cohen, N | 1 |
| Yuan, Y | 1 |
| Schoenwaelder, SM | 1 |
| Cooper, ME | 1 |
| Zhu, C | 1 |
| Jackson, SP | 3 |
| Kulik, A | 1 |
| Abreu, AM | 1 |
| Boronat, V | 1 |
| Kouchoukos, NT | 1 |
| Ruel, M | 1 |
| Moll, F | 1 |
| Baumgartner, I | 1 |
| Jaff, M | 1 |
| Nwachuku, C | 1 |
| Tangelder, M | 1 |
| Ansel, G | 1 |
| Adams, G | 1 |
| Zeller, T | 2 |
| Rundback, J | 1 |
| Grosso, M | 1 |
| Lin, M | 2 |
| Mercur, MF | 1 |
| Minar, E | 3 |
| Ying, R | 1 |
| Jiang, H | 1 |
| Jin, Q | 1 |
| Kuang, J | 1 |
| Shi, Y | 1 |
| Cai, D | 1 |
| Yang, R | 1 |
| Jung, JM | 1 |
| Park, JW | 1 |
| Kim, SU | 1 |
| Kwon, DY | 1 |
| Park, MH | 1 |
| Attard, C | 1 |
| Monagle, P | 4 |
| Ignjatovic, V | 1 |
| Lindquist, DE | 1 |
| Stewart, DW | 1 |
| Brewster, A | 1 |
| Waldroup, C | 1 |
| Odle, BL | 1 |
| Burchette, JE | 1 |
| El-Bazouni, H | 1 |
| Tsukiyama, Y | 2 |
| Kozuki, A | 1 |
| Kijima, Y | 1 |
| Masano, T | 1 |
| Nagoshi, R | 1 |
| Shibata, H | 1 |
| Takeshige, R | 2 |
| Yanaka, KI | 1 |
| Gibler, WB | 1 |
| Song, Z | 1 |
| Han, M | 1 |
| Yu, B | 1 |
| Lv, G | 1 |
| Han, N | 1 |
| Liu, Z | 1 |
| Yin, J | 1 |
| Lim, JW | 1 |
| Chee, SX | 1 |
| Wong, WJ | 1 |
| He, QL | 1 |
| Lau, TC | 1 |
| Beiswenger, AC | 1 |
| Jo, A | 1 |
| Harth, K | 1 |
| Kumins, NH | 1 |
| Shishehbor, MH | 1 |
| Kashyap, VS | 1 |
| De Stefano, V | 3 |
| Rocca, B | 2 |
| Soldati, D | 1 |
| Petrucci, G | 1 |
| Beggiato, E | 1 |
| Bertozzi, I | 2 |
| Betti, S | 2 |
| Carli, G | 1 |
| Carpenedo, M | 2 |
| Cattaneo, D | 1 |
| Cavalca, V | 1 |
| Dragani, A | 1 |
| Elli, E | 1 |
| Finazzi, G | 12 |
| Iurlo, A | 1 |
| Lanzarone, G | 1 |
| Lissandrini, L | 1 |
| Palandri, F | 1 |
| Paoli, C | 1 |
| Rambaldi, A | 3 |
| Ranalli, P | 1 |
| Randi, ML | 4 |
| Ricco, A | 1 |
| Rossi, E | 1 |
| Ruggeri, M | 4 |
| Specchia, G | 1 |
| Timillero, A | 1 |
| Turnu, L | 1 |
| Vianelli, N | 1 |
| Rodeghiero, F | 4 |
| Patrono, C | 11 |
| Brunner, S | 1 |
| Rizas, K | 1 |
| Hamm, W | 1 |
| Mehr, M | 1 |
| Lackermair, K | 1 |
| Huang, F | 2 |
| Galeazzi, R | 1 |
| Olivieri, F | 1 |
| Spazzafumo, L | 1 |
| Rose, G | 1 |
| Montesanto, A | 1 |
| Giovagnetti, S | 1 |
| Cecchini, S | 1 |
| Malatesta, G | 1 |
| Di Pillo, R | 1 |
| Antonicelli, R | 1 |
| Harrington, RA | 3 |
| Chan, NC | 3 |
| Weitz, JI | 6 |
| Kwiatkowski, J | 1 |
| Halupczok-Żyła, J | 1 |
| Bolanowski, M | 1 |
| Kuliszkiewicz-Janus, M | 1 |
| Gulati, S | 1 |
| Solheim, O | 1 |
| Carlsen, SM | 1 |
| Øie, LR | 1 |
| Jensberg, H | 1 |
| Gulati, AM | 1 |
| Madsbu, MA | 1 |
| Giannadakis, C | 1 |
| Jakola, AS | 1 |
| Salvesen, Ø | 1 |
| Godfrey, AL | 1 |
| Campbell, PJ | 2 |
| MacLean, C | 1 |
| Buck, G | 2 |
| Cook, J | 1 |
| Temple, J | 1 |
| Wilkins, BS | 2 |
| Wheatley, K | 2 |
| Nangalia, J | 1 |
| Grinfeld, J | 1 |
| McMullin, MF | 1 |
| Forsyth, C | 1 |
| Kiladjian, JJ | 2 |
| Green, AR | 2 |
| Harrison, CN | 4 |
| Baumann Kreuziger, L | 1 |
| Karkouti, K | 1 |
| Tweddell, J | 1 |
| Massicotte, MP | 1 |
| Hasuike, Y | 1 |
| Saito, T | 2 |
| Matsumura, T | 1 |
| Fujimura, H | 1 |
| Sakoda, S | 1 |
| Tubaro, M | 1 |
| Falaschi, G | 1 |
| Colivicchi, F | 1 |
| Farias, S | 1 |
| Boateng, JS | 1 |
| Boden, WE | 3 |
| Malinova, LI | 1 |
| Furman, NV | 1 |
| Dolotovskaya, PV | 1 |
| Chernousova, LA | 1 |
| Denisova, TP | 1 |
| Yang, FY | 1 |
| Undas, A | 5 |
| Zabczyk, M | 1 |
| Garcia-Garcia, HM | 1 |
| Lin, J | 1 |
| Han, Z | 1 |
| Yi, X | 1 |
| Luo, H | 1 |
| Zhou, Q | 1 |
| Fan, PY | 1 |
| Lee, CC | 1 |
| Liu, SH | 1 |
| Li, IJ | 1 |
| Weng, CH | 1 |
| Tu, KH | 1 |
| Hsieh, MY | 1 |
| Kuo, CF | 1 |
| Chang, TY | 1 |
| Tian, YC | 1 |
| Yang, CW | 1 |
| Wu, HH | 1 |
| Ono, K | 1 |
| Sato, M | 1 |
| Nakatsuka, H | 1 |
| Spinthakis, N | 1 |
| Farag, M | 1 |
| Gue, YX | 1 |
| Srinivasan, M | 1 |
| Wellsted, DM | 1 |
| Gorog, DA | 1 |
| Shehu, S | 1 |
| Deveja, R | 1 |
| Qirjazi, T | 1 |
| Shah, R | 1 |
| Khan, SA | 1 |
| Khan, B | 1 |
| Latham, SB | 1 |
| Sugizaki, Y | 1 |
| Onishi, H | 1 |
| Nagasawa, A | 1 |
| Yanaka, K | 1 |
| Nagano, Y | 1 |
| Yamamoto, H | 1 |
| Kawamori, H | 1 |
| Matsuura, A | 2 |
| Ishihara, T | 1 |
| Matsumoto, D | 1 |
| Igarashi, N | 1 |
| Hayashi, T | 2 |
| Kadotani, M | 1 |
| Fujii, T | 1 |
| Sakakibara, T | 1 |
| Sang, W | 1 |
| Wei, M | 2 |
| Xu, F | 1 |
| Jeger, RV | 1 |
| Pfisterer, M | 2 |
| Vogt, DR | 1 |
| Galatius, S | 1 |
| Abildgaard, U | 2 |
| Naber, C | 1 |
| Alber, H | 1 |
| Eberli, F | 1 |
| Kurz, DJ | 1 |
| Pedrazzini, G | 1 |
| Vuilliomenet, A | 1 |
| Weilenmann, D | 1 |
| Rickli, H | 1 |
| Hansen, KW | 1 |
| Rickenbacher, P | 1 |
| Conen, D | 1 |
| Müller, C | 1 |
| Osswald, S | 1 |
| Gilgen, N | 1 |
| Kaiser, C | 2 |
| Harada, H | 1 |
| Suehiro, S | 1 |
| Murakami, D | 1 |
| Nakahara, R | 1 |
| Nagasaka, T | 1 |
| Ujihara, T | 1 |
| Sagami, R | 1 |
| Katsuyama, Y | 1 |
| Hayasaka, K | 1 |
| Amano, Y | 1 |
| Fazio, S | 1 |
| Barra, ME | 1 |
| Berger, K | 1 |
| Tesoro, EP | 1 |
| Brophy, GM | 1 |
| Saini, A | 1 |
| Joshi, AD | 1 |
| Cowan, KM | 1 |
| Wayne Gatewood, C | 1 |
| Kumar, STK | 1 |
| Allen, J | 1 |
| Shah, SH | 1 |
| Nouer, SS | 1 |
| Jones, T | 1 |
| Knott-Craig, CJ | 1 |
| Boston, US | 1 |
| Griesshammer, M | 3 |
| Besses, C | 2 |
| Dolan, RS | 1 |
| Goldman, D | 1 |
| El-Deiry, M | 1 |
| Kokabi, N | 1 |
| Bercu, ZL | 1 |
| Newsome, J | 1 |
| Martin, JG | 1 |
| Lucotti, S | 1 |
| Cerutti, C | 1 |
| Soyer, M | 1 |
| Gil-Bernabé, AM | 1 |
| Gomes, AL | 1 |
| Allen, PD | 1 |
| Smart, S | 1 |
| Markelc, B | 1 |
| Watson, K | 1 |
| Ridley, AJ | 1 |
| Muschel, RJ | 1 |
| Altıntaş, B | 1 |
| Altındağ, R | 1 |
| Bilge, Ö | 1 |
| Baysal, E | 1 |
| Öztürk, Ö | 1 |
| Yaylak, B | 1 |
| Ede, H | 1 |
| Karahan, MZ | 1 |
| Burak, C | 1 |
| Tanboğa, İH | 2 |
| Eizayaga, FX | 7 |
| Belon, P | 7 |
| Desplat, V | 8 |
| Aguejouf, O | 16 |
| Doutremepuich, C | 17 |
| Spasov, AA | 3 |
| Kucheryavenko, AF | 1 |
| Sirotenko, VS | 1 |
| Anisimova, VA | 2 |
| Divaeva, LN | 1 |
| Kuz'menko, TA | 1 |
| Morkovnik, AS | 1 |
| Ten Cate, H | 2 |
| Jia, YM | 1 |
| Ge, PX | 1 |
| Zhou, H | 1 |
| Ji, JZ | 1 |
| Tai, T | 1 |
| Gu, TT | 1 |
| Zhu, T | 1 |
| Li, YF | 1 |
| Mi, QY | 1 |
| Huang, BB | 1 |
| Xie, HG | 1 |
| Lee, J | 2 |
| Jeong, L | 1 |
| Jung, E | 1 |
| Ko, C | 1 |
| Seon, S | 1 |
| Noh, J | 1 |
| Lee, D | 1 |
| Zou, CC | 1 |
| Yan, HY | 1 |
| Wang, LL | 1 |
| Bian, YY | 1 |
| Pina, LM | 1 |
| Dong, X | 1 |
| Samtani, MN | 1 |
| Bonnet, D | 1 |
| Jefferies, J | 1 |
| Lu, H | 2 |
| Essandoh, M | 1 |
| Elhassan, A | 1 |
| Papadimos, TJ | 1 |
| Pruett, B | 1 |
| Rushing, GD | 1 |
| Kedhi, E | 2 |
| Latib, A | 2 |
| Abizaid, A | 2 |
| Kandzari, D | 1 |
| Simon, D | 1 |
| Worthley, S | 1 |
| Zaman, A | 1 |
| Brar, S | 1 |
| Liu, M | 2 |
| Zheng, L | 1 |
| Yang, C | 1 |
| Xiang, L | 1 |
| Hao, Z | 1 |
| Tomkowski, WZ | 1 |
| Davidson, BL | 1 |
| Cuisset, T | 2 |
| Granger, CB | 3 |
| Scerrati, A | 1 |
| Germanò, A | 1 |
| Trevisi, G | 1 |
| Visani, J | 1 |
| Lofrese, G | 1 |
| D'Angelo, L | 1 |
| Raffa, G | 1 |
| Fazzari, E | 1 |
| Mangiola, A | 1 |
| Cavallo, MA | 1 |
| De Bonis, P | 1 |
| Dahlen, JR | 1 |
| Prabhakaran, A | 1 |
| Whinney, C | 1 |
| Björkman, JA | 1 |
| Zachrisson, H | 1 |
| Forsberg, GB | 1 |
| von Bahr, H | 1 |
| Hansson, GI | 1 |
| Nylander, S | 2 |
| Lanzillo, C | 1 |
| Di Roma, M | 1 |
| Sciahbasi, A | 2 |
| Minati, M | 1 |
| Maresca, L | 1 |
| Pendenza, G | 1 |
| Romagnoli, E | 1 |
| Summaria, F | 1 |
| Patrizi, R | 1 |
| Di Luozzo, M | 1 |
| Preziosi, P | 1 |
| Lioy, E | 1 |
| Romeo, F | 2 |
| Chen, K | 1 |
| Williams, S | 1 |
| Chan, AK | 1 |
| Mondal, TK | 1 |
| Helft, G | 4 |
| Le Feuvre, C | 2 |
| Georges, JL | 1 |
| Leclercq, F | 1 |
| Eltchaninoff, H | 1 |
| Furber, A | 1 |
| Prunier, F | 1 |
| Sebagh, L | 1 |
| Cattan, S | 2 |
| Vicaut, E | 1 |
| Metzger, JP | 2 |
| Lavi, N | 1 |
| Brenner, B | 3 |
| Avivi, I | 1 |
| Marullo, AG | 1 |
| Iacò, AL | 1 |
| Calafiore, AM | 1 |
| Alvarez-Larrán, A | 1 |
| Pereira, A | 1 |
| Arellano-Rodrigo, E | 1 |
| Hernández-Boluda, JC | 1 |
| Cervantes, F | 1 |
| Karathanos, A | 1 |
| Geisler, T | 3 |
| Chakrabarti, AK | 1 |
| Mega, J | 1 |
| Bode, C | 3 |
| Bassand, JP | 3 |
| Verheugt, FW | 10 |
| Goto, S | 3 |
| Mohanavelu, S | 1 |
| Burton, P | 1 |
| Stone, G | 1 |
| Braunwald, E | 6 |
| Jayaprasad, K | 1 |
| Mathew, J | 1 |
| Thankappan, K | 1 |
| Sharma, M | 1 |
| Duraisamy, S | 1 |
| Rajan, S | 1 |
| Paul, J | 1 |
| Iyer, S | 1 |
| Yoshikawa, Y | 1 |
| Kamikubo, Y | 1 |
| Sonoda, H | 1 |
| Yamakage, M | 1 |
| Romualdi, E | 2 |
| Middeldorp, S | 3 |
| Al Habib, HF | 1 |
| Tarola, C | 1 |
| Diamantorous, P | 1 |
| Chu, MW | 1 |
| Park, J | 1 |
| Shin, DH | 1 |
| Kim, BK | 1 |
| Her, AY | 1 |
| Kim, YH | 7 |
| Choi, HH | 1 |
| Kim, JS | 1 |
| Ko, YG | 1 |
| Choi, D | 1 |
| Jang, Y | 1 |
| Hong, MK | 5 |
| Kremke, M | 1 |
| Tang, M | 1 |
| Bak, M | 1 |
| Kristensen, KL | 1 |
| Hindsholm, K | 1 |
| Andreasen, JJ | 1 |
| Hjortdal, V | 1 |
| Jakobsen, CJ | 1 |
| Gao, YX | 1 |
| Yu, XZ | 1 |
| Yuan, YQ | 1 |
| Zhao, XY | 1 |
| Sun, TW | 1 |
| Rouine-Rapp, K | 1 |
| McDermott, MW | 1 |
| Wolzt, M | 2 |
| Gouya, G | 2 |
| Kapiotis, S | 2 |
| Becka, M | 1 |
| Mueck, W | 1 |
| Kubitza, D | 1 |
| Wajnberg, E | 1 |
| Silva, TS | 1 |
| Johnson, AK | 1 |
| Lopes, DK | 1 |
| Akdogan, A | 1 |
| Kilic, L | 1 |
| Akman, U | 1 |
| Dogan, I | 1 |
| Karadag, O | 1 |
| Bilgen, SA | 1 |
| Buyukasik, Y | 1 |
| Kiraz, S | 1 |
| Ertenli, I | 1 |
| Huang, KN | 1 |
| Grandi, SM | 1 |
| Filion, KB | 2 |
| Eisenberg, MJ | 2 |
| Brilakis, ES | 1 |
| Patel, VG | 1 |
| Banerjee, S | 2 |
| Dodd, JM | 1 |
| McLeod, A | 1 |
| Windrim, RC | 1 |
| Kingdom, J | 1 |
| Wolf, AM | 1 |
| Pucci, MJ | 1 |
| Gabale, SD | 1 |
| McIntyre, CA | 1 |
| Irizarry, AM | 1 |
| Kennedy, EP | 1 |
| Rosato, EL | 1 |
| Lavu, H | 1 |
| Winter, JM | 1 |
| Yeo, CJ | 1 |
| Saifan, C | 1 |
| El-Charabaty, E | 1 |
| El-Sayegh, S | 2 |
| Seckeler, MD | 1 |
| D'Souza, MD | 1 |
| Gangemi, JJ | 1 |
| Hoyer, AW | 1 |
| Jayakumar, KA | 1 |
| Jin, S | 1 |
| Gao, W | 2 |
| Francis, DO | 1 |
| Dang, JH | 1 |
| Fritz, MA | 1 |
| Garrett, CG | 1 |
| Tanguay, JF | 4 |
| Bell, AD | 1 |
| Ackman, ML | 2 |
| Bauer, RD | 1 |
| Cartier, R | 1 |
| Chan, WS | 1 |
| Douketis, J | 1 |
| Roussin, A | 1 |
| Schnell, G | 1 |
| Wong, G | 1 |
| Mehta, SR | 2 |
| DeFilippis, AP | 1 |
| Oloyede, OS | 1 |
| Andrikopoulou, E | 1 |
| Saenger, AK | 1 |
| Palachuvattil, JM | 1 |
| Fasoro, YA | 1 |
| Guallar, E | 1 |
| Blumenthal, RS | 1 |
| Kickler, TS | 1 |
| Gerstenblith, G | 1 |
| Schulman, SP | 1 |
| Rade, JJ | 1 |
| Efthymiou, CA | 1 |
| Mills, RJ | 1 |
| O'Regan, DJ | 1 |
| Brigo, F | 1 |
| Storti, M | 1 |
| Lochner, P | 1 |
| Tezzon, F | 1 |
| Nardone, R | 1 |
| Kucheriavenko, AF | 1 |
| Tian', M | 1 |
| Enajat, M | 1 |
| Aziz Mohammadi, M | 1 |
| Debeij, J | 1 |
| van der Hulst, RR | 1 |
| Mureau, MA | 1 |
| Pourrat, O | 1 |
| Neau, JP | 1 |
| Pouget-Abadie, JF | 1 |
| Pierre, F | 1 |
| Sheriff, J | 2 |
| Girdhar, G | 1 |
| Chiu, WC | 2 |
| Jesty, J | 1 |
| Bluestein, D | 2 |
| Velázquez-Sánchez-de-Cima, S | 1 |
| Zamora-Ortiz, G | 1 |
| Hernández-Reyes, J | 1 |
| Vargas-Espinosa, J | 1 |
| García-Chavez, J | 1 |
| Rosales-Padrón, J | 1 |
| Ruiz-Delgado, GJ | 1 |
| Ruiz-Arguelles, A | 1 |
| Ruiz-Argüelles, GJ | 1 |
| Aradi, D | 1 |
| Komócsi, A | 1 |
| Trenk, D | 2 |
| Gulba, D | 1 |
| Kiss, RG | 3 |
| Husted, S | 2 |
| Bonello, L | 3 |
| Sibbing, D | 5 |
| Huber, K | 8 |
| Nishio, R | 1 |
| Nakagawa, M | 1 |
| Inoue, T | 1 |
| Hariki, H | 1 |
| Hiranuma, N | 1 |
| Hirata, K | 2 |
| Cuadrado, MJ | 3 |
| Bertolaccini, ML | 1 |
| Seed, PT | 2 |
| Tektonidou, MG | 2 |
| Aguirre, A | 1 |
| Mico, L | 1 |
| Gordon, C | 1 |
| Egurbide, MV | 2 |
| Gil, A | 1 |
| Houssiau, F | 1 |
| Rahman, A | 2 |
| Martin, H | 1 |
| McHugh, N | 1 |
| Galindo, M | 1 |
| Akil, M | 1 |
| Amigo, MC | 1 |
| Murru, V | 1 |
| Khamashta, MA | 7 |
| Robier, C | 2 |
| Stettin, M | 1 |
| Neubauer, M | 2 |
| Feres, F | 1 |
| Costa, RA | 1 |
| Leon, MB | 5 |
| Marin-Neto, JA | 1 |
| Botelho, RV | 1 |
| King, SB | 1 |
| Negoita, M | 1 |
| de Paula, JE | 1 |
| Mangione, JA | 1 |
| Meireles, GX | 1 |
| Castello, HJ | 1 |
| Nicolela, EL | 1 |
| Perin, MA | 1 |
| Devito, FS | 1 |
| Labrunie, A | 1 |
| Salvadori, D | 1 |
| Gusmão, M | 1 |
| Staico, R | 1 |
| Costa, JR | 1 |
| de Castro, JP | 1 |
| Abizaid, AS | 2 |
| Mathian, A | 2 |
| Tektonidou, M | 2 |
| Forastiero, R | 2 |
| Martinez-Zamora, MA | 2 |
| Balasch, J | 3 |
| Zuily, S | 1 |
| Wahl, D | 4 |
| Amoura, Z | 2 |
| Forslund, T | 1 |
| Wettermark, B | 1 |
| Wändell, P | 1 |
| von Euler, M | 1 |
| Hasselström, J | 1 |
| Hjemdahl, P | 3 |
| Sahebally, SM | 1 |
| Healy, D | 1 |
| Coffey, JC | 1 |
| Walsh, SR | 1 |
| Pergolini, A | 1 |
| Pino, PG | 1 |
| Zampi, G | 1 |
| Polizzi, V | 1 |
| Heidari-Bateni, G | 1 |
| Norouzi, S | 1 |
| Hall, M | 1 |
| Brar, A | 1 |
| Eghtesady, P | 1 |
| Gavornik, P | 1 |
| Dukát, A | 1 |
| Gašpar, L | 1 |
| Rollini, F | 3 |
| Franchi, F | 2 |
| Cho, JR | 2 |
| Degroat, C | 2 |
| Bhatti, M | 2 |
| Ferrante, E | 1 |
| Patel, R | 1 |
| Darlington, A | 1 |
| Desai, B | 2 |
| Ferreiro, J | 1 |
| Muniz-Lozano, A | 1 |
| Zenni, MM | 2 |
| Guzman, LA | 2 |
| Bass, TA | 3 |
| Li, M | 1 |
| Hotaling, NA | 1 |
| Ku, DN | 1 |
| Forest, CR | 1 |
| Tatarunas, V | 2 |
| Jankauskiene, L | 1 |
| Kupstyte, N | 2 |
| Skipskis, V | 2 |
| Gustiene, O | 2 |
| Grybauskas, P | 1 |
| Lesauskaite, V | 2 |
| Daali, Y | 1 |
| Reny, JL | 2 |
| Fontana, P | 4 |
| Kamdar, F | 2 |
| Eckman, P | 1 |
| John, R | 3 |
| Ohnishi, T | 4 |
| Sameshima, H | 3 |
| Koide, T | 4 |
| Tanaka, KA | 2 |
| Ice, DS | 1 |
| Shapiro, TA | 1 |
| Gnall, EM | 1 |
| Kowey, PR | 1 |
| Balasubramaniam, K | 3 |
| Viswanathan, G | 1 |
| Dragone, J | 1 |
| Grose-Hodge, R | 1 |
| Martin, P | 1 |
| Troy, S | 1 |
| Preston, P | 1 |
| Zaman, AG | 6 |
| Samoš, M | 1 |
| Šimonová, R | 1 |
| Kovář, F | 1 |
| Duraj, L | 1 |
| Fedorová, J | 1 |
| Galajda, P | 1 |
| Staško, J | 1 |
| Fedor, M | 1 |
| Kubisz, P | 1 |
| Mokáň, M | 1 |
| Viswanathan, GN | 2 |
| Marshall, SM | 3 |
| Dalén, M | 3 |
| Sartipy, U | 1 |
| Corbascio, M | 1 |
| Lund, LH | 1 |
| Grinnemo, KH | 1 |
| Holm, M | 1 |
| Tornvall, P | 1 |
| van der Linden, J | 2 |
| Durmus, A | 1 |
| Mentese, A | 1 |
| Yilmaz, M | 1 |
| Sumer, A | 1 |
| Akalin, I | 1 |
| Topal, C | 1 |
| Alver, A | 1 |
| Kong, D | 3 |
| Chen, G | 2 |
| Shan, F | 1 |
| Qi, K | 2 |
| Ma, L | 2 |
| Murray, AM | 1 |
| Keville, N | 1 |
| Gray, S | 1 |
| Izumi, T | 2 |
| Savonitto, S | 1 |
| Ferri, M | 1 |
| Corrada, E | 1 |
| Lai, YS | 1 |
| Yang, LT | 1 |
| Kao Yang, YH | 1 |
| Liu, PY | 1 |
| Würtz, M | 3 |
| Jensen, LO | 3 |
| Kaltoft, AK | 2 |
| Tilsted, HH | 2 |
| Meng, H | 1 |
| Chen, P | 1 |
| Gong, X | 1 |
| Bai, J | 1 |
| Zou, F | 1 |
| Yang, Z | 1 |
| Sousa, C | 1 |
| Almeida, J | 1 |
| Dias, P | 1 |
| Almeida, P | 1 |
| Rangel, I | 1 |
| Araújo, V | 1 |
| Macedo, F | 1 |
| Maciel, MJ | 1 |
| Komiya, R | 1 |
| Kamintani, K | 1 |
| Kubo, E | 1 |
| Hattori, M | 1 |
| Kataoka, H | 1 |
| Iwase, Y | 1 |
| Miyoshi, H | 1 |
| Minami, M | 1 |
| Kato, S | 1 |
| Arai, R | 1 |
| Yoshida, H | 1 |
| Salvan, E | 1 |
| Maina, A | 1 |
| De Carolis, S | 2 |
| Bertero, MT | 2 |
| Canti, V | 2 |
| Brucato, A | 1 |
| Bremme, K | 1 |
| Ramoni, V | 1 |
| Mosca, M | 2 |
| Di Poi, E | 1 |
| Caramaschi, P | 1 |
| Galeazzi, M | 1 |
| Halvorsen, S | 1 |
| Andreotti, F | 1 |
| Coccheri, S | 1 |
| Marchioli, R | 6 |
| Morais, J | 1 |
| De Caterina, R | 2 |
| Di Minno, G | 5 |
| Spadarella, G | 2 |
| Cafaro, G | 1 |
| Petitto, M | 1 |
| Lupoli, R | 2 |
| Di Minno, A | 2 |
| de Gaetano, G | 15 |
| Tremoli, E | 2 |
| Neath, SX | 1 |
| Berger, JS | 2 |
| Wu, AH | 1 |
| McConnell, JP | 1 |
| Boone, JL | 1 |
| McCullough, PA | 1 |
| Jesse, RL | 1 |
| Maisel, AS | 1 |
| Lussana, F | 1 |
| Permunian, ET | 1 |
| Stiefelhagen, P | 3 |
| Basili, S | 1 |
| Tanzilli, G | 1 |
| Raparelli, V | 1 |
| Calvieri, C | 1 |
| Carnevale, R | 1 |
| Dominici, M | 1 |
| Placanica, A | 1 |
| Arrivi, A | 1 |
| Farcomeni, A | 1 |
| Barillà, F | 2 |
| Mangieri, E | 1 |
| Trainor, B | 1 |
| Baird, CW | 1 |
| Fynn-Thompson, FE | 1 |
| Pigula, FA | 1 |
| Vollaard, EJ | 1 |
| Brouwers, JR | 1 |
| Satoh, K | 1 |
| Sugano, K | 1 |
| Mayer, K | 1 |
| Bernlochner, I | 1 |
| Braun, S | 3 |
| Schulz, S | 2 |
| Orban, M | 1 |
| Morath, T | 1 |
| Cala, L | 1 |
| Hoppmann, P | 1 |
| Laugwitz, KL | 1 |
| Yildiz, M | 1 |
| Yildiz, BS | 1 |
| Gursoy, MO | 1 |
| Akin, I | 2 |
| Kaliyadan, A | 1 |
| Siu, H | 1 |
| Fischman, DL | 1 |
| Ruggiero, NJ | 1 |
| Jasti, B | 1 |
| Walinsky, P | 1 |
| Ogilby, JD | 1 |
| Savage, MP | 1 |
| Weisshaar, S | 1 |
| Litschauer, B | 1 |
| Mayer, P | 1 |
| Smerda, L | 1 |
| Kyrle, PA | 2 |
| Eichinger, S | 1 |
| Nührenberg, T | 1 |
| Stratz, C | 1 |
| Valina, CM | 1 |
| Hochholzer, W | 1 |
| Almendro-Delia, M | 1 |
| Blanco Ponce, E | 1 |
| Gomez-Domínguez, R | 1 |
| Gonzalez-Matos, C | 1 |
| Lobo-Gonzalez, M | 1 |
| Caballero-Garcia, A | 1 |
| Hidalgo-Urbano, R | 1 |
| Cruz-Fernandez, MJ | 1 |
| Garcia-Rubira, JC | 1 |
| Geraldo, RB | 1 |
| Lourenço, AL | 1 |
| Rampelotto, PH | 1 |
| Castro, HC | 1 |
| Gesheff, M | 1 |
| Liu, F | 1 |
| Bauer, T | 1 |
| Lev, EI | 1 |
| Jeong, YH | 4 |
| Pandya, S | 1 |
| Kang, K | 1 |
| Franzese, C | 1 |
| Gong, Y | 1 |
| Piao, L | 1 |
| Yang, F | 1 |
| Xiao, B | 1 |
| Song, WL | 1 |
| Zhu, L | 1 |
| Funk, CD | 1 |
| Yu, Y | 1 |
| Olivier, CB | 1 |
| Diehl, P | 1 |
| Moser, M | 1 |
| Gitt, AK | 1 |
| Zahn, R | 1 |
| Chieffo, A | 2 |
| Mauri, L | 8 |
| Kereiakes, DJ | 8 |
| Driscoll-Shempp, P | 1 |
| Cutlip, DE | 5 |
| Normand, SL | 2 |
| Wiviott, SD | 6 |
| Cohen, DJ | 4 |
| Krucoff, MW | 1 |
| Dauerman, HL | 1 |
| Simon, DI | 3 |
| Kandzari, DE | 1 |
| Garratt, KN | 1 |
| Lee, DP | 1 |
| Pow, TK | 1 |
| Ver Lee, P | 1 |
| Rinaldi, MJ | 3 |
| Massaro, JM | 4 |
| Huynh, K | 1 |
| Devilliers, H | 1 |
| Lefevre, G | 2 |
| Geersing, GJ | 1 |
| Kappelle, LJ | 1 |
| Braun, OÖ | 1 |
| Bico, B | 1 |
| Chaudhry, U | 1 |
| Wagner, H | 1 |
| Koul, S | 1 |
| Tydén, P | 1 |
| Scherstén, F | 1 |
| Jovinge, S | 1 |
| Svensson, PJ | 1 |
| Gustav Smith, J | 1 |
| van der Pals, J | 1 |
| Warren, J | 1 |
| Tomkiewicz-Pajak, L | 1 |
| Wojcik, T | 1 |
| Chłopicki, S | 2 |
| Olszowska, M | 1 |
| Pajak, J | 1 |
| Podolec, J | 1 |
| Sitek, B | 1 |
| Musiałek, P | 1 |
| Rubis, P | 1 |
| Komar, M | 1 |
| Podolec, P | 1 |
| Sauer, S | 2 |
| Goltz, JP | 1 |
| Gassenmaier, T | 1 |
| Kunz, AS | 1 |
| Bley, TA | 1 |
| Klein, D | 1 |
| Petritsch, B | 1 |
| Santilli, F | 7 |
| Lapenna, D | 1 |
| La Barba, S | 1 |
| Davì, G | 8 |
| Natarajan, D | 1 |
| Lüscher, TF | 2 |
| Steffel, J | 1 |
| van Geffen, JP | 1 |
| Kleinegris, MC | 1 |
| Verdoold, R | 1 |
| Baaten, CC | 1 |
| Cosemans, JM | 2 |
| Clemetson, KJ | 1 |
| Roest, M | 1 |
| de Laat, B | 1 |
| Heemskerk, JW | 2 |
| Jeong, KH | 1 |
| Cho, JH | 1 |
| Woo, JS | 1 |
| Kim, JB | 1 |
| Kim, WS | 1 |
| Lee, TW | 1 |
| Kim, KS | 2 |
| Ihm, CG | 1 |
| Kim, W | 1 |
| Garg, P | 1 |
| Galper, BZ | 1 |
| Carobbio, A | 2 |
| Thiele, J | 2 |
| Rumi, E | 2 |
| Gisslinger, H | 3 |
| Pieri, L | 1 |
| Bedenis, R | 1 |
| Lethaby, A | 1 |
| Maxwell, H | 1 |
| Acosta, S | 1 |
| Prins, MH | 1 |
| Martin-Yuste, V | 1 |
| Alvarez-Contreras, L | 1 |
| Sabaté, M | 2 |
| Kelbaek, H | 1 |
| Saunamäki, K | 1 |
| Jørgensen, E | 1 |
| Kocka, V | 1 |
| Zaliunas, R | 1 |
| Zaliaduonyte-Peksiene, D | 1 |
| Grabauskyte, I | 1 |
| Dovidaitiene, D | 1 |
| Bumblauskas, K | 1 |
| Rahman, M | 1 |
| Donnangelo, LL | 1 |
| Neal, D | 1 |
| Mogali, K | 1 |
| Decker, M | 1 |
| Ahmed, MM | 1 |
| Zhang, YJ | 1 |
| Zhao, YL | 1 |
| Xu, B | 3 |
| Han, YL | 1 |
| Li, B | 1 |
| Liu, Q | 1 |
| Su, X | 1 |
| Pang, S | 1 |
| Lu, SZ | 2 |
| Guo, XF | 1 |
| Yang, YJ | 4 |
| Keeler, BD | 1 |
| Simpson, JA | 1 |
| Fox, SC | 1 |
| Stavrou, CL | 1 |
| Briggs, RA | 1 |
| Patel, P | 1 |
| Heptinstall, S | 1 |
| Acheson, AG | 1 |
| Keaney, JF | 1 |
| Spencer, FA | 4 |
| Guyatt, G | 1 |
| Gershlick, AH | 7 |
| Jacobs, A | 1 |
| Iancu, AC | 1 |
| Schwarz, J | 1 |
| Ovesná, P | 1 |
| Černá, O | 1 |
| Kissová, J | 1 |
| Maaloufová Soukupová, J | 1 |
| Brychtová, Y | 1 |
| Doubek, M | 1 |
| Červinek, L | 1 |
| Cmunt, E | 1 |
| Dulíček, P | 1 |
| Campr, V | 1 |
| Křen, L | 1 |
| Penka, M | 1 |
| Sipahi, I | 1 |
| Dohan, JL | 1 |
| Marrs, JC | 1 |
| Jeger, R | 1 |
| Tomoda, H | 1 |
| Watanabe, H | 1 |
| Furukawa, Y | 1 |
| Yamaji, K | 1 |
| Ando, K | 1 |
| Shizuta, S | 1 |
| Tazaki, J | 1 |
| Kato, Y | 1 |
| Hayano, M | 1 |
| Abe, M | 1 |
| Tamura, T | 1 |
| Shirotani, M | 1 |
| Miki, S | 1 |
| Matsuda, M | 1 |
| Takahashi, M | 1 |
| Ishii, K | 1 |
| Tanaka, M | 2 |
| Aoyama, T | 1 |
| Doi, O | 1 |
| Hattori, R | 1 |
| Kato, M | 1 |
| Suwa, S | 1 |
| Takizawa, A | 1 |
| Takatsu, Y | 1 |
| Shinoda, E | 1 |
| Eizawa, H | 1 |
| Takeda, T | 1 |
| Lee, JD | 1 |
| Inoko, M | 1 |
| Hamasaki, S | 1 |
| Horie, M | 1 |
| Nohara, R | 1 |
| Kambara, H | 1 |
| Fujiwara, H | 1 |
| Mitsudo, K | 1 |
| Nobuyoshi, M | 1 |
| Kita, T | 2 |
| Thompson, DD | 1 |
| Murray, GD | 1 |
| Candelise, L | 1 |
| Sandercock, PA | 1 |
| Whiteley, WN | 1 |
| Stanford, SN | 1 |
| Sabra, A | 1 |
| D'Silva, L | 1 |
| Lawrence, M | 1 |
| Morris, RH | 1 |
| Storton, S | 1 |
| Brown, MR | 1 |
| Evans, V | 1 |
| Hawkins, K | 1 |
| Williams, PR | 1 |
| Davidson, SJ | 1 |
| Wani, M | 1 |
| Potter, JF | 1 |
| Evans, PA | 1 |
| Mir, A | 1 |
| Frank, S | 1 |
| Journeycake, J | 1 |
| Wolovitis, J | 1 |
| Guleserian, K | 1 |
| Heistein, L | 1 |
| Lemler, M | 1 |
| Ciciliano, JC | 1 |
| Sakurai, Y | 1 |
| Myers, DR | 1 |
| Fay, ME | 1 |
| Hechler, B | 1 |
| Meeks, S | 1 |
| Li, R | 1 |
| Dixon, JB | 1 |
| Lyon, LA | 1 |
| Gachet, C | 2 |
| Lam, WA | 1 |
| Jin, L | 1 |
| Song, M | 1 |
| Suzuki, H | 1 |
| Umetsu, R | 1 |
| Uranishi, H | 1 |
| Abe, J | 1 |
| Nishibata, Y | 1 |
| Sekiya, Y | 1 |
| Miyamura, N | 1 |
| Hara, H | 1 |
| Tsuchiya, T | 1 |
| Kinosada, Y | 1 |
| Lee, YS | 2 |
| Jin, CD | 1 |
| Kim, MH | 3 |
| Guo, LZ | 2 |
| Cho, YR | 1 |
| Park, K | 1 |
| Park, JS | 3 |
| Park, TH | 1 |
| Kim, YD | 1 |
| Franchini, M | 2 |
| Sorrentino, R | 1 |
| Cirino, G | 1 |
| Dretzke, J | 1 |
| Riley, RD | 1 |
| Lordkipanidzé, M | 4 |
| Jowett, S | 1 |
| O'Donnell, J | 1 |
| Ensor, J | 1 |
| Moloney, E | 1 |
| Price, M | 1 |
| Raichand, S | 1 |
| Hodgkinson, J | 1 |
| Bayliss, S | 1 |
| Fitzmaurice, D | 1 |
| Moore, D | 1 |
| Oliveira, GH | 1 |
| Al-Kindi, SG | 1 |
| ElAmm, C | 1 |
| Qattan, MY | 1 |
| Deo, S | 1 |
| Medalion, B | 1 |
| Benatti, RD | 1 |
| Osman, MN | 1 |
| Ginwalla, M | 1 |
| Park, SJ | 5 |
| Gilard, M | 4 |
| Morice, MC | 5 |
| Rubboli, A | 4 |
| Calabrò, P | 1 |
| Saia, F | 1 |
| Plicner, D | 1 |
| Mazur, P | 2 |
| Hymczak, H | 1 |
| Stoliński, J | 1 |
| Litwinowicz, R | 1 |
| Drwiła, R | 1 |
| Abo-Salem, E | 1 |
| Alsidawi, S | 1 |
| Jamali, H | 1 |
| Effat, M | 1 |
| Helmy, T | 1 |
| Cuellar, JM | 1 |
| Petrizzo, A | 1 |
| Vaswani, R | 1 |
| Goldstein, JA | 1 |
| Bendo, JA | 1 |
| Keohane, C | 1 |
| McLornan, DP | 1 |
| Sanchez, K | 1 |
| Connor, C | 1 |
| Radia, D | 1 |
| Agewall, S | 1 |
| Franco, AT | 1 |
| Corken, A | 1 |
| Ware, J | 1 |
| Viecelli, AK | 2 |
| Pascoe, E | 1 |
| Polkinghorne, KR | 2 |
| Hawley, C | 2 |
| Paul-Brent, PA | 3 |
| Badve, SV | 2 |
| Cass, A | 3 |
| Heritier, S | 2 |
| Kerr, PG | 2 |
| Mori, TA | 2 |
| Robertson, A | 2 |
| Seong, HL | 1 |
| Irish, AB | 2 |
| Sueta, D | 2 |
| Hokimoto, S | 2 |
| Castiglioni, B | 1 |
| Liu, XW | 2 |
| Li, JY | 2 |
| Mohamed, I | 2 |
| Liu, GR | 1 |
| Zhang, JY | 1 |
| Pottegård, A | 1 |
| García Rodríguez, LA | 2 |
| Poulsen, FR | 1 |
| Hallas, J | 1 |
| Gaist, D | 1 |
| Pascoe, EM | 1 |
| Hawley, CM | 1 |
| Johnson, DW | 1 |
| Scaria, A | 1 |
| Hooi, SL | 1 |
| Ong, ML | 1 |
| Yokoyama, K | 3 |
| Chang, L | 1 |
| Afzal, S | 1 |
| Balzer, J | 1 |
| Rassaf, T | 1 |
| Ken, J | 1 |
| Khangura, D | 1 |
| Stickles, SP | 1 |
| Golukhova, EZ | 1 |
| Grigorian, MV | 1 |
| Ryabinina, MN | 1 |
| Bulaeva, NI | 1 |
| Fortmann, S | 1 |
| Serebruany, VL | 4 |
| Tsoi, MF | 1 |
| Cheung, CL | 1 |
| Cheung, TT | 1 |
| Wong, IC | 1 |
| Kumana, CR | 2 |
| Tse, HF | 2 |
| Cheung, BM | 2 |
| Leonard, JP | 1 |
| Jung, SH | 1 |
| Johnson, J | 1 |
| Pitcher, BN | 1 |
| Bartlett, NL | 1 |
| Blum, KA | 1 |
| Czuczman, M | 1 |
| Giguere, JK | 1 |
| Cheson, BD | 1 |
| Calcagno, S | 1 |
| Lucisano, L | 1 |
| Mancone, M | 1 |
| Cavallo, E | 1 |
| Pennacchi, M | 1 |
| Stio, RE | 1 |
| Sardella, G | 1 |
| Izumi, D | 1 |
| Miyahara, M | 1 |
| Fujimoto, N | 1 |
| Fukuoka, S | 1 |
| Sakai, M | 1 |
| Dohi, K | 1 |
| Ito, M | 2 |
| Costa, F | 1 |
| DeNino, WF | 1 |
| Floroff, C | 1 |
| Uber, WE | 1 |
| Ikonomidis, JS | 1 |
| Kuliczkowski, W | 3 |
| Sliwka, J | 1 |
| Kaczmarski, J | 1 |
| Zysko, D | 1 |
| Zembala, M | 3 |
| Steter, D | 1 |
| Gierlotka, M | 1 |
| Arif, SA | 1 |
| D'Souza, J | 1 |
| Gil, M | 1 |
| Gim, S | 1 |
| Acibuca, A | 1 |
| Gerede, DM | 1 |
| Vurgun, VK | 1 |
| Branch, DW | 1 |
| Levy, RA | 2 |
| Pavord, S | 1 |
| Roccatello, D | 1 |
| Khamashta, M | 3 |
| Vergallo, R | 1 |
| Aguirre, AD | 1 |
| Abtahian, F | 1 |
| Minami, Y | 1 |
| Soeda, T | 1 |
| Chatzizisis, YS | 1 |
| Croce, K | 1 |
| Jang, IK | 2 |
| Bundhun, PK | 1 |
| Qin, T | 1 |
| Chen, MH | 1 |
| Verdoia, M | 2 |
| Pergolini, P | 2 |
| Rolla, R | 2 |
| Nardin, M | 1 |
| Schaffer, A | 1 |
| Barbieri, L | 2 |
| Marino, P | 1 |
| Bellomo, G | 2 |
| Suryapranata, H | 2 |
| De Luca, G | 2 |
| Ganeshan, R | 1 |
| Malm, B | 1 |
| Concato, J | 1 |
| Tannetta, DS | 1 |
| Hunt, K | 1 |
| Jones, CI | 3 |
| Davidson, N | 1 |
| Coxon, CH | 1 |
| Ferguson, D | 2 |
| Redman, CW | 1 |
| Gibbins, JM | 1 |
| Sargent, IL | 1 |
| Tucker, KL | 1 |
| Kim, JY | 1 |
| Choi, YS | 1 |
| Kwon, A | 1 |
| Chung, WB | 1 |
| Park, CS | 1 |
| Kim, HY | 2 |
| Chang, K | 1 |
| Lee, MY | 1 |
| Chung, WS | 2 |
| Seung, KB | 2 |
| Suwita, BM | 1 |
| Laksmi, PW | 1 |
| Wijaya, IP | 1 |
| Buxhofer-Ausch, V | 1 |
| Falcone, C | 1 |
| King, R | 1 |
| Shah, A | 1 |
| Kargoli, F | 1 |
| Madan, S | 1 |
| Levin, AP | 1 |
| Patel, SR | 1 |
| Jermyn, R | 1 |
| Guerrero, C | 1 |
| Nguyen, J | 1 |
| Sims, DB | 1 |
| Shin, J | 1 |
| D'Alessandro, D | 1 |
| Jain, N | 1 |
| Adams-Huet, B | 1 |
| Sarode, R | 1 |
| Toto, RD | 1 |
| Hedayati, SS | 1 |
| Patil, R | 1 |
| Ghosh, K | 1 |
| Mukherjee, S | 1 |
| Shetty, S | 1 |
| Arima, Y | 1 |
| Oimatsu, Y | 1 |
| Sakamoto, K | 1 |
| Kojima, S | 2 |
| Nakagawa, K | 1 |
| Yıldırım, F | 1 |
| Kara, İ | 1 |
| Okuyan, H | 1 |
| Abacı, A | 1 |
| Türkoğlu, M | 1 |
| Aygencel, G | 1 |
| Derle, E | 1 |
| Öcal, R | 1 |
| Kibaroğlu, S | 1 |
| Çelikkol, C | 1 |
| Bayraktar, N | 1 |
| Verdi, H | 1 |
| Ataç, BF | 1 |
| Can, U | 1 |
| Mospan, CM | 1 |
| Morofuji, T | 1 |
| Inaba, S | 1 |
| Hitsumoto, T | 1 |
| Aisu, H | 1 |
| Higashi, H | 1 |
| Saito, M | 3 |
| Ohshima, K | 1 |
| Ikeda, S | 1 |
| Hamada, M | 1 |
| Sumimoto, T | 1 |
| Knowles, RB | 1 |
| Hu, P | 1 |
| Jones, S | 1 |
| Kim, TH | 1 |
| Jin, E | 1 |
| Shim, CH | 1 |
| Choi, SY | 1 |
| Mayor, S | 1 |
| Myles, PS | 4 |
| Smith, JA | 3 |
| Forbes, A | 2 |
| Silbert, B | 2 |
| Jayarajah, M | 2 |
| Painter, T | 3 |
| Cooper, DJ | 2 |
| Marasco, S | 2 |
| McNeil, J | 2 |
| Bussières, JS | 2 |
| Wallace, S | 2 |
| Valerio, L | 1 |
| Tran, PL | 1 |
| Brengle, W | 1 |
| Ghosh, R | 1 |
| Fiore, GB | 1 |
| Lau, YC | 1 |
| Xiong, Q | 1 |
| Ranjit, P | 1 |
| Blann, AD | 4 |
| Lim, GB | 1 |
| Allende, M | 1 |
| Molina, E | 1 |
| Guruceaga, E | 1 |
| Tamayo, I | 1 |
| González-Porras, JR | 1 |
| Gonzalez-López, TJ | 1 |
| Toledo, E | 1 |
| Rabal, O | 1 |
| Ugarte, A | 1 |
| Roldán, V | 2 |
| Rivera, J | 2 |
| Oyarzabal, J | 1 |
| Montes, R | 1 |
| Hermida, J | 1 |
| Secemsky, EA | 1 |
| Spertus, JA | 1 |
| Camenzind, E | 1 |
| Wijns, W | 2 |
| Apruzzese, PK | 1 |
| Bittl, JA | 1 |
| Bradley, SM | 1 |
| Wijeysundera, DN | 1 |
| Jayakumar, T | 1 |
| Yang, CH | 1 |
| Geraldine, P | 1 |
| Yen, TL | 1 |
| Sheu, JR | 2 |
| Bistola, V | 1 |
| Parissis, JT | 1 |
| Lekakis, J | 2 |
| Filippatos, G | 1 |
| Gomez Gomez, E | 1 |
| Campos Hernandez, JP | 1 |
| Cazalilla, M | 1 |
| Triviño, F | 1 |
| Barbudo, J | 1 |
| Prieto, R | 1 |
| Requena Tapia, MJ | 1 |
| Leebeek, FW | 1 |
| Hofstra, JM | 1 |
| Wetzels, JFM | 1 |
| Basaraba, JE | 2 |
| Barry, AR | 2 |
| Gillet, B | 1 |
| Didier, R | 1 |
| Ugo, V | 1 |
| Pencina, MJ | 1 |
| Peterson, ED | 1 |
| Gao, J | 1 |
| Ma, Y | 1 |
| Yang, M | 1 |
| Huang, SW | 1 |
| Kuo, HL | 1 |
| Hsu, MT | 1 |
| Tseng, YJ | 1 |
| Lin, SW | 1 |
| Kuo, SC | 1 |
| Peng, HC | 1 |
| Lien, JC | 1 |
| Huang, TF | 1 |
| Chalayer, E | 1 |
| Chapelle, C | 1 |
| Leleu, X | 1 |
| Elalamy, I | 1 |
| Laporte, S | 1 |
| Tardy, B | 1 |
| Whalen, JD | 1 |
| Davies, G | 2 |
| Du, M | 2 |
| Oguz, M | 2 |
| Bash, LD | 1 |
| Ozer-Stillman, I | 1 |
| Shen, DS | 1 |
| Zhao, XL | 1 |
| Kong, XJ | 1 |
| Shimada, YJ | 1 |
| Bansilal, S | 1 |
| Himmelmann, A | 1 |
| Neely, B | 1 |
| James, SK | 1 |
| Wallentin, L | 1 |
| Cannon, CP | 5 |
| Asher, E | 2 |
| Abu-Much, A | 1 |
| Goldenberg, I | 1 |
| Segev, A | 1 |
| Sabbag, A | 1 |
| Mazin, I | 1 |
| Shlezinger, M | 1 |
| Atar, S | 1 |
| Zahger, D | 2 |
| Polak, A | 1 |
| Beigel, R | 2 |
| Matetzky, S | 3 |
| Yamazaki, M | 3 |
| Yamaguchi, K | 2 |
| Yoneyama, T | 1 |
| Kawashima, A | 1 |
| Kitagawa, K | 1 |
| Uchiyama, S | 2 |
| Deshpande, S | 1 |
| Wann, LS | 1 |
| Aboonabi, A | 1 |
| Singh, I | 1 |
| Morici, N | 2 |
| Perna, E | 1 |
| Cipriani, M | 1 |
| Femia, EA | 1 |
| Oliva, F | 1 |
| Frigerio, M | 1 |
| Alkhodair, A | 1 |
| Cairns, J | 1 |
| Li, WW | 1 |
| Wollersheim, LW | 1 |
| Morshuis, WJ | 1 |
| Hong, KS | 1 |
| Lee, SH | 3 |
| Kim, EG | 1 |
| Cho, KH | 1 |
| Chang, DI | 1 |
| Rha, JH | 1 |
| Bae, HJ | 1 |
| Lee, KB | 1 |
| Kim, DE | 1 |
| Park, JM | 1 |
| Cha, JK | 1 |
| Yu, KH | 1 |
| Lee, SJ | 1 |
| Choi, JC | 1 |
| Cho, YJ | 1 |
| Kwon, SU | 1 |
| Kim, GM | 1 |
| Sohn, SI | 1 |
| Park, KY | 1 |
| Kang, DW | 1 |
| Sohn, CH | 1 |
| Yoon, BW | 1 |
| Sobanski, V | 1 |
| Lanteri, A | 1 |
| Dugo, D | 1 |
| Bordignon, S | 1 |
| Konstantinou, A | 1 |
| Perrotta, L | 1 |
| Fürnkranz, A | 1 |
| Chun, JK | 1 |
| Camaro, C | 1 |
| Damen, SA | 1 |
| Brouwer, MA | 3 |
| Lee, SW | 5 |
| Rognoni, A | 1 |
| van T Hof, AW | 1 |
| Ligtenberg, E | 1 |
| de Boer, MJ | 2 |
| Snyder, A | 1 |
| Pelliccia, F | 1 |
| Borzi, M | 1 |
| Camici, P | 1 |
| Cas, LD | 1 |
| Di Biase, M | 1 |
| Indolfi, C | 1 |
| Mercuro, G | 2 |
| Montemurro, V | 1 |
| Padeletti, L | 1 |
| Filardi, PP | 1 |
| Vizza, CD | 1 |
| Gunarathne, A | 1 |
| Hussain, S | 1 |
| Myat, A | 1 |
| Kubica, J | 1 |
| Liang, JJ | 1 |
| Fenstad, ER | 1 |
| Janish, CD | 1 |
| Sinak, LJ | 1 |
| McGuinness, S | 1 |
| Byrne, K | 1 |
| Chan, MT | 1 |
| Landoni, G | 1 |
| Wang, E | 1 |
| Inaba, K | 1 |
| Cho, J | 1 |
| Byerly, S | 1 |
| Rowe, V | 1 |
| Benjamin, E | 1 |
| Lam, L | 1 |
| Demetriades, D | 1 |
| Dzeshka, MS | 1 |
| Shantsila, A | 1 |
| Smilowitz, NR | 1 |
| Oberweis, BS | 1 |
| Nukala, S | 1 |
| Rosenberg, A | 1 |
| Stuchin, S | 1 |
| Iorio, R | 1 |
| Errico, T | 1 |
| Radford, MJ | 1 |
| Olechowski, B | 1 |
| Ashby, A | 1 |
| Mariathas, M | 1 |
| Khanna, V | 1 |
| Mahmoudi, M | 1 |
| Curzen, N | 3 |
| Tijssen, J | 1 |
| Giustino, G | 1 |
| Guimarães, AH | 1 |
| van Es, GA | 1 |
| Wildgoose, P | 1 |
| Volkl, AA | 1 |
| Zazula, A | 1 |
| Thomitzek, K | 1 |
| Hemmrich, M | 1 |
| Dangas, GD | 1 |
| Petzold, T | 1 |
| Thienel, M | 1 |
| Konrad, I | 2 |
| Schubert, I | 1 |
| Regenauer, R | 1 |
| Hoppe, B | 2 |
| Lorenz, M | 1 |
| Eckart, A | 1 |
| Chandraratne, S | 1 |
| Lennerz, C | 1 |
| Kolb, C | 1 |
| Braun, D | 1 |
| Jamasbi, J | 1 |
| Brandl, R | 2 |
| Siess, W | 2 |
| Schulz, C | 2 |
| Massberg, S | 2 |
| Ivert, T | 1 |
| Ander, C | 1 |
| Stålesen, R | 1 |
| Näsman, P | 1 |
| Lim, W | 2 |
| Rafiq, S | 1 |
| Steinbrüchel, DA | 1 |
| Lilleør, NB | 1 |
| Møller, CH | 1 |
| Lund, JT | 1 |
| Thiis, JJ | 1 |
| Køber, L | 1 |
| Olsen, PS | 1 |
| Korsholm, K | 1 |
| Nielsen, KM | 1 |
| Jensen, JM | 1 |
| Jensen, HK | 1 |
| Andersen, G | 1 |
| Ramachandran, P | 1 |
| King, E | 1 |
| Beekman, RH | 1 |
| Anderson, JB | 1 |
| Owais, T | 1 |
| Rouman, M | 1 |
| Breuer, M | 1 |
| Hüter, L | 1 |
| Fuchs, J | 1 |
| Lauer, B | 1 |
| Kuntze, T | 1 |
| Stevens, SM | 1 |
| Doty, JR | 1 |
| Truong, DT | 1 |
| Johnson, JT | 1 |
| Bailly, DK | 1 |
| Clawson, JR | 1 |
| Sheng, X | 1 |
| Burch, PT | 1 |
| Witte, MK | 1 |
| LuAnn Minich, L | 1 |
| Piccolo, R | 1 |
| Magnani, G | 2 |
| Ariotti, S | 1 |
| Gargiulo, G | 1 |
| Marino, M | 1 |
| Santucci, A | 1 |
| Franzone, A | 1 |
| Tebaldi, M | 3 |
| Heg, D | 1 |
| Ghodsizad, A | 1 |
| Badiye, A | 1 |
| Zeriouh, M | 1 |
| Pae, W | 1 |
| Koerner, MM | 1 |
| Loebe, M | 1 |
| Ambrosi, P | 1 |
| Daumas, A | 1 |
| Villani, P | 1 |
| Giorgi, R | 1 |
| Jalal, Z | 1 |
| Dinet, ML | 1 |
| Combes, N | 1 |
| Pillois, X | 1 |
| Renou, P | 1 |
| Sibon, I | 1 |
| Iriart, X | 1 |
| Thambo, JB | 1 |
| Yonetsu, T | 1 |
| Lee, T | 1 |
| Murai, T | 1 |
| Kanno, Y | 1 |
| Hamaya, R | 1 |
| Ichijo, S | 1 |
| Niida, T | 1 |
| Hada, M | 1 |
| Araki, M | 3 |
| Matsuda, J | 1 |
| Usui, E | 1 |
| Hoshino, M | 1 |
| Kanaji, Y | 1 |
| Kakuta, T | 1 |
| Sun, X | 1 |
| Tong, X | 1 |
| Lo, WT | 1 |
| Mo, D | 1 |
| Gao, F | 2 |
| Miao, Z | 1 |
| Saydam, F | 1 |
| Değirmenci, İ | 1 |
| Birdane, A | 2 |
| Özdemir, M | 1 |
| Ulus, T | 1 |
| Özbayer, C | 1 |
| Çolak, E | 1 |
| Ata, N | 1 |
| Güneş, HV | 1 |
| Aranda, FM | 1 |
| Perés Wingeyer, SDA | 1 |
| Fernández Romero, DS | 1 |
| de Larrañaga, GF | 1 |
| Hudec, V | 1 |
| Bena, M | 1 |
| Artemiou, P | 1 |
| Gasparovic, I | 1 |
| Hulman, M | 1 |
| Payanam Ramachandra, U | 1 |
| Shenoy, SJ | 1 |
| Arumugham, S | 1 |
| Orme, R | 1 |
| Judge, HM | 1 |
| Chase, M | 1 |
| Ozdemir, K | 1 |
| Aygül, N | 1 |
| Can, I | 1 |
| Aribaş, A | 1 |
| Bek, D | 1 |
| Beksaç, B | 1 |
| Della Valle, AG | 1 |
| Sculco, TP | 1 |
| Salvati, EA | 1 |
| Mogami, H | 1 |
| Murakami, Y | 1 |
| Nakamura, T | 1 |
| Kanayama, N | 1 |
| Konno, H | 1 |
| Urano, T | 2 |
| Chighizola, C | 1 |
| Maeng, M | 1 |
| Kaltoft, A | 1 |
| Hansen, HH | 1 |
| Bøttcher, M | 1 |
| Lassen, JF | 1 |
| Thayssen, P | 1 |
| Krusell, LR | 1 |
| Rasmussen, K | 1 |
| Pedersen, L | 1 |
| Sørensen, HT | 1 |
| Johnsen, SP | 1 |
| Thuesen, L | 1 |
| Eizayaga, F | 1 |
| Hudsmith, L | 1 |
| Thorne, S | 1 |
| Clift, P | 1 |
| Azzarelli, S | 1 |
| Galassi, AR | 1 |
| Amico, F | 1 |
| Giacoppo, M | 1 |
| Argentino, V | 1 |
| Giordano, G | 1 |
| Fiscella, A | 1 |
| Halperin, JL | 3 |
| Airaksinen, KE | 2 |
| Buerke, M | 4 |
| Eeckhout, E | 1 |
| Freedman, SB | 1 |
| Schlitt, A | 5 |
| Clappers, N | 1 |
| van Oijen, MG | 1 |
| Sundaresan, S | 1 |
| Te Morsche, RH | 1 |
| Keuper, W | 1 |
| Peters, WH | 1 |
| Drenth, JP | 1 |
| Arai, F | 1 |
| Sasaki, S | 1 |
| Thomas, MD | 1 |
| Wood, C | 1 |
| Lovett, M | 1 |
| Dembo, L | 1 |
| O'Driscoll, G | 1 |
| Khoo, CW | 1 |
| Pokov, I | 1 |
| Vahabi, J | 1 |
| Atar, D | 2 |
| Dropiński, J | 3 |
| Szczeklik, W | 1 |
| Sokołowska, B | 1 |
| Celińska-Lowenhoff, M | 1 |
| Milewski, M | 1 |
| Szczeklik, A | 3 |
| Marcucci, R | 4 |
| Gori, AM | 4 |
| Gensini, GF | 4 |
| Abbate, R | 4 |
| Truss, NJ | 2 |
| Ali, FY | 1 |
| Dhanji, AA | 1 |
| Vojnovic, I | 1 |
| Zain, ZN | 3 |
| Bishop-Bailey, D | 1 |
| Paul-Clark, MJ | 1 |
| Tucker, AT | 2 |
| Hoekstra, J | 1 |
| Giugliano, R | 1 |
| Hollander, JE | 1 |
| Manoukian, SV | 1 |
| Pollack, CV | 1 |
| Saucedo, JF | 1 |
| Zimmermann, N | 1 |
| Hohlfeld, T | 3 |
| Paydas, S | 1 |
| Niesvizky, R | 3 |
| Martínez-Baños, DM | 1 |
| Jackowski, L | 1 |
| Stocks, N | 1 |
| Rowett, D | 1 |
| Onoda, K | 1 |
| Ohashi, K | 1 |
| Hashimoto, A | 1 |
| Okuda, M | 1 |
| Shimono, T | 1 |
| Shimpo, H | 1 |
| Maegdefessel, L | 1 |
| Schubert, S | 1 |
| Reindl, I | 1 |
| Michel, T | 1 |
| Hauroeder, B | 2 |
| Carter, JM | 1 |
| Peetz, D | 2 |
| Werdan, K | 2 |
| Bhattacharyya, M | 1 |
| Karmohapatra, SK | 3 |
| Bhattacharya, G | 1 |
| Bhattacharya, R | 1 |
| Sinha, AK | 3 |
| Müller-Ehmsen, J | 1 |
| Erdmann, E | 1 |
| Jozic, J | 1 |
| Lockshin, MD | 3 |
| Sandner, SE | 1 |
| Zimpfer, D | 1 |
| Zrunek, P | 1 |
| Steinlechner, B | 1 |
| Rajek, A | 1 |
| Schima, H | 1 |
| Wolner, E | 1 |
| Wieselthaler, GM | 1 |
| Natarajan, A | 1 |
| Worthley, SG | 2 |
| Thachil, J | 1 |
| Gatt, A | 1 |
| Martlew, V | 1 |
| Abuladze, G | 1 |
| Jinjolia, N | 1 |
| Narsia, E | 1 |
| Abashidze, R | 1 |
| Kajaia, T | 1 |
| Lansky, AJ | 2 |
| Tsuchiya, Y | 1 |
| Brener, M | 1 |
| Cristea, E | 1 |
| Pietras, C | 1 |
| Grines, CL | 1 |
| Cox, DA | 1 |
| Garcia, E | 1 |
| Tcheng, JE | 1 |
| Guagliumi, G | 2 |
| Stuckey, T | 1 |
| Turco, M | 1 |
| Carroll, JD | 1 |
| Rutherford, BD | 2 |
| Moses, J | 1 |
| Galli, M | 1 |
| Qiao, SB | 1 |
| Zhang, RY | 1 |
| Zhang, JS | 1 |
| Qin, XW | 1 |
| Chen, JL | 1 |
| Shen, WF | 1 |
| Gao, RL | 1 |
| Liao, K | 1 |
| Colvin-Adams, M | 1 |
| Miller, L | 1 |
| Boyle, A | 2 |
| Feher, G | 1 |
| Feher, A | 1 |
| Pusch, G | 1 |
| Lupkovics, G | 1 |
| Szapary, L | 1 |
| Papp, E | 1 |
| Bunimov, N | 1 |
| Laneuville, O | 1 |
| Boncoraglio, GB | 1 |
| Bodini, A | 1 |
| Brambilla, C | 1 |
| Corsini, E | 1 |
| Carriero, MR | 2 |
| Parati, EA | 1 |
| Hofstad, B | 1 |
| Nesbakken, A | 1 |
| Eritsland, J | 1 |
| Brørs, O | 1 |
| Sandset, PM | 1 |
| Laskari, K | 1 |
| Panagiotakos, DB | 1 |
| Moutsopoulos, HM | 2 |
| Paniccia, R | 2 |
| Giusti, B | 2 |
| Fedi, S | 1 |
| Antonucci, E | 2 |
| Buonamici, P | 2 |
| Antoniucci, D | 2 |
| Mrdovic, I | 1 |
| Perunicic, J | 1 |
| Asanin, M | 1 |
| Matic, M | 1 |
| Vasiljevic, Z | 1 |
| Ostojic, M | 1 |
| Irish, A | 1 |
| Dogra, G | 1 |
| Mori, T | 1 |
| Beller, E | 1 |
| Kerr, P | 1 |
| Rosman, J | 1 |
| Starfield, M | 1 |
| Polkinghorne, K | 1 |
| Witkowski, A | 1 |
| Polonski, L | 1 |
| Watala, C | 1 |
| Filipiak, K | 1 |
| Golanski, J | 1 |
| Sitkiewicz, D | 1 |
| Pregowski, J | 1 |
| Gorski, J | 1 |
| Opolski, G | 1 |
| Arnesen, H | 1 |
| Palombo, G | 1 |
| Stella, N | 1 |
| Faraglia, V | 1 |
| Rizzo, L | 1 |
| Capuano, F | 1 |
| Sinatra, R | 1 |
| Taurino, M | 1 |
| Milani, RV | 1 |
| Mohler, ER | 1 |
| Mak, KH | 2 |
| Shao, M | 2 |
| Haffner, SM | 2 |
| Hamm, CW | 4 |
| Hankey, GJ | 5 |
| Johnston, SC | 2 |
| Steinhubl, SR | 8 |
| Fox, KA | 5 |
| Topol, EJ | 8 |
| Jensen, MK | 1 |
| Hüttel, M | 1 |
| Hussein, A | 1 |
| Kasmani, R | 1 |
| Irani, F | 1 |
| Mohan, G | 1 |
| Richard, PR | 1 |
| Libersan, D | 1 |
| Brennan, DM | 3 |
| Berger, PB | 7 |
| Chung, HY | 1 |
| Trendell-Smith, NJ | 1 |
| Yeung, CK | 1 |
| Mok, MY | 1 |
| Dai, X | 1 |
| Makaryus, AN | 1 |
| Makaryus, JN | 1 |
| Jauhar, R | 1 |
| Martinez-Berriotxoa, A | 1 |
| Steinwender, C | 1 |
| Hartenthaler, B | 1 |
| Lambert, T | 1 |
| Kypta, A | 1 |
| Kammler, J | 1 |
| Hönig, S | 1 |
| Hofmann, R | 1 |
| Kerschner, K | 1 |
| Leisch, F | 1 |
| Teixeira, OH | 1 |
| Mehta, AV | 1 |
| Apostolakis, S | 1 |
| Zuern, CS | 1 |
| Lindemann, S | 1 |
| Gawaz, M | 5 |
| Pecot, CV | 1 |
| Fuller, M | 1 |
| Muldowney, JA | 1 |
| Misra, S | 1 |
| Dixon, BS | 2 |
| Beck, GJ | 2 |
| Vazquez, MA | 2 |
| Greenberg, A | 3 |
| Delmez, JA | 3 |
| Allon, M | 2 |
| Dember, LM | 2 |
| Himmelfarb, J | 3 |
| Gassman, JJ | 1 |
| Greene, T | 2 |
| Radeva, MK | 2 |
| Davidson, IJ | 2 |
| Ikizler, TA | 2 |
| Braden, GL | 2 |
| Fenves, AZ | 1 |
| Kaufman, JS | 2 |
| Cotton, JR | 2 |
| Martin, KJ | 1 |
| McNeil, JW | 1 |
| Lawson, JH | 2 |
| Whiting, JF | 1 |
| Hu, B | 2 |
| Meyers, CM | 1 |
| Kusek, JW | 2 |
| Feldman, HI | 2 |
| Lok, CE | 1 |
| Margolis, JR | 1 |
| Jing, Q | 1 |
| Yang, L | 1 |
| Shang, X | 1 |
| Jiang, T | 1 |
| Li, H | 1 |
| Qiu, J | 1 |
| Chen, X | 1 |
| Gao, R | 1 |
| Sorensen, SV | 1 |
| Dewilde, S | 1 |
| Singer, DE | 2 |
| Monz, BU | 1 |
| Plumb, JM | 1 |
| Algra, A | 4 |
| Greving, JP | 1 |
| Feldman, DN | 1 |
| Wong, SC | 1 |
| Bergman, G | 1 |
| Minutello, RM | 1 |
| Chakoutio, V | 1 |
| Ries, F | 1 |
| Roffi, M | 1 |
| Eberli, FR | 1 |
| Suryadevara, S | 1 |
| Grad, E | 1 |
| Golomb, M | 1 |
| Koroukhov, N | 1 |
| Lawson, JA | 2 |
| Lotan, C | 2 |
| Fitzgerald, GA | 3 |
| Danenberg, HD | 1 |
| Alagha, A | 1 |
| Moman, E | 1 |
| Adamo, MF | 1 |
| Nolan, KB | 1 |
| Chubb, AJ | 1 |
| Cosio, BG | 1 |
| Soriano, JB | 1 |
| Kogushi, M | 1 |
| Dastros-Pitei, D | 1 |
| Flather, M | 1 |
| Mani, H | 1 |
| Lindhoff-Last, E | 2 |
| Wang, ZJ | 1 |
| Zhou, YJ | 1 |
| Liu, YY | 1 |
| Yu, M | 1 |
| Shi, DM | 1 |
| Zhao, YX | 1 |
| Guo, YH | 1 |
| Cheng, WJ | 1 |
| Nie, B | 1 |
| Ge, HL | 1 |
| Jia, DA | 1 |
| Yang, SW | 1 |
| Yan, ZX | 1 |
| Bonvini, RF | 1 |
| Barazer, I | 1 |
| Berdagué, P | 1 |
| de Moerloose, P | 2 |
| Schved, JF | 1 |
| Gris, JC | 1 |
| Moussa, ID | 1 |
| Morgan, GP | 1 |
| Weale, AR | 1 |
| Cooper, DG | 1 |
| Hentschel, DM | 1 |
| Sakariassen, KS | 5 |
| Alberts, P | 1 |
| Mann, J | 1 |
| Bounameaux, H | 4 |
| Sorensen, AS | 1 |
| Ray, MJ | 1 |
| Juneja, M | 1 |
| Bett, N | 1 |
| Walters, DL | 1 |
| Tamhane, U | 1 |
| Meier, P | 1 |
| Chetcuti, S | 1 |
| Chen, KY | 1 |
| Grossman, MP | 1 |
| Gurm, H | 1 |
| Treliński, J | 1 |
| Tybura, M | 1 |
| Smolewski, P | 1 |
| Robak, T | 1 |
| Chojnowski, K | 1 |
| Henry, RG | 2 |
| Caylan, R | 1 |
| Keske, S | 1 |
| Durmaz, T | 1 |
| Keles, T | 1 |
| Tasyaran, MA | 1 |
| Yasuda, H | 1 |
| Yamada, M | 1 |
| Sawada, S | 1 |
| Endo, Y | 1 |
| Asano, F | 1 |
| Takeyama, Y | 1 |
| Yoshiba, M | 1 |
| Elsenberg, EH | 1 |
| van Werkum, JW | 6 |
| van de Wal, RM | 1 |
| Zomer, AC | 1 |
| Bouman, HJ | 4 |
| Berg, JM | 1 |
| Hackeng, CM | 5 |
| Dhanji, AR | 1 |
| Chatterjee, T | 1 |
| Rehders, TC | 1 |
| Chatterjee, A | 1 |
| Schüpfer, C | 1 |
| Nienaber, CA | 4 |
| Ince, H | 3 |
| Siller-Matula, JM | 1 |
| Christ, G | 2 |
| Lang, IM | 1 |
| Delle-Karth, G | 1 |
| Sharma, RK | 1 |
| Reddy, HK | 1 |
| Singh, VN | 1 |
| Sharma, R | 1 |
| Voelker, DJ | 1 |
| Bhatt, G | 1 |
| Tacke, J | 1 |
| Kawamura, Y | 1 |
| Takahari, Y | 1 |
| Tamura, N | 1 |
| Eguchi, Y | 1 |
| Ishida, H | 1 |
| Preobrazhenskiĭ, DV | 2 |
| Sidorenko, BA | 2 |
| Batyraliev, TA | 3 |
| Vural, A | 1 |
| Islek, M | 1 |
| Avsar, O | 1 |
| Fettser, DV | 2 |
| Struijk-Mulder, MC | 1 |
| Ettema, HB | 1 |
| Verheyen, CC | 1 |
| Büller, HR | 1 |
| Willerson, JT | 1 |
| Cable, G | 1 |
| Yeh, ET | 1 |
| Nissinen, L | 1 |
| Pentikäinen, OT | 1 |
| Jouppila, A | 1 |
| Käpylä, J | 1 |
| Ojala, M | 1 |
| Nieminen, J | 1 |
| Lipsanen, A | 1 |
| Lappalainen, H | 1 |
| Eckes, B | 3 |
| Johnson, MS | 1 |
| Lassila, R | 2 |
| Marjamäki, A | 1 |
| Heino, J | 1 |
| Okano, K | 2 |
| Naitou, A | 1 |
| Yamamoto, M | 1 |
| Mimura, Y | 2 |
| Ichihara, K | 2 |
| Yamada, O | 1 |
| Shi, Q | 1 |
| Liu, G | 1 |
| Zhang, W | 1 |
| Dai, K | 1 |
| Jambor, J | 1 |
| Spannagl, M | 1 |
| Zwissler, B | 1 |
| Park, SW | 4 |
| Yun, SC | 2 |
| Park, DW | 2 |
| Kim, WJ | 1 |
| Lee, JY | 1 |
| Lee, CW | 4 |
| Kim, JJ | 3 |
| Schwalm, JD | 1 |
| Ahmad, M | 1 |
| Salehian, O | 1 |
| Natarajan, MK | 1 |
| Létienne, R | 1 |
| Leparq-Panissié, A | 1 |
| Calmettes, Y | 1 |
| Nadal-Wollbold, F | 1 |
| Perez, M | 1 |
| Le Grand, B | 1 |
| Moerenhout, CM | 1 |
| Claeys, MJ | 2 |
| Haine, S | 1 |
| Miljoen, H | 1 |
| Bosmans, JM | 2 |
| Vertessen, F | 2 |
| Kluppels, K | 1 |
| Van der Planken, M | 1 |
| Vrints, CJ | 2 |
| Islam, AM | 1 |
| Patel, PM | 1 |
| Kang, SJ | 2 |
| Han, KH | 3 |
| Lee, SG | 1 |
| Seong, IW | 1 |
| Jeong, MH | 1 |
| Yoon, J | 2 |
| Yang, JY | 1 |
| Lee, BK | 2 |
| Choi, YJ | 1 |
| Lim, DS | 2 |
| Cheong, SS | 1 |
| Chae, JK | 1 |
| Nah, DY | 1 |
| Jeon, DS | 1 |
| Jang, JS | 1 |
| Park, HS | 2 |
| Lee, K | 1 |
| Arazi, HC | 1 |
| Doiny, DG | 1 |
| Torcivia, RS | 1 |
| Grancelli, H | 1 |
| Waldman, SV | 1 |
| Nojek, C | 1 |
| Fornari, MC | 1 |
| Dumont, LA | 1 |
| Rongières, M | 1 |
| Tchénio, P | 1 |
| Gangloff, D | 1 |
| Garrido-Stowhas, I | 1 |
| Pickett, AM | 1 |
| Taylor, DA | 1 |
| Morel, O | 2 |
| Kessler, L | 1 |
| Ohlmann, P | 2 |
| Bareiss, P | 2 |
| Patel, RP | 1 |
| Mucksavage, P | 1 |
| Ramchandani, P | 1 |
| Hanno, PM | 1 |
| Malkowicz, SB | 1 |
| Can, MM | 1 |
| Ozveren, O | 1 |
| Karabay, CY | 1 |
| Akgün, T | 1 |
| Türkyilmaz, E | 1 |
| Tokgöz, HC | 1 |
| Kaymaz, C | 1 |
| Slaughter, MS | 1 |
| Naka, Y | 1 |
| Conte, JV | 1 |
| Russell, SD | 1 |
| Aaronson, KD | 1 |
| Sundareswaran, KS | 1 |
| Farrar, DJ | 1 |
| Pagani, FD | 1 |
| Konishi, N | 1 |
| Hiroe, K | 1 |
| Kawamura, M | 3 |
| Lemesle, G | 2 |
| Delhaye, C | 2 |
| Sudre, A | 1 |
| Bauters, C | 1 |
| Lablanche, JM | 1 |
| Mannucci, PM | 2 |
| Hacke, W | 3 |
| Möllmann, H | 2 |
| Nef, HM | 1 |
| Al-Dehneh, A | 1 |
| Virk, H | 1 |
| Alkhouri, Y | 1 |
| Hamdan, A | 1 |
| Bikkina, M | 1 |
| Cholette, JM | 1 |
| Mamikonian, L | 1 |
| Alfieris, GM | 1 |
| Blumberg, N | 1 |
| Lerner, NB | 1 |
| Flather, MD | 2 |
| Kondrat'eva, LV | 2 |
| Patrusheva, NL | 2 |
| Patrushev, LI | 2 |
| Aleksandrova, EN | 1 |
| Kovalenko, TF | 1 |
| Ostriakova, EV | 1 |
| Reshetniak, TM | 2 |
| Finotto, S | 1 |
| Fortuna, S | 1 |
| Tadros, R | 1 |
| Shakib, S | 1 |
| Sternad, H | 1 |
| Quehenberger, F | 1 |
| Rainer, F | 1 |
| Neumeister, P | 1 |
| Geara, AS | 1 |
| Azzi, N | 1 |
| Bassil, C | 1 |
| Hindy-François, C | 1 |
| Le Bonniec, B | 1 |
| Grelac, F | 1 |
| Godier, A | 1 |
| Emmerich, J | 2 |
| Samama, CM | 5 |
| Sonntag, U | 1 |
| Ellert, J | 1 |
| Byrne, RA | 1 |
| Mehilli, J | 1 |
| Schömig, A | 5 |
| d'Udekem, Y | 1 |
| Edmunds, I | 1 |
| Avakian, Z | 1 |
| Breet, NJ | 3 |
| Wulff, LN | 1 |
| Metzler, H | 2 |
| Mucci, L | 1 |
| Weber, R | 1 |
| Diener, HC | 2 |
| Rezaian, GR | 1 |
| Amirghofran, AA | 1 |
| Afifi, S | 1 |
| Moaref, AR | 1 |
| Rezaian, S | 1 |
| Dineen, PF | 1 |
| Curtin, RJ | 1 |
| Harty, JA | 1 |
| Joyner, CD | 1 |
| Faxon, DP | 1 |
| Rupprecht, HJ | 3 |
| Widimsky, P | 1 |
| Macaya, C | 2 |
| Di Pasquale, G | 1 |
| Niemela, K | 1 |
| Ajani, AE | 1 |
| White, HD | 1 |
| Chrolavicius, S | 1 |
| Gao, P | 1 |
| Lin, GM | 1 |
| Chu, KM | 1 |
| Han, CL | 1 |
| Pogliani, EM | 1 |
| Niiazova-Karben, ZA | 1 |
| Besnili, F | 1 |
| Park, Y | 3 |
| Kim, IS | 2 |
| Yun, SE | 2 |
| Kang, MK | 1 |
| Hwang, SJ | 2 |
| Kwak, CH | 2 |
| Hwang, JY | 2 |
| Laizure, SC | 1 |
| Parker, RB | 1 |
| Colli, A | 2 |
| D'Amico, R | 1 |
| Mestres, CA | 2 |
| Pomar, JL | 1 |
| Cámara, ML | 1 |
| Ruyra, X | 1 |
| Mulet, J | 1 |
| Aragam, KG | 1 |
| Ilhan, E | 1 |
| Demirci, D | 1 |
| Güvenç, TS | 1 |
| Calık, AN | 1 |
| Hahn, JY | 1 |
| Song, YB | 1 |
| Choi, JH | 1 |
| Choi, SH | 1 |
| Lee, S | 1 |
| Han, KR | 1 |
| Cho, BR | 1 |
| Gwon, HC | 1 |
| Tentzeris, I | 1 |
| Jarai, R | 1 |
| Brozovic, I | 1 |
| Smetana, P | 1 |
| Geppert, A | 2 |
| Wojta, J | 1 |
| Siller-Matula, J | 1 |
| Mylotte, D | 1 |
| Peace, AJ | 1 |
| Tedesco, AT | 1 |
| Dicker, P | 1 |
| Kenny, D | 1 |
| Foley, DP | 1 |
| Rothwell, PM | 1 |
| Wilson, M | 1 |
| Elwin, CE | 1 |
| Norrving, B | 1 |
| Warlow, CP | 1 |
| Meade, TW | 6 |
| Sanchez-Ross, M | 1 |
| Waller, AH | 1 |
| Maher, J | 1 |
| Klapholz, M | 1 |
| Haider, B | 1 |
| Kaluski, E | 1 |
| Cui, S | 1 |
| Chen, YD | 1 |
| He, GX | 1 |
| Yan, HB | 1 |
| Meng, LJ | 1 |
| Song, XT | 1 |
| Jin, ZN | 1 |
| Ge, CJ | 1 |
| Du, XJ | 1 |
| Shan, L | 1 |
| Gao, XM | 1 |
| Kiriazis, H | 1 |
| Lobo, A | 1 |
| Head, GA | 1 |
| Dart, AM | 1 |
| Philipose, S | 1 |
| Konya, V | 1 |
| Sreckovic, I | 1 |
| Marsche, G | 1 |
| Lippe, IT | 1 |
| Peskar, BA | 1 |
| Sambu, N | 2 |
| Warner, T | 1 |
| Barbhaiya, M | 1 |
| Morimoto, Y | 1 |
| Niwa, H | 1 |
| Nakatani, T | 1 |
| Komarov, AL | 1 |
| Hughes, GR | 4 |
| Singh, PP | 1 |
| Singh, M | 1 |
| Bedi, U | 1 |
| Molnar, J | 1 |
| Arora, R | 2 |
| Khosla, S | 1 |
| Schmidt, T | 1 |
| Tsakiris, DA | 2 |
| Grapow, M | 1 |
| Siegemund, M | 1 |
| Schork, NJ | 1 |
| Passacquale, G | 1 |
| Ferro, A | 1 |
| Václavík, J | 1 |
| Táborský, M | 1 |
| Gaglia, MA | 1 |
| Chu, MB | 1 |
| Turner, RB | 1 |
| Kriegel, DA | 1 |
| Kanellis, J | 1 |
| Mulley, W | 1 |
| Vik-Mo, H | 1 |
| Whatling, C | 1 |
| O'Gara, P | 1 |
| Burmester, GR | 1 |
| Dörner, T | 1 |
| Mohammad, RA | 1 |
| Goldberg, T | 1 |
| Dorsch, MP | 1 |
| Cheng, JW | 1 |
| Bech, FR | 1 |
| Chertow, GM | 1 |
| Kammerer, I | 1 |
| Bach, J | 1 |
| Saggau, W | 1 |
| Isgro, F | 1 |
| Arima, M | 1 |
| Matsuda, A | 1 |
| Nitta, M | 1 |
| Yoshida, K | 2 |
| Shimizu, M | 1 |
| Zamagni, E | 1 |
| Brioli, A | 1 |
| Tacchetti, P | 1 |
| Zannetti, B | 1 |
| Pantani, L | 1 |
| Cavo, M | 2 |
| Kaber, G | 1 |
| Kaiser, B | 1 |
| Baumgärtel-Allekotte, D | 1 |
| Rauch, B | 1 |
| Nossmann, S | 1 |
| Heim, Kh | 1 |
| Weber, A | 1 |
| Nagy, N | 1 |
| Fischer, J | 1 |
| Di Minno, MN | 2 |
| Tufano, A | 1 |
| Ageno, W | 1 |
| Prandoni, P | 1 |
| Harmsze, AM | 1 |
| Dechartres, A | 1 |
| Albaladejo, P | 3 |
| Mantz, J | 2 |
| Ravaud, P | 2 |
| Tubach, F | 2 |
| Yang, EH | 1 |
| Perez, E | 1 |
| Zhiroff, KA | 1 |
| Burstein, S | 1 |
| Briongos Figuero, S | 1 |
| Salido-Tahoces, L | 1 |
| de Juan-Bagudá, J | 1 |
| Martí-Sánchez, D | 1 |
| Park, KS | 1 |
| Park, JR | 1 |
| Koh, EH | 1 |
| Kim, S | 1 |
| Ziegelstein, RC | 1 |
| Green, A | 1 |
| Sauder, M | 1 |
| Nam, D | 1 |
| Lerakis, S | 1 |
| Pagni, S | 1 |
| Trivedi, J | 1 |
| Ganzel, BL | 1 |
| Williams, M | 1 |
| Kapoor, N | 1 |
| Ross, C | 1 |
| Slater, AD | 1 |
| Bacri, JL | 1 |
| Quemeneur, T | 1 |
| Houfflin-Debarge, V | 1 |
| Kyndt, X | 1 |
| Subtil, D | 1 |
| Buckley, T | 1 |
| Hammert, WC | 1 |
| Ardissino, D | 2 |
| Mantovani, F | 1 |
| Demola, MA | 1 |
| Rajendran, S | 1 |
| Parikh, D | 1 |
| Shugman, I | 1 |
| French, JK | 1 |
| Juergens, CP | 1 |
| Gajos, G | 1 |
| Zalewski, J | 1 |
| Rostoff, P | 1 |
| Nessler, J | 1 |
| Piwowarska, W | 1 |
| Campo, G | 2 |
| Miccoli, M | 1 |
| Marchesini, J | 2 |
| Fileti, L | 1 |
| Monti, M | 2 |
| Ferrari, R | 2 |
| Emerson, M | 2 |
| Men, J | 1 |
| Ren, J | 1 |
| Modi, P | 1 |
| Visentin, MS | 1 |
| Bontadi, A | 1 |
| Botta, A | 1 |
| Salvi, S | 1 |
| Nuzzo, M | 1 |
| Rovere-Querini, P | 1 |
| Mitic, G | 1 |
| Boffa, MC | 2 |
| Chinnakotla, S | 1 |
| Klintmalm, GB | 1 |
| Kim, P | 1 |
| Tomiyama, K | 1 |
| Klintmalm, E | 1 |
| Davis, GL | 1 |
| Trotter, JF | 1 |
| Saad, R | 1 |
| Landaverde, C | 1 |
| Levy, MF | 1 |
| Goldstein, RM | 1 |
| Stone, MJ | 1 |
| Garg, N | 1 |
| Rajpurohit, N | 1 |
| Flaker, G | 1 |
| Calabrò, RS | 1 |
| Pezzini, A | 1 |
| Gervasi, G | 1 |
| Pollicino, P | 1 |
| Bramanti, P | 1 |
| Jenkins, J | 1 |
| Babu, K | 1 |
| Hsu-Hung, E | 1 |
| Robinson-Bostom, L | 1 |
| Kroumpouzos, G | 1 |
| Quilici, J | 1 |
| Fugon, L | 1 |
| Roux, P | 1 |
| Gaborit, B | 1 |
| Molines, L | 1 |
| Fourcade, L | 1 |
| Bonnet, JL | 1 |
| Carrieri, P | 1 |
| Yazıcı, HU | 1 |
| Nadiradze, A | 1 |
| Ünalır, A | 1 |
| Ferreiro, JL | 1 |
| Ueno, M | 2 |
| Marret, E | 1 |
| Abhay, K | 1 |
| Loutrel, O | 1 |
| Charbonneau, H | 1 |
| Jaber, S | 1 |
| Thoret, S | 1 |
| Bosson, JL | 1 |
| Piriou, V | 2 |
| Cochrane, A | 2 |
| Roberts, R | 2 |
| Manlhiot, C | 2 |
| Weintraub, R | 2 |
| Szechtman, B | 2 |
| Hughes, M | 2 |
| Andrew, M | 3 |
| Canter, CE | 1 |
| Bakaeen, FG | 1 |
| Chu, D | 1 |
| Guida, A | 1 |
| Camera, M | 1 |
| Colli, S | 1 |
| Priya, N | 1 |
| Singh, P | 2 |
| Bhatia, S | 1 |
| Medhi, B | 1 |
| Prasad, AK | 1 |
| Parmar, VS | 1 |
| Raj, HG | 1 |
| Akoglu, H | 1 |
| Agbaht, K | 1 |
| Piskinpasa, S | 1 |
| Falay, MY | 1 |
| Dede, F | 1 |
| Ozet, G | 1 |
| Odabas, AR | 1 |
| Devereaux, PJ | 1 |
| Cholley, B | 1 |
| Nizard, R | 1 |
| Barré, J | 1 |
| Poirier, N | 1 |
| Mignon, A | 1 |
| Schlumberger, S | 1 |
| Longrois, D | 1 |
| Aubrun, F | 1 |
| Farèse, ME | 1 |
| Das, S | 1 |
| Karachiwala, H | 1 |
| Cherian, SV | 1 |
| Garcha, AS | 1 |
| Jasti, S | 1 |
| Gajra, A | 1 |
| Tomasello, SD | 1 |
| Vazzana, N | 2 |
| Liani, R | 1 |
| Guagnano, MT | 1 |
| Jing, BB | 1 |
| Li, YX | 1 |
| Ren, ST | 1 |
| Li, YP | 1 |
| Zang, WJ | 1 |
| Parodi, G | 1 |
| Valenti, R | 1 |
| Migliorini, A | 1 |
| Labarthe, B | 1 |
| Babin, J | 1 |
| Bryckaert, M | 1 |
| Théroux, P | 1 |
| Bonnefoy, A | 1 |
| Rayoo, R | 1 |
| Sharma, N | 1 |
| van Gaal, WJ | 1 |
| Cardona, L | 1 |
| Ana, G | 1 |
| Luísa, B | 1 |
| Leal, A | 1 |
| António, F | 1 |
| Lídia, S | 1 |
| Cruz, FR | 1 |
| Vogt, A | 1 |
| Mannes, F | 1 |
| Wolf, HH | 1 |
| Plehn, A | 1 |
| Ait-Mokhtar, O | 1 |
| Benamara, S | 1 |
| Paganelli, F | 1 |
| Sangiorgi, GM | 2 |
| Bramucci, E | 1 |
| Ferlini, M | 1 |
| Grinfeld, L | 1 |
| Petronio, AS | 1 |
| Pierli, C | 1 |
| Iadanza, A | 1 |
| Biondi-Zoccai, G | 1 |
| Pant, S | 1 |
| Neupane, P | 1 |
| Ramesh, KC | 1 |
| Barakoti, M | 1 |
| Cantor, WJ | 1 |
| Ernest, JM | 1 |
| Marshburn, PB | 1 |
| Kutteh, WH | 1 |
| Hod, H | 2 |
| Buber, J | 1 |
| Vatury, O | 1 |
| Fukasawa, M | 1 |
| Kondo, T | 1 |
| Sylvester, DC | 1 |
| Coatesworth, AP | 1 |
| Farney, AC | 1 |
| Stratta, RJ | 1 |
| Warkentin, AE | 1 |
| Donadini, MP | 1 |
| Crowther, M | 1 |
| Wilson, R | 1 |
| Gazzala, J | 1 |
| House, J | 1 |
| Akkus, NI | 1 |
| Rajpal, S | 1 |
| Agnani, S | 1 |
| Douketis, JD | 1 |
| Spyropoulos, AC | 1 |
| Jaffer, AK | 1 |
| Eckman, MH | 1 |
| Dunn, AS | 1 |
| Kunz, R | 1 |
| Sun, JC | 1 |
| Fremes, SE | 1 |
| Rubens, FD | 1 |
| Teoh, KH | 1 |
| Hirsh, J | 11 |
| Baglin, TP | 1 |
| Porto, I | 1 |
| D'Amario, D | 1 |
| Crea, F | 2 |
| Sidddiqi, SA | 1 |
| Kamal, AK | 1 |
| Costedoat-Chalumeau, N | 1 |
| Shin, SJ | 1 |
| Park, DI | 1 |
| Kim, SE | 1 |
| Hong, SP | 1 |
| Hong, SN | 1 |
| Yang, DH | 1 |
| Lee, BI | 1 |
| Yang, SK | 1 |
| Kim, HJ | 2 |
| Kim, SH | 2 |
| Esfandiar, N | 1 |
| Otukesh, H | 1 |
| Sharifian, M | 1 |
| Hoseini, R | 1 |
| Krishna, V | 1 |
| Diamond, GA | 1 |
| Kaul, S | 4 |
| Paikin, JS | 1 |
| Clevenger, B | 1 |
| Jaggar, S | 1 |
| Coppola, A | 1 |
| Sturgeon, SA | 2 |
| Mountford, JK | 1 |
| Percoco, G | 1 |
| Tumscitz, C | 1 |
| Castriota, F | 1 |
| Colombo, F | 1 |
| Fucà, G | 1 |
| Kubbajeh, M | 1 |
| Cangiano, E | 1 |
| Minarelli, M | 1 |
| Scalone, A | 1 |
| Cavazza, C | 1 |
| Frangione, A | 1 |
| Borghesi, M | 1 |
| Parrinello, G | 1 |
| Hondo, T | 1 |
| Matsumura, H | 1 |
| Matsuda, K | 1 |
| Iwamoto, A | 1 |
| Eno, S | 1 |
| Kimura, M | 1 |
| Rossi, M | 1 |
| Serraino, GF | 1 |
| Spadafora, A | 1 |
| Renzulli, A | 1 |
| Kiviniemi, T | 1 |
| Karjalainen, P | 1 |
| Pietilä, M | 1 |
| Ylitalo, A | 1 |
| Niemelä, M | 1 |
| Vikman, S | 1 |
| Puurunen, M | 1 |
| Biancari, F | 1 |
| Jaberi, A | 1 |
| Lum, C | 1 |
| Stefanski, P | 1 |
| Thornhill, RE | 1 |
| Dowlatshahi, D | 1 |
| Gerstein, NS | 1 |
| Schulman, PM | 1 |
| Gerstein, WH | 1 |
| Petersen, TR | 1 |
| Tawil, I | 1 |
| Tang, FK | 1 |
| Lin, LJ | 1 |
| Hua, N | 1 |
| Qi, Z | 1 |
| Tang, XZ | 1 |
| Mydin, MI | 1 |
| Dimitrakakis, G | 1 |
| Younis, J | 1 |
| Nowell, J | 1 |
| Athanasiou, T | 1 |
| Kourliouros, A | 1 |
| Frołow, M | 1 |
| Niżankowski, R | 1 |
| Sadowski, J | 1 |
| Ashitate, Y | 1 |
| Tanaka, E | 1 |
| Henary, M | 1 |
| Choi, HS | 1 |
| Frangioni, JV | 1 |
| Flaumenhaft, R | 1 |
| Doğan, A | 1 |
| Icli, A | 1 |
| Varol, E | 1 |
| Erdogan, D | 1 |
| Bassareo, PP | 1 |
| Fanos, V | 1 |
| Iacovidou, N | 1 |
| Tepe, G | 1 |
| Bantleon, R | 1 |
| Brechtel, K | 1 |
| Schmehl, J | 1 |
| Claussen, CD | 1 |
| Strobl, FF | 1 |
| Sheikh-Taha, M | 1 |
| Ghosn, S | 1 |
| Wijetilleka, S | 1 |
| Scoble, T | 1 |
| Gokce, M | 1 |
| Altan, I | 1 |
| Unal, S | 1 |
| Kuskonmaz, B | 1 |
| Aytac, S | 1 |
| Cetin, M | 1 |
| Tuncer, M | 1 |
| Gumruk, F | 1 |
| Gurgey, A | 1 |
| Vidali, M | 1 |
| Parrella, M | 1 |
| Cassani, C | 1 |
| Manzini, M | 1 |
| Portalupi, MR | 1 |
| Serino, R | 1 |
| Prando, MD | 1 |
| Vetter, TR | 1 |
| Boudreaux, AM | 1 |
| Papapietro, SE | 1 |
| Smith, PW | 1 |
| Taylor, BB | 1 |
| Porterfield, JR | 1 |
| Tsantes, A | 1 |
| Ikonomidis, I | 1 |
| Papadakis, I | 1 |
| Kottaridi, C | 1 |
| Tsante, A | 1 |
| Kalamara, E | 1 |
| Kardoulaki, A | 1 |
| Kopterides, P | 1 |
| Kapsimali, V | 1 |
| Karakitsos, P | 1 |
| Travlou, A | 1 |
| Yazbek, MA | 1 |
| Velho, P | 1 |
| Nadruz, W | 1 |
| Mahayri, N | 1 |
| Appenzeller, S | 1 |
| Costallat, LT | 1 |
| Liu, A | 1 |
| Saman, H | 1 |
| Pusalkar, P | 1 |
| Romlin, BS | 1 |
| Wåhlander, H | 1 |
| Strömvall-Larsson, E | 1 |
| Synnergren, M | 1 |
| Baghaei, F | 1 |
| Jeppsson, A | 1 |
| Lindholt, JS | 1 |
| Björck, M | 1 |
| Michel, JB | 1 |
| Ariturk, Z | 1 |
| Islamoglu, Y | 1 |
| Gündüz, E | 1 |
| Yavuz, C | 1 |
| Cil, H | 1 |
| Tekbas, E | 1 |
| Soydinc, S | 1 |
| Kaya, H | 1 |
| Elbey, MA | 1 |
| Yamada, K | 3 |
| Niki, H | 1 |
| Nagai, H | 1 |
| Nakagawa, H | 1 |
| Kuzniatsova, N | 1 |
| Velu, S | 1 |
| Isordia-Salas, I | 1 |
| Olalde-Román, MJ | 1 |
| Santiago-Germán, D | 1 |
| de la Peña, NC | 1 |
| Valencia-Sánchez, JS | 1 |
| Kourlaba, G | 1 |
| Fragoulakis, V | 1 |
| Maniadakis, N | 1 |
| Stephens, G | 1 |
| Tauscher, J | 1 |
| Andre, P | 4 |
| Siegel, FP | 1 |
| Phillips, DR | 4 |
| Petrides, PE | 1 |
| Nogaki, H | 1 |
| Vatankulu, MA | 1 |
| Tasal, A | 1 |
| Erdoğan, E | 1 |
| Göktekin, Ö | 1 |
| Ataya, A | 1 |
| Alraiyes, AH | 1 |
| Auron, M | 1 |
| Lane, DA | 1 |
| Savage, JR | 1 |
| Parmar, A | 1 |
| Robinson, PJ | 1 |
| Fassa, AA | 1 |
| Urban, P | 2 |
| Meade, T | 2 |
| Cevik, C | 1 |
| Shah, N | 1 |
| Wilson, JM | 2 |
| Stainback, RF | 1 |
| Reinhart, WH | 1 |
| Alexander, M | 1 |
| Teoh, KC | 1 |
| Lingaratnam, S | 1 |
| Kirsa, S | 1 |
| Mellor, JD | 1 |
| Schechter, CB | 1 |
| Pircher, J | 1 |
| Fochler, F | 1 |
| Czermak, T | 1 |
| Mannell, H | 1 |
| Kraemer, BF | 1 |
| Wörnle, M | 1 |
| Sparatore, A | 1 |
| Del Soldato, P | 2 |
| Pohl, U | 1 |
| Krötz, F | 1 |
| Lighthall, JG | 1 |
| Cain, R | 1 |
| Ghanem, TA | 1 |
| Wax, MK | 1 |
| Becker, EM | 1 |
| Perzborn, E | 1 |
| Klipp, A | 1 |
| Lücker, C | 1 |
| Bütehorn, U | 1 |
| Kast, R | 1 |
| Vatutin, NT | 1 |
| Taradin, GG | 1 |
| Bakhteeva, TD | 1 |
| Kalinkina, NV | 1 |
| Skliannaia, EV | 1 |
| Meyer, S | 1 |
| Del Gaudio, C | 1 |
| Ercolani, E | 1 |
| Galloni, P | 1 |
| Baiguera, S | 1 |
| Polizzi, L | 1 |
| Bianco, A | 1 |
| Hamidian Jahromi, A | 1 |
| Ito, T | 1 |
| Arai, S | 1 |
| Katsuoka, K | 1 |
| Eto, H | 1 |
| White, H | 1 |
| Bhargava, A | 1 |
| Chopra, A | 1 |
| Bernabela, L | 1 |
| Chopra, T | 1 |
| Ge, H | 1 |
| Zhou, Z | 1 |
| Cerletti, C | 8 |
| Iacoviello, L | 1 |
| Donati, MB | 4 |
| Weikert, U | 1 |
| Rauch, U | 1 |
| Kühl, U | 1 |
| Hohmann, C | 1 |
| Jaster, M | 1 |
| Pauschinger, M | 1 |
| Schwimmbeck, PL | 1 |
| Schultheiss, HP | 1 |
| Jaeschke, R | 1 |
| Gajewski, P | 1 |
| Brozek, J | 1 |
| Melnik, B | 1 |
| Hariry, H | 1 |
| Vakilzadeh, F | 1 |
| Gropp, C | 1 |
| Sitzer, G | 1 |
| Avegliano, G | 1 |
| Evangelista, A | 1 |
| Elorz, C | 1 |
| González-Alujas, T | 1 |
| García del Castillo, H | 1 |
| Soler-Soler, J | 1 |
| Shah, PB | 1 |
| Lilly, CM | 1 |
| Turpie, AG | 4 |
| Fitzmaurice, DA | 1 |
| Bartorelli, AL | 1 |
| Trabattoni, D | 1 |
| Vilela, VS | 1 |
| de Jesús, NR | 1 |
| Inbal, A | 1 |
| Victor, A | 1 |
| Hundt, F | 1 |
| Bickel, C | 1 |
| Meyer, J | 3 |
| Mann, JT | 1 |
| Fry, ET | 1 |
| DeLago, A | 1 |
| Wilmer, C | 1 |
| van Walraven, C | 1 |
| Hart, RG | 3 |
| Laupacis, A | 1 |
| Connolly, S | 1 |
| Petersen, P | 1 |
| Koudstaal, PJ | 2 |
| Chang, Y | 1 |
| Hellemons, B | 1 |
| Nakamura, Y | 3 |
| Korkolis, DP | 1 |
| Passik, CS | 1 |
| Marshalko, SJ | 1 |
| Koullias, GJ | 1 |
| Rouvier, J | 1 |
| Scazziota, A | 2 |
| Altman, R | 2 |
| Bick, RL | 1 |
| Alfar, H | 1 |
| Goedecke, C | 1 |
| Stone, S | 1 |
| Poston, L | 1 |
| Asakura, T | 1 |
| Sakamoto, N | 1 |
| Ishikawa, S | 1 |
| Muroi, S | 1 |
| Saitoh, F | 1 |
| Satoh, M | 1 |
| Suzuki, S | 1 |
| Ono, M | 1 |
| Sakabe, A | 1 |
| Iwai, M | 1 |
| Sando, M | 1 |
| Gotou, J | 1 |
| Watanabe, Y | 1 |
| Nagata, K | 1 |
| Maehara, K | 1 |
| Maruyama, Y | 3 |
| Rossatto, ER | 1 |
| da Silva, LB | 1 |
| Pereira, GS | 1 |
| Bonan, CD | 1 |
| Battastini, AM | 1 |
| Ribeiro, JP | 1 |
| Sarkis, JJ | 1 |
| Cheng, J | 1 |
| Kondo, K | 2 |
| Ikeda, Y | 2 |
| Meng, X | 1 |
| Umemura, K | 5 |
| Chesebro, JH | 20 |
| Pugo, FJ | 1 |
| Biasiutti, FD | 1 |
| Strebel, JK | 1 |
| Silber, S | 1 |
| Baumgart, D | 2 |
| Hehrlein, C | 1 |
| Meinertz, T | 1 |
| Mügge, A | 1 |
| Rutsch, W | 1 |
| vom Dahl, J | 1 |
| Toutouzas, K | 1 |
| Di Mario, C | 1 |
| Falotico, R | 2 |
| Takagi, T | 1 |
| Stankovic, G | 1 |
| Albiero, R | 2 |
| Corvaja, N | 1 |
| Khairy, P | 1 |
| Chauvet, P | 1 |
| Lehmann, J | 1 |
| Lambert, J | 1 |
| Macle, L | 1 |
| Sirois, MG | 1 |
| Santoianni, D | 1 |
| Dubuc, M | 1 |
| Gerschutz, GP | 1 |
| Stoddard, MF | 1 |
| Dawn, B | 1 |
| Longaker, RA | 1 |
| Easton, JD | 2 |
| Lecompte, T | 4 |
| Molina, V | 1 |
| Arruzazabala, ML | 1 |
| Carbajal, D | 1 |
| Más, R | 1 |
| Obialo, CI | 1 |
| Conner, AC | 1 |
| Lebon, LF | 1 |
| Bright, JM | 1 |
| Dowers, K | 1 |
| Powers, BE | 1 |
| Jünger, M | 1 |
| Ziegler, BK | 1 |
| Rasmussen, LH | 1 |
| Hildebrandt, PR | 1 |
| Nielsen, HK | 1 |
| Husted, SE | 2 |
| Michiels, JJ | 12 |
| Steinhubl, S | 1 |
| Berger, P | 1 |
| Rudnicka, AR | 1 |
| Ashby, D | 1 |
| Brennan, P | 1 |
| Mertens, D | 1 |
| Villalobos, MA | 1 |
| De La Cruz, JP | 1 |
| Escalante, R | 1 |
| Arrebola, MM | 1 |
| Guerrero, A | 1 |
| Sánchez de la Cuesta, F | 1 |
| Alarcón-Segovia, D | 1 |
| Branch, W | 1 |
| Gharavi, A | 1 |
| Wilson, W | 1 |
| Roubey, R | 1 |
| Delaney, SM | 2 |
| LaRocca, T | 2 |
| Vincent, D | 2 |
| DeGuzman, F | 1 |
| Jurek, M | 1 |
| Koller, B | 1 |
| Conley, PB | 3 |
| Collart, F | 1 |
| Derouck, D | 1 |
| Kerbaul, F | 1 |
| Feier, H | 1 |
| Mesana, TG | 1 |
| Friess, D | 1 |
| Lämmle, B | 1 |
| Alberio, L | 1 |
| Hodgson, PK | 1 |
| Larsen, RL | 1 |
| O'Connor, TZ | 1 |
| Zhang, JH | 1 |
| Cronin, RE | 1 |
| Fiore, LD | 1 |
| Ganz, MB | 1 |
| Goldfarb, DS | 1 |
| Peduzzi, PN | 1 |
| Schafer, AI | 4 |
| Weiss, HJ | 9 |
| Kopp, CW | 1 |
| Steiner, S | 1 |
| Priglinger, U | 1 |
| Probst, P | 1 |
| Maurer, G | 1 |
| Hohnloser, SH | 1 |
| Petri, M | 4 |
| CRAVEN, LL | 2 |
| ALEXANDER, K | 1 |
| KELLER, H | 1 |
| BORCHARDT, PR | 1 |
| METTENLEITER, MW | 1 |
| MANNHEIM, JH | 1 |
| Bressler, C | 1 |
| Himes, LC | 1 |
| Moreau, RE | 1 |
| Recto, MR | 1 |
| Sobczyk, W | 1 |
| Hadley, T | 1 |
| Yeh, T | 1 |
| Cazenave, JP | 5 |
| Lanza, F | 1 |
| Wiesel, ML | 1 |
| Weir, MR | 1 |
| Sperling, RS | 1 |
| Reicin, A | 1 |
| Gertz, BJ | 1 |
| Disa, JJ | 1 |
| Polvora, VP | 1 |
| Pusic, AL | 1 |
| Singh, B | 1 |
| Cordeiro, PG | 1 |
| Vane, JR | 6 |
| Botting, RM | 1 |
| Gryglewski, RJ | 5 |
| Swies, J | 3 |
| Uracz, W | 2 |
| Marcinkiewicz, E | 1 |
| Musiał, J | 1 |
| Sanak, M | 2 |
| Tuleja, E | 1 |
| Wegrzyn, W | 2 |
| Lin, PH | 1 |
| Sinha, U | 2 |
| Tan, KT | 1 |
| Marcus, AJ | 7 |
| Broekman, MJ | 7 |
| Drosopoulos, JH | 3 |
| Islam, N | 5 |
| Pinsky, DJ | 3 |
| Sesti, C | 1 |
| Levi, R | 2 |
| Spivak, J | 1 |
| Landolfi, R | 7 |
| Kutti, J | 1 |
| Tognoni, G | 4 |
| Nakajima, M | 1 |
| Minematsu, K | 1 |
| Saito, K | 1 |
| Takada, T | 1 |
| Levine, SR | 1 |
| Brey, RL | 2 |
| Tilley, BC | 1 |
| Thompson, JL | 1 |
| Sacco, RL | 1 |
| Sciacca, RR | 1 |
| Murphy, A | 1 |
| Lu, Y | 1 |
| Costigan, TM | 1 |
| Rhine, C | 1 |
| Levin, B | 1 |
| Triplett, DA | 2 |
| Mohr, JP | 1 |
| Szalony, JA | 2 |
| Suleymanov, OD | 2 |
| Salyers, AK | 2 |
| Panzer-Knodle, SG | 1 |
| Blom, JD | 1 |
| LaChance, RM | 1 |
| Case, BL | 1 |
| Parlow, JJ | 1 |
| South, MS | 1 |
| Wood, RS | 1 |
| Nicholson, NS | 2 |
| Bogousslavsky, J | 2 |
| Brass, LM | 1 |
| Cimminiello, C | 1 |
| Csiba, L | 1 |
| Kaste, M | 1 |
| Leys, D | 1 |
| Matias-Guiu, J | 1 |
| Rao, U | 1 |
| Weston, C | 1 |
| Hernandez, MR | 2 |
| Tonda, R | 1 |
| Pino, M | 1 |
| Serradell, M | 1 |
| Arderiu, G | 1 |
| Dutrillaux, F | 1 |
| Maynadié, M | 1 |
| Carli, PM | 1 |
| Denes, AE | 1 |
| Schuepbach, RA | 1 |
| Meili, EO | 1 |
| Schneider, E | 1 |
| Peter, U | 1 |
| Bachli, EB | 1 |
| Torsney, E | 1 |
| Mayr, U | 1 |
| Zou, Y | 1 |
| Thompson, WD | 1 |
| Hu, Y | 1 |
| Xu, Q | 1 |
| Ringleb, PA | 1 |
| Schellinger, PD | 1 |
| Schwark, C | 1 |
| Payne, DA | 2 |
| Hayes, PD | 2 |
| Webster, SE | 1 |
| Ross Naylor, A | 1 |
| Goodall, AH | 2 |
| Shen, YM | 1 |
| Frenkel, EP | 1 |
| Ohashi, N | 1 |
| Sumii, K | 1 |
| Inoue, R | 1 |
| Nakanishi, T | 1 |
| Gomyo, Y | 1 |
| Hwong, TM | 1 |
| Arifi, AA | 1 |
| Wan, IY | 1 |
| Thung, KH | 1 |
| Wan, S | 1 |
| Sung, RY | 1 |
| Yim, AP | 1 |
| Casselman, FP | 1 |
| Meco, M | 1 |
| Dom, H | 1 |
| Foubert, L | 1 |
| Van Praet, F | 1 |
| Vanermen, H | 1 |
| Hourani, SM | 1 |
| Sasaki, T | 1 |
| Kuzuya, M | 1 |
| Cheng, XW | 1 |
| Tamaya-Mori, N | 1 |
| Maeda, K | 1 |
| Kanda, S | 1 |
| Koike, T | 1 |
| Sato, K | 2 |
| Iguchi, A | 1 |
| Levin, RI | 1 |
| Klima, U | 1 |
| MacVaugh, H | 1 |
| Bagaev, E | 1 |
| Maringka, M | 1 |
| Kirschner, S | 1 |
| Beilner, J | 1 |
| Haverich, A | 1 |
| Lee, RT | 1 |
| Ezekowitz, MD | 2 |
| Vilahur, G | 3 |
| Segalés, E | 1 |
| Salas, E | 1 |
| Badimon, L | 12 |
| McBane, RD | 2 |
| Hassinger, NL | 1 |
| Grill, DE | 2 |
| Peerschke, EI | 1 |
| Silver, RT | 1 |
| Weksler, B | 1 |
| Grigg, SE | 1 |
| Savion, N | 2 |
| Varon, D | 2 |
| Blanchet, B | 1 |
| Tanguy, ML | 1 |
| Golmard, JL | 1 |
| Choussat, R | 1 |
| Beygui, F | 1 |
| Payot, L | 1 |
| Vignolles, N | 1 |
| Thomas, D | 1 |
| Umar, A | 1 |
| Boisseau, M | 1 |
| Yusup, A | 1 |
| Upur, H | 1 |
| Bégaud, B | 1 |
| Moore, N | 1 |
| Tran, H | 1 |
| Grüner, S | 1 |
| Prostredna, M | 1 |
| Aktas, B | 1 |
| Moers, A | 1 |
| Schulte, V | 1 |
| Krieg, T | 1 |
| Offermanns, S | 1 |
| Woodward, M | 1 |
| Lowe, GD | 3 |
| Francis, LM | 1 |
| Rumley, A | 1 |
| Cobbe, SM | 1 |
| Crowther, MA | 2 |
| Wisloff, F | 2 |
| Peter, K | 1 |
| Maree, AO | 2 |
| Fitzgerald, DJ | 3 |
| Van der Planken, MG | 1 |
| Van Der Goten, P | 1 |
| Wuyts, FL | 1 |
| Scarpace, SL | 1 |
| Hahn, T | 1 |
| Roy, H | 1 |
| Brown, K | 1 |
| Paplham, P | 1 |
| Chanan-Khan, A | 1 |
| van Besien, K | 1 |
| McCarthy, PL | 1 |
| Elliott, MA | 1 |
| Felmeden, DC | 1 |
| Cheung, G | 1 |
| Lauder, IJ | 1 |
| Ferrari, E | 1 |
| Benhamou, M | 1 |
| Cerboni, P | 1 |
| Marcel, B | 1 |
| Ahn, JC | 1 |
| Song, WH | 1 |
| Kwon, JA | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Oh, DJ | 1 |
| Rho, YM | 1 |
| Verspyck, E | 1 |
| Marpeau, L | 1 |
| Bresalier, RS | 1 |
| Sandler, RS | 1 |
| Quan, H | 1 |
| Bolognese, JA | 1 |
| Oxenius, B | 1 |
| Horgan, K | 1 |
| Lines, C | 1 |
| Riddell, R | 1 |
| Morton, D | 1 |
| Lanas, A | 1 |
| Konstam, MA | 1 |
| Baron, JA | 1 |
| Cheng, Q | 1 |
| Feuerstein, GZ | 2 |
| Hsu, MY | 1 |
| Smith, PL | 1 |
| Seiffert, DA | 1 |
| Schumacher, WA | 4 |
| Ogletree, ML | 3 |
| Gailani, D | 1 |
| Park, JH | 1 |
| Kadakia, RA | 1 |
| Ferguson, JJ | 3 |
| Takasaki, Y | 1 |
| Moussouttas, M | 1 |
| von Beckerath, N | 3 |
| Taubert, D | 2 |
| Pogatsa-Murray, G | 1 |
| Wieczorek, A | 1 |
| Schömig, E | 1 |
| Savi, P | 6 |
| Herbert, JM | 9 |
| Niitsu, Y | 1 |
| Jakubowski, JA | 4 |
| Sugidachi, A | 3 |
| Asai, F | 2 |
| Olson, KE | 1 |
| Kawata, M | 1 |
| Kuramoto, E | 1 |
| Kataoka, T | 1 |
| Saito, A | 1 |
| Adachi, K | 1 |
| Sakamoto, S | 2 |
| Carta, G | 1 |
| Iovenitti, P | 1 |
| Falciglia, K | 1 |
| Tzafettas, J | 1 |
| Petropoulos, P | 1 |
| Psarra, A | 1 |
| Delkos, D | 1 |
| Papaloukas, C | 1 |
| Giannoulis, H | 1 |
| Kalogiros, G | 1 |
| Gkoutzioulis, F | 1 |
| Brancaccio, V | 1 |
| Schinco, P | 1 |
| Musial, J | 2 |
| Baudo, F | 1 |
| Berrettini, M | 1 |
| Kottke-Marchant, K | 1 |
| Kunicki, TJ | 1 |
| Rao, AK | 1 |
| Elsässer, A | 1 |
| Czyz, M | 1 |
| Watała, C | 1 |
| Chien, W | 1 |
| Varvares, MA | 1 |
| Hadlock, T | 1 |
| Cheney, M | 1 |
| Deschler, DG | 1 |
| Ajzenberg, N | 1 |
| Aubry, P | 2 |
| Huisse, MG | 1 |
| Cachier, A | 1 |
| El Amara, W | 1 |
| Feldman, LJ | 1 |
| Himbert, D | 1 |
| Baruch, D | 1 |
| Guillin, MC | 1 |
| Charnigo, R | 1 |
| Moliterno, DJ | 1 |
| Velasco, A | 1 |
| Cordero, A | 1 |
| Fernández-Jarne, E | 1 |
| Coma-Canella, I | 1 |
| East, CL | 1 |
| Bareford, D | 2 |
| van der Walt, JD | 1 |
| Reilly, JT | 1 |
| Grigg, AP | 1 |
| Revell, P | 1 |
| Woodcock, BE | 2 |
| Svenstrup Poulsen, T | 1 |
| Kristensen, SR | 1 |
| Mickley, H | 1 |
| Cadroy, Y | 4 |
| Thalamas, C | 4 |
| Sakariassen, K | 3 |
| Boneu, B | 6 |
| Wu, KK | 3 |
| Boskholov, BP | 1 |
| Ng, HJ | 1 |
| Desai, D | 1 |
| Hasan, A | 2 |
| Wesley, R | 1 |
| Sunderland, E | 1 |
| Pucino, F | 1 |
| Csako, G | 1 |
| Feuring, M | 1 |
| Schultz, A | 1 |
| Losel, R | 1 |
| Wehling, M | 1 |
| Mason, PJ | 1 |
| Jacobs, AK | 1 |
| Freedman, JE | 3 |
| Pijak, MR | 1 |
| Huzicka, I | 1 |
| Gazdik, F | 1 |
| Wenaweser, P | 1 |
| Hess, O | 1 |
| Ringborg, A | 1 |
| Lindgren, P | 1 |
| Jönsson, B | 1 |
| Meyer Samama, M | 1 |
| Song, JM | 1 |
| Kang, DH | 1 |
| Song, JK | 1 |
| Baigent, C | 1 |
| Levy, Y | 1 |
| Shenkman, B | 1 |
| Tamarin, I | 1 |
| Pauzner, R | 2 |
| Langevitz, P | 2 |
| Poston, RS | 2 |
| White, C | 2 |
| Gu, J | 2 |
| Brown, J | 1 |
| Gammie, J | 1 |
| Pierson, RN | 2 |
| Lee, A | 1 |
| Connerney, I | 1 |
| Avari, T | 1 |
| Christenson, R | 1 |
| Tandry, U | 1 |
| Griffith, BP | 2 |
| Billett, HH | 2 |
| Sato, H | 1 |
| Ishikawa, K | 1 |
| Kitabatake, A | 1 |
| Ogawa, S | 1 |
| Yokota, Y | 1 |
| Fukuyama, T | 1 |
| Doi, Y | 1 |
| Mochizuki, S | 1 |
| Takekoshi, N | 1 |
| Hiramori, K | 1 |
| Origasa, H | 1 |
| Matsumoto, M | 2 |
| Yamaguchi, T | 1 |
| Hori, M | 1 |
| Brown, JM | 1 |
| Gammie, JS | 1 |
| Nie, L | 1 |
| Born, G | 1 |
| Daykin, HJ | 1 |
| Jones, C | 1 |
| Wright, CE | 1 |
| Jakiela, B | 1 |
| Murata, M | 1 |
| Laurent, M | 1 |
| Lelong, B | 1 |
| Lenormand, C | 1 |
| De Place, C | 1 |
| Matali, P | 1 |
| Leurent, G | 1 |
| Verhoye, JP | 1 |
| Almange, C | 1 |
| Leguerrier, A | 1 |
| Hayashi, S | 1 |
| Wakizaka, A | 1 |
| Sauer, H | 1 |
| Leschke, M | 1 |
| Fernandez-Ortiz, A | 2 |
| Bernardo, E | 1 |
| Ramírez, C | 1 |
| Jimenez-Quevedo, P | 1 |
| Hernández, R | 1 |
| Moreno, R | 1 |
| Escaned, J | 1 |
| Alfonso, F | 1 |
| Bañuelos, C | 1 |
| Costa, MA | 1 |
| Wåhlander, K | 1 |
| Eriksson-Lepkowska, M | 1 |
| Nyström, P | 1 |
| Eriksson, UG | 1 |
| Sarich, TC | 1 |
| Kalies, I | 1 |
| Elg, M | 2 |
| Bylock, A | 2 |
| Black, HR | 1 |
| Cohen, EA | 1 |
| Creager, MA | 1 |
| Pearson, TA | 1 |
| Weber, MA | 1 |
| Fabry-Ribaudo, L | 1 |
| Booth, J | 1 |
| Guyon, P | 1 |
| Schofer, J | 1 |
| Seth, A | 1 |
| Sousa, JE | 1 |
| Berge, C | 1 |
| Deme, M | 1 |
| Klutmann, M | 1 |
| Tillmanns, C | 1 |
| Gulba, DC | 1 |
| Rogowski, O | 1 |
| Shapira, I | 1 |
| Ben Assayag, E | 1 |
| Bornstein, NM | 1 |
| Toker, S | 1 |
| Melamed, S | 1 |
| Shirom, A | 1 |
| Berliner, S | 1 |
| Di Gennaro, L | 4 |
| Novarese, L | 1 |
| Heestermans, AA | 1 |
| Jaarsma, W | 1 |
| Hautvast, RW | 1 |
| Buller, CE | 1 |
| Pate, GE | 1 |
| Armstrong, PW | 1 |
| O'Neill, BJ | 1 |
| Gallo, R | 3 |
| Schneider, H | 2 |
| Weber, F | 2 |
| Holzhausen, C | 1 |
| Körber, T | 1 |
| Rehders, T | 1 |
| Barsky, AA | 1 |
| Arora, RR | 1 |
| Schmidt, M | 1 |
| Brömsen, J | 1 |
| Blumenstein, M | 1 |
| Buhk, JH | 1 |
| Wellmer, A | 1 |
| Knauth, M | 1 |
| Lutsep, HL | 1 |
| Gaciong, Z | 1 |
| Niccoli, G | 1 |
| Siviglia, M | 1 |
| De Vita, M | 1 |
| Altamura, L | 1 |
| Fusco, B | 1 |
| Leone, AM | 1 |
| Ferrante, G | 1 |
| Rebuzzi, AG | 1 |
| Frelinger, AL | 2 |
| Furman, MI | 4 |
| Linden, MD | 2 |
| Fox, ML | 2 |
| Barnard, MR | 2 |
| Zonder, JA | 2 |
| Barlogie, B | 2 |
| Durie, BG | 2 |
| McCoy, J | 1 |
| Crowley, J | 1 |
| Hussein, MA | 2 |
| Studer, MA | 1 |
| Kennedy, CE | 1 |
| Dreyer, WJ | 1 |
| Price, JF | 1 |
| Moffett, BS | 1 |
| Teitel, ER | 1 |
| Carberry, KE | 1 |
| Morales, DL | 1 |
| McKenzie, ED | 1 |
| Chang, AC | 1 |
| Hegener, HH | 1 |
| Diehl, KA | 1 |
| Kurth, T | 1 |
| Gaziano, JM | 2 |
| Zee, RY | 1 |
| Arnaud, B | 1 |
| Le Gal, G | 1 |
| Abgrall, JF | 1 |
| Boschat, J | 1 |
| Mannini, L | 1 |
| Giglioli, C | 1 |
| Valente, S | 1 |
| Prisco, D | 1 |
| Borgdorff, P | 1 |
| Tangelder, GJ | 1 |
| Paulus, WJ | 1 |
| Mirkhel, A | 1 |
| Peyster, E | 1 |
| Sundeen, J | 1 |
| Greene, L | 1 |
| Domanski, M | 1 |
| Bünger, CM | 1 |
| Grabow, N | 1 |
| Sternberg, K | 1 |
| Ketner, L | 1 |
| Kröger, C | 1 |
| Lorenzen, B | 1 |
| Hauenstein, K | 1 |
| Schmitz, KP | 1 |
| Kreutzer, HJ | 1 |
| Lootz, D | 1 |
| Klar, E | 1 |
| Schareck, W | 1 |
| Collins, P | 1 |
| Ford, I | 1 |
| Greaves, M | 1 |
| Macaulay, E | 1 |
| Brittenden, J | 1 |
| von Beckerath, O | 1 |
| Swallow, RA | 1 |
| Agarwala, RA | 1 |
| Dawkins, KD | 2 |
| Curzen, NP | 1 |
| Berneman, Z | 2 |
| Schroyens, W | 2 |
| Budde, U | 1 |
| van Vliet, HH | 5 |
| Libby, P | 2 |
| Aikawa, M | 1 |
| Jain, MK | 1 |
| Weber, AA | 2 |
| Harder, S | 1 |
| Scirica, BM | 1 |
| Cooper, R | 1 |
| Aster, RH | 1 |
| Brassard, J | 1 |
| McCabe, CH | 2 |
| Charlesworth, A | 1 |
| Skene, AM | 1 |
| Sung, JJ | 1 |
| Keeling, D | 1 |
| Smith, C | 1 |
| Damås, JK | 1 |
| Otterdal, K | 1 |
| Øie, E | 1 |
| Sandberg, WJ | 1 |
| Yndestad, A | 1 |
| Waehre, T | 1 |
| Scholz, H | 1 |
| Endresen, K | 1 |
| Olofsson, PS | 1 |
| Halvorsen, B | 1 |
| Gullestad, L | 1 |
| Frøland, SS | 1 |
| Hansson, GK | 1 |
| Aukrust, P | 1 |
| Chapman, MJ | 1 |
| Chrissoheris, MP | 1 |
| Mruthyunjayanna, V | 1 |
| Donohue, TJ | 1 |
| Marfisi, R | 2 |
| Lindemans, J | 2 |
| Neumann, HA | 1 |
| Ziegler, R | 1 |
| Di Nisio, M | 1 |
| Borrelli, G | 1 |
| Leone, G | 1 |
| Porreca, E | 1 |
| Rutjes, AW | 1 |
| Skrzypczak, J | 1 |
| Topakian, R | 1 |
| Nussbaumer, K | 1 |
| Trenkler, J | 1 |
| Aichner, FT | 1 |
| Modica, A | 1 |
| Karlsson, F | 1 |
| Mooe, T | 3 |
| Wong, PC | 1 |
| Crain, EJ | 1 |
| Watson, CA | 1 |
| Wexler, RR | 1 |
| Lam, PY | 1 |
| Quan, ML | 1 |
| Knabb, RM | 1 |
| Penz, SM | 1 |
| Reininger, AJ | 1 |
| Toth, O | 1 |
| Deckmyn, H | 1 |
| Blinc, A | 1 |
| Poredos, P | 1 |
| Kahn, NN | 2 |
| Kozek-Langenecker, S | 1 |
| Vicenzi, MN | 1 |
| Münch, A | 1 |
| Lisman, T | 1 |
| Porte, RJ | 1 |
| Vivarelli, M | 1 |
| La Barba, G | 1 |
| Cucchetti, A | 1 |
| Lauro, A | 1 |
| Del Gaudio, M | 1 |
| Ravaioli, M | 1 |
| Grazi, GL | 1 |
| Pinna, AD | 2 |
| Faraday, N | 1 |
| Yanek, LR | 1 |
| Mathias, R | 1 |
| Herrera-Galeano, JE | 1 |
| Vaidya, D | 1 |
| Moy, TF | 1 |
| Fallin, MD | 1 |
| Wilson, AF | 1 |
| Bray, PF | 1 |
| Becker, LC | 1 |
| Becker, DM | 1 |
| Meadows, TA | 1 |
| Kikano, GE | 1 |
| Brown, MT | 1 |
| Mahmud, A | 1 |
| Bennett, K | 1 |
| Okechukwu, I | 1 |
| Feely, J | 1 |
| Dahl, OE | 1 |
| Ogren, M | 1 |
| Agnelli, G | 1 |
| Eriksson, BI | 1 |
| Cohen, AT | 1 |
| Mouret, P | 1 |
| Rosencher, N | 1 |
| Panfilov, S | 1 |
| Andersson, M | 1 |
| Gulmez, O | 1 |
| Yildirir, A | 1 |
| Kaynar, G | 1 |
| Konas, D | 1 |
| Aydinalp, A | 1 |
| Ertan, C | 1 |
| Ozin, B | 1 |
| Muderrisoglu, H | 1 |
| Pamukcu, B | 1 |
| Oflaz, H | 1 |
| Onur, I | 1 |
| Oncul, A | 1 |
| Umman, B | 1 |
| Koylan, N | 1 |
| Bugra, Z | 1 |
| Meric, M | 1 |
| Nisanci, Y | 1 |
| Tardin, FA | 1 |
| Avanza, AC | 1 |
| Andião, MR | 1 |
| Rabello, SM | 1 |
| Cristello, Ede M | 1 |
| Baltan, EC | 1 |
| Pegurin, EB | 1 |
| Oliveira, NS | 1 |
| Winters, KJ | 1 |
| Harrison, MJ | 3 |
| Levy, R | 1 |
| Peterson, M | 1 |
| Sammaritano, L | 2 |
| Unalp-Arida, A | 1 |
| Vilela, V | 1 |
| Yazici, Y | 2 |
| Brennan, MT | 1 |
| Wynn, RL | 1 |
| Miller, CS | 2 |
| Chakraborty, K | 1 |
| Heim, HK | 1 |
| Schumacher, M | 1 |
| Dudley, N | 1 |
| Fuller, R | 1 |
| Naylor, AR | 1 |
| Airoldi, F | 1 |
| Cosgrave, J | 1 |
| Buellesfeld, L | 1 |
| Bonizzoni, E | 1 |
| Carlino, M | 1 |
| Gerckens, U | 1 |
| Godino, C | 1 |
| Melzi, G | 1 |
| Michev, I | 1 |
| Montorfano, M | 1 |
| Qasim, A | 1 |
| Briguori, C | 1 |
| Grube, E | 1 |
| Spiess, BD | 1 |
| Mosorjakova, D | 1 |
| Paluch, Z | 1 |
| Alusík, S | 1 |
| San Miguel Hernández, A | 1 |
| Inglada-Galiana, L | 1 |
| García Iglesias, R | 1 |
| Alonso Castillejos, N | 1 |
| Martín Gil, FJ | 1 |
| Eder, C | 1 |
| Funke, U | 1 |
| Schulze, M | 1 |
| Lutze, G | 1 |
| Zimmermann, M | 1 |
| Prasse, T | 1 |
| Töpfer, G | 1 |
| Chelliah, R | 1 |
| Bavry, AA | 1 |
| Matsukawa, M | 1 |
| Soejima, K | 1 |
| Fuchigami, S | 1 |
| Honda, T | 1 |
| Nagayoshi, Y | 1 |
| Shimomura, H | 1 |
| Sugiyama, S | 1 |
| Fujimoto, K | 1 |
| Yoshimura, M | 1 |
| Nakagaki, T | 1 |
| Hossain, N | 1 |
| Paidas, MJ | 1 |
| Casaní, L | 1 |
| Patel, D | 1 |
| Moonis, M | 1 |
| Rossi, ML | 1 |
| Zavalloni, D | 1 |
| Gasparini, GL | 1 |
| Presbitero, P | 1 |
| Kostka, B | 1 |
| Para, J | 1 |
| Sikora, J | 1 |
| Paç, FA | 1 |
| Cağdaş, DN | 1 |
| Chung, TL | 1 |
| Pumplin, DW | 1 |
| Holton, LH | 1 |
| Taylor, JA | 1 |
| Rodriguez, ED | 1 |
| Silverman, RP | 1 |
| Alonso Santor, JE | 1 |
| Inglada Galiana, L | 1 |
| Pérez Paredes, G | 1 |
| Patanè, S | 1 |
| Marte, F | 1 |
| Di Bella, G | 1 |
| Tarr, T | 1 |
| Lakos, G | 1 |
| Bhattoa, HP | 1 |
| Soltesz, P | 1 |
| Szegedi, G | 1 |
| Kiss, E | 1 |
| Riddell, JW | 1 |
| Chiche, L | 1 |
| Plaud, B | 1 |
| Hamon, M | 2 |
| Ruzyllo, W | 1 |
| Gottlieb, S | 1 |
| De Servi, S | 1 |
| Murphy, SA | 1 |
| Riesmeyer, J | 1 |
| Weerakkody, G | 1 |
| Antman, EM | 1 |
| Kuijpers, MJ | 1 |
| Pozgajova, M | 1 |
| Munnix, IC | 1 |
| Holden, RM | 1 |
| Harman, GJ | 1 |
| Holland, D | 1 |
| Day, AG | 1 |
| Cacciola, RR | 1 |
| Di Francesco, E | 1 |
| Pezzella, F | 1 |
| Tibullo, D | 1 |
| Giustolisi, R | 1 |
| Cacciola, E | 1 |
| Blindt, R | 1 |
| Stellbrink, K | 1 |
| de Taeye, A | 1 |
| Müller, R | 1 |
| Kiefer, P | 1 |
| Yagmur, E | 1 |
| Weber, C | 1 |
| Hoffmann, R | 1 |
| Martínez-Baños, D | 1 |
| Jalbrzikowski, J | 1 |
| Christos, P | 1 |
| Furst, J | 1 |
| De Sancho, M | 1 |
| Mark, T | 1 |
| Pearse, R | 1 |
| Mazumdar, M | 1 |
| Zafar, F | 1 |
| Pekle, K | 1 |
| Leonard, J | 1 |
| Jayabalan, D | 1 |
| Coleman, M | 1 |
| Bellucci, S | 1 |
| James, AH | 1 |
| Brancazio, LR | 1 |
| Price, T | 1 |
| Hereng, T | 1 |
| Samor, M | 1 |
| Queyrel, V | 1 |
| Walker, CW | 1 |
| Dawley, CA | 1 |
| Fletcher, SF | 1 |
| Lewis, KG | 1 |
| Dufresne, RG | 1 |
| Palumbo, A | 1 |
| Rajkumar, SV | 1 |
| Dimopoulos, MA | 1 |
| Richardson, PG | 1 |
| San Miguel, J | 1 |
| Harousseau, J | 1 |
| Zangari, M | 1 |
| Attal, M | 1 |
| Belch, A | 1 |
| Knop, S | 1 |
| Joshua, D | 1 |
| Sezer, O | 1 |
| Ludwig, H | 1 |
| Vesole, D | 1 |
| Bladé, J | 1 |
| Kyle, R | 1 |
| Westin, J | 1 |
| Weber, D | 1 |
| Bringhen, S | 1 |
| Waage, A | 1 |
| von Lilienfeld-Toal, M | 1 |
| Lonial, S | 1 |
| Morgan, GJ | 1 |
| Orlowski, RZ | 1 |
| Shimizu, K | 1 |
| Anderson, KC | 1 |
| Boccadoro, M | 1 |
| Sonneveld, P | 1 |
| Castella, M | 1 |
| Gherli, T | 1 |
| Kitahara, H | 1 |
| Fujimoto, Y | 1 |
| Nakayama, T | 1 |
| Kuroda, N | 1 |
| Himi, T | 1 |
| Miyazaki, A | 1 |
| Komuro, I | 1 |
| Simmons, BB | 1 |
| Salzman, BE | 1 |
| Rott, D | 1 |
| Leibowitz, D | 1 |
| Amit, G | 1 |
| Weiss, AT | 1 |
| Orschiedt, L | 1 |
| Koellnberger, M | 1 |
| Lorenz, R | 1 |
| Walter, U | 1 |
| Zharkova, TV | 1 |
| Ataullakhanova, DM | 1 |
| Bykova, ES | 1 |
| Kropacheva, ES | 1 |
| Dobrovol'skiĭ, AB | 1 |
| Titaeva, EV | 1 |
| Panchenko, EP | 1 |
| Pershukov, IV | 1 |
| Mayne, E | 1 |
| Jacobson, B | 1 |
| Louw, S | 1 |
| Bernstein, P | 1 |
| Mayne, A | 1 |
| Tseeng, S | 1 |
| Tanne, D | 1 |
| Katzav, A | 1 |
| Beilin, O | 1 |
| Grigoriadis, NC | 1 |
| Blank, M | 1 |
| Pick, CG | 1 |
| Landenberg, Pv | 1 |
| Chapman, J | 1 |
| Chang, YY | 1 |
| Liu, JS | 1 |
| Lai, SL | 1 |
| Wu, HS | 1 |
| Lan, MY | 1 |
| May, AE | 2 |
| Topcu, Y | 1 |
| Postma, S | 1 |
| Ellahham, S | 1 |
| Curtis, SL | 1 |
| Trinder, J | 1 |
| Stuart, AG | 1 |
| Sevdalis, N | 1 |
| Jacklin, R | 1 |
| Karnicki, K | 1 |
| Leadley, RJ | 1 |
| Baxi, S | 1 |
| Peterson, T | 1 |
| Wysokinski, W | 1 |
| Fareed, J | 2 |
| Hoppensteadt, DA | 1 |
| Fareed, D | 1 |
| Demir, M | 2 |
| Wahi, R | 2 |
| Clarke, M | 2 |
| Adiguzel, C | 2 |
| Bick, R | 2 |
| Fernández-Meré, LA | 1 |
| Fernández Rogríguez, S | 1 |
| Alvarez-Blanco, M | 1 |
| Kapoor, JR | 1 |
| Nagarakanti, R | 1 |
| Sodhi, S | 1 |
| Lee, R | 2 |
| Ezekowitz, M | 1 |
| Navarro-Núñez, L | 1 |
| Lozano, ML | 1 |
| Palomo, M | 1 |
| Martínez, C | 1 |
| Vicente, V | 2 |
| Castillo, J | 1 |
| Benavente-García, O | 1 |
| Diaz-Ricart, M | 1 |
| Brodie, BR | 1 |
| Nishihira, K | 1 |
| Yamashita, A | 2 |
| Imamura, T | 1 |
| Hatakeyama, K | 1 |
| Sato, Y | 1 |
| Nakamura, H | 1 |
| Yodoi, J | 1 |
| Kitamura, K | 1 |
| Asada, Y | 1 |
| Valencia, J | 1 |
| Mainar, V | 1 |
| Bordes, P | 1 |
| Pineda, J | 1 |
| Gómez, S | 1 |
| Sogorb, F | 1 |
| Bird, JE | 1 |
| Giancarli, MR | 1 |
| Allegretto, N | 1 |
| Barbera, F | 1 |
| Wong, P | 1 |
| Seiffert, D | 1 |
| Angiolillo, D | 2 |
| Bates, E | 2 |
| Bhatt, D | 2 |
| Peterson, E | 2 |
| Wiviott, S | 2 |
| Duran, X | 1 |
| Sánchez, S | 1 |
| Iqbal, O | 1 |
| Cunanan, J | 1 |
| O'Brien, JR | 14 |
| McNicol, GP | 3 |
| Ornig, H | 1 |
| Cox, AC | 1 |
| Smith, EO | 1 |
| Taylor, FB | 1 |
| Cheng, TO | 1 |
| Hoak, JC | 3 |
| Czervionke, RL | 1 |
| Fry, GL | 2 |
| Haycraft, DL | 1 |
| Brotherton, AA | 1 |
| Bertelè, V | 2 |
| Kelton, JG | 4 |
| Weichert, W | 2 |
| Pauliks, V | 1 |
| Breddin, HK | 6 |
| Il'in, VN | 1 |
| Stepanov, NV | 1 |
| Ikhaev, ZA | 1 |
| Sharonin, GV | 1 |
| Bogdanets, LI | 1 |
| Lowe, LW | 1 |
| Voigt, T | 1 |
| Voigt, H | 1 |
| Vinazzer, H | 3 |
| Hladovec, J | 8 |
| Buckler, P | 1 |
| Douglas, AS | 3 |
| Bergqvist, D | 2 |
| Stanley, JC | 1 |
| Burkel, WE | 1 |
| Ford, JW | 1 |
| Vinter, DW | 1 |
| Kahn, RH | 1 |
| Whitehouse, WM | 1 |
| Graham, LM | 1 |
| Hiraku, S | 1 |
| Wakitani, K | 1 |
| Katsube, N | 1 |
| Kawasaki, A | 1 |
| Tsuboshima, M | 1 |
| Naito, J | 1 |
| Ujiie, A | 1 |
| Komatsu, H | 1 |
| Iizuka, K | 1 |
| Mitchell, JR | 3 |
| Goldman, MD | 1 |
| Simpson, D | 1 |
| Hawker, RJ | 3 |
| Norcott, HC | 2 |
| McCollum, CN | 5 |
| Cunningham, DA | 1 |
| Kumar, B | 1 |
| Siegel, BA | 1 |
| Gilula, LA | 1 |
| Totty, WG | 1 |
| Welch, MJ | 1 |
| Kester, RC | 2 |
| Mizukami, M | 1 |
| Neichi, T | 1 |
| Yamazaki, T | 1 |
| Noda, Y | 1 |
| Matsushita, H | 1 |
| Hata, S | 1 |
| Nakano, M | 1 |
| Hansen, MS | 2 |
| Birgens, HS | 2 |
| Steer, ML | 1 |
| Salzman, EW | 4 |
| Packham, MA | 10 |
| Mustard, JF | 12 |
| Shimada, S | 1 |
| Kitamura, Y | 1 |
| Ohnishi, H | 1 |
| Kher, A | 1 |
| Gaillard, JL | 1 |
| Samama, M | 3 |
| Aonuma, S | 1 |
| Kohama, Y | 1 |
| Fujimoto, S | 1 |
| Nomura, M | 1 |
| Yamahata, E | 1 |
| Robinson, DR | 1 |
| Born, GV | 3 |
| Görög, P | 4 |
| Begent, NA | 1 |
| Elwood, PC | 2 |
| Fields, WS | 1 |
| Louie, S | 1 |
| Gurewich, V | 2 |
| Breddin, K | 7 |
| Philp, RB | 3 |
| Paul, ML | 2 |
| Loeliger, EA | 3 |
| Viinikka, L | 1 |
| Killackey, JJ | 2 |
| Killackey, BA | 2 |
| Shuto, K | 1 |
| Nakamizo, N | 1 |
| Kinlough-Rathbone, RL | 9 |
| Bourgain, RH | 3 |
| Andries, R | 3 |
| Maes, L | 1 |
| Goldman, M | 3 |
| Hall, C | 1 |
| Dykes, J | 1 |
| McDonald, JW | 2 |
| de Kergommeaux, BD | 1 |
| Ali, M | 1 |
| Hayward, CP | 1 |
| Eyb, R | 3 |
| Knahr, K | 2 |
| Bender, N | 1 |
| Kirchmaier, CM | 1 |
| Rhyner, K | 1 |
| Stenger, M | 1 |
| Block, LH | 1 |
| Lewis, GP | 1 |
| Smith, JR | 1 |
| Mazurov, AB | 1 |
| Leĭtin, VL | 1 |
| Repin, VS | 1 |
| Crow, MJ | 2 |
| Rajah, SM | 2 |
| Lucas, MA | 1 |
| Tilsner, V | 1 |
| Latour, JG | 2 |
| Léger-Gauthier, C | 1 |
| Daoust-Fiorilli, J | 1 |
| Pinon, JF | 1 |
| Kumashiro, R | 2 |
| Pavlides, CA | 1 |
| Kholoussy, AM | 2 |
| Matsumoto, T | 2 |
| Mongin, D | 1 |
| Ville, D | 1 |
| Sagnard, P | 1 |
| Baude, C | 1 |
| Dubernard, JM | 1 |
| Dechavanne, M | 2 |
| Randall, MJ | 1 |
| Wilding, RI | 1 |
| Stratton, JR | 2 |
| Ritchie, JL | 1 |
| Salter, MC | 1 |
| Donaldson, DR | 1 |
| Roberts, TG | 1 |
| Davison, AM | 1 |
| Cuadros, CL | 1 |
| Andriuoli, G | 1 |
| Mastacchi, R | 1 |
| Karczewiczowa, D | 1 |
| Krzystolikowa, Z | 1 |
| Maggi, GC | 1 |
| Gentile, F | 1 |
| Cirino, D | 1 |
| Borghetti, U | 1 |
| Klein-Soyer, C | 1 |
| Beretz, A | 1 |
| Rafiqi, EI | 1 |
| Drolc, Z | 1 |
| Verstraete, M | 2 |
| Morgan, KT | 1 |
| Duchosal, F | 1 |
| Rogg, C | 1 |
| Miescher, PA | 1 |
| Farah, AE | 1 |
| Rosenberg, F | 1 |
| Polli, EE | 1 |
| Cortellaro, M | 2 |
| Myśliwiec, M | 1 |
| Chahil, A | 1 |
| Somers, D | 1 |
| Gaudiani, VA | 1 |
| Miller, DC | 2 |
| Kosek, JC | 2 |
| Burg, J | 1 |
| Jamieson, SW | 1 |
| Kazmier, FJ | 3 |
| Littlejohn, GO | 1 |
| Deck, JH | 1 |
| Reynolds, WJ | 1 |
| Paris, J | 1 |
| Fournau, P | 1 |
| Granero, M | 1 |
| Viens, C | 1 |
| Phillips, BA | 1 |
| Riddell, DG | 1 |
| Rogers, PC | 1 |
| Carter, JE | 1 |
| Pirk, J | 1 |
| Ruzbarský, V | 1 |
| König, J | 1 |
| Krajícek, M | 1 |
| Pavel, P | 1 |
| Firt, P | 1 |
| Hancock, JB | 1 |
| Forshaw, PL | 1 |
| Kaye, MP | 2 |
| Josa, M | 1 |
| Lie, JT | 1 |
| Bianco, RL | 1 |
| Kooiman, AM | 1 |
| Kootstra, G | 1 |
| Zwierstra, RP | 1 |
| Blajchman, MA | 1 |
| Lundh, B | 1 |
| Fagher, B | 1 |
| Margulies, EH | 1 |
| White, AM | 1 |
| Sherry, S | 1 |
| Moncada, S | 9 |
| Mayer, JE | 2 |
| Lindsay, WG | 1 |
| Castaneda, W | 1 |
| Nicoloff, DM | 1 |
| Herman, AG | 1 |
| Harjola, PT | 1 |
| Meurala, H | 1 |
| Groves, HM | 1 |
| Dejana, E | 4 |
| Richardson, M | 1 |
| Clements, IP | 1 |
| Elveback, LR | 1 |
| Smith, HC | 1 |
| Bardsley, WT | 1 |
| Frye, RL | 2 |
| Vlietstra, RE | 1 |
| Pluth, JR | 1 |
| Wallace, RB | 1 |
| Puga, FJ | 1 |
| Orszulak, TA | 1 |
| Piehler, JM | 1 |
| Schaff, HV | 2 |
| Danielson, GK | 1 |
| Sasaguri, Y | 1 |
| Kato, H | 1 |
| Marshall, M | 1 |
| Bradlow, BA | 1 |
| Chetty, N | 1 |
| Schaub, RG | 1 |
| Gates, KA | 1 |
| Roberts, RE | 1 |
| Bodziak, K | 1 |
| Richardson, PD | 1 |
| Zabel-Langhennig, R | 1 |
| Ruttmann, B | 1 |
| Schiele, I | 1 |
| Schäfer, W | 1 |
| Aisch, W | 1 |
| Dujovny, M | 1 |
| Kossovsky, N | 1 |
| Loubeau, JM | 1 |
| Nelson, D | 1 |
| McManus, G | 1 |
| Zimmermann, R | 4 |
| Thiessen, M | 2 |
| Walter, E | 1 |
| Mörl, H | 2 |
| Carson, S | 1 |
| Demling, R | 1 |
| Esquivel, C | 1 |
| Talken, L | 1 |
| Tillman, P | 1 |
| de Castellarnau, C | 1 |
| Galletti, F | 1 |
| Latini, R | 2 |
| Livio, M | 1 |
| Caen, JP | 3 |
| Sidorova, LD | 1 |
| Arkhipov, BF | 1 |
| Degtiareva, MM | 1 |
| Barkagan, LZ | 1 |
| Chernukh, AM | 1 |
| Entsik, LA | 1 |
| Gomazkov, OA | 1 |
| Villaverde, CA | 1 |
| Almirall, L | 1 |
| Borruel, MT | 1 |
| Barthó, L | 1 |
| Lindenauer, SM | 1 |
| Schultz, JS | 1 |
| Penner, JA | 1 |
| Cottafava, F | 1 |
| Brida Di Priò, S | 1 |
| Buono, S | 1 |
| Nardelli, E | 1 |
| Della Casa, C | 1 |
| Boeri, L | 1 |
| Dodero, P | 1 |
| Scheibe, O | 1 |
| Pavlosky, M | 1 |
| Carreras, LO | 1 |
| Lazzari, MA | 2 |
| Albertal, J | 1 |
| Friedman, EA | 1 |
| Bannister, CM | 1 |
| Chapman, SA | 1 |
| Cohen, PJ | 1 |
| Remuzzi, G | 2 |
| Marchesi, D | 1 |
| Schieppati, A | 1 |
| Poletti, E | 1 |
| Mecca, G | 1 |
| Rossi, EC | 3 |
| Kahn, SB | 1 |
| Bygdeman, M | 1 |
| Walker, AM | 1 |
| Jick, H | 1 |
| Reyers, I | 2 |
| Mussoni, L | 2 |
| Schott, G | 1 |
| Reuter, HD | 1 |
| Ernst, FM | 1 |
| Linker, H | 1 |
| Lecker, D | 1 |
| Kumar, A | 1 |
| Clagett, GP | 2 |
| Russo, M | 2 |
| Hufnagel, H | 2 |
| Wechsler, B | 3 |
| Généreau, T | 1 |
| Biousse, V | 1 |
| Vauthier-Brouzes, D | 1 |
| Seebacher, J | 1 |
| Dormont, D | 1 |
| Godeau, P | 2 |
| Heran, CL | 1 |
| Steinbacher, TE | 2 |
| Youssef, S | 1 |
| Shanberge, JN | 1 |
| Kajiwara, Y | 1 |
| Quattrociocchi-Longe, T | 1 |
| Yokota, K | 1 |
| Oda, M | 1 |
| Toyohira, H | 1 |
| Kariyazono, H | 1 |
| Moriyama, Y | 1 |
| Shimokawa, S | 1 |
| Saigenji, H | 1 |
| Taira, A | 1 |
| Merhi, Y | 1 |
| Bernier, J | 1 |
| Marois, Y | 1 |
| Guidoin, R | 1 |
| Toschi, V | 1 |
| Lettino, M | 1 |
| Fallon, JT | 5 |
| Frishman, WH | 1 |
| Burns, B | 1 |
| Atac, B | 1 |
| Alturk, N | 1 |
| Altajar, B | 1 |
| Lerrick, K | 1 |
| Sasa, H | 1 |
| Aoki, K | 1 |
| Ogasawara, M | 1 |
| Kajiura, S | 1 |
| Yagami, Y | 1 |
| Zemour, G | 2 |
| Benveniste, E | 2 |
| Biron, Y | 2 |
| Bourdonnec, C | 1 |
| Faivre, R | 1 |
| Fajadet, J | 2 |
| Gaspard, P | 1 |
| Glatt, B | 2 |
| Joly, P | 2 |
| Van Genderen, PJ | 4 |
| Lasry, JL | 1 |
| Boyer, JC | 1 |
| Bories, H | 1 |
| Kadouch, R | 1 |
| Lagneau, P | 1 |
| Edelman, P | 1 |
| Rouquette, AM | 1 |
| Mori, Y | 1 |
| Okamura, N | 1 |
| Mizuuchi, H | 1 |
| Lyle, EM | 1 |
| Fujita, T | 2 |
| Conner, MW | 1 |
| Connolly, TM | 1 |
| Vlasuk, GP | 2 |
| Lynch, JL | 1 |
| Safier, LB | 3 |
| Kaminski, WE | 2 |
| Hajjar, KA | 2 |
| Jendraschak, E | 2 |
| Silverstein, RL | 2 |
| von Schacky, C | 2 |
| Fliessbach, JH | 2 |
| Doutremepuich, F | 6 |
| Imbault, P | 3 |
| Oualane, FA | 1 |
| Bolz, KD | 1 |
| Nordby, A | 1 |
| Kornowski, R | 3 |
| Chernine, A | 2 |
| Hasdai, D | 1 |
| Ovadia, Z | 1 |
| Battler, A | 2 |
| Valji, K | 2 |
| Bookstein, JJ | 2 |
| Roberts, AC | 1 |
| Oglevie, SB | 1 |
| Pittman, C | 1 |
| O'Neill, MP | 1 |
| Basile, AP | 1 |
| Fiala, TG | 1 |
| Yaremchuk, MJ | 1 |
| May, JW | 1 |
| Mohan, CR | 1 |
| Sharp, WJ | 1 |
| Hoballah, JJ | 1 |
| Kresowik, TF | 1 |
| Schueppert, MT | 1 |
| Corson, JD | 1 |
| Sinzinger, H | 2 |
| Keiler, A | 1 |
| O'Grady, J | 1 |
| Terashita, Z | 1 |
| Imura, Y | 2 |
| Kato, K | 1 |
| Nishikawa, K | 1 |
| Fiane, AE | 1 |
| Seem, E | 1 |
| Geiran, O | 1 |
| Lindberg, HL | 1 |
| Meng, YY | 1 |
| Trachtenburg, J | 1 |
| Ryan, US | 1 |
| Abendschein, DR | 2 |
| Kooistra, MP | 1 |
| van Es, A | 1 |
| Marx, JJ | 1 |
| Hertsig, ML | 1 |
| Struyvenberg, A | 1 |
| Kongsgaard, E | 1 |
| Foerster, A | 1 |
| Aass, H | 1 |
| Madsen, S | 1 |
| Amlie, JP | 1 |
| Gibbs, NM | 1 |
| Crawford, GP | 1 |
| Michalopoulos, N | 1 |
| Warwick, DJ | 1 |
| Pintigny, D | 1 |
| Sertillanges, MN | 1 |
| De Seze, O | 1 |
| Dittel, M | 1 |
| Haushofer, A | 1 |
| Spiel, R | 1 |
| Halbmayer, WM | 1 |
| Prachar, H | 1 |
| Fischer, M | 1 |
| Mlczoch, J | 1 |
| Hamelink, JK | 1 |
| Tang, DB | 1 |
| Barr, CF | 1 |
| Jackson, MR | 1 |
| Reid, TJ | 1 |
| Gomez, ER | 1 |
| Alving, BM | 1 |
| Mujic, F | 1 |
| Taub, NA | 1 |
| Vlachoyiannopoulos, PG | 1 |
| Tsiakou, E | 1 |
| Chalevelakis, G | 1 |
| Raptis, SA | 1 |
| Rivier, G | 1 |
| Herranz, MT | 1 |
| Zotz, R | 1 |
| Pinnau, U | 2 |
| Genth, S | 2 |
| Erbel, R | 3 |
| Brack, MJ | 1 |
| Hubner, PJ | 1 |
| Meyer, BJ | 3 |
| Mailhac, A | 1 |
| Shirakura, S | 1 |
| Higo, K | 2 |
| Takeda, M | 1 |
| Karasawa, A | 2 |
| Ambrus, JL | 1 |
| Ambrus, CM | 1 |
| Stadler, S | 1 |
| Toumbis, C | 1 |
| Markus, G | 1 |
| Pizzetti, G | 1 |
| Belotti, G | 1 |
| Chierchia, SL | 2 |
| Hall, JD | 1 |
| Rittgers, SE | 1 |
| Schmidt, SP | 2 |
| Sreedhara, R | 1 |
| Lazarus, JM | 1 |
| Hakim, RM | 1 |
| Tanira, MO | 1 |
| el-Sabban, FF | 1 |
| Fahim, MA | 1 |
| Wasfi, IA | 1 |
| Zotz, RJ | 1 |
| Stephens, LC | 2 |
| Haire, WD | 3 |
| Schmit-Pokorny, K | 2 |
| Kessinger, A | 3 |
| Kotulak, G | 1 |
| Roth, GJ | 2 |
| Calverley, DC | 2 |
| Lu, HR | 2 |
| Roskams, T | 1 |
| Plow, EF | 1 |
| Gold, HK | 3 |
| Collen, D | 7 |
| Buckley, RC | 1 |
| Davidson, SF | 1 |
| Das, SK | 1 |
| Escudero, MC | 2 |
| Alvarez, L | 4 |
| de Haro, J | 3 |
| Millán, I | 4 |
| Jorge, E | 1 |
| Castillo-Olivares, JL | 4 |
| Noble, MI | 1 |
| Drake-Holland, AJ | 1 |
| Roald, HE | 1 |
| Orvim, U | 2 |
| Bakken, IJ | 1 |
| Barstad, RM | 2 |
| Kierulf, P | 1 |
| Bernat, A | 6 |
| Dumas, A | 1 |
| Aït-Chek, L | 1 |
| Grambow, DW | 1 |
| Valentini, VV | 1 |
| Armstrong, WF | 1 |
| Rosendaal, FR | 1 |
| Stenzinger, W | 1 |
| van de Loo, J | 1 |
| Ansell, J | 2 |
| Recht, L | 1 |
| Shebuski, RJ | 1 |
| Kohmura, C | 1 |
| Yasuda, T | 1 |
| Holt, R | 1 |
| Nedelman, MA | 1 |
| Guerrero, JL | 1 |
| Weisman, HF | 2 |
| Aldhous, P | 1 |
| Meltzer, RS | 1 |
| Vered, Z | 1 |
| Mueller, RL | 1 |
| Scheidt, S | 1 |
| Escudero, C | 1 |
| González, J | 1 |
| Alvarez, MV | 1 |
| Jorge-Herrero, E | 1 |
| Kontny, F | 2 |
| Dale, J | 2 |
| Hegrenaes, L | 2 |
| Lem, P | 2 |
| Søberg, T | 1 |
| Morstøl, T | 2 |
| L-Lacoste, L | 1 |
| Lam, JY | 3 |
| Hung, J | 1 |
| Waters, D | 1 |
| Harker, LA | 10 |
| Korbut, R | 3 |
| Ocetkiewicz, A | 2 |
| Stassen, JM | 5 |
| Rapold, HJ | 2 |
| Vanlinthout, I | 1 |
| Dyken, ML | 1 |
| Vokonas, PS | 1 |
| Hennekens, C | 1 |
| Mehta, P | 1 |
| Mehta, JL | 1 |
| Viganò, G | 1 |
| De Cock, F | 1 |
| Dores, GM | 1 |
| Miller, ME | 1 |
| Thorpe, SL | 1 |
| Kearon, C | 1 |
| Asai, Y | 1 |
| Hirata, Y | 2 |
| Uematsu, T | 4 |
| Nakashima, M | 5 |
| Roderick, PJ | 2 |
| Wilkes, HC | 2 |
| Vesvres, MH | 1 |
| Lalanne, MC | 1 |
| Narita, H | 1 |
| Kaburaki, M | 1 |
| Doi, H | 1 |
| Yasoshima, A | 1 |
| Hall, P | 2 |
| Nakamura, S | 2 |
| Maiello, L | 1 |
| Itoh, A | 2 |
| Blengino, S | 2 |
| Martini, G | 2 |
| Ferraro, M | 2 |
| Kaplon, RJ | 1 |
| Oz, MC | 1 |
| Kwiatkowski, PA | 1 |
| Levin, HR | 1 |
| Shah, AS | 1 |
| Jarvik, RK | 1 |
| Rose, EA | 1 |
| Beaughard, M | 1 |
| Brasset, M | 1 |
| John, G | 1 |
| Massingham, R | 1 |
| Nurden, P | 2 |
| Bihour, C | 1 |
| Smith, M | 1 |
| Raymond, JM | 1 |
| Nurden, AT | 3 |
| Coller, BS | 3 |
| Anderson, K | 1 |
| Goodnight, SH | 1 |
| Etherington, MD | 1 |
| Restifo, RJ | 1 |
| Dumanian, GA | 1 |
| Garrett, KO | 2 |
| Hong, C | 1 |
| Johnson, PC | 3 |
| Blackshear, JL | 1 |
| Baker, VS | 1 |
| Holland, A | 1 |
| Litin, SC | 1 |
| Ahlquist, DA | 1 |
| Ellefson, R | 1 |
| Koehler, J | 1 |
| Mruk, JS | 1 |
| Zoldhelyi, P | 3 |
| Webster, MW | 3 |
| Heras, M | 2 |
| Peters, FP | 1 |
| Doevendans, PA | 1 |
| Erdkamp, FL | 1 |
| Van Der Ent, FW | 1 |
| De Heer, F | 1 |
| Megill, JR | 1 |
| Durham, SK | 1 |
| Nishimura, H | 1 |
| Naritomi, H | 1 |
| Iwamoto, Y | 1 |
| Tachibana, H | 1 |
| Sugita, M | 1 |
| Colwell, JA | 2 |
| Elikowski, W | 1 |
| Psuja, P | 1 |
| Przybył, M | 1 |
| Wendland, M | 1 |
| Wróblewski, D | 1 |
| Jazienicki, B | 1 |
| Przybył, L | 1 |
| Zawilska, K | 1 |
| Hirayama, Y | 1 |
| Koda, H | 1 |
| Nakasawa, O | 1 |
| Kuga, T | 1 |
| Takayanagi, N | 1 |
| Efuku, S | 1 |
| Nobuoka, J | 1 |
| Mochizuki, T | 1 |
| Popiel, M | 1 |
| Grajek, S | 1 |
| Cieśliński, A | 1 |
| Hamers, MJ | 2 |
| Tjønnfjord, GE | 1 |
| Brosstad, FR | 1 |
| Tohgi, H | 1 |
| Watanabe, K | 3 |
| Kuki, H | 1 |
| Shirasawa, Y | 1 |
| Lienhart, Y | 1 |
| Valeix, B | 1 |
| Louvard, Y | 1 |
| Lefevre, T | 2 |
| Guérin, Y | 1 |
| Kaku, S | 1 |
| Kawasaki, T | 1 |
| Hisamichi, N | 1 |
| Sakai, Y | 1 |
| Taniuchi, Y | 1 |
| Inagaki, O | 1 |
| Yano, S | 1 |
| Suzuki, K | 1 |
| Terazaki, C | 1 |
| Masuho, Y | 1 |
| Satoh, N | 1 |
| Takenaka, T | 1 |
| Yanagi, K | 1 |
| Ohshima, N | 1 |
| Rodgers, A | 1 |
| MacMahon, S | 1 |
| Teien, DE | 1 |
| Karp, KH | 1 |
| Eriksson, P | 2 |
| Lip, PL | 1 |
| Zarifis, J | 1 |
| Watson, RD | 1 |
| Beevers, DG | 2 |
| Rai, RS | 1 |
| Regan, L | 1 |
| Chitolie, A | 1 |
| Donald, JG | 1 |
| Cohen, H | 1 |
| Belougne, E | 2 |
| Azougagh Oualane, F | 1 |
| Droy-Lefaix, MT | 1 |
| Iomhair, MM | 2 |
| Lavelle, SM | 3 |
| Teien, D | 1 |
| Karp, K | 1 |
| Maffrand, JP | 2 |
| Gustafsson, D | 1 |
| Lenfors, S | 1 |
| Börjesson, I | 1 |
| Teger-Nilsson, AC | 1 |
| Martín, R | 1 |
| Reininger, A | 1 |
| Litvack, FI | 1 |
| Shah, PK | 5 |
| Forrester, JS | 2 |
| Hutsell, TC | 1 |
| Eigler, NL | 2 |
| Goods, CM | 1 |
| al-Shaibi, KF | 1 |
| Liu, MW | 1 |
| Yadav, JS | 1 |
| Mathur, A | 1 |
| Jain, SP | 1 |
| Dean, LS | 1 |
| Iyer, SS | 1 |
| Parks, JM | 1 |
| Roubin, GS | 1 |
| Markert, T | 1 |
| Bertsch, G | 1 |
| Langenfeld, H | 1 |
| Schanzenbächer, P | 1 |
| Lowe, H | 1 |
| Roy, P | 1 |
| Baron, D | 1 |
| Lachiewicz, PF | 1 |
| Klein, JA | 1 |
| Holleman, JB | 1 |
| Kelley, S | 1 |
| Mariani, M | 1 |
| Biadi, O | 1 |
| Younossi, ZM | 1 |
| Strum, WB | 1 |
| Schatz, RA | 1 |
| Teirstein, PS | 1 |
| Cloutier, DA | 1 |
| Spinks, TJ | 1 |
| Stockmans, F | 1 |
| Vermylen, J | 2 |
| Hoylaerts, MF | 1 |
| Nyström, A | 2 |
| Maugeri, N | 1 |
| Kempfer, AC | 1 |
| Evangelista, V | 1 |
| Baglivo, E | 1 |
| Dosso, A | 1 |
| Pournaras, C | 1 |
| Litvack, F | 1 |
| Ivey, PA | 1 |
| Jordan, RE | 1 |
| Baim, DS | 2 |
| Carrozza, JP | 1 |
| Vasudev, SC | 1 |
| Chandy, T | 2 |
| Sharma, CP | 2 |
| Calvo, F | 1 |
| Barrabés, JA | 1 |
| García-Dorado, D | 1 |
| Peter, FW | 2 |
| Franken, RJ | 1 |
| Wang, WZ | 1 |
| Anderson, GL | 1 |
| Schuschke, DA | 1 |
| O'Shaughnessy, MM | 1 |
| Banis, JC | 1 |
| Steinau, HU | 2 |
| Barker, JH | 2 |
| Kume, S | 1 |
| Huong, DL | 1 |
| Dolmazon, C | 1 |
| De Zuttere, D | 1 |
| Mulder, PG | 1 |
| Waleboer, M | 1 |
| van de Moesdijk, D | 1 |
| Hupkens, P | 1 |
| Keil, Tu | 1 |
| Polasek, J | 1 |
| Shimazawa, M | 1 |
| Takiguchi, Y | 3 |
| Laperche, T | 1 |
| Laurian, C | 1 |
| Roudaut, R | 1 |
| Granger, KA | 1 |
| Farquharson, RG | 1 |
| Bangerter, M | 1 |
| Leenknegt, H | 1 |
| Wehmeier, A | 1 |
| Südhoff, T | 1 |
| Meierkord, F | 1 |
| Manning, WJ | 1 |
| Kleiman, N | 1 |
| Runyon, JP | 1 |
| Broderick, TM | 1 |
| Higby, NA | 1 |
| Martin, LH | 1 |
| Hantsbarger, G | 1 |
| McDonald, S | 1 |
| Anders, RJ | 1 |
| Willoughby, SJ | 1 |
| Fairhead, S | 1 |
| Pearson, TC | 2 |
| Hoffmann, P | 2 |
| Sugimura, S | 1 |
| Ozawa, K | 1 |
| Iriyama, T | 1 |
| Hattori, Y | 1 |
| Sai, N | 1 |
| Terano, T | 1 |
| Hirai, A | 1 |
| Shiina, T | 1 |
| Tamura, Y | 1 |
| Saitoh, Y | 1 |
| Miyazaki, K | 1 |
| Higashihara, M | 1 |
| Peverill, RE | 2 |
| Harper, RW | 1 |
| Smolich, JJ | 1 |
| Hillis, GS | 1 |
| Jennings, KP | 1 |
| Monassier, JP | 1 |
| Elias, J | 1 |
| Spaulding, C | 1 |
| Raynaud, P | 1 |
| Cribier, A | 1 |
| Barragan, P | 2 |
| Juliard, JM | 1 |
| Faugier, JP | 1 |
| Masquet, C | 1 |
| Rioux, P | 1 |
| Bedossa, M | 1 |
| Petiteau, PY | 1 |
| Royer, T | 1 |
| Roriz, R | 1 |
| Meyer, P | 1 |
| Blanchard, D | 1 |
| Khalifé, K | 1 |
| Wheeldon, N | 1 |
| Cumberland, D | 1 |
| Krnic-Barrie, S | 1 |
| O'Connor, CR | 1 |
| Looney, SW | 1 |
| Pierangeli, SS | 1 |
| Harris, EN | 1 |
| Prentice, CR | 4 |
| López-Farré, A | 2 |
| Wolf, DC | 1 |
| Freni, MA | 1 |
| Boccagni, P | 1 |
| Mor, E | 1 |
| Chodoff, L | 1 |
| Birnbaum, A | 1 |
| Miller, CM | 1 |
| Schwartz, ME | 1 |
| Bodenheimer, HC | 1 |
| Byrne, A | 1 |
| Moran, N | 1 |
| Maher, M | 1 |
| Walsh, N | 1 |
| Crean, P | 1 |
| Schneider, MC | 1 |
| Caliezi, C | 1 |
| Seeberger, MD | 1 |
| Iturbe, T | 1 |
| Sánchez, C | 1 |
| Moreno, JA | 1 |
| Olave, T | 1 |
| Azaceta, G | 1 |
| Varo, MJ | 1 |
| Civeira, E | 1 |
| Peleato, J | 1 |
| Cornudella, R | 1 |
| Ott, I | 1 |
| Walter, H | 1 |
| Anzuini, A | 1 |
| Rosanio, S | 1 |
| Legrand, V | 1 |
| Tocchi, M | 1 |
| Coppi, R | 1 |
| Bonnier, H | 1 |
| Sheiban, I | 1 |
| Kulbertus, HE | 1 |
| Choi, IY | 1 |
| Park, MR | 1 |
| Park, TS | 1 |
| Cho, JL | 1 |
| Farré, J | 1 |
| Sánchez de Miguel, L | 1 |
| Romero, J | 1 |
| Gómez, J | 1 |
| Rico, L | 1 |
| Casado, S | 1 |
| Willoughby, S | 1 |
| Salat, A | 1 |
| Boehm, D | 1 |
| Pulaki, S | 1 |
| Murabito, M | 1 |
| Berlakovich, G | 1 |
| Kretschmer, G | 1 |
| Mueller, MR | 1 |
| Thiel, R | 1 |
| Kahn, T | 1 |
| Vögeli, TA | 1 |
| Schneider, D | 1 |
| Machtens, SA | 1 |
| Kuczyk, MA | 1 |
| Becker, AJ | 1 |
| Stief, CG | 1 |
| Jonas, U | 1 |
| Buchmann, M | 1 |
| Stormorken, H | 4 |
| Muzii, L | 1 |
| Marana, R | 1 |
| Brunetti, L | 1 |
| Margutti, F | 1 |
| Vacca, M | 1 |
| Mancuso, S | 1 |
| Belougne-Malfatti, E | 1 |
| Hayes, RM | 1 |
| Meraj, P | 1 |
| Ambrose, JA | 1 |
| Marmur, JD | 2 |
| Bossavy, JP | 3 |
| Sagnard, L | 2 |
| Barret, A | 1 |
| Frederick, LG | 1 |
| Taite, BB | 1 |
| King, LW | 1 |
| Feigen, LP | 2 |
| Asakura, H | 2 |
| Jokaji, H | 2 |
| Uotani, C | 2 |
| Kumabashiri, I | 2 |
| Morishita, E | 2 |
| Aoshima, K | 1 |
| Matsuda, T | 3 |
| Dol, F | 1 |
| Lalé, A | 2 |
| Graf, S | 1 |
| Beckmann, R | 1 |
| Hornykewycz, S | 1 |
| Schuster, E | 1 |
| Binder, BR | 1 |
| Saucedo, J | 1 |
| Pichard, AD | 2 |
| Kent, KM | 2 |
| Marzec, UM | 1 |
| Kelly, AB | 2 |
| Chronos, NR | 1 |
| Sundell, IB | 1 |
| Hanson, SR | 1 |
| Koide, M | 1 |
| Matsuo, T | 3 |
| Popma, JJ | 1 |
| Gordon, PC | 1 |
| Ho, KK | 1 |
| Giambartolomei, A | 1 |
| Diver, DJ | 1 |
| Lasorda, DM | 1 |
| Williams, DO | 1 |
| Pocock, SJ | 1 |
| Kuntz, RE | 1 |
| Ennamany, R | 1 |
| Bingen, A | 1 |
| Creppy, EE | 1 |
| Kretz, O | 1 |
| Gut, JP | 1 |
| Dubuisson, L | 1 |
| Balabaud, C | 1 |
| Bioulac Sage, P | 1 |
| Kirn, A | 1 |
| Shen, ZQ | 1 |
| Liang, Y | 1 |
| Chen, ZH | 1 |
| Liu, WP | 1 |
| Duan, L | 1 |
| Streif, W | 1 |
| South, M | 1 |
| Leaker, M | 1 |
| Calver, AL | 1 |
| Gray, HH | 1 |
| Haywood, GA | 1 |
| Morgan, JM | 1 |
| Simpson, IA | 1 |
| Cleland, JG | 1 |
| Alamgir, F | 1 |
| Kotulak, GD | 1 |
| Wilson, SH | 1 |
| Rihal, CS | 1 |
| Bell, MR | 1 |
| Velianou, JL | 1 |
| Nagamatsu, Y | 2 |
| Tsujioka, Y | 1 |
| Hashimoto, M | 1 |
| Giddings, JC | 1 |
| Yamamoto, J | 2 |
| Ferrer, F | 1 |
| Moraleda, JM | 1 |
| Lockyer, S | 1 |
| Kambayashi, J | 2 |
| Boysen, G | 3 |
| Matsuno, H | 3 |
| Kozawa, O | 1 |
| Nagashima, S | 1 |
| Kanamaru, M | 1 |
| Fuglsang, J | 1 |
| Ravn, HB | 1 |
| Toft, GE | 1 |
| Thorwest, M | 1 |
| Hjortdal, VE | 1 |
| Li, N | 1 |
| Wallén, NH | 1 |
| Patel, A | 1 |
| Toomey, JR | 1 |
| Bugelski, P | 1 |
| Nichols, AJ | 1 |
| Church, WR | 1 |
| Valocik, R | 1 |
| Koster, P | 1 |
| Baker, A | 1 |
| Blackburn, MN | 1 |
| Jafary, FH | 1 |
| Kimmelstiel, CD | 1 |
| Silverstein, MN | 1 |
| Bergmann, L | 1 |
| Pearson, T | 1 |
| Lindblad, B | 1 |
| Nakai, K | 1 |
| Tajima, K | 1 |
| Kishimoto, Y | 1 |
| Katsura, K | 1 |
| Yamamoto, Y | 1 |
| Hanada, M | 1 |
| Zen, K | 1 |
| Amakawa, R | 1 |
| Fujimoto, M | 1 |
| Fukuhara, S | 1 |
| Tsuyuki, RT | 1 |
| Walters, B | 1 |
| Yim, R | 1 |
| Teo, KK | 1 |
| Ogawa, T | 1 |
| Naganuma, H | 1 |
| Osende, JI | 1 |
| Padurean, A | 1 |
| Rodriguez, OX | 1 |
| Igawa, T | 1 |
| Kornhauser, R | 1 |
| Cilla, DD | 1 |
| King, JO | 1 |
| Rossi, C | 1 |
| Fabris, F | 1 |
| Menapace, L | 1 |
| Girolami, A | 1 |
| Sukavaneshvar, S | 1 |
| Solen, KA | 1 |
| Mohammad, SF | 1 |
| Younis, JS | 2 |
| Ohel, G | 1 |
| Haddad, S | 1 |
| Lanir, N | 1 |
| Ben-Ami, M | 1 |
| Li-Saw-Hee, FL | 1 |
| Piette, AM | 1 |
| Blétry, O | 2 |
| Tangelder, MJ | 1 |
| Eikelboom, BC | 1 |
| Guilmot, JL | 2 |
| Diot, E | 1 |
| Gruel, Y | 2 |
| Cissé-Thiam, M | 1 |
| Hayes, R | 1 |
| Taha, R | 2 |
| White, SA | 1 |
| Horsburgh, T | 1 |
| Nicholson, ML | 2 |
| Kobza, II | 1 |
| Hoffman, R | 1 |
| Blumenfeld, Z | 1 |
| Weiner, Z | 1 |
| Momi, S | 1 |
| Paul, W | 1 |
| Leone, M | 1 |
| Mezzasoma, AM | 1 |
| Page, CP | 1 |
| Gresele, P | 1 |
| Kennon, S | 1 |
| Barakat, K | 1 |
| Suliman, A | 1 |
| MacCallum, PK | 1 |
| Ranjadayalan, K | 1 |
| Wilkinson, P | 1 |
| Timmis, AD | 1 |
| Camehn, R | 1 |
| Rehse, K | 1 |
| Kolansky, DM | 1 |
| Klugherz, BD | 1 |
| Curran, SC | 1 |
| Herrmann, HC | 1 |
| Magness, K | 1 |
| Wilensky, RL | 1 |
| Hirshfeld, JW | 1 |
| Ragni, M | 1 |
| Cirillo, P | 1 |
| Scognamiglio, A | 1 |
| Piro, O | 1 |
| Esposito, N | 1 |
| Battaglia, C | 1 |
| Botticella, F | 1 |
| Ponticelli, P | 1 |
| Ramunno, L | 1 |
| Chiariello, M | 1 |
| Wahl, DG | 1 |
| Sarasin, FP | 2 |
| Kaburaki, J | 1 |
| Kuwana, M | 1 |
| Madi, A | 1 |
| Plavec, M | 1 |
| Nawaz, H | 1 |
| Katz, DL | 1 |
| Tani, S | 1 |
| Kangavari, S | 1 |
| Dimayuga, P | 1 |
| Yano, J | 1 |
| Chyu, KY | 1 |
| Fishbein, MC | 1 |
| Cercek, B | 1 |
| Roque, C | 1 |
| Zamboni, G | 1 |
| Malfatti, E | 2 |
| Poliantsev, AA | 1 |
| Mozgovoĭ, PV | 1 |
| Karpenko, AV | 1 |
| Shcherbakov, VN | 1 |
| Kuznetsov, VI | 1 |
| Khomutnikova, AI | 1 |
| Kirichenko, OM | 1 |
| Schweizer, J | 1 |
| Kirch, W | 1 |
| Koch, R | 1 |
| Müller, A | 1 |
| Hellner, G | 1 |
| Forkmann, L | 1 |
| Buchanan, MR | 1 |
| Schwartz, L | 1 |
| Bourassa, M | 1 |
| Brister, SJ | 1 |
| Peniston, CM | 1 |
| McAnulty, JH | 1 |
| Shechter, M | 1 |
| Merz, CN | 1 |
| Paul-Labrador, M | 1 |
| Meisel, SR | 1 |
| Rude, RK | 1 |
| Molloy, MD | 1 |
| Dwyer, JH | 1 |
| Coller, B | 1 |
| Dalen, JE | 3 |
| Gent, M | 4 |
| Roth, G | 1 |
| Murphy, GJ | 1 |
| Windmill, DC | 1 |
| Metcalfe, M | 1 |
| Curry, BH | 1 |
| Paliou, M | 1 |
| Skerrett, PJ | 1 |
| Buring, JE | 1 |
| Ramsay, LE | 1 |
| Sanmuganathan, PS | 1 |
| Wallis, EJ | 1 |
| Jackson, PR | 1 |
| Naber, CK | 1 |
| Kaiser, CA | 1 |
| Rahman, YA | 1 |
| Haude, M | 1 |
| Edmunds, E | 1 |
| Mittal, SR | 1 |
| Castellino, G | 1 |
| Godfrey, T | 1 |
| Hutten, BA | 1 |
| Plokker, HW | 1 |
| Fang, M | 1 |
| Agha, S | 1 |
| Lockridge, L | 1 |
| Cleary, JP | 1 |
| Mazur, EM | 1 |
| Nair, GV | 1 |
| Davis, CJ | 1 |
| McKenzie, ME | 1 |
| Lowry, DR | 1 |
| Walenga, JM | 1 |
| Hoppensteadt, D | 1 |
| Pifarré, R | 1 |
| Fox, NL | 1 |
| Forman, S | 1 |
| Hunninghake, DB | 1 |
| Campeau, L | 1 |
| Herd, JA | 1 |
| Hoogwerf, BJ | 1 |
| Hickey, A | 1 |
| Probstfield, JL | 1 |
| Terrin, ML | 1 |
| Merrill, JT | 1 |
| Buyon, JP | 1 |
| Rowan, JA | 1 |
| McCowan, LM | 1 |
| Raudkivi, PJ | 1 |
| North, RA | 1 |
| Clutton, P | 1 |
| Folts, JD | 1 |
| Joseph, JE | 1 |
| Mackie, IJ | 1 |
| Isenberg, DA | 1 |
| Machin, SJ | 1 |
| McGeer, PL | 1 |
| McGeer, EG | 1 |
| Yasojima, K | 1 |
| Ikeda, U | 1 |
| Shimada, K | 1 |
| Conrad, MH | 1 |
| Adams, WP | 1 |
| Black, C | 1 |
| Paterson, KR | 1 |
| Dulitzki, M | 1 |
| Livneh, A | 1 |
| Kenett, R | 1 |
| Many, A | 1 |
| Xiu, Q | 1 |
| Sun, J | 1 |
| Hong, E | 1 |
| Ndoko, S | 1 |
| Teuma, X | 1 |
| Botosezzy, I | 1 |
| Bouvier, JL | 1 |
| Comet, B | 1 |
| Commeau, P | 1 |
| Macaluso, G | 1 |
| Roquebert, PO | 1 |
| Haulon, S | 1 |
| Susen, S | 1 |
| Koussa, M | 1 |
| Jude, B | 1 |
| Roisinblit, JM | 1 |
| Allende, NG | 1 |
| Neira, JA | 1 |
| Torino, AF | 1 |
| Karmazyn, C | 1 |
| Pardo, P | 1 |
| Scattini, G | 1 |
| Hoppe, UC | 1 |
| Peschon, JJ | 1 |
| Stocking, KL | 1 |
| Ramasamy, R | 1 |
| Connolly, ES | 1 |
| Kiss, S | 1 |
| Choudhri, TF | 1 |
| McTaggart, RA | 1 |
| Liao, H | 1 |
| Price, VL | 1 |
| Maliszewski, CR | 1 |
| Roubey, RA | 1 |
| Benkovic, C | 1 |
| Muehlberger, T | 1 |
| Vogt, PM | 1 |
| Homann, HH | 1 |
| Kuhnen, C | 1 |
| Wiebalck, A | 1 |
| Hsiao, G | 1 |
| Yen, MH | 1 |
| Lee, YM | 1 |
| Fasey, N | 1 |
| Brennan, PJ | 2 |
| Little, JW | 1 |
| McIntosh, BA | 1 |
| Caprino, L | 1 |
| Borrelli, F | 1 |
| Falchetti, R | 1 |
| Cafiero, C | 1 |
| Gandolfo, GM | 1 |
| Loo, J | 1 |
| Faergeman, O | 1 |
| Gormsen, J | 1 |
| Meinertz, H | 1 |
| Stahl, D | 2 |
| Thomsen, K | 2 |
| Hou-Jensen, K | 2 |
| Boughton, BJ | 1 |
| Allington, MJ | 1 |
| King, A | 1 |
| Harter, HR | 1 |
| Burch, JW | 1 |
| Majerus, PW | 1 |
| Stanford, N | 1 |
| Anderson, CB | 1 |
| Weerts, CA | 1 |
| Yasunaga, K | 2 |
| Garcia Rafanell, J | 1 |
| Planas, JM | 1 |
| Puig-Parellada, P | 1 |
| Ranft, K | 1 |
| Brands, W | 1 |
| Coeugniet, E | 1 |
| Didisheim, P | 3 |
| Witczak, W | 1 |
| Badowski, A | 1 |
| Zaraś, T | 1 |
| Baumgartner, HR | 2 |
| Wessler, S | 1 |
| Gitel, SN | 1 |
| Frick, U | 1 |
| Frick, G | 1 |
| Aosaki, M | 1 |
| Kitamura, N | 1 |
| Weissbach, G | 1 |
| Bedford, RF | 1 |
| Ashford, TP | 1 |
| De Mey, C | 1 |
| Wellens, D | 1 |
| Vanhoutte, PM | 1 |
| Gingrich, RD | 1 |
| Amezcua, JL | 2 |
| Zimmerman, R | 1 |
| Weckesser, G | 1 |
| Dmoszyńska-Giannopoulou, A | 1 |
| Pluta, A | 1 |
| McGiff, JC | 1 |
| Schöndorf, TH | 3 |
| Hey, D | 2 |
| Slichter, SJ | 2 |
| Sauvage, LR | 3 |
| Oelz, O | 1 |
| Gent, A | 1 |
| Ingram, GI | 1 |
| Arocha-Piñango, CL | 1 |
| Fenton, P | 1 |
| Buckley, RJ | 1 |
| Haas, S | 1 |
| Fritsche, HM | 2 |
| Ketterl, R | 2 |
| Leimgruber, D | 2 |
| Blümel, G | 2 |
| Myers, TJ | 1 |
| Steinberg, WM | 1 |
| Rickles, FR | 1 |
| Silvestri, G | 1 |
| Spanos, HG | 1 |
| Hecker, JF | 1 |
| Vergroesen, AJ | 1 |
| Gottenbos, JJ | 1 |
| ten Hoor, F | 1 |
| Follea, G | 1 |
| Trzeciak, MC | 1 |
| Kovács, IB | 3 |
| Collins, GJ | 1 |
| Rich, NM | 1 |
| Kauffman, HM | 1 |
| Ekbom, GA | 1 |
| Adams, MB | 1 |
| Hussey, CV | 1 |
| Bruhn, HD | 1 |
| Vera, JC | 1 |
| Fassolt, A | 1 |
| Brändli, F | 1 |
| Braun, U | 1 |
| Dalldorf, FG | 1 |
| Jennette, JC | 1 |
| Umetsu, T | 1 |
| Sanai, K | 1 |
| Rodvien, R | 1 |
| Honour, AJ | 2 |
| Carter, RD | 1 |
| Mann, JI | 2 |
| Clarke, AK | 1 |
| Meng, K | 2 |
| Seuter, F | 1 |
| Jobin, F | 1 |
| Uzunova, AD | 2 |
| Ramey, ER | 2 |
| Ramwell, PW | 2 |
| Thomas, CY | 1 |
| Lyman, BT | 1 |
| Johnson, GJ | 1 |
| White, JG | 2 |
| Schlosshardt, H | 1 |
| Vaisrub, S | 1 |
| Pasotti, C | 1 |
| Capra, A | 1 |
| Pokrovskii, AV | 1 |
| Aleksandrova, NP | 1 |
| Kovalenko, VI | 1 |
| Fernández B de Quirós, J | 1 |
| Dulp-Gollasch, I | 1 |
| Hess, H | 1 |
| Parsons, M | 1 |
| Deykin, D | 3 |
| Genton, E | 4 |
| Scharrer, I | 2 |
| Gavrilov, OK | 1 |
| Rachinskaia, NA | 1 |
| Kaveshnikova, BF | 1 |
| Zekert, F | 2 |
| Kohn, P | 1 |
| Vormittag, E | 1 |
| Loew, D | 6 |
| Zeitler, E | 1 |
| Rodvein, R | 1 |
| Cooke, AR | 1 |
| Aledort, LM | 2 |
| Cohen, LS | 1 |
| Mason, RG | 3 |
| Wolf, RH | 1 |
| Zucker, WH | 2 |
| Shinoda, BA | 3 |
| Roba, J | 1 |
| Claeys, M | 1 |
| Lambelin, G | 1 |
| Köhler, H | 1 |
| Levison, ME | 1 |
| Carrizosa, J | 1 |
| Tanphaichitra, D | 1 |
| Schick, PK | 1 |
| Rubin, W | 1 |
| Hockaday, TD | 1 |
| Ehresmann, U | 1 |
| Alemany, J | 1 |
| Boehme, K | 1 |
| Artik, N | 1 |
| Friedman, EW | 1 |
| Frank, HA | 1 |
| Ponn, R | 1 |
| Weber, U | 1 |
| Lasch, HG | 1 |
| Moore, S | 1 |
| Arfors, KE | 1 |
| Lipinski, B | 1 |
| Danilevicius, Z | 1 |
| Gschwend, J | 1 |
| Encke, A | 1 |
| Stock, C | 1 |
| Dumke, HO | 1 |
| Kelly, G | 1 |
| Eiseman, B | 2 |
| Zieboll, L | 1 |
| Barth, P | 2 |
| Lange, D | 2 |
| Heuchel, G | 1 |
| Hässler, W | 1 |
| Baulande, M | 1 |
| Baulande, G | 1 |
| Tournay, R | 1 |
| Benis, AM | 1 |
| Nossel, HL | 1 |
| Koffsky, RM | 1 |
| Stevenson, JF | 1 |
| Leonard, EF | 1 |
| Shiang, H | 1 |
| Litwak, RS | 1 |
| Gabuzda, TG | 1 |
| Szydlowski, S | 1 |
| Poulos, E | 1 |
| Castaldi, PA | 1 |
| Kelly, GL | 1 |
| Ben Ismail, M | 1 |
| Ghariani, M | 1 |
| Jais, JM | 1 |
| Fregnan, GB | 1 |
| Chieli, T | 1 |
| Eisen, M | 1 |
| Napp, HE | 1 |
| Vock, R | 1 |
| Pevine, PL | 1 |
| Ikematsu, S | 1 |
| Itoh, O | 2 |
| Samori, T | 1 |
| Hosokawa, T | 1 |
| Guccione, MA | 1 |
| MacIomhair, M | 1 |
| Zieboll, J | 1 |
| Hetzer, R | 1 |
| Dragojevic, D | 1 |
| Bender-Götze, C | 1 |
| Suschke, J | 1 |
| Polterauer, P | 1 |
| Gottlob, R | 1 |
| Ries, CA | 1 |
| Manoharan, A | 2 |
| Krupiński, K | 2 |
| Bielawiec, M | 1 |
| Płonowski, A | 1 |
| Giedrojc, J | 2 |
| Kudriashov, BA | 1 |
| Pastorova, VE | 1 |
| Liapina, LA | 1 |
| Kondashevskaia, MV | 1 |
| Wada, K | 2 |
| Harker, LB | 1 |
| Hifumi, S | 1 |
| Shibata, K | 1 |
| Mizuhashi, K | 1 |
| Roche, PC | 1 |
| Ishii, I | 1 |
| Sasaki, Y | 1 |
| Ando, E | 1 |
| Vreys, I | 1 |
| Lesaffre, E | 1 |
| Dzwierzynski, W | 1 |
| Gruel, SM | 1 |
| Hall, RL | 1 |
| Wright, RR | 1 |
| O'Brien, EM | 1 |
| Fagan, D | 1 |
| Hanel, DP | 1 |
| Gould, JS | 3 |
| Kario, K | 1 |
| Tai, S | 1 |
| Yamada, T | 2 |
| Miki, T | 1 |
| Matsuo, M | 1 |
| Haas, SB | 1 |
| Tribus, CB | 1 |
| Insall, JN | 1 |
| Becker, MW | 1 |
| Windsor, RE | 1 |
| Bonnin, P | 1 |
| Bonneau, M | 1 |
| Pignaud, G | 1 |
| Mazoyer, E | 1 |
| Bailliart, O | 1 |
| Viars, P | 1 |
| Drouet, LO | 1 |
| Laraki, R | 1 |
| Cosserat, J | 1 |
| Kelleher, CC | 1 |
| Plotkine, M | 1 |
| Allix, M | 1 |
| Guillou, J | 1 |
| Boulu, R | 1 |
| Wagner, WR | 1 |
| Hubbell, JA | 1 |
| Ratnatunga, CP | 1 |
| Edmondson, SF | 1 |
| Rees, GM | 1 |
| Gameiro, L | 1 |
| Pariente, EA | 1 |
| Dupuis, E | 1 |
| Gervais, T | 1 |
| Viala, JF | 1 |
| Trinh, DH | 1 |
| Mellott, MJ | 1 |
| Holahan, MA | 1 |
| Lynch, JJ | 1 |
| Dunwiddie, CT | 1 |
| Brash, JL | 1 |
| Cornelius, RM | 1 |
| Kaplan, SS | 1 |
| Warty, V | 1 |
| Butler, KD | 1 |
| Ambler, J | 1 |
| Dolan, S | 1 |
| Giddings, J | 1 |
| Talbot, MD | 1 |
| Wallis, RB | 1 |
| Rosove, MH | 1 |
| Brewer, PM | 1 |
| Mobarok Ali, AT | 1 |
| al-Humayyd, MS | 1 |
| Gervasi, GB | 1 |
| Bartoli, C | 1 |
| Carpita, G | 1 |
| Font, J | 1 |
| López-Soto, A | 1 |
| Pallarés, L | 1 |
| Navarro, M | 1 |
| Bosch, X | 1 |
| Ingelmo, M | 1 |
| Cola, C | 1 |
| Scriven, AJ | 1 |
| Lidbury, PS | 1 |
| Nathan, AW | 1 |
| Savoie, FH | 1 |
| Lermusiaux, P | 1 |
| Lang, M | 1 |
| Darnige, L | 1 |
| Rupin, A | 1 |
| Delahousse, B | 1 |
| Leroy, J | 1 |
| Ohtsuka, Y | 1 |
| Doi, I | 1 |
| Aoi, K | 1 |
| Hiraga, T | 1 |
| Munakata, M | 1 |
| Kawakami, Y | 1 |
| Norden, C | 2 |
| Reimann, H | 1 |
| Grunow, G | 1 |
| Misselwitz, F | 2 |
| Rübsamen, K | 1 |
| Eschenfelder, V | 1 |
| Salemark, L | 2 |
| Wieslander, JB | 2 |
| Dougan, P | 2 |
| Arnljots, B | 2 |
| Ferlito, S | 1 |
| Willich, SN | 1 |
| Muller, JE | 1 |
| Hennekens, CH | 1 |
| Vial, JH | 1 |
| McLeod, LJ | 1 |
| Roberts, MS | 1 |
| Steele, PM | 1 |
| Tønnesen, KH | 1 |
| Holstein, P | 1 |
| Andersen, E | 1 |
| Mase, K | 1 |
| Mantz, F | 1 |
| Freund, M | 1 |
| Scheffer, MG | 1 |
| Simoons, ML | 1 |
| Roelandt, JR | 1 |
| Vecchio, C | 1 |
| Chiarella, F | 1 |
| Lupi, G | 1 |
| Bellotti, P | 1 |
| Domenicucci, S | 1 |
| Ip, JH | 1 |
| Minkhorst, AG | 1 |
| Nováková, IR | 1 |
| van Dongen, PW | 1 |
| Wu, ZM | 1 |
| Nijs, H | 1 |
| Motro, M | 1 |
| Barbash, GI | 1 |
| Roth, A | 1 |
| Kaplinsky, E | 1 |
| Laniado, S | 1 |
| Keren, G | 1 |
| Breckwoldt, WL | 1 |
| Belkin, M | 1 |
| Gould, K | 1 |
| Allen, M | 1 |
| Connolly, RJ | 1 |
| Termin, P | 1 |
| Wehrmacher, WH | 1 |
| Domoto, DT | 1 |
| Bauman, JE | 1 |
| Joist, JH | 2 |
| Goldstein, R | 1 |
| Clark, P | 1 |
| Klintmalm, G | 1 |
| Husberg, B | 1 |
| Gonwa, T | 1 |
| Stone, M | 1 |
| Kessler, CM | 1 |
| Lekstrom, JA | 1 |
| Bell, WR | 1 |
| Landymore, RW | 1 |
| MacAulay, MA | 1 |
| Fris, J | 1 |
| Lieberman, RP | 1 |
| Lund, GB | 1 |
| Dong, E | 1 |
| Shi, S | 1 |
| Kraev, Z | 1 |
| Baldev, TS | 1 |
| Dabros, W | 1 |
| Markov, KhM | 1 |
| Müller, TH | 1 |
| Su, CA | 1 |
| Weisenberger, H | 1 |
| Brickl, R | 1 |
| Nehmiz, G | 1 |
| Eisert, WG | 1 |
| Sigwart, U | 1 |
| Berg, KJ | 1 |
| Bratvedt, A | 1 |
| Nygaard, B | 1 |
| Kohno, Y | 1 |
| Sternon, J | 1 |
| Orekhova, NM | 1 |
| Akchurin, RS | 1 |
| Belyaev, AA | 1 |
| Smirnov, MD | 1 |
| Ragimov, SE | 1 |
| Orekhov, AN | 1 |
| Kornalík, F | 1 |
| Krupski, WC | 1 |
| Bass, A | 1 |
| Anderson, JS | 1 |
| Kappa, JR | 2 |
| Fisher, CA | 2 |
| Berkowitz, HD | 2 |
| Cottrell, ED | 2 |
| Addonizio, VP | 2 |
| Sobel, M | 1 |
| Ellison, N | 1 |
| Saniabadi, AR | 1 |
| Madhok, R | 1 |
| Spowart, K | 1 |
| Shaw, B | 1 |
| Barbenel, JC | 1 |
| Forbes, CD | 3 |
| Salzer, M | 1 |
| Frank, P | 1 |
| Blauensteiner, W | 1 |
| Shoenfeld, NA | 1 |
| Yeager, A | 1 |
| Connolly, R | 1 |
| Ramberg, K | 1 |
| Forgione, L | 1 |
| Giorgio, A | 1 |
| Valeri, CR | 1 |
| Callow, AD | 1 |
| Nand, S | 1 |
| Robinson, JA | 1 |
| Bekemeier, H | 1 |
| Hirschelmann, R | 1 |
| Mazzaferro, V | 1 |
| Esquivel, CO | 1 |
| Makowka, L | 1 |
| Belle, S | 1 |
| Kahn, D | 1 |
| Koneru, B | 1 |
| Scantlebury, VP | 1 |
| Stieber, AC | 1 |
| Todo, S | 1 |
| Tzakis, AG | 1 |
| Salem, HH | 1 |
| Haskel, EJ | 1 |
| Adams, SP | 1 |
| Saffitz, JE | 1 |
| Gorczynski, RJ | 1 |
| Sobel, BE | 1 |
| Ahmadi, R | 1 |
| Dudczak, R | 1 |
| Ehringer, H | 1 |
| Virgolini, I | 1 |
| Fitscha, P | 1 |
| Kaliman, J | 1 |
| Vogel, GM | 1 |
| Meuleman, DG | 1 |
| Bourgondiën, FG | 1 |
| Hobbelen, PM | 1 |
| Meuwissen, OJ | 1 |
| Rodríguez, V | 2 |
| Bichille, SK | 1 |
| Joshi, VR | 1 |
| Johannessen, KA | 1 |
| Taulow, E | 1 |
| Osterud, B | 1 |
| von der Lippe, G | 1 |
| Küpper, AJ | 1 |
| Peels, CH | 1 |
| Galema, TW | 1 |
| den Hollander, W | 1 |
| Roos, JP | 1 |
| Ueda, M | 1 |
| Shibata, N | 1 |
| Miyazaki, Y | 1 |
| Miura, M | 1 |
| Miyazawa, Y | 1 |
| Komatsu, Y | 1 |
| Stein, B | 1 |
| Israel, DH | 1 |
| Madsen, JK | 1 |
| Pedersen, F | 1 |
| Amtoft, A | 1 |
| Deding, A | 1 |
| Grande, P | 1 |
| Hansen, JN | 1 |
| Hilden, M | 1 |
| Hornum, I | 1 |
| Jensen, T | 1 |
| Lindskov, J | 1 |
| Silver, MJ | 3 |
| Terres, W | 1 |
| Beythien, C | 1 |
| Kupper, W | 1 |
| Bleifeld, W | 1 |
| Stock, E | 1 |
| Rado, Iu | 1 |
| Chikvashvili, DI | 1 |
| Seiffge, D | 2 |
| Weithmann, KU | 2 |
| Escudero-Vela, MC | 1 |
| del Moral, JH | 1 |
| Galletti, G | 1 |
| Gogolewski, S | 1 |
| Ussia, G | 1 |
| Farruggia, F | 1 |
| Mashburn, JP | 1 |
| McCarthy, PM | 1 |
| Dewanjee, MK | 1 |
| Chikahira, Y | 1 |
| Kadowaki, S | 1 |
| Frølund, F | 1 |
| Greer, IA | 1 |
| Walker, JJ | 1 |
| Calder, AA | 1 |
| Gelman, JS | 1 |
| Mehta, J | 1 |
| Strano, A | 2 |
| Cannizzaro, S | 1 |
| Giubilato, A | 1 |
| Numano, F | 2 |
| Koyama, T | 1 |
| Spranger, M | 1 |
| Aspey, BS | 1 |
| Hunter, TJ | 1 |
| Falkow, LJ | 1 |
| Evancho, MM | 1 |
| Sharp, WV | 1 |
| Weselcouch, EO | 1 |
| Humphrey, WR | 1 |
| Aiken, JW | 1 |
| Kobayashi, N | 2 |
| Takada, M | 1 |
| Andou, K | 1 |
| Maekawa, T | 2 |
| Hayashida, N | 1 |
| Niikura, H | 1 |
| Eckstein, HH | 1 |
| Müller-Bühl, U | 1 |
| Diehm, C | 1 |
| Whitlock, JA | 1 |
| Janco, RL | 1 |
| Sørensen, PS | 1 |
| Juhler, M | 1 |
| Andersen, AR | 1 |
| Boas, J | 1 |
| Olsen, JS | 1 |
| Joensen, P | 1 |
| Lindsay, LA | 1 |
| Olson, RW | 1 |
| Sakane, Y | 1 |
| Ghai, R | 1 |
| Smith, EF | 1 |
| Curl, GR | 1 |
| Bush, HL | 1 |
| Lane, I | 1 |
| Meek, A | 1 |
| Poskitt, K | 1 |
| McCollum, C | 1 |
| Rubin, PC | 1 |
| Horn, L | 1 |
| Decuyper, K | 1 |
| Braquet, P | 1 |
| Zeumer, H | 1 |
| Ferbert, A | 1 |
| Brückmann, H | 1 |
| del Zoppo, GJ | 1 |
| DeCampli, WM | 1 |
| Mitchell, RS | 1 |
| Handen, CE | 1 |
| Cerillo, A | 1 |
| Donzelli, R | 1 |
| Donati, PA | 1 |
| Vizioli, L | 1 |
| Cantatore, G | 1 |
| Maio, N | 1 |
| Villano, M | 1 |
| Perla, N | 1 |
| Muras, I | 1 |
| Botindari, G | 1 |
| Catalano, I | 1 |
| Rehr, RB | 1 |
| DiSciascio, G | 1 |
| Cowley, MJ | 1 |
| Stampfer, MJ | 1 |
| Faigel, D | 1 |
| Stalder, M | 1 |
| Bachmann, F | 1 |
| Sas, G | 1 |
| Pujadas, R | 1 |
| Escrivá, E | 1 |
| Fernández, F | 1 |
| Jané, J | 1 |
| Argimón, J | 1 |
| Fava, P | 1 |
| Galera, MC | 1 |
| Hornstra, G | 2 |
| Baker, RI | 1 |
| Argiolu, F | 1 |
| Marongiu, L | 1 |
| Pinna, DC | 1 |
| Rao, GH | 2 |
| Herd, CM | 1 |
| Rodgers, SE | 1 |
| Lloyd, JV | 1 |
| Bochner, F | 1 |
| Duncan, EM | 1 |
| Tunbridge, LJ | 1 |
| Harris, PL | 1 |
| Makhoul, RG | 2 |
| McCann, RL | 2 |
| Austin, EH | 1 |
| Greenberg, CS | 2 |
| Lowe, JE | 1 |
| Kaplan, S | 1 |
| Marcoe, KF | 1 |
| Zammit, M | 1 |
| Wu, HD | 1 |
| Mathisen, SR | 1 |
| Walker, MW | 1 |
| Fujimoto, T | 1 |
| Yamazaki, H | 1 |
| Kakkar, VV | 1 |
| Thibert, MR | 1 |
| Carroll, SE | 1 |
| Eichler, HG | 1 |
| Jäger, U | 1 |
| Lechner, K | 1 |
| Kempczinski, RF | 1 |
| Ramalanjaona, GR | 1 |
| Douville, C | 1 |
| Silberstein, EB | 1 |
| Ruas, EJ | 1 |
| Wilgis, EF | 1 |
| Kitahora, T | 1 |
| Guth, PH | 1 |
| Rosenthal, D | 1 |
| Mittenthal, MJ | 1 |
| Ruben, DM | 1 |
| Jones, DH | 1 |
| Estes, JW | 1 |
| Stanton, PE | 1 |
| Lamis, PA | 1 |
| Makris, PE | 1 |
| Louizou, C | 1 |
| Markakis, C | 1 |
| Mandalaki, T | 1 |
| Pelz, DM | 1 |
| Buchan, A | 1 |
| Fox, AJ | 1 |
| Barnett, HJ | 1 |
| Vinuela, F | 1 |
| Tartaglia, AP | 1 |
| Goldberg, JD | 1 |
| Berk, PD | 1 |
| Wasserman, LR | 1 |
| Bastida, E | 2 |
| Garrido, M | 1 |
| Rodríguez-Gómez, J | 1 |
| Castillo, R | 2 |
| Ordinas, A | 2 |
| Popov, AI | 1 |
| Di Perri, T | 1 |
| Ullman, HL | 1 |
| Oglesby, TD | 1 |
| Gorman, RR | 1 |
| Ward, JW | 1 |
| Findlay, JM | 1 |
| Lougheed, WM | 1 |
| Gentili, F | 1 |
| Walker, PM | 1 |
| Glynn, MF | 1 |
| Houle, S | 1 |
| Deby, C | 1 |
| Schröer, RH | 1 |
| Lubbe, WF | 1 |
| Liggins, GC | 1 |
| Boss, AH | 1 |
| Olseen, JS | 1 |
| Kovaleva, LG | 1 |
| Sedova, GT | 1 |
| Krasiukova, LI | 1 |
| Piotrowski, JJ | 1 |
| Hashimoto, N | 1 |
| Abels, J | 1 |
| Steketee, J | 1 |
| Vuzevski, VD | 1 |
| Wang, JP | 2 |
| Hsu, MF | 2 |
| Hsu, TP | 1 |
| Teng, CM | 1 |
| Marco, J | 1 |
| Silvernail, PJ | 1 |
| Fournial, G | 1 |
| Choy, DS | 1 |
| Case, RB | 1 |
| Huang, LJ | 1 |
| Gewirtz, H | 1 |
| Sasken, H | 1 |
| Steiner, M | 1 |
| Most, AS | 1 |
| Tani, T | 1 |
| Kanbe, T | 1 |
| Srivastava, R | 1 |
| Srimal, RC | 1 |
| Dhawan, BN | 1 |
| Hennissen, A | 1 |
| Thomas, DP | 1 |
| Marshall, J | 1 |
| Meadows, JC | 1 |
| Russell, RW | 1 |
| Tulevski, V | 1 |
| Heady, JA | 1 |
| Wood, L | 1 |
| Lindsay, RM | 2 |
| Burton, JA | 1 |
| Kingdon, HS | 1 |
| Etherington, M | 2 |
| Jamieson, S | 1 |
| Lawford, P | 1 |
| Evans, G | 1 |
| Perlick, E | 1 |
| Davies, DT | 1 |
| Hughes, A | 1 |
| Tonks, RS | 1 |
| Moschos, CB | 2 |
| Lahiri, K | 2 |
| Lyons, M | 1 |
| Weisse, AB | 1 |
| Oldewurtel, HA | 1 |
| Regan, TJ | 2 |
| Berger, KE | 1 |
| Mansfield, PB | 1 |
| Wood, SJ | 1 |
| Smith, JC | 1 |
| Overton, JB | 1 |
| Ogston, D | 1 |
| Bousser, MG | 4 |
| Reuter, H | 1 |
| Hampton, J | 1 |
| Jenkins, CS | 1 |
| Steffen, R | 1 |
| Zollikofer, H | 1 |
| Smith, JB | 2 |
| Ingerman, CM | 2 |
| Barucha, EP | 1 |
| Schöndoft, TH | 1 |
| Adelson, E | 1 |
| Segal, A | 1 |
| Hynes, KM | 1 |
| Gau, GT | 1 |
| Neef, H | 1 |
| Preusser, KP | 1 |
| McCormick, J | 1 |
| Weily, HS | 1 |
| Steele, PP | 1 |
| Stuart, RK | 2 |
| Ahuja, SP | 1 |
| Coles, JC | 1 |
| Friend, DG | 1 |
| Andrassy, K | 1 |
| Malluche, H | 1 |
| Bornefeld, H | 1 |
| Comberg, M | 1 |
| Ritz, E | 1 |
| Jesdinsky, H | 1 |
| Möhring, K | 1 |
| George, CR | 1 |
| Quadracci, LJ | 1 |
| Striker, GE | 1 |
| Bove, LG | 1 |
| Bouvier, CA | 2 |
| Tobelem, GM | 1 |
| Israel, L | 1 |
| Thomas, T | 1 |
| Thomas, F | 1 |
| Mauer, H | 1 |
| Caul, J | 1 |
| Lee, HM | 1 |
| Praga, C | 1 |
| Pogliani, E | 1 |
| Naess, K | 1 |
| Gautier, JC | 1 |
| Bologna, E | 1 |
| Kricheff, II | 1 |
| Zucker, MB | 2 |
| Tschopp, TB | 1 |
| Kolodjiez, A | 1 |
| Frank, MJ | 1 |
| Frank, N | 1 |
| Kummer, H | 1 |
| Blättler, W | 1 |
| Attar, S | 1 |
| McLaughlin, JS | 1 |
| Masaitis, C | 1 |
| Hammond, GL | 1 |
| Lecrubier, C | 1 |
| Butterfield, WJ | 1 |
| Csalay, L | 1 |
| Marbet, GA | 1 |
| Duckert, F | 1 |
| Bart, JB | 1 |
| Bounameaux, Y | 2 |
| Clark, HG | 1 |
| Banks, DC | 1 |
| Sawyer, PN | 1 |
| Stanczewski, B | 1 |
| Keates, J | 1 |
| Ramsey, WS | 1 |
| Machado, J | 1 |
| Kammlott, GW | 1 |
| Hoch, W | 1 |
| Kocsis, JJ | 1 |
| Tulevski, VG | 1 |
| Madgwick, T | 1 |
| Alkjaersig, N | 1 |
| Fletcher, A | 1 |
| Freed, MD | 1 |
| Rosenthal, A | 1 |
| Fyler, D | 1 |
| Justice, C | 1 |
| Papavangelou, E | 1 |
| Edwards, WS | 1 |
| Willis, AL | 1 |
| Dziewolska, M | 1 |
| Krug, H | 1 |
| Keimowitz, RM | 1 |
| Wright, IS | 1 |
| Peterson, J | 1 |
| Kennedy, AC | 1 |
| Herrmann, RG | 1 |
| Marshall, WS | 1 |
| Crowe, VG | 1 |
| Frank, JD | 1 |
| Marlett, DL | 1 |
| Lacefield, WB | 1 |
| Giromini, M | 1 |
| Dami, R | 1 |
| Denizot, M | 1 |
| Jeannet, M | 1 |
| Geraud, J | 1 |
| Puel, P | 1 |
| Guiraud, B | 1 |
| Bris, J | 1 |
| Gayrard, M | 1 |
| Peter, A | 1 |
| Jesrani, MU | 1 |
| Remmele, W | 1 |
| Danese, CA | 2 |
| Haimov, M | 1 |
| Zbinden, G | 1 |
| Schepping, M | 1 |
| Campanacci, D | 1 |
| Cavalieri, U | 1 |
| Quadri, A | 1 |
| Tammaro, AE | 1 |
| Renaud, S | 1 |
| Godu, J | 1 |
| Voleti, CD | 1 |
| Wajcner, G | 1 |
| Guedon, J | 1 |
| Chapman, A | 1 |
| Mazza, C | 1 |
| Mazzilli, G | 1 |
| Nizzola, GM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age After the Fontan Procedure[NCT02846532] | Phase 3 | 112 participants (Actual) | Interventional | 2016-11-16 | Completed | ||
| COVID-19 Outpatient Thrombosis Prevention Trial A Multi-center Adaptive Randomized Placebo-controlled Platform Trial Evaluating the Efficacy and Safety of Anti-thrombotic Strategies in COVID Adults Not Requiring Hospitalization at Time of Diagnosis[NCT04498273] | Phase 3 | 657 participants (Actual) | Interventional | 2020-09-07 | Terminated (stopped due to an event rate lower than anticipated) | ||
| A Prospective Multicenter Clinical Study of Aspirin for Prophylaxis in Patients With Hereditary or Acquired Thrombotic Thrombocytopenic Purpura[NCT05568147] | Phase 2/Phase 3 | 100 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial[NCT04324463] | Phase 3 | 6,667 participants (Actual) | Interventional | 2020-04-21 | Active, not recruiting | ||
| GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation[NCT01813435] | Phase 3 | 15,991 participants (Actual) | Interventional | 2013-07-01 | Completed | ||
| A Prospective Multi-center Open-label Controlled Trial of Comparison 3 vs 12 Months of Dual Anti-Platelet Therapy After Implantation of Firehawk Sirolimus Target- Eluting Stent in Patients With Stable Coronary Artery Disease[NCT03008083] | Phase 4 | 2,446 participants (Anticipated) | Interventional | 2019-01-10 | Recruiting | ||
| Platelet Sub-study of the TWILIGHT Trial[NCT04001374] | 40 participants (Actual) | Observational | 2015-06-28 | Completed | |||
| Platelet Function Evaluation in Patients With Acute Coronary Syndromes on Potent P2Y12 Inhibitor Monotherapy Versus Dual Antiplatelet Therapy With Aspirin and a Potent P2Y12 Inhibitor[NCT05767723] | Phase 4 | 48 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| Thoratec Corporation MOMENTUM 3, Multi-center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3™ IDE Clinical Study Protocol[NCT02224755] | 1,028 participants (Actual) | Interventional | 2014-09-02 | Completed | |||
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb[NCT04229264] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-01-09 | Recruiting | ||
| Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation: Multicenter Randomized Clinical Trial[NCT05283356] | Phase 4 | 1,206 participants (Anticipated) | Interventional | 2022-01-21 | Recruiting | ||
| Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation[NCT02247128] | Phase 4 | 1,016 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Ischemic And Bleeding Risk Assessment After TAVR (FOCUS ONE Registry)[NCT06000943] | 2,500 participants (Anticipated) | Observational [Patient Registry] | 2023-08-01 | Recruiting | |||
| XIENCE 28 Global Study[NCT03355742] | 963 participants (Actual) | Interventional | 2018-02-09 | Completed | |||
| A Safety Evaluation of 3-month Dual Antiplatelet Therapy in Subjects at High Risk of Bleeding Undergoing Percutaneous Coronary Intervention With XIENCE.[NCT03218787] | 2,047 participants (Actual) | Interventional | 2017-07-19 | Completed | |||
| XIENCE 28 USA Study[NCT03815175] | 1,605 participants (Actual) | Interventional | 2019-02-25 | Completed | |||
| A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves - RIVER[NCT02303795] | Phase 2 | 1,005 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| PREVENTion of Clot in Orthopaedic Trauma (PREVENT CLOT): A Randomized Pragmatic Trial Comparing the Complications and Safety of Blood Clot Prevention Medicines Used in Orthopaedic Trauma Patients[NCT02984384] | Phase 3 | 12,211 participants (Actual) | Interventional | 2017-04-24 | Completed | ||
| Prospective, Non-interventional Study of Disease Progression and Treatment of Patients With Polycythemia Vera in United States Academic or Community Clinical Practices[NCT02252159] | 2,544 participants (Actual) | Observational | 2014-07-31 | Completed | |||
| Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study)[NCT02642419] | Phase 4 | 2,200 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Effects of a Whole Food Based Nutritional Formulation on Trimethylamine N-oxide and Cardiometabolic Endpoints in Healthy Adults.[NCT05795946] | 45 participants (Anticipated) | Interventional | 2023-04-15 | Recruiting | |||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794] | Phase 4 | 222 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298] | Phase 4 | 178 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndromes[NCT04347200] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2015-01-15 | Recruiting | |||
| Analysis of the Platelet Activity State in Patients Implanted With Ventricular Assist Device (VAD)[NCT03255928] | 60 participants (Anticipated) | Observational [Patient Registry] | 2017-06-29 | Recruiting | |||
| Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET Trial): Does Ticagrelor Improve Graft Patency After Coronary Bypass?[NCT02053909] | Phase 4 | 250 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention[NCT01802775] | Phase 2 | 203 participants (Actual) | Interventional | 2013-02-06 | Completed | ||
| Risk of Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs: a Nationwide Study[NCT02481011] | 22,111 participants (Actual) | Observational | 2015-05-31 | Completed | |||
| A Randomised Trial to Compare Aspirin vs Hydroxyurea/Aspirin in 'Intermediate Risk' Primary Thrombocythaemia and Aspirin Only With Observation in 'Low Risk'Primary Thrombocythaemia[NCT00175838] | 1,398 participants (Actual) | Interventional | 1997-07-31 | Completed | |||
| OCT Evaluation of Early Vascular Repair in Patients With Non ST Elevation Acute Coronary Syndrome (NSTE-ACS)[NCT04375319] | 60 participants (Anticipated) | Interventional | 2019-10-28 | Recruiting | |||
| Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting[NCT04694248] | 172 participants (Anticipated) | Interventional | 2021-11-03 | Recruiting | |||
| Onyx ONE Study; A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients[NCT03344653] | 2,000 participants (Actual) | Interventional | 2017-11-02 | Completed | |||
| Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation[NCT00822536] | Phase 4 | 1,798 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| French Aspirin Study in Essential Thrombocythemia: an Open and Randomized Study[NCT02611973] | Phase 3 | 2,250 participants (Anticipated) | Interventional | 2016-03-10 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome[NCT00809965] | Phase 3 | 15,526 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice - Optimize Trial[NCT01113372] | Phase 4 | 3,119 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| The Effect of Remote Ischemic Conditioning (RIC) on Inflammatory Biomarkers and Outcomes in Patients With TBI[NCT03899532] | 120 participants (Anticipated) | Interventional | 2019-09-24 | Recruiting | |||
| Targeting Platelets in Chronic HIV Infection[NCT02578706] | Phase 2 | 27 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Effect of Vitamin C Infusion on Coronary Reperfusion Indexes[NCT01090895] | Phase 4 | 80 participants (Anticipated) | Interventional | 2010-03-31 | Recruiting | ||
| Preprocedural Asprin Reload for Native Coronary Disease Treated by Angioplasty: Reperfusion Indexes Evaluation and Improvement of Clinical Outcome -PANTAREI Study[NCT01374698] | Phase 4 | 100 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| A Prospective, Randomized, Controlled, Analyst-blinded, Parallel Group Study to Investigate the Effect of Antithrombotic Triple Therapy With Ticagrelor and Acetylsalicylic Acid in Combination With Dabigatran or Rivaroxaban or Phenprocoumon on Markers of C[NCT01812200] | Phase 4 | 60 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Percutaneous Coronary Intervention With the ANgiolite Drug-Eluting Stent: an Optical CoHerence TOmogRaphy Study. The ANCHOR Study[NCT02776267] | 100 participants (Anticipated) | Interventional | 2015-05-31 | Completed | |||
| "Outcome of CHAllenging lesioNs and Patients Treated With Polymer Free Drug-CoatEd Stent (Biofreedom): the CHANCE a Multicenter Study"[NCT03622203] | 1,000 participants (Actual) | Observational [Patient Registry] | 2016-01-01 | Completed | |||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Clinical Trial Program of a Medical Instrument Product[NCT01157455] | Phase 4 | 1,900 participants (Anticipated) | Interventional | 2010-05-31 | Recruiting | ||
| Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-segment Elevation Myocardial Infarction[NCT02075125] | Phase 3 | 39 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to Enrolling participants has halted prematurely and will not resume) | ||
| Association Between Perioperative Bleeding and Aspirin Use in Spine Surgery: A Randomized, Controlled Trial[NCT02807441] | Phase 3 | 0 participants (Actual) | Interventional | 2016-07-31 | Withdrawn | ||
| A Randomized Phase II Trial of Rituximab Versus Lenalidomide (REVLIMID™, Cc-5013) (IND#73034) Versus Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That is Not Rituximab-Refractory[NCT00238238] | Phase 2 | 97 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
| A Multicenter, Double-blind, Randomized and Parallel Controlled Study of Hydroxychloroquine Sulfate in the Treatment of Recurrent Miscarriage With Antiphospholipid Syndrome[NCT04624269] | Phase 4 | 384 participants (Anticipated) | Interventional | 2020-12-01 | Not yet recruiting | ||
| Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin[NCT01768637] | Phase 1 | 48 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720] | Phase 3 | 3,400 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | ||
| Personalization of Long-Term Antiplatelet Therapy Using a Novel Combined Demographic/Pharmacogenomic Strategy - The RAPID EXTEND Randomized Study[NCT03729401] | Phase 4 | 390 participants (Anticipated) | Interventional | 2019-08-22 | Suspended (stopped due to Testing supplies unavailable.) | ||
| Randomized 2x2 Factorial Trial Comparing the Cre8 Amphilimus-sirolimus Eluting Stent vs. the Synergy Everolimus-eluting Stent and a Personalized vs. Standard Duration of Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Int[NCT04135989] | Phase 4 | 2,106 participants (Anticipated) | Interventional | 2020-01-01 | Active, not recruiting | ||
| COMbination of Clopidogrel and Aspirin for Prevention of REcurrence in Acute Atherothrombotic Stroke Study: Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial[NCT00814268] | Phase 4 | 358 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491] | Phase 3 | 11,000 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
| Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma. A Double-blind, Placebo-controlled, Multicentre, Randomized Controlled Clinical Trial[NCT03582293] | Phase 3 | 140 participants (Anticipated) | Interventional | 2018-06-19 | Recruiting | ||
| DEPOSITION: Pilot Study Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery[NCT03376061] | Phase 4 | 97 participants (Actual) | Interventional | 2017-12-21 | Completed | ||
| Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) Study[NCT03954314] | Phase 3 | 3,242 participants (Actual) | Interventional | 2019-09-17 | Terminated (stopped due to Upon the Data Safety Monitoring Board review of the interim analysis (75% of participants have finished their follow-up) on November 17, 2023, they made a recommendation to stop recruitment into the trial.) | ||
| Acetylsalicylic Acid Administered in Patients With Type 2 Diabetes Mellitus and Its Effect on the Antioxidant Enzyme System[NCT03341117] | Phase 3 | 21 participants (Actual) | Interventional | 2014-12-02 | Completed | ||
| Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203] | Phase 3 | 1,653 participants (Actual) | Interventional | 2015-12-16 | Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator) | ||
| Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial[NCT03568890] | Phase 4 | 510 participants (Anticipated) | Interventional | 2018-09-01 | Recruiting | ||
| Ongoing WARfarin and Coronary STENTing. A Multi-center, Prospective Registry on Antithrombotic Treatment.[NCT00722319] | 1,000 participants (Anticipated) | Observational | 2009-03-31 | Active, not recruiting | |||
| Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting[NCT00776633] | Phase 4 | 614 participants (Actual) | Interventional | 2008-09-30 | Active, not recruiting | ||
| Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events[NCT02616497] | Phase 4 | 1,220 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Assessment of Platelet-dependent Thrombosis in Patients With Acute Coronary Syndromes Using an ex Vivo Arterial Injury Model[NCT00728286] | 90 participants (Actual) | Observational | 2008-10-31 | Completed | |||
| Assessment of Platelet-dependent Thrombosis by an ex Vivo Arterial Injury Model: a Placebo Controlled Trial of Clopidogrel as Antiplatelet Therapy in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease[NCT00728156] | Phase 4 | 90 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial)[NCT03930875] | 63 participants (Actual) | Observational | 2017-12-12 | Completed | |||
| "Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004] | Phase 4 | 60 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817] | Phase 3 | 15,603 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency[NCT00067119] | Phase 3 | 649 participants (Actual) | Interventional | 2003-01-01 | Completed | ||
| Effect of Beraprost Sodium (Berasil) on Hemodialysis[NCT03142360] | 60 participants (Anticipated) | Interventional | 2017-04-05 | Recruiting | |||
| Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent[NCT00331578] | Phase 4 | 2,077 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| The MAgnitude of Platelet Inhibition and the Pharmacokinetics of a 600 mg Loading Dose of Clopidogrel, in Different Patient CATegories (Stable Angina Versus Acute-coronary Syndromes Versus ST-elevated Myocardial Infarction).[NCT01012544] | Phase 4 | 187 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265] | 31 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated With Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events[NCT00484926] | Phase 4 | 2,000 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events[NCT00590174] | Phase 4 | 1,175 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200] | Phase 4 | 1,724 participants (Actual) | Interventional | 2013-10-05 | Completed | ||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452] | Phase 3 | 25,086 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Optimal Strategy for Side Branch Stenting in Coronary Bifurcation Lesion[NCT00794014] | 258 participants (Actual) | Interventional | 2007-11-30 | Completed | |||
| A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT02748304] | 52 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.) | |||
| Can Pharmacogenomic Testing Improve Response and Avoid Adverse Effects With Clopidogrel Therapy? A Biospecimen Bank for Genetic and Genomic Investigation of Clopidogrel.[NCT01611545] | 130 participants (Actual) | Observational | 2012-06-30 | Completed | |||
| Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI. (The POPular Study)[NCT00352014] | 1,000 participants (Anticipated) | Observational | 2006-01-31 | Completed | |||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing[NCT01477775] | Phase 4 | 4,000 participants (Anticipated) | Interventional | 2012-01-31 | Recruiting | ||
| Association of PeriOPerative Aspirin-ResisTance and CardioVascular Outcome[NCT04053894] | 220 participants (Anticipated) | Observational | 2019-08-31 | Not yet recruiting | |||
| MONET BRIDGE(Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery) - (Mantenimento Della Terapia Antiaggregante Nei Pazienti Portatori di Stent Coronarico Candidati a Chirurgia)[NCT03862651] | Phase 2 | 140 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| Multicenter, Prospective Cohort of Patient With Coronary Stents Undergoing Non Cardiac Surgery or Invasive Procedures.[NCT01045850] | 1,312 participants (Actual) | Observational | 2006-02-28 | Completed | |||
| An International Multi Centre Randomized Clinical Trial Of Anticoagulation In Children Following Fontan Procedures[NCT00182104] | Phase 4 | 111 participants | Interventional | 1998-08-31 | Completed | ||
| Strategy for Managing Antiplatelet Therapy in the Perioperative Period of Non Coronary Surgery[NCT00190307] | Phase 4 | 293 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary. Reclose 2-ACS Registry[NCT01231035] | 1,789 participants (Actual) | Observational | 2008-09-30 | Completed | |||
| EValuation of REsidual Platelet REactivity After Acute Coronary Syndrome in HIV-infected Patients. The EVERE2ST-HIV Study.[NCT02380391] | 260 participants (Actual) | Observational | 2013-12-31 | Completed | |||
| Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
| Must Aspirin be Discontinued Prior to TURBT: a Prospective, Randomized, Non-inferiority Trial Comparing Peri-operative Aspirin Continuation Versus Discontinuation.[NCT02350543] | Phase 4 | 50 participants (Actual) | Interventional | 2015-02-28 | Terminated (stopped due to Insufficient recruitment.) | ||
| Comparison of Small Colorectal Polyp Removal Using Cold Endoscopic Mucosal Resection With Hot Endoscopic Mucosal Resection: a Pilot Study[NCT03000868] | 0 participants (Actual) | Interventional | 2016-12-01 | Withdrawn (stopped due to No participants were enrolled.) | |||
| Risk Stratification for Subclinical Leaflet Thrombosis Post TAVI Using Thromboelastography[NCT03649594] | 100 participants (Anticipated) | Observational | 2020-10-01 | Recruiting | |||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237] | 70 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| A Prospective, Nonrandomized, Study Comparing the Use of Aspirin and Intraoperative Blood Loss and Postoperative Complications Following Open Inguinal Hernia Repair.[NCT02084615] | 300 participants (Anticipated) | Interventional | 2014-08-31 | Enrolling by invitation | |||
| Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547] | 88 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465] | Phase 4 | 60 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591] | 300 participants | Interventional | 2001-04-30 | Active, not recruiting | |||
| Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280] | Phase 4 | 2,505 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| The Effect of Inducing the Cytochrome P450 System on the Pharmacodynamic Efficacy of Clopidogrel[NCT01330589] | 0 participants (Actual) | Interventional | 2011-04-30 | Withdrawn (stopped due to Inability to enroll subjects and changes in standard of care for PCI) | |||
| Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612] | Phase 3 | 200 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| INtra-procedural ultraSound Imaging for DEtermination of Atrial Wall Thickness and Acute Tissue Changes During Isolation of the Pulmonary Veins[NCT03372798] | 12 participants (Actual) | Observational | 2016-10-31 | Completed | |||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| The Effect of Serum LDL Lowering on Aspirin Resistance[NCT00466154] | 40 participants | Interventional | 2005-07-31 | Completed | |||
| Phase 4 Study of Postoperative Prostaglandin E1 in Head and Neck Microsurgery[NCT00733434] | Phase 4 | 242 participants (Anticipated) | Interventional | 2008-07-31 | Recruiting | ||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| Maintenance of an Antiaggregation by Acetylsalicylic Acid, Less or Equal to 250mg While a Extracorporeal Lithotripsy (ECL) Session on a Kidney Stone is Perfomed: Comparative Unicentric Prospective Study[NCT03437057] | 300 participants (Anticipated) | Interventional | 2018-01-08 | Recruiting | |||
| A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of [NCT00282386] | Phase 3 | 2,586 participants (Actual) | Interventional | 1999-12-23 | Completed | ||
| Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428] | 159 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| Does Acetaminophen Potentiate the Gastroduodenal Mucosal Injury of Aspirin? A Prospective, Randomized, Pilot Study.[NCT00594867] | Phase 4 | 94 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study[NCT02869009] | Phase 3 | 3,000 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients[NCT01261273] | 18,000 participants (Actual) | Observational | 2010-08-25 | Completed | |||
| BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With de Novo Coronary Artery Lesions-VI[NCT02870985] | Phase 3 | 440 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Antiplatelet Activity of Aspirin in Infants After Aortopulmonary and Cavopulmonary Shunts[NCT01656993] | 25 participants (Actual) | Observational | 2012-11-30 | Completed | |||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| Clopidogrel and Proton Pump Inhibitors: A Propensity Score Adjusted Cohort Study to Examine a Possible Interaction: A CALIBER Study[NCT01231867] | 24,471 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Induction of Labor at Term Versus Expectant Management Among Women With Abnormal Maternal Serum Biochemical Markers: A Randomized Controlled Trial[NCT02754635] | 320 participants (Anticipated) | Interventional | 2016-03-31 | Recruiting | |||
| P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry[NCT01967615] | 4,500 participants (Actual) | Observational | 2015-01-31 | Completed | |||
| Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention[NCT01456364] | Phase 4 | 70 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| CARDIOBASE Bern PCI Registry[NCT02241291] | 10,000 participants (Anticipated) | Observational | 2009-03-31 | Recruiting | |||
| PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents[NCT01103843] | 1,000 participants (Anticipated) | Interventional | 2010-04-30 | Recruiting | |||
| Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg Twice Daily in Elderly Patients With Acute Coronary Syndrome (ACS)[NCT04739384] | Phase 3 | 50 participants (Actual) | Interventional | 2021-04-01 | Completed | ||
| A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study[NCT00995514] | 4,471 participants (Actual) | Observational | 2009-10-31 | Terminated (stopped due to Administrative reasons) | |||
| Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728] | 1,756 participants (Anticipated) | Interventional | 2018-04-04 | Recruiting | |||
| Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435] | 889 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to Ethics Committe decision) | |||
| Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy[NCT02049762] | Phase 4 | 29 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation[NCT01099566] | Phase 4 | 20 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374] | Phase 4 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| Correlation Between Bleeding Complication and Treatment Failure on P2Y12 Inhibitors and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04580602] | 200 participants (Actual) | Observational | 2020-10-07 | Completed | |||
| Registry of Left Atrial Appendage Occlusion With WATCHMAN® Device in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic Kidney Disease on Hemodialysis[NCT03446794] | 300 participants (Actual) | Observational [Patient Registry] | 2018-03-14 | Completed | |||
| Acute Headache Treatment in Pregnancy: Improvement in Pain Scores With Occipital Nerve Block vs PO Acetaminophen With Caffeine A Randomized Controlled Trial[NCT03951649] | Phase 4 | 62 participants (Actual) | Interventional | 2020-02-10 | Completed | ||
| Rivaroxaban for Improvement of Thromboembolism Outcomes in Patients With Multiple Myeloma on Lenalidomide-based Therapy: RithMM Trial[NCT03428373] | Phase 2/Phase 3 | 86 participants (Anticipated) | Interventional | 2023-07-30 | Recruiting | ||
| An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma[NCT05849610] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-11-30 | Recruiting | ||
| A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma.[NCT01686386] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2010-02-28 | Recruiting | ||
| Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome[NCT02295475] | Phase 4 | 48 participants (Actual) | Interventional | 2014-12-10 | Completed | ||
| Assessment of Anti-Coagulation Therapy on Patient With Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction[NCT05892042] | 320 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | |||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy[NCT03392948] | 1,080 participants (Anticipated) | Observational [Patient Registry] | 2018-02-09 | Active, not recruiting | |||
| A Post-Market, Prospective, Multi-Center, Study to Evaluate Safety and Efficacy of the StarClose™ Vascular Closure System in Patients Who Are Ambulated Early Post-Diagnostic Catheterization[NCT00736086] | 165 participants (Actual) | Observational | 2006-03-31 | Completed | |||
| A Placebo-Controlled, Double-Blind, Randomized Study of the Potential Interaction Between Aspirin and Ibuprofen or Celecoxib.[NCT00565500] | Phase 4 | 24 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)[NCT00272311] | Phase 4 | 70 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)[NCT00272337] | Phase 4 | 37 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [NCT00000527] | Phase 2 | 0 participants | Interventional | 1986-08-31 | Completed | ||
| Pentoxifylline Dose Optimization in Preterm Neonatal Late Onset Sepsis[NCT04152980] | Phase 3 | 40 participants (Anticipated) | Interventional | 2020-01-12 | Recruiting | ||
| A Double-blind, Randomized, Placebo Controlled Pilot Trial to Evaluate the Safety and Efficacy of Vorapaxar in Maturation of Arteriovenous Fistulae for Hemodialysis Access[NCT02475837] | Phase 2 | 17 participants (Actual) | Interventional | 2015-08-26 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Absolute prothrombin time was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 15.46 |
| Rivaroxaban (Part B) | 18.02 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 1.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 16.58 |
| Rivaroxaban (Part B) | 18.76 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 17.95 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 1.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 18.73 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 6-8 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 16.13 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: Up to 3 hours predose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 15.21 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 20.13 |
| Rivaroxaban (Part B) | 18.89 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 2.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 19.14 |
| Rivaroxaban (Part B) | 19.69 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: Up to 3 hours predose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 17.59 |
| Rivaroxaban (Part B) | 16.45 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 31.4 |
| Rivaroxaban (Part B) | 30.69 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 0.5-1.5 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 66.93 |
| Rivaroxaban (Part B) | 99.46 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 1.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 74.06 |
| Rivaroxaban (Part B) | 104.57 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 6-8 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 74.21 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 0.5-1.5 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part B) | 110.90 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 2.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part B) | 93.48 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: Up to 3 hours predose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 60.51 |
| Rivaroxaban (Part B) | 53.41 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 1.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 32.83 |
| Rivaroxaban (Part B) | 30.25 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 36.17 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average for the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 1.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 37.58 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 6-8 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 32.83 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: Up to 3 hours predose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 33.08 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 26.60 |
| Rivaroxaban (Part B) | 31.15 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 2.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 26.74 |
| Rivaroxaban (Part B) | 31.67 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: Up to 3 hours predose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 25.36 |
| Rivaroxaban (Part B) | 28.70 |
TEAEs were defined as those adverse events (AEs) that occurred from the first day of study drug to the last day of study drug + 2 days inclusive. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. (NCT02846532)
Timeframe: Up to 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban (Part A) | 91.7 |
| Rivaroxaban (Part B) | 85.9 |
| Aspirin (Part B) | 85.3 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 0.5-1.5 hours postdose
| Intervention | micrograms per liter (mcg/L) (Mean) |
|---|---|
| Rivaroxaban (Part A) | 46.69 |
| Rivaroxaban (Part B) | 92.86 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 1.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 86.62 |
| Rivaroxaban (Part B) | 103.61 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 0.5-1.5 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 107.58 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 1.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 147.18 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 6-8 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 66.81 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: Up to 3 hours predose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 36.58 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 0.5-1.5 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 86.25 |
| Rivaroxaban (Part B) | 94.12 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 2.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 96.67 |
| Rivaroxaban (Part B) | 102.99 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: Up to 3 hours predose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 38.23 |
| Rivaroxaban (Part B) | 29.41 |
Thrombotic event was defined as the appearance of a new thrombotic burden within the cardiovascular system on either routine surveillance or clinically indicated imaging, or the occurrence of a clinical event known to be strongly associated with thrombus (such as cardioembolic stroke, pulmonary embolism). The event included ischemic stroke, pulmonary embolism, venous thrombosis, arterial/intracardiac thrombosis, and other thrombosis. (NCT02846532)
Timeframe: Up to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any thrombotic event | Ischemic stroke | Pulmonary embolism | Venous thrombosis | Arterial/intracardiac thrombosis | Other thrombosis | |
| Aspirin (Part B) | 8.8 | 2.9 | 0 | 5.9 | 0 | 0 |
| Rivaroxaban (Part A) | 8.3 | 0 | 0 | 8.3 | 0 | 0 |
| Rivaroxaban (Part B) | 1.6 | 0 | 1.6 | 0 | 0 | 0 |
Bleeding events were categorized into major, clinically relevant non-major bleeding (CRNM), and trivial bleeding events. Major bleeding: overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more; or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults; or occurring in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; or contributing to death. CRNM bleeding: overt bleeding not meeting the criteria for major bleeding but associated with: Medical intervention, or Unscheduled contact with a physician, cessation of study treatment, or Discomfort for the subject such as pain, or Impairment of activities of daily life. Trivial bleeding: any other overt bleeding event that does not meet criteria for CRNM bleeding. (NCT02846532)
Timeframe: Up to 12 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Any bleeding event | Major Bleeding | Clinically relevant non-major bleeding | Trivial bleeding | |
| Aspirin (Part B) | 41.2 | 0 | 8.8 | 35.3 |
| Rivaroxaban (Part A) | 33.3 | 0 | 8.3 | 25.0 |
| Rivaroxaban (Part B) | 35.9 | 1.6 | 6.3 | 32.8 |
The primary outcome will be a composite endpoint of need for hospitalization for cardiovascular/pulmonary events, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, ischemic stroke, and all-cause mortality for up to 45 days after initiation of assigned treatment. (NCT04498273)
Timeframe: 45 days
| Intervention | participants (Number) |
|---|---|
| Apixaban 2.5mg | 1 |
| Apixaban 5mg | 1 |
| Asprin | 0 |
| Placebo | 0 |
"BARC definition. We only considered BARC 3 or 5 for this secondary safety endpoint.~Type 3: Clinical, laboratory, and/or imaging evidence of bleeding with:~Type 3a:~Overt bleeding + Hb drop of 3 to < 5 g/dL (provided Hb drop is related to bleed)~Any transfusion with overt bleeding~Type 3b:~Overt bleeding + Hb drop ≥5 g/dL (provided Hb drop is related to bleed)~Cardiac tamponade~Bleeding requiring surgical intervention (excluding dental/nasal/skin/haemorrhoid)~Bleeding requiring intravenous vasoactive agents~Type 3c:~Intracranial haemorrhage (does not include microbleeds or haemorrhagic transformation, does include intraspinal)~Subcategories confirmed by autopsy or imaging or lumbar puncture~Intraocular bleed compromising vision. Type 5: Fatal bleeding~Type 5a:~• Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious~Type 5b:~Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation" (NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 163 |
| Reference Treatment Strategy | 169 |
Number of Participants with a composite of all-cause mortality or non-fatal new Q-wave MI up to 2 years post randomisation. (NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 304 |
| Reference Treatment Strategy | 349 |
shown are the first event per event type for each patient only. Multiple events of the same type within the same patient are disregarded (NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 362 |
| Reference Treatment Strategy | 416 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 64 |
| Reference Treatment Strategy | 64 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 739 |
| Reference Treatment Strategy | 793 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 80 |
| Reference Treatment Strategy | 82 |
(NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 224 |
| Reference Treatment Strategy | 253 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 248 |
| Reference Treatment Strategy | 250 |
(NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 83 |
| Reference Treatment Strategy | 103 |
Survival at 2 years free of disabling stroke (Modified Rankin Score > 3) or reoperation to replace or remove a malfunctioning device (NCT02224755)
Timeframe: The first 366 randomized Subjects will be followed for 24 months or to outcome (transplant, explant, or death), whichever occurs first.
| Intervention | Participants (Count of Participants) |
|---|---|
| HeartMate II (Intent-to-Treat) | 106 |
| HeartMate 3 (Intent-to-Treat) | 151 |
In addition to powering the study on the primary endpoints for PMA approval, the study will pre-specify a powered secondary endpoint to evaluate incidence of pump replacements at 24 months. HeartMate II is the control. (NCT02224755)
Timeframe: As they occur up to 24 months or to Outcome, whichever occurs first
| Intervention | Participants (Count of Participants) |
|---|---|
| HeartMate II (As-Treated) | 57 |
| HeartMate 3 (As-Treated) | 12 |
Rate of all cause rehospitalization (NCT02224755)
Timeframe: From initial discharge to two years post-implant
| Intervention | events per patient year (Number) |
|---|---|
| HeartMate II (As-Treated) | 2.47 |
| HeartMate 3 (As-Treated) | 2.26 |
Survival at 6 months free of disabling stroke (Modified Rankin Score > 3) or reoperation to replace or remove a malfunctioning device (NCT02224755)
Timeframe: The first 294 randomized Subjects will be followed for 6 months or to outcome (transplant, explant, or death), whichever occurs first.
| Intervention | Participants (Count of Participants) |
|---|---|
| HeartMate II (Intent-to-Treat) | 109 |
| HeartMate 3 (Intent-to-Treat) | 131 |
Events-per-patient-year (EPPY) for anticipated adverse events as defined in the study protocol (NCT02224755)
Timeframe: Two years post-implant
| Intervention | events per patient year (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arterial Non-CNS Thromboembolism | Bleeding | Cardiac Arrhythmia | Hepatic Dysfunction | Hypertension | Major Infection | Myocardial Infarction | Stroke | Hemorrhagic Stroke | Ischemic Stroke | Debilitating Stroke | Other Neurological Event | Pericardial Fluid Collection | Psychiatric Episode | Renal Dysfunction | Respiratory Failure | Right Heart Failure | RVAD | Venous Thromboembolism | Wound Dehiscence | Suspected Device Thrombosis | Hemolysis | |
| HeartMate 3 (As-Treated) | 0.01 | 0.61 | 0.37 | 0.03 | 0.07 | 0.82 | 0.01 | 0.08 | 0.03 | 0.04 | 0.04 | 0.09 | 0.04 | 0.08 | 0.11 | 0.19 | 0.27 | 0.03 | 0.04 | 0.01 | 0.01 | 0.01 |
| HeartMate II (As-Treated) | 0.02 | 0.95 | 0.45 | 0.04 | 0.08 | 0.82 | 0.01 | 0.18 | 0.07 | 0.11 | 0.07 | 0.08 | 0.07 | 0.07 | 0.08 | 0.17 | 0.23 | 0.03 | 0.04 | 0.02 | 0.12 | 0.01 |
Quality of Life as measured by EuroQoL 5 Dimension-5 Level (EQ-5D-5L) total score. The EQ-5D-5L questionnaire has patients rate their quality of life across 5 categories of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scores from the 5 dimensions are summed for the total score which ranges from 5 to 25 with higher scores indicating more problems and a worse quality of life. (NCT02224755)
Timeframe: Baseline to 24 months
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 24 months | |
| HeartMate 3 (As-Treated) | 11.1 | 8.5 | 8.8 |
| HeartMate II (As-Treated) | 11.2 | 8.5 | 9.2 |
Quality of life as measured by the visual analogue scale from the EuroQol-5D-5L questionnaire. The patient rates their current state of health with the visual analogue scale. The scale ranges from 0 to 100. Higher scores indicate a better quality of life. (NCT02224755)
Timeframe: Baseline to 24 months
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baselline | 6 months | 24 months | |
| HeartMate 3 (As-Treated) | 50 | 76 | 76 |
| HeartMate II (As-Treated) | 48 | 74 | 75 |
Quality of Life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). Scores range from 0 to 100. Higher scores indicate better quality of life and fewer heart failure symptoms. (NCT02224755)
Timeframe: Baseline to 24 months
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 24 months | |
| HeartMate 3 (As-Treated) | 39 | 70 | 69 |
| HeartMate II (As-Treated) | 40 | 70 | 68 |
Functional status as measured by NYHA classification. NYHA class categorizes patients by the severity of their heart failure symptoms. As the class increases, the degree of symptoms is more severe indicating worse functional status. Class I indicates no limitation of physical activity. Class II indicates slight limitation of physical activity. Class IIIA indicates marked limitation of physical activity where less than ordinary physical activity causes fatigue, palpitation, dyspnea, or angina pain. Class IIIB indicates marked limitation of physical activity where mild physical activity causes fatigue, palpitation, dyspnea, or angina pain. Class IV indicates inability to carry on any physical activity without discomfort. (NCT02224755)
Timeframe: Baseline to 24 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Class I or II at Baseline | Class I or II at 6 Months | Class I or II at 24 Months | |
| HeartMate 3 (As-Treated) | 0 | 340 | 219 |
| HeartMate II (As-Treated) | 0 | 310 | 176 |
Functional status as measured by the Six Minute Walk Test. The Six Minute Walk Test measures the distance a patient is able to walk during 6 minutes without running or jogging. (NCT02224755)
Timeframe: Baseline to 24 months
| Intervention | meters (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 24 months | |
| HeartMate 3 (As-Treated) | 136 | 310 | 323 |
| HeartMate II (As-Treated) | 129 | 327 | 361 |
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 43 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 13 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 30 |
"Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 27 |
"Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 16 |
"Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 11 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 6 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 3 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 3 |
"TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.~A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);~A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 10 |
"TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.~A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);~A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 7 |
"TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.~A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);~A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 3 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 9 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 5 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 70 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 29 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 41 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 45 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 22 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 23 |
"Net Adverse Clinical Endpoint (NACE):~A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 121 |
"Net Adverse Clinical Endpoint (NACE):~A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 55 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 0 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 42 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 21 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 21 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 44 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 22 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 22 |
"Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:~Type 0~Type 1~Type 2~Type 3~Type 4~Type 5~Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BARC Type 2-5 | BARC Type 3-5 | |
| XIENCE | 61 | 27 |
"Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:~Type 0~Type 1~Type 2~Type 3~Type 4~Type 5~Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BARC Type 2-5 | BARC Type 3-5 | |
| XIENCE | 19 | 7 |
"Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:~Type 0~Type 1~Type 2~Type 3~Type 4~Type 5~Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BARC Type 2-5 | BARC Type 3-5 | |
| XIENCE | 44 | 20 |
"Net Adverse Clinical Endpoint (NACE):~A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 2 | 5 | 10 | 15 | 40 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 54 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 48 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 21 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 16 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 26 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 67 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding or autopsy or imaging confirmation" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 41 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 66 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 70 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block, development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI: CK-MB > URL or Troponin > URL with baseline value < UR~The propensity score for each individual was calculated using a logistic regression model that included the study group as the outcome & the baseline demographic, clinical and procedural covariates as the predictors" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 5.4 | 6.7 | 4.0 | 3.6 | 5.8 | 6.9 |
"Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: ICH; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood or packed RBC within 48h;Chest tube output ≥ 2L within 24h~Type 5: Fatal bleeding~The propensity score for each individual was calculated using a logistic regression model that included the study group as the outcome & the baseline demographic, clinical and procedural covariates as the predictors." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 5.1 | 3.9 | 2.7 | 5.4 | 6.0 | 7.7 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even inpatients with coexisting potentially fatal non-cardiac disease (e.g. cancer,infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 64 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even inpatients with coexisting potentially fatal non-cardiac disease (e.g. cancer,infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 23 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even inpatients with coexisting potentially fatal non-cardiac disease (e.g. cancer,infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 40 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 41 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 18 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 24 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 11 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 7 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 18 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 8 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g.,Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 29 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g.,Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 15 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 10 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g.,Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 14 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 103 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 46 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 57 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URLwith baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 68 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URLwith baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 35 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URLwith baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 33 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy or imaging confirmation" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 49 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy or imaging confirmation" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 33 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy or imaging confirmation" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 18 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 0 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 69 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 35 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 34 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 77 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 38 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 39 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI Definition (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Peripheral MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 3.5 | 4.3 | 4.1 | 2.6 | 2.7 | 3.9 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI Definition (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Peripheral MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 6.7 | 4.3 | 6.7 | 6.0 | 7.9 | 8.4 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI Definition (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Peripheral MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 3.2 | 0.0 | 2.7 | 3.4 | 5.5 | 4.4 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions:~Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood/packed red blood cells within a 48h period;Chest tube output ≥ 2L within 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding;no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy/imaging confirmation" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 7.1 | 6.5 | 6.8 | 5.4 | 6.8 | 10.1 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions:~Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood/packed red blood cells within a 48h period;Chest tube output ≥ 2L within 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding;no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy/imaging confirmation" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 2.5 | 2.2 | 1.4 | 3.1 | 2.0 | 3.7 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions:~Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood/packed red blood cells within a 48h period;Chest tube output ≥ 2L within 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding;no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy/imaging confirmation" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 4.9 | 4.3 | 5.5 | 2.3 | 5.2 | 7.0 |
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
The primary objective of this clinical trial will be to evaluate whether, as compared to usual aspirin treatment, ticagrelor early after CABG prevents saphenous vein graft occlusion 1 year after surgery, as assessed by computed tomography (CT) coronary angiography. (NCT02053909)
Timeframe: 1 year after surgery
| Intervention | percentage of veins occluded (Number) |
|---|---|
| Aspirin | 17.4 |
| Ticagrelor | 13.2 |
The secondary objective of this clinical trial will be to evaluate whether, as compared to usual aspirin treatment, ticagrelor early after CABG prevents saphenous vein graft stenosis, defined as >50% narrowing of the graft, 1 year after surgery, as assessed by computed tomography (CT) coronary angiography. (NCT02053909)
Timeframe: 1 year after surgery
| Intervention | percentage of veins stenosed (Number) |
|---|---|
| Aspirin | 4.1 |
| Ticagrelor | 4.2 |
Number of Adjudicated Major Adverse Cardiovascular Events (MACE) which is a composite of non-fatal myocardial infarction (MI), non-fatal stroke and cardiovascular death (NCT01802775)
Timeframe: within 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 1 |
| Edoxaban | 3 |
Number of participants with amputations within 6 months (NCT01802775)
Timeframe: within 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 3 |
| Edoxaban | 1 |
Percentage of participants with re-stenosis/re-occlusion during treatment within 6 months - only the first occurrence of re-stenosis / re-occlusion was counted for each participant (NCT01802775)
Timeframe: within 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Clopidogrel | 34.7 |
| Edoxaban | 30.9 |
"Number of participants with serious adverse events (SAEs) within 6 months~Note: Based on changes to the database structure, clinically significant changes in physical or laboratory parameters are recorded as adverse events (AEs). Details of non-serious adverse events are reported at the 5% reporting threshold in the AE module, as is all-cause mortality." (NCT01802775)
Timeframe: within 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 30 |
| Edoxaban | 31 |
Percentage of participants with clinically relevant bleeding, defined as major bleeding or clinical relevant non-major bleeding, in the on-treatment period based on International Society of Thrombosis and Haemostasis (ISTH) (NCT01802775)
Timeframe: at 3 months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Including Access Site Bleeding (IASB) | Excluding Access Site Bleed (EASB) | |
| Clopidogrel | 8 | 6 |
| Edoxaban | 11 | 6 |
The percentage of participants with major, clinically relevant non-major, and minor bleeding occurring during treatment, within 3 months (NCT01802775)
Timeframe: within 3 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| IASB : Major Bleeding | IASB: CRNM Bleeding | IASB: Minor Bleeding | EASB : Major Bleeding | EASB : CRNM Bleeding | EASB : Minor Bleeding | |
| Clopidogrel | 5 | 4 | 20.8 | 4 | 3 | 17.8 |
| Edoxaban | 1 | 10 | 20 | 1 | 5 | 19 |
The percentage of patients with the first occurrence of the composite of death, myocardial infarction, or stroke. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment. (NCT00809965)
Timeframe: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
| Intervention | Percentage of patients (Number) |
|---|---|
| Placebo | 7.4 |
| Rivaroxaban 2.5 mg Bid | 6.1 |
| Rivaroxaban 5 mg Bid | 6.1 |
The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment. (NCT00809965)
Timeframe: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
| Intervention | Percentage of patients (Number) |
|---|---|
| Placebo | 7.5 |
| Rivaroxaban 2.5 mg Bid | 6.3 |
| Rivaroxaban 5 mg Bid | 6.3 |
The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment. (NCT00809965)
Timeframe: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
| Intervention | Percentage of patients (Number) |
|---|---|
| Placebo | 7.6 |
| Rivaroxaban 2.5 mg Bid | 7.1 |
| Rivaroxaban 5 mg Bid | 7.2 |
The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment. (NCT00809965)
Timeframe: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
| Intervention | Percentage of patients (Number) |
|---|---|
| Placebo | 8.7 |
| Rivaroxaban 2.5 mg Bid | 7.3 |
| Rivaroxaban 5 mg Bid | 7.6 |
The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment. (NCT00809965)
Timeframe: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
| Intervention | Percentage of patients (Number) |
|---|---|
| Placebo | 9.4 |
| Rivaroxaban 2.5 mg Bid | 8.5 |
| Rivaroxaban 5 mg Bid | 8.2 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
Alpha angle is measured using thromboelastography, measured by a tangent to the clotting curve through the 2mm point (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | degree (Mean) |
|---|---|
| Aspirin and Placebo | 0.00 |
| Clopidogrel and Placebo | -0.60 |
| Placebo Only | -0.50 |
The classical monocyte is characterized by high level expression of the CD14 cell surface receptor (CD14++ CD16- monocyte) (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | -0.09 |
| Clopidogrel and Placebo | -0.12 |
| Placebo Only | -0.04 |
Clot formation time is measured using thromboelastography. time from 2 to 20 mm amplitude in seconds. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | seconds (Mean) |
|---|---|
| Aspirin and Placebo | -1.00 |
| Clopidogrel and Placebo | 2.00 |
| Placebo Only | 1.63 |
Clot formation kinetics, or coagulation time, is measured using thromboelastography. time to 2mm amplitude in seconds. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | seconds (Mean) |
|---|---|
| Aspirin and Placebo | 3.00 |
| Clopidogrel and Placebo | 1.00 |
| Placebo Only | -13.13 |
D-Dimer level looks at coagulation of blood. D-dimers are not normally present in blood except when coagulation has occurred. (NCT02578706)
Timeframe: Baseline and 24 weeks
| Intervention | mcg/L (Mean) |
|---|---|
| Aspirin and Placebo | -295.99 |
| Clopidogrel and Placebo | 151.96 |
| Placebo Only | 1109.38 |
Interleukin 6 gene encodes a cytokine that functions in inflammation and implicated in a variety of inflammatory-associated disease states. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | -0.36 |
| Clopidogrel and Placebo | 0.02 |
| Placebo Only | 0.85 |
The intermediate monocyte with high level expression of CD14 and low level expression of CD16 (CD14++CD16+ monocytes). (NCT02578706)
Timeframe: Baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 0.02 |
| Clopidogrel and Placebo | 0.06 |
| Placebo Only | 0.04 |
Maximum Clot Firmness (MCF) is measured using thromboelastography. maximum ampliture in mm (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | mm (Mean) |
|---|---|
| Aspirin and Placebo | 1.38 |
| Clopidogrel and Placebo | 1.20 |
| Placebo Only | 0.38 |
Soluble CD163 is a specific macrophage activation marker, associated with morphological disease grade. A high sCD163 indicates more disease. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 26.88 |
| Clopidogrel and Placebo | 15.8 |
| Placebo Only | -63.38 |
Change in % platelet monocyte aggregates from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet monocyte aggregates (Mean) |
|---|---|
| Aspirin and Placebo | 10.55 |
| Clopidogrel and Placebo | 3.88 |
| Placebo Only | 8.96 |
The non-classical monocyte shows low level expression of CD14 and additional co-expression of the CD16 receptor (CD14+CD16++ monocyte).[ (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 0.002 |
| Clopidogrel and Placebo | 0.03 |
| Placebo Only | -0.03 |
Change in % platelet aggregation in response to stimulation by Adenosine Diphosphate (ADP) from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -7.25 |
| Clopidogrel and Placebo | -32.40 |
| Placebo Only | -6.50 |
Change in % platelet aggregation in response to stimulation by arachidonic acid 1500µM from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -53.33 |
| Clopidogrel and Placebo | -31.00 |
| Placebo Only | -13.25 |
Change in % platelet aggregation in response to stimulation by Collagen 2µg/mL from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -40.37 |
| Clopidogrel and Placebo | -9.60 |
| Placebo Only | 8.62 |
Change in % platelet aggregation in response to stimulation by light transmission aggregometry as measured by epinephrine 5µM from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -35.25 |
| Clopidogrel and Placebo | -21.40 |
| Placebo Only | -10.63 |
Soluble CD14 (sCD14) levels in blood. sCD14 is a nonspecific maker of monocyte activation. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | 35.75 |
| Clopidogrel and Placebo | -251.40 |
| Placebo Only | -101.75 |
Soluble CD40-ligand levels (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | -28.05 |
| Clopidogrel and Placebo | -25.68 |
| Placebo Only | 13.65 |
Change in spontaneous % platelet from baseline to week 24. Spontaneous platelet aggregation? (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet (Mean) |
|---|---|
| Aspirin and Placebo | -0.75 |
| Clopidogrel and Placebo | -0.60 |
| Placebo Only | -0.88 |
Soluble tumor necrosis factor receptor (sTNFR) serum concentration (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/ml (Mean) |
|---|---|
| Aspirin and Placebo | 137.77 |
| Clopidogrel and Placebo | 59.46 |
| Placebo Only | 19.78 |
Soluble tumor necrosis factor receptor (sTNFR) serum concentration (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/ml (Mean) |
|---|---|
| Aspirin and Placebo | 283.13 |
| Clopidogrel and Placebo | 347.00 |
| Placebo Only | 4.25 |
substudy - Change in thrombus formation by Badimon chamber (high shear) from baseline to 24 weeks. Thrombus formation on a blood vessel measured by immunohistochemistry staining of tissue cross sections. The high shear chambers (inner lumen diameter 0.1 mm, Reynolds number 60, shear rate 1690 s- 1) mimic the rheologic conditions of a moderately stenosed coronary artery. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | μ(2)/mm (Mean) |
|---|---|
| Aspirin and Placebo | -3052.20 |
| Clopidogrel and Placebo | -2798.80 |
| Placebo Only | -753.00 |
substudy - Change in thrombus formation by Badimon chamber (low shear) from baseline to 24 weeks. Thrombus formation on a blood vessel measured by immunohistochemistry staining of tissue cross sections. μ(2)/mm is the area of thrombus. The low shear chamber (inner lumen diameter 0.2 mm, Reynolds number 30, shear rate 500 s- 1) simulates flow conditions of a normal coronary artery. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | μ(2)/mm (Mean) |
|---|---|
| Aspirin and Placebo | -1036 |
| Clopidogrel and Placebo | -899.20 |
| Placebo Only | -203.75 |
Safety as measured by a Summary of the number of subjects with at least one grade 3 or higher sign/symptom or laboratory abnormality. A grade 3 sign/symptom was defined as medically significant but not immediately life threatening. (NCT02578706)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and Placebo | 0 |
| Clopidogrel and Placebo | 1 |
| Placebo Only | 0 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 1.70 |
| Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.69 |
| DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.40 |
| DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.03 |
| BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.09 |
| BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.74 |
| DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.53 |
| DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 11.37 |
| Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.04 |
| BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.68 |
| BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 5.62 |
| DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 4.34 |
| DES 12-month DAPT | 5.92 |
Any adverse reaction related to study drug until 30 days after percutaneous coronary intervention. (NCT02075125)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Prasugrel | 0 |
| Ticagrelor | 0 |
Any event related to bleeding including access site bleeding and peri-procedural bleeding based on Bleeding Academic Research Consortium (BARC) criteria. (NCT02075125)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Prasugrel | 0 |
| Ticagrelor | 0 |
Any major adverse cardiac and cerebrovascular event including (death, myocardial infarction, or revascularization and stroke) until day 30. (NCT02075125)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Prasugrel | 0 |
| Ticagrelor | 0 |
Platelet reactivity was measured using VerifyNow (volumetrics accuretic, San Diego, California, USA). Platelet reactivity values were presented as P2Y12 reaction units (PRU). (NCT02075125)
Timeframe: Baseline
| Intervention | PRU units (Median) |
|---|---|
| Prasugrel | 259 |
| Ticagrelor | 261 |
Platelet reactivity was measured using vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay. Platelet reactivity values were presented as platelet reactivity index (PRI). (NCT02075125)
Timeframe: Baseline
| Intervention | percentage (Median) |
|---|---|
| Prasugrel | 51.2 |
| Ticagrelor | 47.5 |
Platelet reactivity were measured by VerifyNow (volumetrics accuretic，San Diego, California, USA), and vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay (BioCytex, Marseille, France) with FACSCalibur flow cytometer (BD Biosciences, San Jose, California, USA) using. Measurement time gap +/- 12 hours were allowed. High platelet reactivity (HPR) is defined as the result of P2Y12 reaction units (PRU) >235 and platelet reactivity index (PRI) >50%. (NCT02075125)
Timeframe: 48 hours after loading dose of study drug
| Intervention | participants (Number) | |
|---|---|---|
| PRU>235 | VASP-PRI>50% | |
| Prasugrel | 0 | 0 |
| Ticagrelor | 0 | 0 |
Platelet reactivity were measured using VerifyNow (volumetrics accuretic, San Diego, California, USA), and vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay (BioCytex, Marseille, France) with FACSCalibur flow cytometer (BD Biosciences, San Jose, California, USA) using. Measurement time gap +/- 12 hours were allowed. Low platelet reactivity (LPR) is defined as the result of P2Y12 reaction units (PRU) <85 and platelet reactivity index (PRI)<16%. The PRU value for LPR, 18 patients were in prasugrel groups and 19 patients in ticagrelor groups, regarding the PRI value for LPR, 16 patients were in each groups. (NCT02075125)
Timeframe: 48 hours after loading dose of study drug
| Intervention | participants (Number) | |
|---|---|---|
| PRU<85 | VASP-PRI<16% | |
| Prasugrel | 18 | 16 |
| Ticagrelor | 19 | 16 |
Response is assessed by investigator according to International Working Group (IWG) criteria. A complete response requires disappearance of all evidence of disease. A partial response is a >/= 50% decrease in the sum of products of 6 largest dominant nodes or nodal masses as well as for splenic and hepatic nodules. No increase in size of nodes, liver or spleen and no new sites of disease. (NCT00238238)
Timeframe: Duration of treatment (12 cycles)
| Intervention | percentage of participants (Number) |
|---|---|
| Arm II - Lenalidomide | 53.3 |
| Arm III - Lenalidomide and Rituximab | 76.1 |
Time to progression (TTP) is defined as the time from study entry until progression or death without progression. The median TTP with 95% CI was estimated using the Kaplan-Meier method. (NCT00238238)
Timeframe: Up to 10 years
| Intervention | years (Median) |
|---|---|
| Arm II - Lenalidomide | 1.1 |
| Arm III - Lenalidomide and Rituximab | 2 |
Citrated whole blood was used to measure platelet aggregation induced by agonist (arachidonic acid at 5 mM concentration) using impedance whole blood platelet aggregometry via a Chrono-log aggregometer. Values at baseline (visit 1) was compared between groups with post treatment values (visit 2) after 2 weeks of aspirin treatment (NCT01768637)
Timeframe: 2 weeks
| Intervention | ohms (Median) | |
|---|---|---|
| Baseline | visit 2 | |
| Chronic Kidney Disease | 21.0 | 0 |
| Normal Controls | 18.0 | 0 |
Citrated whole blood was used to measure platelet aggregation induced by agonist (collagen at 2mM concentration) using impedance whole blood platelet aggregometry via a Chrono-log aggregometer. Values at baseline (visit 1) was compared between groups with post treatment values (visit 2) after 2 weeks of aspirin treatment (NCT01768637)
Timeframe: 2 weeks
| Intervention | ohms (Median) | |
|---|---|---|
| Baseline | visit 2 | |
| Chronic Kidney Disease | 28.5 | 19.5 |
| Normal Controls | 25.0 | 19.0 |
Citrated whole blood was used to measure platelet aggregation induced by agonist (adenosine diphosphate at 20mM concentration) using impedance whole blood platelet aggregometry via a Chrono-log aggregometer. Values at baseline (visit 1) and on aspirin (visit 2) was compared between groups with post treatment values (visit 3) after 2 weeks of aspirin and clopidogrel treatment (NCT01768637)
Timeframe: 4 weeks
| Intervention | ohms (Mean) | ||
|---|---|---|---|
| Baseline | visit 2 | visit 3 | |
| Chronic Kidney Disease | 13.5 | 11.0 | 8.0 |
| Normal Controls | 9.0 | 10.0 | 3.0 |
[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum
| Intervention | grams per deciliter (Mean) |
|---|---|
| Tranexamic Acid | -1.8 |
| Placebo | -1.9 |
Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days
| Intervention | days (Median) |
|---|---|
| Tranexamic Acid | 3 |
| Placebo | 3 |
(NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 35 |
| Placebo | 32 |
This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 108 |
| Placebo | 109 |
This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 233 |
| Placebo | 231 |
[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 892 |
| Placebo | 986 |
Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 20 |
| Placebo | 19 |
This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 29 |
| Placebo | 31 |
This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 649 |
| Placebo | 732 |
[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 12 |
| Placebo | 13 |
[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 339 |
| Placebo | 368 |
Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 201 |
| Placebo | 233 |
[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 162 |
| Placebo | 125 |
This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 0 |
Plasma TxA concentrations measured from blood samples taken upon arrival in the ICU (NCT03376061)
Timeframe: on arrival in ICU within 3 hours
| Intervention | microgram per milliliter per kilogram (Mean) |
|---|---|
| Topical TxA (Intervention) | 0.58 |
| Intravenous TxA (Control) | 1.10 |
Number of hours participants spent in the intensive care unit (ICU) (NCT03376061)
Timeframe: Number of hours spent in ICU from arrival to exit (collected at the Post-Operative Visit).
| Intervention | hours (Median) |
|---|---|
| Topical TxA (Intervention) | 23 |
| Intravenous TxA (Control) | 26 |
Cumulative volume (mL) of fluid collected from mediastinal drainage tubes 24 hours after the surgical procedure (NCT03376061)
Timeframe: Fluid collected in the first 24 hours after the surgical procedure
| Intervention | mL (Median) |
|---|---|
| Topical TxA (Intervention) | 500 |
| Intravenous TxA (Control) | 540 |
The occurrence of death due to any cause (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 1 |
| Intravenous TxA (Control) | 1 |
Patients requiring a red blood cell transfusion (NCT03376061)
Timeframe: Intra-operative and post-operative RBC transfusions
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 19 |
| Intravenous TxA (Control) | 23 |
Occurrence of re-operation for the purpose of bleeding or cardiac tamponade (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 0 |
| Intravenous TxA (Control) | 1 |
Patients experiencing a post-operative seizure (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 0 |
| Intravenous TxA (Control) | 1 |
Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 83 |
| Antiplatelet | 68 |
Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 148 |
| Antiplatelet | 85 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 68 |
| Antiplatelet | 63 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 105 |
| Antiplatelet | 78 |
ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 49 |
| Antiplatelet | 30 |
The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 137 |
| Antiplatelet | 100 |
PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 46 |
| Antiplatelet | 31 |
Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 42 |
| Antiplatelet | 24 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Clopidogrel 300/75/75 mg + ASA Low Dose | 267 |
| Clopidogrel 300/75/75 mg + ASA High Dose | 290 |
| Clopidogrel 600/150/75 mg + ASA Low Dose | 282 |
| Clopidogrel 600/150/75 mg + ASA High Dose | 240 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel + ASA High Dose | 527 | 211 | 251 | 65 |
| Clopidogrel + ASA Low Dose | 546 | 231 | 260 | 55 |
"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 557 | 222 | 274 | 61 |
| Clopidogrel 600/150/75 mg + ASA | 522 | 226 | 237 | 59 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 392 | 132 | 225 | 35 |
| Clopidogrel 600/150/75 mg + ASA | 330 | 130 | 172 | 28 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel + ASA High Dose | 282 | 216 | 73 |
| Clopidogrel + ASA Low Dose | 285 | 215 | 74 |
Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel 300/75/75 mg + ASA | 255 | 195 | 65 |
| Clopidogrel 600/150/75 mg + ASA | 313 | 236 | 83 |
This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Stent trombosis | - Definite | - Probable | |
| Clopidogrel 300/75/75 mg + ASA | 200 | 111 | 89 |
| Clopidogrel 600/150/75 mg + ASA | 135 | 58 | 77 |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 692 |
| Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 797 |
| Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 502 | 573 |
| Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) | ||
|---|---|---|---|
| UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
| Clopidogrel | 565 | 216 | 781 |
| Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 504 | 588 |
| Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
| Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
| Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
(NCT03951649)
Timeframe: 7 days
| Intervention | days (Median) |
|---|---|
| Occipital Nerve Block | 6 |
| Oral Acetaminophen/Caffeine Group | 1 |
(NCT03951649)
Timeframe: 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 9 |
| Oral Acetaminophen/Caffeine Group | 4 |
(NCT03951649)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 7 |
| Oral Acetaminophen/Caffeine Group | 2 |
Other: Pain at injection site (NCT03951649)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 0 |
| Oral Acetaminophen/Caffeine Group | 2 |
(NCT03951649)
Timeframe: 7 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 0 |
| Oral Acetaminophen/Caffeine Group | 0 |
(NCT03951649)
Timeframe: 4 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 9 |
| Oral Acetaminophen/Caffeine Group | 14 |
(NCT03951649)
Timeframe: 5 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 4 |
| Oral Acetaminophen/Caffeine Group | 2 |
Emergency department for treatment of headache since treatment asked at 28 day follow up (NCT03951649)
Timeframe: 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 5 |
| Oral Acetaminophen/Caffeine Group | 1 |
(NCT03951649)
Timeframe: 120 min
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 5 |
| Oral Acetaminophen/Caffeine Group | 5 |
Based on guidelines from the International Headache Society the primary outcome is the portion of women who experience resolution of headache or improvement of headache to mild range (VRS ≤ 3) at 2 hours following treatment with Occipital nerve block as compared to acetaminophen/caffeine cocktail. (NCT03951649)
Timeframe: 60-300 min
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 20 |
| Oral Acetaminophen/Caffeine Group | 16 |
"Visual/verbal Rating Score (VRS). VRS is used to assess pain in patients. With 0 representing no pain at all and 10 representing worst possible pain.~Total Minimum score=0 Total Maximum score=10~Higher values represent worse pain. If VRS=0, then the headache pain is considered resolved." (NCT03951649)
Timeframe: 60 min
| Intervention | score on a scale (Median) |
|---|---|
| Occipital Nerve Block | 6 |
| Oral Acetaminophen/Caffeine Group | 3 |
"Visual/verbal Rating Score (VRS). VRS is used to assess pain in patients. With 0 representing no pain at all and 10 representing worst possible pain.~Total Minimum score=0 Total Maximum score=10~Higher values represent worse pain. If VRS=0, then the headache pain is considered resolved." (NCT03951649)
Timeframe: 180min
| Intervention | score on a scale (Median) |
|---|---|
| Occipital Nerve Block | 6 |
| Oral Acetaminophen/Caffeine Group | 4 |
"Visual/verbal Rating Score (VRS). VRS is used to assess pain in patients. With 0 representing no pain at all and 10 representing worst possible pain.~Total Minimum score=0 Total Maximum score=10~Higher values represent worse pain. If VRS=0, then the headache pain is considered resolved." (NCT03951649)
Timeframe: 2 hrs
| Intervention | score on a scale (Median) |
|---|---|
| Occipital Nerve Block | 6.0 |
| Oral Acetaminophen/Caffeine Group | 6.5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation. (NCT00272311)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| Arm 1 of 5 Randomized Treatment Arms | 27.6 |
| Arm 2 of 5 Randomized Treatment Arms | 27.0 |
| Arm 3 of 5 Randomized Treatment Arms | 31.4 |
| Arm 4 of 5 Randomized Treatment Arms | 25.7 |
| Arm 5 of 5 Randomized Treatment Arms | 28.3 |
Heme oxygenase a downstream target of nitric oxide formation (NCT00272337)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| 1 of 5 Randomized Treatment Arms | 10.0 |
| 2 of 5 Randomized Treatment Arms | 11.2 |
| 3 of 5 Randomized Treatment Arms | 10.0 |
| 4 of 5 Randomized Treatment Arms | 11.0 |
| 5 of 5 Randomized Treatment Arms | 9.6 |
Bleeding events according to GUSTO (criteria for bleeding: Severe, Moderate or Mild) and BARC (bleeding criteria Type 0-5, with 0 being no bleeding and 5 referring to probable or definite fatal bleeding) Criteria (NCT02475837)
Timeframe: up to 238 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Vorapaxar Intervention | 0 |
| Placebo Intervention | 1 |
Participants able to use their AV fistula for dialysis within 180 days of surgery were considered to have met the outcome. (NCT02475837)
Timeframe: up to 238 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Vorapaxar Intervention | 2 |
| Placebo Intervention | 4 |
Criteria for outcome: AV fistula patency at 150-180 days, with at least 50% increase in vein diameter by ultrasound compared with preoperative vein diameter measurement. (NCT02475837)
Timeframe: 150-238 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Vorapaxar Intervention | 1 |
| Placebo Intervention | 5 |
Time to AV fistula functional maturation (defined as successful cannulation of the AV fistula for six hemodialysis sessions within three weeks). (NCT02475837)
Timeframe: up to 238 days
| Intervention | Days to functional maturation (Median) |
|---|---|
| Vorapaxar Intervention | 169 |
| Placebo Intervention | 145 |
534 reviews available for aspirin and Blood Clot
| Article | Year |
|---|---|
Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.
Topics: Fibrinolytic Agents; Humans; Molecular Structure; Thrombosis | 2022 |
Ischemic stroke as a presenting manifestation of polycythemia vera: a narrative review.
Topics: Aspirin; Humans; Ischemic Stroke; Janus Kinase 2; Polycythemia Vera; Thrombosis | 2022 |
What is the optimal management of thromboprophylaxis after liver transplantation regarding prevention of bleeding, hepatic artery, or portal vein thrombosis? A systematic review of the literature and expert panel recommendations.
Topics: Anticoagulants; Aspirin; Hemorrhage; Hepatic Artery; Humans; Liver Diseases; Liver Transplantation; | 2022 |
Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.
Topics: Aspirin; Humans; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis; Quality of | 2022 |
The Effect of Aspirin on the Prevention of Pro-thrombotic States in Hospitalized COVID-19 Patients: Systematic Review.
Topics: Antiviral Agents; Aspirin; COVID-19 Drug Treatment; Humans; Interleukin-6; Lipoxins; Platelet Aggreg | 2022 |
A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet | 2022 |
Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction.
Topics: Aspirin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibito | 2021 |
Antiplatelet agents and anticoagulants for hypertension.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; M | 2022 |
The role of platelets in reproduction
Topics: Aspirin; Blood Platelets; Female; Hemostasis; Humans; Ovarian Hyperstimulation Syndrome; Placenta; P | 2022 |
Pathophysiology and Mechanisms of Saphenous Vein Graft Failure.
Topics: Aspirin; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpla | 2022 |
Comparison of non-criteria antiphospholipid syndrome with definite antiphospholipid syndrome: A systematic review.
Topics: Antiphospholipid Syndrome; Aspirin; Female; Humans; Pregnancy; Pregnancy Outcome; Thrombosis; Venous | 2022 |
Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
SOHO State of the Art Updates and Next Questions | Polycythemia Vera: Is It Time to Rethink Treatment?
Topics: Aspirin; Humans; Hydroxyurea; Janus Kinase 2; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; | 2023 |
Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; P | 2023 |
Meta-Analysis of the Efficacy of Low Molecular Weight Heparin and Aspirin in the Treatment of Thrombosis During Pregnancy and Effects on Coagulation Function.
Topics: Anticoagulants; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Thrombophilia; Th | 2023 |
Personalized Dual Antiplatelet Therapy in Acute Coronary Syndromes: Striking a Balance Between Bleeding and Thrombosis.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Corona | 2023 |
Personalised antiplatelet therapies for coronary artery disease: what the future holds.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Myocardial Infarction | 2023 |
Effectiveness and Safety of P2Y12 Inhibitor Pretreatment for Primary PCI in STEMI: Systematic Review and Meta-analysis.
Topics: Aspirin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inh | 2023 |
The great obstetrical syndromes and the placenta.
Topics: Aspirin; Female; Humans; Infant, Newborn; Inflammation; Placenta; Pre-Eclampsia; Pregnancy; Prematur | 2023 |
Aspirin and Primary Prevention in Patients with Diabetes-A Critical Evaluation of Available Randomized Trials and Meta-Analyses.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Diabetes Complications; D | 2019 |
Antiplatelets, anticoagulants, and colonoscopic polypectomy.
Topics: Anticoagulants; Aspirin; Colonic Polyps; Colonoscopy; Deprescriptions; Embolism; Factor Xa Inhibitor | 2020 |
Antithrombotic therapy after percutaneous coronary intervention from the Japanese perspective.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fi | 2020 |
[Short dual antiplatelet therapy: how, when and why].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Dual Anti-Platelet Therapy; H | 2020 |
Antiplatelet therapies in diabetes.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus; Humans; Platelet Aggregation Inhib | 2020 |
Treatment of thrombotic antiphospholipid syndrome in adults and children.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Child; Humans; Prospective Studies; Throm | 2020 |
Topics: Aspirin; Humans; Pyrazines; Randomized Controlled Trials as Topic; Thrombosis; Treatment Outcome; Ve | 2020 |
Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: systematic review and meta-analysis.
Topics: Aspirin; Cause of Death; Heart Diseases; Humans; Myocardial Infarction; Outcome Assessment, Health C | 2020 |
Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: Systematic Review and Meta-Analysis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Administration Schedule | 2021 |
Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway?
Topics: Angiotensin II; Animals; Aspirin; Blood Coagulation Disorders; Coronavirus Infections; COVID-19; Dip | 2020 |
Platelets in chronic obstructive pulmonary disease: An update on pathophysiology and implications for antiplatelet therapy.
Topics: Aspirin; Blood Platelets; Disease Progression; Elastin; Electron Transport; Humans; Inflammation; Lu | 2020 |
Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans | 2020 |
Risk Factors for Bleeding and Clinical Ineffectiveness Associated With Clopidogrel Therapy: A Comprehensive Meta-Analysis.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Dual Anti-Platelet Therapy; Hemorrhage; Huma | 2021 |
Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Leprostatic Agents; Multiple Myeloma; Ph | 2021 |
Meta-Analysis Comparing the Safety and Efficacy of Single vs Dual Antiplatelet Therapy in Post Transcatheter Aortic Valve Implantation Patients.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemi | 2021 |
Management of Women with Antiphospholipid Antibodies or Antiphospholipid Syndrome during Pregnancy.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Heparin, L | 2021 |
Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Blood C | 2021 |
Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies.
Topics: Adolescent; Adult; Aspirin; Calreticulin; Disease-Free Survival; Erythrocyte Transfusion; Female; Fo | 2021 |
Interventions for preventing thrombosis in solid organ transplant recipients.
Topics: Anticoagulants; Aspirin; Bias; Dipyridamole; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hum | 2021 |
Usefulness of Antiplatelet Therapy After Transcatheter Aortic Valve Implantation.
Topics: Aortic Valve Stenosis; Aspirin; Cause of Death; Clopidogrel; Dual Anti-Platelet Therapy; Endothelium | 2021 |
Aspirin Alone Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation: A Systematic Review and Patient-Level Meta-Analysis.
Topics: Aortic Valve Stenosis; Aspirin; Dual Anti-Platelet Therapy; Humans; Platelet Aggregation Inhibitors; | 2021 |
Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets.
Topics: Aspirin; Blood Platelets; COVID-19; COVID-19 Drug Treatment; Humans; Myocardial Infarction; SARS-CoV | 2021 |
Meta-analysis on aspirin combined with low-molecular-weight heparin for improving the live birth rate in patients with antiphospholipid syndrome and its correlation with d-dimer levels.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin | 2021 |
Thrombotic Events and Anticoagulants in Beta-thalassemia Patients with Focus on Anticoagulants for Atrial Fibrillation: A Brief Review.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; beta-Thalassemia; Hemorrhage; Hu | 2022 |
Efficacy and Safety of Aspirin Combined with Low-Dose P2Y12 Receptor Antagonists in East Asian Patients Undergoing PCI.
Topics: Asia, Eastern; Aspirin; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Purinergic | 2021 |
Meta-Analysis of Short vs. Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation and Role of Continuation with either Aspirin or a P2Y
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction; | 2022 |
Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation.
Topics: Anticoagulants; Aspirin; Blood Coagulation; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrino | 2021 |
Triple Antithrombotic Therapy in Patients With Left Ventricular Assist Devices.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Gastrointestinal Hemorrhage | 2022 |
Do Aspirin and Other NSAIDs Confer a Survival Benefit in Men Diagnosed with Prostate Cancer? A Pooled Analysis of NIH-AARP and PLCO Cohorts.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Comorbidity; Diet Surveys; Early Detection o | 2017 |
Perioperative Venous Thromboembolism: A Review.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductas | 2017 |
A Primer on Bleeding Risk and Management Strategies of Newer Oral Anti Platelet Agents in Cardiovascular Disease.
Topics: Adenosine; Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Gastrointestinal Hem | 2016 |
Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; As | 2017 |
Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration.
Topics: Aspirin; Cardiovascular Diseases; Databases, Factual; Drug-Eluting Stents; Hemorrhage; Humans; Myoca | 2017 |
The role of prasugrel in the management of acute coronary syndromes: a systematic review.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2017 |
[Atherothrombosis : Novel therapeutic strategies].
Topics: Animals; Anticoagulants; Aspirin; Carrier Proteins; Clinical Trials as Topic; Humans; Hydroxymethylg | 2018 |
Antiphospholipid syndrome.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Anticoagulants; Antiph | 2018 |
Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Aspirin; Cost-Benefit Analysis; Drug Therapy, Combination; England; Humans; Models, Economic; Myocar | 2018 |
Pathophysiology of thrombosis and anticoagulation post Fontan surgery.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Fontan Procedure; Heart Defects, Congenital; Humans; T | 2018 |
Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; DNA; Drug Therapy, Combination; Facto | 2018 |
Traditional Chinese medicine: herb-drug interactions with aspirin.
Topics: Aspirin; Carthamus; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Herb-Dru | 2018 |
A systematic review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in peripheral arterial disease.
Topics: Aspirin; Endovascular Procedures; Fibrinolytic Agents; Humans; Peripheral Arterial Disease; Platelet | 2018 |
Stent thrombosis associated with drug eluting stents on addition of cilostazol to the standard dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis of published randomized controlled trials.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Percutaneo | 2018 |
Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Combinations; Drug-Related Side Effects and Adverse | 2018 |
The pathogenesis and available prevention options in patients with diabetic thrombophilia.
Topics: Aspirin; Blood Coagulation; Diabetes Mellitus; Fibrinolysis; Humans; Hypoglycemic Agents; Thrombophi | 2018 |
Antithrombotic therapy management of adult and pediatric cardiac surgery patients.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Blood Coagulation; Cardiac Surgical Procedures; Cardiolo | 2018 |
[Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Co | 2018 |
Single versus Dual Antiplatelet Therapy after Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis.
Topics: Aortic Valve; Aspirin; Cerebrovascular Disorders; Clopidogrel; Drug Therapy, Combination; Heart Valv | 2018 |
Antithrombotic medications and their impact on fibrin clot structure and function.
Topics: Anticoagulants; Aspirin; Fibrin; Fibrinolytic Agents; Humans; Purinergic P2Y Receptor Antagonists; T | 2018 |
Short-term versus long-term triple antithrombotic therapy for patients with coronary stents and requiring oral anticoagulation: a meta-analysis of randomized clinical trials.
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; He | 2019 |
Omission of aspirin in patients taking oral anticoagulation after percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Coronary Artery Disease; Dru | 2019 |
Antithrombotic Agents.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clinical Trials a | 2019 |
Periprocedural Neuroendovascular Antiplatelet Strategies for Thrombosis Prevention in Clopidogrel-Hyporesponsive Patients.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Endovascular Procedures; Humans; Intracranial Aneur | 2019 |
Effects of Ultra-Low-Dose Aspirin in Thrombosis and Haemorrhage.
Topics: Animals; Aspirin; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Hemorrhage; Homeopathy; Human | 2019 |
Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Percuta | 2019 |
Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cerebral Revascularization; Clopidogrel; Cytochro | 2019 |
Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5).
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Th | 2019 |
Total Thrombus-Formation Analysis System (T-TAS): Clinical Application of Quantitative Analysis of Thrombus Formation in Cardiovascular Disease.
Topics: Anticoagulants; Area Under Curve; Aspirin; Blood Platelets; Cardiovascular Diseases; Catheter Ablati | 2019 |
Thrombosis and embolism in pediatric cardiomyopathy.
Topics: Anticoagulants; Aspirin; Cardiomyopathy, Dilated; Cardiomyopathy, Restrictive; Child; Disease Manage | 2013 |
Monitoring aspirin and clopidogrel response: testing controversies and recommendations.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Interv | 2013 |
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Topics: Anticoagulants; Aspirin; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Randomized Cont | 2013 |
Late and very late stent thrombosis in patients with second-generation drug-eluting stents.
Topics: Aspirin; Cardiotonic Agents; Clopidogrel; Drug-Eluting Stents; Everolimus; Humans; Percutaneous Coro | 2013 |
Medical management after coronary stent implantation: a review.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet | 2013 |
Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction.
Topics: Aspirin; Dipyridamole; Eclampsia; Female; Fibrinolytic Agents; Heparin; Humans; Infant; Infant, Low | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; | 2013 |
Early postoperative thrombosis of an aortic bioprosthetic valve: should anticoagulation be patient specific?
Topics: Administration, Oral; Aged; Anticoagulants; Aortic Valve; Aortic Valve Stenosis; Aspirin; Bioprosthe | 2013 |
Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Hemorrhage; Humans; Lupus Erythema | 2014 |
Should patients taking aspirin for secondary prevention continue or discontinue the medication prior to elective, abdominal surgery? Best evidence topic (BET).
Topics: Abdomen; Aspirin; Elective Surgical Procedures; Humans; Platelet Aggregation Inhibitors; Secondary P | 2014 |
[Present and future of pharmaco-arteriothromboprophylaxis in clinical practice. Guidelines of Angiology Section of Slovak Medical Chamber].
Topics: Aspirin; Czech Republic; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Investigati | 2013 |
[Serious organ damage and intractable clinical conditions in rheumatic and connective tissue disease--progress in pathophysiology and treatment. Topics: II. Clinical conditions special attention needed to be paid to; 2. Antiphospholipid syndrome].
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin | 2013 |
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dru | 2014 |
[Basic pathogenesis of, heterogeneity of , and its therapeutic strategy for West syndrome and tuberous sclerosis complex].
Topics: Anticoagulants; Anticonvulsants; Aspirin; Cosyntropin; Female; Gangliosides; Humans; Infant; Infant, | 2014 |
Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; M | 2015 |
Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis.
Topics: Aspirin; Cardiology; Cardiovascular Diseases; Europe; Humans; Primary Prevention; Societies, Medical | 2014 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int | 2014 |
The current and future landscape of urinary thromboxane testing to evaluate atherothrombotic risk.
Topics: Aspirin; Biomarkers; Blood Platelets; Drug Resistance; Fibrinolytic Agents; Humans; Patient Selectio | 2014 |
A systematic review on the effect of aspirin in the prevention of post-operative arterial thrombosis in patients undergoing total hip and total knee arthroplasty.
Topics: Anticoagulants; Arterial Occlusive Diseases; Arthroplasty, Replacement, Hip; Arthroplasty, Replaceme | 2014 |
[Historical and future perspective of antithrombotic agents].
Topics: Anticoagulants; Aspirin; Humans; Platelet Aggregation Inhibitors; Thrombosis; Treatment Outcome; War | 2014 |
[Therapy for prevention of upper gastrointestinal bleeding in patients receiving anti-thrombotic therapy].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Gastrointestinal Hemorrhage; Humans; Platelet Agg | 2014 |
Recent developments in antiplatelet therapy after percutaneus coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervent | 2014 |
Platelets: still a therapeutical target for haemostatic disorders.
Topics: Aspirin; Blood Platelets; Hemostatic Disorders; Humans; Integrins; Platelet Aggregation Inhibitors; | 2014 |
Resistance to antiplatelet drugs: what progress has been made?
Topics: Aspirin; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage; Humans; Percutaneous Coronary Intervent | 2014 |
[Antiplatelet therapy after acute coronary syndrome. Therapeutic strategies and treatment duration].
Topics: Acute Coronary Syndrome; Aspirin; Cardiology; Drug Administration Schedule; Drug Therapy, Combinatio | 2014 |
Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies.
Topics: Antibodies, Antiphospholipid; Aspirin; Cohort Studies; Humans; Primary Prevention; Risk Factors; Thr | 2015 |
[Added value of clopidogrel in cardiology and neurology].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2014 |
Antiplatelet therapy after drug-eluting stent implantation.
Topics: Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Ischemia; | 2015 |
Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus.
Topics: Aldehyde Reductase; Aspirin; Blood Platelets; Diabetes Mellitus, Type 2; F2-Isoprostanes; Glucose; G | 2015 |
Individualized antithrombotic therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Ba | 2016 |
Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery.
Topics: Anastomosis, Surgical; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Graft Occlusion, Vas | 2015 |
Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta-analysis of three large randomized trials.
Topics: Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Intracranial Hemorr | 2015 |
Why we should not skip aspirin in cardiovascular prevention.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Ba | 2016 |
Methylation reactions, the redox balance and atherothrombosis: the search for a link with hydrogen sulfide.
Topics: Animals; Aspirin; Atherosclerosis; Folic Acid; Gasotransmitters; Homocysteine; Humans; Hydrogen Sulf | 2015 |
The prognostic utility of tests of platelet function for the detection of 'aspirin resistance' in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cost-Benefit Analysis; Drug Resistance; | 2015 |
Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials.
Topics: Aspirin; Confidence Intervals; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting | 2015 |
New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Combinati | 2015 |
Platelets at the interface of thrombosis, inflammation, and cancer.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cell Death; Cell Proliferation; Cell-Der | 2015 |
Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective.
Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Folic Acid; Genotype; Homocysteine; Humans; Met | 2016 |
Thrombosis in Lymphoma Patients and in Myeloma Patients.
Topics: Anticoagulants; Aspirin; Female; Humans; Incidence; Lymphoma; Male; Multiple Myeloma; Retrospective | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials.
Topics: Aspirin; Clinical Trials as Topic; Databases, Factual; Drug-Eluting Stents; Hemorrhage; Humans; Myoc | 2015 |
Bleeding versus thrombosis: role of short DAPT in complex lesions.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans | 2015 |
Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Topics: Aspirin; Diagnosis, Differential; Disease Management; Disease Progression; Humans; Janus Kinase 2; P | 2015 |
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; L | 2015 |
The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Cohort Studies; Female; Heparin; H | 2016 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitu | 2015 |
Extended Dual Antiplatelet for Diabetic Elderly Patients After Drug-eluting Stent Implantation: an Evidence-based Clinical Review.
Topics: Aged; Aspirin; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Drug-Eluting Ste | 2015 |
Antithrombotic Therapy After Peripheral Vascular Intervention.
Topics: Angioplasty, Balloon; Aspirin; Atherectomy; Fibrinolytic Agents; Humans; Peripheral Arterial Disease | 2016 |
Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Assoc
Topics: Advisory Committees; American Heart Association; Aspirin; Cardiology; Coronary Artery Disease; Drug | 2016 |
The pharmacodynamics of antiplatelet compounds in thrombosis treatment.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Drug Therapy, | 2016 |
Update of thrombosis in multiple myeloma.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; | 2016 |
What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation?
Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Humans; Percuta | 2016 |
The effectiveness of antioxidant therapy in aspirin resistance, diabetes population for prevention of thrombosis.
Topics: Antioxidants; Aspirin; Blood Platelets; Diabetes Mellitus; Humans; Thrombosis; Treatment Outcome | 2016 |
Short- versus standard-term dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: A meta-analysis.
Topics: Aged; Aspirin; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarc | 2017 |
Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Hu | 2016 |
Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; P | 2016 |
Effects of Aspirin on Endothelial Function and Hypertension.
Topics: Animals; Aspirin; Clinical Trials as Topic; Endothelium, Vascular; Humans; Hypertension; Thrombosis; | 2016 |
Is arachidonic acid stimulation really a test for the response to aspirin? Time to think again?
Topics: Arachidonic Acid; Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Humans; Platel | 2017 |
Prevention of thrombosis in antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Aspirin; Female; Fibrinolytic Agents; Humans; Male; Pregnancy; Pregnancy | 2016 |
Meta-analysis of major bleeding events on aspirin versus vitamin K antagonists in randomized trials.
Topics: Aspirin; Global Health; Hemorrhage; Humans; Incidence; Platelet Aggregation Inhibitors; Randomized C | 2017 |
Antiphospholipid syndrome.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fibrinolyt | 2017 |
Monitoring Antiplatelet Therapy.
Topics: Aspirin; Blood Platelets; Clopidogrel; Drug Monitoring; Humans; Platelet Aggregation Inhibitors; Pla | 2017 |
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi | 2008 |
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi | 2008 |
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi | 2008 |
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combi | 2008 |
Initiation and persistence of warfarin or aspirin as thromboprophylaxis in chronic atrial fibrillation in general practice.
Topics: Aspirin; Atrial Fibrillation; Family Practice; Humans; Premedication; Thrombosis; Warfarin | 2008 |
Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardio | 2008 |
Clinical implications of aspirin resistance.
Topics: Aspirin; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Resistance; | 2008 |
Reducing the risk of adverse thrombotic events - The role of aspirin and clopidogrel.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Thrombosis | 2008 |
Drug-eluting stents and antiplatelet resistance.
Topics: Aspirin; Clopidogrel; Drug Resistance; Drug-Eluting Stents; Humans; Platelet Aggregation Inhibitors; | 2008 |
Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combina | 2008 |
Update on antiphospholipid syndrome.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Blood Coagulation; | 2008 |
Management of surgical patients receiving anticoagulation and antiplatelet agents.
Topics: Anticoagulants; Aspirin; Emergency Treatment; Heparin; Humans; Intraoperative Care; Platelet Aggrega | 2008 |
The genetics of antiplatelet drug resistance.
Topics: Aspirin; Blood Platelets; Clopidogrel; Humans; Platelet Activation; Platelet Aggregation; Platelet A | 2009 |
Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cardiovascular P | 2008 |
[Should platelet inhibitors be discontinued before gastrointestinal endoscopy?].
Topics: Aspirin; Endoscopy, Gastrointestinal; Evidence-Based Medicine; Humans; Platelet Aggregation Inhibito | 2008 |
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
Topics: Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; | 2009 |
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
Topics: Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; | 2009 |
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
Topics: Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; | 2009 |
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
Topics: Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; | 2009 |
Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Cardiovascular Diseas | 2009 |
Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Evidence-Based Me | 2009 |
Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents.
Topics: Aged; Aspirin; Case-Control Studies; Data Collection; Drug-Eluting Stents; Drug-Related Side Effects | 2009 |
Significant gastrointestinal bleeding in patients at risk of coronary stent thrombosis.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Aspirin; Clopidogrel; Coro | 2009 |
[The antiphospholipid syndrome in the 21st century].
Topics: Adult; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Tri | 2009 |
Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management.
Topics: Age Factors; Animals; Aspirin; Clinical Trials as Topic; Female; Gonadal Steroid Hormones; Humans; M | 2009 |
Diabetes and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Dia | 2009 |
Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Drug Resistance; Endothelium, Vascular; Humans; Ischemia; O | 2009 |
[Diagnosis, causes, relevance of a complex phenomenon. Resistance to aspirin and clopidogrel].
Topics: Aspirin; Blood Platelets; Clopidogrel; Drug Interactions; Drug Resistance; Humans; Phosphorylation; | 2009 |
Antiplatelet therapy discontinuation following drug-eluting stent placement: dangers, reasons, and management recommendations.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Co | 2009 |
WHO should consider the benefits of aspirin prophylaxis in middle age?
Topics: Aspirin; Humans; Middle Aged; Platelet Aggregation Inhibitors; Thrombosis; World Health Organization | 2009 |
Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Humans; | 2009 |
Platelet function testing and implications for clinical practice.
Topics: Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Hemorrhage; Hemostasis; Humans; Ischemia; Pl | 2009 |
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis | 2009 |
Antiplatelet resistance--fact or myth?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Huma | 2009 |
Dental management of patients taking antiplatelet medications.
Topics: Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Dental Care for Chronically Ill; Humans; Oral Hemor | 2009 |
Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.
Topics: Aspirin; Humans; Janus Kinase 2; Leukocytosis; Mutation; Platelet Aggregation Inhibitors; Polycythem | 2010 |
[Perioperative antiplatelet therapy of patients with coronary stents].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort S | 2009 |
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Huma | 2009 |
[Medicinal therapy for interventional surgery of the peripheral vascular system].
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Therap | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part IV. therapeutic application of clopidogrel in combination with acetylsalicylic acid in acute coronary syndromes and percutaneous coronary interventions].
Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon; Aspirin; Clinical Trials | 2009 |
Comparing consensus guidelines on thromboprophylaxis in orthopedic surgery.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Blood Loss, Surgical; Cast | 2010 |
Combination antithrombotic therapies.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Pyrid | 2010 |
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hem | 2010 |
Prolonged infusion of eptifibatide as bridge therapy between bare-metal stent insertion and cardiovascular surgery: case report and review of the literature.
Topics: Angioplasty; Anticoagulants; Aspirin; Cardiovascular Surgical Procedures; Clopidogrel; Coronary Arte | 2010 |
Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis.
Topics: Acute Coronary Syndrome; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Complications; D | 2010 |
JAK2 mutation and thrombosis in the myeloproliferative neoplasms.
Topics: Amino Acid Substitution; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Fibrinolytic Ag | 2010 |
Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedu | 2010 |
Drug-eluting stent thrombosis 1,659 days after stent deployment: case report and literature review.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; D | 2010 |
Clot prevention--common questions about medications.
Topics: Anticoagulants; Aspirin; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Huma | 2010 |
Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery.
Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans | 2010 |
TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus.
Topics: Aspirin; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Plaque, Atherosclerotic; Platele | 2011 |
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
Topics: Aspirin; Blood-Brain Barrier; Cilostazol; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy | 2010 |
A review of the use of common antiplatelet agents in orthopaedic practice.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combina | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D | 2010 |
A comparison of the metabolism of clopidogrel and prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Carboxylic Ester Hydrolases; Clopi | 2010 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty; Aspirin; Drug Interactions; Humans; Medication Adherence; Plat | 2011 |
[New aspects on "triple therapy" after coronary stent implantation].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; | 2010 |
Aspirin for the prevention of cardiovascular morbidity.
Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Female; Humans; Male; Myocardial Infarction | 2010 |
Clopidogrel withdrawal: is there a "rebound" phenomenon?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration S | 2011 |
Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Humans; Ma | 2011 |
[Efficacy and safety of various doses of acetylsalicylic Acid in prevention of complications of atherothrombosis].
Topics: Aspirin; Blood Platelets; Blood Vessels; Cardiovascular Diseases; Cerebrovascular Disorders; Clinica | 2010 |
Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fib | 2011 |
Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation.
Topics: Aspirin; Blood Platelets; Humans; Leukocytes; Platelet Activation; Platelet Aggregation; Platelet Ag | 2011 |
Antiplatelet therapy in the perioperative period.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; H | 2011 |
Patients with drug-eluting stents and management of their anticoagulant therapy in cutaneous surgery.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dermatologic Surgical Procedures; Drug-Eluting Stents; Humans; | 2011 |
Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Dose-Response Relatio | 2011 |
Heparin or aspirin or both in the treatment of recurrent abortions in women with antiphospholipid antibody (syndrome).
Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic; Dr | 2011 |
Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Huma | 2010 |
Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.
Topics: Aspirin; Clopidogrel; Drug Monitoring; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors | 2011 |
Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Comorbidity; Female; Humans; Incidenc | 2012 |
Genetic determinants of on-clopidogrel high platelet reactivity.
Topics: Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Su | 2011 |
Clopidogrel hydrogen sulphate for atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Humans; Platel | 2011 |
Antiplatelet therapy: thrombin receptor antagonists.
Topics: Aspirin; Blood Platelets; Humans; Imines; Lactones; Platelet Aggregation; Platelet Aggregation Inhib | 2011 |
Platelet activation in obesity and metabolic syndrome.
Topics: Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Metabolic Syndrome; Obesity | 2012 |
High on treatment platelet reactivity.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Cyclooxygenase Inhi | 2012 |
[Decreasing incidence of stent thrombosis].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap | 2011 |
Obstetric antiphospholipid syndrome: an update on pathophysiology and management.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Hepari | 2011 |
[Clopidogrel resistance--clinical significance, pathogenesis and potential solutions].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Huma | 2011 |
Antiplatelet therapy in ENT surgery: a review.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Decision Making; Drug-Eluting Stents; Humans; Otorhinola | 2012 |
Pancreas graft thrombosis: causes, prevention, diagnosis, and intervention.
Topics: Acute Disease; Anticoagulants; Aspirin; Fibrinolytic Agents; Graft Rejection; Heparin; Humans; Incid | 2012 |
Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagulation; Confidence Intervals; Evidence- | 2012 |
Aspirin in primary and secondary prevention in elderly adults revisited.
Topics: Aged; Aspirin; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Primary Preven | 2012 |
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Aspirin; Cilostazol; Dipyridamole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Evid | 2012 |
Cilostazol and primary-PCI: mirage or good alternative?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Aspirin; Cilostazol; | 2012 |
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Topics: Acute Disease; Age Factors; Alkylating Agents; Anticoagulants; Aspirin; Busulfan; Disease Management | 2012 |
[Management of antiphospholipid syndrome].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; As | 2012 |
Atherothrombosis in von Willebrand disease: an analysis of the literature and implications for clinical management.
Topics: Adult; Aged; Aspirin; Atherosclerosis; Cardiac Surgical Procedures; Coronary Artery Disease; Hemophi | 2012 |
What do you do with the antiplatelet agents in patients with drug eluting stents who then receive a mechanical valve?
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Benchmarking | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Optimal thromboprophylaxis following bioprosthetic aortic valve replacement: still a matter of debate?
Topics: Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Evidence-Based Medicine; Fibrinolytic Agents; | 2012 |
Antiplatelet therapy in children: why so different from adults'?
Topics: Adult; Age Factors; Aspirin; Blood Platelets; Child Development; Child, Preschool; Dipyridamole; Hum | 2012 |
Novel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; beta 2-Glycoprotei | 2012 |
Anti-platelet treatment of middle-sized abdominal aortic aneurysms.
Topics: Animals; Aortic Aneurysm, Abdominal; Aspirin; Clinical Trials as Topic; Disease Models, Animal; Dise | 2013 |
Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary A | 2012 |
Advances in monitoring of aspirin therapy.
Topics: Aspirin; Blood Platelets; Dose-Response Relationship, Drug; Drug Administration Schedule; Hemorrhage | 2012 |
Stents and antiplatelet therapy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug-Eluting Stents; | 2012 |
Thromboxane receptors antagonists and/or synthase inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Clinical Trials as Topic | 2012 |
Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Ischemia; Myocardia | 2012 |
[True polycythemia: current views of pathogenesis, diagnostics and treatment].
Topics: Age Factors; Algorithms; Antineoplastic Agents; Aspirin; Benzamides; Combined Modality Therapy; Hema | 2012 |
Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Cost Savings; Drug Monitoring; Drug Resistance; Drug | 2013 |
Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Blood Coagulation; Fibrin; Humans; Plaque, Atherosclerotic; Platel | 2014 |
Interventional therapy for coronary artery disease.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Atherectomy, Coronary; B | 2002 |
State of the art--a journey through the world of antithrombotic therapy.
Topics: Ambulatory Care; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Coronary Disease; Fibrinolytic A | 2002 |
Bleeding risks of antithrombotic therapy.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; R | 2002 |
Contemporary antithrombotic strategies in patients undergoing coronary stent implantation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Drug Therapy, Combination; Fibrinolytic A | 2002 |
Prevention of thrombosis during pregnancy.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Blood Coagulation Tests; B | 2002 |
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Hemor | 2002 |
[Follow up antithrombotic therapy after thrombolysis].
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Restenosis; Heparin; Humans; Myocardi | 1994 |
[Antithrombotic therapy for ischemic cerebrovascular accident].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Fibrinolytic Agents; Humans; Recurrenc | 2002 |
[Thrombosis and antithrombotic agents in peripheral artery disease].
Topics: Administration, Oral; Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Intermittent Claudicatio | 2002 |
[The best of thrombosis in 2002].
Topics: Abciximab; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Ster | 2003 |
[Anticoagulation and antiaggregation during pregnancy].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Abruptio Placentae; Administration, Oral; Adult; | 2003 |
Sirolimus-eluting stents: a review of experimental and clinical findings.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Animals; Aspirin; Clopidogrel; Coronary Angiography | 2002 |
Evidence with antiplatelet therapy and ADP-receptor antagonists.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Purinergic | 2003 |
[Platelet inhibitors: old and new].
Topics: Abciximab; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Clopidogrel; Coronary Disease; Dipyrid | 2002 |
[Traveler's thrombosis].
Topics: Adult; Age Factors; Aged; Aircraft; Anticoagulants; Aspirin; Case-Control Studies; Clinical Trials a | 2003 |
[Clopidogrel: background information and use in clinical practice].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinol | 2003 |
Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts.
Topics: Aspirin; Blood Platelets; Brain Ischemia; Erythromelalgia; Hemorrhagic Disorders; Humans; Myocardial | 2003 |
What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Brachytherapy; Clopidogrel; Coronary Diseas | 2003 |
Antibody-mediated thrombosis and pregnancy loss.
Topics: Abortion, Spontaneous; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination | 2003 |
Prophylaxis of the antiphospholipid syndrome: a consensus report.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Humans; Lupus Erythematosus, Systemic; P | 2003 |
Aspirin resistance: definition, mechanisms and clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clinical Trials as Topic; Drug In | 2003 |
Aspirin resistance: definition, mechanisms and clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clinical Trials as Topic; Drug In | 2003 |
Aspirin resistance: definition, mechanisms and clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clinical Trials as Topic; Drug In | 2003 |
Aspirin resistance: definition, mechanisms and clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clinical Trials as Topic; Drug In | 2003 |
Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Combinations; Evidence-Based Medicine; Humans; Plate | 2003 |
Evidence-based management of thrombosis in the antiphospholipid antibody syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Evidence-Based Medicine; Humans; International N | 2003 |
Left atrial thrombus formation on a CardioSeal Septal Occlusion device in a patient with elevated factor VIII: resolution with medical therapy.
Topics: Aspirin; Blood Coagulation Disorders; Cardiac Surgical Procedures; Echocardiography, Transesophageal | 2003 |
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Blood | 2003 |
The mechanism of action of aspirin.
Topics: Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase | 2003 |
The mechanism of action of aspirin.
Topics: Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase | 2003 |
The mechanism of action of aspirin.
Topics: Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase | 2003 |
The mechanism of action of aspirin.
Topics: Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase | 2003 |
Aspirin and thrombinogenesis.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Coronary Artery Disease; Drug Resistance; Human | 2003 |
Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1).
Topics: Adenosine Diphosphate; Adenosine Triphosphatases; Animals; Antigens, CD; Apyrase; Aspirin; Cell Comm | 2003 |
Antiplatelet agents in atherothrombotic diseases.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Dipyridamole; Humans; Ischemia; Platelet Aggregation Inhibit | 2004 |
Clopidogrel in the management of cerebrovascular events.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Drug Costs; Drug Therapy, Combination; Humans; Platelet Aggr | 2004 |
Antithrombotic drugs in vascular medicine: a historical perspective.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; Endothelium, Vascular; | 2003 |
Thrombosis and a hypercoagulable state in HIV-infected patients.
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiretroviral Therapy, Highly Active; Aspirin; | 2004 |
Pharmacological approaches to studying platelet function: an overview.
Topics: Animals; Aspirin; Blood Platelets; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GP | 2004 |
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Topics: Administration, Oral; Angina Pectoris; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopido | 2004 |
Platelet function testing in cardiovascular diseases.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Case Management; Clopidogrel; Drug Resistance; H | 2004 |
Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic; Evidence-Based Medicin | 2005 |
Aspirin and coronary artery disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Blood Platelets; Clinical Tria | 2004 |
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
Topics: Aged; Aspirin; Hemorrhage; Humans; Hydroxyurea; Middle Aged; Polycythemia Vera; Risk Factors; Thromb | 2005 |
Antithrombotic therapy in hypertension: a Cochrane Systematic review.
Topics: Aspirin; Blood Pressure; Fibrinolytic Agents; Humans; Hypertension; Middle Aged; Thrombosis; Warfari | 2005 |
[Thrombophilias and vascular placental pathology. A survey of the literature].
Topics: Activated Protein C Resistance; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Cohort Studies; | 2005 |
Optimal antithrombotic treatment for percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation; Clinical Trials as Topic | 2005 |
[NSAIDs for therapy of rheumatoid arthritis. Introduction].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspirin; Cyclooxy | 2005 |
Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
Topics: Adenosine Diphosphate; Animals; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopidogrel; Co | 2005 |
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
Topics: Adenosine Diphosphate; Adult; Animals; Aspirin; Biotransformation; Clinical Trials, Phase I as Topic | 2005 |
Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection.
Topics: Adenosine Diphosphate; Animals; Antigens, CD; Apyrase; Aspirin; Blood Vessels; Cardiotonic Agents; C | 2005 |
[Oral antithrombotic therapy in primary and secondary prevention].
Topics: Animals; Aspirin; Clopidogrel; Fibrinolytic Agents; Humans; Primary Prevention; Secondary Prevention | 2005 |
[Aspirin--the prodigious panacea? Molecular mechanisms of the action of acetylsalicylic acid in the organism].
Topics: Analgesics; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dru | 2005 |
Effects of aspirin and low-dose heparin in head and neck reconstruction using microvascular free flaps.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Child; Child, Preschool; Cohort Studies; Female; F | 2005 |
[Mechanism and drug treatment of atherothrombosis].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; C-Reactive Protein; CD40 Antigens; Clopidogrel; Drug Ther | 2005 |
A critical appraisal of the phenomenon of aspirin resistance.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation; Pl | 2005 |
Anticoagulation therapy in the antiphospholipid syndrome: recent advances.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Humans; Kidney Transplantation; Pregnanc | 2005 |
Therapeutic approaches in arterial thrombosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atherosclerosis; Blood Pl | 2005 |
Determinants of the interindividual variability in response to antiplatelet drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Drug Interactions; D | 2005 |
Effects of dietary supplements on aspirin and other antiplatelet agents: an evidence-based approach.
Topics: Aspirin; Clinical Trials as Topic; Dietary Supplements; Drug Interactions; Evidence-Based Medicine; | 2005 |
Aspirin resistance and atherothrombotic disease.
Topics: Aspirin; Atherosclerosis; Drug Resistance; Humans; Platelet Activation; Thrombosis | 2005 |
Antiphospholipid antibodies in young adults with stroke.
Topics: Adolescent; Adult; Age Factors; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagu | 2005 |
[The new antithrombotic agents].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Azetidines; Benzylami | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Low-dose aspirin for the prevention of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resi | 2005 |
Antiplatelet agents and arterial thrombosis.
Topics: Age Factors; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Dose-R | 2006 |
Antiplatelet drugs.
Topics: Animals; Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Platelet Aggregation; Platelet Agg | 2006 |
[Evidence-based medicine in antithrombotic therapy].
Topics: Aspirin; Evidence-Based Medicine; Fibrinolytic Agents; Heparin; Humans; Thrombolytic Therapy; Thromb | 2005 |
Essential thrombocythemia: scientific advances and current practice.
Topics: Antineoplastic Agents; Aspirin; Bone Marrow Examination; Humans; Hydroxyurea; In Situ Hybridization, | 2006 |
Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Topics: Aspirin; Humans; Myeloproliferative Disorders; Platelet Activation; Polycythemia Vera; Thrombocythem | 2006 |
[Dual antithrombotic therapy after implantation of coronary stents].
Topics: Aspirin; Clopidogrel; Coronary Stenosis; Dose-Response Relationship, Drug; Drug Synergism; Humans; P | 2006 |
Clopidogrel resistance: myth or reality?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Hu | 2006 |
[Prevention of thromboembolism in patients with atrial fibrillation].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disea | 2006 |
Aspirin resistance: does it exist and is it an important clinical problem?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidog | 2006 |
MATCH results: implications for the internist.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Controlled Clinical Trials as Topic; Double-Blind Method; Dru | 2006 |
The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Topics: Aspirin; Bleeding Time; Blood Platelets; Deamino Arginine Vasopressin; Hemorrhage; Humans; Microcirc | 2006 |
Vascular endothelium and atherosclerosis.
Topics: Animals; Aspirin; Atherosclerosis; Cell Adhesion Molecules; Cyclooxygenase Inhibitors; Cytokines; En | 2006 |
Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic, antiinflammatory drugs? Arguments against.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular Diseases; Cl | 2006 |
From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
Topics: Animals; Apoptosis; Aspirin; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Drug Therapy, Co | 2007 |
Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Admi | 2006 |
[Fetus monitoring of a mother suffering from the antiphospholipid syndrome].
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biomarkers; Female | 2006 |
The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Therapy; Dr | 2006 |
Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Diabetic Angiopathies; Humans; Hydroxymethy | 2007 |
[Update on antithrombotic treatments in arterial diseases].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Eptifiba | 2007 |
[Coronary stents, dual antiplatelet therapy and peri-operative problems].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Humans; Perioperative Care; Platelet Aggregati | 2007 |
Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
Topics: Adenosine Diphosphate; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Biomarkers | 2007 |
Antiplatelet medication after liver transplantation: does it affect outcome?
Topics: Aspirin; Hepatic Artery; Humans; Liver Transplantation; Platelet Aggregation Inhibitors; Postoperati | 2007 |
[JPPP].
Topics: Aged; Aged, 80 and over; Aspirin; Humans; Japan; Middle Aged; Practice Guidelines as Topic; Thrombos | 2006 |
Clinical aspects of platelet inhibitors and thrombus formation.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Cilostazol; Clopidogrel; Dipyrid | 2007 |
Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial | 2007 |
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.
Topics: Angina, Unstable; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Humans; Inflam | 2007 |
Aspirin and bleeding in dentistry: an update and recommendations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiovascular Diseases; Dental C | 2007 |
Con: continuation of aspirin/clopidogrel for cardiac surgery.
Topics: Aspirin; Cardiac Surgical Procedures; Clopidogrel; Drug Therapy, Combination; Heart Diseases; Humans | 2007 |
Pro: continuation of aspirin/clopidogrel for cardiac surgery.
Topics: Aspirin; Cardiac Surgical Procedures; Clopidogrel; Heart Diseases; Humans; Platelet Aggregation Inhi | 2007 |
Aspirin resistance.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Thrombos | 2007 |
Clopidogrel: an updated and comprehensive review.
Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Clopidogrel; Drug Approval; Drug Interactions; Hum | 2007 |
Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies.
Topics: Anticoagulants; Aspirin; Female; Fetal Death; Fetal Growth Retardation; Heparin; Humans; Immunoglobu | 2007 |
Clinical implications of aspirin resistance.
Topics: Aspirin; Cyclooxygenase 1; Drug Resistance; Enzyme Inhibitors; Heart Diseases; Humans; Ischemia; Pla | 2007 |
[The antiphospholipid syndrome, an update].
Topics: Abortion, Spontaneous; Acenocoumarol; Adult; Antibodies, Anticardiolipin; Anticoagulants; Antiphosph | 2007 |
Coronary stents and noncardiac surgery.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug-Eluting Stents; Humans; Male; Middle Aged; Plate | 2007 |
A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Humans; Internatio | 2007 |
[Vascular complications of essential thrombocythemia].
Topics: Age Factors; Aspirin; Case-Control Studies; Controlled Clinical Trials as Topic; Humans; Middle Aged | 2007 |
Aspirin and reproductive outcomes.
Topics: Abnormalities, Drug-Induced; Antibodies, Antiphospholipid; Aspirin; Cyclooxygenase Inhibitors; Dose- | 2008 |
Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Evidence-B | 2007 |
A meta-analysis of complications attributed to anticoagulation among patients following cutaneous surgery.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Postoperative Hemorrhage; Skin Diseases; Throm | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
[Platelet response to aspirin and clopidogrel. Biochemical evaluation, clinical impact, and pharmacological modulation].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Flow Cytometry; Humans; Platelet Agg | 2007 |
[Drug-eluting stent thrombosis and its pharmacological prevention].
Topics: Aspirin; Clopidogrel; Death, Sudden, Cardiac; Drug-Eluting Stents; Fibrinolytic Agents; Humans; Inci | 2007 |
Aspirin resistance: biological and clinical implications.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Humans; Platele | 2008 |
Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding.
Topics: Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; | 2008 |
Role of antiplatelet agents in the primary and secondary prevention of atherothrombotic events in high risk-patients.
Topics: Aspirin; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; D | 2008 |
Interaction effects and subgroup analyses in clinical trials: more than meets the eye?
Topics: Aspirin; Bias; Causality; Clinical Trials as Topic; Clopidogrel; Confounding Factors, Epidemiologic; | 2008 |
Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Drug Design; Factor X | 2008 |
Antiplatelet agents and arterial thrombosis.
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggreg | 2008 |
Chronic antithrombotic therapy in post-myocardial infarction patients.
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Humans; Myocardial Infarction; Perip | 2008 |
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Topics: Anticoagulants; Aspirin; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Randomized Cont | 2008 |
The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Humans; Platelet Activation; Plate | 2008 |
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2008 |
Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation; Dr | 2008 |
Antiplatelet agents: rationale and results.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Animals; Arachidonic Acids; Aspirin; Blood Plate | 1983 |
Bleeding associated with antithrombotic therapy.
Topics: 4-Hydroxycoumarins; Aspirin; Dextrans; Dipyridamole; Dose-Response Relationship, Drug; Fibrinolytic | 1980 |
Venous thrombosis and embolism.
Topics: Angiography; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Auscultation; Blood Coagulation; Blo | 1981 |
Pharmacological prevention of thrombotic occlusion in arterial reconstructive surgery.
Topics: Arachidonic Acid; Arachidonic Acids; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Cyclic A | 1983 |
Clinical aspects of the arachidonic acid--thromboxane pathway.
Topics: Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Coagulation; Cerebrovascular Disorders; Epoprost | 1983 |
Cyclic nucleotides in hemostasis and thrombosis.
Topics: Aspirin; Blood Platelets; Calcium; Cyclic AMP; Cyclic GMP; Diet; Hemostasis; Humans; Male; Phosphory | 1980 |
Pharmacology of platelet-affecting drugs.
Topics: Animals; Arachidonic Acids; Arteriosclerosis; Aspirin; Blood Platelets; Cyclic AMP; Dose-Response Re | 1980 |
Platelets, prostaglandins and thrombotic disorders.
Topics: Arachidonic Acids; Arteriosclerosis; Aspirin; Blood Platelets; Calcium; Coronary Disease; Cyclic AMP | 1981 |
[Pharmacology of anti-platelet agents].
Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Cyclic AMP; Cyclooxygenase Inhibitors; Dipyridamo | 1983 |
Prostaglandins and anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Central Nervous System Diseases; Cyclic AMP; Drug Hypers | 1983 |
The biologic background to some therapeutic uses of aspirin.
Topics: Animals; Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Coronary Disease; Humans; In | 1983 |
Aspirin for prevention of stroke: a review.
Topics: Aspirin; Cell Adhesion; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Platelet Aggr | 1983 |
Bleeding and thrombosis in the myeloproliferative disorders.
Topics: Alkylating Agents; Arachidonic Acids; Aspirin; Blood Viscosity; Epinephrine; Hematocrit; Hemorrhage; | 1984 |
[Primary thrombocyte reactions in hemostasis and thrombogenesis and the possibilities of influencing them by drugs].
Topics: Animals; Aspirin; Blood Platelets; Dipyridamole; Dose-Response Relationship, Drug; Drug Evaluation; | 1984 |
An antagonist of prostaglandin synthesis in cardiovascular diseases.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Brain Diseases; Cardiovascular Diseases; Con | 1984 |
Aspirin in the treatment of cardiovascular disease: a review.
Topics: Aspirin; Blood Platelets; Blood Vessels; Cell Adhesion; Clinical Trials as Topic; Cyclooxygenase Inh | 1983 |
Hypothesis: polypharmacy. The treatment of thrombotic risk.
Topics: Aspirin; Blood Coagulation Tests; Clofibrate; Hemorrhage; Heparin; Humans; Thrombosis; Warfarin | 1980 |
Potential therapeutic applications of aspirin and other cyclo-oxygenase inhibitors.
Topics: Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Digestive Sys | 1980 |
Present status of antiaggregating agents in coronary and cerebrovascular disease prevention.
Topics: Animals; Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Dise | 1980 |
[Prevention of thrombosis by thrombocyte inhibition. 2. Clinical results].
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofibrate; Dextrans; | 1980 |
Prostaglandin I2 (prostacyclin).
Topics: Animals; Arteriosclerosis; Aspirin; Blood Vessels; Cardiovascular Physiological Phenomena; Chemical | 1980 |
Prostaglandins and platelets.
Topics: Arachidonic Acids; Aspirin; Blood Platelets; Epoprostenol; Fatty Acids; Humans; Oxygenases; Phosphol | 1980 |
[Treatment of thrombosis and prevention of recurrence].
Topics: Aspirin; Heparin; Humans; Prognosis; Recurrence; Thrombosis | 1980 |
Sulfinpyrazone: a review of its pharmacological properties and therapeutic use.
Topics: Animals; Anti-Arrhythmia Agents; Antibody Formation; Aspirin; Blood Platelets; Cardiovascular Diseas | 1980 |
Platelet-active drugs in the secondary prevention of cardiovascular events: an overview.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Coronary Disease; Dipyridamole; Sulfinpyrazone; T | 1980 |
10. Antithrombotic therapy: role of platelet-inhibitor drugs. II. Pharmacologic effects of platelet-inhibitor drugs (second of three parts).
Topics: Aspirin; Dipyridamole; Drug Therapy, Combination; Epoprostenol; Fibrinolytic Agents; Gastrointestina | 1981 |
The role of prostacyclin and thromboxane A2 in the regulation of platelet behaviour.
Topics: Aspirin; Dipyridamole; Epoprostenol; Hemorrhage; Humans; Platelet Aggregation; Prostaglandins; Throm | 1980 |
Antiplatelet therapy.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Coronary Disease; Dipyridamole; Hea | 1981 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
Evolving concepts in the pathogenesis and treatment of arterial thrombosis.
Topics: Adult; Angioplasty; Animals; Anticoagulants; Antithrombin III; Aspirin; Blood Coagulation Tests; Cor | 1995 |
Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor.
Topics: Abciximab; Amino Acid Sequence; Animals; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Disinteg | 1995 |
Antiplatelet drugs. A comparative review.
Topics: Adenosine Diphosphate; Animals; Aspirin; Base Sequence; Blood Platelets; Consensus Sequence; Humans; | 1995 |
Evaluation of the obstetrical risks of the antiphospholipid syndrome and therapeutic management.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Glucocorticoids; Heparin; | 1995 |
Principles of thromboregulation: control of platelet reactivity in vascular disease.
Topics: Animals; Aspirin; Blood Platelets; Eicosanoids; Endothelium, Vascular; Hemostasis; Homeostasis; Huma | 1995 |
Haemostatic function, arterial disease and the prevention of arterial thrombosis.
Topics: Adult; Aged; Anticoagulants; Arteries; Aspirin; Blood Coagulation Factors; Cardiovascular Diseases; | 1994 |
Aspirin, platelets, and thrombosis: theory and practice.
Topics: Animals; Aspirin; Blood Platelets; Cerebrovascular Disorders; Humans; Models, Biological; Myocardial | 1994 |
The role of serotonin 5HT2 receptor antagonism in the control of coronary artery disease.
Topics: Aspirin; Coronary Disease; Drug Synergism; Humans; Platelet Aggregation; Serotonin Antagonists; Thro | 1994 |
[Controversies in prevention and therapy of thromboses and embolisms].
Topics: Anticoagulants; Aspirin; Embolism; Heparin; Humans; Risk Factors; Thrombosis | 1994 |
Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Dose-Response Relationship, Drug; Humans; Thrombo | 1993 |
Optimal dose for starting and maintaining low-dose aspirin.
Topics: Aspirin; Humans; Thrombosis; Thromboxane B2 | 1993 |
The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials.
Topics: Aged; Aspirin; Cardiovascular Diseases; Digestive System; Female; Gastrointestinal Diseases; Gastroi | 1993 |
Platelet activation mechanisms and markers in arterial thrombosis.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Hemostasis; Humans; Platelet Activation; Platel | 1996 |
Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions.
Topics: Adenosine Diphosphate; Apyrase; Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Eicosanoids; En | 1995 |
New antiplatelet agents: platelet GPIIb/IIIa antagonists.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Anticoagulants; Aspirin; | 1995 |
Antiplatelet therapy with aspirin: from clinical trials to practice.
Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Endothelium, Vascular; Epoprostenol; F | 1995 |
[Contemporary opinions on the use of aspirin, heparin and thrombolytic therapy in unstable angina pectoris--pathogenetic findings versus results of many clinical tests].
Topics: Angina, Unstable; Angiography; Aspirin; Hemorrhage; Heparin; Humans; Thrombolytic Therapy; Thrombosi | 1996 |
Antiplatelet therapy and the prevention of thrombosis.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trial | 1996 |
Antiplatelet therapy.
Topics: Aspirin; Dipyridamole; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Thrombosis; Tic | 1996 |
Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia.
Topics: Adult; Aged; Aspirin; Busulfan; Double-Blind Method; Erythromelalgia; Female; Gangrene; Hemorrhage; | 1996 |
New thoughts on strategies for modulating platelet function through the inhibition of surface receptors.
Topics: Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Evaluation, Preclinical; Endothelium, Vascular; | 1996 |
[Current approach in antithrombotic treatment during coronary interventions: specific thrombocyte aggregation inhibitors and direct thrombin antagonists in high-risk patients].
Topics: Adolescent; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Aspirin; Drug Thera | 1996 |
[Clinical studies of the effectiveness of aspirin in the prevention of major cardio-cerebrovascular occurrences].
Topics: Angina, Unstable; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Myocardial I | 1995 |
Stent thrombosis. Closing in on the best preventive treatment.
Topics: Aspirin; Atherectomy; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Recurrence; Stents; | 1997 |
[The measurement of platelet life span].
Topics: Arachidonic Acids; Aspirin; Blood Platelets; Erythrocyte Aging; Humans; Indium Radioisotopes; Malond | 1997 |
Thrombolytic therapy.
Topics: Aspirin; Clinical Trials as Topic; Heparin; Humans; Metalloendopeptidases; Streptokinase; Thrombolyt | 1997 |
Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents.
Topics: Aspirin; Dipyridamole; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Pla | 1997 |
Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
Topics: Anti-Inflammatory Agents; Arachidonic Acid; Arteriosclerosis; Aspirin; Blood Platelets; Cyclooxygena | 1997 |
Aspirin in essential thrombocythemia: status quo and quo vadis.
Topics: Abortion, Habitual; Aspirin; Cerebrovascular Disorders; Cohort Studies; Contraindications; Erythrome | 1997 |
Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
Topics: Alkylating Agents; Arachidonic Acid; Aspirin; Bleeding Time; Blood Platelets; Bone Marrow; Hematopoi | 1997 |
Role of transesophageal echocardiography in the management of thromboembolic stroke.
Topics: Anticoagulants; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Aspirin; Cerebrovascular Disorde | 1997 |
Mechanism of anti-proliferative action of eicosapentaenoic acid (EPA) in vascular cell growth: its effect on signal transduction system.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Arterioscl | 1997 |
A historical review of hemostasis, thrombosis, and antithrombotic therapy.
Topics: Animals; Anticoagulants; Aspirin; Fibrinolytic Agents; Hematologic Agents; Hemostasis; History, 18th | 1997 |
Dipyridamole: an unfulfilled promise?
Topics: Aspirin; Coronary Artery Bypass; Dipyridamole; Fibrinolytic Agents; Heart Valve Prosthesis Implantat | 1997 |
Pharmacologic prevention of acute ischemic complications of coronary angioplasty.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Constriction, Pathologic | 1997 |
Multifactorial aspects of the treatment of the type II diabetic patient.
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes | 1997 |
[Thrombosis and coronary disease: neutrophils, nitric oxide and aspirin].
Topics: Aspirin; Coronary Disease; Humans; Neutrophils; Nitric Oxide; Platelet Aggregation Inhibitors; Throm | 1998 |
The use of aspirin in polycythaemia vera and primary thrombocythaemia.
Topics: Arachidonic Acid; Aspirin; Cyclooxygenase Inhibitors; Humans; Platelet Aggregation Inhibitors; Polyc | 1998 |
Management of thrombosis and pregnancy loss in the antiphospholipid syndrome.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin | 1998 |
[Heparin-induced thrombocytopenia].
Topics: Anticoagulants; Antithrombins; Arginine; Aspirin; Diagnosis, Differential; Fibrinolytic Agents; Hepa | 1998 |
Aspirin analogs as antithrombotic agents.
Topics: Aspirin; Fibrinolytic Agents; Humans; Thrombosis | 1998 |
Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel.
Topics: Adenosine Diphosphate; Animals; Arteriosclerosis; Aspirin; Clopidogrel; Humans; Platelet Activation; | 1998 |
Antiplatelet therapy. Aspirin, ticlopidine/clopidogrel, and anti-integrin agents.
Topics: Aspirin; Clopidogrel; Humans; Integrins; Platelet Aggregation; Platelet Aggregation Inhibitors; Thro | 1998 |
Low molecular weight heparins in the cardiac catheterization laboratory.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 1999 |
Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications.
Topics: Animals; Arteriosclerosis; Aspirin; Disease Progression; Endothelium, Vascular; Humans; Platelet Act | 1999 |
Antiplatelet therapy in interventional cardiology: I. Newer oral antiplatelet agents.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; | 2000 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
Fertility, pregnancy and the management of myeloproliferative disorders.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Alkylating Agents; Animals; Aspirin; Bone Marrow | 1998 |
Antiplatelet therapy.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Coronary Disease; Humans; Immunoglobulin Fab Fragments; | 2000 |
[Aspirin and antiphospholipid syndrome].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antiphospholipid Syndrome; Arteriosc | 2000 |
[Diagnosis and management for antiphospholipid syndrome].
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biomarkers; Female | 2000 |
Treatment of the antiphospholipid antibody syndrome: progress in the last five years?
Topics: Abortion, Spontaneous; Antiphospholipid Syndrome; Aspirin; B-Lymphocytes; Hematopoietic Stem Cell Tr | 2000 |
Platelet-active drugs : the relationships among dose, effectiveness, and side effects.
Topics: Aspirin; Cyclooxygenase Inhibitors; Dipyridamole; Female; Fibrinolytic Agents; Humans; Platelet Aggr | 2001 |
Aspirin in the treatment and prevention of cardiovascular disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studie | 2000 |
Atrial fibrillation and stroke : concepts and controversies.
Topics: Aged; Aspirin; Atrial Appendage; Atrial Fibrillation; Humans; Intracranial Embolism; Prevalence; Ran | 2001 |
Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 2000 |
Should patients with hypertension receive antithrombotic therapy?
Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hypertension; Myocardial Infarction; Risk Factors | 2001 |
Benefit of ADP receptor antagonists in atherothrombotic patients: new evidence.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Purinergic P2 Receptor An | 2001 |
Aspirin in patients with coronary artery disease: is it simply irresistible?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Benzamidines; Clinical Trials as Topic; Clopidogrel; Cor | 2001 |
The epidemiology of the antiphospholipid syndrome: who is at risk?
Topics: Adolescent; Adult; Age Factors; Aged; Animals; Antibodies, Anticardiolipin; Antibodies, Antiphosphol | 2001 |
Management of thrombosis in antiphospholipid antibody syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Hemorrhage; Heparin; Humans; Lupus Erythematosus | 2001 |
[Platelet function inhibitors as a way of arterial thrombosis prevention in the diabetic].
Topics: Aspirin; Diabetes Complications; Diabetic Angiopathies; France; Humans; Platelet Aggregation Inhibit | 2001 |
Pharmacological control of platelet function.
Topics: Animals; Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Humans; Platelet Aggregation Inhibitor | 2001 |
Reducing the risk: heart disease, stroke and aspirin.
Topics: Acute Disease; Aspirin; Blood Platelets; Chronic Disease; Cost-Benefit Analysis; Drug Costs; Heart D | 2001 |
New antiplatelet agents: ticlopidine and clopidogrel. Antiplatelet therapy but at what cost?
Topics: Aspirin; Bone Marrow; Clopidogrel; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibi | 2001 |
[From the physiopathology of thrombosis to therapeutic targets].
Topics: Arteriosclerosis; Aspirin; Fibrinolytic Agents; Humans; Inflammation; Ischemia; Platelet Aggregation | 2001 |
[Antithrombotic treatment protocols in interventional cardiology].
Topics: Aspirin; Clopidogrel; Drug Resistance; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial | 2001 |
[Peripheral arterial revascularization: which antithrombotic agents?].
Topics: 4-Hydroxycoumarins; Anticoagulants; Arteries; Aspirin; Drug Therapy, Combination; Fibrinolytic Agent | 2001 |
[Do all the patients with adult-onset diabetes mellitus need acetylsalicylic acid?].
Topics: Arteriosclerosis; Aspirin; Blood Coagulation; Contraindications; Diabetes Mellitus, Type 2; Fibrinol | 1999 |
Efficacy and safety of aspirin in the long-term management of atherothrombosis.
Topics: Arteriosclerosis; Aspirin; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Humans; Risk Assess | 2001 |
Bioactive lipids and atherothrombosis.
Topics: Animals; Arachidonic Acids; Arteriosclerosis; Aspirin; Cyclooxygenase Inhibitors; Humans; Thrombopla | 2001 |
Treatment of the antiphospholipid syndrome.
Topics: Abortion, Spontaneous; Antiphospholipid Syndrome; Aspirin; Female; Fibrinolytic Agents; Humans; Nerv | 2002 |
Antithrombotic agents: implications in dentistry.
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Dental Care; Drug Interactions; Embol | 2002 |
[Present status and prospects of platelet inhibitors].
Topics: Adenosine; Aspirin; Blood Platelets; Cyclic AMP; Cyclic GMP; Depression, Chemical; Drug Combinations | 1976 |
The role of prostacyclin in vascular tissue.
Topics: Animals; Arachidonic Acids; Aspirin; Blood Coagulation; Blood Platelets; Blood Vessels; Cyclic AMP; | 1979 |
[Prevention of postoperative thrombosis].
Topics: Adult; Aspirin; Collagen; Coumarins; Dextrans; Epinephrine; Heparin; Humans; Platelet Aggregation; P | 1977 |
[Prevention of thrombosis with coumarin, low doses of heparin, dextran and inhibitors of platelet function].
Topics: Aspirin; Coumarins; Dextrans; Dipyridamole; Heart Valve Prosthesis; Heparin; Humans; Lipids; Platele | 1977 |
Actions and clinical status of platelet-suppressive agents.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Heart Valve Dis | 1978 |
Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis.
Topics: Arachidonic Acids; Aspirin; Epoprostenol; Hemostasis; Humans; Peroxides; Platelet Adhesiveness; Plat | 1978 |
Platelet suppressive therapy.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Coro | 1978 |
[Modern views on the mechanism of action and prospects for therapeutic use of aspirin].
Topics: Aspirin; Blood Coagulation; Fever; Humans; Pain; Thrombosis | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
Coagulation for cardiologists.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Blood Circulation; Blood Coagulation; | 1978 |
Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders.
Topics: Arterial Occlusive Diseases; Aspirin; Blood Platelets; Brain Ischemia; Cell Survival; Clinical Trial | 1977 |
[Prophylaxis of thromboembolism using low dosage heparin (author's transl)].
Topics: Antithrombins; Aspirin; Blood Coagulation; Dipyridamole; Drug Therapy, Combination; Heparin; Humans; | 1979 |
Mode of action of aspirin-like drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acids; Aspirin; Chemical Phenomena; Chemistry; | 1979 |
[Thrombosis prevention and platelet functions following heart valve replacement].
Topics: Adult; Anticoagulants; Aspirin; Blood Flow Velocity; Blood Platelets; Dipyridamole; Female; Heart Va | 1978 |
[Thrombosis prevention and treatment in pediatrics].
Topics: Adolescent; Arterial Occlusive Diseases; Aspirin; Bioprosthesis; Child; Child, Preschool; Coumarins; | 1979 |
Physiopathology and pharmacotherapy of occlusive arterial disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Platelets; Blood Viscosity; Cerebrovas | 1979 |
Platelet-endothelial cell interactions.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Complement System Proteins; Endo | 1979 |
Platelet inhibitors in the treatment of thrombosis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Clinical Trials as Topic; Clof | 1978 |
[Clinical prevention of thrombosis by antiplatelet agents].
Topics: Aspirin; Blood Platelets; Clofibrate; Dipyridamole; Humans; Hydroxychloroquine; Sulfinpyrazone; Thro | 1979 |
[State of thrombosis risk: diagnostic and preventive possibilities].
Topics: Anticoagulants; Aspirin; Dipyridamole; Humans; Platelet Aggregation; Risk; Sulfinpyrazone; Thrombosi | 1979 |
Prostaglandins in circulatory disorders.
Topics: Angiotensin II; Antihypertensive Agents; Arachidonic Acids; Arteriosclerosis; Aspirin; Blood Platele | 1979 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Platelets and thrombosis.
Topics: Aspirin; Blood Platelets; Depression, Chemical; Dipyridamole; Humans; Thrombosis | 1976 |
[Current trends in anticoagulant and thrombolytic therapy of thrombosis].
Topics: Anticoagulants; Aspergillus; Aspirin; Brinolase; Coumarins; Dipyridamole; Disseminated Intravascular | 1975 |
Antiplatelet drugs-a new pharmacologic approach to the prevention of thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Brain; Clofibrate; Dextrans; Dipyridamole; Humans; Ischemi | 1976 |
Aspirin revisited.
Topics: Animals; Aspirin; Blood Platelets; Clinical Trials as Topic; Gastrointestinal Hemorrhage; Hemostasis | 1975 |
Are agents affecting platelet functions clinically useful?
Topics: Aged; Animals; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Clofibrate; Dextrans; Dipyrida | 1976 |
Platelets and thromboembolism.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Dext | 1976 |
Clinical pharmacology of acetylsalicylic acid.
Topics: Absorption; Aspirin; Blood Platelets; Digestive System; Drug Combinations; Drug Hypersensitivity; He | 1976 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
Aspirin, haemostasis and thrombosis.
Topics: Aspirin; Hemostasis; Humans; Myocardial Infarction; Platelet Aggregation; Prostaglandin Antagonists; | 1975 |
Thrombosis and antithrombotic therapy in microvascular surgery.
Topics: Aspirin; Dextrans; Fibrinolytic Agents; Heparin; Humans; Microsurgery; Postoperative Complications; | 1992 |
Antithrombotic therapy. Introduction.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Thrombosis; Warfarin | 1992 |
Aspirin and other platelet-active drugs. The relationship between dose, effectiveness, and side effects.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Dose-Response Relationship, Drug; | 1992 |
Consultation section. Attitudes regarding the concomitant use of anti-coagulants with elective cataract surgery.
Topics: Anticoagulants; Aspirin; Blood Coagulation; Cataract Extraction; Contraindications; Dipyridamole; Ey | 1992 |
Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.
Topics: Aspirin; Blood Platelets; Coronary Disease; Fibrinolytic Agents; Heparin; Humans; Lipid Metabolism; | 1992 |
[Role of antiphospholipid antibodies in fetal loss].
Topics: Abortion, Spontaneous; Adrenal Cortex Hormones; Antibodies, Anticardiolipin; Antibodies, Antiphospho | 1992 |
[Prevention of venous thrombosis with antiplatelet agents].
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Thrombosis | 1992 |
[Portal vein thrombosis and hereditary protein C deficiency. Presentation of a case and review of the literature].
Topics: Aspirin; Follow-Up Studies; Humans; Male; Middle Aged; Portal Vein; Protein C Deficiency; Protein De | 1992 |
Aspirin: how does it prevent thrombosis?
Topics: Aspirin; Blood Platelets; Humans; Thrombosis | 1992 |
Heparin-induced thrombocytopenia and arterial thrombosis: alternative therapies.
Topics: Aspirin; Cardiopulmonary Bypass; Chondroitin Sulfates; Dermatan Sulfate; Epoprostenol; Fibrinolytic | 1990 |
[Prevention of postoperative venous thrombosis and pulmonary embolism. Consensus conference 8 March 1991 by Assistance Publique-Hopitaux de Paris].
Topics: Anesthesia; Aspirin; Bandages; Dextrans; Female; France; Heparin, Low-Molecular-Weight; Humans; Male | 1991 |
[Platelet antiaggregants in the treatment of arterial thrombosis].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Coronary Artery | 1991 |
Aspirin, platelet aggregation, and the circadian variation of acute thrombotic events.
Topics: Aspirin; Cardiovascular Diseases; Circadian Rhythm; Humans; Platelet Aggregation; Thrombosis | 1991 |
The porcine model for the understanding of thrombogenesis and atherogenesis.
Topics: Angioplasty, Balloon, Coronary; Animals; Aorta; Aortic Diseases; Arteriosclerosis; Aspirin; Coronary | 1991 |
Role of thrombin in arterial thrombosis: implications for therapy.
Topics: Animals; Aspirin; Heparin; Hirudin Therapy; Humans; Thrombin; Thrombolytic Therapy; Thrombosis | 1991 |
The pharmacology of aspirin, heparin, coumarin, and thrombolytic agents. Implications for therapeutic use in cardiopulmonary disease.
Topics: Aspirin; Coumarins; Fibrinolytic Agents; Heparin; Humans; Thromboembolism; Thrombolytic Therapy; Thr | 1991 |
Aspirin in the prevention of thrombosis.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Thrombosis | 1991 |
[Pharmacological correction of disorders of the prostacyclin- thromboxane balance in ischemic heart disease: problems and prospects].
Topics: Aspirin; Coronary Disease; Epoprostenol; Humans; Thrombosis; Thromboxane A2; Thromboxane-A Synthase | 1990 |
Aspirin as an antithrombotic drug: from the aggregometer to clinical trials.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Meta-Analysis as Topic; Myocardial Infarction; Platelet | 1990 |
[Current aspects of arterial anti-thrombosis prophylaxis].
Topics: Adult; Aged; Aspirin; Contraindications; Dipyridamole; Humans; Middle Aged; Myocardial Infarction; P | 1990 |
Platelet inhibitor agents in cardiovascular disease: an update.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Graf | 1989 |
[Antithrombotic drugs].
Topics: Adult; Aged; Aged, 80 and over; Aging; Aspirin; Cerebral Hemorrhage; Fibrinolytic Agents; Humans; Mi | 1989 |
Aspirin as an antithrombotic agent.
Topics: Aspirin; Fibrinolytic Agents; Humans; Thrombosis | 1989 |
Platelets and prostaglandins in sudden death: therapeutic implications.
Topics: Adrenergic beta-Antagonists; Animals; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis; Aspirin | 1985 |
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; A | 1986 |
[Thrombosis in various diseases: myocardial infarct].
Topics: Angioplasty, Balloon; Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation; Th | 1986 |
[Thrombosis in various diseases: myeloproliferative disorders].
Topics: Aspirin; beta-Thromboglobulin; Blood Coagulation Factors; Busulfan; Carbazilquinone; Dipyridamole; H | 1986 |
Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty.
Topics: Angioplasty, Balloon; Animals; Arterial Occlusive Diseases; Aspirin; Clinical Trials as Topic; Dipyr | 1987 |
[Significance of acetylsalicylic acid in the secondary prevention of peripheral arterial occlusive diseases].
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Endarterectomy; Humans; Postoperative Ca | 1988 |
Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Blood Platelets; Blood Vessels; Cyclooxygenase Inhibitor | 1985 |
Antiplatelet drugs in the management of patients with thrombotic disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets | 1986 |
Coronary artery bypass grafting. A model for the understanding of the progression of atherosclerotic disease and the role of pharmacological intervention.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Cell Division; Collagen; Coronary Artery Bypass | 1985 |
[Antiplatelet drugs and prevention of aortocoronary bypass occlusion].
Topics: Aspirin; Coronary Artery Bypass; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Sulfinpyrazo | 1988 |
Thrombosis in unstable angina: angiographic aspects.
Topics: Angina Pectoris; Angina, Unstable; Angiography; Arteries; Aspirin; Coronary Circulation; Coronary Di | 1987 |
Tantalus revisited--the search for the ideal anti-thrombotic dose of aspirin.
Topics: Animals; Aspirin; Humans; Thrombosis | 1987 |
[Aspirin as a platelet antiaggregant: indications and controversies].
Topics: Arteriovenous Shunt, Surgical; Aspirin; Coronary Artery Bypass; Female; Heart Valve Prosthesis; Huma | 1987 |
Present-day situation of the "aspirin dilemma".
Topics: Aspirin; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Thrombosis | 1987 |
Current issues in thrombosis prevention with antiplatelet drugs.
Topics: Aspirin; Cell Division; Coronary Artery Bypass; Coronary Disease; Endothelium; Epoprostenol; Fibrin; | 1986 |
[Antiplatelet therapy of thrombosis].
Topics: Animals; Aspirin; Cerebrovascular Disorders; Coronary Disease; Humans; Postoperative Complications; | 1986 |
[Thrombosis in various diseases: arteriosclerosis and thrombosis].
Topics: Animals; Arteriosclerosis; Aspirin; Dipyridamole; Humans; Sulfinpyrazone; Thrombosis | 1986 |
Inhibition of platelet function in thrombosis.
Topics: Arachidonic Acids; Aspirin; Blood Platelets; Chromatography, Gas; Depression, Chemical; Eicosanoic A | 1985 |
Lupus anticoagulant and pregnancy.
Topics: Aspirin; Autoantibodies; Blood Coagulation Factors; Female; Fetal Death; Fetal Diseases; Fetal Growt | 1985 |
[The importance of thrombocytes for thrombogenesis and the pharmacological influencing of thrombocyte function (author's transl)].
Topics: Animals; Anticoagulants; Aspirin; Blood Platelet Disorders; Blood Platelets; Clinical Trials as Topi | 1974 |
[Aggregation inhibitors. The inhibition of platelet function by means of chemical substances].
Topics: Adenosine Diphosphate; Adenylyl Cyclases; Aspirin; Blood Proteins; Calcium; Collagen; Dipyridamole; | 1973 |
Management of thrombotic diseases.
Topics: Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Cerebrovascular Disorders; Coronary Dis | 1971 |
Trends in the development of antithrombotic agents.
Topics: Adenine Nucleotides; Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Anticoagulants; As | 1971 |
[Urgency and technic of thromboembolism prevention in surgery].
Topics: Anticoagulants; Aspirin; Blood Circulation; Blood Platelets; Heparin; Humans; Postoperative Complica | 1973 |
Platelets, thrombosis and coronary artery disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Blood Protein Disorders; Cell Survival; Coronary Disease | 1973 |
Aspirin: the unique drug.
Topics: Aspirin; Blood Platelets; Drug Interactions; Drug Synergism; Gastrointestinal Hemorrhage; Hemorrhage | 1974 |
The prevention of thrombosis.
Topics: Anti-Inflammatory Agents; Anticoagulants; Aspirin; Coumarins; Dipyridamole; Heparin; Humans; Platele | 1974 |
[Summary: Drugs affecting platelet behaviour; experimental and clinical data (author's transl)].
Topics: Adult; Aspirin; Blood Platelets; Child; Clofibrate; Dextrans; Dipyridamole; Drug Combinations; Graft | 1974 |
[Hemostasis and cancer].
Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Blood Coagulation Factors; Cell Adhesion; Endothel | 1974 |
Platelet inhibition in the management of thrombosis.
Topics: Aspirin; Blindness; Blood Platelets; Cell Survival; Cerebrovascular Disorders; Dextrans; Dipyridamol | 1974 |
Anticoagulants.
Topics: Anticoagulants; Aspirin; Blood Platelet Disorders; Dipyridamole; Enzyme Therapy; Factor IX; Factor V | 1974 |
Recent developments in antithrombotic therapy.
Topics: Anticoagulants; Aspirin; Drug Antagonism; Fibrinolytic Agents; Humans; Prothrombin Time; Streptokina | 1969 |
Platelet pharmacology in relation to thrombosis.
Topics: Adenine Nucleotides; Animals; Arteriosclerosis; Aspirin; Binding Sites; Blood Cells; Blood Coagulati | 1970 |
274 trials available for aspirin and Blood Clot
| Article | Year |
|---|---|
Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study.
Topics: Anticoagulants; Aspirin; Child; Factor Xa Inhibitors; Hemorrhage; Humans; Rivaroxaban; Stroke; Throm | 2021 |
Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.
Topics: Adult; Aspirin; COVID-19; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; Double-Blind Me | 2021 |
The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population.
Topics: Aged; Aspirin; Blood Platelets; Hemorrhage; Humans; Incidence; Platelet Aggregation; Platelet Aggreg | 2022 |
A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control.
Topics: Adolescent; Adult; Aspirin; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1 | 2021 |
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone.
Topics: Anticoagulants; Arteries; Aspirin; Endovascular Procedures; Humans; Lower Extremity; Peripheral Arte | 2022 |
CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD).
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Myocardial Infarction; Peripheral | 2022 |
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.
Topics: Aspirin; Canada; Colchicine; COVID-19; Disease Progression; Humans; SARS-CoV-2; Thrombosis; Treatmen | 2022 |
Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Ischemic S | 2023 |
Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2023 |
Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol.
Topics: Aspirin; Brain Ischemia; Clinical Trials, Phase IV as Topic; Humans; Ischemic Stroke; Multicenter St | 2023 |
Design and Rationale of the BIOFLOW-DAPT Trial: a Prospective, Randomized, Multicenter Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination with 1-Month Dual Antipl
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary I | 2023 |
Rivaroxaban in patients with abdominal aortic aneurysm and high-sensitivity C-reactive protein elevation (BANBOO): study protocol for a randomized, controlled trial.
Topics: Aortic Aneurysm, Abdominal; Aspirin; C-Reactive Protein; Humans; Prospective Studies; Randomized Con | 2023 |
Early 6 months usage of single anTiplAtelet OR anTicoAgulant followed by single antiplatelet after transcatheter aortic valve replacement: protocol for a multicentre, open-label, randomised controlled clinical trial.
Topics: Anticoagulants; Aspirin; Humans; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggre | 2023 |
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI.
Topics: Aged; Aspirin; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reva | 2019 |
Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial.
Topics: Aged; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hem | 2020 |
Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT trial.
Topics: Absorbable Implants; Aspirin; China; Clinical Trials, Phase IV as Topic; Coronary Angiography; Coron | 2019 |
Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels.
Topics: Aged; Aspirin; Biomarkers; Blood Coagulation; Clopidogrel; Cross-Over Studies; Diabetes Mellitus, Ty | 2020 |
Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy.
Topics: Aged; Aspirin; Blood; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle A | 2020 |
Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy.
Topics: Aged; Aspirin; Blood; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle A | 2020 |
Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy.
Topics: Aged; Aspirin; Blood; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle A | 2020 |
Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy.
Topics: Aged; Aspirin; Blood; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle A | 2020 |
Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study.
Topics: Administration, Oral; Aspirin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Fa | 2020 |
Influence of lipoproteins and antiplatelet agents on vein graft patency 1 year after coronary artery bypass grafting.
Topics: Aged; Aspirin; Biomarkers; China; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; | 2022 |
Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized
Topics: Acute Coronary Syndrome; Adult; Area Under Curve; Asian People; Aspirin; Clopidogrel; Cross-Over Stu | 2020 |
Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial.
Topics: Angioplasty; Aspirin; Clopidogrel; Critical Illness; Factor Xa Inhibitors; Humans; Ischemia; Leg; Mu | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.
Topics: Administration, Oral; Aspirin; Atrial Fibrillation; Atrial Flutter; Bioprosthesis; Brazil; Cause of | 2021 |
PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients.
Topics: Adult; Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Humans; Multicenter Studies as Topic; | 2021 |
Aspirin versus P2Y
Topics: Aged; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; | 2021 |
Gut Microbe-Generated Trimethylamine
Topics: Adult; Aspirin; Choline; Dietary Fats; Female; Gastrointestinal Microbiome; Humans; Male; Methylamin | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Morphological and pharmacological determinants of peri-procedural myocardial infarction following elective stent implantation: Optical coherence tomography sub-analysis of the PRASFIT-Elective study.
Topics: Aged; Aspirin; Clopidogrel; Creatine Kinase, MB Form; Double-Blind Method; Elective Surgical Procedu | 2017 |
[After the GEMINI-ACS-1 trial].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Humans; Rivaroxaban; Thrombosis | 2017 |
Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
Topics: Adenosine; Aged; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2018 |
Tiny Cerebral Aneurysms Can Be Treated Safely and Effectively with Low-Profile Visualized Intraluminal Support Stent-Assisted Coiling or Coiling Alone.
Topics: Adult; Aged; Aneurysm, Ruptured; Aspirin; Clopidogrel; Embolization, Therapeutic; Endovascular Proce | 2018 |
Impact of ticagrelor versus aspirin on graft patency after CABG: Rationale and design of the TARGET (ticagrelor antiplatelet therapy to reduce graft events and thrombosis) randomized controlled trial (NCT02053909).
Topics: Aftercare; Aged; Aspirin; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Cor | 2018 |
Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Endovascular Procedures; Europe; Factor Xa In | 2018 |
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B
Topics: Aspirin; Biomarkers; Clinical Protocols; Disease Management; Female; Humans; Male; Patient Selection | 2018 |
Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Fema | 2018 |
Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.
Topics: Adult; Aspirin; Australia; Disease Progression; Dose-Response Relationship, Drug; Drug Administratio | 2018 |
Thromboembolic events in polycythemia vera.
Topics: Age Factors; Anticoagulants; Aspirin; Humans; Hydroxyurea; Interferons; Nitriles; Phlebotomy; Polycy | 2019 |
Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study).
Topics: Aspirin; Child; Child, Preschool; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Fontan Procedur | 2019 |
Effect of Aspirin on Reducing Thrombosis of Arteriovenous Fistulae in Uremic Patients Undergoing Hemodialysis.
Topics: Arteriovenous Fistula; Arteriovenous Shunt, Surgical; Aspirin; Catheters, Indwelling; Female; Fibrin | 2019 |
Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy.
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Immunosuppressive Agent | 2019 |
Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
Topics: Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; D | 2013 |
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged | 2013 |
[Prevention of non-acute stent thrombosis after drug-eluting stent implantation].
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Platelet Agg | 2013 |
Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber.
Topics: Adolescent; Adult; Animals; Anticoagulants; Aspirin; Cross-Over Studies; Female; Humans; In Vitro Te | 2013 |
Thromboxane A(2) generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Creatinine; Cyclooxygenase 1; Cyclooxygenas | 2013 |
Primary thrombophilia in México X: a prospective study of the treatment of the sticky platelet syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelet Disorders; Child; Clopidogrel; F | 2015 |
Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cytochrome P-450 | 2013 |
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS).
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoimmune | 2014 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Antithrombotic properties of rafigrelide: a phase 1, open-label, non-randomised, single-sequence, crossover study.
Topics: Adult; Aspirin; Blood Coagulation; Blood Platelets; Cross-Over Studies; Drug Therapy, Combination; H | 2014 |
Inhibition of platelet activation could decrease thrombotic events in hemodialysis PF4/H antibody-positive patients.
Topics: Adult; Aged; Aspirin; Clopidogrel; Female; Humans; Incidence; Male; Middle Aged; Platelet Activation | 2014 |
Aspirin reload before elective percutaneous coronary intervention: impact on serum thromboxane b2 and myocardial reperfusion indexes.
Topics: Aged; Aspirin; Female; Humans; Male; Microvessels; Middle Aged; Myocardial Reperfusion Injury; Percu | 2014 |
Aspirin reload before elective percutaneous coronary intervention: impact on serum thromboxane b2 and myocardial reperfusion indexes.
Topics: Aged; Aspirin; Female; Humans; Male; Microvessels; Middle Aged; Myocardial Reperfusion Injury; Percu | 2014 |
Aspirin reload before elective percutaneous coronary intervention: impact on serum thromboxane b2 and myocardial reperfusion indexes.
Topics: Aged; Aspirin; Female; Humans; Male; Microvessels; Middle Aged; Myocardial Reperfusion Injury; Percu | 2014 |
Aspirin reload before elective percutaneous coronary intervention: impact on serum thromboxane b2 and myocardial reperfusion indexes.
Topics: Aged; Aspirin; Female; Humans; Male; Microvessels; Middle Aged; Myocardial Reperfusion Injury; Percu | 2014 |
Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
Topics: Adenosine; Administration, Oral; Adult; Anticoagulants; Antithrombin III; Aspirin; Austria; Benzimid | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study.
Topics: Adenosine; Adult; Aspirin; Clopidogrel; Cross-Over Studies; Drug Therapy, Combination; Female; Human | 2015 |
Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.
Topics: Aspirin; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous | 2015 |
Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
Topics: Adenosine; Adult; Aged; Asian People; Aspirin; Cardiac Catheterization; Double-Blind Method; Female; | 2015 |
Preoperative platelet aggregation predicts perioperative blood loss and rethoracotomy for bleeding in patients receiving dual antiplatelet treatment prior to coronary surgery.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Drug Combinations; Female; Human | 2015 |
The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms.
Topics: Aspirin; Biomarkers; Female; Hematologic Neoplasms; Humans; Janus Kinase 2; Male; Middle Aged; Nitri | 2015 |
The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Central Venous Catheters; Docosahexaenoic Acids; Double-Blin | 2015 |
Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Australia; Comorbidity; Docosahexaenoic Acids; | 2016 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro | 2015 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro | 2015 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro | 2015 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro | 2015 |
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel | 2016 |
Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up | 2016 |
Stopping vs. Continuing Aspirin before Coronary Artery Surgery.
Topics: Aged; Aspirin; Blood Transfusion; Coronary Artery Bypass; Double-Blind Method; Female; Humans; Lengt | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction.
Topics: Aspirin; Decision Support Techniques; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; M | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular | 2016 |
Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone.
Topics: Aged; Aspirin; Atherosclerosis; Brain; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therap | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D | 2016 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Bypass; Female; Humans; Male; Platelet Aggregation; | 2017 |
Antithrombotic therapy after bioprosthetic aortic valve implantation: Warfarin versus aspirin, a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Heart Valve Prosthesi | 2017 |
Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Aspirin; Clopidogrel; Drug Therapy, Combination; Female | 2017 |
The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Resistance | 2008 |
Tailored thromboprophylaxis for patients with multiple myeloma treated by IMIDs.
Topics: Aspirin; Chemoprevention; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Thrombosis | 2008 |
Inhibition of platelet aggregation by combined therapy with aspirin and cilostazol after off-pump coronary artery bypass surgery.
Topics: Aged; Aspirin; Cilostazol; Coronary Artery Bypass, Off-Pump; Drug Therapy, Combination; Female; Fibr | 2008 |
Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study.
Topics: Anticoagulants; Aspirin; Cardiac Catheterization; Enoxaparin; Eptifibatide; Erythrocytes; Fibrin; Fi | 2008 |
Low molecular weight heparin as an alternative to unfractionated heparin in the immediate postoperative period after left ventricular assist device implantation.
Topics: Aged; Anticoagulants; Aspirin; Dipyridamole; Heart Failure; Heart-Assist Devices; Heparin; Heparin, | 2008 |
Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Arachidonic Acid; As | 2008 |
Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arteriovenous Shunt, Surgical; Aspirin; Clinical Pro | 2009 |
The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease.
Topics: Aged; Aspirin; Body Mass Index; Clopidogrel; Coronary Disease; Female; Fibrinolytic Agents; Hemorrha | 2009 |
Effect of dipyridamole plus aspirin on hemodialysis graft patency.
Topics: Aspirin; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; | 2009 |
Effect of dipyridamole plus aspirin on hemodialysis graft patency.
Topics: Aspirin; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; | 2009 |
Effect of dipyridamole plus aspirin on hemodialysis graft patency.
Topics: Aspirin; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; | 2009 |
Effect of dipyridamole plus aspirin on hemodialysis graft patency.
Topics: Aspirin; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; | 2009 |
Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
Topics: Aged; Angioplasty, Balloon, Coronary; Asia; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Mate | 2009 |
A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagu
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biomarkers; | 2009 |
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis | 2009 |
The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Cell Com | 2009 |
PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Aspirin; Atherosclerosis; Biomarkers; C-Re | 2009 |
Development of an improved assay system for activated platelet counts and evaluation by aspirin monitoring.
Topics: Anticoagulants; Aspirin; Blood Specimen Collection; Drug Monitoring; Female; Fixatives; Flow Cytomet | 2010 |
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR
Topics: Aged; Aspirin; Clopidogrel; Disease Management; Double-Blind Method; Drug Therapy, Combination; Fema | 2010 |
[Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin].
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Coag | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; F | 2010 |
Use of aspirin associates with longer primary patency of hemodialysis grafts.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Aspirin, Dipyridamole Drug Combination; Chronic | 2011 |
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combinati | 2011 |
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; | 2011 |
Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot).
Topics: Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Coagulation; | 2011 |
A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children.
Topics: Anticoagulants; Aspirin; Child; Child, Preschool; Echocardiography; Female; Fontan Procedure; Hepari | 2011 |
Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: the multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial.
Topics: Aged; Aspirin; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Platelet Aggregation | 2011 |
Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; | 2011 |
Protective effect of heparin and aspirin against vascular thrombosis in pediatric kidney transplants.
Topics: Anticoagulants; Aspirin; Child; Creatinine; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels | 2012 |
Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged | 2012 |
Management of peripheral arterial interventions with mono or dual antiplatelet therapy--the MIRROR study: a randomised and double-blinded clinical trial.
Topics: Aged; Angioplasty; Aspirin; Double-Blind Method; Female; Humans; Male; Peripheral Arterial Disease; | 2012 |
Renal function and aspirin resistance in patients with coronary artery disease.
Topics: Aspirin; Coronary Artery Disease; Drug Resistance; Female; Glomerular Filtration Rate; Humans; Kidne | 2012 |
The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Comorbidity; Cytochrome P-450 CYP3A; Drug Resistance; | 2012 |
Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina.
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Fema | 2012 |
Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure.
Topics: Anticoagulants; Aspirin; Child; Child, Preschool; Female; Fontan Procedure; Humans; Male; Postoperat | 2013 |
Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; H | 2013 |
Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial).
Topics: Age Factors; Aged; Aspirin; Clopidogrel; Creatinine; Diabetes Mellitus; Female; Humans; Male; Massac | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Metho | 2002 |
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Heart Failure | 2003 |
Effects of the glycoprotein IIb/IIIa antagonist abciximab on thrombus formation and platelet function in cats with arterial injury.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Arteries; Aspirin; Blood Platelets; Cat Diseases; Cats; | 2003 |
Thrombosis prevention trial: compliance with warfarin treatment and investigation of a retained effect.
Topics: Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Follow-Up Studies; Humans; Male; Mid | 2003 |
Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis.
Topics: Aged; Aspirin; Catheters, Indwelling; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; F | 2003 |
Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic-drug regimen in coronary artery stenting.
Topics: Adult; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; C | 2003 |
Dextran-related complications in head and neck microsurgery: do the benefits outweigh the risks? A prospective randomized analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Child; Dextrans; Female; Head a | 2003 |
Efficacy and safety of low-dose aspirin in polycythemia vera.
Topics: Aspirin; Cardiovascular Diseases; Disease-Free Survival; Double-Blind Method; Female; Hemorrhage; Hu | 2004 |
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke.
Topics: Aged; Antibodies, Antiphospholipid; Anticoagulants; Aspirin; Cohort Studies; Female; Humans; Male; M | 2004 |
Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inh | 2004 |
Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Humans; | 2004 |
Magnetic Vascular Port in minimally invasive direct coronary artery bypass grafting.
Topics: Aged; Aspirin; Clopidogrel; Comorbidity; Coronary Angiography; Drug Therapy, Combination; Equipment | 2004 |
A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial.
Topics: Aged; Aspirin; Biomarkers; Blood Coagulation Factors; Blood Viscosity; C-Reactive Protein; Clopidogr | 2004 |
Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Angiography; Coronary Diseas | 2005 |
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin | 2005 |
Comparison of cilostazol and clopidogrel after successful coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Female; | 2005 |
Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention.
Topics: Aged; Aspirin; Cilostazol; Drug Therapy, Combination; Female; Humans; Incidence; Male; Myocardial In | 2005 |
Recurrent miscarriage associated with antiphospholipid antibodies: prophylactic treatment with low-dose aspirin and fish oil derivates.
Topics: Abortion, Habitual; Adult; Antiphospholipid Syndrome; Aspirin; Docosahexaenoic Acids; Dose-Response | 2005 |
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).
Topics: Administration, Oral; Adult; Algorithms; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholip | 2005 |
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; F | 2005 |
Superior efficacy of clopidogrel plus acetylsalicylic acid compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombogenesis in healthy volunteers.
Topics: Adolescent; Adult; Arteries; Aspirin; Clopidogrel; Collagen; Cross-Over Studies; Delayed-Action Prep | 2005 |
Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting.
Topics: Aprotinin; Aspirin; Biomarkers; Blood Coagulation Tests; Blood Loss, Surgical; Coronary Artery Bypas | 2006 |
Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Japan | 2006 |
Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Genotype; Humans; Integrin beta3; Ma | 2005 |
Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model.
Topics: Administration, Oral; Adult; Anticoagulants; Arteries; Aspirin; Azetidines; Benzylamines; Bleeding T | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; C-Reactive Protein; Case-Control Studies; Cy | 2006 |
Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients.
Topics: Aged; Angina, Unstable; Aspirin; Bleeding Time; Blood Viscosity; Clopidogrel; Drug Resistance; Eryth | 2006 |
Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; | 2006 |
Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy?
Topics: Adult; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; | 2006 |
Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; | 2006 |
Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplast | 2006 |
Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Cre | 2008 |
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiphospholipid Syndrome; Aspirin; Double-Blind Met | 2007 |
Effects of selective cyclooxygenase isoform inhibition on systemic prostacyclin synthesis and on platelet function at rest and after exercise in healthy volunteers.
Topics: Adenosine Diphosphate; Adult; Aspirin; Atherosclerosis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxy | 2007 |
Therapeutic benefit of low-dose clopidogrel in patients undergoing carotid surgery is linked to variability in the platelet adenosine diphosphate response and patients' weight.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Body Weight; Clopidogrel; Endarterectomy, Carotid; | 2007 |
[Warfarin in the treatment of antiphospholipid syndrome].
Topics: Anticoagulants; Antiphospholipid Syndrome; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Coagulation | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
Topics: Adult; Aged; Antithrombin III; Aspirin; Drug Therapy, Combination; Female; Fibrin Fibrinogen Degrada | 2007 |
The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cell Adhesion Molecules; Clopi | 2007 |
Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial.
Topics: Aged; Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Female; Heart Valve Prosthesis; Humans; | 2007 |
Pharmacokinetics of clopidogrel in patients with stent thrombosis.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Pharmacokinetics; | 2008 |
Pharmacology of antiplatelet drugs and clinical trials on thrombosis prevention: a difficult link.
Topics: Acetylation; Aspirin; Blood Platelets; Blood Vessels; Clinical Trials as Topic; Dipyridamole; Humans | 1982 |
Venous thrombosis and embolism.
Topics: Angiography; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Auscultation; Blood Coagulation; Blo | 1981 |
Aspirin and dipyridamole reduce platelet deposition on prosthetic femoro-popliteal grafts in man.
Topics: Arterial Occlusive Diseases; Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Dipyridamol | 1983 |
Platelets and platelet-inhibitor drugs in aortocoronary vein bypass operations.
Topics: Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Artery Bypass; Coronary | 1983 |
British studies of aspirin and myocardial infarction.
Topics: Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial Infarction; P | 1983 |
[The antithrombotic action of oral anticoagulants, acetylsalicylic acid (Aspirin) and dipyridamole (Persantin)].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Fibrinolytic Agen | 1984 |
Aspirin in the treatment of cardiovascular disease: a review.
Topics: Aspirin; Blood Platelets; Blood Vessels; Cell Adhesion; Clinical Trials as Topic; Cyclooxygenase Inh | 1983 |
Does 111indium-platelet deposition predict patency in prosthetic arterial grafts?
Topics: Aspirin; Blood Platelets; Blood Vessel Prosthesis; Dipyridamole; Double-Blind Method; Drug Combinati | 1983 |
The effect of prophylaxis for thrombosis on heterotopic ossification following total hip joint replacement.
Topics: Aspirin; Heparin; Hip Prosthesis; Humans; Ossification, Heterotopic; Oxyphenbutazone; Thrombosis | 1983 |
Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs. conventional antiaggregants: a six-month randomized follow-up study.
Topics: Aged; Aspirin; Dipyridamole; Drug Tolerance; Female; Follow-Up Studies; Humans; Male; Middle Aged; P | 1984 |
[Pharmacologic and gastrointestinal tolerance study of an acetylsalicylic acid-based product].
Topics: Aged; Aluminum Hydroxide; Aspirin; Clinical Trials as Topic; Digestive System; Drug Combinations; Dr | 1982 |
Platelet inhibitory drugs: an in vivo method of evaluation in patients.
Topics: Aorta, Abdominal; Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Dipyridamole; Double-B | 1982 |
Registry of prospective clinical trials--fifth report.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Double-Bl | 1982 |
Present status of antiaggregating agents in coronary and cerebrovascular disease prevention.
Topics: Animals; Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Dise | 1980 |
Secondary prevention of myocardial infarction--the present state of the ART.
Topics: Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Dipyridamole; Humans; Myocardial | 1980 |
Sulfinpyrazone: a review of its pharmacological properties and therapeutic use.
Topics: Animals; Anti-Arrhythmia Agents; Antibody Formation; Aspirin; Blood Platelets; Cardiovascular Diseas | 1980 |
Influence of aspirin and dipyridamole on patency of coronary artery bypass grafts.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Dipyridamole; Drug Therapy, Combination; | 1981 |
Series on pharmacology in practice. 10. Antithrombotic therapy: role of platelet-inhibitor drugs. III. Management of arterial thromboembolic and atherosclerotic disease (third of three parts).
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1981 |
[The antithrombotic effect of dipyridamole and acetylsalicylic acid. A prospective clinical examination].
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Postoperative Co | 1981 |
Drug trials in prevention of occlusion of aorta--coronary artery vein grafts.
Topics: Angiography; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Dipyridamole; Humans; Postop | 1982 |
A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Artery Bypass; Dipyridamol | 1982 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
[5-year controlled therapy study on the prevention of diabetic angiopathy with the platelet-function inhibitor acetylsalicylic acid].
Topics: Adult; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Coronary Disease; Diabetic Angiopathies | 1982 |
[Significance of combined use of anticoagulants and antiplatelet agents in the early stage after prosthetic valve replacement].
Topics: Adult; Aged; Anticoagulants; Aspirin; Blood Coagulation; Depression, Chemical; Drug Therapy, Combina | 1995 |
Intracoronary stenting without coumadin: one month results of a French multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Drug Ther | 1995 |
A comparative evaluation of externally supported polytetrafluoroethylene axillobifemoral and axillounifemoral bypass grafts.
Topics: Aged; Aged, 80 and over; Anastomosis, Surgical; Aorta; Arteriosclerosis; Aspirin; Axillary Artery; B | 1995 |
Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin.
Topics: Adult; Anemia; Aspirin; Cross-Over Studies; Double-Blind Method; Erythropoietin; Female; Hematocrit; | 1994 |
Antiplatelet therapy to prevent thrombosis after hip fracture.
Topics: Aged; Aspirin; Drug Interactions; Heparin; Hip Fractures; Humans; Platelet Aggregation Inhibitors; P | 1995 |
Thrombosis and antiphospholipid syndrome: a preliminary assessment of three antithrombotic treatments.
Topics: Adolescent; Adult; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Aspirin; | 1994 |
Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Double-Blind Method; | 1994 |
Granulocyte macrophage colony stimulating factor: high incidence of apheresis catheter thrombosis during peripheral stem cell collection.
Topics: Aspirin; Blood Component Removal; Blood Transfusion, Autologous; Bone Marrow Transplantation; Cathet | 1993 |
Left ventricular thrombosis and arterial embolism after thrombolysis in acute anterior myocardial infarction: predictors and effects of adjunctive antithrombotic therapy.
Topics: Age Factors; Aspirin; Echocardiography; Embolism; Heart Diseases; Heart Failure; Heart Ventricles; H | 1993 |
A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation.
Topics: Aged; Angiography; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet A | 1996 |
Fecal hemoglobin excretion in elderly patients with atrial fibrillation: combined aspirin and low-dose warfarin vs conventional warfarin therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fe | 1996 |
Intensive insulin therapy in type II diabetes: rationale and collaborative clinical trial results.
Topics: Arteriosclerosis; Aspirin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Res | 1996 |
[Low molecular weight heparin (Fraxiparine) as adjunctive therapy with thrombolysis for acute myocardial infarction: a pilot study with a one year follow up].
Topics: Adult; Aged; Aspirin; Echocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male | 1996 |
Development of large platelet aggregates from small aggregates as determined by laser-light scattering: effects of aggregant concentration and antiplatelet medication.
Topics: Aged; Aspirin; Flow Cytometry; Humans; In Vitro Techniques; Lasers; Male; Middle Aged; Platelet Aggr | 1996 |
[Coronary artery stenting without antivitamin K. Results after a month].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Di | 1996 |
Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; beta-Thromboglobulin; Dose-Response Relations | 1996 |
[Elective coronary implantation of a newly developed stent without conventional anticoagulation].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Female; H | 1996 |
Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy.
Topics: Angioplasty, Balloon; Aspirin; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Eq | 1997 |
[Recent antithrombotic gold standard?].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Thrombosis; Ticlopi | 1997 |
Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
Topics: Abciximab; Administration, Oral; Aged; Antibodies, Monoclonal; Aspirin; Benzamidines; Coronary Disea | 1997 |
Early versus late coronary stenting following acute myocardial infarction: results of the STENTIM I Study (French Registry of Stenting in Acute Myocardial Infarction).
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Feasibility Studies; Female | 1997 |
European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial.
Topics: Aspirin; Dose-Response Relationship, Drug; Europe; Feasibility Studies; Female; Follow-Up Studies; H | 1997 |
Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biphenyl Compounds; B | 1997 |
Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Double-Blind Method; | 1998 |
Wiktor stent for treatment of chronic total coronary artery occlusions: short- and long-term clinical and angiographic results from a large multicenter experience.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Catheterization, Peri | 1998 |
Prophylaxis for deep vein thrombosis with aspirin or low molecular weight dextran in Korean patients undergoing total hip replacement. A randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Dextrans; F | 1998 |
Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Bl | 1998 |
A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans.
Topics: Adult; Arteries; Aspirin; Blood; Blood Platelets; Collagen; Double-Blind Method; Drug Synergism; Dru | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
Double-lumen inferior vena cava catheters for peripheral stem cell apheresis and transplantations.
Topics: Adult; Aged; Aspirin; Bacteremia; Catheterization, Central Venous; Equipment Design; Female; Hematop | 1995 |
Antithrombotic efficacy of the vitamin K antagonist fluindione in a human Ex vivo model of arterial thrombosis : effect of anticoagulation level and combination therapy with aspirin.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Collagen; Drug Synergism; Drug Therapy, Combination; Fib | 1999 |
Intravenous acetylsalicylic acid, magnesium and their combination in experimental arterial thrombosis in rats.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Pressure; Double-Blind Method; Hemorrhage; Magnesium; Male | 1999 |
Evidence for prothrombotic effects of exercise and limited protection by aspirin.
Topics: Adult; Aspirin; Blood; Blood Physiological Phenomena; Blood Platelets; Cell Aggregation; Cross-Over | 1999 |
Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Coronary Disease; Dise | 1999 |
Evaluation of the Clot Signature Analyzer as a hemostasis test in healthy volunteers exposed to low doses of aspirin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Bleeding Time; Blood Coagulation Tests; Collage | 1999 |
Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Disease-Free Survival; Female; Hemorr | 1999 |
Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Dose-Response Relationship, Dru | 2000 |
Antithrombotic effects of abciximab.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Aspirin; Drug Therapy, Combination; Fibrinolyti | 2000 |
Antithrombotic effects of aspirin after renal transplantation.
Topics: Aspirin; Cadaver; Graft Rejection; Humans; Kidney Transplantation; Platelet Aggregation Inhibitors; | 2000 |
[The drug prevention of postoperative thromboses in patients with critical lower limb ischemia].
Topics: Anticoagulants; Aspirin; Critical Illness; Humans; Ischemia; Leg; Nadroparin; Platelet Aggregation I | 1999 |
Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans.
Topics: Adult; Arteries; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug T | 2000 |
Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Arterial Occlusive Diseases; Aspirin; Female; Fibrinolytic | 2000 |
Beneficial antithrombotic effects of the association of pharmacological oral magnesium therapy with aspirin in coronary heart disease patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cell Adhesion; Cholesterol, HDL; Cholesterol | 2000 |
Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications.
Topics: Administration, Oral; Aneurysm, False; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cere | 2001 |
The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment.
Topics: Adult; Aged; Anticoagulants; Aspirin; Coronary Artery Bypass; Coronary Disease; Dose-Response Relati | 2001 |
Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoimmune D | 2001 |
Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Topics: Ambulatory Care; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Cost-Benefit Analysis; Dal | 2002 |
Thrombosis prevention trial: follow-up study of practical implications.
Topics: Anticoagulants; Aspirin; Double-Blind Method; Family Practice; Female; Follow-Up Studies; Humans; Ma | 2002 |
[Possibilities and limits of controlled clinical therapy studies for the demonstration of the effectiveness of antithrombotic therapy].
Topics: Adult; Anticoagulants; Aspirin; Clinical Trials as Topic; Dextrans; Dipyridamole; Dose-Response Rela | 1975 |
Prevention of thrombosis in patients on hemodialysis by low-dose aspirin.
Topics: Acetylation; Adult; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Female; Humans; Male; M | 1979 |
Drug therapy: antiplatelet therapy (second of two parts).
Topics: Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical T | 1978 |
Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders.
Topics: Arterial Occlusive Diseases; Aspirin; Blood Platelets; Brain Ischemia; Cell Survival; Clinical Trial | 1977 |
Aspirin pretreatment prevents post-cannulation radial-artery thrombosis.
Topics: Aged; Arterial Occlusive Diseases; Arteries; Aspirin; Catheterization; Clinical Trials as Topic; Dou | 1979 |
Platelet inhibitors in the treatment of thrombosis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Clinical Trials as Topic; Clof | 1978 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Letter: Prevention of thrombosis by platelet inhibition.
Topics: Aspirin; Clinical Trials as Topic; Dextrans; Heparin; Humans; Thrombosis | 1976 |
Mechanism of action and clinical use of acetylsalicylic acid as a prophylactic agent against thrombosis.
Topics: Aspirin; Cardiac Surgical Procedures; Clinical Trials as Topic; Humans; Leg; Placebos; Platelet Aggr | 1975 |
Anti-aggregants in clinical practice.
Topics: Arteriosclerosis; Aspirin; Clinical Trials as Topic; Embolism; Humans; Platelet Aggregation; Thrombo | 1975 |
[A randomized study on the prevention of postoperative thrombosis with acetylsalicylic acid].
Topics: Aspirin; Clinical Trials as Topic; Humans; Placebos; Postoperative Complications; Pulmonary Embolism | 1976 |
[THE German multicenter double blind study on the prevention of thrombosis with ASA].
Topics: Adult; Aspirin; Clinical Trials as Topic; Drug Evaluation; Female; Germany, West; Humans; Male; Midd | 1976 |
[The action of various drugs in the prevention of re-occlusion following Dotter's catheter disobliteration].
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Bencyclane; Catheterization; Clinical Trials a | 1976 |
Aspirin revisited.
Topics: Animals; Aspirin; Blood Platelets; Clinical Trials as Topic; Gastrointestinal Hemorrhage; Hemostasis | 1975 |
[Use of acetylsalicylic acid in the prevention of re-occlusion following revascularization interventions. Results of a double-blind long term study].
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Double-Blind Method; Female; Follow-Up Studi | 1977 |
[Planning, realization, and biometric evaluation of a long term study with acetylsalicylic acid].
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Biometry; Female; Follow-Up Studies; Humans; Male; Middl | 1977 |
[Low-dose heparin and acetyl-salicylic acid after elective operations on the hip joint (author's transl)].
Topics: Aged; Aspirin; Female; Heparin; Hip Joint; Humans; Joint Prosthesis; Male; Middle Aged; Postoperativ | 1977 |
[Double-blind study for the prevention of postoperative thrombosis].
Topics: Abdomen; Aspirin; Dipyridamole; Humans; Platelet Aggregation; Postoperative Complications; Thrombosi | 1976 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (third of three parts).
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clofibrate; Dipyridamole; Drug Evaluation; Fibrin | 1975 |
Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation.
Topics: Administration, Oral; Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combinatio | 1992 |
Left ventricular thrombus in anterior acute myocardial infarction after thrombolysis. A GISSI-2 connected study.
Topics: Adult; Aged; Aspirin; Atenolol; Embolism; Female; Fibrinolytic Agents; Heart; Heart Diseases; Heart | 1991 |
Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis.
Topics: Aspirin; Blood Coagulation Tests; Blood Platelets; Catheters, Indwelling; Drug Evaluation; Drug Ther | 1991 |
Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo.
Topics: Adult; Aspirin; Blood Platelets; Dipyridamole; Double-Blind Method; Drug Interactions; Endothelium, | 1990 |
[Acetylsalicylic acid in the prevention of arterial thrombosis. Dosage problems in general and in the authors' experiment].
Topics: Adult; Aspirin; Drug Evaluation; Female; Humans; Male; Thrombosis | 1990 |
Usefulness of aspirin plus dipyridamole in reducing left ventricular thrombus formation in anterior wall acute myocardial infarction.
Topics: Aspirin; Blood Coagulation; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Drug Therap | 1989 |
Effect of low dose acetylsalicylic acid on the frequency and hematologic activity of left ventricular thrombus in anterior wall acute myocardial infarction.
Topics: Adult; Aspirin; Blood Platelets; Clinical Trials as Topic; Echocardiography; Heart; Humans; Indium R | 1989 |
[Reduction of mortality in acute myocardial infarction with streptokinase and aspirin therapy. Results of ISIS-2].
Topics: Aged; Aspirin; Clinical Trials as Topic; Drug Combinations; Female; Humans; Male; Middle Aged; Multi | 1989 |
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; A | 1986 |
Antiaggregative aspirin dosage at the affected vessel wall.
Topics: Aortic Arch Syndromes; Arm; Aspirin; Clinical Trials as Topic; Female; Humans; Platelet Aggregation; | 1986 |
Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty.
Topics: Angioplasty, Balloon; Animals; Arterial Occlusive Diseases; Aspirin; Clinical Trials as Topic; Dipyr | 1987 |
Danish very-low-dose aspirin after carotid endarterectomy trial.
Topics: Aspirin; Carotid Arteries; Clinical Trials as Topic; Endarterectomy; Female; Humans; Male; Middle Ag | 1988 |
A comparison of the effects of a thromboxane antagonist and cyclo-oxygenase inhibitor on platelet accumulation in arterial grafts.
Topics: Aorta; Aspirin; Biphenyl Compounds; Blood Platelets; Clinical Trials as Topic; Cyclooxygenase Inhibi | 1987 |
Platelet-inhibitory therapy in reconstructive arterial surgery.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Artery Bypass; Dipyridamole; Double-Bli | 1985 |
A dose-ranging study of the antiplatelet effect of enteric coated aspirin in man.
Topics: Adult; Aspirin; Dose-Response Relationship, Drug; Female; Humans; Male; Platelet Aggregation; Thromb | 1987 |
Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in man in vivo.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aspirin; Bleeding Time; Blood Platelets; Blood Vessels; Double- | 1987 |
Effect of perioperative platelet inhibition on postcarotid endarterectomy mural thrombus formation. Results of a prospective randomized controlled trial using aspirin and dipyridamole in humans.
Topics: Aged; Aspirin; Blood Platelets; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Disorders | 1985 |
Reduction of thrombus formation on dialyser membranes by aspirin and RA 233.
Topics: Aspirin; Blood Cell Count; Blood Coagulation; Blood Platelets; Clinical Trials as Topic; Drug Synerg | 1972 |
[The importance of thrombocytes for thrombogenesis and the pharmacological influencing of thrombocyte function (author's transl)].
Topics: Animals; Anticoagulants; Aspirin; Blood Platelet Disorders; Blood Platelets; Clinical Trials as Topi | 1974 |
Effect of aspirin on brachial artery occlusion following brachial arteriotomy for coronary arteriography.
Topics: Administration, Oral; Angiography; Arterial Occlusive Diseases; Aspirin; Blood Pressure; Brachial Ar | 1973 |
Aspirin in prophylaxis of ischemic heart disease.
Topics: Arteriosclerosis; Aspirin; Clinical Trials as Topic; Coronary Disease; Humans; Platelet Adhesiveness | 1973 |
Platelet survival in patients with prosthetic heart valves.
Topics: Aspirin; Blood Cell Count; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Cell Surviva | 1974 |
Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid. Results of a prospective double blind study.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Coagulation; Clinical Trials as Topic; Female; Humans; | 1974 |
Platelet function studies before and after operation and the effect of postoperative thrombosis.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Blood Cell Count; Blood Platelets; Chromatography; Coll | 1974 |
Two-faced aspirin.
Topics: Aspirin; Blood Platelet Disorders; Clinical Trials as Topic; Humans; Thromboembolism; Thrombosis | 1969 |
Anti-inflammatory drugs and the prevention of thrombosis.
Topics: Analgesics; Aspirin; Blood Coagulation; Cell Membrane; Female; Fibrinogen; Humans; Iodine Isotopes; | 1971 |
1399 other studies available for aspirin and Blood Clot
| Article | Year |
|---|---|
Synthesis, platelet aggregation inhibitory activity, and in vivo antithrombotic activity of new 1,4-dihydropyridines.
Topics: Animals; Cats; Collagen; Dihydropyridines; Humans; Kinetics; Male; Mice; Nitrendipine; Platelet Aggr | 1988 |
2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities.
Topics: Animals; Arteriosclerosis; Cilostazol; Hyperplasia; Platelet Aggregation Inhibitors; Quinolines; Qui | 1998 |
Synthesis, nano-scale assembly, and in vivo anti-thrombotic activity of novel short peptides containing L-Arg and L-Asp or L-Glu.
Topics: Animals; Arginine; Aspartic Acid; Aspirin; Circular Dichroism; Dose-Response Relationship, Drug; Fib | 2008 |
A class of oral N-[(1S,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carbonyl]- N'-(amino-acid-acyl)hydrazine: discovery, synthesis, in vitro anti-platelet aggregation/in vivo anti-thrombotic evaluation and 3D QSAR analysis.
Topics: Administration, Oral; Amino Acids; Animals; Carbolines; Dose-Response Relationship, Drug; Drug Disco | 2011 |
Polysulfated xanthones: multipathway development of a new generation of dual anticoagulant/antiplatelet agents.
Topics: Adult; Animals; Anticoagulants; Factor Xa Inhibitors; Glucosides; Humans; Mice; Platelet Aggregation | 2011 |
A class of novel N-(1-methyl-β-carboline-3-carbonyl)-N'-(aminoacid-acyl)-hydrazines: aromatization leaded design, synthesis, in vitro anti-platelet aggregation/in vivo anti-thrombotic evaluation and 3D QSAR analysis.
Topics: Animals; Chemistry Techniques, Synthetic; Dose-Response Relationship, Drug; Drug Design; Fibrinolyti | 2011 |
Synthesis and evaluation of dual antiplatelet activity of bispidine derivatives of N-substituted pyroglutamic acids.
Topics: Animals; Blood Coagulation; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Hemorrhage; Hu | 2016 |
Preventive effect of a novel diosgenin derivative on arterial and venous thrombosis in vivo.
Topics: Administration, Oral; Animals; Diosgenin; Disease Models, Animal; Dose-Response Relationship, Drug; | 2016 |
Docking based design of diastereoisomeric MTCA as GPIIb/IIIa receptor inhibitor.
Topics: Administration, Oral; Animals; Binding Sites; Blood Platelets; Drug Design; Microscopy, Atomic Force | 2017 |
First Report of Plant-Derived β-Sitosterol with Antithrombotic, in Vivo Anticoagulant, and Thrombus-Preventing Activities in a Mouse Model.
Topics: Animals; Anticoagulants; Antithrombins; Catalysis; Disease Models, Animal; Female; Fibrinogen; Human | 2018 |
Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke.
Topics: Administration, Oral; Animals; Biguanides; Brain Ischemia; Dose-Response Relationship, Drug; Male; M | 2020 |
An attempt to chemically state the cross-talk between monomers of COX homodimers by double/hybrid inhibitors mofezolac-spacer-mofezolac and mofezolac-spacer-arachidonic acid.
Topics: Algorithms; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Blood Coagulation; C | 2021 |
Utility of Platelet Endothelial Cell Adhesion Molecule 1 in the Platelet Activity Assessment in Mouse and Human Blood.
Topics: Animals; Aspirin; Blood Platelets; Cell Adhesion; Endothelial Cells; Endothelium, Vascular; Female; | 2021 |
Platelet reactivity and clinical outcomes following percutaneous coronary intervention in complex higher-risk patients.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Pe | 2022 |
Evaluation of aspirin platelet inhibition in left ventricular assist device population.
Topics: Aspirin; Heart Failure; Heart-Assist Devices; Humans; Retrospective Studies; Thromboembolism; Thromb | 2021 |
Urinary 11-dehydrothromboxane B2 aspirin efficacy testing is sensitive to perioperative inflammation in pediatric solid-organ transplant patients.
Topics: Adolescent; Adult; Aspirin; Blood Platelets; Child; Child, Preschool; Humans; Infant; Infant, Newbor | 2022 |
[Integral tests of the hemostasis system in assessing the efficiency of acetylsalicylic acid in patients with ischemic heart disease].
Topics: Aspirin; Female; Hemostasis; Humans; Male; Myocardial Ischemia; Platelet Aggregation Inhibitors; Thr | 2021 |
Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors.
Topics: Amblyomma; Animals; Antibodies; Anticoagulants; Antidotes; Antithrombins; Aspirin; Drug Development; | 2021 |
Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry.
Topics: Aspirin; COVID-19 Drug Treatment; Humans; Inflammation; Intensive Care Units; Registries; Retrospect | 2022 |
Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette-Guérin?
Topics: Adjuvants, Immunologic; Administration, Intravesical; Anticoagulants; Aspirin; BCG Vaccine; Clopidog | 2022 |
Concurrent Cerebral, Splenic, and Renal Infarction in a Patient With COVID-19 Infection.
Topics: Anticoagulants; Aspirin; COVID-19; Humans; Infarction; Male; Middle Aged; Stroke; Thrombosis | 2022 |
Beneficial Effect of Low Dose Aspirin in Adult Patients with COVID-19: A Retrospective Observational Study in Bangladesh.
Topics: Adult; Aspirin; Bangladesh; Child; COVID-19; Humans; SARS-CoV-2; Thrombosis | 2022 |
COX-1, COX-2 and CYP2C19 variations may be related to cardiovascular events due to acetylsalicylic acid resistance.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Cyclooxygenase 1; Cyclooxygenase 2; Cytochrome P-450 | 2022 |
Eculizumab for refractory thrombosis in antiphospholipid syndrome.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antiphospholipid Syndrome; Aspirin; Clopidogrel; Fema | 2022 |
Impact of aspirin discontinuation on thrombotic complications in laparoscopic colorectal cancer surgery.
Topics: Aspirin; Colorectal Neoplasms; Humans; Laparoscopy; Platelet Aggregation Inhibitors; Postoperative C | 2022 |
Deletion of platelet CLEC-2 decreases GPIbα-mediated integrin αIIbβ3 activation and decreases thrombosis in TTP.
Topics: Aspirin; Blood Platelets; Humans; Hypertension, Pulmonary; Lectins, C-Type; Platelet Activation; Pla | 2022 |
Clinical and therapeutic value of the adjusted Global Antiphospholipid Syndrome Score in primary obstetric antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Humans; Lupus Erythematosus, Systemic; P | 2022 |
Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa.
Topics: Animals; Anticoagulants; Aspirin; Factor XIa; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggr | 2022 |
Both G protein-coupled and immunoreceptor tyrosine-based activation motif receptors mediate venous thrombosis in mice.
Topics: Animals; Aspirin; Blood Platelets; Clopidogrel; GTP-Binding Proteins; Immunoreceptor Tyrosine-Based | 2022 |
Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Drug Therapy, Combination; Fibrinolyti | 2022 |
Therapeutic implementation in arterial thrombosis with pulmonary administration of fucoidan microparticles containing acetylsalicylic acid.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Polysaccharides; Thrombos | 2022 |
Atherothrombosis-on-Chip: A Site-Specific Microfluidic Model for Thrombus Formation and Drug Discovery.
Topics: Aspirin; Drug Discovery; Humans; Microfluidics; Plaque, Atherosclerotic; Reproducibility of Results; | 2022 |
Safety and efficacy comparison between OACs plus single antiplatelet and dual antiplatelet therapy in patients with cerebral venous sinus stenosis poststenting.
Topics: Adult; Anticoagulants; Aspirin; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination; Fe | 2022 |
Exploratory Use of Glycoprotein IIb/IIIa Inhibition in Prevention of Blalock-Taussig Shunt Thrombosis.
Topics: Anticoagulants; Aspirin; Blalock-Taussig Procedure; Cohort Studies; Fibrinolytic Agents; Hemorrhage; | 2022 |
Early prevention and risk factors analysis of portal vein system thrombosis after laparoscopic splenectomy and pericardial devascularization.
Topics: Anticoagulants; Aspirin; Humans; Hypertension, Portal; Laparoscopy; Liver Cirrhosis; Portal Vein; Ri | 2022 |
Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs.
Topics: Aminopyridines; Animals; Aspirin; Fibrinolytic Agents; Humans; Mice; Morpholines; Oxazines; Plaque, | 2022 |
The effect of low-dose and high-dose low-molecular-weight-heparin and aspirin thromboprophylaxis on clinical outcome and mortality in critical ill patients with COVID-19: A retrospective cohort study.
Topics: Anticoagulants; Aspirin; COVID-19; Critical Illness; Hemorrhage; Heparin, Low-Molecular-Weight; Huma | 2022 |
Medium-pressure hyperbaric oxygen therapy for livedoid vasculopathy.
Topics: Adult; Aspirin; Female; Humans; Hyperbaric Oxygenation; Infant; Livedoid Vasculopathy; Thrombosis; W | 2022 |
Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: A multicentre retrospective real-life study.
Topics: Aspirin; Humans; Prognosis; Retrospective Studies; Risk Factors; Thrombocythemia, Essential; Thrombo | 2022 |
Low-dose aspirin, rejection, and thrombosis: Is it the Wonder Drug® of liver transplantation?
Topics: Aspirin; Graft Rejection; Humans; Liver Transplantation; Thrombosis | 2022 |
Variability of antiplatelet response in patients with peripheral artery disease.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Peripheral Arterial Disease; Platelet Aggre | 2023 |
Serial assessment of thrombogenicity and hemodynamics in patients with type II diabetes in a clinical research unit: Evidence for circadian variations in clot formation.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Blood Pressure; Circadian Rhythm; Diabetes Mellitu | 2022 |
Vascular thrombotic events in the era of modern myeloma therapy.
Topics: Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Multiple Myeloma; Thro | 2022 |
A Mobile Thrombus of the Thoracic Aorta.
Topics: Aorta, Thoracic; Aspirin; Embolism; Female; Humans; Thrombosis; Treatment Outcome | 2023 |
Oral anticoagulant management of patients with mechanical heart valves at the Salam Centre of Khartoum: Observations on quality of anticoagulation and thrombotic risk.
Topics: Adult; Anticoagulants; Aspirin; Blood Coagulation; Female; Heart Valves; Hemorrhage; Humans; Male; T | 2022 |
A rare cause of abdominal pain managed unconventionally: acute renal infarction caused by atrial fibrillation: a case report.
Topics: Abdominal Pain; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Diltiazem; Humans; | 2022 |
High-Intensity Exercise Training Improves Basal Platelet Prostacyclin Sensitivity and Potentiates the Response to Dual Anti-Platelet Therapy in Postmenopausal Women.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Cyclooxygenase 1; Diphosphates; Dual Anti-Platelet Therap | 2022 |
Studying the efficacy of antiplatelet drugs on atherosclerosis by optofluidic imaging on a chip.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Constriction, Pathologic; Eptifibatide; Humans; Lab-On-A- | 2023 |
Studying the efficacy of antiplatelet drugs on atherosclerosis by optofluidic imaging on a chip.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Constriction, Pathologic; Eptifibatide; Humans; Lab-On-A- | 2023 |
Studying the efficacy of antiplatelet drugs on atherosclerosis by optofluidic imaging on a chip.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Constriction, Pathologic; Eptifibatide; Humans; Lab-On-A- | 2023 |
Studying the efficacy of antiplatelet drugs on atherosclerosis by optofluidic imaging on a chip.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Constriction, Pathologic; Eptifibatide; Humans; Lab-On-A- | 2023 |
Utility of the Total Thrombus-Formation Analysis System as a Tool for Evaluating Thrombogenicity and Monitoring Antithrombotic Therapy in Pediatric Fontan Patients.
Topics: Anticoagulants; Aspirin; Child; Fibrinolytic Agents; Fontan Procedure; Humans; Prospective Studies; | 2023 |
Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cardiovascular Diseases; Drug Therapy, Combinatio | 2022 |
[Which anticoagulant or antiplatelet treatment for cancer patients with thrombocytopenia ?]
Topics: Anemia; Anticoagulants; Aspirin; Humans; Neoplasms; Platelet Aggregation Inhibitors; Thrombocytopeni | 2023 |
Management and outcomes of women with antiphospholipid syndrome during pregnancy.
Topics: Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn; | 2023 |
Cryo-Shocked Platelet Coupled with ROS-Responsive Nanomedicine for Targeted Treatment of Thromboembolic Disease.
Topics: Aspirin; Fibrinolytic Agents; Humans; Liposomes; Nanomedicine; Reactive Oxygen Species; Stroke; Thro | 2023 |
Acetylsalicylic Acid Is Not Associated With Improved Clinical Outcomes After Microsurgical Breast Reconstruction.
Topics: Aspirin; Breast Neoplasms; Female; Humans; Mammaplasty; Mastectomy; Middle Aged; Necrosis; Postopera | 2023 |
Comparison of clinical outcomes with cangrelor plus aspirin versus oral dual antiplatelet therapy in patients supported with venoarterial extracorporeal membrane oxygenation.
Topics: Aspirin; Drug Therapy, Combination; Extracorporeal Membrane Oxygenation; Hemorrhage; Humans; Percuta | 2023 |
Evidence that platelets from transfusion-dependent β-thalassemia patients induce T cell activation.
Topics: Aspirin; beta-Thalassemia; Blood Platelets; Humans; Platelet Activation; Thrombosis | 2023 |
Controversies in the Management of Antiphospholipid Syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Humans; Thrombosis; Venous Thromboembolism | 2023 |
Small-diameter PCL/PU vascular graft modified with heparin-aspirin compound for preventing the occurrence of acute thrombosis.
Topics: Aspirin; Blood Vessel Prosthesis; Endothelial Cells; Heparin; Humans; Platelet Aggregation Inhibitor | 2023 |
Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Fibrinolytic Agents; Humans; Mice; Plaque, Atheroscleroti | 2023 |
Low dose aspirin and clinical outcomes in patients with SARS-CoV-2 pneumonia: a propensity score-matched cohort analysis from the National SIMI‑COVID‑19 Registry.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; COVID-19; Female; Humans; Male; Multicenter Studie | 2023 |
DAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX: A National Registry Analysis.
Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Female; Hemorrhage; Humans; Ma | 2023 |
Low-Dose Aspirin Reduces the Rate of Renal Allograft Thrombosis in Pediatric Renal Transplant Recipients.
Topics: Adolescent; Age Factors; Aspirin; Child; Child, Preschool; Female; Fibrinolytic Agents; Humans; Infa | 2020 |
Evaluation of commonly used tests to measure the effect of single-dose aspirin on mouse hemostasis.
Topics: Animals; Aspirin; Disease Models, Animal; Drug Evaluation, Preclinical; Hemorrhage; Hemostasis; Male | 2019 |
Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; beta 2-Glycoprotein I; Drug | 2019 |
Do We Have Good Reasons to Pay Bleeding Penalty With Lifelong Aspirin After LAAO?
Topics: Aspirin; Atrial Appendage; Fibrinolytic Agents; Humans; Thrombosis; Treatment Outcome | 2019 |
Reply: Do We Have Good Reasons to Pay Bleeding Penalty With Lifelong Aspirin After LAAO?
Topics: Aspirin; Atrial Appendage; Atrial Fibrillation; Fibrinolytic Agents; Humans; Thrombosis; Treatment O | 2019 |
Reply: Do We Have Good Reasons to Pay Bleeding Penalty With Lifelong Aspirin After LAAO?
Topics: Aspirin; Atrial Appendage; Humans; Incidence; Prospective Studies; Thrombosis; Treatment Outcome | 2019 |
Kawasaki disease: origins and evolution.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Autopsy; Coronary Aneurysm; History, 20th Century; | 2021 |
Upgrading Therapy Strategy Improves Pregnancy Outcome in Antiphospholipid Syndrome: A Cohort Management Study.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Cohort Studies; Drug Dosage | 2020 |
Validation of the Spartan RXCYP2C19 Genotyping Assay Utilizing Blood Samples.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; DNA; Dual Anti-Platelet Therapy; Genotyping Techniqu | 2020 |
Estimating short- and long-term reference change values and index of individuality for tests of platelet function.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Biological Variation, Population; Female; Follow-U | 2019 |
Early Aspirin Nonresponders Identification by Routine Use of Aggregometry Test in Patients With Left Ventricle Assist Devices Reduces the Risk of Pump Thrombosis.
Topics: Aspirin; Blood Coagulation; Blood Coagulation Tests; Drug Resistance; Female; Heart-Assist Devices; | 2019 |
Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease.
Topics: Aged; Aspirin; Blood Coagulation; Coronary Artery Disease; Fibrin; Fibrinolysis; Follow-Up Studies; | 2020 |
Anti-thrombosis management of patients with Kawasaki disease: Results from an international survey.
Topics: Aspirin; Child; Coronary Aneurysm; Humans; Mucocutaneous Lymph Node Syndrome; Thrombosis | 2020 |
Distal Arterial Embolization from an Abandoned Native Brachio-Cephalic Fistula: A Case Report.
Topics: Anticoagulants; Arteriovenous Fistula; Aspirin; Brachial Artery; Embolization, Therapeutic; Exercise | 2020 |
Plasma metabonomics and proteomics studies on the anti-thrombosis mechanism of aspirin eugenol ester in rat tail thrombosis model.
Topics: Animals; Aspirin; Eugenol; Metabolomics; Pharmaceutical Preparations; Proteomics; Rats; Tail; Thromb | 2020 |
Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopi | 2020 |
Anticoagulant and anti-thrombotic therapy in acute type B aortic dissection: when real-life scenarios face the shadows of the evidence-based medicine.
Topics: Anticoagulants; Aortic Aneurysm, Thoracic; Aortic Dissection; Aspirin; Clinical Decision-Making; Clo | 2020 |
Platelet Adhesion and Thrombus Formation in Microchannels: The Effect of Assay-Dependent Variables.
Topics: Adenosine Monophosphate; Aspirin; Blood Platelets; Collagen; Cyclooxygenase Inhibitors; Humans; Male | 2020 |
Cost-effective analysis of clopidogrel versus aspirin for high risk patients with established peripheral arterial disease in China.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Health Expenditures; Humans; Markov Chains; Models, Eco | 2020 |
Hospital Variability Drives Inconsistency in Antiplatelet Use After Coronary Bypass.
Topics: Aged; Aspirin; Comorbidity; Coronary Artery Bypass; Coronary Artery Bypass, Off-Pump; Drug Therapy, | 2020 |
Precision medicine and the antiphospholipid syndrome: what is the future?
Topics: Abortion, Spontaneous; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; An | 2020 |
Efficacy of Cangrelor as Bridging Therapy Post PCI.
Topics: Adenosine Monophosphate; Aged; Aspirin; Colectomy; Colonic Neoplasms; Drug-Eluting Stents; Factor Xa | 2020 |
[Management of antithrombotic therapy in patients with bleeding after percutaneous coronary intervention].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percut | 2020 |
Diffuse saphenous vein graft thrombosis: resolution after one month of apixaban and dual antiplatelet therapy.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Graft Occlusion, Vascular; | 2020 |
Acetylsalicylic acid to fight thrombosis in sepsis.
Topics: Animals; Aspirin; Blood Coagulation; Mice; Sepsis; Staphylococcus aureus; Thrombosis | 2020 |
Ischemic Versus Bleeding Outcomes After Percutaneous Coronary Interventions in Patients With High Bleeding Risk.
Topics: Aged; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Dual Anti-Platelet | 2020 |
Is aspirin needed to prevent thrombotic events in patients treated with a HeartMate 3 left ventricular assist device?
Topics: Aspirin; Heart-Assist Devices; Humans; Thrombosis; Warfarin | 2020 |
Drug-eluting Vein Graft with Acetylsalicylic Acid-Ticagrelor-Unfractionated Heparin Complex Inhibits Early Graft Thrombosis
Topics: Animals; Anticoagulants; Aspirin; Coronary Artery Bypass; Disease Models, Animal; Graft Enhancement, | 2020 |
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Bacteria; Case-Control Studies; Dual Anti-Platelet Therapy; Female; Gastrointestinal | 2020 |
Acute Thrombus Burden on Coated Flow Diverters Assessed by High Frequency Optical Coherence Tomography.
Topics: Acute Disease; Animals; Aspirin; Clopidogrel; Coated Materials, Biocompatible; Disease Models, Anima | 2020 |
Impact of Flow Dynamics on Device-Related Thrombosis After Left Atrial Appendage Occlusion.
Topics: Aged; Antithrombins; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Comput | 2020 |
Longitudinal Monitoring of Flow-Diverting Stent Tissue Coverage After Implant in a Bifurcation Model Using Neurovascular High-Frequency Optical Coherence Tomography.
Topics: Animals; Arteries; Aspirin; Rabbits; Stents; Thrombosis; Tomography, Optical Coherence | 2020 |
Thrombocytopenia and Thromboses in Myocardial Infarction Associated with Eptifibatide-Dependent Activating Antiplatelet Antibodies.
Topics: Antigens, Human Platelet; Arginine; Aspirin; Autoantibodies; Combined Modality Therapy; Coronary Thr | 2020 |
Aspirin Discontinuation in Patients Requiring Oral Anticoagulation Undergoing Percutaneous Coronary Intervention, The Role of Procedural Complexity.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Drug Administration Schedule | 2020 |
Assessment of Platelet Thrombus Formation under Flow Conditions in Patients with Acute Kawasaki Disease.
Topics: Aspirin; Blood Pressure; Child; Child, Preschool; Cohort Studies; Female; Humans; Infant; Lab-On-A-C | 2020 |
Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin.
Topics: Aspirin; Drug Therapy, Combination; Health Care Surveys; Humans; Hungary; Hydroxyurea; Quinazolines; | 2020 |
Profiling the eicosanoid networks that underlie the anti- and pro-thrombotic effects of aspirin.
Topics: Animals; Arachidonic Acid; Aspirin; Blood Platelets; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Ei | 2020 |
New methodological approaches for assessing thrombus formation in cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervent | 2020 |
Net platelet clot strength of thromboelastography platelet mapping assay for the identification of high on-treatment platelet reactivity in post-PCI patients.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Female; Humans; Male; Middle Aged; Myocardial Infa | 2020 |
Aspirin in ET: will twice a day keep thrombosis away?
Topics: Aspirin; Double-Blind Method; Humans; Platelet Aggregation Inhibitors; Thrombocythemia, Essential; T | 2020 |
Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation.
Topics: Adult; Aged; Aspirin; Cohort Studies; Female; Heart-Assist Devices; Humans; Male; Middle Aged; Phosp | 2020 |
Cap-fitted identification and endoscopic haemostasis of a tiny vascular colonic lesion under maintained triple antithrombotic therapy.
Topics: Aspirin; Blood Transfusion; Clopidogrel; Colonic Diseases; Colonoscopy; Combined Modality Therapy; D | 2021 |
Supplemental Fibrinogen Restores Platelet Inhibitor-Induced Reduction in Thrombus Formation without Altering Platelet Function: An In Vitro Study.
Topics: Aged; Aspirin; Calcium Signaling; Female; Fibrinogen; Hemorheology; Heparin; Hirudins; Humans; In Vi | 2020 |
Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug | 2020 |
Successful management of COVID-19 and associated coagulopathy in a patient with durable left ventricular assist device.
Topics: Adult; Anticoagulants; Aspirin; Biomarkers; Blood Transfusion; COVID-19; Cytokine Release Syndrome; | 2020 |
Discontinuation of aspirin before non-cardiac surgery causing ventricular mural thrombus for a patient with left ventricular aneurysm: a case report.
Topics: Aged; Aspirin; Drug Administration Schedule; Elective Surgical Procedures; Fibrinolytic Agents; Hear | 2020 |
Comparison of acetylsalicylic acid and clopidogrel non-responsiveness assessed by light transmittance aggregometry and PFA-100® in patients undergoing neuroendovascular procedures.
Topics: Adenosine Diphosphate; Aged; Alprostadil; Aspirin; Blood Coagulation Tests; Blood Platelets; Clopido | 2020 |
Safety and Efficacy of Single Versus Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiovascular Diseases; Cl | 2020 |
Aspirin with or without statin in the treatment of endotheliitis, thrombosis, and ischemia in coronavirus disease.
Topics: Aspirin; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; En | 2020 |
Acetylsalicylic acid (Aspirin): a potent medicine for preventing COVID-19 deaths caused by thrombosis and pulmonary embolism.
Topics: Aspirin; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Platelet Aggregation | 2020 |
Desmopressin with four-factor prothrombin complex concentrate for life-threatening bleeding: A case series.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagulation Factors; Cerebral Hemorrhage, Tr | 2020 |
Chronic Application of Low-Dose Aspirin Affects Multiple Parameters of Three Blood Cellular Types and Antithrombin Activity: A 1:1:1 Propensity Score Matching Analysis.
Topics: Aged; Aged, 80 and over; Antithrombin III; Aspirin; Blood Platelets; Drug Administration Schedule; E | 2021 |
Complex intracranial vascular complications caused by essential thrombocythemia: a critical case report.
Topics: Adult; Aspirin; Blood Platelets; Female; Hemorrhage; Humans; Magnetic Resonance Imaging; Mutation; M | 2020 |
[Recent advances in polycythemia vera treatment].
Topics: Aspirin; Clinical Trials as Topic; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Polycythem | 2020 |
Vascular protective effect of aspirin and rivaroxaban upon endothelial denudation of the mouse carotid artery.
Topics: Animals; Arteries; Aspirin; Blood Platelets; Carotid Arteries; Carotid Artery Diseases; Carotid Inti | 2020 |
1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y
Topics: Absorbable Implants; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; My | 2020 |
Clinical factors associated with safety and efficacy in patients receiving direct oral anticoagulants for non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulan | 2020 |
Effect of Continued Perioperative Anticoagulant Therapy on Bleeding Outcomes Following Robot-assisted Radical Prostatectomy.
Topics: Aged; Anticoagulants; Antithrombins; Aspirin; Blood Transfusion; Clopidogrel; Continuity of Patient | 2021 |
Comparison of Warfarin to Dual Antiplatelet Therapy Following Transcatheter Aortic Valve Replacement.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2021 |
Anti-thrombotic and anti-inflammatory activity of sulodexide compared to aspirin in the rat model.
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Disease Models, Animal; Glycosaminoglyca | 2021 |
Late Stent Thrombosis After Drug-Coated Balloon Coronary Angioplasty for In-Stent Restenosis.
Topics: Acute Disease; Adult; Aftercare; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angi | 2021 |
Bilateral finger ischemia due to hand artery thrombosis caused by repeated movements.
Topics: Anti-Bacterial Agents; Aspirin; Combined Modality Therapy; Fibrinolytic Agents; Fingers; Hand; Hepar | 2021 |
A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Humans; Plaque, Atherosclerotic; Pr | 2020 |
"Part of the Ritual": Exploring Patient and Physician Decision Making Regarding Anticoagulation Use in Obstetric Antiphospholipid Syndrome.
Topics: Abortion, Spontaneous; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Attitude of Health Person | 2021 |
Multiple aortic thrombi in essential thrombocythaemia.
Topics: Aged; Aorta, Abdominal; Aspirin; Cefazolin; Echocardiography; Heparin; Humans; Hydroxyurea; Male; St | 2021 |
The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients.
Topics: Aged; Aptamers, Peptide; Aspirin; Blood Platelets; Collagen; Female; Humans; Intracranial Arterioscl | 2021 |
Analysis of blood clotting with the total thrombus analysis system in healthy dogs.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Blood Coagulation Tests; Dalteparin; Dogs; Fema | 2021 |
Commentary: Aspirin versus warfarin in patients with a Fontan circulation-the clot thickens.
Topics: Aspirin; Fontan Procedure; Humans; Thromboembolism; Thrombosis; Warfarin | 2021 |
Impact of Aspirin Dosing on Thrombotic Outcomes in Patients with the HVAD.
Topics: Aspirin; Heart-Assist Devices; Humans; Thrombosis | 2021 |
Successful Therapy With Ticagrelor in Three-Vessel Stent Thrombosis Related to Clopidogrel Resistance.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Dual Anti-Platelet Therapy; Humans; Male; Percutan | 2021 |
Platelet Function Monitoring Performed after Carotid Stenting during Endovascular Stroke Treatment Predicts Outcome.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Databases, Factual; Disability Evaluation; Drug Monito | 2021 |
Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; COVID-19; Female; Hospitalization; Hu | 2021 |
Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes.
Topics: Aged; Aspirin; Coronary Artery Bypass; Drainage; Drug Therapy, Combination; Erythrocyte Transfusion; | 2021 |
Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Diabetes, Gestational; Female; Fetal Death; Hemo | 2021 |
Tyrosine Kinase Inhibitor Sunitinib Delays Platelet-Induced Coagulation: Additive Effects of Aspirin.
Topics: Aspirin; Blood Coagulation; Humans; Platelet Aggregation; Protein Kinase Inhibitors; Sunitinib; Thro | 2022 |
Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Pro | 2022 |
Aspirin resistance in infants with shunt-dependent congenital heart disease.
Topics: Aspirin; Heart Defects, Congenital; Humans; Infant; Infant, Newborn; Thrombosis | 2022 |
Acetylsalicylic Acid Compared with Enoxaparin for the Prevention of Thrombosis and Mechanical Ventilation in COVID-19 Patients: A Retrospective Cohort Study.
Topics: Anticoagulants; Aspirin; COVID-19; Enoxaparin; Humans; Respiration, Artificial; Retrospective Studie | 2021 |
Aspirin I.V. Loading during Elective Percutaneous Coronary Intervention.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Dose-Respons | 2021 |
Treatment of Catheter-Related Arterial Thrombosis in Children: A 15-Year Single- Center Experience.
Topics: Adolescent; Anticoagulants; Aspirin; Cardiac Catheterization; Catheters, Indwelling; Child; Child, P | 2021 |
Quantitative Computed Tomographic Volumetry after Treatment of a Giant Intracranial Aneurysm with a Pipeline Embolization Device.
Topics: Adult; Aged; Anticoagulants; Aspirin; Carotid Artery, Internal; Embolization, Therapeutic; Female; H | 2017 |
Cessation of oral anticoagulants in antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Aged, 80 and over; Antibodies, Antiphospholipid; Anticoagulants; Antiph | 2017 |
Spontaneous Regression of Possible Transcatheter Aortic Valve Thrombosis Without Additional Anticoagulant: Two-Year Follow-Up.
Topics: Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Drug Administration Schedule; Follo | 2017 |
Thrombolysis of prosthetic mitral valve thrombosis in an infant.
Topics: Aspirin; Coronary Vessels; Female; Fibrinolytic Agents; Heart Septal Defects, Ventricular; Heart Val | 2017 |
Comparison of dual antiplatelet therapy versus oral anticoagulation following transcatheter aortic valve replacement: A retrospective single-center registry analysis.
Topics: Administration, Oral; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Clopidogrel; | 2017 |
Serological evolution in women with positive antiphospholipid antibodies.
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biomarkers; | 2017 |
Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Vessels; Drug Hypersensitivity; Humans; Male; Middle Aged; | 2017 |
Platelet testing to guide aspirin dose adjustment in pediatric patients after cardiac surgery.
Topics: Aspirin; Body Weight; Cardiac Surgical Procedures; Chemoprevention; Child, Preschool; Dose-Response | 2017 |
Enhanced procoagulant activity of platelets after chemotherapy in non-small cell lung cancer.
Topics: Aged; Antigens, Surface; Aspirin; Bleeding Time; Blood Coagulation; Blood Platelets; Carcinoma, Non- | 2017 |
[Evaluation of the antithrombotic strategy in low thrombotic risk patients who underwent aortic valve replacement with a bioprosthesis].
Topics: Adult; Aged; Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Drug Therapy, Combination; Female | 2018 |
Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study.
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Blood Coagu | 2018 |
Antiplatelet therapy: Aspirin in the elderly - tailored approaches ahead?
Topics: Age Factors; Aged; Aspirin; Hemorrhage; Humans; Medication Therapy Management; Platelet Aggregation | 2017 |
Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Female; Humans; | 2017 |
Impact of Dual Antiplatelet Therapy Beyond 1 Year on Clinical Outcomes of Patients With Stent Fracture or Peri-Stent Contrast Staining After Sirolimus-Eluting Stent Implantation.
Topics: Aged; Aspirin; Death; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; | 2017 |
Thrombosis on a left atrial appendage occluder device: the double-edged sword of stroke prevention strategies in atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Dabigatran; Echocardiography, | 2017 |
Livedo racemosa.
Topics: Aspirin; Female; Homocysteine; Humans; Livedo Reticularis; Middle Aged; Thrombosis | 2017 |
Stability Indicating Liquid Chromatographic Method for Simultaneous Determination of Aspirin and Omeprazole.
Topics: Aspirin; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Combinations; Drug Co | 2018 |
Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Drug Resistance; F | 2018 |
Stopping antithrombotic therapy after acute upper gastrointestinal bleeding is associated with reduced survival.
Topics: Aged; Aspirin; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Gastroscopy; Humans; Male; | 2018 |
The Effect of Continued Low Dose Aspirin Therapy in Patients Undergoing Percutaneous Nephrolithotomy.
Topics: Administration, Oral; Aged; Aspirin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hu | 2018 |
Risk of non-cardiac surgery after percutaneous coronary intervention with drug-eluting stents.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Drug-Eluting Stents; Female; Humans; In | 2017 |
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Factor Xa Inhibitors; F | 2018 |
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Factor Xa Inhibitors; F | 2018 |
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Factor Xa Inhibitors; F | 2018 |
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Factor Xa Inhibitors; F | 2018 |
Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2018 |
Platelet function monitoring for stent thrombosis in critically III patients with an acute Coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Female; Humans; Male; Mi | 2018 |
Perioperative Management of Dual Antiplatelet Therapy.
Topics: Aspirin; Elective Surgical Procedures; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation | 2018 |
Anti-thrombotic efficacy of S007-867: Pre-clinical evaluation in experimental models of thrombosis in vivo and in vitro.
Topics: Animals; Aspirin; Blood Coagulation; Chlorides; Clopidogrel; Dose-Response Relationship, Drug; Ferri | 2018 |
Rivaroxaban with or without aspirin for prevention of cardiovascular disease.
Topics: Aspirin; Blood Coagulation; Cardiovascular Diseases; Clinical Decision-Making; Evidence-Based Medici | 2018 |
Which Antiplatelet Therapy in Patients With Left Ventricular Assist Device and Aspirin Allergy?
Topics: Aspirin; Clopidogrel; Drug Hypersensitivity; Drug Therapy, Combination; Heart Failure; Heart-Assist | 2018 |
[Transient detection of lupus anticoagulant in acute phase of Kawasaki disease].
Topics: Acute-Phase Reaction; Aspirin; Child, Preschool; Humans; Immunoglobulins, Intravenous; Lupus Coagula | 2017 |
WATCHMAN device-related thrombus successfully treated with apixaban: A case report.
Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Factor Xa Inhibit | 2017 |
Ranibizumab and digital ischemia.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Angioplasty; Aspirin; Combined Modality Therapy; Female; | 2018 |
Prognostic Implications of Dual Platelet Reactivity Testing in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Coronary Angiograp | 2018 |
Impact of Multidrug Resistance Protein-4 Inhibitors on Modulating Platelet Function and High on-Aspirin Treatment Platelet Reactivity.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Cohort Studies; Cyclic AMP; Female; Humans; Male; Middle | 2018 |
Comparison of the 9-month intra-stent conditions and 2-year clinical outcomes after Resolute zotarolimus-eluting stent implantation between 3-month and standard dual antiplatelet therapy.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Vessels; Drug Administratio | 2018 |
A clinical risk score to identify patients at high risk of very late stent thrombosis.
Topics: Aspirin; Case-Control Studies; Female; Hemorrhage; Humans; Long Term Adverse Effects; Male; Middle A | 2018 |
Aspirin use is associated with decreased radiologically-determined thrombus sac volume in abdominal aortic aneurysms.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Aortic Aneurysm, Abdominal | 2018 |
Long-haul flights, edema, and thrombotic events: prevention with stockings and Pycnogenol® supplementation (LONFLIT Registry Study).
Topics: Adult; Aircraft; Aspirin; Edema; Female; Flavonoids; Humans; Male; Middle Aged; Plant Extracts; Plat | 2018 |
Design and synthesis of nanoscaled IQCA-TAVV as a delivery system capable of antiplatelet activation, targeting arterial thrombus and releasing IQCA.
Topics: Animals; Aspirin; Blood Platelets; Carotid Arteries; Dimerization; Drug Delivery Systems; Drug Desig | 2018 |
Compression force sensing regulates integrin α
Topics: Adult; Animals; Aspirin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Type 1; Female; Humans; Ma | 2018 |
Aspirin modulates the inflammatory response in a thrombus‑stimulated LMVEC model.
Topics: Animals; Aspirin; Cells, Cultured; Chemokine CX3CL1; CX3C Chemokine Receptor 1; Endothelial Cells; E | 2018 |
Is a variability of platelet inhibitory effect of anti-platelet agents important for predicting new lesion in atherothrombotic stroke?
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Diffusion Magnetic | 2018 |
Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Asp | 2018 |
Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Fem | 2018 |
Evaluation of the antithrombotic activity of Zhi-Xiong Capsules, a Traditional Chinese Medicinal formula, via the pathway of anti-coagulation, anti-platelet activation and anti-fibrinolysis.
Topics: Acute Disease; Animals; Anticoagulants; Antithrombins; Aspirin; Blood Coagulation; Capsules; Carotid | 2018 |
Effect of Physical Exercise on Platelet Reactivity in Patients with Dual Antiplatelet Therapy.
Topics: Adenosine Diphosphate; Aspirin; Chromogranin A; Clopidogrel; Coronary Artery Disease; Electrocardiog | 2018 |
Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alleles; Aspirin; ATP Binding Cassette Transporter | 2018 |
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
Topics: Aspirin; Atherosclerosis; Chronic Disease; Clinical Trials as Topic; Death; Drug Therapy, Combinatio | 2019 |
Antiplatelet therapy in the management of atherothrombosis: recent clinical advances.
Topics: Aspirin; Atherosclerosis; Atrial Fibrillation; Humans; Percutaneous Coronary Intervention; Platelet | 2018 |
[Cerebral embolism in Duchenne muscular dystrophy after respiratory tract infection - Report of two cases].
Topics: Adult; Anticoagulants; Aspirin; Brain; Diffusion Magnetic Resonance Imaging; Echocardiography; Heart | 2018 |
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Development and functional characterization of composite freeze dried wafers for potential delivery of low dose aspirin for elderly people with dysphagia.
Topics: Aged; Aspirin; Carrageenan; Chemistry, Pharmaceutical; Chitosan; Deglutition Disorders; Drug Deliver | 2018 |
Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human | 2018 |
[ADP-Induced Recalcified Blood Clotting Time as a Marker of Rethrombosis Risk and Effectiveness of Antiplatelet Therapy in Acute Coronary Syndrome].
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aspirin; Biomarkers; Humans; Male; Platelet A | 2018 |
The Role of OCT Guidance for Antiplatelet Therapy.
Topics: Aspirin; Clopidogrel; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Thrombos | 2018 |
Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Biomarkers; Brain Ischemia; | 2019 |
A delicate balance: Bleeding versus thrombosis?
Topics: Aspirin; Coronary Artery Bypass; Hemorrhage; Humans; Thrombosis; Tranexamic Acid | 2019 |
Preventing arteriovenous shunt failure in hemodialysis patients: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arteriovenous Shunt, Surgical; Aspirin; Aspirin, Dip | 2019 |
Preoperative continuation of aspirin administration in patients undergoing major abdominal malignancy surgery.
Topics: Abdominal Neoplasms; Aged; Aged, 80 and over; Aspirin; Blood Transfusion; Cohort Studies; Female; He | 2019 |
Effect of P2Y
Topics: Adenosine Monophosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Femal | 2019 |
Impact of Clopidogrel Loading for Coronarography on Bleeding After Urgent First Time CABG.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; Platelet Aggr | 2018 |
Advances in Antithrombotic Therapy.
Topics: Aspirin; Clinical Trials as Topic; Factor XI; Factor XII; Fibrinolytic Agents; Humans; Rivaroxaban; | 2019 |
Impact of dual antiplatelet therapy with adjusted-dose prasugrel on mid-term vascular response in patients undergoing elective percutaneous coronary intervention with everolimus-eluting stents.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug-Eluting St | 2019 |
Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents | 2019 |
Feasibility of gastric endoscopic submucosal dissection with continuous low-dose aspirin for patients receiving dual antiplatelet therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Endoscopic Mucosal Resection; Feasibility Studies; Fe | 2019 |
Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis.
Topics: Anticholesteremic Agents; Aspirin; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Re | 2019 |
High acetylsalicylic acid dosing in infants after modified Blalock-Taussig shunt.
Topics: Administration, Oral; Aspirin; Blalock-Taussig Procedure; Computed Tomography Angiography; Dose-Resp | 2019 |
Image-Guided Percutaneous Gastrostomy Tube Placement is Safe in Patients Requiring Aspirin 325 mg.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Dose-Response Relationship, Drug; Female; Gastrostomy; Head | 2019 |
Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cell Line, Tumor; Cycloo | 2019 |
The effect of ticagrelor based dual antiplatelet therapy on development of late left ventricular thrombus after acute anterior ST elevation myocardial infarction.
Topics: Aged; Anterior Wall Myocardial Infarction; Aspirin; Clopidogrel; Coronary Angiography; Dose-Response | 2019 |
Antithrombotic Activity of a Novel Diazepino[1,2-α] Benzimidazole Derivative on Arterial Thrombosis Model in Rats without Concomitant Pathology and in Rats with Experimental Myocardial Infarction.
Topics: Animals; Animals, Outbred Strains; Aspirin; Azepines; Benzimidazoles; Blood Coagulation Tests; Chlor | 2019 |
Vicagrel enhances aspirin-induced inhibition of both platelet aggregation and thrombus formation in rodents due to its decreased metabolic inactivation.
Topics: Animals; Aspirin; Blood Platelets; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy | 2019 |
Thrombus targeting aspirin particles for near infrared imaging and on-demand therapy of thrombotic vascular diseases.
Topics: Animals; Aspirin; Cytokines; Disease Models, Animal; Fibrinolytic Agents; Hemorrhage; Hydrogen Perox | 2019 |
[Anti-platelet aggregation and anti-thrombotic mechanism of Trichosanthis Fructus combined with aspirin based on network pharmacology].
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Cyclic AMP; Drugs, Chinese Herbal; Fruit; Platelet A | 2019 |
Left Atrial Thrombus Formation in a Patient With Severe Non-rheumatic Mitral Stenosis After Mitral Valve Repair Receiving Dual Antiplatelet Therapy: A Clinical Challenge.
Topics: Aspirin; Clopidogrel; Female; Heart Atria; Humans; Middle Aged; Mitral Valve Stenosis; Monitoring, I | 2019 |
Thromboprophylaxis by rivaroxaban, aspirin, both, or placebo after hospitalization for medical illness.
Topics: Aspirin; Factor Xa Inhibitors; Hospitalization; Humans; Placebo Effect; Platelet Aggregation Inhibit | 2019 |
Timing of Low-Dose Aspirin Discontinuation and the Influence on Clinical Outcome of Patients Undergoing Surgery for Chronic Subdural Hematoma.
Topics: Aged; Aged, 80 and over; Aspirin; Female; Hematoma, Subdural, Chronic; Humans; Male; Platelet Aggreg | 2019 |
Should we stop aspirin before noncardiac surgery?
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Secondary Preventio | 2019 |
High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
Topics: Adenosine; Animals; Arachidonic Acid; Aspirin; Clopidogrel; Dogs; Dose-Response Relationship, Drug; | 2013 |
Cardiac magnetic resonance detection of left ventricular thrombus in acute myocardial infarction.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Echocardiogra | 2013 |
Management of pregnant women with myeloproliferative neoplasms.
Topics: Adult; Aspirin; Blood Viscosity; Female; Gestational Age; Heparin, Low-Molecular-Weight; Humans; Inc | 2013 |
[The difficult choice of antithrombotic therapy after bioprosthetic aortic valve implantation: aspirin, warfarin, or both?].
Topics: Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Fibrinolytic Agents; Heart Valve Prosthesis Im | 2013 |
Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therap | 2013 |
Safety and efficacy of low molecular weight dextran (dextran 40) in head and neck free flap reconstruction.
Topics: Adult; Aged; Aspirin; Dextrans; Female; Fibrinolytic Agents; Free Tissue Flaps; Graft Survival; Head | 2013 |
Unexpectedly resolved multiple mobile thrombi in a normal thoracic aorta associated with colorectal cancer and protein C deficiency.
Topics: Aorta, Thoracic; Aspirin; Blood Coagulation Disorders; Colorectal Neoplasms; Humans; Male; Middle Ag | 2014 |
Successful treatment of mechanical mitral valve thrombosis without thrombolytic therapy or surgery.
Topics: Anticoagulants; Aspirin; Echocardiography; Female; Heart Valve Prosthesis; Humans; Middle Aged; Mitr | 2013 |
Relationship between aspirin/clopidogrel resistance and intra-stent thrombi assessed by follow-up optical coherence tomography after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Confidence Intervals; Co | 2013 |
Antiplatelet therapy at the time of coronary artery bypass grafting: a multicentre cohort study.
Topics: Aged; Analysis of Variance; Aspirin; Blood Transfusion; Clopidogrel; Cohort Studies; Coronary Artery | 2013 |
Perioperative management of a neurosurgical patient with a meningioma and recent coronary artery stent.
Topics: Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Contraindications; Coronary Artery Disease; Drug T | 2013 |
Progressive deconstruction: a novel aneurysm treatment using the pipeline embolization device for competitive flow diversion: case report.
Topics: Adult; Arachnoid; Aspirin; Balloon Occlusion; Cerebral Angiography; Embolization, Therapeutic; Human | 2014 |
Aspirin resistance in systemic lupus erythematosus. A pilot study.
Topics: Adult; Antibodies, Anticardiolipin; Aspirin; Case-Control Studies; Drug Resistance; Electric Impedan | 2013 |
Safety of perioperative aspirin therapy in pancreatic operations.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Female; Humans; Length of | 2014 |
Hyperhomocysteinemia and vascular access thrombosis in hemodialysis patients: a retrospective study.
Topics: Aged; Aspirin; Biomarkers; Chi-Square Distribution; Diabetes Complications; Female; Fibrinolytic Age | 2013 |
Thrombotic occlusion of extracardiac conduit 4 months after Fontan surgery.
Topics: Aspirin; Child, Preschool; Drug Substitution; Drug Therapy, Combination; Fibrinolytic Agents; Fontan | 2013 |
Nanosized aspirin-Arg-Gly-Asp-Val: delivery of aspirin to thrombus by the target carrier Arg-Gly-Asp-Val tetrapeptide.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 1; Dose-Response Relations | 2013 |
Antiplatelet and anticoagulation therapy in microlaryngeal surgery.
Topics: Adult; Aged; Aspirin; Clopidogrel; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Incidence | 2014 |
Aspirin for primary prevention of atherothrombotic vascular events: how much "conclusive" is "conclusive?".
Topics: Aspirin; Dose-Response Relationship, Drug; Humans; Plaque, Atherosclerotic; Platelet Aggregation Inh | 2013 |
[Antithrombotic activity of RU-891 antiaggregant agent].
Topics: Animals; Animals, Outbred Strains; Aspirin; Benzimidazoles; Blood Platelets; Cells, Cultured; Dose-R | 2013 |
Effect of acetylsalicylic acid on microvascular thrombosis in autologous breast reconstruction.
Topics: Adult; Aspirin; Autografts; Fibrinolytic Agents; Humans; Mammaplasty; Middle Aged; Myocutaneous Flap | 2014 |
[Thrombosis risk during pregnancy after history of cerebral venous thrombosis].
Topics: Adult; Anticoagulants; Aspirin; Chemoprevention; Family Health; Female; Humans; Intracranial Thrombo | 2015 |
Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device.
Topics: Aspirin; Blood Donors; Blood Platelets; Female; Heart-Assist Devices; Humans; Male; Platelet Activat | 2014 |
Aspirin discontinuation syndromes: clinical implications of basic research studies.
Topics: Animals; Aspirin; Biomedical Research; Dose-Response Relationship, Drug; Male; Mice; Mice, Knockout; | 2013 |
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Substitution; | 2014 |
Changes in response to antiaggregatory treatment in patients with myeloproliferative neoplasms: a sequential study using multiple electrode aggregometry.
Topics: Adenosine Diphosphate; Adult; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Case-Control Studies | 2013 |
Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Cross-Sec | 2013 |
Anti-phospholipid antibodies.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Aspirin; Autoimmune Diseases; Female; Humans; Male; Pr | 2014 |
Thrombotic aortic restenosis after transapical SAPIEN valve implantation.
Topics: Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Clopidogrel; Echoc | 2014 |
Defining the best practice patterns for the neonatal systemic-to-pulmonary artery shunt procedure.
Topics: Aspirin; Bayes Theorem; Benchmarking; Cardiac Surgical Procedures; Chi-Square Distribution; Drug Adm | 2014 |
Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.
Topics: Adult; Aged; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Cotinine; Female; F | 2014 |
Microfluidic thrombosis under multiple shear rates and antiplatelet therapy doses.
Topics: Aspirin; Blood Coagulation; Blood Coagulation Tests; Dose-Response Relationship, Drug; Humans; Micro | 2014 |
The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Cytochrome P- | 2014 |
Role of paraoxonase-1 in CYP2C19 loss-of-function carriers.
Topics: Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; Female; Humans; Male; Platelet Aggre | 2014 |
Safety of discontinuation of anti-coagulation in patients with continuous-flow left ventricular assist devices.
Topics: Adult; Aged; Anticoagulants; Aspirin; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Heart | 2014 |
Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.
Topics: Adenosine Triphosphate; Adult; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; | 2014 |
Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Diabetes Mellitus, Type 2; Drug Resis | 2014 |
Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male | 2014 |
HeartWare left ventricular assist device thrombosis in aspirin non-responder.
Topics: Aged; Aspirin; Cardiomyopathy, Dilated; Clopidogrel; Drug Resistance; Drug Substitution; Fibrinolyti | 2014 |
Point-of-care testing of clopidogrel-mediated platelet inhibition and risk for cardiovascular events after coronary angiography with or without percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Female; Hu | 2014 |
The thrombotic events in polycythemia vera patients may be related to increased oxidative stress.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Aspirin; Body Mass Index; Bone Marrow; Case-Control St | 2014 |
A cautionary tale on the use of antiplatelet treatment following TURP.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Hematuria; Humans; Male; Myoca | 2014 |
Fatal bleedings with prasugrel as part of triple antithrombotic therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Arteriovenous Malformations; Aspirin; Drug The | 2014 |
Pharmacologic strategy for one repeated stent thrombosis patient with hyporesponsiveness to standard dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Electrocardiography; Huma | 2015 |
24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis.
Topics: Aged; Aspirin; Blood Platelets; Case-Control Studies; Female; Follow-Up Studies; Humans; Male; Middl | 2014 |
Antiplatelet therapy during perioperative period: double-edged sword.
Topics: Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Perioperat | 2014 |
Conservative management of a prosthetic valve thrombosis--report of a successful case.
Topics: Adult; Anticoagulants; Aortic Valve; Aspirin; Fibrinolytic Agents; Heart Valve Prosthesis; Heparin; | 2014 |
[Perioperative management and postoperative complication rates of patients on dual antiplatelet therapies after coronary drug eluting stent implantation].
Topics: Aged; Aged, 80 and over; Aspirin; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneo | 2014 |
Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Europe; Female; Heparin; Hu | 2014 |
[Taking aspirin for prevention of "traveler's thrombosis"?].
Topics: Air Travel; Aspirin; Fibrinolytic Agents; Humans; Thrombosis | 2014 |
Aspirin unresponsiveness predicts thrombosis in high-risk pediatric patients after cardiac surgery.
Topics: Age Factors; Aspirin; Boston; Cardiac Surgical Procedures; Child, Preschool; Drug Resistance; Female | 2014 |
[Interaction between NSAIDs and acetylsalicylic acid disregarded].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Inte | 2014 |
Anticoagulation management of left ventricular assist devices.
Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Heart Failure; Heart Transplantation; Heart Ventricles; | 2015 |
Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Female; Humans; Incidence; Male; Middle Aged; Odds Ratio; Pe | 2014 |
"Very" very late stent thrombosis: acute myocardial infarction from drug-eluting stent thrombosis more than 5 years after implantation.
Topics: Adult; Aged; Aspirin; Dose-Response Relationship, Drug; Drug-Eluting Stents; Female; Humans; Inciden | 2014 |
[Clinical pharmacology of current antiplatelet drugs].
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Surgical Procedures; Coronary Artery Bypass; Drug T | 2014 |
Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Substitution; Female; H | 2015 |
[Antiplatelet therapy in acute coronary syndrome. Prehospital phase: nothing, aspirin or what?].
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Bypass; Drug Therapy, Combination; Emergency Medic | 2014 |
Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients.
Topics: Aged; Aspirin; Cardiac Catheterization; Chi-Square Distribution; Clopidogrel; Cohort Studies; Corona | 2014 |
Aspirin enhances protective effect of fish oil against thrombosis and injury-induced vascular remodelling.
Topics: Animals; Aspirin; Chlorides; Dietary Supplements; Dose-Response Relationship, Drug; Drug Synergism; | 2015 |
[Antithrombotic treatment in patients with stable coronary artery disease. Which drugs and for how long?].
Topics: Aspirin; Atrial Fibrillation; Cardiovascular Surgical Procedures; Coronary Artery Disease; Drug Admi | 2014 |
Dual antiplatelet therapy after drug-eluting stents--how long to treat?
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation I | 2014 |
Antiplatelet therapy: risks and benefits of extended DAPT after stenting.
Topics: Aspirin; Cardiovascular Diseases; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet A | 2015 |
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogr | 2015 |
Aspirin resistance in adult patients after Fontan surgery.
Topics: Adult; Aspirin; CD40 Antigens; Drug Resistance; Endothelium, Vascular; Female; Fontan Procedure; Hea | 2015 |
Partial segmental thrombosis of the corpus cavernosum (PSTCC) diagnosed by contrast-enhanced ultrasound: a case report.
Topics: Adult; Anticoagulants; Aspirin; Contrast Media; Edema; Enoxaparin; Humans; Male; Pain; Penile Diseas | 2014 |
Acute thrombosis during left main stenting using tap technique in a patient presenting with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Drug Combinations; Heparin; Humans; Male; Middle A | 2015 |
Normal platelet activation profile in patients with peripheral arterial disease on aspirin.
Topics: Aged; Aspirin; Blood Platelets; Female; Humans; Male; Middle Aged; Peripheral Arterial Disease; Plat | 2015 |
Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Decision Support Techniques; Drug-Eluting Stents; Fem | 2015 |
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Austria; Female; H | 2015 |
How should I treat subacute stent thrombosis in the context of brain haemorrhage with abciximab?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebral Hemorrhage; Clopidogrel; Embolic Protection Dev | 2015 |
Effect of clinical factors and gene polymorphism of CYP2C19*2, *17 and CYP4F2*3 on early stent thrombosis.
Topics: Aged; Aspirin; Case-Control Studies; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme | 2015 |
Effects of Perioperative Acetyl Salicylic Acid on Clinical Outcomes in Patients Undergoing Craniotomy for Brain Tumor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Brain Neoplasms; Child; C | 2015 |
Heart failure in sinus rhythm: no routine antithrombotic therapy.
Topics: Aspirin; Fibrinolytic Agents; Heart Failure; Hemorrhage; Humans; Patient Safety; Randomized Controll | 2015 |
Prolonged dual antiplatelet therapy after drug-eluting stent reduces the risk of stent thrombosis and major cardiovascular events but increases the rate of bleeding.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Th | 2015 |
Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Everolimus; Female; Humans; Male | 2015 |
An observational study investigating the effect of platelet function on outcome after colorectal surgery.
Topics: Aged; Aspirin; Blood Coagulation Tests; Blood Platelets; Colorectal Surgery; Female; Humans; Male; M | 2015 |
Balancing the risks and benefits of dual platelet inhibition.
Topics: Adenosine; Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inh | 2015 |
ACP journal club. Dual antiplatelets for 30 mo after drug-eluting stents reduced stent thrombosis and CV and cerebrovascular events.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Th | 2015 |
Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide.
Topics: Aged; Aged, 80 and over; Amino Acid Substitution; Aspirin; Female; Fusion Proteins, bcr-abl; Humans; | 2016 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Th | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Th | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Th | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Th | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Th | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Th | 2015 |
Antiplatelet therapy discontinuation and the risk of serious cardiovascular events after coronary stenting: observations from the CREDO-Kyoto Registry Cohort-2.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Restenosis; Drug-Eluting Stents; Female; Hum | 2015 |
New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera.
Topics: Age Factors; Aged; Aspirin; Drug Administration Schedule; Enzyme Inhibitors; Fibrinolytic Agents; Hu | 2015 |
The changes in clot microstructure in patients with ischaemic stroke and the effects of therapeutic intervention: a prospective observational study.
Topics: Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Cohort Studies; Elasticity; Female; Fibrinog | 2015 |
Aspirin Resistance in Single-Ventricle Physiology: Aspirin Prophylaxis Is Not Adequate to Inhibit Platelets in the Immediate Postoperative Period.
Topics: Aspirin; Blalock-Taussig Procedure; Dose-Response Relationship, Drug; Drug Resistance; Female; Follo | 2015 |
Resolving the multifaceted mechanisms of the ferric chloride thrombosis model using an interdisciplinary microfluidic approach.
Topics: Aspirin; Biomechanical Phenomena; Blood Platelets; Cell Aggregation; Chlorides; Erythrocytes; Ferric | 2015 |
Effectiveness of and risk associated with aspirin therapy in hemodialysis patients with a background of antiplatelet factor 4/heparin complex antibody detection.
Topics: Adult; Aged; Antibodies; Aspirin; Coronary Disease; Female; Fibrinolytic Agents; Heparin; Humans; Ma | 2015 |
Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database.
Topics: Adverse Drug Reaction Reporting Systems; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Comb | 2015 |
Platelet inhibition with ticagrelor for left ventricular assist device thrombosis.
Topics: Adenosine; Adult; Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Heart Failure; Heart-Ass | 2015 |
Double antiplatelet therapy duration: standardize or personalize?
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A | 2015 |
Management and outcome of major bleeding in patients on triple therapy after coronary stenting. Clues from the WARfarin and coronary STENTing (WAR-STENT) registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; He | 2015 |
Does aspirin administration increase perioperative morbidity in patients with cardiac stents undergoing spinal surgery?
Topics: Aged; Aspirin; Cardiac Surgical Procedures; Cohort Studies; Endovascular Procedures; Female; Humans; | 2015 |
Invited Commentary.
Topics: Aspirin; Blalock-Taussig Procedure; Drug Resistance; Female; Humans; Hypoplastic Left Heart Syndrome | 2015 |
Could perioperative bleeding complications be predicted using a platelet aggregation test?
Topics: Aspirin; Coronary Artery Bypass; Female; Humans; Male; Platelet Function Tests; Postoperative Hemorr | 2015 |
[The ISAR-SAFE study].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug Administr | 2015 |
Preventive Effect of Aspirin Eugenol Ester on Thrombosis in κ-Carrageenan-Induced Rat Tail Thrombosis Model.
Topics: Adenosine Diphosphate; Animals; Aspirin; Blood Platelets; Carrageenan; Disease Models, Animal; Eryth | 2015 |
Antithrombotic drugs and subarachnoid haemorrhage risk. A nationwide case-control study in Denmark.
Topics: Aged; Aspirin; Case-Control Studies; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Fibrin | 2015 |
Assessing the optimal strategy for dual antiplatelet therapy.
Topics: Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Pyridines; Ri | 2015 |
Platelet reactivity in MitraClip patients.
Topics: Aspirin; Clopidogrel; Cohort Studies; Heart Valve Prosthesis Implantation; Hemorrhage; Ischemia; Mit | 2016 |
Point-of-care Ultrasound to Identify Distal Ulnar Artery Thrombosis: Case of Hypothenar Hammer Syndrome.
Topics: Adult; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Emergency Medical Services; Humans; Mal | 2015 |
Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Angiograp | 2015 |
Impact of residual platelet reactivity under clopidogrel treatment for lesions and the clinical outcome after drug-eluting stent implantation in patients with hemodialysis.
Topics: Aged; Angina, Stable; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Drug Therapy, Com | 2016 |
Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Everolim | 2016 |
Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A | 2015 |
Reply: Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A | 2015 |
Aspirin resistance: A role in left ventricular assist device thrombosis?
Topics: Aspirin; Drug Resistance; Female; Heart-Assist Devices; Humans; Middle Aged; Postoperative Complicat | 2015 |
Low platelet activity predicts 30 days mortality in patients undergoing heart surgery.
Topics: Adenosine Diphosphate; Aged; Aortic Valve; Arachidonic Acid; Area Under Curve; Aspirin; Blood Platel | 2016 |
Bare-metal stent thrombosis two decades after stenting.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Electr | 2015 |
Recurrent myocardial infarctions and premature coronary atherosclerosis in a 23-year-old man with antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Coronary Angiography; Coronary Artery Disease; H | 2016 |
Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cl | 2016 |
Analysis of Dual Antiplatelet Therapy.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A | 2015 |
Reply: Analysis of Dual Antiplatelet Therapy.
Topics: Aspirin; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A | 2015 |
Syncytiotrophoblast Extracellular Vesicles from Pre-Eclampsia Placentas Differentially Affect Platelet Function.
Topics: Adult; Aspirin; Blood Platelets; Case-Control Studies; Extracellular Vesicles; Female; Humans; Micro | 2015 |
It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Evero | 2015 |
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.
Topics: Aspirin; Humans; Janus Kinase 2; Mutation; Risk Factors; Thrombocythemia, Essential; Thrombosis; Wor | 2015 |
Antiplatelet Therapy and Adverse Hematologic Events During Heart Mate II Support.
Topics: Adult; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Dipyridamole; Disease-Free Survival; | 2016 |
Does consumption of platelet-derived microparticles in the fibrin clot explain the decrease in their percentage during pregnancy?
Topics: Abortion, Spontaneous; Anticoagulants; Aspirin; Blood Platelets; Cell-Derived Microparticles; Female | 2016 |
Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy.
Topics: Aged; Area Under Curve; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectio | 2016 |
Diffuse alveolar hemorrhage associated with low molecular weight heparin and dual anti-platelet therapy after percutaneous coronary intervention.
Topics: Adenosine; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combination; Fatal Outcom | 2017 |
Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Asymptomatic Diseases; Blood Platelets; Drug Resistan | 2016 |
What is the appropriate duration of dual antiplatelet therapy?
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; | 2016 |
Usefulness of Intravascular Ultrasound for Predicting Risk of Intraprocedural Stent Thrombosis.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Humans; Japan; Male; | 2016 |
The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy.
Topics: Aspirin; Blood Platelets; Endothelium, Vascular; Humans; Platelet Aggregation Inhibitors; Purinergic | 2016 |
Comparison of Three Tests to Distinguish Platelet Reactivity in Patients with Renal Impairment during Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Hemorrhage; | 2016 |
Taking aspirin before coronary artery surgery does not increase deaths or bleeding, study shows.
Topics: Aspirin; Coronary Artery Bypass; Female; Humans; Male; Platelet Aggregation Inhibitors; Postoperativ | 2016 |
Aspirin has limited ability to modulate shear-mediated platelet activation associated with elevated shear stress of ventricular assist devices.
Topics: Aspirin; Blood Platelets; Heart-Assist Devices; Humans; Platelet Activation; Platelet Aggregation In | 2016 |
Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis.
Topics: Aspirin; Atrial Fibrillation; Clinical Laboratory Techniques; Coronary Artery Disease; Fibrinolysis; | 2016 |
Antiplatelet therapy: Safe to continue aspirin therapy before CABG surgery.
Topics: Aspirin; Coronary Artery Bypass; Female; Humans; Male; Platelet Aggregation Inhibitors; Postoperativ | 2016 |
Hsp70 protects from stroke in atrial fibrillation patients by preventing thrombosis without increased bleeding risk.
Topics: Animals; Aspirin; Atrial Fibrillation; Bleeding Time; Carotid Artery Diseases; Case-Control Studies; | 2016 |
Non-obstructive left ventricular assist device outflow thrombus: What is the appropriate management?
Topics: Aged; Aspirin; Computed Tomography Angiography; Fatal Outcome; Furosemide; Heart-Assist Devices; Hep | 2016 |
Partial thrombosis of the corpus cavernosum: should we dig deeper into coagulopathy disorders?
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Factor V; Humans; Magnetic Resonance | 2016 |
Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?
Topics: Anticoagulants; Aspirin; Glomerulonephritis, Membranous; Humans; Nephrotic Syndrome; Primary Prevent | 2016 |
Multiple Electrode Aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance.
Topics: Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Blood Platelets; Drug Resistance; Electro | 2016 |
Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling.
Topics: Aspirin; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention | 2016 |
Vitamin D-Binding Protein Acts in the Actin Scavenge System and Can Have Increased Expression During Aspirin Therapy.
Topics: Actins; Adult; Aged; Aspirin; Biomarkers; Electrophoresis, Gel, Two-Dimensional; Female; Humans; Imm | 2016 |
A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Arachidonic Acid; Aspir | 2016 |
Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice?
Topics: Aged; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Female; Heparin, Low-Molecular-Weight; Human | 2016 |
A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.
Topics: Aspirin; Cardiovascular System; Clopidogrel; Hemorrhage; Humans; Lactones; Myocardial Infarction; Pl | 2016 |
Evaluation on antithrombotic effect of aspirin eugenol ester from the view of platelet aggregation, hemorheology, TXB2/6-keto-PGF1α and blood biochemistry in rat model.
Topics: 6-Ketoprostaglandin F1 alpha; Administration, Oral; Animals; Aspirin; Blood Chemical Analysis; Eugen | 2016 |
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Early Diagnosis; Female; Humans; Isr | 2016 |
Measurement of residual platelet thrombogenicity under arterial shear conditions in cerebrovascular disease patients receiving antiplatelet therapy.
Topics: Adult; Aged; Arteries; Aspirin; Blood Coagulation Tests; Blood Platelets; Carotid Arteries; Cell Adh | 2016 |
Aspirin in Atrial Fibrillation: The Clot Thickens.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Thrombosis; Warfarin | 2016 |
Ticagrelor for left ventricular assist device thrombosis: A new therapeutic option to be evaluated with caution.
Topics: Adenosine; Aged; Aspirin; Blood Coagulation; Cardiomyopathies; Clopidogrel; Drug Substitution; Drug | 2016 |
Aspirin before Coronary Artery Surgery.
Topics: Aspirin; Coronary Artery Bypass; Female; Humans; Male; Platelet Aggregation Inhibitors; Postoperativ | 2016 |
Aspirin before Coronary Artery Surgery.
Topics: Aspirin; Coronary Artery Bypass; Female; Humans; Male; Platelet Aggregation Inhibitors; Postoperativ | 2016 |
Aspirin before Coronary Artery Surgery.
Topics: Aspirin; Coronary Artery Bypass; Female; Humans; Male; Platelet Aggregation Inhibitors; Postoperativ | 2016 |
Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Biomarkers; Chi-Square Dist | 2017 |
Locked Away: Percutaneous Closure of a Malignant Left Atrial Appendage to Constrain an Unresolvable Thrombus.
Topics: Aged; Aspirin; Atrial Appendage; Atrial Fibrillation; Catheter Ablation; Clopidogrel; Combined Modal | 2016 |
Philip Majerus.
Topics: Aspirin; Blood Coagulation; Faculty, Medical; Fibrinolytic Agents; Hematology; History, 20th Century | 2016 |
Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Human | 2017 |
Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology.
Topics: Adenosine; Aspirin; Cardiology; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Human | 2017 |
Left ventricular non-compaction cardiomyopathy: Incidental diagnosis after ST-elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiomyopathy, Hypertrophic, Familial; Clopidogrel; | 2016 |
Do Antiplatelet and Anticoagulation Agents Matter after Repair of Traumatic Arterial Injuries?
Topics: Anticoagulants; Arteries; Aspirin; Case-Control Studies; Chi-Square Distribution; Female; Follow-Up | 2016 |
Perioperative antiplatelet therapy and cardiovascular outcomes in patients undergoing joint and spine surgery.
Topics: Aged; Aspirin; Blood Loss, Surgical; Coronary Artery Disease; Erythrocyte Transfusion; Female; Human | 2016 |
Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Arteries; Aspirin; Atheroscl | 2016 |
Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cardiac Surgical Procedures; Endovascular Pro | 2017 |
Variability of antithrombotics use in patients with hypoplastic left heart syndrome and its variants following first- and second-stage palliation surgery: a national report using the National Pediatric Cardiology Quality Improvement Collaborative registry
Topics: Aspirin; Cardiac Catheterization; Female; Fibrinolytic Agents; Humans; Hypoplastic Left Heart Syndro | 2017 |
Anticoagulation After Biological Aortic Valve Replacement: Is There An Optimal Regimen?
Topics: Aged; Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Blood Coagulation; Brain Ischemia; Femal | 2016 |
New evidence on old drugs; warfarin versus aspirin after bioprosthetic aortic valve placement.
Topics: Anticoagulants; Aortic Valve; Aspirin; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; | 2017 |
Platelet Inhibition in Shunted Infants on Aspirin at Short and Midterm Follow-Up.
Topics: Aspirin; Cardiac Surgical Procedures; Female; Follow-Up Studies; Heart Defects, Congenital; Hemorrha | 2017 |
Pump Thrombosis following HeartMate II Left Ventricular Assist Device Implantation in a Patient with Aspirin and Plavix Resistance.
Topics: Aged; Aspirin; Clopidogrel; Drug Resistance; Heart Failure; Heart-Assist Devices; Humans; Male; Plat | 2016 |
Percutaneous left atrial appendage closure followed by single antiplatelet therapy: Short- and mid-term outcomes.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Cl | 2017 |
Association Between Prior Aspirin Use and Morphological Features of Culprit Lesions at First Presentation of Acute Coronary Syndrome Assessed by Optical Coherence Tomography.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aspirin; Case-Control Studies; Dyslipidemias; Female; Hu | 2017 |
Risk Factors of Subacute Thrombosis After Intracranial Stenting for Symptomatic Intracranial Arterial Stenosis.
Topics: Adult; Aged; Aspirin; Clopidogrel; Constriction, Pathologic; Female; Humans; Ischemic Attack, Transi | 2017 |
The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Gene Frequenc | 2017 |
Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile.
Topics: Abortion, Spontaneous; Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Antiphospho | 2017 |
Reversible thrombotic mitral valve stenosis after transcatheter mitral valve replacement (TMVR): Is life-long anticoagulation therapy necessary?
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Cardiac Catheterization; Clopidogrel; Female; Heart Va | 2017 |
Improved Pig Model to Evaluate Heart Valve Thrombosis.
Topics: Animals; Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel; Disease Models, Animal; Heart Val | 2016 |
State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction | 2017 |
Antiaggregant and anticoagulant therapy of free-floating thrombus in left atrium.
Topics: Adult; Anticoagulants; Aspirin; Clopidogrel; Diagnosis, Differential; Dyspnea; Echocardiography, Tra | 2008 |
Aspirin decreases the prevalence and severity of heterotopic ossification after 1-stage bilateral total hip arthroplasty for osteoarthrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Hip; Aspir | 2009 |
Real-time analysis of platelet aggregation and procoagulant activity during thrombus formation in vivo.
Topics: Animals; Aspirin; Blood Coagulation; Calcium; Cell Separation; Endothelium, Vascular; Green Fluoresc | 2008 |
Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? No.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic; Contrain | 2008 |
Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases).
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic; Fibrinol | 2008 |
Comparison of stent thrombosis, myocardial infarction, and mortality following drug-eluting versus bare-metal stent coronary intervention in patients with diabetes mellitus.
Topics: Aged; Aspirin; Clopidogrel; Denmark; Diabetes Complications; Drug-Eluting Stents; Female; Humans; Ma | 2008 |
Prothrombotic and hemorrhagic effects of aspirin.
Topics: Animals; Aspirin; Disease Models, Animal; Dose-Response Relationship, Drug; Hemorrhage; Rats; Substa | 2009 |
Spontaneous left atrial thrombus during patent foramen ovale closure.
Topics: Anticoagulants; Aspirin; Atrial Septum; Balloon Occlusion; Drug Therapy, Combination; Echocardiograp | 2008 |
Apical thrombus in a patient with takotsubo cardiomyopathy.
Topics: Administration, Oral; Aspirin; Coronary Angiography; Diagnosis, Differential; Drug Therapy, Combinat | 2008 |
[Perioperative management of patients with drug-eluting coronary stents presenting for non-cardiac surgery].
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cilostazol; Drug Administration Schedule; Drug-Elu | 2008 |
Successful treatment of rotary pump thrombus with the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Adult; Anticoagulants; Aspirin; Female; Heart-Assist Devices; Humans; Platelet Aggregation Inhibitor | 2008 |
Antiplatelet therapy for patients with stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Rando | 2008 |
Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Dyspnea; Fema | 2008 |
[Congestive cardiomyopathy and left intraventricular thrombus as a manifestation of Churg-Strauss syndrome].
Topics: Adult; Aspirin; Cardiomyopathy, Dilated; Churg-Strauss Syndrome; Female; Heart Diseases; Heparin, Lo | 2008 |
Intensive antiplatelet therapy for reduction of ischaemic events.
Topics: Aspirin; Dose-Response Relationship, Drug; Humans; Piperazines; Platelet Aggregation Inhibitors; Pra | 2008 |
Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Blood Platelets; Collagen; Drug | 2008 |
Aspirin as thromboprophylaxis in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Chemoprevention; Humans; Lenalidomide; Mult | 2008 |
The role of leucocytes in the acetyl salicylic acid (aspirin) induced nitric oxide synthesis in the production of interferon-alpha, a potent inhibitor of platelet aggregation and a thrombolytic agent.
Topics: Adenosine Diphosphate; Adult; Animals; Aspirin; Blood Platelets; Cyclic AMP; Cyclic GMP; Female; Fib | 2009 |
[Thrombocyte aggregation inhibitor after surgery for an abdominal aortic aneurysm].
Topics: Aortic Aneurysm, Abdominal; Arteriosclerosis; Aspirin; Blood Vessel Prosthesis Implantation; Cardiov | 2008 |
The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; | 2008 |
The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; | 2008 |
The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; | 2008 |
The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; | 2008 |
Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug | 2008 |
Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug | 2008 |
[Prevention of thrombolitic compications with atrial fibrillation].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Throm | 2008 |
Clopidogrel under scrutiny.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap | 2008 |
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron | 2008 |
Aspirin thromboprophylaxis of asymptomatic antiphospholipid-positive subjects.
Topics: Antibodies, Antiphospholipid; Aspirin; Humans; Thrombosis | 2009 |
Long-term efficacy and safety of Chinese made sirolimus eluting stents: results, including off label usage, from two centres over three years.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Diabetes Complications; | 2008 |
Low thromboembolic risk for patients with the Heartmate II left ventricular assist device.
Topics: Adult; Aged; Anticoagulants; Aspirin; Female; Heart-Assist Devices; Hemorrhage; Humans; Male; Middle | 2008 |
Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease.
Topics: Aged; Aspirin; Cognition Disorders; Drug Resistance; Female; Follow-Up Studies; Hematologic Tests; H | 2009 |
Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Antirheuma | 2009 |
Predicting thrombotic events: creating a complex approach for a complex condition.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Clopidogrel; Colla | 2008 |
Transient left ventricular apical ballooning complicated by a mural thrombus and outflow tract obstruction in a patient with pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Angina Pectoris; Anticoagulants; Aspirin; Che | 2008 |
Safety and effectiveness of combining carotid artery stenting with cardiac surgery: preliminary results of a single-center experience.
Topics: Aged; Aged, 80 and over; Angioplasty; Anticoagulants; Aspirin; Carotid Artery Diseases; Coronary Art | 2009 |
[Bleeding or stent thrombosis in combination with drug-eluting stents].
Topics: Aneurysm, False; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Drug-Eluting St | 2009 |
Athero-embolic isolated splenic infarction following left cardiac catheterization.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aortic Aneurysm, Abdominal; Aspirin; Atherosclerosis | 2009 |
Summaries for patients. What aspirin dose is safest and most effective for preventing heart disease?
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2009 |
Summaries for patients. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2009 |
Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Femal | 2009 |
Degos' disease: a rare condition simulating rheumatic diseases.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diagnosis, Differential; Fatal Outcome; Fem | 2009 |
Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clop | 2009 |
Aortic thrombosis in infancy.
Topics: Anticoagulants; Aortic Diseases; Aspirin; Echocardiography, Doppler; Enoxaparin; Female; Humans; Inf | 2009 |
Evidence guided antiplatelet treatment: time to move from bench to bedside.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiology; Cardiovascular Diseases; Clopidogrel; | 2009 |
A very late stent thrombosis in a patient with diabetes: a call for lifelong dual anti-platelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Follow-Up Studies; Graft Occlusio | 2009 |
Antiplatelet therapy and vascular-access patency.
Topics: Aspirin; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; Graft Occlusion, Vasc | 2009 |
The excel stent: a good DES, but can we really stop clopidogrel after 6 months?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Bioco | 2009 |
Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Heart Diseases; Humans; M | 2009 |
Coronary artery disease: Platelet activity: an obstacle for successful PCI.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combina | 2009 |
Aspirin in primary prevention: sex and baseline risk matter.
Topics: Adult; Aged; Aspirin; Cost-Benefit Analysis; Female; Fibrinolytic Agents; Humans; Male; Meta-Analysi | 2009 |
Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoag | 2009 |
[Antiphospholipid antibody syndrome].
Topics: Adult; Age of Onset; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspiri | 2009 |
Aspirin reduces the prothrombotic activity of C-reactive protein.
Topics: Animals; Aspirin; C-Reactive Protein; Cells, Cultured; Cytochrome P-450 Enzyme System; Drug Interact | 2009 |
Design, synthesis and evaluation of aspirin analogues having an additional carboxylate substituent for antithrombotic activity.
Topics: Arginine; Aspirin; Carboxylic Acids; Catalytic Domain; Chemistry, Pharmaceutical; Drug Design; Ester | 2009 |
Theophylline again? Reasons for believing.
Topics: Anti-Inflammatory Agents; Aspirin; Asthma; Bronchodilator Agents; Humans; Inflammation; Phosphoric D | 2009 |
The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Synergism; Fe | 2009 |
Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Body Mass Index; Clopidogrel; Coro | 2009 |
[The concept of aspirin "resistance": mechanisms and clinical relevance].
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Resistance; Huma | 2009 |
Dipyridamole plus aspirin and hemodialysis graft patency.
Topics: Aspirin; Blood Vessel Prosthesis; Dipyridamole; Drug Therapy, Combination; Graft Occlusion, Vascular | 2009 |
Dipyridamole plus aspirin and hemodialysis graft patency.
Topics: Aspirin; Blood Vessel Prosthesis; Dipyridamole; Drug Therapy, Combination; General Surgery; Graft Oc | 2009 |
A case of Brucella endocarditis in association with superficial femoral artery thrombus.
Topics: Adult; Anti-Bacterial Agents; Aspirin; Brucellosis; Echocardiography; Endocarditis, Bacterial; Femor | 2009 |
Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Co | 2009 |
The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; Cells, | 2009 |
Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness.
Topics: Aspirin; Blood Platelets; Cells, Cultured; Clopidogrel; Drug Combinations; Feasibility Studies; Huma | 2009 |
Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; | 2010 |
Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Brain Ischemia; Clini | 2009 |
Imaging of structural changes in endothelial cells and thrombus formation at the site of FeCl(3)-induced injuries in mice cremasteric arteries.
Topics: Animals; Arteries; Aspirin; Blood Platelets; Chlorides; Clopidogrel; Dose-Response Relationship, Dru | 2009 |
Aspirin therapy: an attempt to explain the events of prothrombotic complications after treatment discontinuation.
Topics: Animals; Aspirin; Blood Coagulation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2010 |
A small-molecule inhibitor of integrin alpha2 beta1 introduces a new strategy for antithrombotic therapy.
Topics: Animals; Aspirin; Bleeding Time; Blood Coagulation; Collagen; Drug Evaluation, Preclinical; Fibrinol | 2010 |
Mechanism of platelet functional changes and effects of anti-platelet agents on in vivo hemostasis under different gravity conditions.
Topics: Actin Cytoskeleton; Adenosine Diphosphate; Animals; Aspirin; Blood Platelets; Calcium; Chelating Age | 2010 |
[Perioperative management of patients with coronary stents in non-cardiac surgery].
Topics: Aspirin; Clopidogrel; Coronary Vessels; Drug-Eluting Stents; Elective Surgical Procedures; Guideline | 2010 |
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up | 2010 |
Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat.
Topics: Animals; Arterial Occlusive Diseases; Arteriovenous Shunt, Surgical; Aspirin; Bleeding Time; Clopido | 2010 |
Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Vessels; | 2010 |
Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Coronary Artery Bypass; Female; Humans; Inflammation; In | 2010 |
[Multicentric study of thrombosis prevention in upper-extremity microsurgery. Survey at the Fesum centers].
Topics: Aspirin; Clopidogrel; Drug Monitoring; Evidence-Based Practice; Fibrinolytic Agents; France; Hemorrh | 2010 |
Paradoxical thrombotic effects of aspirin: experimental study on 1000 animals.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Dose-Response | 2010 |
Idiopathic partial thrombosis of the corpus cavernosum.
Topics: Anticoagulants; Aspirin; Humans; Magnetic Resonance Imaging; Male; Penis; Thrombosis; Tomography, X- | 2010 |
Late common iliac artery stent thrombosis in a patient with terminal malignancy.
Topics: Aged; Angiography; Aspirin; Atherosclerosis; Carcinoma, Renal Cell; Clopidogrel; Humans; Iliac Arter | 2010 |
Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy.
Topics: Anticoagulants; Aspirin; Drug Administration Schedule; Female; Heart Failure; Heart Transplantation; | 2010 |
Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats.
Topics: Animals; Aspirin; Blood Coagulation; Blood Coagulation Tests; Clopidogrel; Drug Synergism; Factor Xa | 2010 |
Aspirin as antiplatelet agent in diabetes. PROS-.
Topics: Aspirin; Diabetic Angiopathies; Evidence-Based Medicine; Humans; Platelet Aggregation Inhibitors; Th | 2010 |
Aspirin as antiplatelet agent in diabetes: Cons.
Topics: Aspirin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Hemorrhage; Humans; Platelet Aggregation | 2010 |
Clinical pharmacology: antiplatelet therapy during surgery.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Humans; Perioperative Care; Platelet Aggregation Inhibit | 2010 |
Aspirin resistance following pediatric cardiac surgery.
Topics: Administration, Oral; Administration, Rectal; Aspirin; Biomarkers; C-Reactive Protein; Cardiac Surgi | 2010 |
Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Tri | 2010 |
Treatment outcome in a cohort of young patients with polycythemia vera.
Topics: Adult; Antineoplastic Agents; Aspirin; Cohort Studies; Combined Modality Therapy; Disease Progressio | 2010 |
Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometry.
Topics: Adenosine Diphosphate; Adult; Aged; Arachidonic Acid; Aspirin; Austria; Case-Control Studies; Clopid | 2010 |
Aspirin resistance in hemodialysis patients.
Topics: Aspirin; Diabetes Complications; Drug Resistance; Humans; Kidney Failure, Chronic; Platelet Aggregat | 2012 |
Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel.
Topics: Animals; Aspirin; Carotid Arteries; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; | 2010 |
Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Comorbidity; Co | 2010 |
The devastating consequences of thrombosis of systemico pulmonary shunts and the blind administration of aspirin.
Topics: Aspirin; Cardiac Surgical Procedures; Drug Resistance; Evidence-Based Medicine; Fibrinolytic Agents; | 2010 |
Hand surgery on anticoagulated patients: a prospective study of 121 operations.
Topics: Anticoagulants; Aspirin; Clopidogrel; Hand; Hemostasis, Surgical; Humans; International Normalized R | 2010 |
Do not adjust the platelet count in light transmittance aggregometry when predicting thrombotic events after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Humans; Ische | 2010 |
High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Female; | 2010 |
Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Ch | 2010 |
Red cells playing as activated platelets in thalassemia intermedia.
Topics: Aspirin; beta-Thalassemia; Blood Platelets; Erythrocytes; Hematology; Hemoglobins; Humans; Hydroxyur | 2010 |
Nitinol wire mesh fracture and traumatic left atrial thrombus in a patient with atrial septal defect amplatzer occluder.
Topics: Adult; Aspirin; Endocardium; Equipment Failure; Female; Heart Atria; Heart Septal Defects, Atrial; H | 2011 |
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Myocardial | 2010 |
From Vaquez to Dameshek through JAK…2 much for polycythemia vera to be feared?
Topics: Aspirin; Fibrinolytic Agents; Humans; Janus Kinase 2; Polycythemia Vera; Thrombosis | 2010 |
Is early antithrombotic therapy necessary after tissue mitral valve replacement?
Topics: Aged; Aged, 80 and over; Animals; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Cattle; Ch | 2010 |
Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids.
Topics: Adult; Anabolic Agents; Angiography; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopid | 2010 |
Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopi | 2010 |
Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Chi | 2010 |
Clopidogrel discontinuation and platelet reactivity following coronary stenting.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Clopidogrel; | 2011 |
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Colonic Neoplasms; Colorectal Neoplasms; Follow-Up Studies; Humans | 2010 |
[Efficacy of stents coated with antibody against CD105 on preventing restenosis and thrombosis in minipigs].
Topics: Animals; Antibodies; Antigens, CD; Aspirin; Clopidogrel; Coronary Restenosis; Endothelial Cells; Neo | 2010 |
Role of intramural platelet thrombus in the pathogenesis of wall rupture and intra-ventricular thrombosis following acute myocardial infarction.
Topics: Animals; Aspirin; Blood Platelets; Clopidogrel; Disease Models, Animal; Hemodynamics; Inflammation; | 2011 |
The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Calcium; Dinoprostone; Dose-Response Relationship, Drug | 2010 |
On the use of prothrombin complex concentrate in patients with coagulopathy requiring tooth extraction.
Topics: Adult; Aspirin; Blood Coagulation Factors; Blood Loss, Surgical; Cellulose, Oxidized; Contraindicati | 2010 |
Hughes syndrome (the antiphospholipid syndrome): a disease of our time.
Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Arterial Occlusive D | 2011 |
[Thrombotic microangiopathy after extracorporeal circulation: important differential diagnosis].
Topics: ADAM Proteins; ADAMTS13 Protein; Aged, 80 and over; Aortic Diseases; Aspirin; Coma; Critical Care; D | 2011 |
Beware of being caught on the rebound.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Co | 2011 |
Catapulting clopidogrel pharmacogenomics forward.
Topics: Amino Acid Substitution; Aryldialkylphosphatase; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy | 2011 |
Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Advisory Committees; Aspirin; Clinical Trials, Phase II as Topic | 2011 |
Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection.
Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Graft Rejection; Humans; Immunoglobulins, Intravenous; | 2011 |
Stopping aspirin before coronary artery surgery: between the devil and the deep blue sea.
Topics: Aspirin; Blood Loss, Surgical; Coronary Artery Bypass; Humans; Preoperative Care; Thrombosis; Withho | 2011 |
[Warfarin combined with blood platelet inhibition].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Hemorrhage; Humans | 2011 |
Conversation with an expert. Plavix: what you need to know.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Costs; Drug | 2011 |
Aspirin and arteriovenous graft thrombosis in hemodialysis: just what the doctor ordered?
Topics: Arteriovenous Shunt, Surgical; Aspirin; Chronic Disease; Dipyridamole; Humans; Kidney Diseases; Plat | 2011 |
Functional evaluation of platelet aspirin resistance after on-pump coronary bypass grafting using multiple aggregation tests.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Cor | 2011 |
A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent.
Topics: Aged; Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Aryl Hydrocarbon Hydroxyl | 2012 |
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethas | 2011 |
Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbit.
Topics: Animal Feed; Animals; Aorta; Aspirin; Atherosclerosis; Cholesterol; Cyclooxygenase 2; Cyclooxygenase | 2011 |
Delphi-consensus weights for ischemic and bleeding events to be included in a composite outcome for RCTs in thrombosis prevention.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Randomized Controlled Trials as Topic; Stroke; Thrombosis; Tr | 2011 |
Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Clopidogrel; Corona | 2011 |
[Multiple arterial thrombosis and resistance to conventional antiaggregation].
Topics: Aged; Angiography; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Electrocardiography; | 2011 |
Dual antiplatelet therapy and the risk of bleeding.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhag | 2011 |
The use of contrast echo to clear the left atrial appendage.
Topics: Aspirin; Atrial Appendage; Clopidogrel; Contrast Media; Drug Therapy, Combination; Echocardiography; | 2011 |
Thoracic aortic mobile thrombus: is there a role for early surgical intervention?
Topics: Adult; Aged; Aged, 80 and over; Aorta, Thoracic; Aortic Diseases; Aspirin; Echocardiography, Transes | 2011 |
Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patients.
Topics: Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; F | 2011 |
Anticoagulation following digital replantation.
Topics: Adult; Amputation, Surgical; Anastomosis, Surgical; Anticoagulants; Aspirin; Dextrans; Finger Injuri | 2011 |
[The CURRENT-OASIS 7 study].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2011 |
High on treatment platelet reactivity and stent thrombosis.
Topics: Adult; Aged; Angioplasty; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middl | 2011 |
Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Aspirin; Collagen; Cycl | 2011 |
Aspirin resistance in off-pump coronary artery bypass grafting.
Topics: Aged; Aspirin; Biomarkers; Case-Control Studies; Coronary Artery Bypass, Off-Pump; Drug Administrati | 2012 |
Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study.
Topics: Abortion, Spontaneous; Adult; Antiphospholipid Syndrome; Aspirin; Autoimmune Diseases; Biomarkers; C | 2011 |
Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiology.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Budd-Chiari Syndrome; Child; Female; Fibrinolytic Agents | 2011 |
Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a).
Topics: Anticholesteremic Agents; Anticoagulants; Aspirin; Atorvastatin; Blood Coagulation Tests; Carotid St | 2011 |
ANCA-positive necrotizing vasculitis and thrombotic vasculopathy induced by levamisole-adulterated cocaine: a distinctive clinicopathologic presentation.
Topics: Adrenal Cortex Hormones; Antibodies, Antineutrophil Cytoplasmic; Aspirin; Biopsy, Needle; Cocaine-Re | 2011 |
Non-adherence to aspirin in patients undergoing coronary stenting: negative impact of comorbid conditions and implications for clinical management.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Comorbidity; Coronary Artery Disease; Female; France; | 2011 |
Historical observations on the discovery of platelets, platelet function testing and the first antiplatelet agent.
Topics: Animals; Aspirin; Blood Platelets; Hematology; History, 17th Century; History, 18th Century; History | 2011 |
Late bare-metal stent thrombosis in a patient with Crohn's disease.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Crohn Disease; Humans; Male; Myocardial | 2011 |
Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Cilostazol; Clopidogrel; Diabetes Mellitus, Type 2; Hum | 2012 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Preventing thrombosis after the Fontan procedure not there yet.
Topics: Anticoagulants; Aspirin; Cardiology; Clinical Trials as Topic; Fontan Procedure; Humans; Randomized | 2011 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting.
Topics: Aspirin; Cerebrovascular Circulation; Clopidogrel; Coronary Artery Bypass; Coronary Vessels; Drug Th | 2011 |
Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.
Topics: Aspirin; Atherosclerosis; Drug Delivery Systems; Drug Design; Hemorrhage; Humans; Myocardial Infarct | 2011 |
Characterization of a unique dihydropyrimidinone, ethyl 4-(4'-heptanoyloxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-one-5-carboxylate, as an effective antithrombotic agent in a rat experimental model.
Topics: Adenosine Diphosphate; Animals; Aorta; Aspirin; Blood Platelets; Collagen; Cyclic GMP; Drug Synergis | 2011 |
High frequency of aspirin resistance in patients with nephrotic syndrome.
Topics: Adolescent; Adult; Aged; Aspirin; Biomarkers; Female; Follow-Up Studies; Humans; Inflammation; Male; | 2012 |
Anticoagulant-resistant thrombophilia in a patient with polycythemia vera: a case report.
Topics: Aged; Anticoagulants; Aspirin; Factor Xa; Factor Xa Inhibitors; Fatal Outcome; Heparin, Low-Molecula | 2011 |
Antithrombotic activity of Z4A5, a new platelet glycoprotein IIb/IIIa receptor antagonist evaluated in a rabbit arteriovenous shunt thrombosis model.
Topics: Animals; Arteriovenous Shunt, Surgical; Aspirin; Blood Coagulation Tests; Disease Models, Animal; Do | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Artery Diseas | 2012 |
A case of acute stent thrombosis during treatment with the thrombopoietin receptor agonist peptide--romiplostim.
Topics: Acute Disease; Aspirin; Chest Pain; Clopidogrel; Eptifibatide; Female; Humans; Middle Aged; Peptides | 2012 |
Thrombus formation on a left atrial appendage closure device.
Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Equipment Design; | 2011 |
[Diagnostic laparoscopy under dual antiplatelet therapy with clopidogrel and aspirin].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Diagnosis, Differential; Drug Substituti | 2011 |
High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype.
Topics: Aspirin; Atherosclerosis; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitor | 2012 |
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistan | 2011 |
Managing antiplatelet therapy during ophthalmic procedures: communication is the key.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiology; Clopidogrel; Humans; I | 2011 |
A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process.
Topics: Abciximab; Adenosine Triphosphate; Adult; Antibodies, Monoclonal; Area Under Curve; Aspirin; Blood P | 2012 |
How to manage children and young adults with myeloproliferative neoplasms.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antiviral Agents; | 2012 |
Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Heparin; Humans; Intra-Aortic | 2012 |
Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Drug Administration Schedule; Elective | 2012 |
Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Drug Administration Schedule; Elective | 2012 |
Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Drug Administration Schedule; Elective | 2012 |
Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Drug Administration Schedule; Elective | 2012 |
Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Aspirin; Catheterization; Combined Modality Therapy; Ductus Arteriosus, Patent; Evidence-Based Medic | 2012 |
A new antiplatelet agent cilostazol--what is the evidence for its use and tolerability?
Topics: Aspirin; Cilostazol; Evidence-Based Medicine; Humans; Platelet Aggregation Inhibitors; Randomized Co | 2012 |
[Korean guidelines for colonoscopic polypectomy].
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colonoscopy; Colorectal N | 2012 |
Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combina | 2012 |
Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combina | 2012 |
Cardiology patient page: Aspirin.
Topics: Aspirin; Blood Coagulation; Cardiovascular Diseases; Coronary Artery Disease; Drug Therapy, Combinat | 2012 |
Anti-platelet therapy in non-cardiac elective surgery.
Topics: Aspirin; Elective Surgical Procedures; Female; Humans; Male; Platelet Aggregation Inhibitors; Postop | 2012 |
Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice.
Topics: Animals; Aspirin; Clopidogrel; Disease Models, Animal; Fibrinolytic Agents; Hemostasis; Mice; Mice, | 2012 |
A case of acute coronary artery occlusion associated with very rapid onset heparin-induced thrombosis without thrombocytopenia.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Aspirin; Autoantibodies | 2012 |
Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrilla | 2012 |
Computed tomography angiography evaluation of internal carotid artery free-floating thrombus--single-center diagnosis, false-positives, and follow-up.
Topics: Aged; Anticoagulants; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Clopidogrel; Diagn | 2012 |
Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease.
Topics: Aged; Angioplasty; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Female; Humans; Male; Mid | 2013 |
Two-wavelength near-infrared fluorescence for the quantitation of drug antiplatelet effects in large animal model systems.
Topics: Analysis of Variance; Animals; Aspirin; Blood Platelets; Cilostazol; Disease Models, Animal; Female; | 2012 |
Multiple gene polymorphisms predisposing to the prothrombotic state in an adolescent with acute myocardial infarction.
Topics: Adolescent; Anticoagulants; Aspirin; Cholesterol Ester Transfer Proteins; Clopidogrel; Coronary Angi | 2012 |
Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
Topics: Aged; Alabama; Antithrombins; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Elective Surgi | 2012 |
Recurrent pediatric thrombosis: the effect of underlying and/or coexisting factors.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Child; Child, Preschool; Chronic Disease; Factor VIII; F | 2012 |
Role of the laboratory in monitoring patients receiving dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Clinical Laboratory Techniques; Clopidogrel; D | 2012 |
The perioperative management of patients with coronary artery stents: surveying the clinical stakeholders and arriving at a consensus regarding optimal care.
Topics: Adult; Advisory Committees; Alabama; Anesthesiology; Aspirin; Blood Loss, Surgical; Cardiac Catheter | 2012 |
Primary antithrombotic prevention in carriers of antiphospholipid antibodies without systemic autoimmune disorders.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Fibrinolytic Agents; Humans; Prima | 2012 |
Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Case-Control Studies; Cell Adhesion Molecul | 2012 |
Extensive skin necrosis induced by low-molecular-weight heparin in a patient with systemic lupus erythematosus and antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Aspirin; Drug Eruptions; Drug Therapy, Combination; Enoxaparin; Female; F | 2012 |
Massive epistaxis in a patient with Eisenmenger syndrome: illustrating the clot-versus-bleed conundrum.
Topics: Adult; Aspirin; Clopidogrel; Eisenmenger Complex; Epistaxis; Female; Humans; Platelet Aggregation In | 2011 |
Monitoring of acetyl salicylic acid-induced platelet inhibition with impedance aggregometry in children with systemic-to-pulmonary shunts.
Topics: Aspirin; Blalock-Taussig Procedure; Double Outlet Right Ventricle; Electric Impedance; Female; Heart | 2013 |
Platelet function testing in atherothrombotic disease.
Topics: Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Drug Resistance; Hum | 2012 |
Effect of hypoglycemic drugs on aspirin resistance in patients with diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Chi-S | 2012 |
Serotonin potentiates high-glucose-induced endothelial injury: the role of serotonin and 5-HT(2A) receptors in promoting thrombosis in diabetes.
Topics: Animals; Aspirin; Cells, Cultured; Cilostazol; Diabetes Mellitus, Experimental; Fibrinolytic Agents; | 2012 |
Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Greece; Human | 2012 |
Sub-optimal inhibition of thrombus formation ex vivo by aspirin in patients with primary thrombocythaemia.
Topics: Aspirin; Blood Coagulation; Female; Humans; Male; Platelet Aggregation Inhibitors; Thrombocytopenia; | 2012 |
Simultaneous assay of activated platelet count and platelet-activating capacity by P-selectin detection using K2-EDTA-treated whole blood for antiplatelet agents.
Topics: Adenosine Diphosphate; Anticoagulants; Aspirin; Blood Platelets; Citrates; Collagen; Drug Monitoring | 2012 |
[Three case reports of the use of herbal combinations resulted in stent thrombosis: herbal combinations; friend or foe?].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Avena; Chest Pain; Clopidogrel; Co | 2012 |
Adult Kawasaki disease.
Topics: Adult; Aspirin; Coronary Vessel Anomalies; Diagnosis, Differential; Dilatation, Pathologic; Humans; | 2013 |
Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Decision Making; Female; Fibrinolytic Agents; He | 2012 |
Antiplatelet drugs in elective ENT surgery.
Topics: Aspirin; Blood Loss, Surgical; Clinical Protocols; Clopidogrel; Data Collection; Elective Surgical P | 2012 |
Multiple left ventricular thrombi in a patient with left ventricular noncompaction.
Topics: Anticoagulants; Aspirin; Echocardiography, Doppler, Color; Echocardiography, Transesophageal; Female | 2012 |
Platelets in vascular disease.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Hemostasis; Humans; Plaque, Atherosclerotic; | 2013 |
Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Cancer Care Facili | 2013 |
Hydrogen sulfide-releasing aspirin derivative ACS14 exerts strong antithrombotic effects in vitro and in vivo.
Topics: Animals; Aspirin; Bleeding Time; Blood Platelets; Cyclic AMP; Disulfides; Fibrinolytic Agents; Human | 2012 |
Effect of postoperative aspirin on outcomes in microvascular free tissue transfer surgery.
Topics: Adult; Analysis of Variance; Aspirin; Chi-Square Distribution; Cohort Studies; Databases, Factual; F | 2013 |
Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis.
Topics: Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Morpholines; Platelet Aggregation; | 2012 |
[Platelet inhibition in clinical practice].
Topics: Aged; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Clo | 2012 |
Aspirin-loaded electrospun poly(ε-caprolactone) tubular scaffolds: potential small-diameter vascular grafts for thrombosis prevention.
Topics: Aspirin; Biocompatible Materials; Blood Vessel Prosthesis; Blood Vessels; Cells, Cultured; Drug Deli | 2013 |
Re: Protective effect of heparin and aspirin against vascular thrombosis in pediatric kidney transplants.
Topics: Anticoagulants; Aspirin; Female; Heparin; Humans; Kidney Failure, Chronic; Kidney Transplantation; M | 2012 |
Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions.
Topics: Adult; Aged; Area Under Curve; Arteries; Aspirin; Automation, Laboratory; Blood Platelets; Capillari | 2013 |
An unusual form of lupus erythematosus profundus associated with antiphospholipid syndrome: report of two cases.
Topics: Administration, Oral; Antiphospholipid Syndrome; Aspirin; Biomarkers; Female; Fibrinolytic Agents; G | 2013 |
Oral contraceptive causing renal artery thrombosis.
Topics: Angiography; Aspirin; Contraceptives, Oral; Female; Fibrinolytic Agents; Humans; Middle Aged; Renal | 2013 |
Ischemic heart disease: the platelet paradox.
Topics: Aspirin; Blood Coagulation Factors; Blood Platelets; Humans; Myocardial Ischemia; Platelet Aggregati | 2002 |
[Increased thrombocyte activation in dilated cardiomyopathy: a risk factor for development of ventricular thrombosis despite anticoagulant therapy?].
Topics: Anticoagulants; Aspirin; Cardiomyopathy, Dilated; Cardiovascular Agents; Drug Therapy, Combination; | 2002 |
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Topics: Aspirin; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Hu | 2002 |
[Malignant atrophic papulosis (Köhlmeier-Degos disease). Failure to respond to interferon alpha-2a, pentoxifylline and aspirin].
Topics: Aspirin; Atrophy; Connective Tissue; Diagnosis, Differential; Disease Progression; Drug Therapy, Com | 2002 |
Acute peripheral arterial ischemia and suspected aortic dissection: usefulness of transesophageal echocardiography in differential diagnosis with aortic thrombosis.
Topics: Acute Disease; Adult; Aged; Amputation, Surgical; Anticoagulants; Aortic Diseases; Arterial Occlusiv | 2002 |
Antithrombotic therapy after myocardial infarction.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Plate | 2002 |
Management of thrombosis during pregnancy.
Topics: Anticoagulants; Antiphospholipid Syndrome; Antithrombins; Aspirin; Blood Coagulation Tests; Drug The | 2002 |
Effects of combined therapy of clopidogrel and aspirin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model.
Topics: Animals; Aspirin; Clopidogrel; Drug Evaluation, Preclinical; Drug Therapy, Combination; Heart Valve | 2002 |
Early bioprosthetic mitral valve "pseudostenosis" after complete preservation of the native mitral apparatus.
Topics: Aged; Aspirin; Bioprosthesis; Combined Modality Therapy; Coronary Artery Bypass; Drug Therapy, Combi | 2002 |
Aspirin resistance.
Topics: Aspirin; Biomarkers; Cyclooxygenase Inhibitors; Drug Resistance; Humans; Platelet Aggregation; Plate | 2002 |
Thrombophilic causes of retinal vascular thrombosis: etiology and treatment outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clinical Laboratory Techniques; Clopidogrel; Da | 2002 |
Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and in healthy pregnancy.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biomarkers; Dalteparin; Endothelium, Vascular; F | 2003 |
Embolic attack in patients with atrial fibrillation and atrial thrombus depends on the character of the thrombus.
Topics: Aged; Aspirin; Atrial Fibrillation; Disease-Free Survival; Drug Therapy, Combination; Echocardiograp | 2003 |
ATP diphosphohydrolase in human platelets from patients with coronary arteries heart disease.
Topics: Acute Disease; Adult; Aged; Apyrase; Aspirin; Blood Glucose; Blood Platelets; Case-Control Studies; | 2003 |
Inhibitory effects of total flavones of Hippophae Rhamnoides L on thrombosis in mouse femoral artery and in vitro platelet aggregation.
Topics: Animals; Arachidonic Acid; Aspirin; Dose-Response Relationship, Drug; Drug Combinations; Drugs, Chin | 2003 |
Aspirin and mortality from coronary bypass surgery.
Topics: Aspirin; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Postoperative Care; Postop | 2003 |
The IST registry.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Brachytherapy; Clopidogrel; Coronary Resten | 2002 |
Lower incidence of thrombus formation with cryoenergy versus radiofrequency catheter ablation.
Topics: Animals; Anticoagulants; Aspirin; Catheter Ablation; Cryosurgery; Dogs; Female; Heart Atria; Heart V | 2003 |
Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Echocardiography, Tran | 2003 |
Synergistic effect of D-003 and aspirin on experimental thrombosis models.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arachidonic Acid; Aspirin; Death, Sudden; Disease Models, Ani | 2003 |
Maintaining patency of tunneled hemodialysis catheters--efficacy of aspirin compared to warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Catheters, Indwelling; Equipment Failure; F | 2003 |
Antiplatelet drugs.
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein G | 2003 |
Effects of camonagrel, a selective inhibitor of platelet thromboxane synthase, on the platelet-subendothelium interaction.
Topics: Adolescent; Adult; Animals; Aspirin; Blood Platelets; Dose-Response Relationship, Drug; Humans; Imid | 2003 |
P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries.
Topics: Animals; Aspirin; Fibrinolytic Agents; Humans; Membrane Proteins; Mesenteric Arteries; Mice; Mice, I | 2003 |
Regression of intracardiac heparin-induced thrombosis after aortic root surgery.
Topics: Aged; Anticoagulants; Aortic Aneurysm, Thoracic; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Drug | 2003 |
Qualitative platelet defect and thrombohaemorrhagic complications in a patient with polycythaemia vera. Case 10.
Topics: Aged; Aspirin; Blood Platelet Disorders; Clopidogrel; Hemorrhage; Humans; Male; Platelet Aggregation | 2003 |
Cardiology patient page. Antiplatelet therapy.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel; Heart Diseases; Humans; Platelet Aggregati | 2003 |
Genetic and acquired determinants of individual variability of response to antiplatelet drugs.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Interactions; Drug Resistance; Genetic Varia | 2003 |
The discovery of the antiplatelet effect of aspirin: a personal reminiscence.
Topics: Aspirin; Bleeding Time; History, 20th Century; Humans; Platelet Aggregation Inhibitors; Platelet Fac | 2003 |
[Stroke is not equal to stroke. Keep track of the causes].
Topics: Adult; Antihypertensive Agents; Aspirin; Carotid Artery, Common; Carotid Artery, External; Carotid S | 2003 |
Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis.
Topics: Aspirin; Coronary Disease; Coronary Thrombosis; Humans; Thrombosis | 1953 |
[Testing of antirheumatic agents such as prednisolone, phenylbutazone, pyramidon and aspirin on depolarization thrombosis in cats].
Topics: Aminopyrine; Animals; Antirheumatic Agents; Aspirin; Cats; Phenylbutazone; Prednisolone; Rheumatic D | 1962 |
[THE EFFECT OF ASPIRIN ON THE VITAMIN K CONTENT OF THE BLOOD AND ITS CLINICAL USE].
Topics: Antifibrinolytic Agents; Aspirin; Blood; Drug Therapy; Heparin Antagonists; Humans; Naphthoquinones; | 1964 |
Portal vein and aortic thromboses in a Siberian husky with ehrlichiosis and hypothyroidism.
Topics: Animals; Aorta, Thoracic; Aspirin; Diagnosis, Differential; Dog Diseases; Dogs; Doxycycline; Ehrlich | 2003 |
[Platelets and arterial thrombosis].
Topics: Adenosine Diphosphate; Angioplasty, Balloon; Anti-Bacterial Agents; Arterial Occlusive Diseases; Art | 2003 |
[Dual platelet inhibition with clopidogrel and ASS. Who profits from the combination?].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi | 2003 |
Mechanisms of angiotensin-converting enzyme inhibitor induced thrombolysis in Wistar rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Bradykinin; Calcium; Cattle; Cells, Cult | 2003 |
Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.
Topics: Amino Acid Chloromethyl Ketones; Animals; Anticoagulants; Antithrombins; Aspirin; Blood Coagulation; | 2003 |
Red vs white thrombi: treating the right clot is crucial.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhi | 2003 |
Daily aspirin--only half the answer.
Topics: Aspirin; Humans; Phlebotomy; Platelet Aggregation Inhibitors; Platelet Count; Polycythemia Vera; Thr | 2004 |
A case of frequently recurring amaurosis fugax with atherothrombotic ophthalmic artery occlusion.
Topics: Amaurosis Fugax; Angiography, Digital Subtraction; Arterial Occlusive Diseases; Arteriosclerosis; As | 2004 |
Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time.
Topics: Animals; Aspirin; Bleeding Time; Body Weight; Disease Models, Animal; Factor VIIa; Macaca fascicular | 2003 |
Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood.
Topics: Adenosine Diphosphate; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Blood Pla | 2004 |
Low-dose aspirin in polycythemia vera.
Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Thrombocythemia, Es | 2004 |
Low-dose aspirin in polycythemia vera.
Topics: Aspirin; Cardiovascular Diseases; Erythrocyte Volume; Hematocrit; Humans; Platelet Aggregation Inhib | 2004 |
Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia.
Topics: Afibrinogenemia; Aspirin; Blood Coagulation Tests; Drug Therapy, Combination; Heparin; Hirudins; Hum | 2004 |
Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Arteries; Disease | 2004 |
Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance?
Topics: Aged; Aged, 80 and over; Angioplasty; Arachidonic Acid; Aspirin; Blood Platelets; Case-Control Studi | 2004 |
A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP).
Topics: Aged; Aspirin; Cause of Death; Coronary Disease; Europe; Female; Humans; Male; Neoplasms; Platelet A | 2004 |
[A 78-year-old man with anterior chest pain].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Biomarkers; Cardiomyopathie | 2004 |
Rupture of a giant coronary artery aneurysm due to Kawasaki disease.
Topics: Anticoagulants; Aspirin; Cardiac Tamponade; Child, Preschool; Combined Modality Therapy; Coronary An | 2004 |
Multivessel distal sutureless off-pump coronary artery bypass grafting procedure using magnetic connectors.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Corona | 2004 |
[Cardiovascular pharmacology].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Fatty Acids, Omega-3; Fibrinolytic Agents; Graft Occl | 2004 |
A novel model of occlusive thrombus formation in mice.
Topics: Animals; Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Carotid Artery, Common; Dise | 2004 |
Theriac found? Nitric oxide-aspirin and the search for the universal cure.
Topics: Acetylation; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Design; Europe; History, 19th Ce | 2004 |
Ask the doctor. Does low-dose Coumadin plus aspirin prevent blood clots?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Humans; International Norma | 2004 |
Anticoagulation interruptus: not without risk.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Blood Loss, Surgical; Carotid Arteri | 2004 |
Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model.
Topics: Adenosine Diphosphate; Amino Acids; Animals; Aspirin; Benzoates; Blood Pressure; Clopidogrel; Collag | 2004 |
Acetylsalicylic acid, possible preventive of coronary thrombosis.
Topics: Aspirin; Coronary Thrombosis; Humans; Thrombosis | 1950 |
The impact of vitamin K-dependent factor depletion by warfarin on platelet-rich thrombosis after deep arterial injury.
Topics: Angioplasty; Animals; Arteries; Aspirin; Blood Coagulation Factors; Blood Platelets; Dose-Response R | 2004 |
Ex vivo evaluation of erythrocytosis-enhanced platelet thrombus formation using the cone and plate(let) analyzer: effect of platelet antagonists.
Topics: Anticoagulants; Aspirin; Blood Platelets; Creatine Kinase; Erythrocytes; Hematocrit; Humans; Phospho | 2004 |
Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes.
Topics: Acute Disease; Administration, Oral; Aged; Aspirin; Cardiovascular Agents; Cohort Studies; Drug Ther | 2004 |
Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxy | 2004 |
Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antibodies, Monoclonal; | 2004 |
Pharmacotherapy in cardiovascular diseases and vascular interventions.
Topics: Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Cardiovascular Diseases; Endothelium, V | 2004 |
Arterial thrombosis in four patients treated with thalidomide.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Drug Therapy, Combination; Female; Humans; Intracranial | 2005 |
Long-term combination therapy with aspirin and clopidogrel.
Topics: Angina, Unstable; Arteriosclerosis; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Double-Blind Me | 2004 |
Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis.
Topics: Aged; Angina Pectoris; Aspirin; Coronary Artery Disease; Female; Fibrinolytic Agents; Graft Occlusio | 2005 |
Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel.
Topics: Aspirin; Cilostazol; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Femal | 2004 |
Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice.
Topics: Animals; Arteries; Aspirin; Bleeding Time; Blood Flow Velocity; Carotid Arteries; Carotid Artery Dis | 2005 |
Atrial fibrillation: when the heart loses its rhythm. You may not even feel it happening, but if the atria of the heart don't beat correctly you could be in danger of a stroke.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Function, Left; Atrial Function, Right; Humans; | 2005 |
Emerging therapies: clopidogrel and aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopid | 2005 |
A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite.
Topics: Aged; Aspirin; Biotransformation; Clopidogrel; Drug Monitoring; Drug Resistance; Humans; Male; Plate | 2005 |
Early antiplatelet and antithrombotic therapy in patients with a history of recurrent miscarriages of known and unknown aetiology.
Topics: Abortion, Habitual; Adolescent; Adult; Aspirin; Drug Therapy, Combination; Female; Gestational Age; | 2005 |
Aspirin resistance: position paper of the Working Group on Aspirin Resistance.
Topics: Aspirin; Blood Platelets; Consensus; Drug Resistance; Endothelium, Vascular; Humans; Thrombosis | 2005 |
Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Clopidogrel; Coronary Disease; | 2005 |
Resistance to antiplatelet resistance is it justified?
Topics: Aspirin; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors | 2005 |
[Myocardial infarction and subacute intrastent thrombosis in a patient with aspirin resistance].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Resistance; Humans; Male; Middle Aged; Myocar | 2005 |
When and how to treat essential thrombocythemia.
Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia | 2005 |
Novel mechanisms of aspirin pharmacologic actions: a model for studying herbal natural products.
Topics: Animals; Aspirin; Blood Coagulation; Drug Evaluation, Preclinical; Evidence-Based Medicine; Fibrinol | 2005 |
[Aspirin resistance: position paper of the working group on aspirin resistance of the international society on thrombosis and haemostasis].
Topics: Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Drug Resistance; Hemostasis; Humans; Longitudin | 2005 |
Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clinical Trials | 2005 |
Coxibs and cardiovascular risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; | 2005 |
Stent thrombosis is associated with an impaired response to antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Humans; Risk Factors; Stents; Thrombosis; Ticlopidine | 2005 |
Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation.
Topics: Adult; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Drug Resistance; Female; Humans; Male; Midd | 2005 |
The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2005 |
Aspirin: quitting cold turkey could be dangerous. Studies have linked aspirin withdrawal to heart attacks.
Topics: Aspirin; Brain; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Hemorr | 2005 |
Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; | 2005 |
Platelets and thrombosis in myeloproliferative diseases.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Endothelium, Vascular; Hematocrit; Humans; Janus | 2005 |
Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events.
Topics: Adult; Aged; Antiphospholipid Syndrome; Aspirin; Blood Platelets; Extracellular Matrix; Female; Huma | 2005 |
Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting.
Topics: Aged; Aspirin; Coronary Artery Bypass, Off-Pump; Drug Resistance; Endothelium, Vascular; Female; Fib | 2006 |
Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat.
Topics: Animals; Anticoagulants; Aspirin; Bleeding Time; Carotid Arteries; Clopidogrel; Dose-Response Relati | 2006 |
[Early non-obstructive thrombosis of mechanical mitral valve prostheses].
Topics: Adult; Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Echocardiography, Transesophageal; | 2005 |
[Significance of the stool occult blood test in patients with thrombotic disease under treatment with low dose aspirin].
Topics: Aged; Aged, 80 and over; Aspirin; Female; Gastrointestinal Hemorrhage; Humans; Male; Occult Blood; T | 2005 |
[Recommendations for peri-procedural thrombocyte aggregation inhibition].
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; He | 2006 |
Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Fema | 2006 |
Viewpoint.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Patient Participation; Premedication; Thrombos | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
[Postoperative antithrombotic treatment in diabetic patients].
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mell | 2006 |
Lack of significant effect of low doses of aspirin on the concentrations of C-reactive protein in a group of individuals with atherothrombotic risk factors and vascular events.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Biomarkers; C-Reactive Pr | 2006 |
[Thrombosis of a coronary stent after discontinuing treatment with clopidogrel].
Topics: Adult; Aged; Angina Pectoris; Aspirin; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Pla | 2006 |
Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment.
Topics: Abciximab; Adult; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2006 |
Late in-stent thrombosis following carotid angioplasty and stenting.
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Angioplasty, Balloon; Anticoagulants; Aph | 2006 |
[Drug-releasing stents. Little use in cardiology despite excellent data--what next?].
Topics: Aspirin; Clopidogrel; Delayed-Action Preparations; Humans; Platelet Aggregation Inhibitors; Risk Fac | 2006 |
[Clopidogrel and aspirin versus aspirin alone in prevention of atherothrombotic events. The results of CHARISMA study].
Topics: Aged; Arteriosclerosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middl | 2006 |
A case of fatal stent thrombosis after Carbostent implantation: is clopidogrel alone antiplatelet therapy a safe alternative to aspirin alone antiplatelet therapy?
Topics: Aged; Aspirin; Clopidogrel; Fatal Outcome; Humans; Male; Platelet Aggregation Inhibitors; Stents; Th | 2007 |
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Clopidogrel; Coronary Artery Disease; Cyclooxygena | 2006 |
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Dexamethasone; Fibrinolytic Agents; Humans; | 2006 |
Plavix isn't for everyone. Adding Plavix to aspirin doesn't help people without heart disease.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarc | 2006 |
An alternative treatment strategy for pump thrombus in the DeBakey VAD Child: use of clopidogrel as a thrombolytic agent.
Topics: Adolescent; Aspirin; Cardiomyopathy, Dilated; Clopidogrel; Equipment Failure; Fibrinolytic Agents; H | 2006 |
Dose of aspirin and bleeding risks.
Topics: Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Humans; | 2006 |
Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin.
Topics: Aged; Angioplasty; Aryl Hydrocarbon Hydroxylases; Aspirin; Cell Adhesion Molecules; Clopidogrel; Cor | 2006 |
Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation.
Topics: Animals; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Stenosis; Cyclooxygenase Inhibitors; | 2006 |
Frequency of aspirin resistance in a community hospital.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Resistance; Female; Hospitals, Community; Humans; Inci | 2006 |
Iliac anastomotic stenting with a biodegradable poly-L-lactide stent: a preliminary study after 1 and 6 weeks.
Topics: Absorbable Implants; Anastomosis, Surgical; Animals; Arteritis; Aspirin; Clopidogrel; Feasibility St | 2006 |
Surgical revascularisation in patients with severe limb ischaemia induces a pro-thrombotic state.
Topics: Aged; Aged, 80 and over; Antithrombin III; Arterial Occlusive Diseases; Aspirin; Blood Coagulation; | 2006 |
Biosignatures in thrombotic disorders.
Topics: Aspirin; Biomarkers; Clopidogrel; Drug Therapy, Combination; Gene Expression Profiling; Humans; Pati | 2006 |
Combining aspirin with antithrombotic agents.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Th | 2006 |
Platelet hyperactivity and risk of recurrent thrombosis.
Topics: Aspirin; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Pred | 2006 |
Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation.
Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Arteries; Aspirin; beta-Thromboglobulin; Blood Pla | 2006 |
Late thrombosis of drug-eluting stents after discontinuation of clopidogrel: report of two cases and review of the literature.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Male; Middle Aged; Myocardial | 2006 |
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera.
Topics: Aged; Aspirin; Female; Follow-Up Studies; Humans; Leukocyte Count; Leukocytosis; Male; Middle Aged; | 2007 |
Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thromboph
Topics: Aged; Anticoagulants; Aspirin; Drug Resistance; Erythromelalgia; Female; Humans; Ischemia; Male; Mic | 2006 |
[Prevention of atherothrombosis with low doses of acetylsalicylic acid].
Topics: Aspirin; Cyclooxygenase Inhibitors; Humans; Platelet Aggregation Inhibitors; Prostaglandins I; Throm | 2006 |
The haematocrit and platelet target in polycythemia vera.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Progression; Female; Follow-Up Studi | 2007 |
Modifications produced by indomethacin and L-NAME in the effect of ultralow-dose aspirin on platelet activity in portal hypertension.
Topics: Animals; Aspirin; Blood Coagulation Tests; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug I | 2006 |
Late in-stent thrombosis following carotid angioplasty and stenting.
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Angioplasty, Balloon; Anticoagulants; Aph | 2007 |
Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection.
Topics: Acute Disease; Aged; Aged, 80 and over; Aspirin; Biomarkers; C-Reactive Protein; Drug Resistance; Fe | 2007 |
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
Topics: Animals; Aspirin; Blood Coagulation; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; | 2007 |
Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Antibodies, Monoclonal; Aspirin; Atherosclerosis; Bl | 2007 |
Late blood clots tarnish drug-coated stents. Uncommon complication raises questions about who really needs a drug-coated stent and how long to continue drug therapy after getting one.
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Drug Implants; Forecasting; Foreign Bodies; Humans; Plate | 2007 |
The thrombolytic effect of aspirin in animal model.
Topics: Adenosine Diphosphate; Adult; Animals; Aspirin; Disease Models, Animal; Female; Fibrinolysis; Humans | 2007 |
Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation?
Topics: Aspirin; Female; Hepatic Artery; Humans; Incidence; Liver Transplantation; Male; Middle Aged; Platel | 2007 |
Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1.
Topics: Adult; Arachidonic Acid; Aspirin; beta-Thromboglobulin; Black or African American; Blood Platelets; | 2007 |
Heritability, platelet function, and aspirin: a link established but cause unknown.
Topics: Arachidonic Acid; Aspirin; Black or African American; Blood Platelets; Cardiovascular Diseases; Cycl | 2007 |
National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing.
Topics: Age Factors; Aged; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Cyclooxygen | 2007 |
Aspirin-resistant platelet aggregation in a cohort of patients with coronary heart disease.
Topics: Aged; Aspirin; Cohort Studies; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Middl | 2007 |
Combined rTPA and aspirin therapy for intracardiac thrombosis in neonates.
Topics: Aspirin; Diseases in Twins; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heart Diseases; | 2007 |
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.
Topics: Adenosine Diphosphate; Adult; Aspirin; Biomarkers; Blood Cells; Calcium; Cells, Cultured; Female; Hu | 2007 |
The role of nitric oxide in aspirin induced thrombolysis in vitro and the purification of aspirin activated nitric oxide synthase from human blood platelets.
Topics: Adult; Aged; Aspirin; Blood Platelets; Female; Fibrin Fibrinogen Degradation Products; Fibrinolysin; | 2007 |
Comment on the WASPO study.
Topics: Aged; Aged, 80 and over; Aspirin; Humans; Risk Factors; Stroke; Thrombosis; Warfarin | 2007 |
Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment.
Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Incidence; Male; Middle | 2007 |
[Soluble CD40 ligand: a potential marker of cardiovascular risk].
Topics: Abciximab; Acute Coronary Syndrome; Alanine; Angina, Unstable; Animals; Antibodies, Monoclonal; Anti | 2007 |
[Modified platelet aggregation test in patients on ASA and/or clopidogrel].
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Clopidogrel; Collagen; Dose-Response Relatio | 2007 |
Drug-eluting stents: dual antiplatelet therapy for every survivor?
Topics: Algorithms; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Incidence; Paclitaxel; Platelet | 2007 |
Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; A | 2007 |
A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
Topics: Administration, Oral; Animals; Aorta; Aspirin; Bleeding Time; Blood Coagulation; Clopidogrel; Diseas | 2007 |
Modifications produced by selective inhibitors of cyclooxygenase and ultra low dose aspirin on platelet activity in portal hypertension.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Dinopros | 2007 |
Very late multivessel thrombosis of bare metal stents with concomitant patent drug-eluting stents after withdrawal of aspirin.
Topics: Aspirin; Drug-Eluting Stents; Humans; Male; Middle Aged; Radiography; Stents; Substance Withdrawal S | 2008 |
A multiparameter test of clot formation and fibrinolysis for in-vitro drug screening.
Topics: Antifibrinolytic Agents; Aspirin; Blood Coagulation Tests; Dose-Response Relationship, Drug; Drug Ev | 2007 |
Treatment of massive cardiac thrombi in a patient with protein C and protein S deficiency.
Topics: Anticoagulants; Aspirin; Cardiomyopathy, Dilated; Child, Preschool; Female; Fibrinolytic Agents; Hea | 2007 |
Prevention of microsurgical anastomotic thrombosis using aspirin, heparin, and the glycoprotein IIb/IIIa inhibitor tirofiban.
Topics: Anastomosis, Surgical; Animals; Anticoagulants; Aspirin; Drug Therapy, Combination; Heparin; Male; P | 2007 |
Catastrophic early drug eluting stents thrombosis and aspirin hypersensitivity.
Topics: Aged; Aspirin; Catastrophic Illness; Drug Hypersensitivity; Drug-Eluting Stents; Electrocardiography | 2008 |
Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up.
Topics: Adult; Antibodies, Antiphospholipid; Antibody Specificity; Anticoagulants; Antiphospholipid Syndrome | 2007 |
Post-stenting antithrombotic drug therapy in patients with atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Fibrinolytic Agents; Humans; Practice Guidelines as Topic | 2007 |
Role of murine integrin alpha2beta1 in thrombus stabilization and embolization: contribution of thromboxane A2.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Aspirin; Chlorides; Col | 2007 |
Major bleeding in hemodialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Drug Therapy, Combination; Fema | 2008 |
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; Heparin, Low-Molecul | 2007 |
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients.
Topics: Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Aspirin; Disease Progression; Female; | 2008 |
Late stent thrombosis in patients receiving ticlopidine and aspirin after sirolimus-eluting stent implantation.
Topics: Aged; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; In | 2008 |
Aspirin + clopidogrel therapy: how does your care compare to the evidence?
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; | 2008 |
Coronary artery stenting in patients treated by clopidogrel without aspirin.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Agg | 2009 |
Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo.
Topics: Animals; Aorta; Apolipoproteins E; Aspirin; Atherosclerosis; Blood Platelets; Carotid Arteries; Chol | 2008 |
Need for additional trials of primary prophylaxis in patients with high-risk antiphospholipid antibody profiles: comment on the article by Erkan et al.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; As | 2008 |
[Effect of acenocoumarol and aspirin on platelet function, markers of thrombinemia, and intracardiac thrombosis in patients with atrial fibrillation].
Topics: Acenocoumarol; Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Platelets; Female; F | 2007 |
The utility of thrombo-elastography in the monitoring of aspirin therapy.
Topics: Analysis of Variance; Aspirin; Blood Coagulation; Dose-Response Relationship, Drug; Humans; Middle A | 2007 |
Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome.
Topics: Alprostadil; Analysis of Variance; Animals; Antiphospholipid Syndrome; Aspirin; Behavior, Animal; be | 2008 |
Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; | 2008 |
Cerebellar hemorrhage provoked by combined use of nattokinase and aspirin in a patient with cerebral microbleeds.
Topics: Aspirin; Diffusion Magnetic Resonance Imaging; Female; Fibrinolytic Agents; Herb-Drug Interactions; | 2008 |
Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; | 2008 |
Reverse effect of aspirin: is the prothrombotic effect after aspirin discontinuation mediated by cyclooxygenase 2 inhibition?
Topics: Animals; Aspirin; Bleeding Time; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy | 2007 |
Acute thrombosis of a prosthetic mitral valve in pregnancy in spite of adjusted-dose low-molecular-weight heparin and aspirin.
Topics: Adult; Aspirin; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Fol | 2008 |
Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
Topics: Administration, Oral; Animals; Aspirin; Bleeding Time; Blood Coagulation; Carotid Artery Injuries; C | 2008 |
[Stents, antiplatelet therapy, and surgery].
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cesarean Section; Enoxaparin; Female | 2008 |
Platelet activation and atherothrombosis.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; M | 2008 |
Apigenin inhibits platelet adhesion and thrombus formation and synergizes with aspirin in the suppression of the arachidonic acid pathway.
Topics: Apigenin; Arachidonic Acid; Aspirin; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Drug | 2008 |
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Fibri | 2008 |
Thioredoxin in coronary culprit lesions: possible relationship to oxidative stress and intraplaque hemorrhage.
Topics: Aged; Angina Pectoris; Aspirin; Female; Gene Expression Regulation; Glycophorins; Hemorrhage; Humans | 2008 |
Observance of antiplatelet therapy after stent implantation in patients under chronic oral anticoagulant treatment.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogr | 2008 |
Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis.
Topics: Animals; Anticoagulants; Arginine; Arteriovenous Shunt, Surgical; Aspirin; Bleeding Time; Chlorides; | 2008 |
Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2.
Topics: Animals; Aspirin; Base Sequence; Blood Vessels; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase I | 2008 |
Platelets and the vessel wall: how much aspirin?
Topics: Aspirin; Dose-Response Relationship, Drug; Humans; Platelet Aggregation; Thrombosis | 1980 |
Antiplatelet drugs in the secondary prevention of myocardial infarction. One view of the present position.
Topics: Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Myocardial Infarction; Recurrence; | 1980 |
[Pre-operative and postoperative thrombosis prophylaxis (author's transl)].
Topics: Adrenergic alpha-Agonists; Aged; Aspirin; Bandages; Binding, Competitive; Dihydroergotamine; Dose-Re | 1980 |
Failure of aspirin to prevent incorporation of indium-111 labelled platelets into cardiac thrombi in man.
Topics: Aspirin; Blood Platelets; Heart Aneurysm; Heart Diseases; Heart Ventricles; Humans; Indium; Platelet | 1981 |
Aspirin and emboli.
Topics: Aspirin; Coronary Disease; Heart Aneurysm; Humans; Thrombosis | 1981 |
Role of the vascular endothelium.
Topics: Animals; Arginine; Arteries; Aspirin; Blood Platelets; Cattle; Cells, Cultured; Dansyl Compounds; En | 1981 |
Multiple therapy for thrombosis, a multifactorial process.
Topics: Anticoagulants; Aspirin; Blood Platelets; Drug Therapy, Combination; Humans; Thrombosis | 1983 |
Laser-induced thrombi in rat mesenteric vessels and antithrombotic drugs.
Topics: Animals; Aspirin; Blood Platelets; Dipyridamole; Disease Models, Animal; Fibrinolytic Agents; Hepari | 1983 |
[Postoperative antithrombotic therapy in acute occlusion of the major arteries of the extremities].
Topics: Acute Disease; Adolescent; Adult; Aged; Arm; Arterial Occlusive Diseases; Aspirin; Dextrans; Female; | 1980 |
[Prophylaxis of thrombosis in surgical gynecology and obstetrics (author's transl)].
Topics: Adult; Aged; Aspirin; Bandages; Dextrans; Dose-Response Relationship, Drug; Early Ambulation; Female | 1980 |
[Prevention of thrombosis].
Topics: Administration, Oral; Anticoagulants; Aspirin; Dextrans; Dose-Response Relationship, Drug; Heparin; | 1981 |
Experimental model of thrombus adherence to the vessel wall.
Topics: Adenosine Diphosphate; Animals; Aprotinin; Aspirin; Female; Hematocrit; Platelet Adhesiveness; Rats; | 1982 |
Antithrombotic treatment.
Topics: Ancrod; Aspirin; Cerebrovascular Disorders; Dextrans; Dipyridamole; Drug Administration Schedule; He | 1983 |
Enhanced patency of small-diameter, externally supported Dacron iliofemoral grafts seeded with endothelial cells.
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Dogs; Endothelium; Evaluation Studies as To | 1982 |
Pharmacological studies on OKY-1581: a selective thromboxane synthetase inhibitor.
Topics: Acrylates; Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Biological Assay; Blood Platelets; | 1983 |
Aspirin inhibition of platelet deposition at angioplasty sites: demonstration by platelet scintigraphy.
Topics: Adult; Aged; Angioplasty, Balloon; Arteries; Arteriosclerosis; Aspirin; Blood Platelets; Humans; Ind | 1984 |
The thrombogenicity of Dacron arterial grafts and its modification by platelet inhibitory drugs.
Topics: Arteries; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Dipyridamole; Drug Therapy, Combination | 1984 |
Effects of AVS (1,2-bis(nicotinamido)propane) on platelet function and vascular endothelium.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Platelets; Blood Vessels; Cerebrovascul | 1984 |
[Prevention of thrombosis by thrombocyte inhibitors. 1. Cell regulation mechanisms and pharmacological modification].
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Cyclic AMP; Dextrans; Dipyridamole; Humans; Hydroxy | 1980 |
Antithrombotic activity and the mechanism of action of trapidil (Rocornal).
Topics: Adenosine Triphosphate; Animals; Aspirin; Blood Coagulation; Blood Platelets; Dipyridamole; Disease | 1982 |
Studies on aspirin derivatives with very little side effect. IV. Inhibitory effect of aspirin-isopropylantipyrine (AIA) on several experimental thromboses.
Topics: Adenosine Diphosphate; Adenylyl Cyclases; Animals; Antipyrine; Arachidonic Acid; Arachidonic Acids; | 1983 |
The antithrombotic effect of aspirin and dipyridamole in relation to prostaglandin synthesis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Dipyridamole; Epoprostenol; Fibrinolytic Agents; Mal | 1983 |
The aspirin dilemma revisited.
Topics: Aspirin; Epoprostenol; Humans; Thrombosis; Thromboxane A2 | 1984 |
Effects of aspirin dosage and time of administration on arterial prostacyclin production and platelet aggregation in rats.
Topics: Animals; Arteries; Aspirin; Biological Assay; Collagen; Drug Administration Schedule; Epoprostenol; | 1984 |
The influence of dose, time of administration, body temperature and salicylate kinetics on the antithrombotic action of acetylsalicylic acid in male rats.
Topics: Animals; Aspirin; Body Temperature; Cyclooxygenase Inhibitors; Disease Models, Animal; Kinetics; Mal | 1983 |
Inhibition of platelet aggregation by a new agent, 2,2'-dithiobis-(N-2-hydroxypropyl benzamide) (KF4939).
Topics: Adenosine Diphosphate; Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Benzamides; Collagen; | 1983 |
Effect of cyclooxygenase inhibition on platelet-vessel wall interaction.
Topics: Animals; Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Epoprostenol; Male; Mesenteric Arterie | 1983 |
Sensitivity of rabbit platelet and aortic cyclooxygenase to inhibition by aspirin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta; Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Pl | 1983 |
On the mechanism of platelet activation during hemostasis and thrombosis and on the effects of platelet inhibiting drugs.
Topics: Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Hemostasis; Humans; Platelet Aggregation; Throm | 1984 |
[Divergence between the pharmacologic and clinical effects of inhibitors of prostaglandin synthesis].
Topics: Aspirin; Blood Platelets; Dipyridamole; Drug Interactions; Epoprostenol; Humans; Platelet Aggregatio | 1984 |
Prostaglandin endoperoxides and thromboxane A2 in thrombus formation in the hamster cheek pouch in vivo.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Cheek; Cricetinae; Cyclooxygenase Inhibitors; | 1984 |
[Thrombocyte interaction with a collagen substrate: the role of thrombocyte-synthesized prostaglandin endoperoxides and thromboxane A2].
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Arachidonic Acid; Arachidonic Ac | 1984 |
Antithrombotic therapy for vascular prosthesis: an experimental model testing platelet inhibitory drugs.
Topics: Aspirin; Blood Circulation; Blood Platelets; Blood Vessel Prosthesis; Dipyridamole; Humans; Methods; | 1980 |
[Problems of hemostatic therapy after myocardial infarct].
Topics: Aspirin; Coumarins; Humans; Middle Aged; Myocardial Infarction; Placebos; Platelet Aggregation; Thro | 1984 |
The effects of high doses of aspirin and related benzoic acid derivatives on arterial thrombosis in male rats.
Topics: Animals; Aspirin; Benzoates; Male; Rats; Rats, Inbred Strains; Structure-Activity Relationship; Thro | 1984 |
Vasoactive agents and production of thrombosis during intravascular coagulation 1--comparative effects of norepinephrine in thrombin and adenosine diphosphate (ADP) treated rabbits.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Aminocaproic Acid; Animals; Aspirin; Blood Coagulatio | 1984 |
The role of the platelets.
Topics: Adenosine Diphosphate; Angina Pectoris; Animals; Aspirin; Blood Platelets; Coronary Disease; Hemodyn | 1984 |
In vivo study of platelet aggregation in rats.
Topics: Adenosine Diphosphate; Animals; Aspirin; Collagen; Diet; Dose-Response Relationship, Drug; Male; Met | 1984 |
Thrombotic etiology of stress ulcers. 1. The effect of anticoagulant and antiplatelet aggregators in the development of stress ulcers in rats.
Topics: Animals; Anticoagulants; Aspirin; Dipyridamole; Gastric Acidity Determination; Gastric Mucosa; Hepar | 1983 |
[Comparative study of acetylsalicylic acid and calcium heparinate in the prevention of venous thrombosis after transurethral resection of the prostate].
Topics: Adult; Aged; Aspirin; Heparin; Humans; Male; Middle Aged; Premedication; Prostatectomy; Thrombosis | 1983 |
Acute arterial thrombosis in rabbits: reduced platelet accumulation after treatment with dazoxiben hydrochloride (UK 37,248-01).
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Blood Platelets; Electric Stimulation; Imidazoles; I | 1983 |
The effects of antithrombotic drugs in patients with left ventricular thrombi: assessment with indium-111 platelet imaging and two-dimensional echocardiography.
Topics: Adult; Aged; Anticoagulants; Aspirin; Dipyridamole; Echocardiography; Heart Ventricles; Humans; Indi | 1984 |
Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.
Topics: Adenosine Diphosphate; Aspirin; Bleeding Time; Blood Platelets; Fibrinolytic Agents; Humans; Thiophe | 1984 |
Prevention of platelet deposition and thrombus formation on hemodialysis membranes: a double-blind randomized trial of aspirin and dipyridamole.
Topics: Adult; Aspirin; Blood Platelets; Cellulose; Dipyridamole; Double-Blind Method; Female; Humans; Male; | 1984 |
One hundred percent patency of one-millimeter polytetrafluoroethylene (Gore-tex) grafts in the carotid arteries of rats.
Topics: Animals; Aspirin; Bleeding Time; Blood Platelets; Blood Vessel Prosthesis; Carotid Arteries; Graft S | 1984 |
Antithrombotic activity of a glycosaminoglycan (sulodexide) in rats.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Aspirin; Blood Platelets; Fibrinolytic Agents; Glycosaminogl | 1984 |
[Use of calciparin, curantyl and polopirin S in the treatment of retinal vein thrombosis].
Topics: Adult; Aged; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; | 1984 |
[Thrombogenic properties of the vessel and their inhibition].
Topics: Aspirin; Blood Coagulation; Blood Platelets; Blood Vessels; Cells, Cultured; Endothelium; Epoprosten | 1982 |
Effect of aspirin and aspirin lysinate on platelet function in smokers and non-smokers.
Topics: Adenosine Diphosphate; Adult; Aspirin; Bleeding Time; Blood Platelets; Humans; Lysine; Male; Middle | 1980 |
[Various aspects of the regulation and role of fibrinolysis in the organism].
Topics: Animals; Aspirin; Epoprostenol; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Male; Plasmino | 1982 |
Effect of aspirin and sodium salicylate on thrombosis, fibrinolysis, prothrombin time, and platelet survival In rabbits with indwelling aortic catheters.
Topics: Animals; Aorta; Aspirin; Blood Coagulation; Blood Platelets; Catheterization; Catheters, Indwelling; | 1983 |
Veno-venous allografts: patency, subendothelial proliferation, and the role of platelet-active agents.
Topics: Animals; Aspirin; Blood Platelets; Cell Division; Dipyridamole; Dogs; Female; Graft Survival; Male; | 1983 |
Antithrombotic therapy.
Topics: Anticoagulants; Aspirin; Blood Platelets; Dipyridamole; Fibrinolytic Agents; Humans; Sulfinpyrazone; | 1983 |
Dermatomyositis associated with platelet thrombi formation and responsive to antiplatelet therapy.
Topics: Adult; Aspirin; Blood Platelets; Dermatomyositis; Dipyridamole; Female; Humans; Sulfinpyrazone; Thro | 1983 |
Anti-thrombotic effect of very low doses of acetyl salicylic acid in rats.
Topics: Animals; Aspirin; Blood Platelets; Carotid Arteries; Dose-Response Relationship, Drug; Extracorporea | 1983 |
A case of probable thrombotic thrombocytopenic purpura responding to exchange transfusion.
Topics: Aspirin; Diagnosis, Differential; Exchange Transfusion, Whole Blood; Female; Hemolytic-Uremic Syndro | 1982 |
The effect of antiaggregating drugs on the patency of grafts in the arterial system.
Topics: Animals; Anticoagulants; Aorta, Abdominal; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Dogs; Erg | 1980 |
Non-steroidal anti-inflammatory agents and coronary heart disease.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Caroti | 1980 |
Gore-Tex (polytetrafluoroethylene) in canine coronary artery bypass.
Topics: Animals; Anti-Bacterial Agents; Aspirin; Blood Vessel Prosthesis; Coronary Angiography; Coronary Art | 1980 |
Reduction of thrombosis in canine coronary bypass vein grafts with dipyridamole and aspirin.
Topics: Animals; Aspirin; Coronary Artery Bypass; Dipyridamole; Dogs; Femoral Vein; Thrombosis | 1981 |
Portal hypertension in children due to thrombosis of the portal vein.
Topics: Adolescent; Aspirin; Catheterization; Child; Child, Preschool; Esophageal and Gastric Varices; Femal | 1982 |
The anti-thrombotic effects of prostacyclin.
Topics: Animals; Arteries; Aspirin; Cardiovascular Diseases; Dipyridamole; Epoprostenol; Fatty Acids; Hemost | 1980 |
[The role of prostacycline, thromboxane A2 and prostaglandins in platelet aggregation (author's transl)].
Topics: Arteriosclerosis; Aspirin; Epoprostenol; Hemostasis; Platelet Aggregation; Prostaglandin Antagonists | 1981 |
Effect of dipyridamole and prostacyclin on rabbit platelet adherence in vitro and in vivo.
Topics: Animals; Aorta; Aspirin; Blood Platelets; Cell Adhesion; Dipyridamole; Endothelium; Epoprostenol; In | 1982 |
Regression of aneurysms in Kawasaki disease: a pathological study.
Topics: Aneurysm; Aspirin; Axillary Artery; Calcinosis; Child, Preschool; Endothelium; Female; Femoral Arter | 1982 |
Aspirin to prevent arterial thrombosis.
Topics: Arteries; Aspirin; Blood Platelets; Dipyridamole; Female; Humans; Male; Thrombosis | 1982 |
[Platelet function inhibition and anticoagulation in coronary, cerebral and peripheral arterial occlusive disease. 2. Secondary prevention].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Ischemic Attack, Transient; M | 1982 |
[Inhibition of platelet function in pediatric medicine (author's transl)].
Topics: Age Factors; Aspirin; Child; Dipyridamole; Glomerulonephritis; Graft Rejection; Heart Defects, Conge | 1982 |
Dosage frequency for suppression of platelet function by low dose aspirin therapy.
Topics: Adenosine Diphosphate; Aspirin; Cell Survival; Collagen; Depression, Chemical; Dose-Response Relatio | 1982 |
Effect of aspirin on collateral blood flow after experimental thrombosis of the feline aorta.
Topics: Animals; Aortic Diseases; Aspirin; Cat Diseases; Cats; Collateral Circulation; Hindlimb; Platelet Ag | 1982 |
Turnover of adherent platelets: some effects of shear rate, ASA, and reduced anticoagulation.
Topics: Aspirin; Blood Coagulation; Humans; In Vitro Techniques; Platelet Adhesiveness; Thrombosis | 1982 |
Scanning electron microscopic and X-ray energy spectrographic analysis of the inner surface of human atherosclerotic carotid plaques.
Topics: Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Dipyridamole; Female; Humans; Intracrani | 1981 |
Paradoxical effect of high and low dose aspirin in experimental arterial thrombosis.
Topics: Animals; Aorta, Abdominal; Arteries; Aspirin; Blood Coagulation; Body Weight; Dose-Response Relation | 1980 |
Testing and treatment of arterial graft thrombosis.
Topics: Animals; Arteries; Aspirin; Blood Vessel Prosthesis; Constriction, Pathologic; Disease Models, Anima | 1981 |
Salicylate-aspirin interaction and thrombosis prevention trials.
Topics: Animals; Aspirin; Drug Interactions; Rats; Salicylates; Thrombosis | 1981 |
[From logical discovery to therapy (author's transl)].
Topics: Animals; Arachidonic Acids; Aspirin; Blood Platelets; Dogs; Fibrinolytic Agents; Glycoproteins; Hemo | 1981 |
[Hemostasis disorders and their treatment in patients with chronic myeloproliferative diseases].
Topics: Aged; Aspirin; Chronic Disease; Hemorrhagic Disorders; Humans; Male; Myeloproliferative Disorders; P | 1981 |
[Effect of aspirin, indomethacin and imidazole on thrombus formation at the site of a vascular wall injury by a laser ray].
Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Imidazoles; Indomethacin; Lasers; Male; Mesenter | 1981 |
[Sulfinpyrazone and aspirin in experimental microthrombosis].
Topics: Animals; Aspirin; Blood Vessels; Endothelium; Platelet Aggregation; Rats; Rats, Inbred Strains; Sulf | 1981 |
[Is there a need for a delayed-action acetylsalicylic acid preparation in the prevention of thrombosis?].
Topics: Anticoagulants; Aspirin; Delayed-Action Preparations; Humans; Thrombosis | 1981 |
Direct comparison of biomaterials and endothelium in an ex vivo shunt.
Topics: Animals; Arteriovenous Shunt, Surgical; Aspirin; Biocompatible Materials; Blood Vessels; Dogs; Endot | 1981 |
[Thrombocytosis. Considerations on a case with intestinal thrombosis diagnosed at the age of 4 months and treated with platelet anti-aggregants].
Topics: Aspirin; Dipyridamole; Female; Humans; Infant; Intestinal Diseases; Thrombocytosis; Thrombosis | 1981 |
[The meaning of specialist and adequate documentation for retrospective analysis of sicknesses (author's transl)].
Topics: Aspirin; Documentation; Duodenal Ulcer; Humans; Postoperative Complications; Prospective Studies; Ra | 1981 |
[Hemorrhagic complications in anticoagulant therapy].
Topics: Acenocoumarol; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation; Prothro | 1981 |
Prevention of thrombosis by low-dose aspirin in patients on hemodialysis.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Humans; Renal Dialysis; Thrombosis | 1980 |
The influence of systemic aspirin on rat small diameter vein grafts: a scanning electron microscopic study.
Topics: Animals; Aspirin; Blood Coagulation; Cerebral Revascularization; Endothelium; Female; Jugular Veins; | 1980 |
Aspirin and catheter size.
Topics: Aspirin; Catheterization; Humans; Research Design; Risk; Thrombosis | 1980 |
Aspirin and thrombosis in patients undergoing hemodialysis.
Topics: Aspirin; Humans; Renal Dialysis; Thrombosis; Uremia | 1980 |
Prevention of thrombosis with antiplatelet drugs.
Topics: Aspirin; Blood Platelets; Dipyridamole; Humans; Sulfinpyrazone; Thrombosis | 1980 |
Clinical applications.
Topics: Abortion, Induced; Aspirin; Blood Pressure; Cardiovascular Diseases; Cervix Uteri; Digestive System; | 1980 |
Predictors of bleeding during heparin therapy.
Topics: Adult; Aged; Alcohol Drinking; Aspirin; Dose-Response Relationship, Drug; Epistaxis; Female; Hematom | 1980 |
Failure of aspirin at different doses to modify experimental thrombosis in rats.
Topics: Animals; Aorta, Abdominal; Aspirin; Dose-Response Relationship, Drug; Male; Prostaglandins; Rats; Th | 1980 |
[The value of anti-thrombosis agents in acute peripheral obstructions in the extremities].
Topics: Anticoagulants; Aspirin; Dipyridamole; Embolism; Fibrinolytic Agents; Humans; Streptokinase; Thrombo | 1980 |
[Current aspects of acetylsalicylic acid use for thrombosis prevention].
Topics: Aspirin; Fibrinolytic Agents; Humans; Male; Prostaglandins; Thrombosis | 1980 |
Effects of 6-[p-(4-phenylacetylpiperazin-l-yl)-phenyl]-4,5-dihydro-3(2H)-pyridazinone (CCl 17810) and aspirin on experimental arterial thrombosis in rats.
Topics: Animals; Arterial Occlusive Diseases; Aspirin; Carotid Arteries; Male; Platelet Adhesiveness; Pyrida | 1980 |
Platelet changes after placement of aortic prostheses in dogs. II. Impaired surface-induced arterial thrombosis.
Topics: Animals; Aorta; Arterial Occlusive Diseases; Arteries; Aspirin; Blood Coagulation; Blood Platelets; | 1981 |
Effect of anticoagulation and inhibition of platelet aggregation on arterial versus venous microvascular thrombosis.
Topics: Animals; Aspirin; Blood Coagulation; Dipyridamole; Femoral Artery; Femoral Vein; Fibrinolytic Agents | 1995 |
Pregnancy complicated by cerebral venous thrombosis in Behçet's disease.
Topics: Adrenal Cortex Hormones; Adult; Aspirin; Behcet Syndrome; Cerebral Veins; Female; Heparin; Humans; M | 1995 |
Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis.
Topics: Animals; Aspirin; Bleeding Time; Bridged Bicyclo Compounds, Heterocyclic; Carotid Artery Thrombosis; | 1993 |
Effect of aspirin and iloprost on adhesion of platelets to intact endothelium in vivo.
Topics: Animals; Aspirin; Cricetinae; Endothelium, Vascular; Iloprost; Male; Mesocricetus; Platelet Adhesive | 1995 |
Streptokinase-prostacyclin--nitric oxide: in vivo interactions.
Topics: Animals; Arginine; Aspirin; Blood Pressure; Cats; Epoprostenol; Extracorporeal Circulation; Fibrinol | 1995 |
Anti-thrombotic activity of KBT-3022 in experimental models of thrombosis.
Topics: Animals; Arachidonic Acid; Aspirin; Cyclooxygenase Inhibitors; Extracorporeal Circulation; Guinea Pi | 1995 |
Acute thrombogenicity of arterial prostheses exposed to reduced blood flow in dogs: effects of heparin, aspirin, and prostacyclin.
Topics: Administration, Oral; Analysis of Variance; Animals; Anticoagulants; Aspirin; Blood Vessel Prosthesi | 1995 |
A successful pregnancy in a woman with an elevated level of beta 2-glycoprotein I dependent anticardiolipin antibodies, despite a progressive thrombotic condition.
Topics: Adult; Antibodies, Anticardiolipin; Aspirin; beta 2-Glycoprotein I; Enzyme-Linked Immunosorbent Assa | 1995 |
Epidemiological feasibility of cardiovascular primary prevention in general practice: a trial of vitamin E and aspirin. Collaborative group of the Primary Prevention Project.
Topics: Aged; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clinical Protocols; Contraindications; Dia | 1995 |
Hydroxyurea in essential thrombocytosis.
Topics: Aspirin; Follow-Up Studies; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Thrombocytosis; Th | 1995 |
[Results of endoprostheses in the iliac arteries; an experience apropos of 47 implantations].
Topics: Angiography; Angioplasty, Balloon; Aortic Dissection; Aspirin; Blood Vessel Prosthesis; Female; Foll | 1994 |
[A report of two endometrial cancer cases in that low-dose aspirin was effective for hypercoagulopathy caused by medroxyprogesterone acetate].
Topics: Adenocarcinoma; Adult; Aspirin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; M | 1995 |
Effect of inhibitors of factor Xa or platelet adhesion, heparin, and aspirin on platelet deposition in an atherosclerotic rabbit model of angioplasty injury.
Topics: Angioplasty, Balloon, Coronary; Animals; Arteriosclerosis; Arthropod Proteins; Aspirin; Blood Platel | 1995 |
Effect of the low molecular weight heparin/non steroidal anti-inflammatory drugs association on an experimental thrombosis induced by laser.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combination; Indomethacin; | 1995 |
In vivo thrombogenicity of intravascular ultrasound imaging catheters.
Topics: Angiography; Aspirin; Blood; Catheterization; Equipment Design; Femoral Artery; Femoral Vein; Hepari | 1995 |
Beneficial effect of nitroglycerin on arterial rethrombosis after thrombolysis. Results from a rabbit thrombosis model.
Topics: Animals; Aspirin; Blood Flow Velocity; Blood Pressure; Disease Models, Animal; Drug Therapy, Combina | 1995 |
Pulse-spray pharmacomechanical thrombolysis of thrombosed hemodialysis access grafts: long-term experience and comparison of original and current techniques.
Topics: Anastomosis, Surgical; Angioplasty, Balloon; Aspirin; Blood Vessel Prosthesis; Catheterization; Graf | 1995 |
The antithrombotic effects of ticlopidine and aspirin in a microvascular thrombogenic model.
Topics: Administration, Oral; Animals; Aspirin; Femoral Artery; Graft Occlusion, Vascular; Male; Microsurger | 1995 |
Arterial wall rather than platelets is responsible for diminished thrombogenicity during isradipine therapy.
Topics: Animals; Arteries; Aspirin; Blood Platelets; Endothelium, Vascular; Epoprostenol; Humans; In Vitro T | 1995 |
Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury.
Topics: Animals; Aspirin; Bleeding Time; Endothelium, Vascular; Fatty Acids, Monounsaturated; Femoral Vein; | 1995 |
CarboMedics valve in congenital heart disease. Midterm follow-up study of 14 patients.
Topics: Aortic Valve; Aspirin; Child; Dipyridamole; Female; Follow-Up Studies; Heart Defects, Congenital; He | 1994 |
Potentiation of endogenous nitric oxide with superoxide dismutase inhibits platelet-mediated thrombosis in injured and stenotic arteries.
Topics: Animals; Arteries; Aspirin; Blood Platelets; Cardiovascular Agents; Constriction, Pathologic; Cyclic | 1995 |
Power and temperature guided radiofrequency catheter ablation of the right atrium in pigs.
Topics: Animals; Aspirin; Catheter Ablation; Heart Atria; Heart Diseases; Heparin; Lung Injury; Postoperativ | 1994 |
Thrombelastographic patterns following abdominal aortic surgery.
Topics: Aged; Aged, 80 and over; Analgesia, Epidural; Anesthesia, General; Antithrombin III; Aorta, Abdomina | 1994 |
Thrombogenic properties of ultra-low-dose of acetylsalicylic acid in a vessel model of laser-induced thrombus formation.
Topics: Animals; Aspirin; Endothelium, Vascular; Lasers; Male; Rats; Rats, Wistar; Thrombosis | 1994 |
[Changes in antithrombin III, prothrombin fragment 1 + 2 and thrombin-antithrombin III complex following implantation of a coronary Palmaz-Schatz stent].
Topics: Aged; Angina Pectoris; Anticoagulants; Antithrombin III; Aspirin; Blood Coagulation Factors; Female; | 1995 |
Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model.
Topics: Animals; Aspirin; Blood Platelets; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Th | 1995 |
The management of thrombosis in the antiphospholipid-antibody syndrome.
Topics: Adolescent; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Follow-Up Studies; Hu | 1995 |
The management of thrombosis in the antiphospholipid-antibody syndrome.
Topics: Adolescent; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Follow-Up Studies; Hu | 1995 |
The management of thrombosis in the antiphospholipid-antibody syndrome.
Topics: Adolescent; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Follow-Up Studies; Hu | 1995 |
The management of thrombosis in the antiphospholipid-antibody syndrome.
Topics: Adolescent; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Follow-Up Studies; Hu | 1995 |
Antiphospholipid syndrome: clinical and therapeutic aspects.
Topics: Adolescent; Adult; Antiphospholipid Syndrome; Aspirin; Dose-Response Relationship, Drug; Female; Hum | 1994 |
Platelet activation and arterial thrombosis. Report of a meeting of Physicians and Scientists, University of Texas Health Science Center at Houston and Texas Heart Institute, Houston.
Topics: Aspirin; Hemorheology; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platel | 1994 |
[Transthoracic and transesophageal follow-up in patients with left atrial thrombosis].
Topics: Aged; Aspirin; Combined Modality Therapy; Echocardiography; Echocardiography, Doppler, Color; Echoca | 1994 |
Anticoagulation after intracoronary stent insertion.
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clinical Protocols; Coronary Disease; Drug Adminis | 1994 |
Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy.
Topics: Animals; Aspirin; Fibrinogen; Heparin; Hirudin Therapy; Partial Thromboplastin Time; Swine; Thrombin | 1994 |
Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs.
Topics: Animals; Arterial Occlusive Diseases; Aspirin; Benzimidazoles; Benzoxepins; Blood Coagulation; Blood | 1994 |
Potentiation of thrombolytic therapy by enzyme combinations and with aspirin or pentoxifylline.
Topics: Animals; Aspirin; Drug Synergism; Drug Therapy, Combination; Macaca; Pentoxifylline; Platelet Aggreg | 1994 |
[Left ventricular thrombosis after acute myocardial infarction: relationship with thrombolytic therapy and the patency of the "guilty" vessel].
Topics: Adult; Aged; Aspirin; Female; Heart Diseases; Heart Ventricles; Heparin; Humans; Male; Middle Aged; | 1994 |
Effect of controlled local acetylsalicylic acid release on in vitro platelet adhesion to vascular grafts.
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Delayed-Action Preparations; Dogs; Hemorheology; Lactates | 1994 |
Acetyl salicylic acid alleviates increased susceptibility to thrombosis in pial microvessels of dehydrated mice.
Topics: Animals; Arterioles; Aspirin; Cerebral Veins; Dehydration; Disease Susceptibility; Male; Mice; Mice, | 1994 |
Left atrial thrombi despite anticoagulant and antiplatelet therapy.
Topics: Aged; Aspirin; Atrial Fibrillation; Dilatation, Pathologic; Echocardiography; Echocardiography, Tran | 1994 |
Inhibitory effect of KW-3635, a new thromboxane A2-receptor antagonist, on arterial thrombosis in guinea pigs.
Topics: Animals; Arachidonic Acid; Aspirin; Benzimidazoles; Benzoxepins; Collagen; Disease Models, Animal; F | 1993 |
Time course of the effects of a single bolus injection of F(ab')2 fragments of the antiplatelet GPIIb/IIIa antibody 7E3 on arterial eversion graft occlusion, platelet aggregation, and bleeding time in dogs.
Topics: Animals; Antibodies, Monoclonal; Aspirin; Bleeding Time; Carotid Arteries; Dogs; Femoral Artery; Imm | 1994 |
The role of various antithrombotic agents in microvascular surgery.
Topics: Administration, Oral; Anastomosis, Surgical; Animals; Aspirin; Bleeding Time; Disease Models, Animal | 1994 |
Prevention of thrombus formation on biomaterials exposed to blood using different antiplatelet drugs: experimental study in dogs.
Topics: Animals; Aspirin; Biocompatible Materials; Blood; Dipyridamole; Dogs; Indium Radioisotopes; Male; Pl | 1994 |
Modulation of thrombotic responses in moderately stenosed arteries by cigarette smoking and aspirin ingestion.
Topics: Adult; Arteries; Aspirin; beta-Thromboglobulin; Blood Platelets; Cell Adhesion; Collagen; Constricti | 1994 |
Effect of aspirin and clopidogrel on platelet-dependent tissue factor expression in endothelial cells.
Topics: Adenosine Diphosphate; Animals; Aorta; Aspirin; Blood Platelets; Cattle; Clopidogrel; Endothelium, V | 1994 |
Thrombolytic therapy and intravenous heparin in acute myocardial infarction do not affect the incidence of left ventricular mural thrombus formation.
Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Heart Diseases; Heart Ventricles; Heparin; Humans; | 1994 |
[20,000 kg aspirin and 45 pages British Medical Journal].
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clinical Trials as Topic; Coronary Disease; Hu | 1994 |
Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Coagulation Disorders; Brain Ischemia; Cerebral Infar | 1994 |
Interruption of thrombosis and hemostasis by anti-platelet agents.
Topics: Amino Acid Sequence; Aspirin; Hemostasis; Humans; Molecular Sequence Data; Platelet Aggregation; Pla | 1993 |
A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons.
Topics: Animals; Aspirin; Female; Femoral Artery; Hemostasis; Humans; Immunoglobulin Fab Fragments; Male; Mi | 1993 |
A hearty endorsement for aspirin.
Topics: Aspirin; Cardiovascular Diseases; Female; Humans; Male; Meta-Analysis as Topic; Risk Factors; Thromb | 1994 |
[No benefit in the addition of dipyridamole to, nor of anticoagulants in comparison to, a low dose of acetylsalicylic acid (50 mg) in the prevention of venous transplant stenosis following coronary bypass surgery].
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Humans; Postoperative Complications; | 1993 |
Does external ultrasound accelerate thrombolysis? Results from a rabbit model.
Topics: Animals; Aspirin; Femoral Artery; Platelet Activation; Rabbits; Recurrence; Regional Blood Flow; Rep | 1994 |
History of drugs for thrombotic disease. Discovery, development, and directions for the future.
Topics: Animals; Aspirin; Canada; Europe; Fibrinolytic Agents; Heparin; History, 17th Century; History, 18th | 1994 |
Prevention of arterial thrombosis by a monoclonal antibody against the 100 to 109 amino acid sequence stretch of the beta-subunit of the human platelet fibrinogen receptor: a comparative study with low dose aspirin.
Topics: Animals; Antibodies, Monoclonal; Aspirin; Dogs; Humans; Indium Radioisotopes; Male; Organometallic C | 1994 |
Oral verapamil inhibits platelet thrombus formation in humans.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Blood Pressure; Delaye | 1994 |
Use of antiplatelet agents in the management of thrombotic disorders.
Topics: Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Thrombosis | 1993 |
Aspirin and the prevention of thrombosis.
Topics: Aspirin; Humans; Platelet Aggregation; Stomach Diseases; Thrombosis | 1993 |
Nitric oxide complements prostacyclin in the regulation of endothelial thromboresistance under flow conditions.
Topics: Animals; Aorta, Thoracic; Arginine; Aspirin; Blood Platelets; Endothelium, Vascular; Epoprostenol; I | 1993 |
Comparative effects of enoxaparin and heparin on arterial and venous clot lysis with alteplase in dogs.
Topics: Animals; Aspirin; Dogs; Drug Synergism; Femoral Artery; Femoral Vein; Hemostasis; Heparin; Heparin, | 1993 |
Adverse effect of warfarin in acute myocardial infarction: increased left ventricular thrombus formation in patients not treated with high-dose heparin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Dose-Response Relationship, Drug; Dru | 1993 |
Effects of aspirin in arterial thrombosis: why don't animals behave the way humans do?
Topics: Animals; Aspirin; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Humans; Platelet A | 1993 |
Low-dose aspirin and bleeding in uremia.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; | 1993 |
Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.
Topics: Animals; Aspirin; Bleeding Time; Femoral Artery; Femoral Vein; Fibrinolytic Agents; Heparin; Humans; | 1993 |
Platelet adhesion at low shear rate: study of a normal population.
Topics: Adult; Aspirin; Collagen; Contraceptives, Oral; Female; Fibronectins; Humans; Male; Menopause; Menst | 1993 |
Effect of ibudilast on microcirculation thrombosis in rat inner ear.
Topics: Animals; Aspirin; Cochlear Nerve; Ear, Inner; Hearing Disorders; Laser-Doppler Flowmetry; Microcircu | 1993 |
Effects of aspirin on embolization in an arterial model of laser-induced thrombus formation.
Topics: Animals; Arterioles; Aspirin; Disease Models, Animal; Embolism; Lasers; Lysine; Male; Platelet Aggre | 1993 |
Antithrombotic effect of TA-993, a novel 1,5-benzothiazepine derivative, in conscious rats.
Topics: Administration, Oral; Animals; Antithrombins; Aspirin; Diltiazem; Dose-Response Relationship, Drug; | 1995 |
Miniature axial flow pump for ventricular assistance in children and small adults.
Topics: Adult; Animals; Anticoagulants; Aspirin; Blood Vessel Prosthesis; Child; Coronary Circulation; Elect | 1996 |
Failure of calcium channel blockade to reduce platelet-mediated cyclic flow variations in dogs with coronary stenosis and endothelial injury.
Topics: Animals; Aspirin; Calcium Channel Blockers; Coronary Circulation; Coronary Disease; Diltiazem; Disea | 1995 |
Platelet activation and thrombosis: studies in a patient with essential thrombocythemia.
Topics: Adenosine Diphosphate; Adult; Antibodies, Monoclonal; Aspirin; Blood Platelets; Disease Susceptibili | 1996 |
Another antithrombotic action of aspirin.
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Thrombosis | 1995 |
Prostacyclin production at the human microvascular anastomosis: its effect on initial platelet deposition.
Topics: Anastomosis, Surgical; Arachidonic Acid; Aspirin; Endothelium, Vascular; Epoprostenol; Humans; Micro | 1996 |
Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Topics: Animals; Aspirin; Blood Platelets; Carotid Arteries; Drug Therapy, Combination; Fibrin; Fibrinolytic | 1996 |
Low molecular weight heparin-induced thrombocytopenia and thrombosis.
Topics: Adenocarcinoma; Aged; Arterial Occlusive Diseases; Aspirin; Dextrans; Embolism; Female; Femoral Arte | 1996 |
A ferret model of electrical-induction of arterial thrombosis that is sensitive to aspirin.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Aspirin; Blood Platelet | 1996 |
In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis.
Topics: Animals; Aspirin; Carotid Artery Diseases; Carotid Artery Injuries; Carotid Artery, Common; Cerebrov | 1996 |
[A case of Evans's syndrome with antiphospholipid antibody syndrome].
Topics: Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents; Antiphospholipid Syndrome; Aspirin; Female; | 1996 |
Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow.
Topics: Aspirin; Blood Flow Velocity; Humans; In Vitro Techniques; Male; Platelet Activation; Platelet Aggre | 1996 |
Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
Topics: Animals; Antibodies, Monoclonal; Aspirin; Bleeding Time; Dose-Response Relationship, Immunologic; Fi | 1996 |
Dynamics of left ventricular thrombi in patients with acute anterior myocardial infarction treated with thrombolytics.
Topics: Adult; Aged; Aspirin; Female; Fibrinolytic Agents; Heart Diseases; Heart Ventricles; Humans; Male; M | 1995 |
Placental thrombosis and second trimester miscarriage in association with activated protein C resistance.
Topics: Abortion, Habitual; Adult; Aspirin; Blood Coagulation Disorders; Factor Xa; Female; Humans; Placenta | 1996 |
Experimental thrombosis model induced by laser beam. Application of aspirin and an extract of Ginkgo biloba: EGb 761.
Topics: Animals; Aspirin; Free Radical Scavengers; Ginkgo biloba; Lasers; Male; Plant Extracts; Rats; Rats, | 1996 |
Antithrombotic effects of aspirin and LMWH in a laser-induced model of arterials and venous thrombosis.
Topics: Administration, Cutaneous; Animals; Aspirin; Disease Models, Animal; Heparin, Low-Molecular-Weight; | 1996 |
Effect of aspirin-dipyridamole and heparin and their combination on venous thrombosis in hypercoagulable or thrombotic animals.
Topics: Animals; Aspirin; Blood Coagulation; Dipyridamole; Drug Combinations; Drug Therapy, Combination; Ell | 1996 |
Long term follow up of patients with anterior myocardial infarction complicated by left ventricular thrombus in the thrombolytic era.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Echocardiography; Female; Follow-Up Studies; Heart Diseases | 1996 |
The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat.
Topics: Animals; Aspirin; Bleeding Time; Cell Division; Drug Synergism; Female; Fibrinolytic Agents; Platele | 1996 |
Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time.
Topics: Animals; Antithrombins; Arginine; Aspirin; Bleeding Time; Disease Models, Animal; Fibrinolytic Agent | 1996 |
[Atrial fibrillation, carotid stenosis and stroke].
Topics: Aspirin; Atrial Fibrillation; Brain; Carotid Stenosis; Cerebrovascular Disorders; Cyclooxygenase Inh | 1996 |
Platelet function and platelet-leukocyte adhesion in symptomatic coronary heart disease. Effects of intravenous magnesium.
Topics: Adenosine Diphosphate; Adult; Aged; Angina Pectoris; Aspirin; Cell Adhesion; Coronary Disease; Dose- | 1996 |
Inhibition of acute stent thrombosis under high-shear flow conditions by a nitric oxide donor, DMHD/NO. An ex vivo porcine arteriovenous shunt study.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arteriovenous Shunt, Surgical; Asp | 1996 |
Aspirin fails to prevent experimental arterial thrombosis induced by oxygen free radicals.
Topics: Animals; Aspirin; Free Radicals; Heparin; Male; Oxygen; Platelet Aggregation Inhibitors; Rats; Rats, | 1996 |
Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting.
Topics: Aged; Aspirin; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Plate | 1996 |
Combined ticlopidine and aspirin versus aspirin therapy alone after stent implantation.
Topics: Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Postoperative Care; Ste | 1996 |
Why aspirin cannot prevent arterial thrombosis.
Topics: Animals; Arteries; Aspirin; Humans; Platelet Aggregation Inhibitors; Thrombosis; Treatment Failure | 1996 |
Pneumatic compression or aspirin prophylaxis against thromboembolism in total hip arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Female; Gravity Suits; Hip Prosthesis; Huma | 1996 |
Effect of combined anticoagulation and low-dose aspirin treatment on upper gastrointestinal bleeding.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroi | 1997 |
A technique to investigate microvascular mural thrombus formation in arteries and veins: II. Effects of aspirin, heparin, r-hirudin, and G-4120.
Topics: Animals; Anticoagulants; Aspirin; Carotid Artery Thrombosis; Cricetinae; Disease Models, Animal; Dos | 1997 |
Enhanced response to chemotactic activation of polymorphonuclear leukocytes from patients with heart valve replacement.
Topics: Anticoagulants; Aspirin; Cells, Cultured; Chemotaxis; Female; Heart Valve Prosthesis; Humans; Male; | 1997 |
Thrombus and branch retinal vein occlusion.
Topics: Aspirin; Calcium Channel Blockers; Fluorescein Angiography; Fundus Oculi; Humans; Hyperlipidemias; H | 1997 |
Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis.
Topics: Abciximab; Analysis of Variance; Animals; Antibodies, Monoclonal; Arteriovenous Shunt, Surgical; Asp | 1997 |
Development of chitosan/polyethylene vinyl acetate co-matrix: controlled release of aspirin-heparin for preventing cardiovascular thrombosis.
Topics: Animals; Anticoagulants; Aspirin; Cattle; Chemistry, Pharmaceutical; Chitin; Chitosan; Delayed-Actio | 1997 |
[Should individuals without evidence of coronary disease and with risk factors receive continuous treatment with aspirin? Arguments in favor].
Topics: Age Factors; Aspirin; Cost-Benefit Analysis; Diabetes Complications; Female; Humans; Hypercholestero | 1996 |
Effect of low dose aspirin on thrombus formation at arterial and venous microanastomoses and on the tissue microcirculation.
Topics: Anastomosis, Surgical; Animals; Aspirin; Male; Microcirculation; Rats; Rats, Wistar; Thrombosis; Vas | 1997 |
Complete recovery of right intraventricular thrombus and pulmonary arteritis in Behçet's disease.
Topics: Adrenal Cortex Hormones; Aneurysm; Antirheumatic Agents; Arteritis; Aspirin; Azathioprine; Behcet Sy | 1997 |
Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Female; Follow-Up Studies; Hemorrhage; Huma | 1997 |
Comparison of arterial and venous patency in a rat model of subendothelium-stimulated thrombosis.
Topics: Animals; Anticoagulants; Arteries; Aspirin; Dipyridamole; Endothelium, Vascular; Femoral Vein; Hepar | 1996 |
Acetylsalicylic acid and vitamin E in prevention of arterial thrombosis.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Drug Interactions; Humans; Myocardial Infarcti | 1997 |
Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022.
Topics: Animals; Aspirin; Femoral Artery; Light; Male; Phenylacetates; Platelet Aggregation; Platelet Aggreg | 1997 |
Mobile thromboses of the aortic arch without aortic debris. A transesophageal echocardiographic finding associated with unexplained arterial embolism. The Filiale Echocardiographie de la Société Française de Cardiologie.
Topics: Adult; Aorta, Thoracic; Arteriosclerosis; Aspirin; Blood Coagulation Tests; Diabetes Complications; | 1997 |
Obstetric outcome in antiphospholipid syndrome.
Topics: Abortion, Spontaneous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Anticardiolipin; | 1997 |
The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link?
Topics: Aged; Alkylating Agents; Aspirin; Erythromelalgia; Female; Fibrinolytic Agents; Hemorrhage; Hemorrha | 1997 |
Clopidogrel: a new safe and effective antiplatelet agent. But unanswered questions remain.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Myocardial Infarction; Pl | 1997 |
Postpartum thrombosis in primary thrombocythaemia.
Topics: Adult; Aspirin; Female; Humans; Pregnancy; Pregnancy Complications, Hematologic; Thrombocytosis; Thr | 1997 |
Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GP IIb/IIIa antagonist, in rabbits: comparison with clopidogrel and aspirin.
Topics: Animals; Aspirin; Benzylamines; Clopidogrel; Hemodynamics; Hemostasis; Male; Piperidines; Platelet A | 1997 |
[Results of heart valve replacement: especially on the selection criteria for valve prostheses and on a new anticoagulation regimen].
Topics: Adult; Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Female; Heart Valve Prosthesis; Humans; | 1989 |
[antiplatelet therapy of thrombosis].
Topics: Aspirin; Blood Platelets; Humans; Platelet Aggregation Inhibitors; Thrombosis | 1997 |
CARS trial: warfarin and thrombin generation. Coumadin Aspirin Reinfarction Study.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Thrombin; Thrombo | 1997 |
A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow | 1997 |
Thromboprophylaxis in elective orthopaedic surgery -- what is the purpose?
Topics: Anticoagulants; Aspirin; Bone and Bones; Chemoprevention; Elective Surgical Procedures; Femoral Neck | 1997 |
The role of nitric oxide in blood cell interaction.
Topics: Animals; Aspirin; Blood Cells; Blood Platelets; Cell Communication; Coronary Disease; Humans; Neutro | 1997 |
Low-dose aspirin therapy is associated with few side effects but does not prevent hepatic artery thrombosis in liver transplant recipients.
Topics: Adolescent; Adult; Aged; Aspirin; Child; Child, Preschool; Female; Hepatic Artery; Humans; Infant; L | 1997 |
Antiplatelet therapy or low-dose heparin and neuraxial anaesthesia.
Topics: Anesthesia, Epidural; Anesthesia, Spinal; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; A | 1997 |
[Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses].
Topics: Acenocoumarol; Adult; Aged; Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Drug Evaluation | 1997 |
Reduction of monocyte-platelet interaction and monocyte activation in patients receiving antiplatelet therapy after coronary stent implantation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood | 1997 |
Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
Topics: Animals; Aspirin; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Fibrinoly | 1998 |
C-reactive protein and risks of future myocardial infarction and thrombotic stroke.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; C-Reactive Protein; Humans; Myocardial | 1998 |
ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation. American Society of Health-System Pharmacists.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; C | 1998 |
Possibility of checking compliance and efficacy of antiaggregatory treatment following femoro-popliteal vein bypass surgery.
Topics: Anastomosis, Surgical; Arteriosclerosis Obliterans; Aspirin; Blood Coagulation; Female; Femoral Vein | 1998 |
Idiopathic partial thrombosis of the corpus cavernosum.
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Diag | 1998 |
[Thrombosis prophylaxis after stroke].
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Clopidogrel; Heparin; Humans; Middle Aged; Plate | 1998 |
Partial unilateral penile thrombosis: magnetic resonance imaging and management.
Topics: Adult; Anticoagulants; Aspirin; Bicycling; Heparin; Humans; Magnetic Resonance Imaging; Male; Penis; | 1998 |
Iohexol, platelet activation and thrombosis. II. Iohexol-induced platelet secretion does not affect collagen-induced or tissue-factor-induced thrombus formation in blood that is anticoagulated with heparin and aspirin.
Topics: Anticoagulants; Aspirin; beta-Thromboglobulin; Blood Platelets; Collagen; Contrast Media; Drug Inter | 1998 |
Postoperative adhesion prevention with low-dose aspirin: effect through the selective inhibition of thromboxane production.
Topics: Abdominal Muscles; Animals; Aspirin; Female; Ovary; Platelet Aggregation Inhibitors; Postoperative C | 1998 |
Combination of two doses of acetyl salicylic acid: experimental study of arterial thrombosis.
Topics: Administration, Cutaneous; Animals; Aspirin; Hemorrhage; Lasers; Male; Mesenteric Arteries; Platelet | 1998 |
Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist.
Topics: Animals; Aspirin; Benzylamines; Bleeding Time; Carotid Artery Injuries; Collagen; Fibrinolytic Agent | 1998 |
Protective effect of oral xemilofiban in arterial thrombosis in dogs: increased activity in combination with aspirin.
Topics: Administration, Oral; Animals; Arterial Occlusive Diseases; Aspirin; Benzamidines; Binding Sites; Do | 1998 |
Prothrombin fragment 1 + 2 measures treatment effect in patients with antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Aspirin; Biomarkers; Humans; Peptide Fragments; Platelet Aggregation Inhi | 1998 |
The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit.
Topics: Animals; Aspirin; Clopidogrel; Constriction, Pathologic; Drug Synergism; Femoral Artery; Fibrinolyti | 1998 |
Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease.
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Coronary Disease; Cross-Sectional Studies; Female; Humans; H | 1998 |
Procedural results and long-term clinical outcomes following coronary stenting in perimyocardial infarction syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Disease-Free Survival; Female; Follow | 1998 |
Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates.
Topics: Animals; Aspirin; Bleeding Time; Clopidogrel; Drug Interactions; Endarterectomy; Hemostasis; Heparin | 1998 |
Coronary-artery stents--gauging, gorging, and gouging.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination | 1998 |
Some effects of prophylactic aspirins and heparins on concurrent arterial and venous thrombosis in the same animal.
Topics: Animals; Aortic Diseases; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Rats; Rats, S | 1998 |
Aspirin and heparin prevent hepatic blood stasis and thrombosis induced by the toxic glycoprotein Bolesatine in mice.
Topics: Agglutination; Animals; Aspirin; Blood Platelets; Chemical and Drug Induced Liver Injury; Dose-Respo | 1998 |
Effects of copper-aspirin complex on platelet aggregation and thrombosis in rabbits and mice.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arachidonic Acid; Aspirin; Copper; Drug Combinations; Female; | 1998 |
Spontaneous arterial thrombosis in children.
Topics: Aspirin; Child; Diagnostic Errors; Female; Fibrinolytic Agents; Heparin; Humans; Popliteal Artery; R | 1999 |
Intracoronary Multi-link stents: experience in 218 patients using aspirin alone.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Combined Modality Therapy; Coronary Disease; Coronary Vesse | 1998 |
Aspirin, myocardial infarction, and gastrointestinal bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dyspepsia; Gastrointestinal Hemorrhage; Humans; My | 1999 |
Aspirin, myocardial infarction, and gastrointestinal bleeding.
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhoids; Humans; Male; Myocardial Infarction; Platelet Agg | 1999 |
Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Cor | 1999 |
The differential effects of aspirin on platelets, leucocytes and vascular endothelium in an in vivo model of thrombus formation.
Topics: Animals; Aspirin; Blood Coagulation; Blood Platelets; Disease Models, Animal; Dose-Response Relation | 1999 |
Antithrombotic therapy after coronary-artery stenting.
Topics: Anemia, Aplastic; Aspirin; Coronary Disease; Drug Administration Schedule; Drug Therapy, Combination | 1999 |
Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis.
Topics: Animals; Antifibrinolytic Agents; Antithrombins; Arterial Occlusive Diseases; Aspirin; Blood Platele | 1999 |
[Thrombosis prophylaxis in stomach ulcer].
Topics: Aspirin; Contraindications; Fibrinolytic Agents; Humans; Stomach Ulcer; Thrombosis | 1999 |
Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates.
Topics: Animals; Aspirin; Biphenyl Compounds; Cricetinae; Fibrinolytic Agents; Heptanoic Acids; Male; Pipera | 1999 |
Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats.
Topics: Anesthesia; Animals; Antibodies, Monoclonal; Anticoagulants; Arterial Occlusive Diseases; Aspirin; B | 1999 |
Warfarin or aspirin: both or others?
Topics: Aged; Anticoagulants; Aspirin; Embolism; Female; Heart Diseases; Humans; Male; Middle Aged; Platelet | 1999 |
Antithrombotic drug therapy after infrainguinal vascular surgery.
Topics: Administration, Oral; Anticoagulants; Aspirin; Graft Occlusion, Vascular; Humans; Leg; Platelet Aggr | 2000 |
[Bone marrow transplantation-associated thrombotic microangiopathy manifested by visual disturbance].
Topics: Adult; Aspirin; Bone Marrow Transplantation; Dipyridamole; Female; Humans; Leukemia, Myeloid, Acute; | 2000 |
Re: The Clinical Quality Improvement Network (CQIN) Investigators. Thromboembolic prophylaxis in 3,575 hospitalized patients with atrial fibrillation. 1998;14:695-702.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Heart Diseases; Humans; Pra | 2000 |
Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
Topics: Adenosine Diphosphate; Administration, Oral; Alanine; Animals; Arteriovenous Shunt, Surgical; Aspiri | 2000 |
In vivo dynamic real-time monitoring and quantification of platelet-thrombus formation: use of a local isotope detector.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Anticoagulants; Aspirin; Blood Platelets; Ca | 2000 |
An in-vitro model to study device-induced thrombosis and embolism: evaluation of the efficacy of tirofiban, aspirin, and dipyridamole.
Topics: Animals; Anticoagulants; Aspirin; Blood Flow Velocity; Cattle; Dipyridamole; Dose-Response Relations | 2000 |
The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Factor V; | 2000 |
Interpretation of Dutch BOA trial. Dutch Bypass Oral anticoagulants or Aspirin study group.
Topics: Administration, Oral; Anticoagulants; Aspirin; Graft Occlusion, Vascular; Humans; Platelet Aggregati | 2000 |
[Contribution of platelet aggregation inhibitors in the prevention of complications of atherothrombosis].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk Factor | 2000 |
[Comparative study of the antithrombotic effect of aspirin and Bay U3405, antagonist of a thromboxane A2 receptor].
Topics: Animals; Aspirin; Carbazoles; Fibrinolytic Agents; Guinea Pigs; Male; Mesenteric Arteries; Platelet | 1999 |
Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.
Topics: 3' Untranslated Regions; Abortion, Habitual; Activated Protein C Resistance; Adult; Anticoagulants; | 2000 |
Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Aspirin; Disease Models | 2000 |
Influence of previous aspirin treatment and smoking on the electrocardiographic manifestations of injury in acute myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Confidence Intervals; Electrocardiography; F | 2000 |
New NO donors with antithrombotic and vasodilating activities, Part 29. N-(1-cyanocyclohexyl)-C-phenylnitrones and glyoxaldinitrones.
Topics: Administration, Oral; Animals; Aspirin; Cyclohexanes; Fibrinolytic Agents; Glyoxal; Lasers; Nitric O | 2000 |
Combination therapy with clopidogrel and aspirin after coronary stenting.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged | 2000 |
Endogenous tissue factor pathway inhibitor modulates thrombus formation in an in vivo model of rabbit carotid artery stenosis and endothelial injury.
Topics: Animals; Antibodies; Aspirin; Blood Coagulation; Blood Flow Velocity; Carotid Artery Injuries; Carot | 2000 |
Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis.
Topics: Administration, Oral; Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulan | 2000 |
Peri-operative aspirin can prevent post-operative ischemia and thrombosis.
Topics: Aspirin; Humans; Intraoperative Period; Platelet Activation; Postoperative Complications; Thrombosis | 2000 |
Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity.
Topics: Aged; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Aspirin; Carotid Arteries; Carotid Artery | 2000 |
Effect of aspirin on platelet desaggregation induced by SR121566, a potent GP-IIb/IIIa antagonist.
Topics: Adenosine Diphosphate; Animals; Arachidonic Acid; Aspirin; Benzylamines; Blood Flow Velocity; Blood | 2000 |
Effects of acetyl salicylic acid therapy on an experimental thrombosis induced by laser beam.
Topics: Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Disease Models, Animal; Fibrinogen; Lasers; | 2000 |
Unusual effects of aspirin on ticlopidine induced thrombolysis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Drug Sy | 2000 |
Antiplatelet drugs in cardiovascular prevention: stroke prevention in patients with thrombogenic heart disease.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Drug Therapy, Combination; E | 2000 |
[Prevention of early thrombotic complications after reconstructive operations in occlusions of the aorto-iliac segment].
Topics: Adult; Aged; Anticoagulants; Aorta, Abdominal; Aortic Diseases; Arterial Occlusive Diseases; Aspirin | 2000 |
Results of the BRAT study--a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery.
Topics: Aspirin; Bleeding Time; Coronary Artery Bypass; Female; Follow-Up Studies; Humans; Male; Middle Aged | 2000 |
Time related neutralization of two doses acetyl salicylic acid.
Topics: Animals; Aspirin; Bleeding Time; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Eval | 2000 |
Is optimal antithrombotic therapy after myocardial infarction well defined?
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Humans; Myocardial Infarction; Platelet Aggregati | 2001 |
Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation.
Topics: Aspirin; Biopsy, Needle; Chronic Disease; Cyclooxygenase Inhibitors; Follow-Up Studies; Graft Reject | 2001 |
Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Femal | 2001 |
Aspirin for primary prevention. Treatment policy should be based on all trial evidence, not subgroup analysis.
Topics: Aspirin; Clinical Trials as Topic; Humans; Hypertension; Platelet Aggregation Inhibitors; Primary Pr | 2000 |
[Late stent thrombosis after intracoronary brachytherapy. A case report and review of the literature].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Brachytherapy; Clinical Trials as Topic; C | 2001 |
Aspirin therapy: need to develop individulized approach.
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Thrombosis | 2000 |
Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antiphospholipid Syndrome; Asp | 2001 |
Medical management of a large aortic thrombus in a young woman with essential thrombocythemia.
Topics: Aorta, Abdominal; Aortic Diseases; Aspirin; Biopsy, Needle; Drug Therapy, Combination; Female; Follo | 2001 |
High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin.
Topics: Adult; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Fetal Death; Heparin; | 2001 |
Enoxaparin treatment in women with mechanical heart valves during pregnancy.
Topics: Adult; Antibodies; Anticoagulants; Aspirin; Enoxaparin; Factor Xa; Female; Heart Valve Diseases; Hea | 2001 |
Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis.
Topics: Adult; Aged; Annexin A5; Antiphospholipid Syndrome; Arthritis, Rheumatoid; Aspirin; Blood Platelets; | 2001 |
Cardiovascular events and COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Cyclo | 2001 |
Oral anticoagulation therapy during and after coronary angioplasty.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Stenosis; Co | 2001 |
Pharmacologic optimization of microsurgery in the new millennium.
Topics: Anastomosis, Surgical; Animals; Anticoagulants; Aspirin; Cyclooxygenase Inhibitors; Dextrans; Fibrin | 2001 |
Anti-platelet and anti-thrombotic effects of triacetylshikimic acid in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta, Abdominal; Aspirin; Blood Platelets; Cyclic AMP; Cycli | 2002 |
Efficacy and safety of aspirin in the long-term management of atherothrombosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Platelets; Cardiovascular | 2002 |
Reduced tissue factor pathway inhibitor-1 after pharmacological thrombolysis: an epiphenomenon or potential culprit in rethrombosis?
Topics: Animals; Anticoagulants; Arteriosclerosis; Aspirin; Fibrinolytic Agents; Heparin; Humans; Lipoprotei | 2002 |
Local thrombus as an isolated sign of traumatic aortic injury.
Topics: Accidents, Traffic; Adult; Aorta, Thoracic; Aspirin; Echocardiography, Transesophageal; Female; Foll | 2002 |
Oral anticoagulation for acute coronary syndromes.
Topics: Administration, Oral; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Clopi | 2002 |
[How is prevention of thrombosis in paroxysmal absolute tachyarrhythmia managed?].
Topics: Aspirin; Female; Heart Atria; Heparin, Low-Molecular-Weight; Humans; Middle Aged; Tachycardia, Parox | 2002 |
Atherosclerosis: the new view.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Arterie | 2002 |
Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain.
Topics: Adenosine Triphosphatases; Animals; Antigens, CD; Apyrase; Aspirin; Brain Ischemia; Disease Models, | 2002 |
Effects of desmopressin on thrombogenesis in aspirin-induced platelet dysfunction.
Topics: Animals; Aspirin; Blood Platelets; Deamino Arginine Vasopressin; Hemostatics; Male; Platelet Aggrega | 2002 |
Antithrombotic effect of PMC, a potent alpha-tocopherol analogue on platelet plug formation in vivo.
Topics: Adenosine Diphosphate; Animals; Antioxidants; Aspirin; Bleeding Time; Blood Pressure; Chromans; Fluo | 2002 |
Ditazole activity and its interaction with urokinase on experimental thrombosis.
Topics: Animals; Aspirin; Carotid Arteries; Drug Evaluation, Preclinical; Drug Interactions; Endopeptidases; | 1977 |
Anti-platelet drugs and portacaval anastomosis for homozygous hypercholesterolaemia.
Topics: Adolescent; Adult; Aspirin; Child; Dipyridamole; Female; Homozygote; Humans; Hypercholesterolemia; M | 1976 |
Prevention of thrombosis.
Topics: Antioxidants; Arterial Occlusive Diseases; Aspirin; Fibrinolytic Agents; Humans; Prostaglandins; Thr | 1977 |
Degos' disease treated with platelet-suppressive drugs.
Topics: Adult; Aspirin; Dipyridamole; Drug Therapy, Combination; Humans; Male; Skin; Skin Diseases; Syndrome | 1977 |
Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin.
Topics: Animals; Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Depression, Chemical; Dipyridamole; Do | 1978 |
Platelet and plasma beta thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis.
Topics: Aspirin; Beta-Globulins; Blood Platelets; Female; Humans; Male; Myeloproliferative Disorders; Thromb | 1978 |
Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls.
Topics: Arachidonic Acids; Aspirin; Blood Platelets; Blood Vessels; Cyclic AMP; Dietary Fats; Epoprostenol; | 1979 |
Comparison of the inhibitory effects of acetylsalicylic acid and trifusal on enzymes related to thrombosis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aspirin; Cattle; Cyclooxygenase Inhibitors; Fibrinolyt | 1979 |
[Complications of antithrombotic prophylaxis with acetylsalicylic acid (ASS) in polycythemia (author's transl)].
Topics: Aged; Aspirin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Male; Polycythemia Vera; Thromb | 1978 |
Lymphokines and thrombosis. Thrombocyte and coagulation activation by culture supernatants of concanavalin-A-stimulated human lymphocytes. Some physicochemical properties and inhibition by chemical compounds.
Topics: Adult; Aprotinin; Aspirin; Blood Coagulation; Blood Platelets; Cell Survival; Concanavalin A; Dipyri | 1979 |
[Arteriosclerosis and thrombosis, new pathogenetic viewpoints].
Topics: Arteriosclerosis; Aspirin; Blood Circulation; Endothelium; Epoprostenol; Factor VIII; Humans; Thromb | 1978 |
Prostacyclin, thromboxane A2 interactions in haemostasis and thrombosis.
Topics: Animals; Aspirin; Blood Platelets; Dose-Response Relationship, Drug; Epoprostenol; Humans; Platelet | 1979 |
The paradoxical thrombogenic effect of aspirin in experimental thrombosis.
Topics: Animals; Aorta, Abdominal; Aspirin; Blood Coagulation; Dose-Response Relationship, Drug; Epoprosteno | 1979 |
[Informative value of control methods for postoperative supervision of medication with aspirin and heparin (author's transl)].
Topics: Aged; Antithrombins; Aspirin; Blood Coagulation Tests; Collagen; Female; Heparin; Humans; Lysine; Ma | 1977 |
Platelet consumption by arterial prostheses: the effects of endothelialization and pharmacologic inhibition of platelet function.
Topics: Aged; Animals; Arteries; Aspirin; Blood Coagulation Factors; Blood Platelets; Blood Vessel Prosthesi | 1977 |
[Action mechanism and clinical indications for thrombocyte aggregation inhibitors].
Topics: Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Humans; Ischemic Attack, Transient; Myocard | 1979 |
Central retinal vein thrombosis: serial treatment with defibrination, aspirin and plasminotropic drugs.
Topics: Aged; Ancrod; Aspirin; Batroxobin; Ethylestrenol; Humans; Male; Phenformin; Retinal Vein; Thrombosis | 1979 |
[Effects of heparin, sulfinpyrazone and acetylsalicylic acid on the collagen-induced thromboyte aggregation].
Topics: Aspirin; Heparin; Humans; In Vitro Techniques; Platelet Aggregation; Sulfinpyrazone; Thrombosis | 1979 |
Polycythemia vera and mesenteric arterial thrombosis. A disease association resulting from decreased platelet sensitivity to aspirin.
Topics: Aspirin; Drug Resistance; Humans; Intestine, Small; Male; Mesenteric Vascular Occlusion; Middle Aged | 1979 |
[Medical therapy of thrombosis].
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Fibrinolytic Agents; Humans; Hypolipidemic Agents; | 1979 |
Effects of heparin, aspirin and dipyridamole on thrombus formation on venous catheters.
Topics: Animals; Aspirin; Catheterization; Dipyridamole; Disease Models, Animal; Face; Heparin; Polyethylene | 1979 |
Effects of acetylsalicylic acid, sulfinpyrazone and dipyridamole on platelet adhesion and aggregation in flowing native and anticoagulated blood.
Topics: Animals; Aspirin; Blood Platelets; Blood Vessels; Citrates; Dipyridamole; Dose-Response Relationship | 1979 |
Dietary prevention of atherosclerosis: new aspects.
Topics: Animals; Arteriosclerosis; Aspirin; Cholesterol, Dietary; Diabetes Mellitus; Diet; Heart; Hypertensi | 1979 |
[Antiplatelet drugs (author's transl)].
Topics: Aspirin; Blood Platelets; Clofibrate; Dipyridamole; Female; Humans; Hydroxychloroquine; Ischemic Att | 1979 |
Inhibitors of platelet function and atherogenesis.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Dipyridamole; Disease Models, Animal; Humans; P | 1979 |
Laser-induced thrombosis test suitable for pharmacological screening studies.
Topics: Animals; Aspirin; Bencyclane; Blood Coagulation; Cycloheptanes; Drug Evaluation, Preclinical; Lasers | 1979 |
Aspirin dosage and antithrombotic effect.
Topics: Animals; Aspirin; Blood Platelets; Dogs; Platelet Aggregation; Thrombosis | 1979 |
Hypercoagulability: a cause of vascular access failure.
Topics: Antithrombin III Deficiency; Aspirin; Dipyridamole; Humans; Intraoperative Period; Plasma; Renal Dia | 1979 |
[Prevention and therapy with anticoagulants. Indications, experiences, results].
Topics: Anticoagulants; Aspirin; Blood Coagulation; Coumarins; Dipyridamole; Fibrinolysis; Heparin; Humans; | 1979 |
Antiplatelet agents in the treatment of thrombotic complications of primary thrombocythemia.
Topics: Aged; Aspirin; Humans; Male; Sulfinpyrazone; Thrombocythemia, Essential; Thrombosis | 1979 |
[Antithrombotic agents for the prevention of thromboses during infraclavicular vena cava catheterizaiton].
Topics: Adolescent; Adult; Aged; Aspirin; Catheterization; Dextrans; Female; Heparin; Humans; Male; Middle A | 1979 |
Fatal meningococcal septicemia.
Topics: Adolescent; Adrenal Glands; Adult; Aspirin; Female; Humans; Infant; Kidney; Lung; Meningococcal Infe | 1977 |
Antithrombotic effects of some flavonoids alone and combined with acetylsalicylic acid.
Topics: Animals; Aspirin; Blood Vessels; Drug Therapy, Combination; Endothelium; Flavonoids; Platelet Adhesi | 1977 |
Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141), an anti-aggregating compound, on experimental thrombosis in rats.
Topics: Animals; Aspirin; Dipyridamole; Imidazoles; Male; Pyridines; Rats; Thrombosis | 1978 |
Thrombotic and hemorrhagic problems in surgery.
Topics: Aspirin; Blood Coagulation Factors; Dextrans; Extracorporeal Circulation; Female; Hemostasis; Hepari | 1978 |
The effects of treatment with aspirin and an antithrombotic agent SH1117 upon platelet thrombus formation in living blood vessels.
Topics: Adenosine Diphosphate; Animals; Aspirin; Biphenyl Compounds; Drug Synergism; Fibrinolytic Agents; Ma | 1977 |
Femoral vein thrombosis and total hip replacement.
Topics: Aspirin; Femoral Vein; Hip; Humans; Postoperative Complications; Thrombosis | 1977 |
Effect of acetylsalicylic acid on experimentally induced arterial thrombosis in rats.
Topics: Animals; Arterial Occlusive Diseases; Aspirin; Male; Platelet Aggregation; Rats; Thrombosis; Time Fa | 1977 |
[Platelet-inhibiting drugs].
Topics: Anti-Bacterial Agents; Aspirin; Dextrans; Dipyridamole; Hemorrhage; Humans; Indomethacin; Platelet A | 1978 |
Gonadal hormones and pathogenesis of occlusive arterial thrombosis.
Topics: Animals; Aspirin; Estradiol; Female; Flutamide; Male; Rabbits; Rats; Sex Factors; Testosterone; Thro | 1978 |
Antiplatelet therapy (first of two parts).
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Blood Coagulation; Blood Platelets; Cell Survival; Clofi | 1978 |
Platelets in thrombocythemia.
Topics: Aspirin; Female; Hemorrhage; Humans; Platelet Aggregation; Thrombocytosis; Thrombosis | 1978 |
Dose-dependent inhibition of experimental arterial thrombosis by carbenicillin and ticarcillin.
Topics: Animals; Arteries; Aspirin; Carbenicillin; Dogs; Dose-Response Relationship, Drug; Fibrinolytic Agen | 1978 |
[Observations and results of photodocumentation of retinal thromboses treated with Colfarit (author's transl)].
Topics: Aspirin; Fibrinolytic Agents; Follow-Up Studies; Fundus Oculi; Humans; Photography; Retinal Diseases | 1978 |
On teaching an old dog new tricks.
Topics: Aspirin; Female; Humans; Male; Platelet Aggregation; Sex Factors; Thrombosis | 1978 |
[Antithrombotic treatment in the acute phase of myocardial infarct].
Topics: Adult; Aged; Aspirin; Female; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Thrombosis | 1978 |
[Correction of disorders of rheologic properties of blood in reconstructive operations on the abdominal aorta].
Topics: Adult; Aged; Aorta, Abdominal; Aortic Diseases; Arteriosclerosis; Aspirin; Blood Viscosity; Dipyrida | 1978 |
Malignant atrophic papulosis: treatment with aspirin and dipyridamole.
Topics: Adult; Aspirin; Dipyridamole; Humans; Infarction; Male; Platelet Aggregation; Skin; Skin Diseases; T | 1978 |
[Influence of Anturane on platelets aggregation. Comparative study with acetylsalicylic acid in patients with and without oral anticoagulant therapy].
Topics: Administration, Oral; Anticoagulants; Aspirin; Coumarins; Drug Evaluation; Drug Interactions; Drug T | 1978 |
Unstable metabolites of arachidonic acid aspirin and the formation of the haemostatic plug.
Topics: Animals; Arachidonic Acids; Aspirin; Blood Coagulation Tests; Dose-Response Relationship, Drug; Hemo | 1978 |
[Thrombosis prevention with heparin and acetylsalicylic acid in elective hip joint surgery].
Topics: Aspirin; Drug Therapy, Combination; Heparin; Hip Joint; Humans; Postoperative Complications; Thrombo | 1979 |
Antithrombotic therapy. Rationale and application.
Topics: Anticoagulants; Arteries; Arteriosclerosis; Aspirin; Blood Coagulation; Blood Coagulation Factors; D | 1979 |
[Effect of heparin, acetylsalicylic acid and sulfinpyrazone on thrombocyte morphology].
Topics: Aspirin; Blood Platelets; Heparin; Humans; Sulfinpyrazone; Thrombosis | 1979 |
Dynamics of thrombus formation on an artificial surface in vivo. Effects of antithrombotic agents.
Topics: Animals; Aspirin; Dextrans; Fibrinolytic Agents; Haplorhini; Silicone Elastomers; Thrombosis; Time F | 1976 |
Antiplatelet and antithrombogenic effects of suloctidil.
Topics: Adenosine Diphosphate; Animals; Aspirin; Blood Pressure; Dogs; Female; Fibrinolytic Agents; Haplorhi | 1976 |
Use of newer platelet function tests ot define abnormalities of hemostasis and thrombosis.
Topics: Acute Disease; Adult; Aged; Aspirin; Blood Cell Count; Blood Platelets; Edetic Acid; Hemostasis; Hum | 1975 |
[Prophylaxis and therapy of shunt thrombosis in terminal renal insufficiency (author's transl)].
Topics: Anticoagulants; Arteriovenous Shunt, Surgical; Aspirin; Dextrans; Dipyridamole; Hemorrhagic Disorder | 1977 |
Effect of aspirin on thrombogenesis and on production of experimental aortic valvular Streptococcus viridans endocarditis in rabbits.
Topics: Animals; Aortic Valve; Aspirin; Endocarditis, Bacterial; Female; Rabbits; Streptococcus; Thrombosis | 1977 |
Arachidonate-induced thrombosis in mice: effects of gender or testosterone and estradiol administration.
Topics: Administration, Oral; Animals; Arachidonic Acids; Aspirin; Blood Platelets; Delayed-Action Preparati | 1977 |
The synergistic effect of aspirin and dipyridamole upon platelet thrombi in living blood vessels.
Topics: Adenosine Diphosphate; Alloxan; Animals; Aspirin; Dipyridamole; Drug Synergism; Male; Platelet Aggre | 1977 |
Patency of venous grafts in small veins: influence of aspirin and warfarin sodium.
Topics: Animals; Aspirin; Drug Therapy, Combination; Female; Jugular Veins; Male; Platelet Aggregation; Post | 1977 |
Effect of drugs of platelets and complications of vascular disease.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Clofibrate; Coronary Disease; | 1977 |
Platelets, thrombosis and atherosclerosis.
Topics: Arteries; Arteriosclerosis; Aspirin; Blood Platelets; Cell Division; Cell Survival; Dipyridamole; En | 1977 |
Platelets, thrombosis and atherosclerosis.
Topics: Arteries; Arteriosclerosis; Aspirin; Blood Platelets; Cell Division; Cell Survival; Dipyridamole; En | 1977 |
Platelets, thrombosis and atherosclerosis.
Topics: Arteries; Arteriosclerosis; Aspirin; Blood Platelets; Cell Division; Cell Survival; Dipyridamole; En | 1977 |
Platelets, thrombosis and atherosclerosis.
Topics: Arteries; Arteriosclerosis; Aspirin; Blood Platelets; Cell Division; Cell Survival; Dipyridamole; En | 1977 |
Haemostasis in the microvasculature of the rabbit mesentery, effects of some pharmacological agents of current interest in haemostasis and thrombosis.
Topics: Animals; Aspirin; Blood Coagulation; Dextrans; Female; Hemostasis; Heparin; Male; Mesenteric Arterie | 1976 |
[Experimental thrombosis and treatment with acetylsalicylic acid in animals].
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Disease Models, Animal; Germ-Free Life; Heparin; Rats; T | 1976 |
Evaluation of antithrombotic properties of suloctidil in comparison with aspirin and dipyridamole.
Topics: Animals; Aspirin; Dipyridamole; Disease Models, Animal; Drug Evaluation, Preclinical; Fibrinolytic A | 1976 |
Editorial: Much hope but little proof.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Coronary Disease; Humans; Physical Exertion; Platel | 1976 |
[Ovulation inhibitors from a neurological viewpoint].
Topics: Adult; Aspirin; Cerebrovascular Disorders; Contraceptives, Oral; Contraceptives, Oral, Hormonal; Est | 1976 |
Management of small arterial injuries: clinical and experimental studies.
Topics: Aspirin; Brachial Artery; Femoral Artery; Follow-Up Studies; Heparin; Humans; Postoperative Complica | 1976 |
[Comparative studies on the antithrombotic effect of acetylsalicylic acid and anticoagulants on an experimental model of thrombosis].
Topics: Animals; Anticoagulants; Aspirin; Disease Models, Animal; Rabbits; Thrombosis | 1976 |
[The antithrombotic treatment and prevention of recurrence with acetylsalicylic acid in myocardial infarct].
Topics: Animals; Anticoagulants; Aspirin; Dogs; Drug Hypersensitivity; Gastrointestinal Hemorrhage; Humans; | 1976 |
[Circulatory dynamics and excitomotor currents. A preventive association in the prophylaxis of postoperative thrombosis].
Topics: Anticoagulants; Aspirin; Bandages; Dextrans; Electric Stimulation Therapy; Female; Humans; Male; Pos | 1976 |
Extracorporeal model for study of factors affecting thrombus formation.
Topics: Animals; Aspirin; Blood Coagulation; Blood Flow Velocity; Disease Models, Animal; Dogs; Drug Synergi | 1975 |
Letter: Familial occurrence of spontaneous platelet aggregation.
Topics: Aspirin; Blood Platelet Disorders; Female; Humans; Platelet Adhesiveness; Platelet Aggregation; Thro | 1975 |
The emergency cold leg.
Topics: Aspirin; Dextrans; Embolism; Emergencies; Femoral Artery; Heparin; Humans; Ischemia; Leg; Methods; P | 1975 |
Prophylactic agents for thrombosis.
Topics: Aspirin; Dipyridamole; Fibrinolytic Agents; Humans; Platelet Adhesiveness; Platelet Aggregation; Thr | 1975 |
Civilian vascular injuries.
Topics: Adolescent; Adult; Age Factors; Aged; Aneurysm; Arteries; Arteriovenous Fistula; Aspirin; Blood Vess | 1975 |
[Pregnancy, heart valve prostheses and anti-platelet aggregation treatment].
Topics: Adult; Anticoagulants; Aspirin; Dipyridamole; Drug Combinations; Female; Heart Valve Prosthesis; Hum | 1975 |
The effect of a new anti-inflammatory agent, the ethoxy methyl ester of N-(2,6-dichloro-m-tolyl)-anthranilic acid (A3), on platelet behaviour "in vivo" and "in vitro".
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Inflammatory Agents; Arterial Occlusive | 1975 |
The effect of some antithrombotic drugs on experimental arterial thrombosis.
Topics: Acute Disease; Animals; Anticoagulants; Arteries; Aspirin; Dipyridamole; Drug Synergism; Fibrinolysi | 1975 |
[Inhibition of platelet aggregation under estrogen-treatment in patients with carcinoma of the prostate (author's transl)].
Topics: Aspirin; Blood Coagulation Disorders; Blood Platelets; Diethylstilbestrol; Estrogens; Humans; Male; | 1975 |
Editorial: Platelet-function tests: predictive value.
Topics: Aspirin; Blood Platelets; Cell Survival; Humans; Lipids; Methods; Peroxides; Platelet Aggregation; P | 1975 |
[A case of consumption coagulopathy due to atrial giant thrombus. Detection of thrombus by scintillation camera using fibrinogen labelled with 125I, 131I and warfarin-aspirin combination therapy (author's transl)].
Topics: Aspirin; Coronary Disease; Disseminated Intravascular Coagulation; Drug Therapy, Combination; Female | 1975 |
Inhibition of platelet adherence to damaged surface of rabbit aorta.
Topics: Albumins; Animals; Aorta, Thoracic; Aspirin; Citrates; Microscopy, Electron, Scanning; Platelet Adhe | 1975 |
Proceedings: The anti-thrombotic effect of warfarin, dipyridamole and aspirin in the rat.
Topics: Animals; Aspirin; Dipyridamole; Disease Models, Animal; Rats; Thrombosis; Warfarin | 1975 |
Proceedings: The antithrombotic effect of acetylsalicylic acid, heparin and phenprocoumon in experimental thrombosis.
Topics: Animals; Aspirin; Coumarins; Heparin; Phenprocoumon; Rabbits; Thrombosis | 1975 |
[Prevention of thrombosis using acetylsalicylic acid following vascular prosthesis and endarterectomy].
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Dogs; Endarterectomy; Platelet Adhesiveness; Postoperativ | 1975 |
[Experience with acetylsalicylic acid in long-term prevention of thrombosis in children].
Topics: Aspirin; Child; Female; Humans; Thrombosis; Time Factors | 1975 |
[Acetylsalicylic acid and dipyridamole: aggregation inhibition in the rabbit experiment].
Topics: Administration, Oral; Animals; Aspirin; Dipyridamole; Drug Therapy, Combination; Injections, Intrave | 1975 |
Pharmacological properties of drug inhibiting platelet aggregation.
Topics: Aspirin; Dipyridamole; Humans; In Vitro Techniques; Platelet Aggregation; Sulfinpyrazone; Thrombosis | 1975 |
Platelet kinetics--1975.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Cell Survival; Extracorporeal Circulation; Heart Valve | 1975 |
Heparin-induced skin reaction with low molecular-weight heparin.
Topics: Adult; Aspirin; Drug Hypersensitivity; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Skin | 1992 |
[Evaluation of the antithrombotic effects of pentoxifylline, acetylsalicylic acid and low molecular weight heparin in the laser model of thrombosis].
Topics: Animals; Aspirin; Disease Models, Animal; Heparin, Low-Molecular-Weight; In Vitro Techniques; Lasers | 1992 |
Effects of combinations of a prostacyclin analogue (Cicaprost) with different antithrombotic agents in a rat microcirculatory thrombosis model.
Topics: Animals; Aspirin; Drug Synergism; Drug Therapy, Combination; Epoprostenol; Fibrinolytic Agents; Hepa | 1992 |
[Fibrinolytic complexes of low-molecular heparin and acetylsalicylic acid].
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation Tests; Drug Combinations; Drug Evaluation, Precl | 1992 |
Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.
Topics: Animals; Aspirin; Biphenyl Compounds; Dose-Response Relationship, Drug; Heptanoic Acids; Injections, | 1992 |
Arterial thrombosis model with photochemical reaction in guinea-pig and its property.
Topics: Animals; Aspirin; Biphenyl Compounds; Disease Models, Animal; Femoral Artery; Fibrinolytic Agents; G | 1992 |
Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation.
Topics: Aged; Antithrombin III; Aspirin; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Peptide Fra | 1992 |
Antithrombotic effect of ticlopidine on He-Ne laser-induced thrombus formation in rat mesenteric microvessels.
Topics: Animals; Aspirin; Blood Cell Count; Blood Coagulation Tests; Helium; Humans; Lasers; Male; Mesentery | 1992 |
Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
Topics: Animals; Antithrombins; Arginine; Aspirin; Blood Coagulation; Cricetinae; Disease Models, Animal; Dr | 1992 |
The de-endothelialized rat carotid arterial graft: a versatile experimental model for the investigation of arterial thrombosis.
Topics: Anastomosis, Surgical; Animals; Aspirin; Blood Coagulation Tests; Blood Vessel Prosthesis; Carotid A | 1992 |
Congenital protein C deficiency and myocardial infarction:concomitant factor VII hyperactivity may play a role in the onset of arterial thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Coagulation Factors; Factor VII; Humans; Male; Middle | 1992 |
The significance of calf thrombi after total knee arthroplasty.
Topics: Aspirin; Humans; Knee Prosthesis; Leg; Phlebography; Postoperative Complications; Pulmonary Embolism | 1992 |
Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig.
Topics: Animals; Aspirin; Bleeding Time; Clopidogrel; Disease Models, Animal; Female; Femoral Artery; Fibrin | 1992 |
Efficacy of adjunctive intrathrombic heparin with pulse spray thrombolysis in rabbit inferior vena cava thrombosis.
Topics: Animals; Aspirin; Heparin; Rabbits; Radiography; Thrombolytic Therapy; Thrombosis; Tissue Plasminoge | 1992 |
[Experimental antithrombotic activity of oral isosorbide dinitrate].
Topics: Administration, Oral; Animals; Arginine; Aspirin; Isosorbide Dinitrate; Male; NG-Nitroarginine Methy | 1992 |
Evidence for a role in thrombus stabilization for thromboxane A2 in human platelet deposition on collagen.
Topics: Aspirin; Biphenyl Compounds; Blood Platelets; Citrates; Collagen; Heparin; Heptanoic Acids; Humans; | 1992 |
High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation.
Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Female; Hemostasis; Humans; Male; | 1992 |
Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis.
Topics: Animals; Anticoagulants; Aspirin; Bleeding Time; Dogs; Factor Xa Inhibitors; Female; Femoral Artery; | 1992 |
Delivery of passivating proteins to sutures during passage through the vessel wall reduces subsequent platelet deposition by blocking fibrinogen adsorption.
Topics: Adsorption; Albumins; Arteries; Aspirin; Blood Platelets; Blotting, Western; Fibrinogen; Hemoglobins | 1992 |
A non-occlusive model of arterial thrombus formation in the rat and its modification by inhibitors of platelet function, or thrombin activity.
Topics: Animals; Aorta; Aspirin; Disease Models, Animal; Immunoenzyme Techniques; Infusions, Intravenous; In | 1992 |
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
Topics: Aged; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hepa | 1992 |
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
Topics: Aged; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hepa | 1992 |
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
Topics: Aged; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hepa | 1992 |
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
Topics: Aged; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hepa | 1992 |
Enhancement of antithrombotic effect of aspirin by metoclopramide in rats.
Topics: 5-Hydroxytryptophan; Administration, Oral; Animals; Aspirin; Benzamides; Body Temperature; Bridged B | 1991 |
A new low molecular weight heparan sulphate antagonizes kappa-carrageenan-induced thrombosis in rats.
Topics: Animals; Aspirin; Carrageenan; Fibrinolytic Agents; Glycosaminoglycans; Heparin, Low-Molecular-Weigh | 1991 |
The 'primary' antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients.
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin | 1991 |
Effects of laser-generated tissue debris on aggregation of human platelets.
Topics: Aged; Angioplasty, Laser; Animals; Aorta; Aortic Diseases; Arteriosclerosis; Aspirin; Blood Coagulat | 1991 |
Evaluation of the effect of pharmacologic agents on crush-avulsion arterial injuries: a scanning electron microscopy study.
Topics: Animals; Arteries; Aspirin; Dextrans; Ear, External; Endothelium, Vascular; Femoral Artery; Fibrin; | 1991 |
Usefulness of antiplatelet drugs in the management of heparin-associated thrombocytopenia and thrombosis.
Topics: Aged; Aorta, Abdominal; Aspirin; Dipyridamole; Female; Femoral Vein; Heparin; Humans; Iliac Artery; | 1991 |
[A case of hypereosinophilic syndrome followed by bronchial asthma, intraventricular thrombus, and duodenitis].
Topics: Adult; Aspirin; Asthma; Duodenitis; Eosinophilia; Heart Diseases; Humans; Male; Myocarditis; Prednis | 1991 |
[Thrombophilia in patients with arterial occlusive diseases and its therapeutic modification].
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Blood Coagulation Tests; Coronary Disease; Cor | 1991 |
Reocclusion after thrombolysis: a problem solved by hirudin?
Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heparin; Hirudin Therapy; H | 1991 |
Effect of low and ultra low oral doses of acetylsalicylic acid in microvascular surgery. An experimental study in the rabbit.
Topics: Administration, Oral; Animals; Aspirin; Blood Platelets; Ear, External; Female; Male; Microscopy, El | 1991 |
Rebound elevation in urinary thromboxane B2 and 6-keto-PGF1 alpha excretion after aspirin withdrawal.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aspirin; Blood Platelets; Disease Susceptibility; Female; Human | 1991 |
Antithrombotic therapy for deep arterial injury by angioplasty. Efficacy of common platelet inhibition compared with thrombin inhibition in pigs.
Topics: Angioplasty, Balloon; Animals; Arteries; Aspirin; Dipyridamole; Fibrinolytic Agents; Heart Diseases; | 1991 |
Femoro-popliteal artery occlusions treated by percutaneous transluminal angioplasty and enclosed thrombolysis: results in 55 patients.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Combined Modali | 1991 |
[Effect of antiplatelet therapy on prevention of thrombotic diseases].
Topics: Arachidonic Acid; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Humans; Myocardial Infa | 1991 |
[Arterioarterial shunt coated with collagen. A model of acute arterial thrombosis for testing antithrombotic agents in rats].
Topics: Animals; Aspirin; Carotid Arteries; Clopidogrel; Collagen; Disease Models, Animal; Fistula; Graft Oc | 1991 |
Thrombocythemia and coronary artery disease.
Topics: Adult; Aged; Aspirin; Busulfan; Coronary Disease; Female; Humans; Male; Middle Aged; Polycythemia Ve | 1991 |
Idiopathic thrombocythemia and pregnancy; a case report.
Topics: Adult; Aspirin; Female; Humans; Melphalan; Pregnancy; Pregnancy Complications, Hematologic; Thromboc | 1991 |
Effects of different hirudins and combinations of low doses of hirudin, heparin and acetylsalicylic acid in a rat microcirculatory thrombosis model.
Topics: Animals; Aspirin; Drug Combinations; Drug Synergism; Fibrinolytic Agents; Heparin; Hirudin Therapy; | 1991 |
Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator.
Topics: Animals; Aspirin; Dogs; Heparin; Recombinant Proteins; Thrombophlebitis; Thrombosis; Tissue Plasmino | 1991 |
Incidence of left ventricular thrombi formation after thrombolytic therapy with recombinant tissue plasminogen activator, heparin, and aspirin in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Female; Heart Diseases; Heparin; Humans; Incidence; Male; Middle Aged; Myocardial Inf | 1991 |
Modification of the thrombogenicity of a self-expanding vascular stent.
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Dogs; Female; Heparin; Indium Radioisotopes; Male; Micros | 1991 |
[Diagnosis and therapy of thrombosis].
Topics: Aspirin; Disseminated Intravascular Coagulation; Heparin; Humans; Platelet Aggregation Inhibitors; R | 1991 |
An aspirin a day.
Topics: Aspirin; Humans; Thrombosis | 1991 |
Anticoagulant and antithrombotic effects of combinations of defibrotide with heparins and other antithrombotic agents in an animal thrombosis model.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Drug Interactions; Fibrinolytic Agents; Heparin | 1991 |
Prevention of recurrent thrombosis following liver transplantation for Budd-Chiari syndrome associated with myeloproliferative disorders: treatment with hydroxyurea and aspirin.
Topics: Adult; Aspirin; Budd-Chiari Syndrome; Female; Humans; Hydroxyurea; Liver Transplantation; Male; Myel | 1991 |
Effect of aspirin on intimal hyperplasia and cholesterol uptake in experimental bypass grafts.
Topics: Animals; Arteriosclerosis; Aspirin; Cell Division; Cholesterol; Dogs; Graft Occlusion, Vascular; Hyp | 1991 |
Translumbar inferior vena cava catheters.
Topics: Aspirin; Bone Marrow Transplantation; Catheterization, Central Venous; Cell Separation; Hematopoieti | 1991 |
[Effects of the combination of aspirin and nifedipine on platelet aggregation and thrombogenesis].
Topics: Animals; Aspirin; Drug Synergism; Female; Male; Nifedipine; Platelet Aggregation; Platelet Aggregati | 1990 |
[The drug prevention of thrombotic complications of the vascular approach--arteriovenous fistulae and synthetic prostheses in patients on hemodialysis with antistenocardin].
Topics: Adolescent; Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Vessel Prosthesis; Child; Dip | 1990 |
A biological method for studying the interaction between platelets and vascular endothelium.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Aspirin; Blood Platelets; Endothelium, Vascular; Epopros | 1990 |
Time of low-dose acetylsalicylic acid administration influences in vivo platelet function and thrombus formation following arteriotomy and intimectomy; an experimental study in small arteries of rabbits.
Topics: Animals; Arteries; Aspirin; Blood Coagulation; Blood Platelets; Ear, External; Female; Male; Microsc | 1990 |
[Coronary endoprostheses (stents)].
Topics: Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Coronary Angiography; Coronary Dis | 1990 |
A new model for photochemically induced thrombosis in the inner ear microcirculation and the use of hearing loss as a measure for microcirculatory disorders.
Topics: Action Potentials; Animals; Aspirin; Cochlea; Disease Models, Animal; Ear, Inner; Hair Cells, Audito | 1990 |
Local prevention of thrombosis in animal arteries by means of magnetic targeting of aspirin-loaded red cells.
Topics: Animals; Aspirin; Dogs; Drug Carriers; Erythrocyte Transfusion; Magnetics; Male; Rabbits; Thrombosis | 1990 |
Antithrombotic activity of an unsaturated fatty acid preparation.
Topics: Animals; Aspirin; Drug Interactions; Endothelium, Vascular; Fatty Acids, Unsaturated; Female; Fibrin | 1990 |
Aspirin-independent antithrombotic effects of acutely attached cultured endothelial cells on endarterectomized arteries.
Topics: Animals; Aorta; Aspirin; Cell Adhesion; Cells, Cultured; Endarterectomy; Endothelium, Vascular; Male | 1990 |
Heparin-induced platelet activation in sixteen surgical patients: diagnosis and management.
Topics: Adult; Aged; Aspirin; Epoprostenol; Female; Heparin; Humans; Iloprost; Male; Middle Aged; Platelet A | 1987 |
Carotid endarterectomy in patients with heparin-induced platelet activation: comparative efficacy of aspirin and iloprost (ZK36374).
Topics: Aged; Aspirin; beta-Thromboglobulin; Cardiovascular Agents; Carotid Arteries; Drug Evaluation; Endar | 1987 |
Red blood cells mediate spontaneous aggregation of platelets in whole blood.
Topics: 2-Chloroadenosine; Adenosine; Adult; Aged; Aspirin; Epoprostenol; Erythrocytes; Humans; Iloprost; In | 1987 |
Heterotopic ossification with total hip endoprostheses in various models of thrombosis prophylaxis.
Topics: Aspirin; Bone and Bones; Choristoma; Dextrans; Heparin; Hip Prosthesis; Humans; Indomethacin; Oxyphe | 1988 |
A new primate model for the study of intravenous thrombotic potential and its modification.
Topics: Animals; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Dextrans; Graft Occlusion, Vascular; Hep | 1988 |
Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis.
Topics: Amputation, Surgical; Aspirin; Dextrans; Female; Heparin; Humans; Intermittent Claudication; Ischemi | 1988 |
Role of eicosanoids in the kappa-carrageenin rat tail thrombosis.
Topics: Aminopyrine; Animals; Aspirin; Benzydamine; Cardiovascular Agents; Carrageenan; Diclofenac; Epoprost | 1988 |
Hepatic artery thrombosis after pediatric liver transplantation--a medical or surgical event?
Topics: Anastomosis, Surgical; Aspirin; Blood Coagulation Tests; Celiac Artery; Child; Child, Preschool; Dex | 1989 |
Endothelium in the pathogenesis of main vascular diseases.
Topics: Animals; Arteriosclerosis; Aspirin; Cholic Acid; Cholic Acids; Endothelium, Vascular; Heparin; Homoc | 1989 |
Platelet aggregating activity in the plasma of patients with established thrombosis.
Topics: Adult; Aged; Aspirin; Benzamidines; Blood Coagulation Factors; Edetic Acid; Humans; Middle Aged; Pla | 1989 |
Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors.
Topics: Amino Acid Sequence; Animals; Aspirin; Dogs; Femoral Artery; Microscopy, Electron, Scanning; Molecul | 1989 |
Platelet disposition at angioplasty sites and platelet survival time after PTA in iliac and femoral arteries.
Topics: Angioplasty, Balloon; Aspirin; Femoral Artery; Humans; Iliac Artery; Organometallic Compounds; Oxyqu | 1989 |
Evidence for 20 mg aspirin (ASA) as being optimal.
Topics: Arachidonic Acids; Aspirin; Blood Platelets; Dose-Response Relationship, Drug; Humans; Platelet Aggr | 1989 |
Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans.
Topics: Animals; Arteriovenous Shunt, Surgical; Aspirin; Blood Coagulation Factors; Blood Platelets; Chondro | 1989 |
[Reevaluation of postoperative thrombosis prevention].
Topics: Anticoagulants; Aspirin; Coumarins; Dextrans; Dihydroergotamine; Heparin; Humans; Postoperative Comp | 1985 |
[Use of aspirin in the primary prevention of vascular thrombi. A comparative study with other anti-aggregant drugs].
Topics: Animals; Aspirin; Dipyridamole; Dogs; Drug Evaluation; Drug Therapy, Combination; Platelet Aggregati | 1989 |
Aspirin how much?
Topics: Aspirin; Humans; Thrombosis | 1989 |
[A case of mitral stenosis with left atrial thrombus arose and reduced in a short-term].
Topics: Aspirin; Female; Heart Atria; Heart Diseases; Humans; Middle Aged; Mitral Valve Stenosis; Thrombosis | 1989 |
[Laboratory diagnostic monitoring of individually dosed antithrombotic therapy with acetylsalicylic acid in patients with atherosclerosis].
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Dose-Response Relationship, Drug; Humans; Malonates; Mal | 1989 |
Effects of aspirin and prostaglandin E1 on in vitro thrombolysis with urokinase. Evidence for a possible role of inhibiting platelet activity in thrombolysis.
Topics: Adult; Alprostadil; Aspirin; Drug Synergism; Female; Fibrinolysis; Humans; In Vitro Techniques; Male | 1989 |
Coronary thrombolysis.
Topics: Aged; Aspirin; Heart Diseases; Humans; Myocardial Infarction; Streptokinase; Thrombosis | 1989 |
[Effect of long-term anticoagulant and antithrombocytic therapy on the size of intracavitary thrombus and the incidence of thromboembolic complications in patients with acute myocardial infarction].
Topics: Aspirin; Heart Diseases; Humans; Myocardial Infarction; Phenindione; Thromboembolism; Thrombosis; Ti | 1989 |
Update on the pharmacology of pentoxifylline and its combination with low-dose acetylsalicylic acid (HWA 5112).
Topics: Animals; Aspirin; Blood Flow Velocity; Blood Viscosity; Dose-Response Relationship, Drug; Drug Thera | 1989 |
Prevention of the formation of arterial thrombi using different antiplatelet drugs: experimental study in dogs.
Topics: Animals; Aspirin; Dipyridamole; Dogs; Indium Radioisotopes; Platelet Aggregation Inhibitors; Salicyl | 1989 |
Long-term patency of regenerated neoaortic wall following the implant of a fully biodegradable polyurethane prosthesis: experimental lipid diet model in pigs.
Topics: Animals; Aorta; Aspirin; Biodegradation, Environmental; Blood Vessel Prosthesis; Cod Liver Oil; Micr | 1989 |
Thrombogenicity of canine free internal mammary artery autografts.
Topics: Animals; Aspirin; Blood Platelets; Coronary Artery Bypass; Dipyridamole; Dogs; Fibrinogen; Kinetics; | 1989 |
Effect of aspirin on heparin-induced thrombocytopenia (HIT) in a patient requiring hemodialysis.
Topics: Aged; Aspirin; Blood Platelets; Heparin; Humans; Immunoglobulin G; Kidney Failure, Chronic; Male; Re | 1989 |
[Acetylsalicylic acid for thrombosis prevention].
Topics: Anticoagulants; Aspirin; Blood Coagulation; Humans; Thrombosis | 1989 |
[Behavior of platelets and leukocytes on the luminal surface of small caliber prosthetic grafts].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aspirin; Blood Vessel Prosthesis; Cell Adhesion; Dogs; | 1988 |
Aspirin with an adrenergic or a calcium-channel-blocking agent as new combination therapy for arterial thrombosis.
Topics: Aspirin; Drug Synergism; Ethanolamines; Humans; Labetalol; Nicardipine; Nifedipine; Platelet Aggrega | 1985 |
Sex difference in antithrombotic effect of aspirin.
Topics: Adult; Aged; Aspirin; Female; Humans; Male; Menopause; Middle Aged; Orchiectomy; Osmolar Concentrati | 1989 |
Effects of antiplatelet agents in combination with endothelial cell seeding on small-diameter Dacron vascular graft performance in the canine carotid artery model.
Topics: Animals; Aspirin; Benzofurans; Blood Platelets; Blood Vessel Prosthesis; Carotid Arteries; Dipyridam | 1985 |
Can endogenous prostacyclin contribute to the antithrombotic effect of low dose aspirin in vivo?
Topics: Animals; Aspirin; Coronary Vessels; Dogs; Epoprostenol; Humans; Platelet Aggregation; Thrombosis | 1985 |
Effect of changes in prostaglandin synthesis by platelets and vessel wall on the formation of arterial thrombosis in rabbits.
Topics: Animals; Aspirin; Blood Platelets; Femoral Artery; Platelet Aggregation; Prostaglandins; Rabbits; Th | 1985 |
Antithrombotics in view of thrombosis models.
Topics: Animals; Anticoagulants; Arteries; Aspirin; Dipyridamole; Female; Hydroxyethylrutoside; Ketanserin; | 1986 |
Restenosis after arterial angioplasty: a hemorrheologic response to injury.
Topics: Angioplasty, Balloon; Animals; Arterial Occlusive Diseases; Arteries; Aspirin; Microscopy, Electron, | 1987 |
Management of protein S deficiency.
Topics: Aspirin; Glycoproteins; Humans; Protein Deficiency; Protein S; Thrombosis | 1988 |
Dazoxiben, UK 38,485 and aspirin: duration of effect for preventing thrombotic sudden death in rabbits.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Imidazoles; Mal | 1986 |
Beneficial effect of aspirin in maintaining the patency of small-caliber prosthetic grafts after thrombolysis with urokinase or tissue-type plasminogen activator.
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Dogs; Graft Occlusion, Vascular; Platelet Aggregation; Po | 1986 |
Preeclampsia: platelets and antiplatelet therapy.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Diagnosis, Differential; Female; Fetus; Humans; Hyperte | 1988 |
Exchange of cyclooxygenase dependent metabolites between vessel wall and platelets in arterial thrombosis.
Topics: Adenosine Diphosphate; Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Platelets; Cyclo | 1988 |
Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease.
Topics: Acute Disease; Adult; Aged; Arterial Occlusive Diseases; Aspirin; Basilar Artery; Female; Fibrinolyt | 1988 |
Effects of aspirin, dipyridamole, and cod liver oil on accelerated myointimal proliferation in canine veno-arterial allografts.
Topics: Animals; Aspirin; Cholesterol, Dietary; Cod Liver Oil; Dipyridamole; Dogs; Elastic Tissue; Endotheli | 1988 |
[Prevention of thromboses in vascular microanastomoses. Experimental study on the role of anti-aggregant drugs. Preliminary remarks].
Topics: Animals; Aspirin; Isoindoles; Male; Microsurgery; Phenylbutyrates; Platelet Aggregation Inhibitors; | 1988 |
[Effect of various doses of aspirin on the development of aseptic thrombotic aortic endocarditis experimentally induced in the rabbit].
Topics: Animals; Aortic Diseases; Aspirin; Cardiac Catheterization; Disease Models, Animal; Dose-Response Re | 1988 |
Effect of dietary lipids on arterial thrombus formation: rationale for the support of drug therapy by diet.
Topics: Animals; Arteriosclerosis; Aspirin; Diet, Atherogenic; Dietary Fats; Disease Models, Animal; Fish Oi | 1988 |
Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time.
Topics: Aged; Aspirin; Blood Platelet Disorders; Blood Platelets; Female; Follow-Up Studies; Hemorrhage; Hum | 1988 |
Indications and results for splenectomy for beta thalassemia in two hundred and twenty-one pediatric patients.
Topics: Aspirin; Blood Transfusion; Cerebrovascular Disorders; Child; Dipyridamole; Female; Follow-Up Studie | 1988 |
Influence of anti-platelet drugs on platelet-vessel wall interactions.
Topics: Aspirin; Calcium Channel Blockers; Endothelium, Vascular; Humans; In Vitro Techniques; Platelet Aggr | 1987 |
Experimental models for evaluating antithrombotic therapies in replantation microsurgery.
Topics: Animals; Aspirin; Femoral Artery; Femoral Vein; Fibrinolytic Agents; Heparin; Microsurgery; Rabbits; | 1987 |
Management of problems related to the occluded femoro-distal bypass.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Vessel Prosthesis; Femoral Artery; Graft Occlusion, Va | 1987 |
Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery.
Topics: Adult; Aged; Aspirin; Cardiopulmonary Bypass; Coronary Artery Bypass; Dipyridamole; Emergencies; Fem | 1987 |
The effect of predetermined thrombotic potential of the recipient on small-caliber graft performance.
Topics: Animals; Aspirin; Blood Cell Count; Blood Vessel Prosthesis; Carotid Arteries; Dogs; Drug Therapy, C | 1986 |
Transient effect of aspirin on collagen-induced platelet accumulation.
Topics: Adolescent; Adult; Aspirin; Blood Platelets; Collagen; Dose-Response Relationship, Drug; Epoprosteno | 1986 |
Oral acetylsalicylic acid improves patency rates in small-vessel anastomoses.
Topics: Administration, Oral; Animals; Aspirin; Femoral Artery; Male; Platelet Aggregation; Postoperative Co | 1986 |
Thrombogenicity of a fibronectin-coated, experimental polytetrafluoroethylene graft.
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Dogs; Fibronectins; Platelet Adhesiveness; | 1987 |
Scanning electron microscopy of crush/avulsion arterial trauma:effect of heparin and aspirin administration.
Topics: Animals; Arteries; Aspirin; Blood Coagulation; Blood Platelets; Femoral Artery; Fibrin; Heparin; Mic | 1987 |
Surprising effects of the sequential administration of pentoxifylline and low dose acetylsalicylic acid on thrombus formation.
Topics: Administration, Oral; Animals; Aspirin; Drug Administration Schedule; Drug Synergism; Lasers; Male; | 1987 |
Effect of aspirin plus hydrochloric acid on the gastric mucosal microcirculation.
Topics: Animals; Aspirin; Capillaries; Constriction, Pathologic; Drug Interactions; Gastric Mucosa; Hemorrha | 1987 |
The effects of aspirin, dipyridamole and warfarin in femorodistal reconstruction: long-term results.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis Obliterans; Arteriovenous Shunt, Surgical; Aspirin; | 1987 |
Long lasting sitting position and haemostasis.
Topics: Adult; Aspirin; Blood Coagulation; Fibrinolysis; Hemostasis; Humans; Platelet Aggregation; Posture; | 1986 |
Intraluminal thrombus of the internal carotid arteries: angiographic demonstration of resolution with anticoagulant therapy alone.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Female; Hepari | 1986 |
Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera.
Topics: Aspirin; Dipyridamole; Female; Hemorrhage; Humans; Male; Phosphorus Radioisotopes; Platelet Aggregat | 1986 |
Low dose aspirin does not prevent fibrinolytic response to venous occlusion.
Topics: 6-Ketoprostaglandin F1 alpha; Analysis of Variance; Aspirin; Fibrinolysis; Hematocrit; Humans; Isoin | 1986 |
Heparin-associated thrombocytopenia and thrombosis: a serious clinical problem and potential solution.
Topics: Aspirin; Female; Heparin; Humans; In Vitro Techniques; Male; Platelet Aggregation; Thrombocytopenia; | 1986 |
Epinephrine reverses the inhibitory influence of aspirin on platelet-vessel wall interactions.
Topics: Aspirin; Blood Platelet Disorders; Blood Platelets; Blood Vessels; Drug Interactions; Epinephrine; H | 1986 |
Sex-related differences in the effects of aspirin on the interaction of platelets with subendothelium.
Topics: Administration, Oral; Adult; Aspirin; Blood Platelets; Blood Vessels; Endothelium; Female; Humans; M | 1986 |
[Effect of the nonspecific prevention of thrombogenic complications on late results in the combined treatment of bladder cancer].
Topics: Adult; Aged; Aspirin; Combined Modality Therapy; Female; Follow-Up Studies; Gamma Rays; Humans; Male | 1987 |
[Acetylsalicylic acid. The dosage question].
Topics: Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Humans; Thrombosis | 1987 |
[Prevention and medical treatment of polyregional vascular lesions].
Topics: Adult; Anticoagulants; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Diet; Dipyridamole; D | 1985 |
Antithrombotic effects of acetylsalicylic acid (ASA) and pentoxifylline in laser-induced thrombosis in rat mesenteric vessels.
Topics: Animals; Aspirin; Dose-Response Relationship, Drug; In Vitro Techniques; Laser Therapy; Male; Mesent | 1985 |
The tachyphylactic effect of arachidonic acid on in-vivo ADP induced arterial platelet thrombosis.
Topics: Adenosine Diphosphate; Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Coagulation; Dru | 1985 |
Antithrombotic potential of pentoxifylline. A hemorheologically active drug.
Topics: Animals; Aspirin; Blood Coagulation; Cricetinae; Epoprostenol; Fibrinolysis; Haplorhini; Hemostasis; | 1985 |
Effect of incremental doses of aspirin on bleeding time, platelet aggregation and thromboxane production in patients with cerebrovascular disease.
Topics: Adult; Aged; Aspirin; Bleeding Time; Brain Ischemia; Cerebrovascular Disorders; Dose-Response Relati | 1985 |
[Preventive correction of hemostasis in patients with polycythemia vera].
Topics: Aspirin; Humans; Niacin; Pentoxifylline; Polycythemia Vera; Theobromine; Thrombosis | 1986 |
Protein/platelet interaction with an artificial surface: effect of vitamins and platelet inhibitors.
Topics: Adsorption; Amino Sugars; Animals; Aspirin; Blood Platelets; Blood Proteins; Cattle; Dipyridamole; F | 1986 |
The effect of antithrombotics in a new model of arterial thrombosis.
Topics: Animals; Aspirin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fibrinolytic Age | 1986 |
Antiplatelet aggregators inhibit development of stress ulcers in Sprague-Dawley rats.
Topics: Animals; Anticoagulants; Aspirin; Capillaries; Dipyridamole; Gastric Mucosa; Male; Platelet Aggregat | 1985 |
Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia.
Topics: Adult; Aged; Analgesics; Arteries; Arterioles; Arteritis; Aspirin; Blood Platelets; Erythromelalgia; | 1985 |
Antihemostatic and antithrombotic effects of capsaicin in comparison with aspirin and indomethacin.
Topics: Adenosine Diphosphate; Animals; Aspirin; Blood Coagulation; Capsaicin; Hemostasis; Indomethacin; Mic | 1985 |
Complete patency in thrombus-occluded arteries two weeks after laser recanalization.
Topics: Animals; Aspirin; Dipyridamole; Dogs; Femoral Artery; Laser Therapy; Thrombosis; Time Factors | 1985 |
Antihemostatic and antithrombotic effects of XC386.
Topics: Animals; Aspirin; Blood Coagulation; Hematocrit; Heparin; Indomethacin; Mice; Platelet Aggregation; | 1985 |
Impaired arteriolar vasodilation induced by thrombosis of a coronary arterial stenosis.
Topics: Animals; Arterial Occlusive Diseases; Aspirin; Coronary Circulation; Heart Rate; Hemodynamics; Imida | 1985 |
Effect of cilostazol on platelet aggregation and experimental thrombosis.
Topics: Adenosine Diphosphate; Animals; Aspirin; Azoles; Cilostazol; Dogs; Fibrinolytic Agents; Humans; In V | 1985 |
Anti-thrombotic effect of curcumin.
Topics: Animals; Aspirin; Blood Platelets; Catechols; Collagen; Curcumin; Epinephrine; Macaca mulatta; Male; | 1985 |
Interaction of platelets with subendothelium in humans treated with aspirin and dipyridamole alone or in combination.
Topics: Adenosine Triphosphate; Adult; Animals; Aorta, Abdominal; Aspirin; Blood Platelets; Chymotrypsin; Di | 1985 |
Aspirin and the prevention of experimental arterial thrombosis: difficulty in establishing unequivocal effectiveness.
Topics: Animals; Aspirin; Disease Models, Animal; Male; Rats; Rats, Inbred Strains; Statistics as Topic; Thr | 1985 |
Aspirin against clotting.
Topics: Aspirin; Blood Platelets; Humans; Preoperative Care; Thrombophlebitis; Thrombosis | 1971 |
Aspirin against arterial and venous thrombosis.
Topics: Aspirin; Humans; Thrombophlebitis; Thrombosis | 1971 |
Aspirin, thrombosis, and the future.
Topics: Animals; Aspirin; Blood Platelets; Fibrinolytic Agents; Humans; Platelet Adhesiveness; Thrombosis | 1971 |
Effect of aspirin in amaurosis fugax.
Topics: Aspirin; Blindness; Dipyridamole; Recurrence; Retinal Vessels; Thrombosis | 1971 |
Rate of fibrinogen turnover in thrombosis.
Topics: Age Factors; Analysis of Variance; Aspirin; Fibrin; Fibrinogen; Humans; Iodine Radioisotopes; Method | 1972 |
Treatment of atherosclerosis and thrombosis with aspirin.
Topics: Adult; Age Factors; Animals; Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Diabetes | 1972 |
Anticoagulants: a guide for practitioners.
Topics: Angina Pectoris; Anticoagulants; Aspirin; Dicumarol; Disseminated Intravascular Coagulation; Electri | 1973 |
Letter: Heparin thrombin clotting-time and platelet factor 4.
Topics: Adult; Arteriosclerosis; Aspirin; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Te | 1974 |
Effects of salicylates on human platelets.
Topics: Adenine Nucleotides; Aspirin; Blood Coagulation Tests; Blood Platelets; Blood Viscosity; Centrifugat | 1968 |
Platelet-surface reaction and thrombosis.
Topics: Animals; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Carbon Isotopes; Endarterectomy; Extraco | 1968 |
[The inhibition of thrombocyte aggregation in vitro and in vivo].
Topics: Anti-Inflammatory Agents; Arachidonic Acids; Aspirin; Blood Platelets; Dipyridamole; Fatty Acids, Es | 1969 |
[Collagen and thrombocytes].
Topics: Aorta; Arteriosclerosis; Aspirin; Blood Platelets; Collagen; Hemorrhage; Humans; Phenylbutazone; Pla | 1969 |
[Aspirin--an always new drug].
Topics: Anticoagulants; Aspirin; Humans; Prostaglandin Antagonists; Thrombosis | 1974 |
Salicylates, platelets and adenine nucleotides.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Aspirin; Blood Platelets; Blood Viscosity; Humans; Thro | 1968 |
Relation of microcirculatory thrombosis to thrombus in the proximal coronary artery: effect of aspirin, dipyridamole, and thrombolysis.
Topics: Animals; Aspirin; Blood Platelets; Chromium Isotopes; Coronary Circulation; Coronary Disease; Dipyri | 1973 |
Future directions in the development of arterial prostheses for small and medium caliber arteries.
Topics: Animals; Arteries; Aspirin; Blood Flow Velocity; Blood Vessel Prosthesis; Dipyridamole; Endothelium; | 1974 |
Blood and neoplastic diseases. Haemostasis, haemorrhage, and thrombosis.
Topics: Adenosine Diphosphate; Animals; Aspirin; Blood Coagulation; Blood Coagulation Factors; Blood Platele | 1974 |
[Prostaglandins, blood platelets, and thrombosis].
Topics: Animals; Aspirin; Blood Platelets; Cell Aggregation; Cyclic AMP; Drug Antagonism; Prostaglandins; Ra | 1973 |
Modification of platelet function.
Topics: Animals; Antigen-Antibody Complex; Aspirin; Blood Coagulation; Blood Platelets; Calcium; Cell Moveme | 1972 |
Letter: Aspirin and atherosclerosis.
Topics: Aspirin; Humans; Platelet Adhesiveness; Thrombosis; Time Factors | 1974 |
Blood platelets and the inflammatory process.
Topics: Aspirin; Blood Platelets; Blood Proteins; Capillary Permeability; Hemostasis; Histamine; Humans; Ind | 1974 |
Editorial: Platelets.
Topics: Aspirin; Blood Platelets; Humans; Myocardial Infarction; Platelet Aggregation; Thrombosis | 1974 |
Platelet function tests in uraemia and under acetylsalicylic acid administration.
Topics: Aspirin; Blood Platelet Disorders; Female; Humans; Male; Platelet Adhesiveness; Platelet Aggregation | 1974 |
Influence of simultaneous administration of low-dose heparin and acetylsalicylic acid on blood coagulation and platelet functions.
Topics: Adult; Aged; Aspirin; Blood Cell Count; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; | 1974 |
Antithrombotic drugs and experimental thrombosis.
Topics: Animals; Aspirin; Dextrans; Dipyridamole; Disease Models, Animal; Drug Combinations; Fibrinolytic Ag | 1972 |
Editorial: Anticoagulation IV: Preventing thrombosis by modifying platelet behavior.
Topics: Anticoagulants; Aspirin; Blood Platelets; Dipyridamole; Drug Therapy, Combination; Hemorrhagic Disor | 1974 |
A kinetic evaluation of hemostasis in renal disease.
Topics: Aspirin; Blood Coagulation; Complement System Proteins; Diabetic Nephropathies; Dipyridamole; Fibrin | 1974 |
Quality control of thrombogenic properties of clinical ALG.
Topics: Animals; Antilymphocyte Serum; Aspirin; Blood Coagulation; Humans; Kidney Transplantation; Platelet | 1973 |
Standardzed bleeding time in the study of drugs interfering with platelet function.
Topics: Aspirin; Blood Coagulation Tests; Blood Platelets; Ergolines; Hemostasis; Humans; Platelet Adhesiven | 1972 |
[Analgesics and bleeding tendency].
Topics: Adult; Aspirin; Blood Coagulation; Female; Hemorrhage; Humans; Thrombosis | 1972 |
[Experimental arterial thrombosis. In vivo and in the vitro effects of aspirin and prostaglandin E1].
Topics: Adenosine Diphosphate; Animals; Aspirin; Blood Coagulation; Blood Platelets; Cerebral Arteries; Coll | 1972 |
Influence of some drugs on platelet aggregation: a study in hypertensive patients.
Topics: Adenosine Diphosphate; Anti-Inflammatory Agents; Aspirin; Benzyl Compounds; Blood Cell Count; Blood | 1972 |
Inhibition of thrombosis on vascular catheters in cats.
Topics: Adenosine Diphosphate; Animals; Aspirin; Carbon Isotopes; Catheterization; Cats; Connective Tissue; | 1973 |
Prophylactic aspirin?
Topics: Aspirin; Coronary Disease; Humans; Thrombosis | 1973 |
[New possibilities in the prevention of thrombosis].
Topics: Aspirin; Dextrans; Dipyridamole; Heparin; Humans; Thrombosis | 1973 |
[Acetylsalicylic acid and the prevention of thrombosis].
Topics: Anti-Inflammatory Agents; Aspirin; Cell Membrane Permeability; Cell Survival; Humans; Platelet Adhes | 1973 |
Clinical application of platelet aggregation.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Dipyridamole; Epinephrine; Humans; Intracranial Emb | 1973 |
The treatment of pulmonary embolism.
Topics: Adult; Aspirin; Blood Coagulation Tests; Cholelithiasis; Diabetes Complications; Female; Heparin; Hu | 1973 |
Dipyridamole and aspirin tested against an experimental model of thrombosis.
Topics: Animals; Aspirin; Blood Vessels; Dipyridamole; Disease Models, Animal; Dogs; Hematoma; Hemorrhagic D | 1973 |
[Experimental platelet aggregation and arterial thrombosis. Effect of aspirin].
Topics: Adenosine Diphosphate; Animals; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Collagen; Epi | 1973 |
Effects of combined prostaglandin E1 and aspirin on experimental arterial thrombosis in rabbits.
Topics: Animals; Aspirin; Blood Platelets; Drug Synergism; Platelet Adhesiveness; Prostaglandins; Rabbits; T | 1973 |
Aspirin in the prevention of thrombosis.
Topics: Aspirin; Fibrinogen; Humans; Iodine Radioisotopes; Platelet Adhesiveness; Postoperative Complication | 1973 |
Laser-induced thrombosis in the microcirculation of the hamster cheek pouch and its inhibition by acetylsalicyclic acid.
Topics: Animals; Aspirin; Cheek; Constriction; Cricetinae; Disease Models, Animal; Injections, Intraperitone | 1973 |
Action of coagulation factors on experimental thrombogenesis and their changes after thrombosis.
Topics: Animals; Aspirin; Benzopyrans; Blood; Blood Cell Count; Blood Coagulation Factors; Blood Platelets; | 1973 |
Preventing thrombosis.
Topics: Aspirin; Dipyridamole; Humans; Thrombosis | 1973 |
[Clinical use of anti-aggregative agents].
Topics: Aspirin; Dipyridamole; Humans; Hydroxychloroquine; Platelet Adhesiveness; Thromboembolism; Thromboph | 1973 |
Controlled-flow instruments for simulating in vivo thrombosis.
Topics: Adolescent; Adult; Aspirin; Blood Cell Count; Blood Coagulation Tests; Blood Platelets; Blood Viscos | 1973 |
Leucocytes and thrombosis. 3. Effect on white cell behaviour of substances which induce or inhibit platelet aggregation.
Topics: Adenosine; Aspirin; Catecholamines; Collagen; Dipyridamole; Epinephrine; Isoproterenol; Leukocytes; | 1973 |
[Study on experimental thrombosis, with special reference to the prevention of thrombus formation (author's transl)].
Topics: Animals; Aspirin; Benzopyrans; Female; Hemostatics; Male; Platelet Adhesiveness; Prostaglandins; Rab | 1973 |
Modern-anticoagulation therapy: the rational use of heparin and dextran in clinical vascular surgery.
Topics: Animals; Aspirin; Blood Vessels; Dextrans; Heparin; Humans; In Vitro Techniques; Rats; Thrombosis; V | 1973 |
Inhibition of platelet-induced thrombus formation.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Brain Diseases; Dipyridamole; Epinephrin | 1974 |
Arachidonic acid causes sudden death in rabbits.
Topics: Animals; Arachidonic Acids; Aspirin; Death, Sudden; Injections, Intravenous; Microcirculation; Plate | 1974 |
Attempts to reduce arterial thrombosis after cardiac catheterization in children: use of percutaneous technique and aspirin.
Topics: Adolescent; Age Factors; Arteries; Aspirin; Boston; Cardiac Catheterization; Child; Child, Preschool | 1974 |
Prevention of thrombosis with agents which reduce platelet adhesiveness.
Topics: Animals; Anticoagulants; Aspirin; Dextrans; Dipyridamole; Dogs; Femoral Artery; Molecular Weight; Pl | 1974 |
Isolation of a chemical trigger for thrombosis.
Topics: Animals; Arachidonic Acids; Aspirin; Bromine; Carbon Radioisotopes; Chlorides; Chromatography, Thin | 1974 |
Experimental interactions of components of hemodialysis units with human blood.
Topics: Albumins; Aspirin; Biocompatible Materials; Blood Coagulation; Blood Coagulation Tests; Dextrans; Hu | 1974 |
[Role of thrombotic agent in coronary insufficiency--therapeutic implications (author's transl)].
Topics: Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelet Disorders; Coronary Disease; | 1974 |
The effect of adenosine monophosphate, arcaine and anti-inflammatory agents on thrombosis and platelet function in rabbits.
Topics: Adenine Nucleotides; Animals; Anti-Inflammatory Agents; Aspirin; Blood Platelets; Blood Pressure; Ca | 1970 |
Studies on thrombus formation and prevention within hemodialysis.
Topics: Aspirin; Blood Platelets; Chromium Isotopes; Humans; Microscopy, Electron, Scanning; Renal Dialysis; | 1972 |
[Acetylsalicylic acid in thromboembolic diseases].
Topics: Anticoagulants; Aspirin; Blood Platelets; Humans; Postoperative Complications; Thromboembolism; Thro | 1972 |
Effect of a new anti-inflammatory drug, fenoprofen, on platelet aggregation and thrombus formation.
Topics: Adenosine Diphosphate; Analysis of Variance; Animals; Anti-Inflammatory Agents; Aspirin; Blood Plate | 1972 |
Effect of dipyridamole and aspirin in thrombotic microangiopathy.
Topics: Adult; Anemia, Hemolytic; Aspirin; Dipyridamole; Humans; Male; Platelet Adhesiveness; Purpura, Throm | 1972 |
[Action of Aspirin on the vascular manifestations of thrombocythemia].
Topics: Aspirin; Blood Platelet Disorders; Epinephrine; Humans; Male; Platelet Adhesiveness; Thrombocythemia | 1972 |
Effect of aspirin upon experimental coronary and non-coronary thrombosis and arrhythmia.
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Blood Platelets; Coronary Disease; Dogs; Femoral Artery; Thr | 1972 |
[Studies on the number and function of platelets in experimental endotoxic shock of the rabbit].
Topics: Adrenal Glands; Animals; Aspirin; Blood Cell Count; Blood Platelets; Blood Pressure; Capillary Resis | 1972 |
Inhibition of experimental arterial thrombosis in dogs with platelet-deaggregating agents.
Topics: Administration, Oral; Animals; Aspirin; Blood Cell Count; Blood Platelets; Carotid Arteries; Cyprohe | 1971 |
[Pharmacodynamic prevention of thrombosis].
Topics: Adenosine Diphosphate; Amitriptyline; Anticoagulants; Aspirin; Collagen; Dipyridamole; Guanethidine; | 1971 |
[Effect of drugs on blood platelet characteristics].
Topics: Adenine Nucleotides; Adenosine Diphosphate; Animals; Aspirin; Blood Coagulation; Blood Platelets; Ep | 1971 |
Aspirin ingestion compared with bleeding disorders--search for a useful platelet antiaggregant.
Topics: Adenine Nucleotides; Aspirin; Blood Coagulation Disorders; Blood Coagulation Tests; Blood Platelet D | 1970 |
[Prevention of thrombosis using aspirin? nfluence of acetylsalicylic acid on thrombocyte aggregation in vitro and in vivo].
Topics: Aspirin; Blood Coagulation Tests; Blood Platelets; Dipyridamole; Female; Humans; Middle Aged; Papave | 1969 |
Platelet function studies in human beings receiving 300 mg. of aspirin per day.
Topics: Adult; Aspirin; Blood Platelets; Cell Aggregation; Collagen; Humans; Middle Aged; Platelet Adhesiven | 1970 |
[Current aspects of aspirin therapy].
Topics: Aspirin; Blood Coagulation; Embolism; Hemorrhage; Humans; Joint Diseases; Myocardial Infarction; Thr | 1970 |
[Drug inhibition of blood platelet function. A new trend in the prevention of thromboembolic diseases].
Topics: Adolescent; Adult; Aspirin; Blood Platelets; Cell Aggregation; Female; Humans; Middle Aged; Thromboe | 1970 |
[Preliminary clinical uses of aspirin as an anticoagu.ant. (Preliminary note)].
Topics: Aged; Arteriosclerosis Obliterans; Aspirin; Female; Humans; Intracranial Arteriosclerosis; Male; Mid | 1970 |
Thrombosis prevention by acetylsalicylic acid in hyperlipemic rats.
Topics: Adenine Nucleotides; Adult; Animals; Aspirin; Blood Coagulation Tests; Collagen; Disease Models, Ani | 1970 |
[Anti-adhesion and anti-coagulant substances in thrombosis therapy. Acetylsalicylic acid and Persantin in the spotlight].
Topics: Animals; Aspirin; Coronary Disease; Dipyridamole; Humans; Thrombophlebitis; Thrombosis | 1971 |
Protection by aspirin against experimentally induced arterial thrombosis in dogs.
Topics: Animals; Aspirin; Axillary Artery; Blood Platelets; Carotid Arteries; Dogs; Femoral Artery; Placebos | 1971 |
Inhibition by dipyridamole of arterial thrombosis in rats.
Topics: Animals; Aspirin; Dipyridamole; Heparin; Mesenteric Arteries; Rats; Thrombosis; Warfarin | 1968 |
[Acute anuric renal insufficiency with necrosing arteriolitis. Etiologic problems].
Topics: Acute Kidney Injury; Adult; Anemia, Hemolytic; Angioedema; Anuria; Arteritis; Arthritis; Aspirin; Dr | 1968 |
[Platelet aggregation in retinal venous thrombosis and its modification by pharmacological agents].
Topics: Adult; Aspirin; Blood Platelets; Eye Diseases; Female; Humans; Male; Middle Aged; Platelet Adhesiven | 1968 |